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ABSTRACT 
God has bestowed man with the unique quality of thinking and intellect 
distinguishing him from all'dther creatures made by God. Man has utilized his 
intellectual mind for his own benefits as well as benefits at all society at large 
intellectual property is one such outcome of the exercise of intellectual faculty 
by human beings and it is because of his unique faculty from individual to 
individual which has been accepted from personal property of the individual 
exercising his intellectual faculty for a particular purpose which needs 
protection by law. 
The grant of IPR and their proper enforcement facilitated fair trade and 
access of consumers to quality products while ensuring the safety to human and 
animals, product's price shelf life and degradation etc. The new technology 
developments, particularly in biotechnology, demonstrate the significance and 
usefulness of traditional knowledge for development of new products of 
commercial importance. Research and creativity originating from research 
institutions in the field of science and technology like institutions of 
technology, university and industrial Houses engaged in R& D activities. 
The fast technological metamorphosis and globalization require 
constant exploration of emerging issues in IPR. The WIPO Agenda on the 
Global Intellectual Property issue aims at enhancing of the coterminous, 
proximate and reciprocal relationships between intellectual property and 
traditional knowledge, bio-technology and biological diversity and collateral 
aspects of economic, social, cultural and technological development. The 
overall objective of the Global Intellectual Property Issue Division (Global 
Issues Division-GID) is promoted the constant viability, enhanced efficiency 
and broader coverage of the intellectual property system. In a world 
increasingly epitomized as the "global information society", the rapid 
emergence of modem information technologies, an increasing awareness about 
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traditional knowledge and its spiritual, cultural and economic values have 
become central to human discourse. 
. Traditional knowledge (TK) is a collectively owned property and is 
integral to the cultural or spiritual identity of the social group in which it 
operates and is preserved. Traditional Knowledge is now at the centre of the 
discussions on intellectual property rights and has assumed immense 
significance. India does not have any specific legislation for protecting 
traditional knowledge. But the Patents Act, Plant Variety Protection and 
Farmers Rights Act, Biological Diversity Act, 2002 and Geographical 
Indication of Goods (Registration and Protection) Act, 1999 have provisions 
that can be utilized for protecting traditional knowledge. The concept of 
benefit-sharing, which is an integral part of protecting traditional knowledge, 
has been analysed in detail with specific reference to the Biological Diversity 
Act and also the Plant Variety Protection and Farmers Rights Act. The case 
study of Jeevani drug gives an insight into the concept of benefit sharing. The 
importance of traditional knowledge is highlighted in the revocation of patent 
granted to derivatives of neem on the ground that they were part of the 
traditional knowledge of our country and that fungicide qualities of the neem 
tree and its use had been known in India for over 2,000 years. A discussion of 
the patent granted to turmeric that was effectively challenged by the CSIR 
based on the ancient Sanskrit text also figures in the work. Along with this, a 
case study of Basmati has also been done. The thesis also focuses on the 
international initiatives at protecting traditional knowledge including the 
Convention on Biological Diversity, International Undertaking on Plant 
Genetic Resources for Food and Agriculture and the Agreement on Trade 
Related Aspects of Intellectual Property Rights. But there are no uniform 
norms regarding the protection of different types of traditional knowledge 
owned by local communities. The reason for this divergence of laws is that the 
international community never had an occasion to look at the protection of 
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traditional knowledge in its entirety. Measures to ensure that traditional 
knowledge is protected should be taken at the auspices of the World Trade 
Organization which should lay down general mandatory provisions to be 
complied by member countries. 
With the advent of Trade Related Aspect of Intellectual Property 
(TRIPS) Agreement in the international scenario, all the countries signatory of 
WTO and TRIPS Agreement, become bound to mandate certain drastic 
changes in the patent systems through out the world. Under the TRIPS 
Agreement it is the obligation of the member countries where their patent laws 
are not consistent with the TRIPS provisions of the agreement, to take steps to 
modify their legislation to make them consistent. The TRIPS Agreement 
provide a period of 5 years from 1995 for developing countries to implement 
the TRIPS provisions further it also provide a additional period of 5 years to 
developing countries like India to comply with the TRIPs Agreement. 
Patents in India have their origin by the 1856 Act. After independence, 
relative inaccessibility and affordability, or even non availability of essential 
life saving medicines led to the government to appoint two committees: the 
Tek Chand Patents Enquiry committee (1948-50) and the Ayyangar Committee 
(1959). Consequent to the recommendations of these committees the Indian 
Patents law was enacted in 1970. The Indian Patent Act, 1970 was also enacted 
with a view to make patents serve the needs of economy as well as to make 
them a vehicle of rapid growth. 
The enactment of the Patents Act, 1970 has proven a boon for Indian 
pharmaceutical industry (especially the generic pharma segment). The 
traditional medicine continues to play an important role in health care but the 
general lack of research on safety and efficacy of traditional medicines is of 
great concern. Fortunately in many developing countries, traditional medicine 
offers a major and accessible source of health care. India has also focused on 
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the role of traditional medicine in national health care strategies, supporting the 
development of clinical research into the safety and efficacy of traditional 
medicine, advocating the rational use of traditional medicine. Indian 
Pharmaceutical Industry also has a significant contribution of Indian System of 
Traditional Medicine. The newly enforced product patent regime would be in 
favour of the traditional medicinal knowledge of India. Taking the product 
patent on traditional herbal drug will certainly work to prevent 
misappropriation of traditional herbal drugs and its knowledge by the western 
countries. 
Medicinal plants the world's oldest known health care products, play a 
key role in traditional medicine. But these plants are not only used for primary 
health care; many widely used pharmaceuticals are derived from plants and 
other natural sources. Traditional medicines is used the world over but is 
particularly relied on in developing countries. In the South, some 80% of 
people endeavor to protect or restore health using methods that have been 
handed down from generation to generation. 
In India medicinal plants have made a good contribution to the 
development of ancient India Materia Medica. One of the earliest treatises on 
Indian medicine, the Charak Samhita (1000 B.C.,) records the use of over 340 
drugs of vegetable origin. Medicinal plants have curative properties due to the 
presence of various complex chimerical substances of different composition, 
which are found as secondary plant metabolites in one or more parts of these 
plants. 
The Indian traditional medicines also have a significant presence in the 
Indian Pharmaceutical Industry. The Indian system of medicine was prevalent 
about 1500 years over Southeast Asia. It comprises of 3 major systems namely 
Ayurveda, Siddha and Unani this traditional medicines now comes under the 
Indian system of Medicine. In 1995 to boost the growth of traditional 
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medicines The Department of Indian system of Medicine and Homeopathy 
(now has been known as AYUSH) was estabHshed by the Ministry of Heahh & 
Family welfare. 
An insight to India pharmaceutical industry tells the position of IPI. It 
rank 4"^  in terms of volume and 13"' in terms of value. Indian firms produce 
approximately 1.5% of the global pharmaceutical market of $ 480 billion. The 
Indian pharmaceutical industry meets around 70% of the country's demand. IPI 
provides direct employment to 5, 00,000 people. And indirect employment to 
approximately 24, 00,000 people. 
"The Indian pharmaceutical industry is a success story providing 
employments for millions and ensuring that essential drugs at affordable prices 
are available to the vast population of this subcontinent. " said Richard Grester 
India is emerging favoured destination for level of expenditure on R & 
D is about 5% of turnovers, which is much lower compared to most of the 
developed countries which is 15 to 20%. Some of the leading firms who take 
the initiative in the investment in R & D are Dr. Reddy's and Ranbaxy. Today 
contract research contract manufacturing formation alliances in research & 
development between the Indian and foreign pharmaceutical companies have 
strengthened the prospects of the Indian pharmaceutical sector in post Jan, 
01.2005 regime. The Indian pharmaceutical companies' mergers and 
acquisitions of foreign companies is another evidence of its rise of Indian 
Pharmaceutical Industry. 
India being a member of WTO also realized the need to protect the 
interests of plant breeders, farmers and promote conservation of genetic 
resources and seed industry. TRIPS under Article 27.3(b) of the TRIPS 
agreement provides that member states may exclude essentially biological 
processes for the protection of plants or animals other than non-biological and 
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variety protection, Article 27.3(b) gives Member countries an option to protect 
plant varieties by patents or an effective sui-generis system or both, 
India's first sui-generis law Protection of Plant Varieties and Farmers' 
Rights Act, 2001 tries to strike a balance between the monopoly rights granted 
to the intellectual property rights holders and the benefits of society through the 
provisions of compulsory licensing, researcher's rights, exclusion of certain 
varieties from registration etc. Though certain loopholes are also present in the 
Act such as to avail the monopoly right registration of the variety is necessary 
and for retaining registration they have to pay royalty to the Government on the 
other hand it can also be consider as a check on the breeder's monopoly right. 
In the absence of this provision, obligation relating to benefit sharing and 
payment of compensation will not be workable by amending the provisions of 
the Act these loopholes can be closed. By the enactment of Protection of Plant 
Varieties Act, legislators tried to maintain the equilibrium between the Indian 
dual goals of protection of agrarian economy and protection of private 
investment in the development of new plant varieties and also recognizing the 
protecting the rights of plant breeders and farmers. 
CBD affirms the sovereign rights of the states over their biological 
resources and India being a member of CBD decided to bring a piece of 
legislation in the form of Biological Diversity Act, 2002. The Biodiversity Act 
also plays an important role in the conservation of biodiversity protection of 
traditional knowledge, equitable sharing of benefits and to regulate access to 
biological resources. Section 3,4 6 and 7 the key provisions relating to regulate 
access to biological resources and traditional knowledge and exemption to 
certain persons such growers and cultivator, Vaids & Hakims make a good 
combination of access and denial at some extent it is being able to present 
biopiracy. Since it is an innovative legislation with adequate measures to 
safeguard biodiversity and protection of economic interest of local and 
traditional comminutes, it will work as a tool for protection of traditional 
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knowledge after the averseness of different state holders and its effective 
implementation. 
The other pertinent question would be as to who are entitled to seek 
protection of which forms of traditional knowledge and who may confer 
recognition and status on the holders of traditional knowledge in a sui-generis 
modality raises a number of questions about the role of communities and 
functions of communally held knowledge in traditions that are part of heritage 
and culture as well as living traditions of habitat presentation and human 
interactions. At last to conclude it can be said that for the protection if traditional 
Indian knowledge, a separate sui generis system is required. Traditional 
knowledge is not an area of patent. Patent requires novelty essential elements of 
patentability which cannot be fulfill by traditional knowledge. The new patent 
regime does not directly affect the traditional knowledge. If the patent regime 
affect it would be at the extent of the aspect of traditional medicines. On one hand 
where for the protection of plant varieties a separate sui-generis law has been 
framed which was also not an area of patent on other hand the need of an hour is 
to frame a sui-generis law for the protection of traditional Indian knowledge. The 
below stated Hypothesis framed by researcher for the research work has been 
proved. 
Hypothesis 
There is no law for the protection of traditional knowledge but 
traditional knowledge is protected under other IPR legislation such as Patent, 
Copyrights, Trademarks, Geographical Indication, Biodiversity and Plant 
varieties and India also amended its municipal laws in consonance of TRIPS 
agreement and different international conventions, treaties and protocols. Now 
the pertinent question is that whether our traditional knowledge and indigenous 
knowledge ought to be protected under any else legislation or not? 
Abstract 
1. It is hypothesized that thought he TRIPS agreement under Article 27 talks 
about a sui-generis legislation and also for the protection of traditional 
knowledge but this does not specifically give any guidelines to protect the 
T.K. 
2. It is hypothesized that most of our traditional knowledge is patented by 
developed countries. On large scale our traditional knowledge has been 
patented by US, Germany and other developed countries, should we opt for 
such a strong legislation which can prevent our traditional knowledge from 
being patented by these western countries? 
3. Though India has already placed a legislation for the protection of farmers' 
as well as breeder's rights. Even than question arises what are the farmers" 
rights to be enunciated in any sui-generis legislation for the protection of 
traditional knowledge, whether this legislation would be complementary to 
the protection of traditional knowledge? 
4. It is hypothesized that India is among one of the twelve richest mega-
biodiversity rich countries. Biopiracy is directly related to biodiversity and, 
a separate legislation has been framed to protect biodiversity of the country 
but the enactment and implementation of this law has no effective purview 
to prevent biopiracy. 
5. It is hypothesized that along with biodiversity legislation to protect the 
traditional rights of the farmers and to protect the plant varieties, protection 
varieties Act is a significant form oisui-generis legislation. 
6. It is hypothesized that India is the richest source of traditional knowledge 
not only in medicinal area but it has a rich heritage of folklore, Art, Music, 
Dance Handicrafts, and Skills etc. which needs protection through separate 
sui-generis legislation. 
It is hypothesized that whether proposed sui-generis legislation would be 
recognized internationally in absence of international rules and guidelines for 
such a law? 
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The discussion carried out in five chapters of this research work has made 
it crystal clear that a lot of steps have been taken by the international community 
for the protection of valuable asset in the form of traditional knowledge yet there 
are certain gaps which need to be filled so as to make protection of traditional 
knowledge regime effective. It is necessary for the effective and integrated 
implementation of the three Acts, Protection of Plant Varieties and Farmers' 
Rights Act, 2001, Biodiversity Act, 2002 and Seeds Bill 2004, to protect the T.K. 
In India a National patent programme should be started to make masses aware of 
its benefits challenges and be ready to face global new patent regime. Patent 
literacy is a must for India. The following important suggestion may be advanced 
for taking certain initiatives for the protection traditional knowledge. 
SUGGESTIONS 
No doubt, protection of T.K is a global problem demand globals 
solution. This T.K should be respected in all patent laws. Since T.K is often 
owned by an entire community, the entire community should have some share 
in the patent rights. This is one of the surest ways to fight biopiracy. This is 
also proposed that traditional communities should be integrated mainstream of 
the country origin. It is submitted that the TRIPS trade treaty needs to be 
revised to protect traditional knowledge and prevent bio-piracy. Further the 
TRIPS and CBD treaties should made workable to altercate contradictions and 
inconsistencies in the two agreements. 
Public awareness campaign should be lunched by the government as 
there is an urgent need to educate the T.K holders, and communities. The effect 
of product patent would be more profound on pharmaceuticals but India should 
set up a new agenda as new challenges are a head. It is well recognized fact that 
there exist basic human rights to a clean and safe natural environment. The 
effects of Bio-piracy and industrial agriculture also clearly threaten. These 
human rights surveying the existing material on protection of T.K researcher 
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reached on the conclusion that the jobs, livelihood, employment, food security 
and safety, equity, the precautionary principle should not be ignored for IP 
regime in biodiversity. 
1. In India, in order to check bio-piracy an exercise has been initiated to 
prepare easily navigable computerized database of documented TK 
relating to use of medicinal and other plants, known as Traditional 
Knowledge Digital Library (TKDL). However, documentation of TK is 
only one of the means of giving recognition to knowledge holders. Mere 
documentation may not enable sharing of benefits out of the use of such 
knowledge unless it is backed by some kind of mechanism for protecting 
knowledge. Documentation of TK may only serve a defensive purpose, 
namely that of preventing the patenting of this knowledge in the form 
of which it exists. 
2. The Bio-Diversity Act, 2002, which regulates access to genetic 
resources and associated knowledge, contains no provision for the 
involvement of communities in decision-making. The Act is very much 
influenced by Bonn Guidelines. The National Bio-Diversity Authority 
(NBA) is the principal body for granting access to genetic resources. 
Thus, there is a need to include more stakeholders from amongst the 
traditional communities so that its representative nature may be 
improved. 
3. National level mechanisms and legal provisions to prevent bio-piracy as 
well as to install informed consent mechanisms to ensure reward to TK 
holders should also be given international recognition for their effective 
implementation and for their enforcement in other countries. Thus, there is 
a need for development of an international mechanism for protecting TK. 
4. Considering the fact that TK also needs international protection, it is 
imperative to define the characteristics of the international mechanism, 
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which must include the following:-
(a) Local protection of the rights of the TK holders through national sui 
generis regimes including customary laws. 
(b) There is an urgent need for the effective enforcement of municipal 
level sui generis regimes through positive comity of protection of TK 
which include co-ordination and co-operation amongst national 
authorities of various countries in undertaking measures for protection of 
TK. 
(c) A procedure whereby the use of TK from one country is allowed 
particularly for seeking IPR protection, or commercialization, only after 
such use is disclosed and PIC is obtained from the competent national 
authority of the country of origin. 
5. That patent must not be granted with out prior consent of the country, 
origin should be incorporated. No patenting plants should be carried out 
with out prior informed consent of government and communities holders in 
country origin. 
6. Prior informed consent for the use of TK is necessary whether the use of 
TK is commercial or non-commercial. The right to TK should be treated as 
basic Human Rights. 
7. Since development of an appropriate form of protection for the 
knowledge of local communities is of great importance, therefore, 
there is a need for various bio-diversity rich developing countries to 
work together inter-governmental expedition towards developing 
an international instrument for the recognition of diverse national 
sui generis system. Thus, various bio-diversity rich countries should take 
steps for the preservation and protection of TK, and should come 
together for making concerted efforts in order to obtain international 
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recognition of their national level systems of protection of TK. 
8. There is a long felt need to harmonize the provision of TRIPS and 
CBD. The CBD while reaffirming the sovereign rights of nations over 
their biological resources, calls for equitable sharing of benefits arising out 
of the utilization of these resources and associated TK. TRIPS 
agreement, on the other hand, recognizes IPR to be private rights and 
provides for rewarding inventions without referring to the source of 
biological material and associated TK and without commitment for fair 
and equitable sharing of benefits with the country of origin of such 
knowledge. The adverse implications of the TRIPS Agreement on 
protection and sustainable use of TK needs to be rectified. The TRIPS 
Agreement should be used not only to reward the inventors but also the 
local people and community who have conserved and developed the 
TK, which provide valuable base for such inventions. Therefore, the 
developing countries must utilize the mandate given by Doha 
Ministerial Declaration on the relationship between CBD and TRIPS, 
which needs to be harmonized, 
9. An action may be taken on the following three broad fronts: -
(a) To put into place well considered legislations and 
complimentary arrangements which would help address the 
needs of the holder of TK. 
(b) To establish the institutional structure needed for effective 
implementation of the legislations; and 
(c) To review various legislations enacted both by the Central 
Government and different State Governments, with a view to 
amend those that may undermine the rights of the traditional 
communities over the resources they have been using. 
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10. Institutional structures should be established to provide the traditional 
communities with an opportunity to partake of the benefits arising out of 
the biological diversity and/or associated knowledge. The need for an 
institutional structure arises from the fact that the use of contracts for the 
sharing of benefits suffers at least two limitations which need to be taken 
into consideration. In the first place, they are voluntary agreements 
between the parties concerned. Given their nature, contracts cannot 
be relied upon as a way of realizing the objectives of the CBD. The second 
and the more important limitation of contracts is that it would prevent fair 
and equitable sharing of benefits which may arise when the parties 
involved are of vastly unequal bargaining strengths, as usually large 
companies having significant market power and the traditional 
communities, are at the fringe of the market system. 
11. If bio-piracy has to stop, then the U.S. patent laws must change, and 
Article 102 must be redrafted to recognise prior art of other countries. 
This is especially important given that the U.S. patent laws have been 
globalizing through the TRIPS agreement of the WTO. Article 102 lays 
down that "A person shall be entitled to a patent unless: 
A. The invention was known or used by others in this country or patented 
or described in a publication in this or a foreign country before the 
invention thereof by the applicant for patent: OR 
B. The invention was patented or described in a trade publication in this 
or a foreign country or in public use or on sale in this country more 
than one year prior to the date of the application for patent in the 
United States. " 
Thus, use in a foreign country does not constitute 'prior art' in U.S. patent 
law. This is the basis of bio-piracy of traditional Indian knowledge systems, 
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and indigenous uses of biological resources being patented. The U.S. style patent 
laws can only pirate indigenous knowledge. They cannot recognize or protect it. 
The issue of providing legal protection on TK in line with the existing 
IPR regime is a complex one because of the very nature and clustered 
pattern of distribution of TK held within and between various communities 
across the world. Positive and defensive protection measures along with 
development of sui- generis laws may perhaps be the best and immediate options 
for countries like India to provide intellectual property rights to TK holders. 
Thus, it can aptly be said that unless India, acquires the R&D along with 
industrial capabilities in order to use its knowledge base after giving due share to 
the custodians of these knowledge, the nation will not be in a position to take 
the advantage of the new patent system. This makes a strong case for a sui 
generis law in India to recognize and protect the interest of the custodians of 
TK. If the TRIPS Agreement is designed to promote industrial growth 
based on the western technological development, the sui-generis legislation 
must be one to protect and promote traditional knowledge for the revival and 
growth of the village industries in India for the economic prosperity of the down 
trodden lots of these villages. It is this legislative vacuum and the technological 
and industrial backwardness in India that are responsible for the transfer of the 
traditional knowledge to scientific community in the developed nations to reap 
the new fortunes without any obligations to the custodians of TK. This is in 
clear violation of the basic human rights-cultural, social and economic -of these 
people. As India leapfrogs into this new century of knowledge based industry 
and growth, its growth and development may not be determined only by its 
strategies of generation of new knowledge and innovation but also by the 
protection and exploitation of existing traditional knowledge and intellectual 
property. Thus, in India there exists an urgent need to both protect and utilize the 
existing traditional knowledge. 
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To mitigate the problem of protecting traditional knowledge, the 
Government of India has taken steps to create a Traditional Knowledge Digital 
Library (TKDL) on traditional medicinal plants and systems, which will also 
lead to a Traditional Knowledge Resources Classification (TKRC).Though 
linking this to an internationally accepted International Patent Classification 
(IPC) System will mean building a bridge between the knowledge contained in 
an old Sanskrit shloka and the computer screen of a patent examiner in 
Washington. Even then the traditional knowledge existing in this vast population 
of India needs more attention to protect not only the medicinal knowledge but 
every aspect of the traditional knowledge. Hopefully this will eliminate the 
problem of the grant of wrong patents since the examiner, all over the world 
wilt be aware of the Indian rights to that knowledge. There is an urgent need 
for a timely legislafion so that Traditional Knowledge in India may be protected 
without wasting any more time because delay can cause big national loss. The 
researcher therefore proposes the model law to be adopted in our country. 
For the suggestions to be meaningfiil it has to be implemented to serve the 
interests of different groups. The government should do a great service by 
amending or enacting a new and appropriate legislation on the lines suggested by 
the researcher. It is submitted that the universifies. Bio-technological institutions 
lawyers, and academicians can debate over the suggested action plan and 
remedies and help in benefiting the community and T.K. holders. 
Lastly our submission is that India needs to protect the Traditional 
Knowledge by enacting suitable legislation on the line of African Model or it 
must be sui-generic in character as Traditional Knowledge has different 
characters. 
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INTRODUCTION 
Statement of Problem 
God has bestowed man with the unique quality of thinking and intellect 
distinguishing him from all other creatures made by God. Man has utilized his 
intellectual mind for his own benefits as well as benefits at all society at large 
intellectual property is one such outcome of the exercise of intellectual faculty 
by human beings and it is because of his unique faculty from individual to 
individual which has been accepted from personal property of the individual 
exercising his intellectual faculty for a particular purpose which needs 
protection by law. 
The grant of IPR and their proper enforcement facilitated fair trade and 
access of consumers to quality products while ensuring the safety to human and 
animals, product's price shelf life and degradation etc. The new technology 
developments, particularly in biotechnology, demonstrate the significance and 
usefulness of traditional knowledge for development of new products of 
commercial importance. Research and creativity originating from research 
institutions in the field of science and technology like institutions of 
technology, university and industrial Houses engaged in R&D activities. 
The fast technological metamorphosis and globalization require constant 
exploration of emerging issues in IPR. The WIPO Agenda on the Global 
Intellectual Property issue aims at enhancing of the coterminous, proximate and 
reciprocal relationships between intellectual property and traditional 
knowledge, bio-technology and biological diversity and collateral aspects of 
economic, social, cultural and technological development. The overall 
objective of the Global Intellectual Property Issue Division (Global Issues 
Division-GID) is promoted the constant viability, enhanced efficiency and 
broader coverage of the intellectual property system. In a world increasingly 
epitomized as the "global information society", the rapid emergence of modem 
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information technologies, an increasing awareness about traditional knowledge 
and its spiritual, cultural and economic values have become central to human 
discourse. 
. Traditional knowledge (TK) is a collectively owned property and is 
integral to the cultural or spiritual identity of the social group in which it 
operates and is preserved. Traditional Knowledge is now at the centre of the 
discussions on intellectual property rights and has assumed immense 
significance. India does not have any specific legislation for protecting 
traditional knowledge. But the Patents Act, Plant Variety Protection and 
Farmers Rights Act, Biological Diversity Act, 2002 and Geographical 
Indication of Goods (Registration and Protection) Act, 1999 have provisions 
that can be utilized for protecting traditional knowledge. The concept of 
benefit-sharing, which is an integral part of protecting traditional knowledge, 
has been analysed in detail with specific reference to the Biological Diversity 
Act and also the Plant Variety Protection and Farmers Rights Act. The case 
study of Jeevani drug gives an insight into the concept of benefit sharing. The 
importance of traditional knowledge is highlighted in the revocation of patent 
granted to derivatives of neem on the ground that they were part of the 
traditional knowledge of our country and that fungicide qualities of the neem 
tree and its use had been known in India for over 2,000 years. A discussion of 
the patent granted to turmeric that was effectively challenged by the CSIR 
based on the ancient Sanskrit text also figures in the paper. Along with this, a 
case study of Basmati has also been done. The thesis also focuses on the 
international initiatives at protecting traditional knowledge including the 
Convention on Biological Diversity, International Undertaking on Plant 
Genetic Resources for Food and Agriculture and the Agreement on Trade 
Related Aspects of Intellectual Property Rights. But there are no uniform 
norms regarding the protection of different types of traditional knowledge 
owned by local communities. The reason for this divergence of laws is that the 
international community never had an occasion to look at the protection of 
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traditional knowledge in its entirety. Measures to ensure that traditional 
knowledge is protected should be taken at the auspices of the World Trade 
Organization which should lay down general mandatory provisions to be 
complied by member countries. 
The pressing need of the hour is to enact a sui generis, or alternative law 
to protect traditional knowledge. The history of patent reform in India started 
from 17'*' century. The Government of India has offered its citizens of the 
country an opportunity to protect their intellectual property for almost 150 
years. In 1856 the first IPR legislation was enacted in British India, to grant 
certain privileges. This Act was modified in 1859 in which patent monopolies 
were granted known as exclusive privileges. Again a comprehensive law was 
enacted by the British rulers in 1911 replacing the earlier Act of 1859. This was 
known as Patent and Designs Act, 1911. 
This Act was designed to serve the foreign interest and for control over 
markets for finished goods by multinational corporations. In case of 
pharmaceuticals almost 85 percent were supplied by the multinationals 
Kefauver Committee of USA showed in its report that the prices of antibiotics 
and other medicines in India were highest in the world. Soon after the 
independence, two committees were appointed in 1949 and 1959 presided by 
Justice Bakshi Tek Chand and Justice Rajgopala Ayyangar. For further 23 
years various commentators and commissioners debated the propriety of such a 
law to India's economic needs Based on the recommendations of these two 
prominent Committee reports a bill was framed which ultimately came in the 
shape of The Patents Act, 1970. The Patent law has gone through the several 
reforms in itself 
With the enactment of the Act, Indian companies, specifically the 
pharmaceutical sector grew with a sharp pace and their market share and 
availability of drugs went up to 85 percent. Along with this the prices of 
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medicines became the lowest in the world. The major provisions which were 
enacted and implemented in the Act of 1970 specially in favour of 
pharmaceutical sector were the process patent regime (industrial sector was 
covered by process patent only) there was no product patent for food, chemical 
and pharma products the term of patent was 7 years from the date of 
application or 5 year from the date of sealing of patent whichever was lower 
though in other areas terms of patent was fixed for 14 years. A provision of 
licence of right was introduced for the pharmaceutical sector. There were no 
constraints on exports. The Introduction of Drug Price Control order along with 
the implementation of the new Act of 1970 showed the sudden differences in 
the prices of drugs in the country. The process of reverse engineering became a 
major factor for the availability of cheap drugs and medicines in the 
pharmaceutical sector. 
With the advent of Trade Related Aspect of Intellectual Property 
(TRIPS) Agreement in the international scenario, all the countries signatory of 
WTO and TRIPS Agreement, become bound to mandate certain drastic 
changes in the patent systems through out the world. Under the TRIPS 
Agreement it is the obligation of the member countries where their patent laws 
are not consistent with the TRIPS provisions of the agreement, to take steps to 
modify their legislation to make them consistent. The TRIPS Agreement 
provide a period of 5 years from 1995 for developing countries to implement 
the TRIPS provisions further it also provide a additional period of 5 years to 
developing countries like India to comply with the TRIPs Agreement. 
The major change which needed to be introduced in the patent law was 
the product patent regime. India had a long transition phase which ended on 
January 1, 2005. During this transition phase the product patent applications 
could be filed from 1 Jan 1995 and kept in the 'mail box' which were to be 
taken out after the completion of the transition phase on I Jan 2005 certain 
Exclusive Marketing Rights (EMRs) were also granted for 5 years by India 
Intfoduetion 
before the patent on product was either granted or rejected in India. These 
changes were introduced in the patent law by the first amendment Act in 1999. 
In addition it had for compulsory licensing' and mailbox facility^ for 
pharmaceuticals and agro chemicals. 
In 2002 the Parliament passed the second Amendment Act considered as 
Patent (Amendment) Act, 2002. This Act make the Indian patent law not only 
TRIPs compliant but also incorporate safeguards for protection of public 
interest, national security, biodiversity, traditional knowledge etc. Important 
changes included in the amended Act were definition of invention has been 
\modified; uniform term of patent protection extended to 20 years for all 
categories of invention and changes in compulsory licencing provision, a 
provision for hearing of appeal use of invention by the central government was 
also incorporated. India's traditional knowledge is also added as non patentable 
by this amendment. 
The gaps which were still remain after the amendment of 2002 required 
to be filled by another amendment in 2005. But the main objective behind the 
introduction and passing the Patent (Amendment) Act, 2005 was to meet 
India's deadlines 31 December 2004 to comply with the TRIPs Agreement. 
This amendment introduced product patent regime in new Patent Act. The 
Patent (Amendment) Act, 2005 was the out come of TRIPs Agreement and 
Doha Declaration. 
For public health proponents TRIPs enhanced the interests of 
transnational pharmaceutical companies and industrializes countries with large 
pharmaceutical industries especially the US, Japan and European Union at the 
express of access to affordable medicines by millions in genuine need. Concern 
for public health protection led to the Doha Declaration in 2001 and followed 
1. The Patents (Amendment) Act, 1999 Sec. 24C and 24D 
2. M, Sec. 5(2). 
Introduction 
by the implementation of paragraph 6 Decision 2003. This was the point of 
time when public needs protection takes primacy over trade. 
The new patent law addresses three sets of issues that could have 
immediate impact y?r5/ is the adoption of a new definition for "pharmaceutical 
substances," which should be a new entity involving one or more inventive 
steps. Second is the exclusion of mere discovery of a new form of a known 
substance and new use for a known substance from the ambit of patenting 
which could prevent grant of patents on formulations. And the third one is to 
protecting the interests of producers who are already producing the production 
that may be granted patent protection in new regime. 
Provisions related to compulsory licence are another important feature 
of the Amended Patent Act, 2005. This is meant to facilitate the Indian industry 
to drugs to those Least Developed Countries (LDCs) that do not have adequate 
domestic manufacturing capabilities. After the amendment there was insertion 
of the additional provision for pre-grant opposition along with the provision for 
filing post -grant apposition. In recent time pre-grant opposition has been filed 
by Indian pharma companies. The most highlight case related to pre-grant 
opposition is Gleevec case. 
An insight to India pharmaceutical industry tells the position of IPI. It 
rank 4 in terms of volume and 13 in terms of value. Indian firms produce 
approximately 1.5% of the global pharmaceufical market of $ 480 billion. The 
Indian pharmaceutical industry meets around 70% of the country's demand. IPI 
provides direct employment to 5, 00,000 people. And indirect employment to 
approximately 24, 00,000 people. 
"The Indian pharmaceutical industry is a success story providing 
employments for millions and ensuring that essential drugs at affordable prices 
are available to the vast population of this subcontinent." Said Richard 
Grester. 
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India is emerging favoured destination for level of expenditure on R & 
D is about 5% of turnovers, which is much lower compared to most of the 
developed countries which is 15 to 20%. Some of the leading firms who take 
the initiative in the investment in R & D are Dr. Reddy's and Ranbaxy. 
FDI confidence survey, 2004 at Kearney has rated India as the 3'^ '^  most 
th attracting investment destination (Behind China and USA) compared with 15 
position two years ago and 6"' last year. FDI in pharmaceutical sector in India 
has a direct relation with strong patent regime. Before the product patent 
regime the IPI rise by the process of reverse engineering with the advent of 
product patent regime there is an increase in FDI inflow in pharmaceutical 
sector. In 2004 there was a sharp increase in FDI, it declined in 2005 but again 
it increases in 2006. 
Today contract research contract manufacturing formation alliances in 
research & development between the Indian and foreign pharmaceutical 
companies have strengthened the prospects of the Indian pharmaceutical sector 
in post Jan, 01.2005 regime. The Indian pharmaceutical companies' mergers 
and acquisitions of foreign companies is another evidence of its rise of Indian 
Pharmaceutical Industry. 
The Indian traditional medicines also have a significant presence in the 
Indian Pharmaceutical Industry. The Indian system of medicine was prevalent 
about 1500 years over Southeast Asia. It comprises of 3 major systems namely 
Ayurveda, Siddha and Unani this traditional medicines now comes under the 
Indian system of Medicine. In 1995 to boost the growth of traditional 
medicines The Department of Indian system of Medicine and Homeopathy 
(now has been known as AYUSH) was established by the Ministry of Health & 
Family welfare. 
The immense biotech wealth of India has approximately 7000 species 
reportedly used for the medicinal purposes, mostly for the extraction of rare 
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drugs Utilization extent shows that there are about over 0.36 miUions Ayurveda 
practitioners, 29.7 thousand Unani and 11.6 thousand Siddha speciaHsts in 
India. Village based health traditions are still carried on by housewives birth 
attendants and vaid-hakems (herbal healers), making it 70% of the health care 
need so India which is dependent on the medicinal plants. The global market of 
herbal medicines was estimated at $ 16.5 billion in 1997, which rose to $ 22 
billion in 2000. 
The Patents Act of 1970 did not talk about the protection of Indian 
traditional knowledge. It was after 2002 when the Patent Act kept the 
traditional knowledge out of the ambit of patentable invention and considered it 
as non patentable.^ Basically the traditional knowledge relates to traditional 
medicinal knowledge. Through ages knowledge about use of medicinal plants 
and herbs exist in the form of local folklore available with families, tribes and 
cultures, handed down from generation to generation. 
It is said, 'knowledge is valuable only, when shared' but when this 
concept of sharing start causing threat to the vary knowledge and its holder 
then the need arises for the protection of traditional knowledge this threat may 
be by the way of exploiting the knowledge and claiming monopoly right over 
such knowledge. This threat has been created by the western world. 
There are many aspects of traditional knowledge but here it deals only 
with the protection of knowledge of farming community concerning wild as 
well as domesticated varieties and the knowledge of heaters concerning 
medicinal properties of plants. The World Health Organization has stated 80% 
of the world's population depends on traditional medicine for its primary 
health care. 
Many tribal and social communities survive on the bases of their 
traditional knowledge. The products they use and manufacture is a part of their 
3. The Patents (Amendment) Act, 2002 Sec. 3 (p). 
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livelihood. Even today in Asian countries many indigenous communities fulfill 
their basic needs from products of their traditional knowledge plant extracts 
and several herbs of medicinal properties are the source of their medication. 
With the development of science and technology the traditional 
knowledge is drawing global attention.The modem manufacturing industries 
(textile, handicrafts, pharmaceutical, seed etc) commercially exploit the 
traditional knowledge using new technology without the permission and 
sharing of profits with the communities. 
There are about 7000 species of medicinal plants and over 15,000 
medicines are based on herbal formulations in different system, growing 
attention to the Ayurvedic and Unani medicines because of the side effects of 
allopathic making the traditional medicinal system popular not only in India 
but also at global level. Protection of traditional knowledge is the need of hour, 
to avoid the misappropriation and exploitation. Traditional knowledge needs 
protection to improve the livelihoods of TK holders, benefits to national 
economy, conservation of environment and prevention of biopiracy. 
Certain national and international efforts have been taken for the 
protection of traditional knowledge. The World Trade Organization has taken 
some steps to protect the traditional knowledge at the international level. The 
TRIPs Agreement also does not much recognize the importance of traditional 
knowledge. Though there has been a constant demand to review the Article 
27.3(b) and also a review of the whole agreement. TRIPS agreement in 
reference to protection of traditional knowledge only required the member 
countries to protect the plant varieties. By a 'sui-generis system' the sui-
generis system would recognize the traditional knowledge relating to genetic 
resources and promote access and benefit sharing. 
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The Convention on Biological Diversity has recognized the rights of the 
indigenous people over the genetic resources. Article 1 and 8(j) of the 
Conventions deals with equitable benefit sharing that arise out of the use of 
traditional knowledge. 
Art 8(j) said, state parties are required to "respect preserve and maintain 
knowledge innovations and practices of indigenous and local communities 
embodying traditional lifestyles relevant for the conservation and sustainable 
use of biological diversity and promote the wider application with the approval 
and involvement of the holders of such knowledge innovations and practices 
and encourage the equitable sharing of the benefits arising from the utilization 
of such knowledge innovation and practices ". "^  
CBD says that a prior informed consent is required from the local 
community, for the utilization of the biological resource. But the consent is not 
required if the knowledge is already in the public domain. Example of 
Arogyapacha of Kani Tribes is a landmark in case of access benefit sharing and 
prior informed consent. 50% of the gains from Arogyapacha were given to the 
Kani Tribe and a 2% of royalty from the sate of the drug also given. 
World Intellectual Property Organization (WIPO) began its work on TK in 
1978. WIPO has brought traditional knowledge and intellectual property rights 
under Intergovernmental Committee on Genetic Resources, Traditional 
Knowledge and Folklore constituted in 2000. 
In its various works committee considered a study prepared by WIPO on 
disclosure requirement in patent law that were relevant to traditional 
knowledge or genetic resources used in course of developing a claimed 
invention. 
4. Convention on Biological Diversity 1992 Rio.De-Jenario 
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Agenda 21, International Labour organization (ILO, United Nations, 
Draft Declaration on the Rights of the Indigenous people, United Nations Food 
and Agriculture Organization (FAO), United Nations Development Programme 
(UNDP) and the IBRD or the world Bank, and United Nations Conference on 
trade and development (UNCTAD) all these organizations have taken various 
initiatives to talk about the protection of traditional knowledge as well as the 
rights of the TK holders. 
Though, India does not have a specific sui-generis /egislation to protect 
traditional knowledge and folklore. National initiatives taken by the 
Government of India are in the form of statutes passed. Important among the 
passed statutes is the Biological Diversity Act, 2002. This legislation provides 
for conservation of biological diversity sustainable use of its components and 
fair and equitable sharing of the benefits arising out of the use of biological 
resources. Under the Act, National Biodiversity Authority (NBA) keeps check 
on the appropriation of biological resources. 
The Protection of Plant Varieties and Farmers' Rights Act, 2001 is 
another legal instrument which acknowledges the concept of effective benefit 
sharing. Mandatory disclosure of geographical location from where the genetic 
material has been taken and information relating to the contribution of farming 
community evolved is required. 
The Geographical Indications of Goods (Registration and Protection) 
Act, 1999 is another step taken by India for the protection of traditional 
knowledge. Along with this Patents (Amendment) Act, 2002 introduced certain 
provisions for mandatory disclosure of source and geographical origin of the 
biological material used in the invention of a product while applying for patents 
in India. If there is no disclosure or wrong disclosure of such source the patent 
application will be rejected and if the patent has already been granted same 
11 
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will be revoked. The Copy right Act, 1957, The Design Act, 2000 and the 
Trade marks Act, 1999 also at some extent protect the traditional knowledge. 
Patentability of plant breeding got recognition from the decision of 
German Court in Diamand v Chakraborty after the formation of WTO in mid 
1990 all WTO member countries were committed through TRIPS agreement to 
promote effective protection of intellectual property right in all fields of 
technology. The TRIPS Agreement requires that its members shall provide for 
the protection of plant varieties either by patenting or by an effective sui-
generis system. 
The enacted Act of plant varieties protection primarily extends to protect 
the rights of the farmers while at the same time protecting the rights of plant 
breeders contribution of the farmers in conserving, improving and making 
available the plant genetic resource for the development of new plant varieties 
is also protected by the Act which is reciprocal to the protection of traditional 
knowledge. 
The Protection of Plant Varieties Act, 2001 provides adequate protection 
to the traditional knowledge of the farmers by recognizing their role as 
cultivator and conserver. Farmers do not breed in ideal laboratory conditions 
but on actual knowledge of the environmental conditions through national 
selection and continuous evolving process. Indian farmer's house evolved 
many varieties that are resistant to salt, flood, drought etc. if the breeders who 
develop a new variety from the existing genetic resources, have a right of 
develop the new variety, the farmers also have a right of identifying, 
conserving and developing the traditional variety. It is the farmer who has 
safeguarded the tremendous biodiversity that breeders and seed industry use as 
a raw material."^ 
5. Elizabeth Verkey, Law of Plant varieties Protection ,p . 146 (2007) 
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So the farmers and breeders have also been covered under the Plant 
Variety Protection Act, 2001 by considering the fact that protecting the farmers 
and breeder's right is protecting the Indian traditional knowledge. 
Biopiracy refers to the appropriation, generally by means of patents, of 
legal rights over indigenous knowledge especially traditional biomedical 
knowledge without compensation to the indigenous groups who originally 
developed such knowledge. In recent years there has been increasing number of 
reported cases of misappropriation & commercial exploitation of TK under 
patents and other IPRs. In many cases claims in the patents on plants and their 
genetic resources are not fundamentally different from the practices applied by 
the traditional communities in the utilization of these plants as food, cosmetics 
or traditional medicines. Though some of these cases of misappropriation have 
been successfully challenged but other still remain to be challenged. This raises 
the legal protection of traditional knowledge. Important cases among them are 
of Turmeric, Neem, Basmati rice etc. at national level and at internationally 
Hoodia cactus case is the prominent one. 
Thus the present study aims to throw light on the existing product patent 
system to accord legal protection to traditional knowledge and it also highlights 
the need to have a sue-generis protection for the traditional knowledge, so that 
the intellectual as well as customary rights of traditional Holders can be 
respected, recognized and rewarded. 
Review of Literature 
The present study required in depth of study and understanding of patent 
system, TRIPS Agreement, DOHA Declaration, position of Indian 
pharmaceutical sector and issue of "access to medicines" thereby, help from 
many books, journals, articles, websites have been taken besides the bare act of 
Patent Act, 1970. The prominent among them were: 
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Kotwal/Banarjee's Biodiversity Conservation in managed and 
Forests and Protected Areas.(1998) In the recent years, the concern of the 
Government towards the conversation of biodiversity has grown considerably. 
In a bid to contributing towards to cause of biodiversity conservation, the 
Indian Institute of Forest Management organized a National Workshop titled 
"Biodiversity Conservation in managed and Forests and Protected Areas" from 
November 29 to December 01, 1995 in which a number of variant issues 
related to the subject. This book is an outcome of the selected papers 
contributed by many authors. 
Justin Malbon and Charles Lawson's Interpreting and 
Implementing the TRIPS Agreement, Is it fair. (2008)? This edited 
collection enjoins the global intellectual property debate by offering a range of 
perspective about how the World Trade Organization's Agreement on Trade-
Related Aspects of Intellectual Property Rights (TRIPS) is and should be 
interpreted and implemented. 
P.C. Trivedi's Medicinal Plants: Traditional Knowledge. (2007) This 
book is a well documented and comprehensive review of significant 
investigation on traditional medicinal plants which covers holistic information 
on medicinal plants, their uses, ethno-botanical importance, commercial 
potential and standardization of herbal formulations etc, with special reference 
to India. An article on some sacred trees and their medicinal uses has added 
value to the book. 
Elezabelth Verkey. The law of Plant Varieties Protection (2007). The 
author trace out the historical aspect of plant varieties protection. He has 
discussed the protection given to plant verities in Europe and the sui generis 
protection given in India the author also gone. 
Dr. M.K Bhandari's Law Relating to Intellectual Property 
Rights.(2006) The book is an outcome of intense study made by the author, 
14 
Introduction 
long teaching and research experience of the subject and continuous 
participation and interaction of author with several legal scholars, lawyers, 
scientists, entrepreneur who are one way or other concerned with the 
intellectual property system. All possible efforts have been made to give 
comprehensive coverage to the various aspects of the intellectual property 
system and include all latest amendments and case law developed by High 
Courts, Supreme Court and even the newly established Intellectual Property 
Appellate Board (IPAB). 
C.B. Raju, intellectual Property Rights (2007). This book is an 
assemblage of 20 research articles of eminent scholars in India having rich 
teaching experience. These articles focus on law relating to intellectual 
property rights such as copyright, patent, trademarks, industrial designs, 
geographical indications etc. some articles in this books have been discussed in 
the light of new economic policy and intellectual property regime. Some 
articles such as product patent Regime: Challenges and opportunities, 
protection of Traditional Knowledge a case for concern has been specifically 
gone through by the researcher. 
Ramesh Chandra, Issues of intellectual Property Rights (2007). 
Protection of intellectual property has always been a different task as it is not a 
thing that can be kept in a close of protection the author of this book has 
examine the intellectual property rights and its use in the society. The author 
also covered the aspect of technology, information infrastructure and digital 
dilemma dimensions of intellectual property inventions, which has discussed in 
details. 
Philippe Gullet's Intellectual Property Protection and Sustainable 
Development.(2005) This book analyses certain recent developments in the 
field of intellectual property protection. More specifically two main lines of 
enquiry are pursued. Firstly this book examines the rapidly evolving 
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international legal and institutional framework for intellectual property rights 
and for sustainable development. Secondly it examines some of the challenges 
that have surfaced in India as the country has grappled with the need to 
implement its international commitments through the adoption of new 
legislative instruments and major amendments to existing legislation, in 
particular of the Patents Act 1970. 
W.R Cornish's Intellectual Property: Patents, Copyright, Trade 
Marks and Allied Rights; (2000). The look is valuable in understanding 
patent system. It highlights the characteristics of patent and holds it to be a 
system deep rooted in capitalist society. 
Dr. P. Narayanan; Intellectual Property Law; 2006. The strength of 
the book lies in the discussion of Indian Patent System in simplified way. This 
book is must for first hand knowledge of the patent system. 
Keith E Masker's; The WTO Intellectual Property Rights and the 
Knowledge Economy (2004) is a collection of various articles helping in 
understanding social costs and benefits of introducing patent protection for 
pharmaceutical drugs in developing countries. In one of its articles "Do 
stronger patents induce more innovations? (By Mariko Sakakileara and 
Lee Bransteter) and by giving evidence from the 1988 Japanese patent law 
reform and concludes that no evidence of an increase in innovative effort or 
innovative output that could be plausibly attributed to patent reform. 
Luis Mariano Genovesi's Compulsory Licenses after Doha 
Declaration on the TRIPS Agreement and Public Health (2005). The article 
analyses the interpretation of TRIPS Agreement under the Doha Declaration 
and suggest caution measures to be adopted by the developing/least developed 
countries so as to make optimum advantages of the loopholes provided in 
TRIPS Agreement [Article 7, 8, 30, 31 etc.] 
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Biswajit Dhar's Post 2005 TRIPS Scenario in patent protection in 
the pharmaceutical sector: The case of the generic pharmaceutical 
industry in India at http;//www.iprpatents.html. The writer has thrown Hght 
on the development of Indian Pharmaceutical sector [in tabulation form] and 
critically analyzed the TRIPS Agreement compliant patent amendment Acts. 
Ronald D. Kayanja's Anti Retroviral Drugs for All? Obstacles to 
Access to HIV/AIDS Treatment at http://www.panosaids.org. The article is 
study of 5 countries (Ethiopia, Haiti, India, Nepal, Zambia) And makes 
research of the experience and needs of people living with HIV/AIDS. It gives 
knowledge of broad challenges before the accessibility of HIV/AIDS drugs and 
possible cures. 
D.K NauriyaPs TRIPS- compliant New Patents Act and Indian 
Pharmaceutical sector: Directions in strategy and R & D published in 
Indian Journal of Economics and Business, Special Issue China and India 
(2006) at http;//www.findarticles.com. It talks of possible strategies [compete 
and CO operate strategy, contract research and manufacturing and the formation 
of alliances] that can be adopted by Indian Pharmaceutical sector to continue its 
magnificent growths under TRIPS scenario. 
Laura Bloodgood's Competitive conditions for Foreign Direct 
Investment in India July 2007 at http://www.google.com. This article is of 
great help when it comes to pharmaceutical FDI in India. It analyses the growth 
of patent law and its impact on the FDI in pharmaceutical sector. Through its 
many figures it argues that only post 1999 reforms by product patents there has 
been advent of pharmaceutical FDI in India. 
Prof. Saleem Akhtar's New Patent Regime and Human Rights: 
Effects on health care and Pharmaceutical Industry [Indian Journal of 
Politics July-Sep 2005] makes critical analysis, new patent regime on an 
individual's fundamental right to life. Through comparative analyses of India 
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(Pre 2005) and Pakistan, it brings out the differences in the prices of medicines 
in the process and product patent regime and thereby denial of accessibility to 
medicines. 
India is Considered to be a 'Next Wave' Country for HIV/AIDS" at 
http;//www.expresspharmaonline.com. It is conversation between Arsliya 
Khan (journalist) and T.Vijay Kumar (Senior Manager-Export Formulations, 
Aurobindo Pharma) regarding the ARV market in India. It helps in having a 
quick look of growth, characteristics, opportunities for ARV market and 
speculations rose by WHO on the quality of drugs in India and see the hand of 
powerful western drug manufacturers in the WHO speculation. 
K.P.S Mahalwar & Vishal Mahalwar's Protection of Traditional 
Knowledge and Intellectual Property Rights: India <& International 
Perspectives. This article is of great help to understand the concept of 
protection of traditional knowledge need for the protection of TK the author 
trace out the areas of IPR where the TK has been protected. Along with this a 
study has been done on the efforts and initializes taken at national as well as 
international level for the protection of traditional knowledge. 
Saleem Akhtar's, New Patent Regimes: Protection of Indian's 
Heritage: In this article author has pointed out the effect of new patent regime 
in the protection of Indian's Traditional Heritage. Traditional Knowledge 
generally refers to the knowledge related to medicines. The author has made a 
competitive study of five countries and its cost structure of the drugs in patent 
protected regime and non patent protected regime. The author also analyzed the 
fundamental requirements of a patent grant. India is a big source of traditional 
knowledge neem, tulsi turmeric are in everyday use of an Indian theft of 
Indian's traditional knowledge has been challenged and has always been won 
the author has also borough out the trends in patents for herbal products from 
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1990 to 1999. In last author has suggested planning a national strategy to 
counter biopiracy. 
Dr. Sreenivasulu N.S. and Subha Malhai's, Sui Generis system for 
the Protection of Plant Varieties and Farmers' Rights in India. This article 
emphasizes on the IPR protection given to plant varieties and farmers' rights. 
Author throws light on the provisions for the protection of plant varieties under 
Indian sui generis system for the protection of plant verities. Term of 
Protection, rights and privileges and compulsory licensing infringement of 
rights conferred and relief provided for that & infringement has also been 
discoursed the author also examine the administration in case of protection of 
plant varieties. 
R.M. Dungawat's, Protection of Traditional Knowledge, National 
and International Perspectives. Author focus on why traditional knowledge is 
needed to be protected. Protection of TK at International level and national 
level has been given a detailed study Asia Traditional Medicine Network at 
International at floor and at national floor it has been categorized as 
Governmental efforts and non-governmental efforts and legislative initiatives. 
Article is concluded with the proposed bill the Indian 2000 drafted by N.S. 
Gopala Krishnan. 
Mayank Kumar's, Parallel Imports in the Pharmaceutical sector: 
Benefits for Developing and least Developed the author has analyzed the legal 
statues of parallel imports in the pharmaceutical sector in developing and least 
developed countries in the light of TRIPS and Doha trade round the author 
deliberates its impact on price of pharmaceuticals and benefits/drawbacks 
associated with it. In addition to this the article also highlights potential policy 
considerations on the same issue. 
Shashi Sharma,s, New Patent Regime in India Challenges and 
Future of the Pharmaceutical Industry. This article reflect the intense views 
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of the author regarding the challenges going to be face by the Indian 
pharmaceutical industry and future of Indian pharmaceutical industry in new 
patent regime. Author has divided the article in four parts. First, dealing with 
an overview of Indian pharmaceutical industry and its progress by moving 
towards adopting to emerging new business models such as contract research 
contract manufacturing and to marketing alliances second part deals with new 
patent regime in Indian mentioning the background of patent Regime in India 
to the newly amended patent law considered as TRIPS Compliant further the 
author discuss the challenges for Indian pharmaceutical industry mentioning 
the Novartis case Yoga, generic pharmaceutical manufacturing prices of drugs 
and access to medicines for the poor. Because of cheap manufacturing 
capabilities in China, Indian pharmaceutical industry is expected to face 
challenge from china pharmaceutical industry. Discussing the business avenues 
the author also draws attention to traditional knowledge aspect and measures to 
protect it. 
N. Lalitha's, Doha Declaration and Public Health issues this article 
brings out the flexibilities given by the Doha Declaration which are 
directly related to the public health issues. Author pinpointed the option of 
compulsory licensing clause which eases the access of necessary medicines. 
The Doha Declaration provides for access to medicines particularly by 
simplifying the compulsory licensing clause. The amendments carried out by 
the Indian government also facilitate production of generic versions of patented 
drugs that would facilitate exports under the CL option as well. The author says 
that however in order to facilitate the options available in the Doha 
Declaration, countries will have to incorporate the necessary changes in their 
national laws. 
Varressa Brad ford Kerry and Kelley lee's, TRIPS, the Doha 
Declaration and Paragraph 6 Decision, What are the Remaining Steps for 
Providing Access to Medicines? The author begins this article by briefly, 
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reviewing progress to date on the public health protections available under the 
TRIPS agreement. It describes how, despite these important clarification, there 
remain concerns about the capacity of LMICS to implement specific measures. 
The article consider the further threat posed by TRIPS plus measures and calls 
for their critical assessment. Central to debate about implementation and 
TRIPS plus is an understanding of fundamental unbalances in power and 
influence, both within and across countries, defining what interest can 
influence trade policy decisions. The author concludes by reviewing potential 
ways forward to ensure that access to medicines by the poor is secured within 
all trade agreements. 
Gopakuman G Nair, Impact of TRIPS on Indian Pharmaceutical 
Industry. In this article author has discussed the significance of the new IP 
regime on pharmaceutical industry in India, the amendment to the patents Act, 
1970 making it TRIPS compliant. Along with this related developments in 
other fields of IP as well as enforcement of new patent regime on 
pharmaceutical industry are compressively discussed. The author also gives a 
brief description of regulatory interfaces of patents in the Indian and 
international context. The key elements of the TIPRS agreement which led to 
the three consecutive amendments to the patents Act 1970 has been 
highlighted. The author examines the significance of the patent amendments in 
1999, 2002, 2005 and as well as need for such amendments in fulfillment of 
TRIPS obligations. The author finally study the impact of post TRIPS scenario 
in Indian pharmaceutical industry with special reference to the international 
operations and the regulatory interfaces, the related fields like biodiversity and 
plant varieties has also been touched by the author. 
N.S. Gopala Krishnan's, TIPRS Agreement and Public Health An 
Overview of International Issues. The author in this article deals with brief 
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overview of the developments of international provisions on IPR related to 
public health. Here he also discuses the flexibilities before and after TRIPS 
agreement and difficulties faced by developing countries in implementing 
TRIPS obligations and protecting public health. The author also examine the 
reasons for the Doha Declaration and issues relating to implementation of para 
6 of the Declaration. He also discusses the inadequacy in the compulsory 
licence based approach to solve public health arises and argues for a more 
comprehensive approach to find a long term solution to the public health 
issues. 
Elezabelth Verkey's, The law of Plant Varieties Protection (2007). 
The author trace out the historical aspect of plant varieties protection. He has 
discussed the protection given to plant verities in Europe and the sui generis 
protection given in India. The author also gone analyzed the Plant Variety Act 
and its procedural aspect along with farmers' rights, breeder's rights and 
researcher's rights. International initiatives taken for the protection of plant 
varieties has also been discussed. 
Sajeev Chandran, Archanan Roy, Lokesh Jain, Implications of New 
Patent Regime on Indian Pharmaceutical Industry Challenges and 
Opportunities. This paper gives on overview of pharmaceutical industry in 
India and the likely impact of product patent regime on it. It also review the 
existing patent and drug control laws in Indian and how they affected the 
growth and structure of pharmaceutical industry in the country. Author also 
discussed the strategies to meet the new challenges and opportunities that 
TRIPS agreement present to pharmaceutical industry in India. 
C.B. Raju, Intellectual Property Rights (2007). This book is an 
assemblage of 20 research articles of eminent scholars in India having rich 
teaching experience. These articles focus on law relating to intellectual 
property rights such as copyright, patent, trademarks, industrial designs. 
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geographical indications etc. some articles in this books have been discussed in 
the light of new economic policy and intellectual property regime. Some 
articles such as product patent Regime: Challenges and opportunities, 
protection of Traditional Knowledge a case for concern has been specifically 
gone through by the researcher. 
Ramesh Chandra, Issues of intellectual Property Rights (2007). 
Protection of intellectual property has always been a different task; as it is not a 
thing that can be kept in a closet of protection the author of this book has 
examine the intellectual property rights and its use in the society. The author 
also covered the aspect of technology, information infrastructure and digital 
dilemma dimensions of intellectual property inventions, which has discussed in 
details 
Objective of the study 
1. To find out the historical aspect of patent law in India. 
2. To identify the changes occurred by the three amendments in the patent 
law. 
3. To analyze the position of Indian herbal medicine industry and factors 
affecting the growth of Indian pharmaceutical industry in new patent 
regime. 
4. To study the national and international efforts taken for the protection of 
traditional knowledge. 
5. To know the status of protection given to the Indian traditional 
knowledge. 
6. To assess the role of CBD in protecting the biodiversity and traditional 
knowledge. 
7. To examine the role of Plant Varieties Protection and Farmers' Rights 
Act, 2001 for the protection of traditional knowledge. 
8. To assess and evaluate the role of judiciary in case of biopiracy. 
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Research Methodology 
Present study is based on the doctrinal and non-doctrinal method of 
research. The research has drawn help from various books, articles, 
newspapers, journals, gazettes, reports of commission and committees and 
judicial decisions. The researcher has used both primary and secondary sources 
of data. 
Hypothesis 
There is no law for the protection of traditional knowledge but 
traditional knowledge is protected under other IPR legislation such as Patent, 
Copyrights, Trademarks, Geographical Indication, Biodiversity and Plant 
varieties and India also amended its municipal laws in consonance of TRIPS 
agreement and different international conventions, treaties and protocols. Now 
the pertinent question is that whether our traditional knowledge and indigenous 
knowledge ought to be protected under any else legislation or not? 
1. It is hypothesized that thought he TRIPS agreement under Article 27 talks 
about a sui-generis legislation and also for the protection of traditional 
knowledge but this does not specifically give any guidelines to protect the 
T.K. 
2. It is hypothesized that most of our traditional knowledge is patented by 
developed countries. On large scale our traditional knowledge has been 
patented by US, Germany and other developed countries, should we opt for 
such a strong legislation which can prevent our traditional knowledge from 
being patented by these western countries? 
3. Though India has already placed a legislation for the protection of farmers' 
as well as breeder's rights. Even than question arises what are the farmers' 
rights to be enunciated in any sui-generis legislation for the protection of 
traditional knowledge, whether this legislation would be complementary to 
the protection of traditional knowledge? 
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4. It is hypothesized that India is among one of the twelve richest mega-
biodiversity rich countries. Biopiracy is directly related to biodiversity and, 
a separate legislation has been framed to protect biodiversity of the country 
but the enactment and implementation of this law has no effective purview 
to prevent biopiracy. 
5. It is hypothesized that along with biodiversity legislation to protect the 
traditional rights of the farmers and to protect the plant varieties, protection 
varieties Act is a significant form of sui-generis legislation. 
6. It is hypothesized that India is the richest source of traditional knowledge 
not only in medicinal area but it has a rich heritage of folklore. Art, Music, 
Dance Handicrafts, and Skills etc. which needs protection through separate 
sui-generis legislation. 
7. It is hypothesized that whether proposed sui-generis legislation would be 
recognized internationally in absence of international rules and guidelines 
for such a law? 
The study is organized into five chapters. 
Chapter-I History of Patent System in India 
This chapter portraits the historical aspect of patent law in India and 
meaning, object, subject matter procedure for obtaining patent administration 
infringement of patent remedies, silent features of the three Patents Act as well 
as the role played by the patent law in the protection of traditional knowledge 
has been pointed out. 
Chapter-II Traditional Knowledge under IPR Regime 
This chapter deals with the concept of traditional knowledge, subject 
matter of TK, rationale behind the protection of TK. Current international 
development for the protection of TK, regional efforts, governmental and non 
governmental initiatives protection of TK and types of protection given under 
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IPR regime has been discussed. An analysis of Indian efforts towards 
traditional knowledge protection and existing legal framework for the 
protection are also dealt here. An action plan has also been discussed for the 
protection of traditional knowledge. 
Chapter -III Traditional Knowledge under WTO, TRIPS 
And Pharmaceutical Industry 
This chapter has been divided into two parts, one part is confined to 
traditional system of medicine and traditional herbal drugs, second part give the 
overall performance of Indian pharmaceutical industry in the product patent 
regime. Chapter deals with the concept of traditional medicinal knowledge 
present in Ayurvedic, Unani, Siddha and homeopathic system, its contribution 
in Indian pharmaceutical industry. The other half covers the impact of TRIPS 
on pharmaceutical industry, and challenges faced by the Indian pharmaceutical 
industry in the new product patent regime. Impact of the product patent on 
prices of drugs and their accessibility has been discussed. Impact on the FDI in 
pharmaceutical industry has been analyzed. 
Chapter -IV Traditional Knowledge under Protection of Plant Varieties 
And Farmers' Rights Act 
This chapter has been framed under two parts, one covers the protection 
given to plant varieties at international level specifically US and European 
countries, second part covers the national perspective. Chapter explore the 
rationale behind the protection of plant varieties, international developments 
through UPOV, CBD, Agenda 21, CGIAR, FAO, Sui-generis system and Plant 
Variety Protection, African model legislation as an example of sui-generis 
system. This chapter also deals with the Protection of Plant Varieties Act which 
discusses the object of the Act, varieties covered under the Act and Farmer's 
rights and breeder's right, rights of researchers', protection of public interest 
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and compulsory licencing, New Seeds Bill of 2004. Scheduled Tribes and 
Other Traditional Forest Dwellers (Recognition of Forest Rights) Act, 2006 are 
discussed keeping in view the initiatives taken for the protection of farmers' 
traditional rights. 
Chapter -V Traditional Knowledge under CBD and Biopiracy 
This chapter has been devoted to biopiracy and role of CBD to counter 
biopiracy. This chapter is divided into two parts. First deals with traditional 
knowledge under CBD and the biodiversity and second with biopiracy. 
Biodiversity deals with meaning and significance of bio-diversity, role of CBD 
and protecting biodiversity and along with this Indian government, has passed 
the Biodiversity Act, 2002 for the protection of biodiversity and prevention of 
bio-piracy at some extent. 
The second part deals with biopiracy, difference between biopiracy and 
bio-prospecting, biopiracy of traditional medicinal knowledge, concept of 
access and benefit sharing and prior informed consent are the areas discussed 
under this part. The relevant case study of India and International cases has also 
been included. 
Conclusion and Suggestion 
This has been devoted to summary of findings. The work ends with 
conclusion and has been concluded with some suggestions. 
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HISTORY OF PATENT SYSTEM IN INDIA 
Of the entire living creature's only man has been endowed with 
intellectual mind and the same has been effectively utilized by him in 
improving his standard of living right from the time immemorial. Intellectual 
property is the property which has been created by exercise of intellectual 
faculty. India has a long and creditable record of protection of intellectual 
property right through a system of well developed substantive laws and 
established legal and administrative infrastructure for the enforcement of 
Intellectual Property Rights (IPR).' 
Intellectual property is a world wide accepted instrument which is 
created by human brain or scholarly faculty, most of the time which requires 
fierce study and research. More commonly, Intellectual Property (IP) covers 
internationally recognized instruments which include concept, protection, 
exploitation of natural things and novel creation or invention as well as 
innovation. Intellectual Property Law (IPL) within its scope covers patent, 
trade secret, copyright, know-how, industrial design, trade marks and so on. 
This list is not complete rather it is increasing in the concurrent dynamic 
society with fast changing thoughts and cuhure. 
'Intellectual Property Legislation' relates to the acquisition and use of 
a range of rights covering different types of creations, including creations of 
an aesthetic character (e.g. artistic works and industrial designs), technologies 
(e.g. patents) as well as information and signs of a purely commercial value 
(e.g. trademarks).^ 
The primary object of the IPL is to safeguard intellectual creations 
which are either in written form or expressed and to define their boundary 
areas in the interest of society. Every law must have public oriented goals and 
1. N.R. Seth, Patent System in India, Lecture notes on Patents, (TIFAC) p. 19 (2001), 
2. Institute of Company Secretaries of India, World Trade Organization, International Trade, Joint 
Ventures & Foreign Collaborations (2004) 
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on this point IPL is not an exception. It has some objectives to achieve for the 
promotion of intellectual culture, political and economic expectations. 
International conventions, treaties, e.g. World Trade Organization (WTO), 
Agreement on Trade Related Aspect of Intellectual Property Rights (TRIPS), 
Berne convention, Doha Convention have had great impact on development 
and protection of IP and in encouraging original and novel creation 
worldwide. Therefore, United Nations had set up certain guidelines which 
were to be followed by all the member countries and signatories within 
certain period by amending and passing their own domestic laws according to 
their own circumstances. 
Ideas and knowledge are ever increasingly important part of trade. Most 
of the value of new medicines and other high technology products lie in the 
amount of invention, innovation, research, design and testing involved. 
Films, music recordings, books, computer software and on-line services are 
bought and sold for the information and creativity they contain and not for 
the plastic, metal or paper, used to make them.^  
The best known and arguably economically, the most valuable form of 
protections of rights by the law of intellectual property come in the form of the 
patent. A patent is in essence, the grant of a monopoly is not absolute; patents 
are only granted for a limited period and are accompanied by public discloses 
enabling others in the field to consider and perhaps subsequently improve on it. 
The oldest example to grant of exclusive rights, by kings and rulers to 
private inventors and innovators to practice their new arts and skills goes back 
to the fourteenth century when Flamish and Brabant the clock makers were 
induced to settle in England, which at that time was a developing country when 
compared to continental Europe. The English kings also summoned foreign 
craftsmen from Belgium, Holland, France and Italy to England. They were 
3. [bid, 
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granted the privilege to run their business for limited time for the sole purpose 
of rapid introduction of their skills to its negative populations.'' 
The original use of patents had little to do with the present predominant 
assumption that Patents are effective instruments for stimulating and rewarding 
inventions and innovations. In the beginning patents referred to letters patent (a 
literal translation of the Latin Litterae patents). The adjective patent means 
'Open'. Originally Patent referred to the patent letters or open letters which 
were official documents by which certain privileges/rights, ranks or titles were 
conferred by sovereign rulers. They were open because they were publicly 
announced and had a seal of the sovereign grantor. The openness had nothing 
to do with disclosure of an invention as is commonly assumed in the present 
day context.^  
Litterae patents had their beginning in the sixth century in Europe. For 
the discovery and conquest of foreign lands Charters and letters were issued by 
European monarchs. They were used for colonization and for establishing 
import monopolies. The Charter granted to Christopher Columbus is a crystal 
example of it. The most frequent phrase used in the Charter was the 
conjunction of the two verbs 'discover' and 'conquer.' It was used seven times 
to assert rights to all islands and main lands before their discovery. Columbus 
intended to sail to India but landed in America by mistake, it is interesting to 
think through the fact that what Columbus carried as a piece of parchment was 
the potential right to own India. It was instead used to 'conquer and own' the 
lands of America's indigenous people and hence they have been called Red-
Indians ever since as a reminder of Columbus mistaken discovery. Thus the 
history of Patents has been associated with colonization. 
It's evident from the above noted example that the right conferred by a 
patent is a right to exclude others from making, using or selling the patented 
4. M. P. Bhatnagar, "IPR and Patenting System", Lecture notes on Patent, June (2001) 
5. Vandna Shiva, Patents: Myth and Reality,'p. 11-12. (2001). 
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invention during the term of the patent or for a limited period in consideration 
of the disclosure of the invention to the pubHc. Thus it can be said that a patent 
is a contract between society as a whole and individual inventor to encourage 
the disclosure of information to the public by rewarding the inventor for his or 
her endeavours. In other words, patent is an exclusive right granted to a person 
who has invented a new and useful article or an improvement of an existing 
article or a new process of making an article. It consists of an exclusive right to 
manufacture the new article according to the invented process for a limited 
period. After the expiry of the donation of patent anybody can make use of the 
invention. 
A patent is not granted for an idea or principle as such but for some 
article or the process of making some article, applying the idea. On the expiry 
of the life of the potent the public are enabled to work the invention themselves 
and in competition with each other. ^  .6 
Patent: Position in Different Countries:' 
The history of patents and patent laws is believed to have started in Italy 
with a Venetian Statute of 1474 which was issued by the Republic of Venice. 
They issued a decree by which new and inventive devices, once they had been 
put into practice, had to be communicated to the Republic in order to get hold 
of legal protection against potential infringers. The period of protection was 10 
years. 
Patents, however, existed before the law. The first Italian patent was 
actually awarded by the Republic of Florence in 1421 and from the available 
evidence it can be suggested that something like patents was used among some 
ancient Greek cities. In 500 BC, in the Greek city of Sybaris (which is now 
located in southern Italy), people were encouraged to discover any new 
6. P. Narayanan, 7me//ec/Mo/ Property Law 'p. 12-13. (2007). 
7. History of Patents in Different Countries available at wikipedia, the fi-ee encyclopedia at 
http:/www/google.com. 
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refinement in luxury. Profits arising fi-om this discovery were secured to the 
inventor by patent for a period of a year. 
England 
The Crown of England issued letters of patent providing any person 
with a monopoly to produce particular goods or provide particular services. 
The first such letter was granted by Henry VI in 1449 to a Flemish man for a 
20 year monopoly for his invention. 
This was the beginning of a long tradition by the English Crown of 
awarding patent letters which granted monopolies to favour people or to the 
people who were prepared to pay for them. This process was used to raise 
money for the Crown, and was widely abused, as the Crown granted patents in 
respect of all sorts of common goods (salt, for example). Consequently, the 
Court interrupted and limited the circumstances in which patents could be 
granted. After public remonstration, James I of England was compelled to 
revoke all existing monopolies and it was declared that they were only to be 
used for 'projects of new invention'. This was then assimilated into the 'Statute 
of Monopolies' in which Parliament constrained the Crown's power explicitly 
so that the King could only issue letters patent to the inventors or introducers of 
original inventions for a fixed number of years. 
The lawyers of the English Court during the reign of Queen Anne 
(1702-1714), developed a new requirement that a written description of the 
invention must be submitted. These developments, which were in place during 
the colonial period before independence of the U.S., were the basic foundation 
of patent law in United States, New Zealand and Australia. 
James Puckle's 1718 patent for a machine gun is considered to be one of 
the first to be required to provide a 'specification'- written description. The 
famous patent of Arkwright for spinning machines became void for the lack 
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of an adequate specification in 1785, after its existence of 10 years. 
Extensive litigation on Watt's 1796 patent for steam engine set out the 
important principle that valid patents could be granted for improvement in a 
known machine. 
However, patent had become extremely in-efficient by the mid of \9^^ 
century. The great exhibition of 1851 accelerated demand for patent reform. 
The patent office was introduced to meet the public concerns over this state of 
affairs and was established by the Patent Law Amendment Act of 1852. A 
successive Act in 1883 brought into existence the Office of Controller General 
of Patents and a staff of Patent Examiners to perform a limited form of 
examination, but without any investigation into novelty. One of the important 
milestones in the development of British Patent System was the Act of 1902, 
which introduced a limited investigation into the novelty of invention before 
granting a Patent.^  
In the United Kingdom, the Patents Act, 1977 synchronized UK patent 
law with the European Patent Convention. Therefore, UK patent law is no 
longer based on the Statute of Monopolies, but a combination of UK and 
European practices. Inadvertently, the current length of UK/EU patents is still 
20 years which is similar to the original declaration by Henry VI on the 
manufacture of stained glass (destined for Eton College). 
United States 
A few inventors were able to obtain monopolies (i.e. "patents") to 
produce and sell their inventions during the period of America's Thirteen 
Colonies. These monopolies were granted by petition to a given colony's 
legislature. 
8. Available at- www.ipo.gov.uk/types/patent/p-about/p-whattis/p-history 
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For example, the Province of Massachusetts Bay granted inventor 
Joseph Jenks Sr., in 1646, the exclusive right to set up water mills using a 
speedier engine which he had developed for making edged tools, such as 
scythes. His monopoly was to run for 14 years. James Madison and Charles 
Cotesworth Pincknev proposed The Patent and Copyright Clause of the US 
Constitution in 1787. In Federalist No. 43, Madison wrote, 'The utility of the 
clause will scarcely be questioned. The copyright of authors has been solemnly 
adjudged, in Great Britain, to be a right of common law. The right to useful 
inventions seems with equal reason to belong to the inventors. The public good 
fiilly coincides in both cases with the claims of the individuals.' The Patent 
Commission of the U.S. was created in 1790. The first three members of this 
commission were, Secretary of State Thomas Jefferson, Secretary of War 
Hemy Knox and Attorney General Edmund Randolph.^ 
Samuel Hopkins of Philadelphia was granted the first patent on July 31, 
1790 for a method of producing potash (potassium carbonate), an essential 
ingredient used in making soap, glass, and gunpowder 
The earliest law required that a working model of each invention be 
submitted with the application. Patent applications were examined to determine 
if an inventor was entitled to the grant of a patent but later the requirement for a 
working model was eventually dropped. 
The Patent Law was revised in 1793. The rate of patent grants had 
grown to about 20 per year and the time burden on the Secretary of State was 
considered to be too burdensome. Patent applications were no longer examined. 
Patents were granted simply by submitting a written description of an 
invention, a model of the invention, if appropriate, and paying a fee of $30 
($1000 in 2006 US dollars). (35 U.S.C. Sec. 112) requires a written description. 
9. Available at www.ipo.gov.uk/types/patent/p-about/p-whattis/p-history 
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The Commissioner of the USPTO may ask for additional information, patent 
drawings, or diagrams if the description is not clear. 
The Patent Board was replaced by a clerk in the Department of State. 
James Madison, Secretary of State, created a separate Patent Office within the 
State Department and he appointed Dr. William Thornton as its first 
superintendent in May 1802. On May 5, 1809 Mary Dixon Kies became the 
first woman to be awarded a U.S. patent. In that same year a Philadelphia court 
ruled that all patent holders were "in violation of public rights." The ruling was 
overturned a short time later. In 1810, the Patent Office moved from the 
Department of State to Blodgetts Hotel. In the same year, they opened the 
patent model storage to the general public. 
The patent laws were again revised in 1836. The examination of patent 
applications was reinstituted. The number of patents granted per year had 
grown to about 700. Also in 1836 the government began construction of what 
is now called the Old Patent Office Building, where the offices and models 
were housed from 1840 until 1932. The Patent Office is now housed in its own 
building in Alexandria, Virginia. 
The first 10,000 patents issued by the USPTO from July 1790 to My 
1836 were destroyed in a fire in December 1836. About 2800 of them were 
later recovered, but the majority of them are still missing. The recovered 
patents are now called X-Patents because their patent numbers end with an "X." 
In 1870 Congress passed 'an Act to revise, consolidate, and amend the 
Statutes relating to patents and Copyrights' (16 Stat. 198). This law mainly 
reorganized and re-enacted existing law, but also made some important 
changes, such as giving the commissioner of patents the authority to draft rules 
and regulations for the patents office. 
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From 2005-2009, three consecutive US congressional sessions have 
attempted to pass a patent reform act that would shift the US to a first-to-file 
rule, limit damages for patent violations, and provide patent defendants more 
methods for defence. The most recent being the Patent Reform Act of 2009. 
Evolution of Patent System in India 
The base of Indian laws is the Anglo Saxon jurisprudence. However in 
India a patent has always been the sole creation of statutes, quite unlike Great 
Britain where the concept of a patent originated from the exercise of the royal 
prerogative to grant monopolies. 
Growth of Patent Law in India till 1950 
Origins of India's patent law of the nineteenth century are sheathed with 
considerable legal controversy. The Attorney General supported by the 
Solicitor General-in-Council, in response to a letter of 23 September, 1835 by 
the Governor General-in-Council, were firmly of the opinion that the existing 
government of India, if it could be called that, could not confer 'exclusive 
privileges" as that would conflict with the privilege of the Crown. 
Despite being warned by the Governor General in a minutes of 3 February 
1841 that India was much too backward so that it would be cheaper to import 
rather than manufacture in India, anxious to press for such exclusive privileges, 
the Court of Directors of the East India Company were interested to proceed 
for legislation in this area. Parliament's compromise in 1853 (Chapter xxvi of 
16 and 17 Victoria) produced a response which was unmanageable and which 
dealt with the problems of the royal prerogative rather than the specific 
problems of 'exclusive privileges'. There were no laws and regulations made 
by the Governor General in council which could trespass on the royal 
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prerogative with the previous sanction of the Majesty and counter signed by the 
President of the Board of Commissioners.'° 
To examine the various issues a select committee was appointed which 
tried to balance the competing rights of the 'actual inventor' the manufacturer 
and importer, giving the actual inventor some limited rights against others. 
Other than routine questions the other major issue concerned whether the 
preliminary inquiry as to the novelty of the alleged invention would be limited 
to India, India and England or the whole world. English patent holders were 
allowed to register patent in India within six months of Registration in 
England. Later in July, 1855 was the Bill introduced which received the 
Governor's consent as an Act for granting exclusives privileges to the 
inventors." This bill was considered as first Act relating to patent of 1856 
which granted certain exclusive privileges to inventors for the period of 14 
years, which was repealed the very next year by the Act (IX) of 1857 for the 
strong objection of the Court of Directors of the East India Company that the 
Act though passed by the legislative council and approved by the Governor 
General, had not received their consent. 
In India the first real patent legislation was the Act (XV of) 1859 -"Act 
for granting exclusive privileges to inventors", which required exclusive 
privileges to have some utility, to not have been published or generally publicly 
known and not to be enlarged consequently by amendment of specification so 
as to ensure that English patents holders could acquire a right to Indian markets 
or manufacture, they could register their patents within 12 months of the 
registration in England. The general transnational right to priority that was to 
become such an important part of the use of patents for world market 
domination under the Paris Convention 1883 was quite similar to this Act. In 
10. Rajeeve Dhavan, "Power without Responsibility an Aspect of the Indian Patent Legislation," 33 
Journal of Indian Law Institute, p. 2 (1991). 
W.lbid. 
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this case in point it was more limited (in that it applied only to India and 
England) and one sided as it was an option available only to English patent 
holders. 
Protection of designs was included in 'The Pattern and Designs 
Protection Act, 1872' which was not covered by previous legislation; and the 
Inventions and Designs Act, 1888 protected inventions disclosed at exhibitions 
were for their novelty. Both these changes were fuelled by the prevalent 
ideological belief in scientific and industrial creativity. People were encouraged 
to bring their creative ideas into the public domain and they were offered 
protection for the exclusive economic rights for the exploitation of such 
creativity. Whilst the debate continued to honour the inventor's creativity, the 
art of protection was clearly rendered to the industrialist, manufacturer and 
importer. The existence of such patent legislation in India would also ensure an 
overall subtle control on important manufacturing, distribution and commodity 
movements within and into and out of India. 
A new consolidating Act was brought in to deal with inventions and 
designs separately. The untidy encroachments of previous legislation were 
assimilated into this new Act. According to this Act exclusive privileges could 
be awarded for seven and in exceptional cases fourteen years by a simplified 
procedure and relatively modest fees. The inventor would be called upon to 
elucidate how and in what best possible way the invention or design would be 
used. But some newly introduced features created a controversial wave of 
interest at the Pairs Convention in 1883 and they remain important to our 
national and international discussion about patent law. The first of these 
concerned the rights of the Government. Though the 'crown' was bound by the 
exclusive privileges, only on the terms which were either mutually agreed or 
decreed by the Governor General these privileges could be used by the 
government. The second was the awarding of compulsory licenses where the 
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'exclusive privileges' was not being worked to best advantage or at all in India 
or where the reasonable requirements of the public were not being met. 
"Exclusive privileges" were replaced by the term "Patent" in the Indian 
Patents and Designs Act, 1911. For the first time in India, this act established a 
system of patent administration under the management of the controller of 
patents. Till the arrival of patents Act 1970, the 1911 legislation determined 
pre-set time limits for processing application keeping them secret while they 
were being processed, providing a time boxed framework for objections, better 
administration arrangements and a clarification of the substantial rules about 
use and compulsory licensing in the event of insufficient or inadequate use. 
The Indian Patent and Designs (Amendment) Act 1920 provided the 
possibility of reciprocal arrangements as regards the right to priority to file 
patents in other countries which were part of Britain's Dominion. This emerged 
because India was not a member of the Paris "International Convention for the 
Protection of Industrial Property" of 1883. Now, with some tact and diplomacy, 
a kind of Paris Convention could, in fact be incrementally set up for the 
Empire. 
The Indian Patent and Designs Amendment Act, 1930 extended the 
period of patents from fourteen to sixteen years, provided for disputes to be 
settled by the High Court rather than the government, made it possible to grant 
a patent of addition for the rest of the duration of the patent in respect of any 
additions improvements and modifications and allowed certain patents relating 
to defense to be made secret if assigned to government. The Indian Patents and 
Designs (Amendment) Act, 1945 made it possible to apply for a provisional 
specification which could be matured into a complete specification within nine 
months. 
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Position of Patent Law 1950 Onwards 
At this point of time the Government of India appointed the Patent 
Enquiry Committee to review the working of the patent laws in India. It was 
presided by Justice Bakshi Tek Chand, a retired judge of the Lahore High 
Court.'^ Apart from a number of complaints about the working and 
administration of the system the committee passed somewhat sober verdict 
that: 
"The Indian patent has failed in its main purpose, namely to stimulate 
invention among Indians and to encourage the development and exploitation of 
new inventions for industrial purposes in the country so as to secure benefits 
thereof to the largest selection of the people. "'^ 
To make it sure that the patent system is beneficial to the national interest, 
the points to be worked upon were-' 
• to survey and report on the working of the patent system in India; 
• to examine the existing patent legislation in India and to make 
recommendations for improving it, particularly with reference to the 
provisions concerned with the prevention of abuse of patent rights; 
• to consider whether any special restrictions should be imposed on 
patent regarding food and medicine; 
• to suggest steps for ensuring effective publicity to the patent system and 
to patent literature, particularly as regards patents obtained by Indian 
inventors; 
• to consider the necessity and feasibility of setting up a National Patents 
Trust; 
• to consider the desirability or otherwise of regulating the profession of 
patent agents 
• to examine the working of the Patent Office and the services rendered by 
12. Report of the Patents Enquiry Committee (1948-50). 
13. W. Para 5 p. 2. 
14. History of Indian Patent System, Draft Patent Manual (2008) for detail see 
www.centad.org/download/draftpatent-manual-2008pdf. 
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it to the public and make suitable recommendations for improvement; and 
• to report generally on any improvement that the Committee thinks fit to 
recommend for enabling the Indian Patent System to be more conducive 
to national interest by encouraging invention and the commercial 
development and use of inventions. 
The interim report was submitted by the said committee on 4"" August, 
1949 recommended the prevention of misuse or abuse of patent right in India 
and suggested amendments to sections 22, 23 and 23A of the Patents and 
Designs Act, 1911 on the lines of the United Kingdom Acts 1919 and 1949. 
It was also observed by the committee that the Patents Act should 
contain clear indication to ensure that food and medicine and surgical and 
curative devices are made available to the public at the cheapest price 
commensurate with giving reasonable compensation to the patentee. On 
Committee's recommendation, the 1911 Act was amended in 1950 (Act 
XXXII of 1950) in relation to working of inventions and compulsory 
license/revocation. Other provisions were related to endorsement of the patent 
with the words 'license of right' on an application by the Government so that 
the Controller could grant licenses. In 1952 (Act LXX of 1952) an 
amendment was made to provide compulsory license in relation to patents in 
respect of food and medicines, insecticide, germicide or fungicide and a 
process for producing substance or any invention relating to surgical or 
curative devices. The compulsory license was also available on notification by 
the Central Government. Based on the recommendations of the Committee, a 
bill was introduced in the Parliament in 1953 (Bill No.59 of 1953). However, 
the Government did not press for the consideration of the bill and it was 
allowed to lapse.'^ 
15. www.ipindia.nic.in/ipr/patent/patents/htm. 
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In 1957, the Government of India appointed Justice N. Rajagopala 
Ayyangar Committee to examine the question of revision of the Patent Law 
and advise government accordingly. The report of the Committee, which 
comprised of two parts, was submitted in September, 1959. The first part dealt 
with general aspects of the Patent Law and the second part gave detailed note 
on the several clauses of the lapsed bills 1953. The first part also deah with 
evils of the patent system and solution with recommendations in regards to the 
law. The committee recommended retention of the Patent System, despite its 
shortcomings. This report recommended major changes in the law which 
formed the basis of the introduction of the Patents Bill, 1965. 
Based on these studies, Committees made recommendations for the 
modification of the Indian Law relating to patents, so as to make the patent 
system an effective tool for our industrial and economic growth. This Patent 
Bill of 1965 mainly based on recommendations of the detailed report 
incorporating a few changes in the light of further examination made 
particularly with reference to food, drugs and medicines was introduced in the 
Lok Sabha on 21 '^ September 1965. It was referred to a Joint Committee with 
the amended Bill was presented to Lok Sabha on P' November, 1966. The 
Patent Bill 1965 as reported by the Joint Committee was formally moved in 
Lok Sabha on 5'*^  December, 1966 but could not be proceeded with for want of 
time and eventually lapsed with the dissolution of the third Lok Sabha on 3'^ '' 
March, 1967. Again an amended bill known as Patent Bill, containing 
comprehensive provisions to amend and consolidate the law relating to patents 
and also embodying the amendments recommended by the Joint Committee 
was introduced in the budget session of the fourth Lok Sabha on 12'^  August, 
1967 as a fresh bill of 1967. Then it was referred to another Joint Committee 
of Parliament. The Joint Committee after considering the various 
representations written memoranda and oral evidence before them presented 
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their report with the amended Bill to Lok Sabha on 2f^ February, 1970. While 
giving a brief note on the recommendations of the two committees during the 
discussion the then minister of Commerce and Industry Dr. Dinesh Singh said: 
"These two reports contained very valuable information on the origin and 
development of the patent system, the experience of various countries of the 
world on the part played by the patent system in their industrial development 
and its relevance to India in the present context. "'^ 
"Historically speaking the concept of patents is based on two main 
legal and social justifications. One that the patents are private property, that 
is to say that the inventor has exclusive right in his invention and the other 
that they are privileges for a limited period granted by Government to 
encourage research and invention and to induce researchers to disclose their 
inventions for industrial exploitation thereby providing new avenues for 
economic growth and development. " 
Further the minister said, we have to see how we can make patents 
serve the needs of our economy, how can we make them a vehicle of rapid 
growth. As a developing country where a bulk of patents are foreign owned, 
we have also to see whether on balance, the patent system can play a useful 
rule in the transfer of technology from the developed countries or whether it 
will lead to greater exploitation. 
Dr Sushila Nayar from opposition in support to Mr. Dinesh Singh 
observed that, "two committees in their report showed that all of the patents 
that were applicable in India only 10 per cent were those of Indians. This 
showed that even after independence it was foreigner who got the benefit out 
of patent and not the Indians by and large. She further pointed out that the 
16. Lok Sabha Debate 20 August 1970 
n.Ibid 
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area of drugs in the whole area of patents given, you find that not more than 
5per cent of those are drugs out of the 10 per cent of those given to Indians. " 
She further mentioned that some years ago the American Senate had 
appointed a committee called Kefauver Committee to examine the investment, 
cost structure and the cartels that have been set up. The committee came to the 
conclusion that 6 per cent was being spent on research and 25 percent on sale 
promotion by the drug industry. This shows that money spent on research is 
just a fraction of what they spend on advertisement and sales promotion. 
Dr. Nayar while quoting an example said, "It is for Government to 
ensure that the generic names are displayed clearly and as prominently as the 
trade names and secondly that a curb is put on too many products of similar 
nature. This will reduce expenditure on sale promotion it is necessary to see 
that patents are only given to genuine new inventions. This Bill has made a 
provision for that. If that is properly applied, it will be good for our 
country The present bill provides power for the Government to import for 
the hospitals, dispensaries and other institutions of a non-profit nature. This is 
a very welcome step and I am sure this will give considerable relief 
immediately." 
With the concluding remarks Mr. Veni Shankar Sharma said, 
"Inventors in our country are brilliant, they work for self satisfaction which 
can never be measured in money. Money is required only by capitalists. I want 
these inventors to be awarded. They should be given national awards. We 
should give them an award as generous as Nobel Prize, to give them the 
to 
respect they deserve. " 
After threadbare discussion in the Parliament the Patents Act, 1970 was 
ultimately passed. This Act repealed and replaced the 1911 Act so far as the 
patents law was concerned. However, the 1911 Act continued to be applicable 
\i.lbid 
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to designs. Most of the provisions of tiie 1970 Act were brought into force on 
20"" April 1972 with publication of the Patent Rules, 1972. 
This Act remained in force for about 24 years without any change till 
December 1994. An ordinance effecting certain changes in the Act was issued 
on 31'' December 1994, which ceased to operate after six months. 
Subsequently, another ordinance was issued in 1999. This ordinance was 
subsequently replaced by the Patents (Amendment) Act, 1999 that was brought 
into force retrospectively from 1^ ' January, 1995. The amended Act provided 
for filing of applications for product patents in the areas of drugs, 
pharmaceuticals and agro chemicals though such patents were not allowed. 
However, such applications were to be examined only after 31-12-2004. 
Meanwhile, the applicants could be allowed Exclusive Marketing Rights 
(EMR) to sell or distribute these products in India, subject to fulfillment of 
certain conditions. The second amendment to the 1970 Act was made through 
the Patents (Amendment) Act, 2002 (Act 38 of 2002). This Act came into force 
on 20"" May 2003 with the introduction of the new Patents Rules, 2003 by 
replacing the earlier Patents Rules, 1972. 
The third amendment to the Patents Act, 1970 was introduced through 
the Patents (Amendment) ordinance, 2004 w.e.f 1^ ' January 2005. This 
ordinance was later replaced by the Patents (Amendment) Act, 2005 (Act 15 of 
2005), on 4 the April, 2005 which was brought into force from 1-1-2005. 
Meaning of the Term Patent 
Patent means a grant of some privilege, property or authority made by 
the government or the sovereign of the country to one or more individuals. The 
instrument by which such grant is made is known as Patents.'^ 
19. B. L .Wadhera , Law Relating to Patent, Trade .Marks, Copyright, Designs and Geographical 
Indications, p. 5 , (2003).. 
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According to the statutory meaning in India "Patent" means a patent for 
any invention granted under this Act.^ ° Patent is a grant by the Government to 
the inventor for a limited span with a privileged right to make use, exercise and 
sell his invention. It conveys to the inventor substantive rights and secures to 
him the valuable monetary right which he can enforce for his own advantage 
either by using it himself or by conveying the privileges to others. 
Thus patent is sole right granted to a person who has invented a new and 
useful article or an improvement of an existing article or a new process of 
making an article. It consists of an exclusive right to manufacture the new 
article according to the invented process for a limited period. After the expiry 
of the duration of patent anybody can make use of the invention. 
Object of Patent Law 
The main aim or object of patent law is to protect the interest of inventor 
by rewarding him the monopoly right for that invention it is a legal reward to a 
person stimulates technology and industrial growth as a tool which to 
encourage for further invention, it is also a tool to stimulate technology and 
industrial growth. 
In a significant judgments M/s Bishwanath Prasad Radhey Shyam v 
Hindustan Meta Industries,^' has aptly explained the object of patent law in the 
following words: "The object of patent law is to encourage scientific research, 
new technology and industrial progress. Grant of exclusive privilege to own 
use or sell the method or the product patented for a limited period stimulates 
new inventions of commercial utility. The price of the grant of the monopoly is 
the disclosure of the invention at the patent office which after expiry of the 
fixed period of the monopoly passes into the public domain. "^^ 
20. The Patents (Amendment) Act, 2005 Sec.2 (I) (m) 
21. AIR 1982 SC 1444 
22./rf, para 17 p. 1447 
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The considerations which are said to constitution the quid pro quo for 
the grant of a patent monopoly are. 
1. The working of the invention within the country so as to resuh in the 
establishment in the country of a new industry or an improvement of an 
existing industry which would profitably employ the labour and capital 
of the country and this increases the national wealth. 
2. It induces the inventor to disclose the invention rather than keeping it as 
a trade secret. 
3. It also encourages the public to work the invention themselves and in 
completion with each other significance of patent law in the field of 
industrial enterprise, research and development are the key factors for 
economic prosperity of a nation. Monopoly right to the inventor induces 
him more and more in the field of research and technological 
developments. In almost all countries some kind of patent protection for 
invention has been adopted. The ever increasing number of applications 
for patent received by the patent offices in all industrially advanced 
countries is an indication of the universal recognition of the value of a 
patent system Most of the discoveries and inventions made in 
technology in all fields are published in the patent specifications field at 
the patent offices of different countries. A world wide exchange of 
technical information has been made possible only by the publication of 
such patent specifications. But of the existence of patent system which 
enable the inventors to disclose their invention without fear of the 
benefits of their labour being last to competitors much of the 
technological innovations would have remained secret."'^ ^ 
Superiority and prosperity of USA in all sphere of technological and 
industrial area can be attributed to its strong and vibrant patent regime. 
23. P. Narayanan, Intellectual Property Law, p. 14 (2001). 
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Essentia] requirements of a patent 
Not all inventions are patentable. In order to qualify the patent 
protection an invention must fulfill three requirements: 
(1) Novelty 
(2) Inventive step 
(3) Utility 
In Imperial Chemical Industries v. Controller General of Patents Designs and 
Trade Marks,^"^ it was held that the following propositions are the salient 
features of a patent. 
1. The patent must be in respect of an invention and not a discovery. 
2. In respect of one single invention there must be one single patent 
3. A patent may be in respect of a substance or in respect of process 
4. But it is not possible to bifurcate a patent and state that one relates to the 
substance 
5. In order to have a complete patent the specifications and the claims must 
be clearly and distinctly mentioned. 
6. It is the claims and claims alone which constitute the patent. 
Under Section 2 (1) (j) of the Patents (Amendment) Act, 2002 a patent 
can be obtained only for an invention which is new and useful. An invention is 
defined as follows: "Invention means a new product or process involving an 
inventive step and capable of industrial application. " 
A patent can be obtained only for an invention which is new and useful. 
The invention must relate to a machine article or substance produced by 
manufacture, or the process of manufacture of an article. A patent may also be 
obtained for process of manufacture. In regard to medicine or drug and certain 
24. AIR 1978 Cal 77 p. 82. 
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classes of chemicals no patent is granted for the substance itself even if new but 
a process of manufacturing the substance is patentable.^^ 
Value of patent system has now been realized at global level. This is 
evident by the fact that almost in all advanced countries the number of patents 
granted has shown substantial increase. Now India has also brought its patent 
legislation modified to bring it in tune with Trade Related Aspect of 
Intellectual Property Rights (here in after TRIPS) requirements. 
Subject Matter of Patents or Patentability Criteria 
In Bombay Aggarwal Co. Akola v. Ramchand Deewanchancf^ it was 
said, in patent cases it must be determined whether I. There is proper subject 
matter of the patent 2. There is novelty 3. There is utility. The subjects matter 
of a Patents means the exact advanced upon existing knowledge which the 
patentee claims. The subject must be of substantial proportions. However, a 
slight advance may also be acceptable if it conduces to a better result than what 
had been achieved before hand. Further the date of the knowledge or use by 
any other person is a date before the invention not before the patent.^'' 
It must be new, useful industrial application and non-obvious. The 
Patent Act, 1970 defines ''Patenf' as patent for any invention granted under 
this Act, which means patent is granted for an invention. 
The Patent (Amendment) Act, 2002 defined invention as- "invention 
means a new product or process involving an inventive step and capable of 
industrial application"'^^ meaning thereby patent can be obtained only for an 
invention which is new and useful. 
25. P.Narayanan, Intellectual Property Law p. 17(2001) 
26. AIR 1953 Nag. ] 54 DB. 
27. 20(2) Halsbury Laws of India IPR -II p. 185.1427 
28. 5eeSec.2(l))(m) 
29. 5ee, Sec. 2(1)0) 
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The principle is that every simple invention that is claimed, so long as it is 
something novel or new, is an invention and the claims and the specifications 
must be read in that light and a new invention may consist of a new combination 
of all integers so as to produce a new or important result or may consist of 
altogether new integers. The invention for which a patent is claimed may be a 
product or an article or a process, and in the case of an article, the patent is in 
the end product or the article, and in the case of a process, the patent does not lie 
in the end product but only in the process by which it is arrived at. 
In Raj Parkash v Mangat Ram Choudhury,^" case it is stated that an 
invention means, to find out or discover something not found or discovered by 
anyone before and it is not necessary that the invention must be complicated 
the essential thing being that the inventor was the first one to adopt it. 
Section 2 (1) (1) defines "new invention" as "new invention means any 
invention or technology which has not been anticipated by publication in any 
document or used in the country or else where in the world before the data of 
filing of patent application with complete specification, i.e. the subject matter 
has not fallen in public domain or that it does not form part of the state of the 
art. '•" 
Unlike the Patents Act, 1970, the Act of 1911 does not specify the 
requirement of being useful in the definition of invention. But the courts are 
always of the view that a patentable invention a part from being a new 
manufacture must also be useful. 
(i) Newness or Novelty 
First requirement of a patent is newness i.e novelty in an invention. It 
depends upon the state of prior art i.e the existing knowledge and similar 
30. AIR 1978 Del 1. (1977) Raj LR 440 (DB). 
31. The Patents(Amendment)Act,2005 
50 
!}fistoty of latent System in India 
inventions already known in the patents field. There would be no novelty if 
there has been prior publication and prior art of an identical invention. An 
invention is the act or operation of finding out something new; the process of 
contriving and producing something not previously known or existing by the 
exercise of independent investigation and experiment.^^ 
In Cadila Pharmaceutical Ltd. v. Instance Laboratories Ltd.^^ The High 
Court held that the process which appellant Cadila pharmaceuticals Ltd. claim 
to be developed after years of research and development is really in use for 
decades it may be that said process has been first time adopted for making a 
combination of drug of penicillin and Jactobacilli. But what is patented is the 
process and not the combination drug itself.'''' So the defendant instance 
laboratories Pvt. Ltd. can not be restrained from using the said process for its 
products and for marketing them. This it can be deduced that novelty is 
essential for granting patent. 
Thus according to this definition of new invention, The Act Talks of 
absolute novelty, i.e the invention should have neither been used anywhere in 
the world nor published in any part of the world. However, the later sections of 
the Act for the purpose of anticipation and opposition proceedings deal with the 
relative novelty i.e not used in India and not published in any part of the world. 
Further entire Act refers to the word invention and not new invention. 
Therefore, for all purpose relative novelty is the criteria.^^ 
32. Nichols Smith V, 88 US 22 L Ed. 566; Hollister V Mfg Co, 113 US 28 L Ed 901. 
33.2001 PTC 472 (Guj). 
34. /t/.para 12.p.480 
35. Press Metal Corp. Ltd. v. Noshri Sorabji AIR 1983 Bom 144-There is no hard and fast rule to 
consider what is the new and useful method of manufacture obviousness is to be judge by the 
standard of a man skilled in the art concerned. 
51 
history of (Patent System in ImRa 
Exception of Novelty 
Novelty is of core value even then there are few exceptions to the rule of 
novelty. These exceptional cases are as foUows:^ ^ 
(a) Subject matter published without the consent of the inventor 
(b) The invention was published in consequence of the display in an 
exhibition notified by the Government or reading the paper before a 
learned society. Grace period of 12 months is given in such cases to 
file this patent application. 
(c) Previous communication to Government of India 
(d) Public working for reasonable trials. 
(ii) Non-obviousness or Inventive step or Inventiveness 
Second requirement of a patentable invention is inventive step. More 
extensions or modifications upon already existing article or thugs can not be 
considered as a ground for inventive step patent inventive step can be 
considered as a step which was inventive step not obvious a step which was 
nation the mind of pubic, a step which comes out of a person's intellect a step 
which is new to every one. 
Section 2(1) (a) of the Act defines inventive step as "Inventive step 
means a feature of an invention that involves technical advance as compared to 
the existing knowledge or having economic significance or both and that makes 
the invention not obvious to a person skilled in the art. " Before the amendment 
Act of 2005, inventive step meant a feature that makes the invention obvious to 
a person skilled in the Art. 
From the above stated definition if the word 'both' is removed the 
definition of inventive step would not be comprehensive. This definition 
36. Krishna Chandra Jena, "An Overview of the Patent Law in India" Cochin University Law Reveiw 
fCULR)p.\51{2004). 
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contains technical advancement as well as the economic significance adding to 
it. In absence of the word 'both' to judge the inventive step in presence of one 
aspect other would be ignored. Inventive step would be consider either on the 
basis of technical advancement to the existing knowledge or the economic 
significance it contains. In case of the presence of the two things 
simultaneously it would be difficult to assess the criteria to grant patent. 
3. Industrial application 
The third requirement for the grant of patent is industrial applicability. 
The Patent Act, 1970 under section 2 (j) talks about the usefulness. Utility of an 
invention means that the invention must be useful for the purpose indicated by 
the inventor or patentee However; this was amended by the Act of 2002 and 
substituted by industrial application. But by the Act of 1970 very limited 
protection was given. Essential elements of invention were new, useful and 
manner of manufacturer. '^ 
In Dimminaco AG v. Controller of Patents 2002 this practice has been 
changed by the verdict of Calcutta High Court. Now the definition of invention 
is interpreted keeping in mind the term industrial applicability in section 2(1) 
0). 
Section 2(1) (ac) also defines "capable of industrial application" in 
relation to an invention means that the invention is capable of being made or 
used in an industry.^ * Position in England is also that of same, if an invention 
does not have any industrial applications what so ever it may also have to 
clearly pass the test of utility and qualify for a patent. 
37. The Patent Act, 1970 Sec. 2 (j) "Invention" means any new and useful-
(i) art, process, method or manner of manufacture 
(ii) machine apparatus or other article 
(iii) substance produce by manufacture 
and includes any new and useful improvement of any of them and an alleged invention. 
38. The Patent (Amendment) Act, 2005 Sec. 2 (I) (ac) 
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What is Not Patentable 
Law restrict grant of patent to certain categories of invention. Section 3 
of the Act, deals with non- patentable inventions. 
Section 3 of the Act deals with non patentable inventions^' 
a. Inventions which are frivolous or contrary to well established natural 
law. For example: inventions relating to perpetual motion alleged to be 
giving output without any input is not patentable as it is contrary to 
natural law.'"' 
Merely making in one piece, articles, previously made in two or more 
pieces is frivolous. Mere usefulness is not sufficient (Indian Vacuum 
Brake co. Ltd vs. Laurel), 
b. Inventions whose primary or intended use or commercial exploitation 
could be contrary to public order or morality (such as something against 
accepted norms of a culture in a society), or which causes serious 
prejudice to human, animal or plant life or health or to the 
environment.'" 
For example terminator technology which involves inserting a gene 
sequence in a seed to stop germination or growing recombinant plants 
leading to disappearance of butterflies. 
c. The mere discovery of a scientific principle or the formulation of an 
abstract theory or discovery of any living thing or non-living 
substances occurring in nature."*^ However isolation of living thing or 
non-living substances is patentable as it involves human technical 
intervention. 
39. The Patent Act, 1970 Sec. 3 
40. See. Sec. 3 (a) 
41.5ee, Sec. 3(b) 
42 See Sec. 3 (c) 
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d. Mere discovery of a new form of a known substance which does not 
result in the enhancement of the known efficacy of that substance, or 
mere discovery of any new property, or new use of a known 
substance, or mere use of known process, machine, or apparatus unless 
such known process results in a new product or employs at least one 
new reactant/"' (As in Cadila Pharmaceutical case). 
Substances obtained by mere admixture such as pmisjcal admixture are ^ 
not patentable under the Act 44 
However, compositions consisting of combine 
comprising of two or more known active ingredients are patentable if 
'synergism' or 'super additive' effect is shown clearly, for example 
pharmaceutical compositions or any other chemical compositions 
f The mere arrangement or re-arrangement or duplication of known 
devices each functioning independently of one another in a known 
way."*^  
g. Omitted by Act 38 of 2002 
h. Methods of agriculture or horticulture/^ For example a method of 
producing a new form of a known plant even if it involved a 
modification of the conditions under which natural phenomena would 
pursue their inevitable course is not patentable. 
i. Processes for medical, surgical, curative, prophylactic, diagnostic, 
therapeutic, or other treatment of human beings or animals that would 
render them free of disease or to increase their economic value or that of 
43 See Sec .3 (d) 
44. See Sec. 3 (e) 
45. See Sec. 3 (f). 
46. See, Sec.3 (h) 
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their product/^ (e.g. A process of treating malignant tumor cells is not 
patentable) 
j . Plants and animals in whole or any part thereof other than 
microorganisms but including seeds, varieties and species and 
essentially biological processes for production or propagation of plants 
and animals.'*^ (For example clones and new variety of plants are not 
patentable. But process/method of preparing genetically modified 
organisms is patentable subject matter). 
k. A mathematical method or a business method or computer program per 
se, or, algorithms.''^  
1. Literary, dramatic, musical or artistic work or any other aesthetic 
creations including cinematographic works and television productions^^ 
are not patentable as they are covered under the copyrights, design and 
entertainment laws. 
m. A mere scheme/rule/method of performing a mental act or method of 
playing a game, '^ 
n. Presentation of information." Unfortunately neither the Act nor the 
Rules defines a mathematical method, or a business method or a 
computer program per se or algorithm. Under such circumstances, one 
has to rely on the practices buiU tip under Articles 52(1), 52(2) and 
52(3) of the EPC, where similar provisions corresponding to the Indian 
Act under section 3(k), 3(m), and 3(n) exists. 
47. See. Sec. 3 (i) 
48. 5ee, Sec. 3 (j) 
49. See, Sec. 3 (k) 
50. 5ee. Sec. 3 (1) 
51.5ee, Sec. 3 (m) 
52. See, Sec. 3 (n) 
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0. Topography of integrated circuits.'^ 
p. An invention failing within the scope of traditional knowledge '^* such as 
the use of herbal medicines, (as of turmeric patent case). 
Inventions relating to atomic energy are not patentable^^. Such 
applications are referred to the Department of Atomic Energy. The 
decision of the Department of Atomic Energy is final and no appeal lies 
to the decisions of the Department of Atomic Energy. 
Kinds of Patents 
Generally the patents can be classified into two types viz (i) process 
patents (ii) product patents. 
(1) Process Patents: Process patent means that when a substance is 
invented or produced. A patent is not granted to the substance itself but 
it is only the method or the process of manufacture of a substance that is 
granted a patent. So in this kind of patent the patent is granted to the 
process but not to the product. 
(2) Product Patents: In product patents the patent is granted not to the 
method or process of manufacture of a substance but to the substance 
itself. Therefore in this kind of patent it is the product that is covered, 
claims, and may be of a product or an article. In Raj Prakash Mangat 
Ram Chaudhery'^ case it was held in the case of an article patent is the 
end product or the article. In case of a process the patent does not lie in 
the end product but only in the process by which it is carried in Sec. 5 of 
the Patent Act, 1970. 
53. See. Sec. 3 (o) 
54. See, Sec. 3 (p) 
55. See. Sec. 4 
65.AIR 1978 Delhi 1.(1977) Raj L R 440 (DB). 
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Procedure for Obtaining a Patent 
Various stages are involved in acquisition of patent starting from filing 
of application and ends with the grant and sealing of the patent. The patent 
right is territorial in nature and inventors, their assignees will have to file 
separate patent applications in countries of their interest along with necessary 
fees for obtaining patents in those countries. These stages are: 
(i) Filing an application accompanied by provisional or complete 
specification 
(ii) Publication 
(iii) Examinationof an application 
(iv) Acceptance and advertisement in official gazette, 
(v) Opposition to grant of patent on any reasonable grounds 
A. Pre-grant opposition 
B. Post grant opposition 
(vi) Granting and sealing of patent 
(I) Filing an application 
An application for a patent in the prescribed form'^ ^ along with the 
prescribed fee should be filed in the appropriate office of the patent office. The 
application should be accompanied by a provisional or complete specification. 
A provisional specification need describe the invention only briefly and need 
not contain the claims. Where the application is accompanied by a provisional 
specification a complete specification should be filed within twelve months 
from the date of filing the application.^* If this is not done the application will 
be deemed abandoned. The complete specification should fully and particularly 
describe the invention and the method by which it is to be carried out.^ ^ It 
should disclose the best method of performing the invention known to the 
applicant and end with a claim or claims defining the scope of the invention for 
57. The Patent Act, 1970 Sec .7 
58. See Sec. 9. 
59. See Sec. 10(4Xa) 
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which protection is claimed.^^ There shall be an abstract along with complete 
specification to provide technical information related to the invention.^' A 
single invention or a group of inventions can be claimed the specification 
should be accompanied by drawings." Where appropriate and necessary but 
the specification should relate to a single inventions. An application for a 
patent will not be open to public for a period of eighteen months from the date 
of filing or date of priority" which is earlier.*'' 
Publication 
After the stage of filing of application it comes to publication. 
Thereafter the application will be published. All the applications are published 
in Patent Office Journal just after 18 months from the date of filing of 
application or the date of priority. But those applications which are prejudicial 
to the defenses of India or abandoned due to non filing of complete 
specification within 12 months after filing the provisional or withdrawn within 
15 months filing the applications are not published. Those applications which 
are related to-
(1) Secrecy directions imposed under section 3 5 of the Act 
(2) Application has been abandoned under section 9( 1) 
(3) The applicant has withdrawn his application three months prior to 
the expiry of said prescribed period of 18 months. 
After the publication of the application within the prescribed period a 
request for examination of applications should be made by the applicant or 
interested person failing which the application will be treated as withdrawn.*^ 
60. 5eeSec. 10(4)(b)(c). 
61. See Sec. 10 (4) (d) 
62. See Sec. 10(2). 
63. The priority date is the date on which the patentee claims his invention. Normally the priority date 
is the date of filing the provisional specification provided the claims are based on the matters 
disclosed in provisional specification. 
64. The Patent (Amendment) Act,2005 Sec 11 A (1) to (3). 
65. See Sec. 11 B(!)to(4). 
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(II) Examination of an application 
The application is examined by examiners of patents to see whether it 
complies with the requirements of the Act and the Rules,^ ^ Whether there is 
any lawful ground of objection to the grant of the patent^ ^ and whether the 
invention has already been published or claimed by any other person the 
examiner makes a search in the publications available in the patent applications 
and patent to see whether the same invention has already been published or 
claimed or is the subject matter of existing or expired patents. After 
examination of the application the patent office will communicate to the 
applicant the objections, if any, to the grant of a patent.^ * The objections 
generally relate to the drafting of the specification and claims anticipation of 
any of the claims in prior publication of any specifications or claims or 
documents. If the objections are not satisfactorily met the controller of patents 
after giving an opportunity of hearing to the applicant will refiise the 
application.^ ^ 
(III) Acceptance and advertisement in the official gazette 
Where the applicant has satisfactorily removed the official objections 
the controller will accept the complete specification and advertise it in the 
official Gazette. From the date of acceptance to the date of grant of patent.^ " 
The applicant will get the benefits of the grant of the patent except that he will 
not be entitled to institute infringement proceedings until the patent is 
granted. '^ 
66. See Sec. 12(1) (a). 
67.5eeSec. 12(1) (3). 
68. See Sec. 14. 
69. See Sec. 15. 
70. See Sec. 23. 
71 .See Sec. 24. 
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(iv) Opposition to grant of patent on any reasonable ground 
Any person interested may give notice of opposition within three 
months from the date of publication in the Official Gazette. The controller will 
forward a copy of the notice of opposition to the applicant who may file a reply 
statement within one month from the date of receipt of the copy thereafter the 
parties may file their evidence in support of their respective cases and the mater 
will be heard and decided/^ 
The Indian patent system provides for two opposition proceedings, one 
before the grant of the patent and one after the grant of the patent. The grounds 
of opposition are same in both pre-grant and post grant opposition.'''' 
Pre-grant Opposition Procedure 
Where an application for a patent has been published but a patent has 
not been granted, any person may, in writing represent by way of opposition to 
the Controller against the grant of any Patent. The pre-grant opposition 
proceeding may be carried out in parallel with the examination proceeding. 
The opponent is required to submit statement and evidence, if any, in 
support of the representation and request for a hearing if he so desires. 
However, the representation is not considered by the Controller unless a 
request for examination is filed by the applicant. 
On receipt of the request for examination from the applicant, the 
Controller initiates Examination proceeding and also issues a notice to the 
applicant along with the copy of the statement and evidence filed by the 
opponent. 
The applicant may file his statement and evidence in support of his 
application within three months from the date of the notice. Thereafter, after 
72. See Sec. 25. 
73. See Sec. 25. 
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the Controller has considered the submission and the representations made, the 
patent is either granted or rejected. The acceptance may be with or without 
amendment to the specification. The decision is issued ordinarily within one 
month from the date of the completion of the proceedings. It may be noted that 
no fee is required to be paid for entering into pre-grant oppositions. An appeal 
can be filed in the appellate board against such decision. 
Post-grant Opposition Procedure 
The process of post grant opposition initiates with a notice of opposition 
filed by the opponent (who is an 'interested person') within 1, year from the 
date of publication of grant along with full written statement and evidence to 
the Controller. The patentee is required to file a reply statement and evidence 
within two months failing which, the application will be abandoned. This time 
period is extendible by one month provided the request for extension is filed 
within the two-month period. Reply evidence filed by opponents is to be 
strictly confined to patentee's evidence. Further evidence may however be filed 
with the leave of the Controller. 
All the documents are handed over to the Opposition Board constituted 
by the Controller for recommendation. Controller takes decision after a hearing 
along with the members of the Opposition Board. An appeal may be made 
against the decision before the Appellate Board within three month from date 
of the order. 
(v) Granting and sealing of patent 
Where the application is accepted either without opposition or after 
opposition a patent will be granted if a request for sealing is made by the 
applicant.^" An inventor if he so desires may make a request for mentioning his 
name in the patent. The controller if safisfied will cause his name to be 
74.5ee Sec. 43. 
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mentioned as inventor in the patent granted in the complete specification and in 
the register of patents. The mention of the inventors name in the patent will not 
confer or derogate from any right under the patent.^ ^ 
(vi) Term of Patent 
The term of every patent shall be twenty years after the commencement 
of the Patents (Amendment) Act, 2002. Those patents which have not expired 
and which have not ceased to have effect on the date of commencement of the 
Patents (Amendment) Act, 2002 shall be 20 years form the date of filing of an 
application. A patent can be kept alive only by paying the renewal fee from 
time to time. 
(vii) Patents of Addition 
Where an application is made for a patent in respect of any improvement 
or modification as referred to the main invention, if the patentee request so, the 
controller may grant the patent and such patent is called as 'patent of addition'. 
Apart from main invention a patentee is also a patentee in respect to the patent 
of improvement and modification. On the request of the patentee the controller 
may revoke the patent for the improvement or modification and grant patent of 
addition, in respect thereof bearing the same date as the date of the patent so 
revoked.^ ^ 
For the grant of 'patent of addition' the date should be same or later than 
the application for patent in respect to the main invention.''^  
The term of the patent of addition will be equal to that of the patent for 
the main invention or until the censor of the patent for main invention if the 
patent for main invention is revoked on request the controller may declare the 
75. See Sec. 28. 
16. See Sec. 54(1) (2). 
77. See Sec. 54 (3). 
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patent of addition as independent patent and for the remainder period for the 
patent for the main invention. No renewal fee shall be paid in case of patent of 
addition but on becoming an independent patent the required fee as for patent 
of main invention shall be paid. 
Rights of Patentees^ * 
A patent is a statutory grant conferring certain monopoly rights on the 
grantee for a defined period subject to certain conditions. Patent confers the 
right to exclude others from manufacturing in a particular way and using a 
particular to the exclusive use of a patented invention during the period of its 
protection is a right to property. The Patent Act, 1970 contains various 
provisions in Section 48, 50, 53, 63 and 68 etc rights summarized are 
(1) Right to exploit the patent 
(2) Right to assign and licence 
(3) Right to surrender the patent 
(4) Right before sealing 
A patent is a kind of limited monopoly granted to the true and first 
inventor as a regard for the creation of something view and useful which might 
benefit the public. But no patent is absolute and therefore it can be revoked by 
the Government or can be surrendered by the patentee under certain 
circumstances.^ ^ 
Where a patent covers a process, the patentee has the exclusive right to 
exclude others from performing, without his authorization, the act of using that 
process, using and offering for sale, selling or importing for those purposes, the 
product obtained directly by that process in India. 
78.5ee Sec. 48 . 
79. See Sec. 64 to 66 , 
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In Addition, to this Right to Exploit Patent, different rights covered 
under the Act are-
1. Right to assign and licence the patent to other for consideration. If he is 
co-owner of the patent he can assign his share of the patent or grant 
licences to others to use the patent only with the consent of the co-
proprietors or under the directions of the Controller. 
2. Right to surrender his patent. But before accepting the offer of 
surrender a notice of surrender is given to the persons whose name is 
entered in the register as having an interest in the patent and their 
objection, if any, considered. 
3. Rights before sealing. During the period from the date of 
advertisement of the acceptance of complete specification and the date 
of sealing of the patent, the applicant for the patent can exercise all 
the privileges and the rights of the patentee except filling of the suit 
for infringement. This provision is now deleted by the Patents 
(Amendment) Act, 2005. 
4. Right to sue for infringement. It can be done by instituting a suit in a 
court not lower than the District Court in case of any infringement. 
5. Right to make a convention application. 
6. Right to apply for patents of addition 
However, these rights are not absolute and are circumscribed 
by various conditions and limitations such as-
1. Power of the central government to use the inventions for the purpose of 
government even without the consent of the patentee, payment of any 
royalties in case of medicine or drug. 
2. Compulsory licenses can be granted if the patent is not worked so as to 
satisfy the reasonable requirements of the public at the reasonable price. 
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3. There can be revocation of the patent in case of non-working of it. 
4. The inventions relevant for the defense purposes may be subject to 
certain secrecy provisions. 
5. When a patent which has once lapsed has been restored, certain 
limitations are enforced on the rights of the patentee. For example, the 
Controller may impose conditions for the protection or compensation of 
the persons who may have begun to make the use of the inventions avail 
themselves of the inventions during the period when the patent was 
not effective due to lapse. 
Patent Administration in India-
The Office of the Controller General of Patents and Designs administers 
of the Patent Act, 1970 and the Rules made there under. Any reference to the 
"Central Government" in the Act or the Rules refers to the Government of 
India, typically represented by the Secretary, the Department of Commerce and 
Industry. The Office of the Controller General of Patents and Designs is also 
responsible for the administration of Trademarks and Geographical Indications. 
The Ministry of Industrial Policy & Promotion, through the Joint Secretary, has 
administrative and supervisory control over the office of the Controller General 
of Patents, Designs, Trade Marks and Geographical Indications. For the 
purposes of the Patents Act, 1970 and the Rules, the Controller General acts as 
the Controller of Patents. Further, the Act also provides for an Appellate Board 
to entertain and admit appeals arising out of the orders of the Controller of 
Patents and to exercise jurisdiction with respect to proceedings to revoke a 
patent other than through a counterclaim in a suit for infringement. An 
Intellectual Property Appellate Board (IPAB) was established under Section 83 
of the Trade Marks Act, 1999 to act as the Appellate Board for the purposes of 
the Patents Act, 1970. 
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The Office of Controller of Patents 
The Controller of Patents is the principal officer responsible 
for administering the patent system in India. The Controller is the overall 
supervisor of the four Patent Offices in Chennai, Delhi, Mumbai and Calcutta. 
Since the Controller also acts as the Registrar of Trademarks with the Head 
Office of Trade Marks in Mumbai the Controller of Patents functions from his 
office in Mumbai. Officially, the Head Office of Patents is in Calcutta. The 
Examiners of Patents appointed under the Patents Act and other officers of the 
Patent Office discharge their functions under the direction of the Controller. 
The hierarchy of the officers at the Patent Office is illustrated below: 
Intellectual Property Appellate Board 
The Intellectual Property Appellate Board (IPAB) was established on 
September 15, 2003 by the Central Government under the provisions of section 
83 of the Trade Marks Act, 1999. The Patents Act, 1970 (as amended in 2002) 
provided for designation of IPAB as the Appellate Board for the purposes of 
the Patents Act, 1970. The Ministry of Commerce and Industry, Government of 
India recently announced the appointment of a Technical Member on the IPAB 
effective from April 2, 2007. The IPAB is headquartered in Chennai and also 
conduct hearings on rotation in Chennai, Delhi, Mumbai, Kolkata regarding the 
grant of patent. 
Powers and Jurisdiction of the Appellate Board 
As of April 2, 2007, the Appellate Board is empowered to receive, hear 
and dispose of all appeals from any order or decision of the Controller and all 
cases pertaining to the revocation of a patent, other than through a counter 
claim in a suit for infringement. The Appellate Board may proceed with the 
matter either de novo or from the stage at which it was transferred on appeal. 
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The jurisdiction to hear patent infringement cases continues with the High 
Court. 
Surrender and Revocation of Patent 
Surrender- A patentee may at any time offer to surrender his patent, by 
giving notice in the prescribed manner to the Controller. When such notice is 
received, the Controller will advertise the offer in the prescribed manner and 
also notify every person whose name appears in the register as having an 
interest in the patent. Any person interested may within the time prescribed 
after advertisement give notice to the Controller of opposition to the surrender. 
The Controller will notify the patentee of such notice. After hearing the parties 
if so desired by the parties, the Controller may accept to offer and revoke the 
patent if he is satisfied that patent may properly be surrendered. The aggrieved 
party may appeal against the decision of the Controller. The procedure for 
surrendering a patent is contained in Section 63 and Rule 71. A notice of the 
offer to surrender the patent must be given on Form 33. 
Revocation of a Patent:- A patent, whether granted before or after the 
commencement of the Act, may be revoked on a petition of any person 
interested or of the Central Government by the Appellate Board or on a 
counter-claim in a suit for infringement of the patent by the High Court on 
grounds namely patent was granted on an application of person not entitled to 
apply for the patent or on non-compliance with the requirements for use of an 
invention or on petition by a person interested on various specified grounds. It 
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can be done by various modes namely revocation in the public Interest by the 
Government or relating to atomic energy by Controller. A Patent may also be 
revoked for non-working. 
Infringement of Patents and Remedies 
Infringement of a patent is the violation of the exclusive rights of the 
patentee. Determination of infringement depends on the scope of exclusive 
rights of the patentee, whether the infringer's acts amount to making, using, 
selling or distributing a product or using a method and if in fact, the acts 
amount to an infringement. The burden of proof is on the patent owner for 
proving infringement. Infringement of a patent can be: 
1. Direct i.e. when someone without authority, makes, uses, or sells a 
patented invention in the country where the patent is valid and is 
enforceable. 
2. Induced i.e. when a person actively and knowingly aids and abets direct 
infringement of a patent by another person. 
3. Contributory i.e. when any person, without authority sell a component 
of a patented invention, for use in practicing a patented process, or 
machine constituting a material part of the invention, knowing the same 
to be especially made or adapted for use in the infringement of such 
patent, and not a staple article of commerce suitable for substantial non-
infringing use. 
4. Through Colourable Imitations or Equivalents Sections 104 to 117 of 
the Act deals with the suits concerning infringement of Patents. An 
action for infringement of a patent must be instituted by way of a suit in 
any District Court or High Court having jurisdiction to try the suit. 
Where a counter-claim for revocation (Section 64) of the patent is made 
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by the defendant, the suit, along with the counter-claim, will be 
transferred to the High Court for decision. 
Defences- The defendant in a suit for infringement may plead one or 
more defenses. He can claim the patent owner is not entitled to sue for 
infringement or deny any infringement. Any leave or license express or 
implied to use the invention does not amount to infringement and where 
infringement is invalid on certain grounds: 
Acts done in connection with government use, experiment, research, 
education and falling within the scope of innocent infringement or done after 
failure to pay renewal fee or before the date of amendment of the specification 
do not amount to infringement. A defendant may also counter claim for 
revocation of patent. 
Reliefs- The reliefs available to a successful plaintiff in a suit for 
infringement include: 
1. An injunction, 
2. Either damages or an account of profits, and 
3. An order of seizure, forfeiture or destruction of the materials and 
impediments used in the creation of the infringing goods. 
The granting of these reliefs is discretionary. The injunction may be 
subject to terms as the court may think fit to impose. In all cases it will be 
limited to the term of the patent. Provisions relating to reliefs in Patents 
(Amendment) Act, 2005 are not exhaustive. Thus, it would appear that the 
court is not debaned from ordering delivery-up or destruction of the infringing 
articles. 
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SALIENT FEATURES OF THE THREE PATENT ACTS 
The Indian Patents Act, 1970: 
The features of the Patents Act, 1970 reveals the basic patent policy of 
India. This Act reflects the concerns of a developing country, balanced with the 
interest and needs of the inventors. Under the Act, the patents are granted to 
encourage inventions and secure that the inventions are worked in India on a 
commercial scale and to the fullest extent reasonably practicable, without 
undue delay; and patents are not granted merely to enable patentees to enjoy a 
monopoly for the importation of the patented article. The Act accords special 
status to patents relating to medicine, food items and chemicals. No product 
patent can be granted relating to medicines, food items and chemicals, only the 
process of manufacturing such products can be can be patented .In case of grant 
of patents for certain substances which are not food items or drugs as such but 
are capable of being used as food and drugs, the same are deemed to be 
endorsed with the words "licences of rights". The significance is that a patent 
endorsed with these words, does not retain exclusive use is limited only to three 
years. This is for the use of invention in certain circumstances for general good. 
But after the implementation of the Patent Act, 1970 certain loopholes and 
lacunae were still found. 
Being the signatory of International Conventions along with TRIPS 
agreement the differences were observed between Patents Act, 1970 and 
TRIPS agreement, such as: 
1. The Patent Act 1970, only allows the process patenting in food, 
medicine ad chemicals whereas TRIPS says to implement the process as 
well as product patent in almost all fields of technology. 
2. The Patent Act, 1970 fix the term of patent 14 years and 5-7 years in 
case of chemicals and drugs whereas TRIPS allows the term of patent 
for 20 years. 
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3. The Patent Act, 1970 enact provisions relating to compulsory licensing 
as well as of licence of rights where as TRIPS talks for limited 
compulsory licence and for no licence of right. 
4. Under Patent Act, 1970 several areas were excluded from patentability 
such as methods of agriculture, any process for medicinal, surgical or 
other treatment of animals and plants to render them free of disease or 
increase economic value of products on the other hand TRIPS says 
almost all fields of technology is patentable. Only area conclusively 
excluded from patentability is plant varieties and some areas of 
agriculture and biotechnology. 
5. Patent Act, 1970 do not give complete monopoly to patent holders on 
certain grounds. Government is allowed to use patented invention to 
prevent scarcity where as TRIPS give very limited scope for government 
to use patent inventions. 
India's commitment to implement the agreement on TRIPS required 
about three sets of amendments to its patents law. The first amendment of the 
Patent Act, 1970 by the Patent (Amendment) Act, 1999 introduced 
requirements under the transitional arrangements through Section 5 (2) which 
allowed product patent application to be filed while chapter 1V-A provided for 
the grants of Exclusive Marketing Rights (EMRs). 
On January, 2000 a second Amendment Patent (Amendment) Act, 2002 
had to be introduced for bringing the Patents Act in conformity with all the 
substantive provisions of the TRIPS Agreement barring those related to the 
production of product patents. The key issues included in the second 
amendment were redefining patentable subject matter, extension of the term of 
patent protection to 20 years and amending the compulsory licensing system. 
These differences in patent system led to disputes in the GATT 
negotiations on the inclusion of IPRs in the WTO. The main objection of the 
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US in the provision of India's patent law tiiat allows for process but not product 
patents in the area of food drug or medicine. The United States term the 
activities of India to find alternative processes as piracy. According to the US, 
Indian firms are copying technology developed by advanced nations. This is 
leading to large scale losses to the US the pharmaceutical industry in the US 
has been especially vocal on this issue. "Phrma," the association that represents 
USA based pharmaceutical companies points out based on the refusal of the 
Government to provide pharmaceutical patent protection Indian has become a 
haven for bulk pharmaceutical manufactures who pirate the intellectual 
property of the world's research base pharmaceutical industry.^ ° 
India's patent policy undergone enormous shifts and it revised the patent 
policy to conform to TRIPS and agreed to include IPR in the WTO. Since India 
was a developing country it had a 10 years transition period until January 2005 
to implement the said provisions of TRIPS. The longer transition period 
however, came with a set of conditions elaborated in Articles 70.8 and 70.9 of 
the TRIPS Agreement. Article 70.8 of the TRIPS Agreement required India to 
provide a means, by which product patent applications can be filed from 
January 1, 1995. If the products figuring in these applications were granted a 
patent in any of the WTO member countries and the products had obtained 
marketing approval in any of these WTO member countries then according to 
Article 70.9, five years Exclusive Marketing Rights (EMRs) had to be granted 
by India before granting or rejecting in India. As under TRIPS Agreement of 
the WTO all member countries were to provide product patents for all 
segments including Pharmaceuticals and agrochemical from January 1, 1995. 
But due to transition period under Art 70.8 and 70.9 India has to accept 
applications (which would be considered after Jan I, 2005) for patents and 
provide Exclusive Marketing Rights (EMRs) respectively for Pharmaceuticals 
and agrochemicals from the date of establishment of the WTO i.e. 1 January 
1995 Art 70.9 of the TRIPS agreement India has to give an EMR only if four 
80. http;//www.phrma.org/issues/in/india.httnl. 
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conditions are met: (i) That patent application has been filed in another member 
country after the entry into force of the WTO agreement from January 1, 1995; 
(ii) that a patent has been granted in that member country after January 1, 1995 
(iii) That marketing approval has also been obtained in India, (iv) Applicants 
for EMRs in India world also has to file the product patent application. Only 
then they can make applications to the controller of patent for grant of EMRs. 
India's commitment to implement the TRIPs Agreement required the patents 
amendment in the patents law. 
The Patents (Amendment) Act 2002 was introduced and some important 
changes were made-
(a) The definition of the term "invention" has been modified in consonance 
with international practices and consistent with TRIPs Agreement. 
(b) Section 3 of the present Act has been modified to include exclusions 
permitted by TRIPs Agreement and also subject matter like discovery of 
any living or non living substance occurring in nature in the list of 
exclusions which in general do not constitute patentable inventions and 
also to specifically exclude inventions which in effect are traditional 
knowledge. 
(c) The rights of patentee had been aligned as per Article 28 of the TRIPs 
Agreement. 
(d) A provision for reversal of bourdon of proof in case of infringement suit 
on process patent in accordance with Articles 34 of the TRIPs 
Agreement has been added. 
(e) Uniform term of patent protection of 20 years for all categories of 
invention as per Article 33 of the TRIPs Agreement has been prescribed. 
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(f) The provision relating to compulsory licensing has been modified to suit 
the public interest requirements and also to comply with TRIPS 
agreement 
(g) A provision has been incorporated for enabling parallel import of 
patented products at lowest international prices. 
(h) To ensure smooth transition of a product from the monopoly statues 
created by the patent to the public domain a provision has been 
incorporated for obtaining marketing approval from the appropriate 
regulatory authorities and traditional knowledge. 
(i) Several provisions have been incorporated for protecting bio-diversities 
and traditional knowledge. 
(j) Provision relating to national security has been strengthened 
(k) A provision has been incorporated for hearing of appeals which at 
present lie before high count by the intellectual property appellate 
aboard for speedy disposal of such appeals. 
(1) Several provisions have been incorporated with a view to simplifying 
and rationalizing the procedures. 
After the amendment of 2002 certain gaps were still there. To fill these 
gaps again the desire arose to make a new amendment in the existing Act of 
2002. Beside this the main objective behind the introduction and passing of 
The Patents (Amendment) Act, 2005 was to meet India's deadline 31 Dec. 
2004 to comply with the TRIPS Agreement. 
Silent Features of the Patent (Amendment) Act, 2005 
1. Extension of product patent protection to all fields of technology (i.e. 
drugs, food & chemicals). 
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2. Deletion of the provisions relating to Exclusive Marketing Rights 
(EMRS) (which would now have become redundant) and introduction of 
transitional provision for safeguarding EMRS already granted. 
3. Introduction of a provision for enabling grant of a compulsory licence 
for export of medicines to countries which have insufficient or no 
manufacturing capacity, to meet emergent public health situations (in 
accordance with the Doha Declaration on TRIPS and Public Health). 
4. Modifications in the provisions relating to opposition procedures with a 
view to streamlining the system by having both pre-grant and post-grant 
opposition in the patent office. 
5. Addition to a new provision in respect of mailbox applications so that 
patent rights in respect of the mailbox shall be available only from the 
date of grant of patent and not retrospectively from the date of 
publication. 
6. Strengthening the provisions relating to national security to guard 
against patenting abroad of dual use technologies. 
7. Rationalization of provisions relating to timelines with a view to 
introducing flexibility and reducing the processing, time for patent 
applications and simplifying and rationalizing proc^du,!^. ^AJT^-
TK under WTO and TRIPS V l ^ 
Most Developing Countries in Asia are signature^^^t&;ii^^ 
agreements. In order to comply with the WTO commitments, those countries 
must reform their laws and regulations in several areas. The WTO obligations 
that require significant reform of the law are those found in TRIPS. Member 
countries are obliged to substantially eliminate IP infringements and to bring IP 
laws up to the TRIPS standards. Although TRIPS did not make any specific 
significant provisions for protecting traditional knowledge and no uniform 
norms were laid down for the protection of traditional knowledge, even then 
Article 27.3 (b) of the agreement allows members countries to excludes 
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patenting of plants animals and essentially biological process but makes its 
mandatory for their to patent micro organism and micro biological process. 
Moreover members must patent plant varieties or otherwise protect them of 
through an effective sui-generis system Doha Declaration of 2001 in WTO 
ministerial conference, says that TRIPS council should examine the relation 
between the TRIPS agreement and the UN convention on Biodiversity the 
protection of Traditional Knowledge and folklore, etc. to date one of the most 
prominent provisions on traditional knowledge is Article 8(j) of the 
Biodiversity convention. '^ Even then there are certain provisions under TRIPS 
agreement which protect traditional knowledge. Provisions relating to the 
obligation to protect geographical indications under the agreement can be used 
to protect traditional knowledge associated with the goods. Indian being a 
signatory to the TRIPS agreement and to comply with its requirements for the 
first time incorporates measures for the protection of biodiversity and 
traditional knowledge by the Patents (Amendment) Act of 2002. Traditional 
knowledge was considered as non-patentable under Sec 3 (p). Further with 
the Amendment Act of 2005 it is compulsory for patent applicant to disclose 
source and geographical origin of biological material used in invention. Along 
with this, failure to disclose source and geographical origin of biological 
material used in invention would be good ground for opposing patent 
application. By these amendments traditional knowledge take place in patent 
law also. 
Though IP system is not designed to protect traditional knowledge and 
may not suit the needs of indigenous and local communities in protecting their 
traditional knowledge Because the current IP systems adopt standards of 
protection that are too high & the criteria for protection are difficult to satisfy 
by innovations generated at community level. For example, a traditional 
81. A detailed Study of Article 8(j)has been done under Chapter-2 
82. Sec 3 (p) an invention which is effect is traditional knowledge or which is an aggregation or 
duplication of known properties of traditionally known components or components. Are not 
invention and thereby non-patentable. 
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knowledge based product which generally comprises active substances found 
in nature rather than a pure form of substance, would not be considered new 
and inventive and would hence be denied patent protection on the contrary, 
when researchers and companies take the next step by using the same 
knowledge in laboratories, such as by isolating, altering or purifying an active 
chemical of the herbal plants the substance would become a novel and 
inventive piece of knowledge and thus patentable. And above all the objective 
of IP protection which aims to protect individual and corporate interests is 
different from the objective for the protection of traditional knowledge. 
Conclusion 
Historically the concept of patents is based on legal and social justification. The legal 
justification is that inventor should have an exclusive right over his invention as a 
reward and the social justification is that not to grant monopoly right, they are 
privileges granted by the government to encourage research and inventions to disclose 
their inventions for industrial exploitation thereby providing new avenues for 
economic growth and development. The Indian Patent Act, 1970 was also enacted 
with a view to make patents serve the needs of economy as well as to make them a 
vehicle of rapid growth. The enactment of the Patents Act, 1970 was proved a boon 
for Indian pharmaceutical industry (especially the generic pharma segment).Several 
changes has been made in the Patents Act, 1970 through amendments, bringing it, in 
present shape of Patents (Amendment) Act, 2005. The Patents Act, of 1970 was not in 
conformity with the TRIPS agreement; the need was to bring the Act, 1970 in 
conformity of TRIPS agreement though TRIPS agreement does not specifically talks 
about traditional knowledge in patent regime. Moreover patents cover invention and 
traditional knowledge is not an invention which can be protected under patent Act, 
though the Amendment Act of 2002 gave protection to traditional knowledge 
considering it as a non-patentable thing. But now there is a need for an alternative 
approach which will bring a balance between formal intellectual property system 
covering patents, copy rights, trade marks and several aspects of traditional 
knowledge filing of complete specification require to mention the origin of biological 
resources. 
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Conclusion: 
Historically the concept of patents is based on legal and social 
justification. The legal justification is that inventor should have an exclusive 
rights over his invention as a reward and the social justification is that not to 
grant monopoly right, they are privileges granted by the government to 
encourage research and inventions to disclose their inventions for industrial 
exploitation thereby providing new avenues for economic growth and 
development the Indian patent Act, 1970 was also enacted with a view to make 
patents serve the needs of economy as well as a to make their a vehicle of rapid 
growth. The enactment of the Patents Act, 1970 was proved a boon for Indian 
pharmaceutical industry (especially the generic pharma segment). The Patents 
Act, 1970 under gone several changes through three amendments. Bringing it 
into the shape of Patents (Amendment) Act, 2005. The patents Act, of 1970 
was not in confirmedly with the TRIPS agreement, the need was to bring the 
Act, 1970 in confirmedly of TRIPS agreement though TRIPS agreement does 
not specifically talks about traditional knowledge in patent regime. Moreover 
patents cover invention and traditional knowledge is not an invention which 
can be protected under patent. Act, but the Amendment Act of 2002 gave 
protection to traditional knowledge considering it as a non-patentable thing. 
But now there is a need for an alternative approach which will bring a balance 
between formal intellectual property system covering patents, copy rights, trade 
marks and several aspects of traditional knowledge filing of complete 
specification require to mention the origin of biological resources. 
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TRADITIONAL KNOWLEDGE UNDER INTELLECTUAL 
PROPERTY RRIGHTS REGIME 
No specific definition can be given for the word 'traditional Icnowledge.' 
However, many debates and discussions have taken place at various levels to 
explain its meaning. It can be said it is systematic information that remains in 
the informal sector. Normally they are in unwritten and preserved in oral 
tradition rather than in the forms of documents. Traditional knowledge is not 
confined to any specific field. It covers medicines, health care, biodiversity, 
conservation, environment, foundry and agriculture etc. Sometimes it also 
covers music, dance, textiles plastic arts and crafts etc. Therefore, traditional 
knowledge reflects the aesthetic beliefs history, ethics and traditions of a 
particular group of people. The basic feature of the traditional knowledge is 
that it is not created or produced systematically. But it is created or produced 
collectively or individually in relation to ones cultural and traditional 
environment. Besides this tradition knowledge represents cultural values of a 
particular group.' 
Traditional knowledge is not in document in any form but it is 
transported form one generation to another orally. This knowledge is the 
knowledge of traditional people and it cannot be departed from them. 
Traditional knowledge is also very much related to plants, whether they are 
medicinal or harvesting. To protect this valuable traditional knowledge a patent 
can also be claimed to it. 
1. Meaning and Concept of Traditional knowledge 
The word tradition is derived from the Latin word 'tradition' which 
means to hand down or hand over or 'beliefs' or 'customs' taught by one 
1. Dr. Raju C.B. and Dr. Sreenivasulu N.S. "Intellectual Property Rights and Traditional Knowledge 
the Thin Line between Bio-Prospecting and Biopiracy" M/PR Vol. 2 p. A-2 (2008 ). 
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generation to the next often orally. Oxford English dictionary defines 
Knowledge variously as (i) expertise and skill required by a person through 
experience or education, the theoretical or practical understanding of a subject. 
Traditional knowledge is too wide a term to define and limit. It may be 
generally described as the knowledge possessed by a traditional or indigenous 
community or even a group of persons whose life and livelihood depend on 
such knowledge. Since such knowledge forms part of the culture and traditions 
of such community or persons, it needs to be preserved and maintained. Any 
misappropriation of such knowledge by third parties for commercial gain could 
threaten such community's existence. 
Daniel Gervais has noted the following elements of traditional 
knowledge to mean knowledge:^  
a) Which is traditionally only to the extent that its creation and used are part of 
the cultural traditional of a community 'traditional; therefore, does not mean 
necessarily mean that the knowledge is ancient or static. 
b) is representative of the cultural values of people and, thus is held 
collectively 
c) is not limited to any specific field of technologies or the arts. 
In April 2001, World Intellectual Property Organization (hereinafter 
WIPO) published its report on fact-finding missions on intellectual property 
and traditional knowledge (1998-1999): Intellectual Property needs and 
Expectations of Traditional Knowledge Holders. In that report WIPO's use of 
the term 'traditional knowledge' referred to 'tradition based literary, artistic or 
scientific works; performances; inventions: scientific discoveries; designs; 
marks, names and symbols; undisclosed information; and all other tradition-
based innovations and creations resulting from intellectual activity in the 
2. Daniel Gervais, The TRIPS Agreement-Drafting History and Analysis p. 5 (2003). 
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industrial, scientific, literary or artistic fields^. The emphasis is clearly 
influenced by intellectual property concepts, but the report goes on to clarify 
the distinguishing feature, namely, that these elements are 'tradition-based'. 
Here WIPO refers to 'knowledge systems, creations, innovations and cultural 
expressions which: have generally been transmitted from generation to 
generation; are generally regarded as pertaining to a particular people or its 
territory; and are constantly evolving in response to a changing environment. 
Among the various categories of traditional knowledge listed in the report, 
WIPO includes' agricultural knowledge; scientific knowledge; technical 
knowledge; medicinal knowledge, including related medicines and remedies: 
biodiversity related knowledge**. 
Traditional knowledge is now widely recognized as having played and 
still playing crucial roles in economic, social and cultural life and development, 
not only traditional societies but also in modern sciences. 
To evolve it takes over a period of time as a result of contributions of 
members of a particular society. Modified, enlarged and enriched, it became a 
valuable knowledge for the particular society and stood the test of time. What 
makes traditional knowledge "traditional" is not an antiquity but the way it is 
inherently dynamic, as it evolves a response posed by the environment alerts its 
forms and content; thus it is subject to a continuous process of verification, 
adaptation and creation. This traditional knowledge encompasses an entire field 
of behavior. 
The traditional knowledge is somewhere defined as; the indigenous people 
of the world possess an immense knowledge for their environment based on 
centuries of living, close to nature. Living in and from richness and variety of 
complex ecosystem, they have an understanding of the properties of plants and 
3. Kiran M.Nadagoudatv, "International Legal Regime Relating to Protection of Traditional Knowledge: 
An Analysis" 19 Kanataka Law Journal (Kar.U) 33 (2005). 
4. S.K.Vcrma, Intellectual Property Rights, Global vision, Indian Law Institute p. 43 (2004). 
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animals, the functioning of ecosystem and the techniques of using and 
managing them that is particular and often detailed. In rural communities of 
developing countries, locally occurring tribes are relied on many natural 
products for, foods, medicine, fuels building materials and other necessaries. 
Equally the people's knowledge and perceptions of environment and their 
relationship with it are often important elements of cultural identity. 
This cultural heritage or traditional knowledge, which has been integral 
part of several communities, is at stake due to undue interest shown by western 
science. The combination of traditional knowledge and modem scientific 
knowledge, in bringing new products and new uses of existing products, 
especially, in the filed of health and agriculture including biotechnology. No 
doubt this is a welcome step in the field of science and technology. But the 
seriousness of the situation is that such commercial exploitation of traditional 
knowledge as is taking place have resulted in 'bio-piracy' without prior 
permission of the communities, which are the sole custodians of this traditional 
lore. Such communities have not been allowed to share, at least in a fair and 
equitable manner, the benefits arising from the appropriation of their 
knowledge for commercial gain. 
Traditional knowledge (TK), indigenous knowledge (IK), and local 
knowledge generally refers to the matured long-standing traditions and 
practices of certain regional, indigenous, or local communities. Traditional 
knowledge also encompasses the wisdom, knowledge, and teachings of these 
communities. In any cases, traditional knowledge has been orally passed for 
generations from person to person. Some forms of traditional knowledge are 
expressed through stories, legends, folklore, rituals, songs, and even laws. 
Other forms of traditional knowledge are often expressed through different 
means.' 
5. Available at. http://en.wikipedia.org/wiki/Traditional_knolwedge 
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This is a community-based system of knowledge that has been developed, 
preserved and maintained over many generations by the local and indigenous 
communities through their continuous interactions, observations and 
experimentations with their surrounding environment. It is unique to a given 
culture or society and is developed as a result of the co-evolution and co-
existence of both the indigenous cultures and their traditional practices of 
resources use and ecosystem management. TK is a general term, which refers 
to the collective knowledge, beliefs and practices of indigenous/local people on 
sustainable use and management of their resources. Through years of 
observations and analysis, trial, error or experimentations, the traditional 
communities have been able to identify useful as well as harmful elements of 
their ambient flora and fauna. Such knowledge (acquired through ages) has 
always remained as part of their life, culture, traditions, beliefs, folklores, arts, 
music, dance, etc. TK covers a broad spectrum of the local and indigenous 
people's traditional lie and culture, art, music, architecture, agriculture, 
medicine, engineering and a host of other spheres of human activity. TK thus 
can be of direct or indirect benefit to society as it is often developed, in part as 
an intellectual response to the necessities of their life. Protection and 
maintenance of TK of local and indigenous communities is vital for their well-
being and sustainable development and for their intellectual and cultural 
vitality. 
2. Subject Matter for the Protection of Traditional Knowledge 
Though there is not any area specified for the protection of traditional 
knowledge and traditional knowledge has also not been confined in any 
particular field. It includes safeguarding or preserving existing as well as the 
social, economic, environmental, cultural spiritual context within which the 
knowledge evolves. Oral traditions and expressions, performing arts and social 
practices are the other aspects of traditional knowledge. 
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Traditional Agricultural Practice, Indigenous Technological Knowledge, 
Traditional Bio-resource Management, Traditional Meditation and Yoga 
Therapies, Traditional Handloom Handicrafts and dyeing Techniques, 
Traditional Manufacturing of Musical Instruments, Traditional Storage System 
(of grains, pulses, fodder etc). Traditional Philosophical system. Traditional 
Forest Knowledge & Bio conservation, Traditional Food Processing is the 
other aspects also need protection. 
Here the subject matter for the protection is the knowledge of farmers 
concerning wild as domesticated varieties. It also includes the knowledge of 
healers, concerning useful medicinal properties of plants, knowledge of 
therapeutic combination of plants as well as processes for extracting relevant 
properties. The World Health Organization has stated that 80% of the world's 
population depends on traditional medicine for its primary health care.^  6 
WIPO and UNESCO jointly took the initiative for the development of 
model legislation for protection of folklore. Another attempt was made by the 
United Nations Draft Declaration of Rights of Indigenous People also talked 
about the protection of traditional knowledge but here also the claim of 
ownership was lacking. TRIPS also did not talk about any protection of 
traditional knowledge though it has mentioned for the protection of plant 
varieties through a sui-generis system. 
But Art 8 (j) of CBD provides that "contracting parties shall as far as 
possible and appropriate and subject to their national legislation, respect 
preserve and maintain knowledge, innovations and practices of indigenous and 
local communities embodying traditional lifestyle relevant for the conservation 
and sustainable use of biological diversity and promote their wider 
application with the approval and involvement of the holder of such, 
knowledge, innovates and practices and cowage the equitable sharing of the 
6. WHO Report. (1993). 
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benefits arising of from the utilization of such knowledge, innovations and 
practices." 
International Labour Organization's convention No. 169 also recognizes 
and protects the social, cultural religions and spiritual values and practices of 
indigenous and tribal people. 
The India's Biodiversity Act, 2002, Patent Act, 2005, Geographical 
Indications Act, 1999 tries to protect and preserve the traditional knowledge. 
All these are framed according to the guideline of Intellectual Property Rights. 
The current IPR system cannot protect traditional knowledge for three reasons 
firstly the current system seeks to privatize ownership and is designed to be 
held by individuals or corporations, whereas traditional knowledge has 
collective ownership. Secondly this protection under IPR system is time bound 
whereas traditional knowledge is held in perpetuity from generation to 
generations. Thirdly it adopts a restricted interpretation of invention which 
should satisfy the criterion of novelty and be capable of industrial application, 
whereas traditional knowledge is incremental, informal and occurs every time. 
So a sui-generis law for the protection of traditional knowledge is required.'' 
A number of countries have already legislated on certain aspects of 
traditional knowledge, laws are already framed by a number of countries such 
as Peru, Costa Rica, Portugal and Thailand have their own sui-generis regimes 
with their own defined objectives. 
Dimensions to Traditional Knowledge 
The potential role of intellectual property rights in the protection of 
traditional knowledge is an emerging field. This requires thorough exploration. 
Although, there is no clear, precise and specific international intellectual 
property standard for protecting such knowledge. There are many issues which 
7. M.K. Bhandari, Law Relating to Intellectual Property Rights p. 218. (2006). 
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require considerable clarity. For example the distinction between indigenous 
knowledge and traditional knowledge is a subtle one. Essentially, indigenous 
knowledge is a term used to identify the knowledge possessed by indigenous 
people and there is a not universally accepted formal definition o indigenous 
person although indigenous knowledge is generally considered traditional 
knowledge but at the same time not all traditional knowledge is indigenous 
knowledge. Since indigenous knowledge is otherwise similar to traditional 
knowledge in its transmission, scope and diversity it is appropriate to consider 
indigenous knowledge a subset of traditional knowledge. The importance of 
resorting to the term indigenous knowledge emerges were one wants to 
describe the type of knowledge and the people who hold it. Therefore, in search 
of model that makes the intellectual property system and traditional knowledge 
more compatible, the WIPO has initiated a programme of activities to assess ad 
address the needs of the holders of this beautiful landscape of knowledge's 
3. Rationale for the Protection of Traditional Knowledge 
Awareness of indigenous knowledge and concerns of protecting it are 
growing overtime. Most of indigenous knowledge descends from ancient 
traditions and needs a proper validation and documentation. The rationale for 
protecting traditional knowledge centers on questions of fundamental justice 
and the ability to protect, preserve and control one's cultural heritage. There is 
also the concomitant right to receive a fair return on what these communities 
have developed. Many area of traditional knowledge have potentially lucrative 
applications. 
It is believed that the knowledge rich research and development systems 
of the corporate entities and institutions of the developed countries have vested 
interest in the biodiversity as well as its related knowledge and know how of 
the developing countries. Such entities and institutions have consistently 
8. Saleem Akhtar, "The Protection of Traditional Knowledge under Intellectual Property Rights 
Regime" in Rais Ahmed, The WTO and Agriculture p. 1013 (2009) 
88 
nra£tiona[%ji(yw(edge VmCer I^^fgime 
arguing about the benefits of their research and development ultimately passing 
on the well being of the human kind. Seeking protection from their 
governments these business entities generally try to find a safe route for their 
nearly developed products into the global market through the instrumentality 
of their biotech marketing practice for the huge margins of profits without any 
trickle of these profits passing on to the holder of bioresearches. In turn, the 
holders of these bioresearches find their biodiversity, ecology national 
resources as well as its related know how appropriated exploited and finally left 
endangered of innovations that have occurred in the developed world were 
created and developed out of the material resources as in related knowledge of 
the developing world. Often the produce has been staunched and huge profits 
have been earned without sharing its benefits or without acknowledging the 
factual truth about its real owners. The real owners of bio-resources and 
holders of its application knowledge are left betrayed and cheated.' And from 
here the rationale for the protection of TMK arise. 
The arguments advanced for the IPR protection of Traditional knowledge, 
as relevant to TMK will be presented in the coming pages. 
(a) Equity 
Proposals for the protection of traditional knowledge (including codified 
and non codified TRM) are often based, explicitly or implicitly on equity 
considerations. The main objective of protection would be to obtain recognition 
and some compensation for the commercial use of TRM outside the 
community or the society which generated it either by excluding the 
unauthorized use by third parties or by ensuring a right to remuneration (or 
benefits sharing) for such sue. 
9. A..K.Kantroo, "Intellectual Property Debates: Protection of Biodiversity Genetic Resources and 
Ecosystems" Goppeshwar Law Review p.9 (2005-2006). 
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Equity can also be understood, in this context, in the sense of allowing 
indigenous people to access a system (IPRs) that other peoples can access to 
gain reward for their own knowledge or innovations, so that they have the 
capacity to be rewarded through licensing or undertaking commercialization 
themselves. This second interpretation of 'equity' is a common implicitly 
assumed rationale for expanding IPRs to cover traditional knowledge. 
There is some experience with "bio-prospecting" of medicinal plants 
under agreements that provide for benefit sharing with the local and indigenous 
communities that supplied the relevant knowledge and materials. However, 
TRM knowledge holders should not be assumed to necessarily expect a 
monetary reward for the knowledge they supply (or is otherwise appropriated). 
While Western IPRs assume that the act of innovation or creation is largely 
motivated by financial gain, local or indigenous communities generally believe 
that knowledge is socially created, through interaction amongst humans and 
nature, and that individuals are obliged to put their knowledge to use for the 
benefit of the community without expecting a monetary compensation. Thus, 
the way most healers are paid, at least the traditional ones in Eastern and 
Southern Africa, is through a voluntary system including pro bono work and 
soft loans. The voluntary aspect functions because of social aspects: fear of 
ancestors, spirits or whatever force is believed to be behind the medicine, 
makes people pay what they are able to because otherwise they believe the 
medicine will not work. The voluntary system is extremely important as it 
serves a social purpose, fitting what might be described as the healers' 
Hippocratic Oath.'° 
Hence, equity-based claims of protection are not necessarily equivalent to 
demands of remuneration. Moreover, in some communities a monetary 
payment may be regarded as morally unacceptable, or custodians of knowledge 
10. 'Rationale for Protection' available at 
<www.southcentre.org/publication/traditionalmedicine/traditionalmedicine.03.htm 
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may not be free to make money out of it, or to transmit it for use outside their 
cultural or spiritual context. In fact, to do so can cause a great deal of offence, 
resentment and even distress. 
A study on herbal medicines made in Kenya revealed that: "Eighty per 
cent of those interviewed are well-informed about the commercial value of 
their knowledge and were quick to indicate that access to it can always be 
negotiated. Five of the herbalists indicated that futile attempts have been made 
by foreigners to obtain information on particular herbal remedies. Seven of the 
herbalists indicated that they have been approached by local scientists for 
information. Apparently the herbalists were aware that the information so 
given was to be used in research and the information was given in mutual trust 
and confidence. Surprisingly, none of the herbalists had entered into any 
agreement about the future of the results or final destiny of the information so 
given" }^ 
In many instances, they may rather seek a moral recognition of their 
contribution to the development of the knowledge. The communities may not 
want to be ripped off but they also may not want some kind of IPR-type system 
to be imposed on them. In many cases, they may not be interested in an 
economic compensation but just in respect for and recognition of their culture 
and beliefs. 
b. Preservation 
The protection of Traditional Medicine (herein after TRM)may also aim at 
its preservation requiring actions of very different nature, such as avoiding uses 
that may erode TRM addressing problems that negatively affect the life or 
culture of the communities that hold it and documenting the relevant 
knowledge. Further, cultural erosion may be a powerful factor in the loss of 
TRM. As youth move to urban areas and education de-emphasize the value of 
W.Ibid 
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traditional culture and knowledge, TRM loses its heirs. Thus it has been noted 
that in the Asian context: 
"Urbanization and the advent of the nuclear family leading to the virtual 
disappearance of the grandmother, the mother-in law, and the village elders, 
have led to a situation where common remedies which had been administered 
with out any doctor for years have now became questionable for a new 
generation of western-educated urban public exposed only to the allopathic 
system and allopathic drugs. The age old practice of maintaining kitchen 
gardens and visit to a village grocer who stocks all the dried herbs have gone 
in to disuse in the cities. Knowledge about which part of the plant is to be used, 
namely the root, stem, bark or leaves, has been effaced. Yet for centuries this 
has been the mainstay of entire population, long before allopathic came to the 
scene, and continues to be so for tribal and village people in many developing 
countries even today.'" 
An obvious action to preserve TRM knowledge is to document it. India 
has pioneered initiatives for the documentation of traditional knowledge 
including TRM. It launched an all India Coordinated Research Project on 
Ethno biology (AICRPE) under the Man and the Biosphere Programme in 
1982. The overall objective of AICRPE was to make an in-depth study and 
analysis of the multidimensional perspectives of life, culture, tradition and 
knowledge system of the tribal communities of India. Initially the project was 
administered under the Department of Science and Technology, but was later 
transferred to the Indian Ministry of Environment and Forests. It operated at 27 
centers within India, utilized approximately 600 scientists drawn from botany, 
zoology, sociology, anthropology, ayurveda, chemistry and pharmacology and 
lasted for 16 years (1982-1998). The AICRPE project documented the use of 
over 10,000 wild plants used by tribal peoples to meet a variety of their 
needs.'^ 
\2.Ibid., 
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The 'Gene Campaign' project has also aimed at documenting the 
biodiversity and related knowledge of three tribal populations in India: the 
Mundas in South Bihar (in the Chotanagpur region); the Bhils of Madhya 
Pradesh; and the Tharus of the Trai region. Similar initiatives have been taken 
in other countries. For example in the Peoples Democratic Republic of Laos, 
the Traditional Medicines Resource Centre (TRMC) works with local healers 
for documentation of all traditional medicine with a view to promoting a 
sharing of practices within Laos. The TRMC is also collaborating with the 
International Co-operative Biodiversity Group (ICBG) in efforts to discover 
prospective medicinal products. Any profits or royalties realized from plants 
and knowledge recovered during the collaboration will be shared with all the 
involved communities. 
In the Ivory Coast a TRM programme was set up by Ministry of Health 
in 1978. In order to protect traditional medicinal knowledge and promote 
proper use of traditional medicine, this programme conducted surveys of 
traditional health practitioners in 7 out of 19 regions of the Ivory Coast and has 
recorded more than 1,000 medicinal plants, used by traditional health 
practitioners. 
In the United Arab Emirates, there is a long history in the use of 
traditional medicine. The Zayed Complex for Herbal Research & Traditional 
Medicine (ZCHRTM) was established in 1996. One of its basic missions is to 
collect record and analyze the traditional medicine knowledge from traditional 
practitioners. 
The Government of Iran has, since 1990, supported the development of 
a national inventory of medicinal plants. Up to now, 2.500 floras of 8.000 
plants have been listed, classified and divided into 20 volumes. The National 
Academy of Traditional Medicine in Iran was established in 1991. One of its 
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objectives is to study the history of Iranian traditional medicine and preserve 
Iran's traditional medicine. 
c. Preventing Misappropriation 
The first instances related to unauthorized appropriation of TRM based 
products for process and biological resources was the 'turmeric' case. 
In May 1995 the US patent Office granted to the University of Mississippi 
Medical Center a patent for "Use of Turmeric in Wound Healing". The patent 
was promptly challenged by Dr. R.A. Mashelkar, an Indian scientist who has 
done much to awaken India to Intellectual Property Rights issues. After four 
months of submissions it was established that the use of turmeric as a healing 
agent was well-known in India. The patent was annulled. 
In 1996, Vandana Shiva - an icon for Third World Knowledge Rights-
began to challenge the patent granted to the firm of W.R. Grace & Co by the 
European Patent Office, Munich for Tungicidal uses of neem oil. Shiva and 
Ajay Phadke (who had researched neem for Rhone Poulenc in India) fiagged 
ancient Indian texts for their eminences in Munich to convince them that there 
was no 'novelty factor in neem's magical- properties that Grace had unveiled 
Indians had known them for long. This patent too was vacated indeed to battles 
were when but there are many ahead. London of observer says more than 100 
Indian plants are waiting for the patent plant at the US patent office. Some 
important plants have already been granted patent such as Amla, Jar Amla, 
Anar, Salai, Dudhi, Gulmendhi, Bagbherenda, Karela, Rangoon-ki-bel, Erand, 
Vilayetishishman, Chamkura etc, and all household Indian names. These need 
to be vacated. 
d. Promoting Self Determination 
The right to self-determination essentially recognizes the right of peoples 
to define their own way of life, in all its many facets. This right, though 
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applying to all peoples in international law, is seen by indigenous scholar, 
leaders and communities as particularly important for the advancement of the 
interests of indigenous peoples. 
The IPRs protection of TRM will, arguably, be consistent with the spirit 
of the right to self-determination, and various specific rights in international 
law (both binding and non-binding), only if indigenous peoples, desire, or at 
least do not object to the availability of such protection. Protection that is 
incompatible with the values of indigenous peoples, or inappropriate for other 
reasons as determined by them, is unlikely to meet such criteria. 
e. Promoting Development 
Another goal that has been suggested as a rationale for the protection of 
TRM is based on its potential contribution to economic development, 
particularly development that would benefit local/indigenous communities. The 
role of IPRs as instruments to promote and support commercialization and 
thereby economic development may be significantly different in the case of 
codified as compared to non codified, TRM systems. The commercial 
exploitation of herbal medicines, for instance, has opened up important 
business opportunities for Chinese and Indian companies, both domestically 
and internationally. 
There may also be cases where local indigenous community's desire to 
not only gain intellectual property right, but to take on the commercialization 
of their TRM knowledge themselves provided that they have the capital and 
managerial capacity to do so. IPRs may strengthen the community's market 
position in these cases.'^ 
n.lbid., 
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Other Reasons for Protecting Traditional Knowledge: 
The traditional knowledge needs protection. Apart from treaties and 
emerging international norm, which imply both legal and moral imperatives for 
protecting TK, there are number of reasons why developing countries want to 
protect their TK. 
(i) Improvement of Livelihoods of TK holders: 
TK is a valuable asset first and foremost to Indigenous and local 
communities that depend on TK for their livelihoods and well being as well as 
for enabling them to sustain ably manage and exploit their local ecosystem (for 
example through sustainable low input agriculture). 
(ii) Benefits to National Economy: 
TK is used as an input into modem industries such as pharmaceuticals 
botanical medicines cosmetics and toiletries, agriculture and biological 
pesticides that can harness advanced scientific, technological and marketing 
capabilities capture virtually al the value added in the products. This situation 
needs to be addressed so that developing countries can capture much more of 
the value added. 
Attempts have been made to estimate the contribution of TK, 
particularly biodiversity related TK, to modem industry and agriculture. 
Traditional knowledge base of plant based medicines may enable India to 
accelerate drug development. In 1985 the estimated market value of plant based 
medicines sold in Organization for Economics Co-operation and Development 
(OECD) countries in 1985 was US$43 billion. The distinguished 
pharmacognosist Norman Farms, worth observed that "out of 119 plant based 
compounds used in medicine worldwide, 74 percent had the same or related 
uses as the medicinal plants from which they were derived." It is particularly 
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difficult to estimate the contribution of traditional crop varieties (land races) to 
the global economy. However, a study on the use and value of land races for 
rice breeding in India estimated that rice land races acquired from India and 
overseas contributed 5-6 percent or US$75 million. The global value added to 
rice yields by use of land races can be estimated at US$ 400 million per year. 
But accurately estimating the full value of TK in monitory term is 
impossible. It seems that protecting TK has the potential to improve the 
performance of many developing countries economy by enabling greater 
commercial use of their biological wealth and increasing exports of TK related 
products. 
(Hi) Conservation of Environment: 
A large number of field studies have proved that the conservation ethic 
is prevalent feature of the subsistence and resource management practices of 
many present day indigenous or native people and traditional communities. 
Several academic studies on traditional communities provide ample evidence 
that the protection of TK can provide significant environmental benefits. For 
example many forest areas, members of traditional society's plant, forest, 
gardens and manage the regeneration of bushes follows in ways that take 
advantage of natural processes and mimic the biodiversity of natural forests. 
Much of the world's crop diversity is in the custody of farmers who 
follow age old farming and land use practices in ecologically complex 
agricultural systems which enable the conservation of biodiversity. These 
traditional communities maintain the centres of crop genetic diversity, which 
include the traditional cultivators and land races, that constitute essential part 
of the world's crop genetic heritage and non domesticated plant and animal 
species. 
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(iv) Prevention of Biopiracy 
Another reason for the protection of TK is to counter or prevention of 
biopiracy. It normally refers to either to the unauthorized extraction of 
biological resources and associated TK from developing countries, or to the 
patenting without compensation, of spurious inventions based on such 
icnowledge or resources. Turmeric, Neem, Bansmati rice are few case of 
biopiracy. Within the context of scientific progress, modem intellectual 
property laws have allowed the industries particularly the pharmaceutical 
industries to monopolize the benefit derived from the use of indigenous 
knowledge with disregard for their moral rights and material (financial) 
interests of indigenous people themselves. 
4. Tools for Protecting Traditional Knowledge 
For the protection of traditional knowledge two key directions are available -
(i) Defensive protection 
Defensive protection seeks to prevent using or securing intellectual 
property rights over traditional knowledge.''* The tool of defensive protection 
of traditional knowledge ensures that IP rights over TK are not given to parties 
other than the customary TK holders. These measures have included the 
amendment of WIPO administered patent systems (the international patent 
classification system and the Patent. Co-operation Treaty Minimum 
Documentation) some countries and communities are also developing TK 
databases that may be used as evidence of prior art to defeat a claim to a patent 
on such TK. 
(ii) Positive protection: The positive protection seeks to protect legal rights 
over traditional knowledge with the resulting possibility of preventing other for 
14. K.P.S Mahalwar., Vishal Mahalwar, "Protection of Traditional Knowledge and Intellectual 
Property Rights: Indian and International Perspectives" \)A5 M.D.U. Law Journal {2006}. 
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using the TK without permission. In some countries, sui-generis legislation has 
been developed specifically to address the positive protection of traditional 
knowledge provides and users may also enter into contractual agreement or use 
existing IP systems of protection.'^ 
(i) Defensive Protection of TK: A main tool for defensive protection is 
requiring relevant patent applications to include disclosure of the source of the 
genetic resources and associated TK as well as evidence of prior informed 
consent and benefit sharing. A few countries have recently started to implement 
this at the national level. As has been mentioned earlier, developing countries 
have also repeatedly proposed at the international level to include this 
requirement in the TRIPs agreement. Such a measure would facilitate 
traceability and benefit sharing.'^ 
It was discussed in seminar'^ on traditional knowledge that the Like 
Minded Megadiverse countries (LMMC),'* rich in biological diversity and 
associated traditional knowledge have agreed to join effort for effectively 
negotiating the development of an international regime on access and benefit 
sharing (ABS). The 17 members are Bolivia, Brazil, China Colombia, Costa 
Rica, Democratic Republic of Congo, Equador, India, Indonesia, Kenya, 
Madagascar, Malaysia, Mexico, Peru, Philippines, South Africa and Venezuela. 
These possess 60-70% of the world's biodiversity. 
The Megadiverse Countries have agreed to ensure that the proposed 
access and benefit sharing (ABS) includes prior informed consent of the 
country of origin and mutually agreed upon terms between the country of 
origin and user country. 
15. Available at- http:/www.wip.int/tk/en/tk 
16. http://www.in.wikipedia.org/wiki/suigeneris 
17 National Roving Seminar on Traditional Knowledge 13-14 Aug. 2008 (Organized by Government 
of India and WIPO). 
18. Megadiverse Countries is a group of countries that harbour the majority of earth species and are 
therefore consider extremely bio-diverse. 
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Traditional knowledge existing in public domain, for example, the 
codified Indian Systems of Medicine (herein after ISM) needs to be made 
available to patent examiners in format and language understandable by patent 
examiners, preferably in patent application format. Such a database could help 
establish the existence of prior art and therefore prevent the granting of bad 
patents. 
(ii) Positive Protection of TK 
Areas where the defensive protection tool have little impact, traditional 
knowledge holding communities like to influence their claim to their 
knowledge and to have this recognized in national and international law, that 
could be done by positive protection such as by the foundation of legislative 
frame work. This legislative tool would be able to recognize the rights of these 
local & indigenous communities and their traditional knowledge. A part from 
this recognition of customary laws a national legislation would be another tool 
for the protection. Customary laws have little impact or effect outside these 
communities unless they are recognized in notional legislation or the formal 
judicial system. This approach is widely supported by indigenous and local 
communities as it respects their values and belief and allows them to continue 
their traditional lifestyle.'^  
Another possible tool is the creation of a traditional knowledge 
Registries, where putting TK into the database actually constitute, establishing 
a legal claim over TK. This idea also merits further exploration. Activities such 
as People's Biodiversity Register (PBR),^ ° which was initiated for some Indian 
villages is an example PBR is aimed at promoting sustainable use and equitable 
benefit sharing while conserving the biological diversity. It generates village 
level biodiversity management plan eventually to occupy legislative and 
political spaces for decentralized governance. Besides protection of immediate 
19. Available at- http://www.in.wikipedia.org/wiki/suigeneris. 
20. "Taxonomy in India" available at- http:// ces.iisc.ernet.in/PBR.html. 
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natural resource rights of villagers, broader objectives is also to include 
protection of their intellectual property rights, by creating documentary 
evidences useful in litigation. Some other objectives are- '^ 
(1) To provide a record of local knowledge for the use of present and future 
generation of village community people. 
(2) To promote the revitalization of local knowledge by 
(a) Rewarding outstanding knowledge skill, techniques and conservation 
practices 
(b) Recognizing the range of such knowledge 
(c) Validating and promoting sound local knowledge and resource 
management traditions. 
(d) Promoting intercommunity transfer knowledge for capacity 
enhancement 
(3) To alert conservationists about the need for action concerning threatened 
resource and need for protection of local resource rights. 
(4) To protect local biodiversity and knowledge from misappropriation by 
companies such as through patenting of modified products, process and 
biological. The first people biodiversity register was prepared and released 
in 1997. According to the proposal this register should be kept at 
panchayat. 
RUPAYAN an NGO promoted by late Komal Kothari of Rajasthan has 
done great efforts for preservation and recognition of rich heritage of art and 
culture of Marwar region of Rajasthan. Similarly the Lok Kala Mandal of 
Udaipur under the guidance of late Devilal Sombhar, has earned a great 
accolade for preservation of local art of Mewar region.^ ^ 
21. The Main Function of BMC is to Prepare PBR in Consultation with Local People. The Register 
Shall Contain Comprehensive Information on Availability and Knowledge of Local Biological 
Resources, Their Medicinal or any other use or any other Traditional Knowledge Associated with 
them. 
22. R.M. Dungawat, "Protection of Traditional Knowledge. National and International Perspectives" p. 
335.in Shiv Sahai Singh, The Law of Intellectual Property Rights (2005) 
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5. Existing Legal Framework for the Protection under IPR Regime 
Intellectual Property is a branch of law which protects some of the finer 
manifestations of human achievement that are of commercial value. The 
protection of TK under existing form of IPRS raises some of the important 
issues, which shall be dealt in detail in the following sub-section: 
1. Patents and Protection of TK 
Patent refers to a grant of some privilege, property or authority made by 
the government, by the sovereign of the country to one or more individuals. 
The instrument by which such grant is made is known as "Patent".^ -' 
The term "Patent" acquired statutory meaning in India when the Patent 
Act, 1970 was enacted. In order to satisfy' the requirements of patent three 
essential criteria should be met under The Patent Act, 1970 as amended by The 
Patents (Amendment) Act, 2005 are (a) novelty '^'; (b) Inventive Step;^ ^ and (c) 
Industrial Application^*. 
(a) Concept of Novelty and TK 
The most important element of the concept of novelty is the non 
disclosure of the invention to the public. This presupposes that there should not 
be any prior knowledge of the invention by the public. The two requirements to 
find out whether an invention is disclosed or not are (a) prior publication^^ and 
(b) prior use.^ * The prior publication include (1) the publication of the 
information through the patent claims already filed before the authorities 
anywhere in the world or (2) the existence of the information in any publication 
or document available for public examination irrespective of whether any 
23. B.L. Wadehra, Law Relating to Intellectual Property p. 4(2007). 
24. The Patents Act, 1970 Sec. 2(1). 
25. The Patents (Amendment) Act, 2005 Sec.20a). 
26. The Patents (Amendment) Act, 2002 Sec. 2(ac). 
27. The Patents Act, 1970 Sec. 64(f). 
28. Id., Sec. 64(e). 
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member of the public including the person claiming the invention has read it or 
not. '^ The prior use is the use of the information in the course of the trade by a 
person or is within the common knowledge of the public or those involved in 
the trade.-'" In the first case the novelty is lost as much as the common public is 
aware of the invention and that it is in use i.e. there is prior knowledge and 
prior use of the invention. Thus, the lack of novelty will disqualify the products 
based on the knowledge to be treated as invention for the purpose of patent 
protection. 
(b) Inventive Step 
The Patent Act, 1970 defines invented step in Sec. 2 (j), as inventive 
step means a feature that makes the invention not obvious to a person skilled in 
the art. Lord Hoffmann usefully described different forms of invention in 
Biogen Inc v. Medeva pic"^ "Sometimes, it is the idea of using established 
techniques to do something which no one had previously thought of doing. In 
that case, the inventive step will be doing the new things. Sometimes, it is 
finding a way of doing something which people had wanted to do but could not 
think how. The inventive idea would be the way of achieving the goal. 
In Windsurfing International Inc v Tabur Marine (Great Britain) Ltd. ^^  
being: (1) Identify the inventive concept emobodied in the patent in suit; (2) 
identify what, if any, differences exist between the matter cited as being 
'known and used' and the alleged invention; (3) the court then asks itself the 
question whether, viewed without any knowledge of the alleged invention, 
those differences constitute steps which would have been obvious to the skilled 
man or whether they require any degree of invention. 
29. Lalubhai Chakubhai Jariwal v. Chimanlal & Co., AIR 1936 Bom.99. 
30. Automatic Coll Winder Co. Ltd. v. Taylor Electrical Instruments Ltd., (1994) RPC41. 
3I.22(1997)RPC 1. 
32. 28 (1985) RPC 59 at 73. 
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Thus, the requirement of the inventive step is to ensure that substantial 
intellectual labour of the inventor is involved in the creation of the new 
invention. So, the test applied by the courts is to examine whether there is any 
application of inventive faculty of the invention." The quantum of application 
independent though, ingenuity and skill of the inventor is the matter of inquiry 
in this regard.^'' 
One of the significant features of the traditional knowledge is the fact of 
it being passed on to the present generation by the previous one. This gives a 
prima facie impression that the present custodians of this knowledge are not 
the creators but only the successors in interest of the earlier creators. It is thus 
obvious that the present claimants have not contributed any independent 
thought, ingenuity or skill to establish a valid patent claim. 
(c) Industrial Application 
The Patent Act of 1970 .defines 'industrial application' in sec.2 (ac) as 
that the invention is capable of being made or used in an industry. Another 
requirement is that the invention is capable of industrial application. This 
requirement demonstrates the practical nature of patent law, which requires 
that the invention should be something which can be made industrially or relate 
to an industrial process. 
The origin and development of patent system from the very inception is 
linked to the industrial growth and economic development of a nation. So, it 
has always been the underlying principle of patent system that only inventions 
that are useful to the society are recognized for patent protection. 
One of the positive aspects of the TK is its use to the society. It is only 
that knowledge that is found to be of social use that has been passed on to the 
next generation. It is the proven success of the information that qualifies for its 
33. Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries, AIR 1982 SC 1444. 
34. Killick v. Pye. (1958) RPC 366. 
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long existence and use in the society as traditional knowledge. So it may 
always be possible to demonstrate its use for patent protection provided the 
other requirements are satisfied. 
To conclude, it is evident from the above analysis that TK is not 'novel' 
in the strict sense of 'Patent requirement' so it will not fulfill the requirements 
of patentability. 
2. Copyright and Protection of TK 
Copyright is a property right that subsists in certain specified types of 
works as provided for by the Copyright, Design & Patents Act, 1988.^ ^ The 
owner of the copyright can control the exploitation of the work, e.g. by making 
or selling copies to the public or by granting permission to another to do this in 
return of a payment. Thus, copyright is an exclusive right given by law for a 
certain term of years to an author, composer etc. to print, publish and sell 
copies of his original work. 
In order to secure copyright protection what is required is that the author 
must have bestowed upon the work "Sufficient judgment, skill, labour and 
capital.^* Thus to be eligible for copyright protection, work must be original, it 
must be fixed in some tangible form and it must qualify as a "work of 
authorship". Copyright protects the skill and labour employed by the author in 
the production of his work." 
Since, in order to get a copyright over the work, that work should be 
original. The question is whether TK falls within the ambit of originality. 
Identification of the holders of TK is not easily possible since it has originated 
over the centuries and it cannot be held by the community collectively. 
Therefore, TK cannot be given copyright protection. Moreover, the copyright 
35. David Bainbridge, Intellectual Property p. 27 (2002). 
36. Copyright Act, 1957. Section 13(1) 
37. Ravencraft v Herbert. 1980, RPC 103. 
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cannot be vested in the entire tribe or community, as the law does not 
recognize community ownership. 
The Copy Right provides for protection to the traditional knowledge 
concerning works like literary work, pictorial work, musical work, sculptures, 
wood, stone carves etc these provisions of the Act says that if any work is 
already in the public domain or prior published, then it can't be registered 
under the Copy Right Act.^ * Copy Right Act, indirectly protects the indigenous 
people and communities, against unauthorized reproduction and exploitation.^^ 
3. Trademarks, Geographical Indications and TK 
A trade mark is a visual representation attached to goods for the purpose 
of indicating their trade origin. Thus, a trade mark serves the purpose of 
identifying the source of origin of goods. It advertises the product; it creates an 
image of the product in the minds of the public, particularly consumers of the 
prospective consumer of such goods. 
Thus, trade marks can be seen as serving two main purposes, firstly, to 
protect business reputation and goodwill and secondly, to protect consumers 
from deception, i.e. to prevent the buying public purchasing inferior goods or 
services in the mistaken belief that they originate from or are produced by 
another trader. 
Geographical indication (hereinafter GI) denotes that the product 
originates from a particular place, which has a reputation for certain 
characteristics attributable to that place of production of manufacture''". 
Thus, TK cannot be given protection under trade marks as trade mark is 
a proprietary in nature, with exclusive right on the owner to use the mark. It is 
38. The Copy Right Act, 1957 Sec. 13 
39. W.. Sec. 4, 13, 16, 
40. Geographical Indication of Goods (Registration and Protection) Act, 1999, Sec. 2(e). 
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in kind of some private monopoly rights and TK, in contrast is communally 
own. TK can also not be given protection under both Trade Marks & GI 
basically for two reasons: 
(1) Trade marks and GIs are applied for goods and services provided by 
certain properties, in form of goods and TK is intangible in nature. 
(2) The purpose of both Trade marks and GIs is commercial benefit whereas 
the holder of TK may not always be interested in monetary benefit but 
may only want recognition. 
Under the Trade Marks Act, 1999, Trade Marks shall not be registered 
which consists exclusively of marks or indications which may serve in trade to 
designate the kind quality, intended purpose value, geographical origin or time 
of production of the goods or rendering of the current or other characteristics of 
the goods or services'*' has become customary in the servant language or in the 
bonafide and established practices of the trade.''^  
4. The Designs Act, 2000 
To protect the owner's right for the design created by him Indian 
Parliament enacted Designs Act, 2000. The enacted Design Act, 2000 repealed 
the Design Act, 1911, which was earlier applicable in India. Like other 
intellectual property law, the Designs Act, 2000 also provides indirect 
protection to the traditional knowledge. It prohibits registration of the design if 
it (a) is not new or original or (b) has been disclosed to the public any where in 
India or any other country (c) is not significantly distinguishable from known 
designs (d) or comprises or contains scandalous or obscene matter.'*^  
41. Trade Marks Act,, 1999 Sec. 9 (1) (b) 
42./rf, Sec9(l)(c) 
43. Designs Act, 2000. Sec 4, 
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5. The Geographical Indications of Goods (Registration and Protection) 
Act, 1999. 
Geographical Indication can also be a tool to protect the traditional 
knowledge. Geographical indication means any indication which defines the 
goods as originating of a country or a region or locality in that territory, 
provided a given quality reputation or other characteristics of the products is 
essentially attributable to its geographical origin. The Act provides the 
protection against the unauthorized persons from misusing geographical 
indications. Moreover, it protects consumer from deception. The product 
simply needs to have territorial roots and derive its special qualities from its 
specific geographic origin."** Geographical indications do not protect novel 
elements but rather an accumulated good will built up over the years. Since 
geographical indications tend to reward tradition based commercial products, 
they have been seen more as protector of traditional knowledge than any type 
of intellectual property rights 
6. International Developments for the Protection of TK 
The matter of traditional knowledge is has always been a part of 
discussion in several international organizations. The issues of traditional 
knowledge and intellectual property right have been dealt with by UNEP or 
CBD, WIPO, UNCTAD, WTO and FAO. These organizations cooperated with 
each other. The role of WIPO is the major one to protect the traditional 
knowledge and benefit sharing aspect. Here are some moves taken by these 
international organizations. 
(i) The Convention on Biological Diversity 
CBD is the only international treaty that particularly recognizes the role 
of traditional knowledge. It also acknowledges the innovation and practices in 
44. Sumathi Subbiah,"Reaping what they sow; The Basmati Rice Controversy and Strategies for 
Protecting Traditional Knowledge", 27 B.C. Intl. andComp. L. Rev. Spring, p. 547 (2004). 
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biodiversity conservation and sustainable development. The provisions in the 
Convention on Biological Diversity (CBD) 1992 to local and indigenous 
communities in the genetic materials and share, the benefit denied out of its use 
seems to be the first express international commitment. 
CBD talks about traditional knowledge as that each contracting party 
shall subject to its national legislation respect, preserve and maintain their 
knowledge, innovations and practices of indigenous and local communities and 
conservation and sustainable use of biodiversity and shall also encourage the 
benefit sharing out of the use of resources.''"^  
CBD addresses two critical issues. First regulation of access to genetic 
resources and equitable benefit sharing and second ensuring legal protection of 
traditional knowledge, particularly in its relation to biodiversity and intellectual 
property."^ Protection of traditional knowledge also includes prior consults of 
the provider of the resources. 
(ii) World Intellectual Property Organization 
WIPO began its work on TK related subject matter in 1978, when it 
initiated discussions on sui-generis protection of expression of folklore in 
collaboration with the United Nations Educational, Scientific and Cultural 
Organization (UNESCO). This work resulted in 1982 in the adoption of the 
"Model Provisions for National Laws on the Protection of Expressions of 
Folklore against Illicit Exploitation and Other Prejudicial Actions". Following 
the adoption of the Model provision in 1998, WIPO began a new set of 
activities designed to explore the IP aspects of the protection of TK. The main 
objective of these activities was to identify and explore the IP needs and 
expectations of the holders of TK in order to promote the contribution of the IP 
system to their social, cultural and economic development. 
45. CBD Article SQ) 
46, Committee on Trade and Environment (1995) 
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After discussions among WIPO Member states beginning in September 
1999 about intellectual property and genetic resources, the WIPO General 
Assembly decided that a distinct body should be established with in WIPO to 
facilitate discussions among Member States on issues related to genetic 
resources, TK and expressions of folklore. The member states decided to 
establish this body in the form of an Intergovernmental Committee on 
Intellectual Property and Genetic Resources, Traditional knowledge and 
Folklore (The Intergovernmental Committee, IGC). 
The IGC constitutes a forum for discussions among Member States on 
intellectual property issues arising in the context of (i) access to genetic 
resources, and benefit sharing (ii) protection of Traditional knowledge whether 
or not associated with those resource, and (iii) protection of expression of 
folklore. In considering the relationship between IP and genetic resources, TK 
and Folklore, the committee has undertaken information gathering policy 
discussion and practical capacity building in these three policy areas. This work 
has highlighted the overlapping nature of this subject matter and pointed to the 
benefits of an integrated approach to continuing international co-operation on 
these IP concerns. 
The committee developed a series of studies on legal protection of TK 
which included surveys of national experiences with IP protection of TK, 
analysis of the element of a sui-generis TK system and analysis of the 
definition of TK these documents included details of national sui-generis laws 
for protection of TK and the range of experiences reported using IP laws {sui 
generic & otherwise) to protect TK. These materials can form the basis for 
continuing international policy discussions on specific TK protection, and can 
be used to support notional policy making and the assessment of practical 
options both for the use of existing IP tools and the new forms of IP protection. 
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The committee gave extensive consideration to tlie use of databases, 
registries and other collections and inventories for the protection of TK and this 
discussion clarified that databases could be used for the preservation, positive 
protection and defensive protection of TK. The role of data of databases for the 
positive protection of TK was shown in the use of databases with security or 
access controls, which give effect to customary laws and protocols governing 
the authorized access and distribution of knowledge. 
A detailed analysis was also given to the use of databases and other 
collections of information in the context of general defensive protection 
strategies. This focused on approaches to ensure that existing disclosed TK was 
taken into account in the patent examination process. Based on responses to 
widely distributed questionnaires inventories of relevant on line to databases 
and periodicals were developed to assist in the creation of tools for more ready 
access to publicity disclosed TK in searches for relevant prior art. This turn led 
to the creations of a TK portal as a pilot version of a potential searching toll for 
patent examiners. The purpose of this was not to induce the disclosure of TK 
but to ensure that any TK already disclosed would be taken into account when 
potentially relevant patent claims were being assessed. 
A further defensive mechanism that was considered by the committee, 
concerned with use of disclosure requirements in the patent system to ensure 
disclosure of TK and potentially also its origin and the legal circumstances 
surrounding its access that is used in the development of a claimed invention. 
The work of committee on IP aspects of genetic resources associated 
with TK took two general directions. First it considered licensing practices 
concerning IP aspects access to genetic resources, and second it considered the 
role of patent disclosure requirements in relation to inventions that are based on 
access to genetic resources. The operational principle for intellectual property 
clauses of contractual agreements concerning access to genetic resources and 
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benefit sharing were considered. The main objectives of this exercise were to 
provide information about possible licensing practices to the parties needing 
such information, and to develop this guidelines or principals on the IP aspects 
of licensing access to genetic resources. The committee further considered a 
technical study prepared by WIPO on disclosure requirements in patent law 
that were relevant to traditional knowledge or genetic resources used in the 
course of developing a claimed invention. These documents considered the 
interaction between legal systems governing access to TK and genetic 
resources on the one hand and established patent law in line with existing 
international standards and aim at providing input for policymakers the 
discussions at WIPO have highlighted the expectation of a number of countries 
that specific steps should be taken to strengthen TK protection including the 
development of specific new international instruments. The significance of the 
issues and their complexity mean that farther analysis and clarification is 
needed before crystallizing formal outcomes and more work needs to be done 
to explore the full potential of existing IP rights and system to protect TK. 
(iii) World Trade Organization 
WTO deals with international trade in general but through its Committee 
on Trade and Environment (herein after CTE)"^  on environment it has 
occasionally raised the issue of protection of P.K. the WTO has also addressed 
biodiversity and TK related concerns in the context of the review of the TRIPS 
Agreement regarding article 27.3 (b). The WTO council for TRIPS is currently 
revising Art 27.3 (b) of the TRIPS Agreement which deals with the 
patentability of traditional knowledge. The Doha declaration of the fourth 
WTO Ministerial Conference made it clear that work in the TRIPS council 
under the reviews (Art 71.1) and on outstanding implementation issues should 
47. CBD Article. 10 (c) and Art 8(j) 
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cover the relationship between the TRIPS Agreement and the U.N Convention 
on Biological Diversity, the protection of traditional knowledge and folklore 
and other relevant new developments that member governments raise in the 
review of the TRIPS Agreement. 
(iv) Food and Agriculture Organization 
FAO encourages the development of particular projects and initiatives 
taken for the enhancement and preservation of traditional knowledge but it 
especially related to agriculture. Very first involvement of FAO in T.K. 
protection began in 1983 with the adoption of international undertaking on 
plant Genetic Resources. It was the first comprehensive international 
agreement dealing with plants genetic resources for food and agriculture as an 
instrument to promote international harmony in matter regarding access to 
plant genetic resources for food and agriculture.'^ * The matter of Farmer's 
Rights in context of traditional knowledge was discussed within FAO and was 
formally recognized through a resolution and recently by international treaty 
recognizes the contribution made by the farmers and their communities and the 
efforts done for the conservation & developments of plants genetic resources. 
This treaty is the basis for Farmer's Rights which include the protection of 
traditional knowledge as well as the right of benefit sharing. It also gives 
government the responsibility for implementing these rights. 
(v) United Nations Conference on Trade and Development (UNCTAD) 
An Expert Meeting on Systems and National Experiences for Protecting 
Traditional Knowledge Innovations and Practices was held under the guidance 
of UNCTAD on 30 October 1 Nov. 2000 over 250 people from 80 countries 
participated and some 50 papers on country expensiveness were presented. The 
fifth session held on 19-23 February 2001, it was focused on agreed 
48. FAO Conference Adopted the International Treaty on Plant Genetic Resources for Food and 
Agriculture in November 2001. 
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recommendations on sustainable use of biological resources, systems and 
national experiences for the protection of traditional knowledge, innovations 
and practices. Sixth session held on 4-8 February 2002 in Geneva, in which 
UNCTAD addressed the issue raised by developing countries that the TRIPS 
Agreement needed to protect the traditional knowledge and biodiversity. 
UNCTAD also provides opportunities and elements for the positive protection 
of traditional knowledge.'*^ 
(vi) United Nations Educational, Scientific and Cultural Organization 
(UNESCO) 
UNESCO and WTO have together planned model provisions for 
national laws on the protection of folklore; some of the recent developments of 
UNESCO's work regarding traditional knowledge include discussions of 
knowledge systems at the UNESCO ICSU. World conference on science 
(Budapest, June 1999) the Indigenous knowledge side event at Johannesburg in 
2002 and UNESCO's new intersectional project launched in 2002 on "Local 
and Indigenous Knowledge in systems in Global Society" (LINKS) along with 
an ICSU report on science & T.K. in 2002, UNESCO has a goal to promote 
science, education and culture. These objectives are directly linked to issues of 
sustainable use of genetic resources and protection of traditional knowledge.^ *^ 
(vii) Association of South East Asian Nations (ASEAN) 
ASEAN is a geo-political and economic organization of 10 countries located 
in Southeast Asia, which was formed on 8 August 1967 by Indonesia, Malaysia, the 
Philippines, Singapore and Thailand. Since then, membership has expanded to include 
Brunei, Burma (Myanmar), Cambodia, Laos, and Vietnam. Its aims include the 
acceleration of economic growth, social progress, cultural development among its 
49. K.P.S. Mahalwar and Vishal Mahalvar, "Protection of Traditional Knowledge & Intellectual 
Property Rights: Indian & International Perspectives",p.54 M.D.U. Law Journal (2006). 
50.Id. at p.55 
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members, the protection of the peace and stability of the region, and to provide 
opportunities for member countries to discuss differences peacefully. 
Member State declared that member states have sovereignty over 
biological and genetic resources within their territories in accordance with the 
provisions of CBD. Each member state shall recognize, respect, preserve and 
maintain the knowledge, innovations and practices of indigenous peoples and 
local communities embodying traditional lifestyle to their natural resources and 
shall also ensure the fair and equitable benefits sharing from utilization of 
biological as well as genetic resources. Framework also asks to reject the 
application of the patent system considering biological and genetic resources as 
sacred heritage. 
Objectives of the framework Agreement are-Conservation and 
sustainable use of biological and genetic resources to recognize and protect the 
traditional knowledge of indigenous people and local communities and to 
facilities fair and equitable sharing of benefits with the said community and the 
prior informed consent, the agreement also promote transfer of technology and 
capacity building at community region and national basis. 
(viii) World Health Organisation (WHO) 
The WHO involvement in TK relates to its work on traditional 
medicine. The World Health Organization, the United Nations specialized 
agency for health was established on 7"" April 1948.^' 
The WHO objective as set out in its constitution, is the attainment by all 
people of the highest level of health, as the economic and trade value of TK, 
particularly the knowledge of traditional medicine and medicinal plants, in 
becoming increasingly recognized, more and more WHO member states have 
51. "World Health Organisation," available at 
<http//en.wikipedia.org/wiki/worId_health_organisation> 
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become concerned with the need to protect it and to secure the fair end 
equitable sharing of any benefit derived from its utilization. 
The WHO supports its member states in their efforts to formulate 
national policies on the traditional medicine, to study the practical usefulness of 
traditional medicine, including evaluation of practices and examination of the 
safety and efficacy of remedies, to upgrade the knowledge of traditional and 
modem health practitioners, the general public about proven traditional health 
practices. 
WHO organized an inter-regional workshop.^ ^ This workshop inter alia 
discussed solutions for the protection of knowledge of traditional medicine. 
This workshop stressed the important role of traditional medicine in the 
developing countries and reiterated that countries should develop a national 
traditional medicine policy, which should include the issue of Research and 
Development in the area of traditional medicine, the formal recognition of 
traditional medicine systems and the integration of traditional medicine in the 
national healthcare system. The meeting also notice that many activities and 
products based on environmentally sustainable routes to economic 
development for large parts of population in many developing counters. 
WHO'S Traditional Medicine Strategy 2002-2005," had four main 
pillars, namely: 
(a) policy- Integrate traditional and complementary or alternative 
medicine (TM/CAM) with national health care system. 
(b) Safety, efficiency and quality: provide evaluation, guidance and 
support for effective regulation. 
52. "Workshop on Traditional Medicine in Bangkoic," available at 
<www.who/int/medicinedoc/en/d/jh2924e.z> visited on. 
53. Dr. Xiaoruyi Zhang, "WHO Traditional Medicine Strategy," available at 
<http//www.in/medicine/pubiication/traditionalpolicy/en/index.htmI>. 
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(c) Access: ensure availability and affordability of TM/CAM, 
including essential herbal medicines. 
(d) Rational use: Promote therapeutically sound use to TM/CAM by 
providers and consumers 
At present WTO is supporting clinical studies on antimalarials in three 
African countries, the studies are revealing good potential for herbal 
antimalarials. In Tanzania, WHO, in collaboration with China, is providing 
technical support to the government for the production of antimalarials derived 
from the Chinese herb Artemisia annua. Local production of medicine will 
bring the price of one dose down from US$6 or $7 to an affordable $2.^ '* 
To conclude, so far, no international regime for the protection of TK has 
emerged, although an incremental progress has been registered though 
piecemeal efforts, namely the FAO's ITPGRFA and the CBD's Bonn 
Guidelines on access to genetic resources and benefit sharing. Their scope, 
however, is limited to access to GRs and benefit sharing and they thus relate to 
the physical aspects of these resources rather than their intellectual or 
intangible aspects, which are mainly related to TK and are the subject matter of 
intellectual property protection. 
The measures, however, are not comprehensive enough to address the 
concerns and needs of developing countries, which desire an international 
mechanism acknowledge the holistic nature of TK and collective rights of 
indigenous or local communities overhead. Developing countries would like to 
see faster progress towards an international regime of some kind, and the 
suigeneris mode, according to them, would e most appropriate to protect the 
holistic character of TK and to tackle the problem of illegal acquisition of GRs. 
54. "Traditional Medicine," available at <www.who.int/mediacentre/factsheets/fsl34/enl> 
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A. Other Current Initiatives: 
First attempt perhaps was made by WIPO-UNESCO on developing the 
model provisions of national legislation for protection of folklore Another 
attempt was in United Nation Draft Declaration on Rights of Indigenous People 
1994. The convention agreed that for traditional knowledge can be used with 
prior approval of the community. Both have not recognized ownership over 
traditional knowledge. TRIPs did not make any significant provision for 
protecting traditional knowledge." It has failed to recognize the importance of 
traditional knowledge. 
(i). Doha Ministerial Conference 
A key issue raised at the fourth WTO Ministerial meeting in Doha, in 
November 2001, was that the TRIPs agreement needs to be amended in order 
to provide that the members shall require an applicant for a patent relating to 
biological materials or to traditional knowledge shall provide, as a condition to 
acquiring patent rights. 
(i) Disclosure of the source and country of origin of the biological resource 
and of the traditional knowledge used in the invention. 
(ii) Evidence of prior informed consent (PIC) through approval of 
authorities under the relevant national regime. 
(iii) Evidence of fair and equitable benefit sharing under the relevant 
national regime. 
Amendments to the TRIPs Agreement to include an obligation to 
disclose the origin of genetic resources and associated traditional knowledge 
and to provide evidence of PIC and fair and equitable benefit sharing are 
55. R.M. Dungawat, "Protection of Traditional Knowledge National & International Perspectives, p. 
331 in Shiv Sahai Singh, The Law of Intellectual Property Rights (2005) 
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imperative to implement the TRIPs Agreement and the CBD in a mutually 
sportive and complementary way. This obligation would ensure transparency as 
regards the origin of biological materials that are used in the patent claim, as 
well as make the CBD provisions on the PIC and fair and equitable benefit 
sharing more effective. 
(ii) Conference of CBD Members 
The sixth meeting of the conference of the parties to convention on 
Biological Diversity (C0P6) held in Hague in April 2002. It considered the 
progress made in the integrations of the relevant tasks of the programmer of 
work on Article 8 (j) in the thematic programmes of the convention, and 
identified action to be taken with respect to forest biological diversity, marine 
and costal biological diversity, inland water ecosystem and agricultural 
biological diversity. 
Main issues were of sui-generis systems for the protection of traditional 
knowledge based on Article 8 (j) and related provisions of the CBD. The focus 
was in particular on identifying the main elements to be taken into 
consideration in the development of sui-generis systems and the equitable 
sharing of benefits arising from the utilization of traditional knowledge, 
irmovations and practices of indigenous and local communities. 
(Hi) Global Biodiversity Forum 
At the 18"^  session of the Global Biodiversity Forum (GBF) held in 
September 2003 in Cancun, Mexico, biodiversity and sustainable livelihood 
issues related to international trade were discussed. 
The overall objective of this session was to provide a platform for the 
trade and biodiversity communities to consider how the pursuit of their 
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respective goals and objectives migiit complement or hinder each other. The 
interlink age between trade and biodiversity was felt to lie in three areas 
(a) trade and sustainable livelihood 
(b) risk precaution and bio- security 
(c) The relationship between the convention of Biological diversity and the 
Agreement on Trade related Aspect of Intellectual property Rights 
(TRIPS) 
B. Regional Efforts for the Protection of TK 
To pinpoint some of the regional efforts for protecting traditional 
knowledge a brief mention is made in the following pages: 
(i) Andean Community Common System on Access to Genetic Resource 
This is adopted by Andean community member countries/*^ This system 
recognizes historical contribution to bio-diversity, its conservation by 
traditional community. The most important aspect of this system is that it has 
introduced concept of 'intangible components' means any knowledge 
innovation or practice of an individual or collective or actual or potential value 
associated with genetic resources or derivative or the biological resources 
confirming them whether or not it is protected by IPR system."^ ^ 
An agreement between Aguamas people of Peru and Searle demonstrate 
a case of traditional knowledge. The Aguamas and their know- how agreement 
with Searle show how traditional knowledge is respected protected through no 
IPR system. In Peru, the Aguaruna people have negotiated know-how license 
56. Bolivia, Colambia, Ecuador, Peru, Venenzula. 
57. Common Access System on Genetic Resources Art-1 available at 
http://www.iclark.edu/law/clinics/intematioal_invironment_iaw_prqject/andean_english.php 
120 
TrtuRtionaflOuywlei^e VruCer I(P^^^me 
with Searle (Pharmaceutical div. of Monsanto). The Aguamas agreed to pass 
on medicinal plants and knowledge to the company in exchange of knows how 
license fee. This fee will increase to reflect success in research and 
development even before a product reaches market. This license is non 
exclusive in that it does not affect the right of any Aguamas communities to 
use share or sell or otherwise transfer plant or knowledge, whether or not they 
are parties to agreement a trust fund is created to distribute the benefits. A 
board appointed to administer the ftind within the Aguranas people including 
representatives of both participating and non participating communities. Legal 
ownership of biological resources is not a precondition for communities to 
benefits.^ * 
(ii) Costarica Biodiversity Law 
The object of present law is conservation of biodiversity and sustainable 
use of resources as well as distributes in an equitable manner the benefits and 
derived costs." '^ The objective of this law among others is protection of 
scientific and traditional knowledge of biodiversity (through IPR system of sui-
genris) education and public awareness. The law aims at that holder of each 
kind of knowledge have equal entitlement to protection. It is the duty of 
national seeds office and intellectual and industrial property Registries to 
consult National Biodiversity Management Commission to ensure that 
invention does not come within exception of IPR regime. Among others one of 
the exceptions is invention essentially derived from knowledge associated with 
traditional biological or cultural biological practices in public domain. ^ 
A certificate of origin by the technical office of the commission and 
statement of prior informed consent will have to be presented with IPR 
58. R.M. Dungawat, "Protection of Traditional Knowledge National & International Perspectives, in 
Shiv Sahai Singh,(ed.) The Law of Intellectual Properly Rights p. 332 (2005). 
59. Costa Rica (Biodiversity) law Art I 
60. Costa Rica (Biodiversity) law 23/4/1998, No. 7788 
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application. Indigenous peoples and local communities are fiilly entitled to 
refuse access to their resources and knowledge of any reason. 
The state has recognized sui-generis community intellectual rights i.e. 
the knowledge innovations and practices of indigenous people and local 
communities. The indigenous peoples and peasant will determine the nature 
extent & conditions oisui-generis community intellectual rights. 
(iii) African Unity Draft Legislations*' 
The main aim of this legislation shall be to ensure conservation, 
evaluation and sustainable use of biological resources including agriculture 
genetic resources and knowledge and technologies in order to maintain and 
improve their diversity as a mains of all life support system." 
Article 5 of draft legislation exclusively dealt with local communities. It 
provide that local communities are recognized as lawful and sole custodians of 
the relevant knowledge, innovations and practices. And the state is required to 
recognize and protect the rights of local .communities to collectively benefit 
from their knowledge, innovations and practices and to receive compensation 
for conservation of biological as well as genetic resources. The communities 
have given right to veto access to their knowledge, technology and sources.*^ 
7. National Developments for the Protection of Traditional Knowledge 
(a) Patent Law 
The very first initiative for the protection of traditional knowledge in 
India was after the amendment Act of 2002. The Patent Act of 1970 does not 
61. African Model Legislation for the Protection of the Rights of Local Communities Farmers and 
Breeders and for the Regulation of Access to Biological Resources (OAU Model Law Algeria 
2000). 
62. Id, Part I objective 
63. R.M. Dungawat, "Protection of Traditional Knowledge National & International Perspectives, in 
Shiv Shai Singh,(ed.) The law of Intellectual Property Rights p.332 (2005), 
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protect the traditional knowledge. In 2002 traditional knowledge got some 
protection. Following provisions of the amended Act shows the concern for the 
protection of traditional knowledge :-
(i) An invention which is based on traditional knowledge or which is an 
aggregation or duplication of known properties of traditionally 
known components.^ '* 
(ii) It is compulsory for the applicant to disclose the source and 
geographical origin of any biological material developed in leu of 
description.*^ 
(iii) In case of failure to disclose source and geographical origin of 
biological material used in invention would be a good ground of 
opposing patent application.** 
The Patents (Amendment) Act 2005, Passed by the Parliament recently, 
has also introduced some important provisions. Section 25(3),*^ dealing with 
post-grant opposition further stipulates that at any time after the grant of patent 
but before the expiry of a period of one year from the date of publication of 
grant of a patent, any person interested may give notice of opposition to the 
Controller in the prescribed manner on certain specified grounds. The eleven 
grounds stipulated for such post-grant opposition include the following two 
grounds, (i) That the complete specification does not disclose or wrongfully 
mentions the source and geographical origin of biological material used for the 
invention; (ii) That the invention so far as claimed in any claim of the complete 
specification was anticipated having regard to the knowledge, oral or 
otherwise, available within any local or indigenous community in India or 
elsewhere. 
64. The Patent (Amendment) Act, 2002. Sec. 3 (p) 
46. See Sec. 10(d)(D) 
66. See Sec. 25 (j) 
67. Kasturi Das, "India Combating Biopiracy-The Legal Way", available at 
http://www.india/ogether.org/2005/may/env-biopiracy.htm 
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These two provisions ensure protection of the rights of the source 
country of a biological material or traditional knowledge of local or indigenous 
community, and thereby enabling recognition and reward of source countries 
and traditional knowledge holders through appropriate benefit sharing 
mechanisms. 
Thus, provisions included in the Indian Patents Act in conjunction with 
the PIC and benefit sharing requirements incorporated in the Biological 
Diversity Act 2002 create sufficient room for combating the biopiracy threats 
at the national level in India. Nevertheless, the problem remains that existence 
of a similar protective shield for Indian bioresources and TK cannot be 
guaranteed under the national patent laws of other countries. The Agreement 
does not make it obligatory for the member countries to include in their 
respective patent laws provisions aimed at protecting the bioresources and TK 
of the country of origin against biopiracy. However, the protection of these 
precious assets cannot be guaranteed until and unless certain compulsory 
provisions are included in TRIPS in this regard, which all the Member 
countries would be obliged to comply with. 
(b) The Biological Diversity Act, 2002 
The Act provides defensive protection to traditional knowledge. The 
main objective of biodiversity legislation is to provide for conservation of 
biological diversity, sustainable use of its components and equitable sharing of 
the benefits arising out the use of biological resource and for matters connected 
therewith or incidental there to. Act provides that no person shall apply for the 
intellectual property right by what ever name called, in or outside India for any 
invention based on any research or information on a biological resource 
obtained form India without obtaining the previous approval of the national 
biodiversity authority before making such application.*^ The Biodiversity Act 
68. The Biodiversity Act, 2002 Sec. 6 
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provides, "No person shall without previous approval of the NBA transfer the 
results of any research relating to any biological resources occurring or 
obtained from India for monetary consideration or otherwise to any person who 
is not a citizen of India or body corporate or organization which is not 
registered or incorporated in India or which has any non-Indian participation in 
its share capital or management." 
The publication of research paper collaborative research project may 
involve biological resources or information or knowledge. Publication has not 
been declared transfer within Sec. 4. The central government which is 
empowered to frame guidelines in this connection should be very cautious. The 
guidelines should ensure that in guise of publication of research paper 
traditional knowledge should not go out of country. 
Act also seeks to constitute state Biodiversity Board (SBB) to promote 
and protect biodiversity. No Indian citizen or person or body corporate is 
allowed to obtain biological resource for commercial utilization without 
obtaining prior intimation of S.B.B. However this recognizes traditional 
knowledge of the local people and communities including Vaids and Hakims 
practicing indigenous medicine. They are kept out of intimation restriction.*' 
(c) Protection of Plant Varieties and Farmer's Right Act, 2001 
Protection of plant varieties and Farmer's Rights Act, 2001 is the good 
illustration of sui-generis system regarding the protection of farmer's 
traditional right in India is one of the first countries in the world to have 
adopted an intellectual property rights legislation which grants rights 
simultaneously to both breeders «& farmer's the enactment of Protection of 
plant varieties and farmer's Rights Act, 2001 is not only the result of 
69. R.M. Dungawat, "Protection of Traditional Knowledge National & International Perspectives, in 
Shiv Sahai Singh,(ed.) The Law of Intellectual Property Rights p. 337 (2005). 
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compliance to TRIPS agreement but also discharging our international 
obligation for PGRFA'^ Treaty. 
The Protection of Plant Varieties and Farmer's Rights Act 2001 Mainly 
focuses on the definition of formal plant breeders rights and follows closely the 
model of UPOV convention and strives to achieve the following objectives for 
recognizing traditional knowledge: 
(1) Benefit sharing and protection of the traditional rights of the farmers 
and breeders. '^ 
(2) Act recognized concept of benefit sharing between provider and 
recipient of the plant genetic resources. 
(3) Promotion and growth of the seed industry through domestic and 
foreign investment. 
(4) Recognition of role of farmers as cultivators, conservators; 
(5) The contribution of traditional rural and tribal communities to the 
country agro biodiversity and 
(6) Stimulation of investment for research and development in public 
and private sectors of the development of new plant verities by 
ensuring returns on such investments. While providing for an 
effective system of protection the Act seeks to safeguard farmers and 
researcher's rights including their traditional rights to save, use, 
share or sell the farm proceedings.^ ^ 
(i) Governmental Initiatives 
The government of India has prepared traditional knowledge in digital 
library on traditional medicinal plants and systems which also lead to 
70. Anitha Ramanna, "India's Plant Variety and Fanner's Rights Legislation Potential Impact on 
Stakeholder Access to Genetic Resources" at http/www.ifpri.org/dp/papers/epldp96.pdfp. 1 
71. Plant Genetic Resource for Food and Agriculture (Treaty). 
72. The Protection of Plant Varieties and Farmers Rights Act, 2001. Sec. 6 
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traditional knowledge resource classification." Five Indian government 
organizations led by the Council for Scientific and Industrial Research (CSIR) 
and the department of Ayurveda Yoga &Naturopathy, Unani, Siddha and 
Homeopathy (AYUSH) started developing the database in 1999. 
(a) Traditional Knowledge Digital Library (TKDL): standing 
committee on Information technology (SCIT), world Intellectual property 
organization (WIPO) at the 3"* plenary session held at Geneva in June 1999 and 
attended by 170 member states of WIPO was held under the chairmanship of 
Dr. R.A. Mashelkar, Director General, CSIR, India. SCIT strategic plan for 21'' 
century recognized the concern by WIPO member states regarding the granting 
of intellectual property rights due to a lack of traditional knowledge being 
documented in the public domain. The SCIT suggested taking the initiative by 
including activities in its work programme to support WIPO member states, in 
particular developing countries in their creation of databases in the area of 
traditional knowledge available in public domain so that prior art gets 
established. An approach paper was prepared by India and was sent to SCIT in 
December 1999. In the discussion by 170 member states of WIPO at Geneva 
SCIT agreed to the Indian approach. 
The TKDL report along with Traditional Knowledge Recourse 
Classification (TKRC)^ '' was prepared in May 2000. The main aim of TKDL is 
to bring the knowledge in public domain in international languages, to prevent 
the grant of wrong patents. The government of India has granted the EPO 
access to its Traditional Knowledge Digital Library, which is a 30 million page 
searchable database of traditional knowledge translated from Hindi, Sanskrit, 
73. M.K. Bhandari, Law Relating to Intellectual Property Rights p.216 (2006) 
74. TKDL Classified the entire TK related information in a modem system as per the format of IPC in 
to sections, subclasses, Main groups and subgroups. This classification system evolved by India is 
known as Traditional Knowledge Resource Classification. 
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Arabic, Persian, Urdu and Tamil into English, Japanese, French, German and 
Spanish. The EPO began using the database on February 2, 20097' Now 
examiners at European Patent Office can use 500-year old traditional Indian 
medical texts when examining patent applications. Recently India and US 
agreed to fast-track and conclude within a given timeframe agreements on 
enhancing and deepening trade and investment engagement and intellectual 
property rights co-operation agreement and an agreement for putting in place 
traditional knowledge digital library.'^  Developed countries are also taking 
initiatives to simplify complexities taking place in granting patent along with 
the protection of traditional knowledge. 
(b) PCT Minimum Journals 
Patent Cooperation Treaty (PCT) is a multinational patent-application 
processing treaty. Most of the countries in the world are PCT members. PCT 
patent applications are administered by the WIPO. The treaty is the result of an 
effort by many countries to provide some streamlining of patent applications 
across several countries at once. 
In the Fifth Session of PCT meetings in 1981 about 169 periodicals were 
identified as PCT Minimum Journals for search and examination by the 
International Search Authorities (ISA). In 1995, the list was narrowed to about 
135. In 2004 the list was further reduced to bring the number of periodicals in 
Non-Patent literature (NPL) list to 131. 
India made a strong representation in August, 2004 for including the 
prestigious Science and Technology Journals brought out by Council of 
Scientific and Industrial Research in the NPL list. In the submission it was 
pointed out that the two journals brought out by NISCAIR, Indian Journal of 
75 Available at - http://www.managingip.com/popups/PrintArticle.aspx?Articleid=2 
76 The Hindu 27 October 2009 
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Traditional Knowledge (IJTK) and Medicinal and Aromatic Plant Abstracts 
(MAP A) do meet the criteria of selection adopted by PCT/CTC. 
The Eleventh session of the Meeting^^  of International Authorities under 
the PCT approved their inclusion in the NPL list which marks a major 
breakthrough since this is for the first time two periodicals form developing 
counties have been included in the NPL list. 
(ii) Non-Governmental Initiatives 
Non governmental actors such as indigenous people organization, other 
advocacy group are seeking to influence international agreements on benefit 
sharing from biotechnological research through use of local or traditional 
knowledge. A model community IPR act has been devised by third world 
network as sui-genris system protecting the knowledge and innovation of local 
communities. According to section 1, para 1, the local communities shall at all 
time and in perpetuity be lawful and sole custodian and stewards of all 
innovations. The definition of innovation explicitly recognizes knowledge of 
indigenous group or communities. Section 5 of the CIPR Act enshrines a 
provision for register of innovation in which community can register its 
innovations.^ * 
The third World Network has also developed a model of collector of 
biological resource. The Act seeks to establish office of collectors of genetics 
resources and traditional knowledge. From time to time many suggestions and 
plans have been proposed by many intellectuals and scholars. Among them one 
action plan has been proposed by Prof Saleem Akhtar is as stated below: 
77. Feb, 21 to Feb, 25 2005 (Geneva, Switzerland). 
78. R.M. Dungawat, "Protection of Traditional Knowledge National & International Perspectives, in 
Shiv Sahai Singh,(ed.) The Law of Intellectual Property Rights p. 334 (2005). 
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Proposed Action Plan '^: 
1. Sensitize communities to value and protect their knowledge: 
Sensitization of local communities and in particular, of women and 
unprivileged groups that are carriers of significant biodiversity related 
knowledge to understand the full value of their knowledge including its value 
to outside world and to protect it from "theft" by the outsider with the 
knowledge of the communities which can be done through the communities 
forms, institutional structure and association, with the help of MHRD and 
MOEF, in association with pachayat training institution, Adivasi, small 
farmers' organizations and relevant NGOs. 
2. Sensitize all stake holders: Including forest, fisheries, agriculture and 
medicinal plants as well as social service departments to traditional knowledge 
system by organizing training programmes for them conducted by expert local 
women and men as resource person. 
3. Community based documentation for traditional knowledge: There 
is a need to strengthen and expand the process of documentation of traditional 
knowledge through the community based and controlled process of making 
community of People's Biodiversity Registers, so that the documented 
knowledge can legally protected against bio-piracy or other misuses. 
4. Networking of the traditional knowledge holders and database at 
State, District and National levels. 
5. Develop community based intellectual rights system: The 
Government should develop a community based intellectual property Regime, 
either under the appropriate provisions in the Biodiversity Act or prepared a 
separate legislation and also the development of sui-generis system. 
79. Saleem Akhtar, "The Protection of Traditional Knowledge under Intellectual Property Rights 
Regime" in Rais Ahmed,(ed.) The WTO and Agriculture (2009) 
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6. To Prepare traditional knowledge digital library: As stated above 
the government has already approved the plan to setup an on-line computer 
library to store information about ancient Ayurvedic and Unani medicines in 
order to prevent traditional medicines being commercially patented. Sound 
documentation would prevent traditional knowledge passed down over 
generations and recorded in Ancient texts from being patented as "no-obvious" 
discoveries. 
The Department of Indian System of Medicine & Homeopathy has 
formulated a plan to provide the information of 35000 Ayurvedic and Unani 
preparations a digital format intelligible to the patenting officers and Research 
across the world. 
7. To protect India's Traditional knowledge & biodiversity through the 
Geographical Indication Act 1999. In India for the time the Kerala Government 
has proposed a Tribal Intellectual Property Bill, 1996. According to this Bill 
the process of chalking out biodiversity conservation access and benefit sharing 
strategy. 
8. No patents should be granted without benefit sharing with local 
communities. Benefit sharing with local communities is still figures low on the 
priority list of Ministry of Environment and Forest. Like US patent Office, our 
patent office should take legal and administrative measures to ensure that all 
benefit generated from the use of traditional knowledge within and outside 
India are shared equitably with the communities. Our patent office should not 
grant patent if local communities will not benefited. 
For the protection of traditional knowledge two proposals were there in 
Draft Bills. The first one is Traditional Knowledge (Preservation and 
Protection Bill 2000 which was prepared by Dr. N.S. Gopala Krishnan. 
131 
TmRtiond'KjuywtJufye XJndtr I^^fgime 
The features of the proposed bill are to facilitate collective management 
of traditional knowledge and to protect it from unauthorized appropriation 
(knowledge which is in public domain). 
- To set up trusts at different level ranging from panchayats, districts, States 
and at the national level. 
- One important element of this proposal is that it does not provide for 
individual claims over specific traditional knowledge. 
- Condition of prior informed consent in case of commercial exploitation of 
traditional knowledge is proposed in the bill (Meaning thereby, where prior 
informed consult is not obtained, the applicant can go above traditional 
holders and seek consultation from a board whose members are not 
traditional knowledge holders.)*" 
- The civil remedies that are provided to include injunctions damages and 
accounts of profits. The bill also provides for a maximum imprisonment of 3 
years and a maximum fine of rupees two Lakhs. 
The second proposal is the Biological Resources and Traditional 
Knowledge (Protection and Regulation) Bill 2003 the main feature of this 
proposal was that it provides an integrated legal framework for the protection 
of traditional knowledge. It proposes the replacement of biodiversity act and 
certain necessary amendments to the plant variety protection act. The concept 
of this bill would by having one national authority dealing with all aspects 
related to biodiversity, plant varieties and traditional knowledge.*' 
Conclusion 
Traditional knowledge is a valuable heritage of for the communities and 
cultures that develop and maintain it, as well as for other societies and the 
world as a whole. Traditional knowledge importance recently has been 
80. Phillip Cullet, Intellectual Property Rights and Sustainable Development, p. 346 (2005). 
81./^.,p.347. 
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acknowledged by other disciplines and sectors of society and it is now 
considered a subject of protection under intellectual property law. It is essential 
to preserve the benefits of traditional knowledge for the entire mankind 
because it is culturally, socially and economically valuable. Traditional 
knowledge is an important lead to the developed countries for their new 
developments and manufacture of new products. There is a need for a effective 
and vibrant steps taken and worked for its protection at national and 
international levels efforts are being taken. All member countries of WTO are 
trying to fulfill the minimum requirements of TRIPS and also trying to cover 
the traditional knowledge within the ambit of intellectual property law. 
Defensive as well as positive protections have been taken by the countries. 
Though efforts have been done to protect traditional knowledge through 
various aspects of intellectual property laws, but still there is requirement to 
enact the stringent law for the protection of traditional knowledge. The sui-
generis system is considered to be the only course lift after the experience of 
sui-generis PVPFR Act, 2001. It has to be concerned both at the national and 
international level. In India profit of Traditional Knowledge Digital Library has 
been accomplished and has been made available to EPO for consultation from 
2009. At international level different organization like WIPO, WHO, WTO, 
UNESCO, UNCTADE are also at work for the protection of traditional 
knowledge within the ambit of their international from work. WIPO has 
received legislations as to traditional knowledge from many countries. These 
legislations are useful for us in formulating legislative and administrative 
strategy for protected traditional knowledge. In our country a proposed by bill 
by Dr. N.S. Gopalakrishnan school of legal studies, cochin, University of 
science and technology is a welcome step towards an effective protection of the 
rights of the holders of traditional knowledge and a guarantee for the fair share 
for letting others use their knowledge. There is a ray of hope from the sui-
generis system, which we are sure will show our traditional knowledge holders, 
the light of the day. 
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TRADITIONAL KNOWLEGE UNDER WTO, TRIPS AND 
MEDICINAL PLANTS 
L WTO and TRIPS Agreement 
Being a founding member of WTO, India was bound to comply with the 
provisions of the TRIPS Agreement. To fulfill the obligations of TRIPS 
agreement the amendment of Patent Act, 2005 came into existence and a 
product patent regime was reintroduced in India after a gap of 35 years. 
Behind the evolution of WTO the original intention was to create a third 
institution handling international economic cooperation to join the 'Bretton 
Woods' institutions now known as the world Bank and the International 
Monetary Fund. The complete plan, as envisaged originally was to create an 
International Trade Organization (ITO) as a specialized agency of the United 
Nations. The draft ITO charter was ambitious it extended beyond world trade 
disciplines, to include rules on employment commodity agreements, restrictive 
business practices, international investment and services.' 
The combined package of trade rules and tariff concessions became 
known as the General Agreement on Tariffs and Trade (GATT). It entered into 
force in January 1948 while the ITO Charter was still being negotiated. The 23 
participants (who decided in 1946 to negotiate to reduce and bind custom 
tariffs and agreed to accept some of the trade rules of draft ITO charter) 
became the GATT founding members (officially contracting parties).^  
For almost half a century GATT (a provisional agreement) remained a 
basic legal text for trade. Much of this was achieved through a series of 
multilateral negotiations known as trade rounds. The earlier seven rounds of 
negotiations confined themselves to trade issues with a view to liberalizing the 
1. Institute of Company Secretaries of India, IVorld Trade Organization, International Trade Joint 
ventures & Foreign Collaborations (2004) p. 33 
2. Ibid., 
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global trade in goods. The eighth round of negotiations which was communed 
in Punta del Esta, Uruguay in 1986 was the latest and most extensive of all. It 
took seven and a half years. It was the largest trade negotiations ever of any 
kind in international trade history. The subjects namely for Uruguay Rounds 
were tariffs non tariff barriers, natural resource products, textile and clothing, 
agriculture, tropical products, GATT articles, Tokyo Round codes, 
antidumping, subsidies, intellectual property, investment measures, dispute 
settlement, services and the GATT system. 
On 15th April 1994, the deal was signed by ministers from most of the 
123 participating governments at a meeting in Marrakech Morocco. The 
agreement concluded with the establishment of WTO. The WTO began life on 
1 January 1995. The WTO agreements cover goods, services and intellectual 
property. The agreement starts with broad principles: The General Agreement 
on Tariffs and Trade (GATT), the General Agreement on Trade in Services 
(GATS), the Agreement on Trade Related Aspect of Intellectual Property 
Rights (TRIPS). This TRIPS agreement is the most comprehensive multilateral 
agreement on intellectual property. There are 73 articles with 7 parts in the 
TRIPS. 
WTO and TRIPS can be considered as first binding tool which can 
protect the TK of developing as well as developed countries. Here it is 
important to discuss the initiatives taken through TRIPS for the protection of 
TK. at vary first instance Traditional knowledge term gives the impression of 
traditional medicinal knowledge though the TK is directly related to the 
biodiversity. But biodiversity can be important only when it consist of social, 
economical and medicinal value. This chapter gives a detail study of traditional 
system of medicines and its significance to the present Indian pharmaceutical 
industry. With out mentioning the aspect of medicinal knowledge of traditional 
knowledge this would be an incomplete task to accomplish. 
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However, our knowledge of medicinal plants has mostly been inherited 
traditionally. Use of plants for caning various ailments are not confined to the 
doctors only but is well known to several house holds as well. Spreading and 
preserving this knowledge on indicial plants and the use have become 
important for human existence. There is growing tendency all over the world to 
shift from synthetic to natural based products including medicinal plants. 
In modem medicine also plants occupy a very significant place as raw 
material for some important drugs such as in aspirin, digoxin, morphine etc. 
Although synthetic drugs as antibiotic in ought about a revolution in 
controlling different diseases which were thought to be fatal in past countries. 
But these synthetic drugs are out of reach to majority of the world population 
the trials and rural people who live in remote places dense forests and small 
villages or Dhamris mostly depend on traditional healers when they now and 
trust. 
Further the chapter has been discussed under the two areas one is 
traditional system of medicine and its present status and impact of the product 
regime on Indian pharmaceutical industry 
The TRIPS agreement says patent protection must be available for 
inventions for at least 20 years. Patents protection must be available for both 
products and processes in almost all fields of technology subject to the normal 
test of novelty, inventiveness and industrial applicability. It is also required that 
patents be available and patent rights employable with out discrimination as to 
the place of invention and whether products are imported or locally produced 
(Article 27.1). 
Government can refuse to issue a patent for an invention if its 
commercial exploitation is prohibited for reasons of public order or morality. 
(Article 27.2) This is the first exception to the basic rule on patentability. 
Second exception is that Members may exclude from patentability diagnostic, 
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therapeutic and surgical methods for the treatment of humans or animals 
(Article 27.3 (a)). Members may exclude plants and animals other than micro-
organisms and essentially biological processes for the production of plants or 
animals other than non biological and micro-biological processes. Plant 
varieties, however must be protectable by patents or by a special system (such 
as the breeders right provided in the conventions of UPOV the international 
union for the protection of New Varieties of plants or by an effective sui-
generis system of protection (Article 27.3 (b)). The agreement describes the 
minimum rights that a patent owner must enjoy. But it also allows certain 
exceptions with a view to deal with abase of patent by a patent owner. The 
agreement empowers governments to issue compulsory licences, allowing a 
competitor to produce the product or use the process under licences. But this 
can only be done under certain conditions aimed at safeguarding the legitimate 
interest of the patent holders. If a patent is issued for a production process the 
rights must be extend to the product directly obtained from the process. Under 
certain conditions alleged infringer may be ordered by a court to prove that 
they have not use the patented process. 
Part-A Traditional Knowledge and Indian Herbal Industry 
With the signing of the TRIPS agreement, it is almost evident that the 
cost of allopathic medicines prepared under patent law might increase 
considerably. It may be the ideal time for Ayurveda Unani and homeopathic 
emerges as a boon for Indians, and to expand its scope and application in other 
parts of the world. In today's perspective when US companies are filing patents 
for turmeric, tulsi, neem, jammun, brinjal which are very well described in our 
ancient literatures, it is a right time to focus on our own heritage and propagate 
the national wealth of herbs and other medicinal plants through different 
scientific techniques. That is why here it is important to analyze the traditional 
system of medicine and it contribution to the Indian pharmaceutical industry. 
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The stories of healing using medicinal plants have been passed on for 
hundreds of years from generation to generation. The understanding of the use 
of medicinal plants for remedies is accumulated into a traditional knowledge of 
health care. Before the modem systems for health care was introduced to the 
people, medicinal plants had been the only means for people to cure from 
illness. Empirical cases that were exposed or told by the older generation were 
the only reason for using specific plant as remedy for specific symptom of 
illness. The empirical evidences collected from ones who had experience of 
being healed by consuming certain plants, constitute traditional knowledge, 
which will direct further investigation. In the meantime people tend to use the 
medicinal plants in treating similar cases, and their success rate increases the 
confidence level among the herbal users. 
Medicinal plants the world's oldest known health care products, play a 
key role in traditional medicine. But these plants are not only used for primary 
health care; many widely used pharmaceuticals are derived from plants and 
other natural sources. Traditional medicines is used the world over but is 
particularly relied on in developing countries. In the South, some 80% of 
people endeavor to protect or restore health using methods that have been 
handed down from generation to generation. 
These plants play a key role in the development and advancement of 
modem studies on biological activities of substances. Traditional health care 
systems using medicinal plants can be recognized and used as a starting point 
of or the development of novelties in drugs. The use of plant substances for 
medication is believed to be less toxic compared to that of synthetic chemical 
compounds; while there is general concem about the negative side effects of 
synthetic compounds, the medicinal plant substances are considered to be less 
dangerous. However, scientific documentations on the efficacy and safety of 
medicinal plants to cure major health problems in India, however, are still very 
limited. To date, there is no integration between modem health care systems 
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and the traditional systems in India, they simply coexist and the individual 
patients are free to switch between the two or take both simultaneously. 
WHO defines traditional medicine as the health practices approaches, 
knowledge and beliefs incorporating plant and animal and mineral based 
medicines, spiritual therapies, manual techniques and exercises, applied 
singularly or in combination to treat diagnoses and prevent illness or maintain 
well being."' 
(2) Traditional Indian System of Medicine 
The Indian system of Medicine prevalent about 1500 years over south-
east Asia, comprises of 3 major systems namely Ayurveda, Siddha and Unani. 
Traditional Indian medicine developed in 3 phases, Prehistoric or Pre-Vedic, 
Vedicand Ayerrvedic. Records of ancient Hindu medicine are found in 
Artharva-Veda, Ayarveda, Charak-Samhita and the Sushruta Samhita. 
(a) Ayurveda 
Ayur means life and Veda meaning knowledge thus meaning knowledge 
of life span. Ayurveda is a more than 6000 years old comprehensive system of 
medicine based on a holistic approach rooted in Vedic Culture and Hinduism. 
According to the ancient Ayurvedic scholar Charaka "Ayur is comprised of 
four essential parts, combination of mind, body, sense and the soul. 
Ayurveda is a system that helps maintain health in a person by using the 
inherent principals of nature to bring the individual backs into equilibrium with 
their true self In Ayurveda a universe is made up of five primary elements 
(pane amah-a-bhutas). 
The elements are (space), air, fire, water and earth. Certain elements are 
seen to have an ability to combine to create various physiological functions 
3. Traditional Medicine at <http://en.wikipedia.org/wii<i/tradition/medicine. 
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ether and air combine to form what is known in Ayurveda as the Veda dosha. 
Vata governs the principal of movement and therefore can be seen as the force, 
which directs nerve impulses, circulation, respiration and elimination. Fire and 
water are the elements that combine to form the Pitta dosha. The Pitta dosha is 
the process of transformation or metabolism. Pitta is also responsible for 
metabolism in the organ and tissue system as well as cellular metabolism the 
water and earth elements combine to form the Kapha Dosha. Kapha is what is 
responsible for growth, adding structure unit by unit and offer protection. 
Human beings are all made up of unique proportion of vata, Pitta and Kapha. 
These ratios of the doshas vary in each individual and because of this Ayurveda 
sees each person as a special mixture the accounts for diversity. 
In Ayurveda, each individual has a unique make up of the three dos has 
and to thereby design treatment protocols that specifically address a person's 
health challenges. When any of the doshas became accumulated, Ayurved will 
suggest specific lifestyle and nutritional guidelines to assist the individual in 
reducing the dosha that has become excessive. 
The holistic science notes that the bodily health is determined by the 
biological humar. In the diagnosis, Ayurveda uses the pulse system, urine 
samples, the coating of the tongue, external system and examines the genetic 
history of illness that had been in inherit in the family. Ayurvedic medicine was 
conceptualized and practiced as 8 major clinical subspecialties of medicine i.e 
Internal medicine (Kaya Chikitsa) General surgery (Shalya tantra) 
Othorhinolaryngoly (Shalakaya), Pediatrics and obstetrics/Gynecology 
(Kumararabhrtya), Phsychiatry (Bhutavidya), Toxicology (Agada Tantra), 
Nutrition, Detoxification and Rejuvenation (Rosayand Tantra),Fertility and 
virility (Vajikarana). 
4. http://veensnott.blogspot.com/2009/05/traditional-indian-medicine-take-look.html 
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(b) Siddha 
Siddha means achievements. According to Sidha system Man is not 
merely muscles and nerves but there is a close relation between him and the 
humans. The oldest pharmacological and therapeutically writings were written 
by Siddhars the material medica of Siddha system of medicine contains 
vegetables, minerals, metals and marine products. 
Siddha system developed an auxiliary to medicine and alchemy and ender 
aware of several alchemical operations which can be divided into several 
processes calcinations, sub-limations, distillation, fusion, separation, 
fermentation. They were polypharmarcist and engaged in boiling, dissolving 
precipitating and coagulating chemical substances. 
(c) Unani 
Unani was founded by the great philosopher and physician, Hippocrates, 
during the Greek period in the Egyptian era; pharmacy was very much 
developed Persia encouraged and delectated physicians. 
The eminent scholar IBNE SINA gave the final shape to Unani 
Medicine. His book Alqanoon (canon of medicine) was an internationally 
accepted book on medicine and was taught in European countries till the 17* 
century. When the Mangolas ravaged Persia and central Asia, scholars and 
physicians, of Unani flee to India Unani gained Zenith in the 13-17 century in 
India. 
Unani medicine is based upon two important concepts. First the 
Doctrine of the Nationals establishes the standards of the human body, from 
which diseases states are deduced by identifies and explain the reasons for the 
deviations from the norms. Diagnosis is based mainly on with the help of pulse 
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physical examination of urine and stool. 
Avicenna sets forth six primary factors which are evaluated in depth to 
discern the cause of a disease the air of one's environment food and beverages, 
movement and rest sleep and wakefulness evacuation and eating and emotions. 
In addition other conventional methods such as palpation, percussion and 
auscultation have been used by the Unani physician. 
The base used in Unani medicines is often honey. Honey is considered 
by some to have healing properties and hence is used in food and medicine. 
Real pearls and metals are also used in the making of Unani medicine based on 
the kind of ailment it is aimed to heal. Today Unani system of medicine has 
been accepted widely in the Middle Eastern countries and Europe . 
Recently is has been expressed to the recognition of TK has prior art 
patent has been granted for TK related invention which did not fulfill the 
requirements of novelty and inventive step when compare with the relevant 
prior art this prior art consisted of TK that could not be identified by the patent 
granting authority during the examination of patents application But recently 
the seconds amendment Act 2002 provides certain provisions for the protection 
of rich TK heritage is widely used by the pharmaceutical industry. Therefore 
the TK is used widely in allopathic and ayurvedic medicines. In the village 
community, tribal and indigenous people also have a TK of biodiversity which 
serves largest genetic resources for breeding activities but gene giant for seed 
giant through IPR regime. Firstly it is important to discuses the recent patent 
amendment 2002: 
5. http://veensnott.blogspot.coni/2009/05/traditional-indian-medicine-take-look.html 
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The Patents Amendment Act, 2002 
The very first initiative for the protection of traditional knowledge in 
India was after the amendment Act of 2002. The Patent Act of 1970 does not 
protect the traditional knowledge. In 2002 traditional knowledge got some 
protection. Following provisions of the amended Act shows the concern for the 
protection of traditional knowledge. 
An invention which is based on traditional knowledge or which is an 
aggregation or duplication of known properties of traditionally known 
components is not patentable. The amended Patents Act make it is compulsory 
to disclose the sources and geographical origin biological material in the 
specification, when used in an invention.^ 
Certain changes has also been made in the opposition proceedings to grant 
of patents section 25 Subsection (1) (J) says that if complete specification does 
not disclosed or wrongly mentions the source or geographical origin biological 
materials used for inventions and if the inventions so far as claimed in any 
claim of the completed specification is anticipated having regard to the 
knowledge, oral or otherwise, available within any local or indigenous 
community in India or elsewhere. It can be a good ground for pre-grant 
opposition. Same grounds can also be used for the post-grant opposition. 
Medicinal plants play a key role in the development and advancement of 
modem studies on biological activities of substances. Traditional health care 
systems using medicinal plants can be recognized and used as a starting point 
for the development of novelties in drugs. The use of plant substances for 
medication is believed to be less toxic compared to that of synthetic chemical 
compounds which there is general concern about the negative side effects of 
synthetic compounds, the medicinal plant substances are considered to be less 
dangerous. However, scientific documentations on the efficacy and safety of 
6. The Patents (Amendment) Act, 2002 Sec. 10 (4) (d )(ii) (D) 
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medicinal plants to cure major health problems in India, however, are still 
every limited. To date, there is no integration between modem health care 
systems and the traditional systems in India, they simply coexist and the 
individual patients are free to switch between the two or take both 
simultaneously. Here the work specifically deals with India's traditional 
medicinal knowledge and its role and significance in Indian pharmaceutical 
industry 
(3) Role of Medicinal Plants in India 
India's abundant natural resources in its tropical forests, years of 
experiences and empirical knowledge of many Indian tribes in using many 
plants for food and medicines are assets, which are too valuable to be ignored 
in the development of natural based industry of the country. 
India has 16 agro-climatic zones and is immensely rich in medicinal 
plants occurring in diverse ecosystems. World Health Organization (hereinafter 
WHO) has listed over 21,000 plant species used around the world for medicinal 
purposes (National Bureau of Plant Genetic Resources (NBPGR) booklet, 
1996). It has been estimated that India has 47,000 species of plants and is 
ranked No. 8 in world biodiversity. Out of these, medicinal plants comprise of 
8,000 species. Indian system of medicine (ISM) uses around 2,500 plant 
species belonging to more than 1,000 genera. About 800 species are used by 
industry of which approximately 25% are cultivated. 
Overall, 119 plants derived prescription drugs are commonly used in 
different countries, 74% of which were discovered due to chemical isolation of 
active compounds of plants used in traditional systems of medicines. For 
examples cardiac glycosides Digoxin from Digitalis purpurea, used in 
traditional medicines, Respire, a tranquilizer and anti-hypertensive agent from 
Rauwolfia serpentine known for its value in Ayurveda and Vinblastin from 
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Catharanthns roseus used as anticancer drug. 
(a) Some Medicinal Plants in India 
Medicinal plants the world's oldest known health care products, play a 
key role in traditional medicine. But these plants are not only used for primary 
health care; many widely used pharmaceuticals are derived from plants and 
other natural sources. Traditional medicines is used the world over but is 
particularly relied on in developing countries. In the South, some 80% of 
people endeavor to protect or restore health using methods that have been 
handed down from generation to generation. 
In India medicinal plants have made a good contribution to the 
development of ancient India Materia Medico. One of the earliest treatises on 
Indian medicine, the Charak Samhita (1000 B.C.,) records the use of over 340 
drugs of vegetable origin. Medicinal plants have curative properties due to the 
presence of various complex chimerical substances of different composition, 
which are found as secondary plant metabolites in one or more parts of these 
plants. Here is a comprehensive account on some of the important trees, which 
are not only being used in sacrificial rites and rituals but also in medicine, 
particularly in India'. 
(i). Bel -(Aegle Marmelos) 
This plant is considered as one of the most screed trees of India. When 
dried before it is ripe, the fruit is used in decoction in diarrhea and dysentery. 
Pulp is aromatic and cooling when used in the form of sherbet. It is a 
medicament for diabetes mainly. Leaves are medicinal. Roots are included in 
the Dashamoola an important ayurvedia preparation. 
7. P.C. Trivedi, G. Gupta and S. Chaudhary, Some Sacred Trees and their Medicinal Uses, P.C. 
Trivedi (ed) Medicinal Plants Traditional Knowledge, p. 129, (2007). 
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(ii). Neem-(Azadirachta Indica) 
It is said that when nectar was being taken to heaven from the world 
below for the sue of Goods, a few drops fell on the neem. Hence, on New 
Year's Day of Shak Samvat, Hindus eat its leaves in the hope that they will 
acquire freedom from diseases. The plant is regard as the village Dispensary in 
India because of the use of all its parts for various ailments in the indigenous 
system of medicines as follows: Fruits (berries) are antiperiodic, anthelmintic, 
astringent, emollient, purgative and tonic; beneficial in piles and in urinary 
diseases, seeds (oil) is antiseptic, locally used in eczema and leprosy. 
(Hi). Dhak, (Butea monosperma) 
The flowers and leaves of B. monosperma are astringent, depurative, 
diuretic and aphrodisiac. These are used against boils and pimples and are also 
prescribed to take internally in flatulent colic, worms and piles. Red colored 
gum, root bark and a seeds of the tree also possess medicinal properties. Gum 
is used for the treatment of diarrhea, which constrains tannins. The flowers and 
seeds are mixed in a decoction and used as wormicide against tapeworms and 
ringworms. 
(iv). Nariyal- (Cocos nucifera) 
Weakness after child birth is treated with liquid extracted from the stem. 
Juice from midrib at the lower base of the leaf is used in treating material 
postpartum illness. Coconut milk is used to treat fish poisoning. In New guinea 
sores and scabies are treated with parts of the plant. The root may is also 
employed in treating stomach-ache and blood in the urine. Oil from the kernel 
is rubbed on to stiff joints. The oil is also used to treat rheumatism and back 
pains or as an ointment to maintain smooth, soft skin. 
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(v.) Amla- (Emblica officinalis) 
Almost all the parts of Amla tree are of great economic importance. 
Fruits are very good sources of vitamins and minerals and hence, used as a 
constituent of food and medicines. The fruit pulp contains 1200-1800 mg 
Vitamin C in lOOg. Interestingly, Emblica fruits are proved to be the richest 
natural sources of vitamin C. Normally one Emblica fruit contain 20 times 
more vitamin C compared to oranges. 
(vi). Gular-(ficus racemosa) 
The barks and figs are used in medicine. The bark is used for healing 
ulcers, skin diseases, cooling and highly efficacious in threatened abortions, 
gonorrhea, monorrhagia, leucorrhea, urinary diseases, hemorrhage, skin 
diseases and ulcers. It promotes complexion, overcome pitta, kapha and 
vatarakta, burning sensation and thirst. Decoction of the tree bark is useful 
as an ablution for various forms of skin diseases and ulcers and its paste in 
inflammatory swellings and boils. The unripe fruits arc astringent, sweet, 
carminative digestive and are useful in dysentery, diarrhea, dyspepsia, 
hemorrhage and monorrhagia. The ripe fruits are sweet, cooling and are 
sued in hemoptysis, thirst and vomiting. 
(vii). Ghrita Kumari (Aloe vera) 
It acts as a source of nourishment for HIV patients, stimulates 
immune response against cancer. The gel and powder from Aloe vera has 
great international demand*. 
(viii). Artemisia annua 
The active principle in this plant (called Quinghao) is artemisinine. It is 
used in treatment of fever, malaria and cerebral malaria. The plant is 
cultivated in temperate regions and provides attractive returns. 
8. G.R. K. Sharma, Commercial use of Medicinal Plants and Traditional Knowledge in India, in PC. 
Trivedi (ed; Medicinal Plants Traditional Knowledge, p. 129, (2007). 
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(ix). Aswagandha (Withania somnifera) 
Aswagandha is used for treatment of rheumatism, gout, iiypertension, 
cancer and as tonic and sex stimulant. The plant is cultivated as an annual crop. 
Fig. Percentage of plant parts utilized in treatment of various diseases/ailments 
Here the graphical representation shows the percentage of plant parts 
utilized in treatment of various diseases/ailments. Traditional medicinal plants 
have always been remaining as a source of bio-piracy in India. 
(b) Ethno-Medicine in India 
India has a wealth of biological resources and is home to a large number 
of different ethnic and cultural groups, many of which have developed their 
own, distinct health care systems. Old stories on healing have been transferred 
from generation to generation and have been practiced for hundreds of years 
using the available medicinal plants. As a result, the country is rich in both 
biological resources i.e. medicinal plants and traditional knowledge. The 
traditional medicine may be codified, regulated, taught openly and practiced 
widely and systematically, and benefit from thousands of years of experiences, 
therefore, WHO defines traditional medicines as including diverse health 
practices, approaches, knowledge and beliefs incorporating plants, animal, 
and/or mineral based medicines, spiritual therapies, manual techniques and 
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exercises applied singularly or in combination to maintain well-being, as well 
as to treat, diagnose or prevent illness. The terms "complementary" or 
"alternative" or "non-conventional" or sometimes "parallel" are used to refer to 
a broad asset of health care practices that are not part of a country's own 
traditional, or not integrated into its dominant health care system. The 
traditional knowledge of the local community needs to be collected and 
preserved as well. Wile modem or medicine remains the mainstreams of health 
care in the country traditional medicinal treatments continue to enjoy 
considerable popularity and be practiced by numerous healers and practitioners 
all over the country.' 
Traditional medicine apparently is perceived as efficient, safe, cost 
effective and affordable; moreover, it is accessible, especially for the poor and 
for those living in remote areas, WHO tend to depend more on traditional and 
herbal medicines than people living in urban areas. Furthermore, during the 
past decade, the utilization of traditional medicine has increased sharply, 
because formal health care became less accessible and less affordable due to 
the economic crisis. Apart from some experimental exceptions in India, 
traditional and conventional or modem health care services are not integrated; 
they merely co-exist. In recent years, the Indian Ministry of Health has adopted 
a policy for the modemization of traditional medicines, while retaining its 
identity. This modemization encompasses several aspects, such as diagnosis 
through the use of modem techniques while providing treatment by traditional 
methods, as well as modemization of the production processes and quality 
control of traditional medicines. The modemization policy also includes efforts 
to encourage scientific research, including clinical trials, to document the 
effectiveness and safety of traditional medicines. Medicinal plants as raw 
materials for traditional medicines, which can also be used as materials for 
9. G.R.K.Sharmq, "Commercial Use of Medicinal Plants and Traditional Knowledge in India" in 
P.C.Trivedi, Medicinal Plants Traditional Knowledge p. 121(2006) 
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pharmaceutical products, foods, cosmetics, perfumery, are the very good 
example for potential future exports. In India, therefore, these commodities 
have a big potential for export, so long as they are produced in an international 
standard quality to meet the requiremenSt of the international commodity 
markets. Many efforts have been done but more still need to be planned and 
well executed with the supports, not only from India but also other countries 
for the benefit of the human kind. The knowledge and experience of many 
tribes in India still need to be documented, even rediscovered, and thoroughly 
researched. The objective should include finding ways not only to explore and 
to exploit, but also to preserve the availability and sustainability of the 
medicinal plants for the benefits of mankind. 
Commercial use of medicinal plants as well as traditional knowledge can 
be very prospective in the future, and its development may take route through 
forms as follows: 
(i) From Traditional Knowledge to Herbal Medicines 
The stories of healing using medicinal plants have been passed on for 
hundreds of years from generation to generation. The understanding of the use 
of medicinal plants for remedies is accumulated into a traditional knowledge of 
health care. Before the modem systems for health care was introduced to the 
people, medicinal plants had been the only means for people to cure from 
illness. Empirical cases that were exposed or told by the older generation were 
the only reason for using specific plant as remedy for specific symptom of 
illness. The empirical evidences collected from ones, who ahs experience of 
being healed by consuming certain plants, constitute traditional knowledge, 
which will direct further investigation. In the meantime, people tend to use the 
medicinal plants in treating similar cases, and their success rate increases the 
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confidence level among the herbal users. 
(ii) Form Herbal Medicines to Phytopharmaca 
To harness the full potentials of medicinal plants, further research 
focusing on the identification of biological activity, clinical trials in human and 
concerted efforts along these lines are critical if the long-term objectives are to 
provide good health care to all. The Practice in industry is not only to judge the 
raw materials according to their content of important constituents, but also the 
extent to which the desired secondary metabolites are technically and 
biologically exploitable is also a governing consideration. 
(iii) Form Medicinal Plants to New Chemical Entities 
With the increasing requirements associate with the demonstration of the 
safety and efficacy of a compound, drugs discovery programs have become 
costly. The high costs when one active constituent has been isolated, studies are 
performed in animals (rodent species) to investigate the mechanism of action. 
Acute and chronic toxicity studies are required, to ensure the safety of the drug. 
Proper does of the drug must be determined, clinical studies are to be carried 
out and stable enough to be launched on the market. All this consumes many 
resources, which discourage companies from entering new drug development 
programs unless there is a fair chance that the returns will eventually be much 
higher and there is protection of intellectual property. 
There is an enormous scope for India to emerge as a major player in the 
global herbal market. But unfortunately various lacunae pertaining to quality of 
herbal drugs become major hindrances to come up to the expected level of 
trade of these traditional medicines both within and outside India. One of the 
initiatives can be taken in the form of: 
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(c) Development of Sources of Materials 
This initiative is to assure the sustainable balance between the supply 
and demand of standardized and good quality of materials. This initiative 
should include the provision of accurate information concerning market needs, 
a programmed cultivation activities i.e. from planting, maintenance, pre and 
post harvesting activities, to distribution in order to prevent over storage at 
farmers and industry level, as well as stock-out. Utilization of non-productive 
lands will be encouraged and maximized through the technical assistances and 
research done by universities, in collaboration with society of farmers, local 
government institutions, and the industry. The abundant sources of many 
varieties and uniqueness of medicinal plants for herbal medicines opens 
opportunity for the development of competitive phytopharmaca and 
pharmaceutical products to supply the domestic and export markets. If the 
empowerment of these commodities is well-supported by a good knowledge 
and technology and equipped with strong marketing and distribution network 
then it is not impossible that the integrated herbal medicines industry will 
create completive herbal medicines products. 
(4) Vision for the Future: Global Trends and Perspectives 
With the progress in chemical techniques, crude drugs came to be 
replaced in the pharmaceutical industry by pure chemical drugs and the 
developed countries witnessed a decline in popularity of medicinal plant 
therapy. But the present developments indicate that, in these countries, the 
pendulum has swung again and there is a resurgence of interest in study and 
use of medicinal plants. They are increasingly used as (1) source of direct 
therapeutic agents. (2) as a raw material, (3) as models for new synthetic 
compounds and (4) as taxonomic markets for the plants and phytomedicines 
are, therefore, expected to grow at more than the historical rate of 7% per year 
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throughout the world. Ayushkati Ayurved's promoter Pankaj Naram said, "The 
herbal market has an annual compounded growth rate of 20 and 25 per cent, 
respectively. India is followed by China as the largest producer of medicinal plants 
having more than 40 per cent global diversity". The World Health Organisation 
(WHO) has projected that the global herbal market will grow to $5 trillion by 2050. 
Indian Exports 
The export of medicinal plants from India is in four forms: 
• As dried plants or plant parts e.g. liquorice roots, Senna leaves, Vica 
Rosa {Catharanthus roseus) herbs. 
• As extracts e.g Sag of opium poppy. 
• As isolated and purified active ingredients/intermediates e.g. Gymnema 
powder, Atropise Sulphate, Menthal crystals. Calcium sennoside. 
• As formulations e.g. Proprietary formulations. 
Among herbs and plants, Ginseng roots, Isabgul husk and Senna leaves 
and pods dominate. USA, Federal Republic of Germany, UK, France, 
Switzerland, Japan, Italy and the Netherlands account for majority of the Indian 
exports followed by Asian and African countries. It is also clear that India is 
exporting very less number of "value-Added Products" and the main focus is 
on the export of dried plants or plant parts, powders. 
Marketing Channel 
Medicinal plants are mostly collected in wild. They are purchased by 
traders and then sold again either to exporters or to industry. The export of 
medicinal plants is also in raw form either by way of roots, branches, barks, 
etc. or crude extraction powders and the opportunities present themselves in 
two ways: 
10. G.R. K. Sharma, Commercial use of Medicinal Plants and Traditional Knowledge in India, in P.C. 
Trivedi (ed; Medicinal Plants Traditional Knowledge, p. 129, (2007). 
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• Increasing market size, both national and global, for plant-based 
products: As described earlier, this market is increasing due to limitations 
of modem medicines, new discoveries/rediscoveries of several medicinal 
properties of plants and herbs, and larger reach of health services to people. 
The rise in cosmetic and health food industry is also contributing to this 
increase. India can and must take a larger share of this market. 
• Increasing research capability: With its wealth of knowledge on 
medicinal plants and herbs India is the most suitable candidate for 
fundamental and application oriented research in this field. In fact, next to 
information Technology and Biotechnology, research in medicinal plants, 
which combines both these technologies, should emerge as the most 
sustainable growth sector in the years to come. 
Challenges Ahead 
• The National Herbal Medicines Industry is facing many problems and 
complexities to improve its performance today. The problems range from 
plants cultivation, production, processes, technology and product 
development including research ad development and marketing. Variances 
in quality of raw materials from different sources were also the adding 
problems towards complexities in development of the industry. 
Unavailability of scientific reports supporting the safety and efficacy of the 
traditional medicines has been the biggest concern for a wider acceptance 
by the medical professionals. The marketing efforts of traditional medicines 
are constrained by the fact of usually non-standardized products, lack of 
scientific information to support the products and insufficient financial 
resource in most small and medium companies, insufficient market 
information, less innovative and inappropriate choice especially concerning 
the international markets. To cope with the aforementioned problems, an 
integrated approach for the development of National Medicines Industry 
needs to be designed and planned. In the long run, all the constraining 
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factors should be appropriately addressed and minimized so as to yield 
positive outcomes for the welfare of the people. Given this large industry's 
unorganized nature, obtaining reliable information is difficult, yet there is a 
widely recognized crisis in the supply of Ayurvedic herbs and unsustainable 
and destructive extraction has been widely reported. 
(5) Role of World Health Organization 
The wealth of accumulated clinical experience and knowledge with 
traditional medicine deserves to be acknowledged and combined with 
methodologically sound research into the extent and limitations of traditional 
practices. Patients, governments, traditional practitioners and practitioners of 
modem medicine all stand to benefit from evidence-based practice of 
traditional medicine. The support of the scientific community and practitioners 
of modem medicine will be needed if traditional medicine is to be brought into 
mainstream of health services. Health policy-makers worldwide are 
recognizing that traditional medicine and the use of herbal medicinal plants 
continue to be a strong part of a country's culture, history and beliefs, and that 
those practices in most parts ought to be analyzed as being part of the country's 
health system. In this regard, the current objectives of WHO in traditional 
medicines are: 
• To develop their own herbal medicine and integrate it into their 
national health care systems. 
• To ensure appropriate, safe and effective use of herbal medicine. 
• To increase access, among Member States, Scientific community and 
the users to accurate information on herbal medicine issues. 
According to this WHO strategy document, about 80% of the people in Africa 
use traditional medicine as their normal everyday means of healthcare. In western 
countries, the use of herbal and other traditional alternatives is on the upswing. 
75% of the population in France has used complementary medicine at least once; in 
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Germany, 77% of pain clinics provide acupuncture; and in the United Kingdom, 
expenditure on complementary or alternative medicine stands at US$ 2300 million per 
year. 
WHO and its Member States cooperate, to promote the use of traditional 
medicine for health care. The collaboration aims to: 
• support and integrate traditional medicine into national health systems in 
combination with national policy and regulation for products, practices 
and providers to ensure safety and quality; 
• ensure the use of safe, effective and quality products and practices, 
based on available evidence; 
• acknowledge traditional medicine as part of primary health care, to 
increase access to care and preserve knowledge and resources; and 
• ensure patient safety by upgrading the skills and knowledge of 
traditional medicine providers 
Traditional medicinal plants have always been remaining as a source of 
bio-piracy in India. Many cases of the theft of traditional knowledge relating to 
medicines have taken place in India few of them are as follows: 
(a) The Turmeric Patent Case 
The rhizomes of turmeric are used as a spice for flavouring Indian 
cooking. It also has properties that make it an effective ingredient in medicines, 
cosmetics and as dyes. As a medicine, it has been traditionally used for 
centuries to heal wounds and rashes. 
In 1955, two expatriate Indians at the University of Mississippi Medical 
Centre (Suman K. Das and Hari Har P. Cohly) were granted a US patent (no.5, 
401,504) on use of turmeric in wound healing. The Council of Scientific & 
11.http://www.communicationagents.com/sepp/2004/06/30/who_issues_guidelines_for_herbal medici 
ne_press_exaggerates_wamings.htm 
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Industrial Research (CSIR), India, New Delhi filed a re-examination case with 
the US PTO challenging the patent on the grounds of existing prior art. CSIR 
argued that turmeric has been used for thousands of years for healing wounds 
and rashes and therefore its medicinal use was not a novel invention. Their 
claim was supported by documentary evidence of traditional knowledge, 
including ancient Sanskrit text and a paper published in 1953 in the Journal of 
the Indian Medical Association. Despite an appeal by the patent holders, the 
US PTO upheld the CSIR objections and cancelled the patent. The turmeric 
case was a landmark judgment case as it was for the first time that a patent 
based on the traditional knowledge of a developing country was successfully 
challenged. The US Patent Office revoked this patent in 1997, after 
ascertaining that there was no novelty; the findings by innovators having been 
known in India for centuries. 
(b) Neem Patent Case 
Neem extracts can be used against hundreds of pests and fungal diseases 
that attack food crops; the oil extracted from its seeds can be used to cure cold 
and flu; and mixed in soap, it provides relief from malaria, skin diseases and 
even meningitis. In 1994, European Patent Office (EPO) granted a patent (EPO 
patent No.436257) to the US Corporation W.R. Grace Company and US 
Department of Agriculture for a method for controlling ftingi on plants by the 
aid of hydrophobic extracted Neem oil. In 1995 a group of international NGOs 
and representatives of Indian farmers filed legal opposition against the patent. 
They submitted evidence that the fungicidal effect of extracts of Neem^ seeds 
had been known and used for centuries in Indian agriculture to protect crops, 
and therefore was a prior art unpatentable. In 1999, the EPO determined that 
according to the evidence all features of the present claim were disclosed to the 
public prior to the patent application and the patent was not considered to 
involve an inventive step. The patent granted on was Neem was revoked by the 
EPO in May 2000. EPO, in March 2006, rejected the challenge made in 2001 
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by the USDA and the chemicals muhinational, W. R. Grace to the EPO's 
previous decision to cancel their patent on the fungicidal properties of the seeds 
extracted from the neem tree.'^ 
(c) Case of Kani Tribes of Kerala 
Below mentioned case study is related to the benefit sharing 
arrangement that has been made between the Tropical Botanical Garden and 
Research Institute (TBGRI) a publicly funded research institute based in 
Trivandrum and the Kani tribes of Kerala, involving the medicinal plant called 
arogyapaacha (Trichopus zeylantcits). The Kani tribes were using the fruit of 
this plant as an instant source of energy and vitality. The know-how about the 
plant was provided by three Kani tribal members to the team of TBGRI 
scientists during a research operation in the forest areas inhabited by the Kanis. 
Detailed scientific investigation of the plant was subsequently carried 
out by the TBGRI, including chemical screening to isolate the active 
principles, and pharmacological screening. The TBGRI scientists 
developed a drug, "Jeevani", by adding three other medicinal plants as 
ingredients. 
In a separate resolution approved both by the Governing Body and the 
Executive Committee of the TBGRI, it was decided that the Kani tribes 
would receive 50 percent of the license fee, as well as 50 percent of the 
royalties obtained by the TBGRI on sales of the drug, as part of the benefit-
sharing arrangement for divulging the information. In November 1997, with 
the assistance of the TBGRI, a trust was registered, under the name of Kerala 
Kani Samudaya Kshema Trust comprising of nine members. All the nine 
registered members of the Trust were Kani tribesmen. The president and 
vice-president of the Trust were the two Kanis who imparted the traditional 
12. http://www.tkdI.res.in/tkdl/langdefault/conimon/Biopiracy.asp#Neem 
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knowledge to the TBGRI regarding arogyapaacha. The objectives of the 
Trust are: 
a. welfare and development activities for Kanis in Kerala; 
b. preparation of a biodiversity Register to document the 
knowledge-base of the Kanis; and 
c. evolving and supporting methods to promote sustainable use and 
conservation of biological resources. 
A first payment of US$ 13,000, and royalties of US$ 500 for the 
benefit-sharing formula, was deposited in the account of the Kani 
Samudaya Kshema Trust at Kuttichal Union Bank. 
The case involving the Kanis appeared to be a solution towards the 
evolution of a framework for benefit-sharing with traditional communities at 
the first instance. However, this case also threw up its usual share of 
problems. Kanis from other areas expressed their misgivings about the 
arrangements, especially in relation to the fact that the TBGRI had not 
consulted them. From the TBGRI's point of view, there was no legal 
requirement, and they were not told of any customary requirements for 
seeking the permission of the medicinal practitioners among the Kanis 
before using the plant. Further, the Kanis according to them were not an 
organized community with an identifiable governance structure, which could 
have been approached for permission. 
(d) The Hoodia Case 
For thousands of years, African tribesmen have eaten the Hoodia cactus 
to stave off hunger and thirst on long hunting trips. The Kung bushmen, 'San 
who live around the Kalahari desert in southern Africa used to cut off a stem of 
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the cactus about the size of a cucumber and munch it. 
Hoodia is now at the centre of a bio-piracy row. In 1995, South African 
Council of Scientific & Industrial Research (CSIR) patented Hoodia's appetite-
suppressing element (P57) and hence, its potential cure for obesity. In 1997 
they licensed P57 to British Biotech Company, Phytopharm. In 1998, Pfizer 
acquired the rights to develop and market P57 as a potential slimming drug and 
cure for obesity (a market worth more than £ 6 billion), from Phytopharm for $ 
32 million. The San people eventually learned of this exploitation of their 
traditional knowledge, and in June 2001, launched legal action against South 
African CSIR and the pharmaceutical industry on grounds of bio-piracy. They 
claimed that their traditional knowledge has been stolen, and the South African 
CSIR had failed to comply with the rules of the Convention on Biodiversity, 
which requires the prior informed consent of all stakeholders, including the 
original discoverers and users. 
Phytopharm conducted extensive enquiries but were unable to find any 
of the knowledge holders. The remaining San were apparently at the time 
living in a tented camp 1500 miles away from their tribal lands. The South 
African CSIR claimed that they have planned to inform the San of the research 
and share the benefits, but wanted to make sure that the drug proved 
successful. 
The two sides entered into negotiations for a benefit-sharing agreement, 
despite complications regarding who should be compensated: the person who 
originally shared the information, their descendants, the tribe, or the entire 
country. The San are nomads spread across four countries. 
However, in March 2002, a landmark was reached in which the San will 
receive a share of any future royalties. The settlement will not directly affect 
Phytopharm or Pfizer since the San would be paid out of the CSIR's royalties, 
as South African CSIR is the patent holder. South African CSIR will probably 
160 
rx VndefWro "BJCPS d Medkim[(p[ants 
receive a royalty of around 10% from Phytopharm, which itself will receive 
royalties from sales from Pfizer. Thus San are likely to end up with only a very 
small percentage of eventual sales. 
In this regard, it is important to ensure that adequate legislation is 
developed, whether based on the intellectual properly system or a sui generis 
model. 
(6) Present Status of Indian System of Medicine 
The age-old system of Indian system of medicine has been neglected 
mainly because of the rapid expansion of allopathic medical treatment. 
Presently, the Indian system of medicine uses over 1100 medicinal plants and 
most of them are collected from the wild regularly, of which over five dozen 
species are said to be in great demand. |n many cases, there are no standards 
fixed for the raw materials and physical appearance verification generally 
becomes impossible because of the large quantities of material involved. 
Since these plants are collected from the wild in large quantities, adulterants 
are alleged to be widely used. No effort has been made either by the 
government or the industry to ensure the availability of good quality standard 
raw material free from adulterants at a suitable price and thereby leading to a 
threat to the herbal research and industry. 
The world population is expected to cross 800 crores by the turn of this 
century and this will further escalate the health budget especially those of the 
developing countries. The developing countries spend roughly 40-50% of 
their total health budget on drugs and, as a strategy to reduce the financial 
burden on developing countries, the WHO encourages, recommends and 
provides for the inclusion of herbal medicines in natural health care 
programmes. Such herbal medicines are easily available at a cheaper price 
for the common man. They are time-tested and considered safer than some of 
the modem synthetic drugs. The market for herbal medicines in the 
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developed countries is growing at a faster rate than other pharmaceutical 
products. Some of the reasons are: 
I. The realization that allopathic drugs have harmful side effects. 
II. Allopathic medicines are said to be ineffective against many chronic 
diseases like cancer. Moreover, many people suffering from 
diabetes, arthritis, respiratory diseases, skin ailments, gastric 
problems, jaundice, etc. are said to be turning more and more to 
Ayurveda and Unani for permanent cures, 
III. Herbal medicines are comparatively less expensive. 
IV. The western medical profession has begun to acknowledge the value 
of herbal medicines. This also explains the fact that many purely 
allopathic units have also adopted the use of formulations that include 
natural herbal drugs. 
In the world market for phytomedicines, Germany has the largest share at US 
$ 1.5 billion (Rs. 4800 crores), i.e. 2.2% of the total. The share of the Indian 
market is negligible, notwithstanding the fact that we have a varied emporium of 
medicinal plants and are the exporters of over 200 major drugs and 
pharmaceuticals. 
Only in Ayurvedic sector two of the largest companies involved with 
providing traditional medicine products, are Himalaya Drug Company and Universal 
Medicaments (in Nagpur). Universal Medicaments has a joint venture for research 
and manufacturing of herbal products with Cipla Ltd. and Lupin Ltd, two leading 
pharmaceutical companies of India. Universal is engaged in manufacturing and 
exports of both pharmaceutical formulations and research-based herbal medicines. 
Exports of Ayurvedic medicines have reached a value of IQO million 
dollars a year (about 10% the value of the entire Ayurvedic industry in India). 
About 60% of this is crude herbs (to be manufactured into products outside 
India), about 30% is finished product shipped abroad for direct sales to 
consumers, and the remaining 10% is partially prepared products to be finished 
in the foreign countries''' 
13 http://www.itmonline.org/ 
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The department of Indian system of Medicine and Homeopathy 
(ISM&H) was established in the Ministry of Health & Family welfare in March 
1995. It was given a name viz Department of Ayurveda, Yoga, Naturopathy, 
Unani Siddha and Homeopathy (means long life in November 2003). There are 
two regulatory bodies (1) Central Council of Indian Medicine (CCIM) New 
Delhi, (II) Central Council of Homeopathy (CCH) New Delhi. These councils 
are responsible for laying down & maintaining the minimum standards of 
education maintaining central Register of Practitioners and regulating the 
professional practices by prescriptions of Indian system of Medicine and 
Homeopathy. There are also four apex research councils. 
(a) Central Council for Research in Ayurveda & Siddha (CCRAS) New Delhi. 
(b) Central Council for Research in Unani Medicine (CCRAS) New Delhi. 
(c) Central Council for Research in Yoga & Naturopathy (CCRAS) New Delhi. 
(d) Central Council for Research in Homeopathy (CCRH) (CCRH) New Delhi. 
Six National Institutes has been established 
(i) National Institute of Ayurveda (Jaipur) 
(ii) National Institute of Homeopathy (Kolkata) 
(iii) National Institute of Unani Medicine (Bangalore) 
(iv) National Institute of Naturopalthy (Pune) 
(v) Morarji Desai National Institute of Yoga (New Delhi) 
(vi) National Institute of Siddha (Chennai) 
There are 9493 licenced manufacturing units of Ayush in the Country 
with an estimated total annual turnover of around Rs 8800 crore Most of the 
units (>90%) are in the small and cottage scale sector with annual turnover of 
less than Rs 1 crore per annum. Less than 1% segment of the industries have 
turnover of Rs 25 crore per annum. In this top 1% segment around 50 
manufacturing units have turnover of in the range of Rs. 150-800 crore per 
annum. 
In India, 60% of registered physicians are involved in non-allopathic 
163 
T.% Vnder WTO T<SJ(PS<P(iarmaceutica[Industry 
systems of medicine. In addition to the nearly 400,000 Ayurvedic practitioners, 
there are over 170,000 homeopathic physicians; India has about 500,000 
medical doctors (similar to the number in the U.S., but serving nearly 4 times 
as many people). Reliance on Ayurvedic medicine is heavy in certain regions 
of India, such as Kerala in the Southwest. Many Ayurvedic practitioners in 
small villages are not registered. 
TABLE: NO-1 
SYSTEM WISE DETAIL OF MANUFACTURING UNITS 
System 
Ayurveda 
Unani 
Siddha 
Homeopathy 
Total 
Manufacturing Units 
7997 
391 
446 
659 
9493 
FIGURE: NO-2 
GRAPHICAL REPRESENTATION OF PERCENT WISE DETAIL OF 
MANUFACTURING UNITS 
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TABLE: NO-2 
THE COMPOSITION OF INDIAN PHARMACEUTICAL EXPORTS 
DURING THE YEARS 2003-04 TO 2006-07 
India's Exports of Bulk Drugs, Formulations, Ayurvedic, Unani, Homeo & 
Herbal Products (figs. In Rs. Crores) 
Commodity 
Name 
Exports of 
Formulations 
Exports of Basic 
Drugs, Fine 
Chemicals & 
Intermediates 
Exports of 
Herbals 
Medicants & 
Medicaments of 
Ayurvedic 
System 
Medicants & 
Medicaments of 
Homeopathic 
System 
Medicants & 
Medicaments of 
Unani System 
Medicants & 
Medicaments of 
Siddha System 
Mar-03 
5,952.93 
2,493.36 
390.79 
743.88 
8.19 
0.00 
0.00 
Mar-04 
7,481.45 
7,207.79 
318.44 
192.75 
10.30 
2.08 
0.42 
Mar-05 
9,066.94 
8,091.69 
293.63 
399.82 
2.11 
1.89 
0.47 
Mar-06 
10,829.55 
10,740.51 
307.48 
233.07 
1.87 
1.13 
0.30 
Mar-07 
14,382.55 
11,868.29 
377.02 
259.54 
2.74 
0.70 
0.02 
Mar-08 
16,647.36 
13,299.33 
470.73 
321.44 
3.05 
1.13 
0.42 
Source: Report of the task force. Ministry of Commerce and Industry, Dec. 12.2008. 
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The above mentioned table show an increase in the export of 
pharmaceuticals from March 03 to March 08 but there is no significant increase 
in ayurvedic unani homeopathic and siddha medicines. 
PART-B IMPACT OF TRIPS ON INDIAN PHARMACEUTICAL 
INDUSTRY 
Pharmaceutical is one of the most successful industries. Almost the 
entire domestic demand is met by the industry's indigenous production. The 
industry began when the Bengal Chemical and Pharmaceutical Works was 
established in Calcutta. Subsequently and in quick succession institutes like 
Kings Institute of Preventive Medicine Chennai, Pastures Institute Coonor, 
Control Drug Research Institute, Kasauli and other institutes were set up. Post 
independence was setting up of public sector firms like the Hindustan 
Antibiotics Ltd. (Indian Drugs and Pharmaceutical Ltd) etc were setup to 
reduce the imports of important antibiotic and also to meet the country's 
demand by indigenous production. The industry was given its due by the 
successive government in India. Five Years Plans and the industry was 
promoted through direct investment, intellectual property price regulation and 
above all the support for scientific research, public investment in R & D, 
education and direct production have been more successful.''' 
The TRIPS Agreement was signed in Marrakech Morocco, on 15th 
April. All the member countries of WTO are bound to make their laws 
complaint to the TRIPS Agreement. India also being a signatory to the WTO is 
bound to implement the provisions of the TRIPS Agreement. The impact of 
TRIPS on Indian pharmaceutical industry is being treated on the lines in which 
it evolved during emergence of TRIPS and the steps taken for compliance with 
the TRIPS by India. As the Patent Act, 1970 went through three amendments 
14. Ashok Ram Kumar," Impact of TRIPS on Pharma" Chronicle Special December 2, 2004 
www.pharmabiz.com. 
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and a new patent regime emerged from process patent to product patent in 
India, the Indian pharmaceutical industry was impacted. 
Role of Intellectual Property Rights (IPR) in Pharmaceuticals 
The TRIPS Agreement deals not only with patents but also with other 
forms of IPR such as copyright, trademark, industrial designs, geographical 
indications and others. Among them three intellectual property which play 
important role in development and commercialization of pharmaceutical 
industry are patents, trademarks and trade secrets. 
(a) Trademarks: The widest and largest use of IPR in Pharmaceutical industry 
is in use of trademarks. In pharmaceutical industry the registration of 
trademarks helps brand building for value creation. Branded queries or 
medicines help the patients and medical profession to identify the manufactures 
and potentially reliable quality inherent in the branded product. Trademarks in 
medicines help to build trust and confidence in the minds of the doctors and 
patients.'^ 
Section 13 of Indian Trademark Act, 1999 states that words which are 
declared by the World Health Organization and notified in the prescribed 
manner by the Registrar from time to time as international proprietary Names 
shall not be registered; this prohibition stands against the generic names 
registration as trademark. In a recent case, where Dr. Reddy' Challenged 
Torrent Pharmaceutical against the registration of dopamine the Intellectual 
Property Appellate, Board held that Dopamine con not be registered as it is an 
international non-proprietary name allotted by WHO. 
(b) Copyright: Copyright protects the literary, artistic, dramatic or musical and 
cinematographic creations of author for an exclusive period of time. In 
pharmaceutical industry documents recording the researches instruction 
15. Gopakumar. G. Nair, "Impact of TRIPS on Indian Pharmaceutical Industry" J/PR Sept.(2008) p. 
434 
167 
TX VruCerWiO l^cPS <^ !MecfidnaC(PQints 
manuals, dossiers & literature texts are protected through copyright. In case of 
non-prescription drugs and over the counter (OTC) drugs, various slogans or 
one-liners (Jingles) are also protected through copyrights. As copyright also 
protect the artistic creations, different drawings pictures, graphic or colour 
combination used on cartons, tubes, labels of pharmaceutical products are 
copyright protected. 
(c) Industrial Designs: Designs Act protects shape or appearances applied to 
an article for commercial or industrial purpose. Design protections are 
available for outer packaging of bottles, shapes of medical instruments designs 
over the tablet cover etc. Use of design protection in Indian pharma sector is 
comparatively low. Though medical devices, syringes, inhaler etc have 
increasingly acquired protection under the Designs Act 2000. 
(d) Trade Secret Data Exclusivity 
Though there is no specific Act for providing protection, trade secret 
protection is conferred to any formula, pattern, device, consumer lists etc. 
which are crucial information for trade and commerce through common law. 
India still lacks a legislation to protect confidential information. Presently 
however, trade secrets continue to have to seek protection through law of 
contracts and tort. 
One of the most controversial and widely debated topics, presently in 
India related indirectly to confidential information is the 'data exclusivity'. 
Data exclusivity refers to a practice whereby for a fixed period of time, drug 
regulatory authorities do not allow the dossier or regulatory documents of an 
originator to be referred or used to register a therapeutically equivalent generic 
version of that product. TRIPS Agreement under article 39 (3) also talks about 
protection of undisclosed test data against unfair commercial uses.'^ 
16. Article 39 (3) Members when requiring as a conditions of approving the mariceting of 
pharmaceutical or of agricultural chemical products which utilize new chemical entities the 
168 
"TTC VnderWTO T^(PS d medicinaC(PCants 
(8) Indian Patent Act and TRIPS Agreement 
On 15 April 1994 India become party to the TRIPS Agreement that time 
India's existing enactment of the patent Act 1970 directly contravened Article 
27 of the TRIPS Agreement. And being the member of WTO India has to matce 
their patent provisions compliant to the TRIPS Agreement. TRIPS gave the 
transitional period for WTO members to introduce legislation complying with 
the obligations. 
For developing countries like India the deadline given was 2000 but for 
those countries that do not grant product patents an additional period of 5 years 
was also given to introduce product patent protection India has the advantage 
of this extra transition period. Where the TRIPS itself deals with the 
pharmaceutical aspect, the Indian patent Act is also works in the light of the 
provisions of the TRIPS Agreement. 
TRIPS Agreement & Pharma 
Article 27 of the TRIPS Agreement is most relevant provision relating 
to pharmaceutical industry. Article 27.1 give a wide definition of patentable 
inventions it says that patent shall be available for any invention whether 
product or processes, in all fields of technology, provided they are new, involve 
an inventive step and are capable of industrial application. It also says that 
patent is available and its right is enjoyable without any discrimination of place 
of invention or field of technology or whether products are imported or locally 
produced but subject to Para 4 of Article 65, Para 8 of Article 70 and Para 3 of 
this Article 27.2 describe where the exclusion can be given to the patentable 
inventions, the prevention within their territory of the commercial exploitation 
of which is necessary to protect order public or morality, including to protect 
human, animals or plant life or health or to avoid serious prejudice to the 
submission of undisclosed test or other data, the origination of which involves a considerable 
efforts, shall protect such data against unfair commercial use. In addition, members shall protect 
such data against disclosure, except where unnecessary to protect the public or unless steps are 
taken to ensure that the data are protected against unfair commercials use. 
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environment, provided that such exclusion is not made merely because the 
exploitation is prohibited by their law. Apart from this members have been 
given some more exclusion from patentability. Article 27.3 (a) diagnostic 
therapeutically and surgical methods for the treatment of humans or animals 
may also be excluded from patentability. Article 27.3 (b) again gives a chance 
to exclude from patentability plants and animals other than microorganism. But 
further grant of patents for product or processes for microorganisms have made 
compulsory. Members shall provide for the protection of plant varieties either 
by patent or by an effective sui-generis system or by any combination there of 
A uniform patent term extinction of 20 years in return for disclosing the 
invention to the public in the patent application with sufficient details to enable 
a person skilled in the relevant technology to practice the claimed invention is 
also provided by TRIPS." TRIPS also include those exceptions to exclusive 
rights which have been conferred by the patent. In case of process patent the 
burden of proof is to be made available by the member countries under Article 
34. Provision of Data Exclusivity is also available in the agreement. A 
provision relating to protection of undisclosed information has been given 
under Article 39.3 except to that extant where it is necessary to protect public 
or against unfair commercial use. To extend the protection to product patent a 
transitional period of 5 years should be given to the developing country and for 
least developed countries it is 10 years period'*. Transitional arrangement and 
protection of existing subject matter during the transition phase are also dealt 
with under Article 70.8 of the TRIPS Agreement. 
India's commitment to implement the Agreement on TRIPS required 
about three sets of amendments to its patent law. The first amendment of the 
patent Act 1970 introduced requirements under the transitional arrangements 
through sections 5(2). The amendment of 1999 introduced exclusive Marketing 
Rights provisions on 1, January 1995. Section 5 of the patent Act 1970 was 
17. Supra "Note 15.p.l 
18. TRIPS Agreement Article 65 and Article 66. 
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linked to newly introduced chapter IVA, Section 24 A to 24F of exclusive 
marketing rights. The Act of 1970 talks about only of process patent and those 
countries who have no provisions for product patent in their law, has to alter 
their patent regime to be in conformity with the provisions of TRIPS 
Agreement. India also avails the transitional phase of 10 years, during this 
phase all applications for the product patent was kept in the mail box till 2005. 
Some experts predicted that all 8500 applications filed for EMR in India will 
become EMR and will cause harm to Indian pharmaceutical industry. But 
contrary to that only 14 were filed out of which majority of them got rejected. 
EMR Grant in India 
In most cases appropriate tests were conducted prior to 1^ ' January 1995 
and in other cases there have been non-matching of applicant or subject matter 
or lack of convention status of the country of research or other technical 
grounds. One of the EMRs granted was stayed by Calcutta High Court and 
related product patent (mailbox application) was rejected thereafter, in post 
2005, product patent examination (on pre-grant apposition). Another EMR 
which had been granted to an Indian company for a topical composition of 
known substances has also lapsed. Thereafter, the composition (product) patent 
application has been granted on the pre-grant apposition. A third EMR 
application filed by a Swiss based Pharmaceutical Corporation led to the grant 
of an EMR. The Swiss Pharmaceutical Corporation thereafter successfully 
obtained an injunction against majority of other Indian companies, post 2005, 
when the product patent (mailbox) application was taken up for examination a 
large number of pre-grant opposition were filed and product patent applications 
were rejected leading to the extinction of the EMR thereof An EMR for 
pesticides has been granted to an Indian company and was replaced by the 
grant of a product patent post 2005 
Parliament again amended the Patent Act in 2002 to set in turn with the 
provisions of the TRIPS agreement to a greater however not to a fiiilest 
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extent. The key issues included in the second amendment were redefining 
patentable subject matter, extension of the term of patent protection to 20 years 
and amending the compulsory licencing system, deleted the provision of 
licence of right. Reversal of burden of proof under section 104-A had been 
inserted. The Patents (2nd Amendment) Act 2002 incorporated the research 
exemption under section 107-A. 
The TRIPS Agreement also under the heading exceptions to rights 
conferred, give liberty "members may provide limited exceptions to the 
exclusive rights conferred by a patent, provided that such exceptions do not 
unreasonably conflict with a normal exploitation of the patent and do not 
unreasonably prejudice the legitimate interests of patent owner taking account 
of the legitimate interests of third parties.'^ '^  The Patent Act of 1970 also gives 
certain exemptions. Section 47(3) says that any person can use patented 
product or process for the purpose of experiment or research including 
imparting of instructions to pupils. Section 107A (a) states that any act of 
making, constructing, using selling or importing a patented invention solely for 
uses related to the development and submission of information does not 
amount to infringement of patent. By going through these two sections it can be 
considered that these sections enable the pharmaceutical companies to conduct 
further research & experimental work over the patented product. This 
exemption is specifically useful for generic manufacturers to prepare generic 
version in advance of patent expiry. These research exemptions are also known 
a Bolar Provision. Beside these provision section 3 (g)^° was also deleted by 
the Patent (Amendment)Act 2005 Deletion of this section widened the scope of 
patentability of testing methods or processes which can be also useftil for the 
manufacturing of drugs in pharmaceutical industry. 
19. TRIPS Agreement Article 30 
20. The Patents Act, 1970 Sec. 3(g) method or process of testing applicable during the process of 
manufacture for rendering the machine apparatus or other equipment more efficient or for the 
improvement or restoration of the existing machine apparatus or other equipment or for the 
improvement or control of manufacture. 
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The New Patent Regime of Product Patent came with the 3rd 
amendment of Patent Act 1970. Inclusion of clause (ja) was there and defines 
'inventive step' as a feature of an invention that involves technical advance as 
compared to the existing knowledge or having economic significance or both 
and that makes the invention not obvious to a person skilled in the art. Product 
patent have now been made available to all fields of inventions including 
pharmaceuticals food and chemical. Another section 92-A has inserted 
provisions for Compulsory Licence for the export of patented pharmaceutical 
products. This is meant to facilitate the Indian industry to continue supplying 
chapter generic versions of patented drugs to those Least Developed Countries 
(LDCs) that do not have adequate domestic manufacturing capabilities. 
The Patent (Amendment) Act 2005 has also omitted section 24A to 24F 
of chapter IVA of the Patent Act of 1970. Before amendment of the Act 1970, 
there was provision for opposition of an accepted patent application by any 
interested person under the Patent Act, 1970 but after the amendment there was 
insertion of the additional provision for pre-grant opposition along with the 
provision for filing post grant opposition. Section 25 (1) of the Patent Act, 
1970 lays down the grounds on which a patent application can be opposed in 
India. It also stresses that provisional specifications should be updated with 
complete specification within 12 months with no provision for further grace 
period. 
While making the necessary Amendments to the Indian Patent Act 
(passed by the parliament on 22 March 2005), the Indian Government has 
strived to ensure that not only is India's commitment to the WTO community 
for providing strong intellectual property protection is taken care of but also the 
protection of the domestic industry, the consumers and the economy at large is 
ensured. 
Pre-grant oppositions by pharmaceutical companies in India have been 
in news in recent time as per various industry and legal sources it is believed 
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that till date. Indian pharma companies have filed 148 pre grant oppositions in 
to patent applications. Indian drug companies such as Ranbaxy Labs, Cipla and 
Torrent pharma are believed to have filed around 15 and 50 pre-grant 
oppositions, respectively. With regard to such pre-grant oppositions, MNC; 
pharma companies feel that the same are used by domestic pharma companies, 
such as a strategy to delay the grant of their patents. However, a pre-grant 
opposition regime accretion of information, which otherwise the patent office 
would not have been aware of it, also helps the patent office in rejecting 
frivolous and non patentable invention.'^ ' And now when pre as well as post 
grant opposition has come into existence the doubts of these 'Big' 
multinational pharma companies will be removed. 
9. Patentability Criteria of Pharmaceutical Inventions 
In this new product patent regime criteria of patentability play a key role 
in determining whether an invention is patentable or not in India. For 
pharmaceutical industry the amended section 3(d) in its form has become a 
major concern. 
Sec.3. "What are not inventions- following are not inventions within the 
meaning of this Act^ .^ 
(d) the mere discovery of a new form of a known substance which does 
not result in the enhancement of the known efficacy of that substance or the 
mere discovery of any new property or new use of a known substance or of a 
mere use of a known process machine or apparatus unless such known process 
results in a new product or employs at least one new reactant. 
Explanation- for the purposes of this clause, salts, esters, ethers 
polymorphs, metabolites, pure form particle size, isomer, mixtures of isomers, 
21. Sunil .B Krishna , "Indian Regime on Protection of Pharmaceutical Industry Innovation" MIPR 
Vol, 3 p.A-140 (2007). 
22. The Patent (Amendment) Act,2005. 
174 
TX Vnd:erWlOT:^(PS €i Me£cim[(PCants 
complexes, combinations and other derivatives of known substances shall be 
considered to be the same substance, unless they differ significantly in 
properties with regard to efficacy." 
So if an applicant points out that new form or new property is more than 
a mere new form or mere new property of the known substances having a 
significant difference in property with regard to efficacy he may justify the 
grant of a patent. Along with this the combinations of a known substance 
delivered in a unique formulation where the efficacy of the formulation 
increases then that application would qualify for a patent. 
Section 3(e) of the Act^ ^ Says-
"(e) a substance obtained by a mere admixture resulting only in the 
aggregation of the properties of the components thereof or a process for 
producing such substances," manual of patent practice and precedence 
published by patent office, India 2005 cites an example regarding to this 
provision example-
(iii) a composition of two drugs i.e. Paracetamol and Ibuprofen for 
curing fever and pain or process of preparation thereof is not patentable for the 
reasons that the composition is mere admixture of two drug components 
resulting into aggregation of properties thereof since Paracetamol is well 
known for treatment of fever and other one for treatment of pain. But if the 
mixture of drugs can give same unexpected results or synergistic properties in 
the treatment them the process of preparation of such composition may be 
considered patentable. The constitutional validity of section 3 (d) was 
challenged in Gleevec case (Novartis). 
23. The Patent Act, 1970. 
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The Novartis Case: Applying Section 3(d) through pre-Grant Opposition 
Though the TRIPS Agreement attempts to create a uniform patent 
regime, the inherent flexibiUties in the Agreement coupled with emerging 
markets need to protect pubHc health and promote access to medicines has 
resulted in a minimum standard global regime with distinct national differences 
in prosecution and protection of patents. The post TRIPS era has witnessed 
difficulties faced by many pharmaceutical companies in prosecuting their 
patents largely due to the exceptions to patentability which can be applied to 
challenge a patent application before its grant. An open application before its 
grant has increased number of challenges to patent application is evident from 
the number of patent oppositions initiated by patient groups in India. The most 
significant of these opposition proceedings was the pre-grant opposition to 
Novartis' patent application for its drug, Imatinib Mesylate brought about by 
some leading generic companies and a patient group has been discussed in 
detail. 
Novartis' Application for Gleevec in India 
In 1993, Novartis filed a US patent application for the anti-cancer drug, 
Gleevec (Imatinib) and was granted US Pat No. 5521184 for the same on 28 
May 1996. At that point due to the fact that the Indian law did not offer product 
patents for pharmaceuticals no application was filed in India. With the regime 
change brought about by the TRIPS Agreement, which provided for filing mail 
box applications and Exclusive Marketing Rights (EMR), Novartis filed an 
application (No 1602/MAS/98) on 17 July 1998 for the beta crystalline form of 
Imatinib Mesylate. In November 2003, the Controller of patents granted EMR 
to Novartis. The drug containing Imatinib Mesylate did not enjoy patent 
protection in India, though it was patented in various other countries. Under 
Chapter IVA of the Patents Act, 1970, Novartis was able of obtain an EMR for 
Imatinib Mesylate. The grant of EMR meant that Novartis could exclusively 
sell and distribute the drug Imatinib Mesylate which is the subject matter of 
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EMR. This move affected six Indian pharmaceutical companies who have been 
manufacturing the same drug, Imatinib Mesylate, under different trade names. 
These companies and an NGO instituted pre-grant opposition against Novartis' 
patent application for Gieeve. 
After a string of infringement actions instituted by Novartis on the basis 
of its EMR and after two contradicting High Court decisions, the Controller of 
Patents rejected the patent application for Gleevec. On 25 January 2006, the 
Controller of Patents refused to proceed with the patent application for this 
drug pursuant to opposition proceedings initiated by the competitors. With the 
rejection of Novartis' patent application for Gleevec, Novartis appealed against 
the Controller's decision and challenged the constitutional validity of Section 
3(d) which was one of the main grounds on which its application was rejected. 
At the heart of the Novartis case was the issue of standard of 
patentability under the Indian Patents Act. The TRIPS Agreement being a 
minimum standard agreement requires its members to grant patents for 
inventions in all fields of technology for a period of 20 years if it satisfies the 
universally accepted criterion of patentability. It is widely proclaimed that the 
Indian Act, after a series of amendments which concluded in the years 2005, is 
in full compliance with the obligations under the TRIPS Agreement. The time 
that Novartis chose to enter India was the one in which rampant changes were 
made to the Indian law. To put Novartis's case in perspective, the Indian 
Patents Act, 1970 underwent three critical amendments in 1999, 2002 and 2005 
which brought the Patents Act in compliance with the TRIPS Agreement, since 
Novartis filed its patent application in 1998. 
The Novartis case had many firsts to its credit. It signified the first 
instance of grant of a patent-like right known as EMR, which led to the world's 
first contentious case of EMR. It was also the first time a foreign multinational 
questioned the constitutional validity of a provision of the Indian Patents Act. 
As soon as the law changed in India, Novartis preferred an application for p 
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crystalline form of Imatinib Mesylate (Gleevec) in 1998. Imatinib as a free 
base molecule was invented by Novartis in 1992 and Patented in US and other 
countries in 1993. Novartis however choose not to apply for a patent for the I 
matinib free base in India as did not offer product patent protection in 1993. It 
is pertinent to note that the 1993 US patent of imatinib disclosed the salt 
Imatinib Mesylate. 
But in 1998, Novartis came up with an application for a p crystalline 
form of Imatinib Mesylate which was, in the terms of Section 3(d) of the 
patents Act 1970, a new form of a known substance. The application was 
challenged by the generic companies and an NGO by way of pre-grant 
opposition on many grounds, inter alia, that the subject of any claim of the 
complete specification is not an invention within the meaning of the Act, or is 
not patentable under the Act, in particular under Sections 3(d) of the Act. 
Section 3(d) of the Act, states that mere discovery of a new form of a known 
substance which does not result in the enhancement of the known efficacy of 
that substance shall not be treated as an invention within the meaning of the 
Act. Phrased differently, it meant that the new form of a known substance will 
be entitled for a patent if it results in the enhancement of the known efficacy of 
that substance. Novartis tried to demonstrate before the Controller how there 
was an enhancement of efficacy and submitted that there was an enhanced 
bioavailability of 30% in studies conducted on rats. The bioavailability of a 
drug refers to the extent to which and the rule at which the drug appears in the 
blood stream after administration in dosage form. It is one of the indicators of 
efficacy of a drug. The controller rejected this submission and held that 
Novartis had failed to demonstrate the enhancement in efficacy as required 
under the Act. 
Enhancement of Efficacy 
The case failed a Novartis failed to discharge the burden of showing 
enhancement of efficacy. This was due to the indiscriminate adoption of its 
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PCT application without taking the special needs under the, Indian Patents Act 
into account. Section 3(d) has an in-built guideline for determining the 
enhancement of efficacy. It states that with known efficacy, as the benchmark, 
the person seeking patent ahs to show the enhancement of efficacy. The 
explanation to section 3(d) requires such enhancement to be significant. 
Novartis' case suffered as the patent application did not shown how 30% 
increase was critical in the performance of the drug and how increase in 
enhancement of efficacy made a difference when compared to known efficacy. 
Troubles with the Law 
Aggrieved by the order of the Controller, Novartis approached the 
Madras High Court with two batches of writ petitions: one Challenging the 
constitutional validity of Section 3(d) and the other challenging the order of the 
Controller with the request for quashing the same as the appeal mechanism 
(appeal from a Controller's order to, the Intellectual Property Appellate Board-
IPAB) under the Patents Act has not come into force by then. In the writ 
petition challenging the constitutional propriety of section 3(d), Novartis took a 
contradicting plea that the provisions in Section 3(d) are vague and arbitrary 
despite trying its best to plead its case on the lines of Section 3(d) before the 
Controller. Though the Madras High Court had dismissed the writ petitions 
filed by Novartis challenging Section 3(d), The High Court had directed the 
transfer of other batch to IPAB questioning the order of the Controller after 
converting the same into a statutory appeal. 
The judgment of the Madras High Court and the impact of Section 3(d) 
must be understood better by knowing what it permits and what it prohibits. 
Patents for pharmaceutical substances today fall into two broad categories: 
Radical innovation and incremental innovation. Without doubt, the law with 
regard to radical innovation in India is just the same as it is in any part of the 
globe; the Patents Act 1970 grants patents for radical innovation of the three 
prerequisites of novelty, inventive step and industrial application are 
179 
TX VncCer WIO 'W(PS d Mecficina[(Pknts 
satisfied. The second category, incremental innovations is an area where there 
is no consensus with regard to what actually amounts to incremental innovation 
and the extent to which such innovations should be protected. In any case, the 
language of Section 3(d) permits incremental innovation. But it is for the 
applicant to demonstrate why a fresh patent should be granted to a known 
substance, for which he will have to demonstrate an increase in efficacy of the 
substance over the known efficacy. The applicant has to demonstrate this in its 
patent application and the failure of Novartis to do so has been an important 
cause for all its troubles. 
Another area where a problem has been felt by the pharmaceutical 
sectors is of patentability of diagnostic method. Section 3 (i) of the Act, talks 
about it. "3 (i) may process for the medicinal, surgical, curative, prophylactic 
diagnostic, therapeutic or other treatment of animals to render them free of 
disease or to increase their economic value or that of their products." (Not 
considered as invention). 
The Indian law as it stands does not distinguish between in-vitro and in-
vivo methods of diagnosis. While in-vitro methods of diagnosis would involve 
tests on samples taken from the body and performed outside the body, like 
taking blood samples and testing for diagnosis of a disease like malaria, the in-
vivo methods of diagnosis would include performing the methods of on the 
human body (like CT scan MRI etc) it can be safely concluded that while the 
patentability of in-vivo diagnostic methods may be considered as a patentable 
subject matter by suitably projecting the method of diagnosis a process.^ " 
10. An Insight to Indian Pharmaceutical Industry 
At the time of independence, India controlled only (10%) percent of its 
pharmaceutical market. The drug prices were touching sky with foreign 
corporations controlling the remaining substantial ninety percent of the 
24. Sunil .B Krishna, "Indian Regime on Protection of Pharmaceutical Industry innovation" MIPR 
Vol, 3 p.A-140 (2007) 
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business. Subsequently and more importantly between 1967 and 1970 
applications for patents by foreign nationals exceed that of Indians by over 
340%.^' 
It was the regime of both product and process but the position of Indian 
pharmaceutical industry was infirm. Because of that the Government of India 
enacted the Indian Patent Act 1970. The object was to implement the 
protectionist measures on pharmaceutical industry. Section 5 of the Patent (39 
of 1970) Act provided an exception in the area of pharmaceuticals where it 
provided only process patent and that too for a short period of seven years. 
Because of process patent provision that can be considered as weak patent laws 
Indian pharmaceutical companies became able to reproduce the existing 
generic drugs at rapid pace and low manufacturing cost. This improved the 
positions of Indian pharmaceutical industry since 1996 Indian owned 
pharmaceutical companies comprises 85% of the domestic market while the 
remaining 15% is controlled by pharmaceutical companies from United States 
and Europe. But India had to comply with the TRIPS provisions so the 
amendment act of 2005 came into existence. "The omission of section 5 from 
the principal act, by the patent amendment act, 2005 is the most critical aspect 
and product patents shall now be available for inventions claiming 
pharmaceutical food and agricultural chemical products for a term of 20 years. 
Now it the end product of the Indian company is identical with that of a brand 
name company, it should be violation of patent law because it is the same 
product. The omission created tribulations to the growth of the generic 
pharmaceutical industry in India, which has ensured public access to cheaper 
drugs for decades"^^. An annual turnover ofRs. 226 billion with a growth rate 
of 5.1% exports to over 65 countries, ranked 4th in terms of volume, providing 
direct employment to 5,00,000 people and indirect employment to 
25. Abhishek Dubey, "TRIPS, Patents & the Indian Pharmaceutical Industry Addressing New Twist In 
the Tail," Madras Law Journal, p.22 (2006) 
26. Manoj Pillai, "The Patent Amendment Act, 2005 and TRIPS Compliance- A Critique" JIPR May 
(2005). 
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approximately 24,00,000 people forming large intellectual capital of the world 
is, in brief, an overview of the Indian pharmaceutical industry most definitely 
27 
the new age sunrise industry. 
The Indian pharmaceutical sector has emerged as a prominent provider 
for healthcare products catering to more than 95% pharmaceutical needs of the 
country with a population of 1.1 billion. There has been a paradigm shift in the 
policies and programmes governing Indian pharmaceutical industry resulting in 
this industry, almost non existent till 1970, transforming to a US $6 billion 
industry growing at a Compound Annual Growth Rate (CAGR) of 13.7%. It 
currently ranks 4th and 13 th in terms of global volume and value, respectively 
in global pharmaceutical business. India's pharmaceutical exports constitute 
almost 40%) of total production of pharmaceuticals in India and valued at over 
US $3-5 billions of which formulation and bulk drugs constitute 55% and 45% 
respectively. The export revenue now contributes almost half of the total 
revenue for the top 3 pharma majors: Dr Reddy's, Ranbaxy and Cipla. The 
Indian pharmaceutical industry has over 20000 manufacturing units of which 
around 260 are in the organized sector.^* Indian pharmaceutical industry has 
progressed significantly by moving from traditional business models and 
adapting to emerging new business models. 
The leading 250 pharmaceutical companies control 70%) of the market, 
with market leaders holding nearly 7% of the market share. Requirement for 
85%) of bulk drugs and almost all formulations is met with in India itself There 
are around 465 main bulk drugs used in India and out of these, around 425 bulk 
drugs are totally manufactured in India around 60 are also partially exported. 
Another notably feature of the Indian pharmaceutical industry is its 
capacity to produce drugs at lowest prices. It is estimated that Indian firms have 
27. Priyanka Kher, "The Indian Pharmaceutical Industry: Prospects & Development" Company Law 
Journal vol 3 p. 1 (2005) 
28. "Competitiveness of the Indian Pharmaceutical Industry in the New Product Regime", March 2005 
available at http://www.ficci.com/studies/pharma. 
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lower costs estimated to be one eighth in (R&D) to one fifth (in manufacturing) 
compared with western firms. India at present ranks thirteenth in world 
production by value but ranks fourth in the volume of pharmaceutical 
produced. In volume terms, Indian drugs are estimated to account for more than 
20% of global consumption. The large difference between value and volume 
arise out of kind segment the high volume, low-price the Indian firms cater to 
with overall production of 7.3 billion (finished product, domestic consumption, 
plus exports) Indian firms produce approximately 1.5% of the global 
pharmaceutical market of $480 billion. It is a truly amazing turnaround for an 
industry which until the sixties was dominated by foreign companies with 
domestic manufacturing largely limited to two public sector companies. The 
pharmaceutical industry in India meets around 70% of the country's demand 
for bulk drugs, drug intermediation pharmaceutical formulations, chemicals, 
tablets, capsules, orals & ingestible. There are about 250 large units and about 
8000 small scale units, which form the core of the pharmaceutical industry in 
India (including 5 central public sector units). These units produce the 
complete range of pharmaceutical formulations i.e. medicines ready for 
consumption by patents and about 350 bulk drugs i.e. chemical having 
therapeutic value and used for production of pharmaceutical formulations.^^ 
"The Indian pharmaceutical industry is a success story providing 
employment for millions and ensuring that essential drugs at affordable prices 
are available to the vast population of this subcontinent" once has been said by 
Richard Grester. 
11. Strength, Weakness, Opportunity and Threat (SWOT) analysis of 
Indian Pharmaceutical Industry: 
The Indian pharmaceutical market size is very less compare to 
international market. But it is a major economic sector in India. According to 
29. Sivaprakasam Kannan, "Testing Times for India's Pharma Industry" available at. 
www.atimes.com/atimes/South Asia/FCl lDf04.html -
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Indian Drug Manufacture's Association (IDMA) annual publication, the 
estimated value of production of bulk drugs and formation in India during 
2000-01 was approximately Rs. 22,187 Crores out of which Rs. 4,344 Crores is 
for bulk drugs and Rs. 17,843 Crores for the formulation. 
Strengths 
1. Cost competitiveness 
2. Developed Industry with strong Manufacturing base 
3. Well established R&D infrastructure 
4. Access to pool of highly trained scientists 
5. Strong marketing and distribution network Rich Biodiversity 
6. Competencies in Chemistry and process development 
People of India is a great asset for Indian pharmaceutical industry large 
number of scientist in the specialized field like bio-technology molecular 
biology, genomics, sufficient number of medical pharmacy «fe science 
graduates, which contributes to the strengthening of Indian pharmaceutical 
industry. 
TABLE: NO- 3 
COST OF DEVELOPMENT 
Stages 
Discovery 
Preclinical 
invivo/invitrotesting/animal studies 
Limited animal studies 
Phase I: A-B 
Phase/Ill 
Phase III 
In regulated Market 
10-20 
4-5 
3-6 
(15-30 Volunteers)20 
(15-80 
Volunteers) 150-200 
(5000 Volunteers) 
India 
7-14 
1-1.5 
1-5 
-
1-5 
90-140. 
Sources: Business world 14 June 2004 p. 24. 
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Due to existence of the process patent since 1972-2004 Indian 
manufactures could make bulk drugs and formulations by "reverse 
engineering" the overseas patented medicine without any obligation of the 
payment of royalty, licence for or spending much or R & D, the prices of the 
drugs were the lowest in the world (however this strength exists no more after 
Amendment 2005). 
TABLE -4 
COST OF MANUFACTURING 
Formulation plants for 
Tablets 
Soft Capsules 
Injectiables 
Cost of Manufacturing Formulation 
Regulated Market 
30-40 
30-40 
24+ 
30.50 
India 
10 
10 
7.2 
20 
Sources: Business world 14 June 2004, p. 24. 
Cost per molecule in $ million. 
The above mentioned two tables prove the low cost of development and 
manufacture of drugs in India. 
Low labour cost as well as highly educated people is the major strengths 
of the Indian pharmaceutical industry. Any pharmaceutical industry needs 
employee from the field of organic chemistry, Biochemistry, Pharmacology, 
Analytical chemistry. With a very well developed and diverse education 
system, India produces students who can meet these requirements of Indian 
pharmaceutical industry. 
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Weaknesses 
1. Low investments in innovative R&D 
2. Lack of resources to compete with MNCS for New Drug Discovery, 
Research and Commercialization of Molecules on a world wide basis 
3. Lack of strong linkages between industry and academia 
4. Low medical and healthcare expenditure in the country 
5. Inadequate regulatory standards 
6. Production of spurious and low quality drugs 
Through the R & D spends of the top 20 pharma companies has more 
than doubled over the last 5 years from $20 billion in 1995 to $40 billion in 
2000, but R&D expenditure is very title amount when compared to US 
30 
companies. 
Availability of funds is a major weakness of Indian pharmaceutical 
industry. The Indian pharmaceutical industry is investing significant funds in 
bio-technology genomics, proteomics and altered information based research 
which need very high amount of capital but there is no guarantee of success. 
Opportunities 
1. Significant export potential 
2. Licensing deals with MNCs for NCES and NDDS 
3. Marketing alliances for MNC products in domestic market and 
international market. 
4. Contract manufacturing arrangements with MNCs 
5. Potential for developing India as a centre for international clinical trials. 
6. Niche player in global pharmaceutical R&D 
India is the largest democracy in the world. Its GDP is $4.7 billion. 
India's GDP grow at an average rate of 5.5% between 1990 and 1997. During 
30. Collector's Edition Volume II 2003 Business Today p-I23. 
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the current 5 year plan it is expect to grow at 6.4% and in the next 5 year plan 
it is projected to be 9%. The Indian government policies are open to foreign 
investment and country is developing the necessity for economic growth. 
India's huge middle class approximately 250 million people has a vigorous 
buying capacity with an annual expenditure of pharmaceutical products, could 
be opportunity for near future. 
Threats 
1. Product patent regime poses serious challenge to domestic industry 
unless it invests in research and development. 
2. R & D efforts of Indian pharmaceutical companies hampered by lack of 
enabling regulatory requirement. For instance, restrictions on animal 
testing outdated patent office. 
3. Drug price control order puts unrealistic ceilings on product prices and 
profitability and prevents pharmaceutical companies from generating 
investible surplus. 
4. Lowering of tariff protection. 
5. Export efforts hampered by procedural hurdles in India as well as non 
tariff barriers imposed abroad. 
1'' Jan., 2005 was a historical day for Indian pharmaceutical industry 
because from that date product patent has been implemented in India, so no 
copy cut method will be implemented in this industry. Now the organization 
which is having very strong R&D or which is financially very sound for 
licensing, any patent product can be smoothly run. There will be tremendous 
competition between India and multinational pharmaceutical organizations. 
The Indian pharmaceutical Market may face the threat of the damping of bulk 
drugs and formulations by neighboring countries. There are certain concerns 
over the patent regime regarding its current structure. It might be possible that 
31. Arbinda Bhandari, Dr Verma, "SWOT Analysis of Indian Pharmaceutical Industry" Available at 
http://www.pharmatech.com 
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new government may change certain provisions of the patent act formulated by 
the preceding government. 
TABLE -5 
GROWTH OF INDIAN PHARMACEUTICAL INDUSTRY (IPI) 
RS (IN CRORES) 
Capital investment 
Production Formulation 
Bulk Drugs 
Impact 
R & D Expenditure 
1965 
-66 
140 
150 
18 
8.20 
3 
1980 
-81 
500 
1200 
240 
42.54 
14.75 
1997 
-98 
1840 
12068 
2623 
2868.00 
220.00 
2001 
-02 
2150 
13878 
3148 
3128.00 
260.00 
2002 
-03 
2500.00 
15960.00 
3777.00 
3441.00 
320.00 
2005 
-06 
3200.00 
18750.00 
5113.00 
4267.00 
560.00 
12. Effect of Earlier Patent and Drug Control Laws on IPI; 
In the post independence era up to the year 1970 India employed 
western style patent legislation and recognized product patents in addition to 
process patents on drugs. As a result foreign companies prospered well in the 
country with over 90% of the IPI's market share and 80% of ownership 
dominated by them. This made the country increasingly dependent on import 
for bulk drugs and formulation and thus drug prices were amongst the highest 
in the world in 1970. The Indian government took two important steps to break 
the multinational domination and foster a self reliant indigenous industry. It 
introduced drug price control order (DPCO). 
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TABLE NO-6 
IMPACT OF PRODUCT PATENT REGIME ON PHARMACEUTICAL 
Indicators 
Cost of 
Drugs 
Availability 
Imports 
Exports 
R&D 
Prel970 product 
& Process 
High 
Low 
High 
Low 
Absent 
1970-1995 
process 
Low 
High 
Low 
High 
negligible to 
low 
1995-2005 & after product 
Statues-quo 
Therapeutic segment 
dependent. 
Constant (may rise in future) 
High(relatively constant) 
Moderate increase (overall 
still low) 
Source: JIPR July 2005, volume-JO, p-272 
The Indian Patent Act of 1970 by ignoring product patent permitted 
companies to reverse engineer products of their multinational competitors. 
Indian companies were free to ship reverse engineered drugs to patent 
recognizing countries on or after the day of expiry (with no lag time) such a 
liberal patent environment benefited Indian firms at the expense of MNC's 
causing some MNC's to opt for minimal presence in India. As a result foreign 
ownership in Indian drug industry decreased to just 39% in 1993 as compared 
to 80% in 1970 before the introduction of this act. 
Drug Price Control Order (DPCO) 
DPCO was introduced to guarantee the citizens access to essential 
medicine or drugs at a reasonable cost with adequate rate of return to 
companies without compromising quality, the DPCO exempted smaller firms 
from price controls thereby encouraging them to participate in pharmaceutical 
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industry. Now the small companies represented more prominently than might 
otherwise be expected. Many firms discontinued producing essential drugs 
because of strict conditions and rules laid down by DPCO and essential drugs 
were become more difficult to access. The Government revised the DPCO in 
1995 the DPCO of 1995 declassified 70 out of 146 drugs, dropped some 
clauses that favoured small companies and exempted newly (local) produced 
products from price controls. 
13. Pharma Policy and Administration 
(a) National Pharmaceutical Pricing Authority (NPPA) 
The NPPA was established in 1997, to improve the speed and 
transparency of the process of fixing the prices of bulk drugs and formulation. 
It is expected to reduce the time lag between price revisions, thereby providing 
stable margins for formulations and revise the list of bulk drugs under price 
control within reasonable time. 
This stage can be regarded as golden period for Indian pharmaceutical 
sector. Taking full advantage of no product patent regime a 'reverse 
engineering' the industry witnessed phenomenal growth as never before 
whether in terms of volume, sales export number of manufacturing units etc. 
Before 1970 the total investment (at current prices) in the pharmaceutical 
sector was just Rs. 24 Crore in 1952 (Hathi Committee Report-1975) which 
rose to Rs. 200 crore in 1972. More recently, total investment is Rs. 5,253 crore 
(estimated) in 2003-04 (BDMA report).^ '' 
32 . Sanjeev Chandran.Archana Roy, Lokesh Jain," Implications of New patent Regime on Indian 
Pharmaceutical industry'V//'/?, July p. 271(2005) 
33. Bulk Drug production involves the production of the active ingredients present in the drug, called 
the active pharmaceutical ingredient (API) formulation production involves the processing of bulk 
drugs into finished dosage forms such as tablets, capsules, injections ointments etc. 
34. Ravinder Jha," Options for Indian Pharmaceutical Industry in Changing Government" EPW Sept. 
29, (2007) p. 3959. 
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The compound annual rate of growth, rate of production of bulk drugs 
from 1991 to 2005 was 8.4 percent while that of formulations was 4.9 percent 
over the same period. It was revealed that bulk drugs production and 
formulation production was growing with a similar pace till 1995 but after that 
1995 onwards the production of bulk drugs was almost doubled compare to 
formulation production. 
TABLE NO-7 
COMPOUND ANNUAL GROWTH RATES OF PRODUCTION IN IPI: 
Years 
1980-81 to 1989-90 
1991-92 to 1994-95 
1995-96 to 2004-05 
1991-92 to 2004-05 
Bulk Drug 
5-0 
7.6 
10.2 
8.4 
Formulation 
5.5 
7.25 
5.5 
4.9 
Source: Bulk Drugs Manufactures Association Bulk Drugs industry at a 
Glance various issues. 
Production have a direct effect on the trade aspect along with the 
increase production of drugs the India's trade relating to drug and 
pharmaceutical also increase this can be observe by the table given below: 
(b) National Pharmaceutical Policy, 2006 
The Pharmaceutical policy of 2002 was controversial as it reduced the 
span of price control which in turn would have resulted in increase of essential 
life saving drugs. It has been replaced by national pharmaceutical policy 2006 
which aimed at strengthening of drug regulatory system the formulae proposed 
for fixing equitable prices for bulk drugs and their formulations include cost 
plus margins models negotiated prices, differential prices, reference prices bulk 
purchase prices etc. The policy provided for 'Rastriya Swasthya Beema 
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Yojana' for the 'Below Poverty Line' (BPL) families and other schemes. The 
maximum allowed post marketing expenses have been increased to 150 percent 
from 100 percent as provided under Drug price control order, 1995 with an 
extra 50 percent for products of R & D intensive companies. In April 2008, the 
Health Ministry expressed strong reservations against the proposals in the draft 
policy. One of the major reasons in that the chemical ministry wants to 
establish a separate pharmaceutical department." 
(c) Sawant Reddy Report 
Indian has emerged as one of the important producers of generic 
medicines in the world. There has been a prolonged debate on the likely impact 
of data protection provisions on the growth of pharmaceutical industry and on 
availability of cost generic medicines India does not have a data protection law 
like the Hatch & Waxman Act. TRIPS agreement Art 39.3 seeks to give 
protection to the originator for the investment in time and money in the 
generations of registration data. The Sawant Reddy panel as constituted by the 
central government submitted its report on steps to be taken by government of 
Indian in the context of data protection provision of TRIPS Agreement Art 39.3 
on 31st May 2007. The panel has come out with following recommendations:^ ^ 
1. During the period of Data exclusivity the government would ensure 
prevention of leakage of data or unauthorized use of research material. 
2. During the transitional period, the minimum requirements under Art 
39.3 that is, nondisclosure of test data and non acceptance of 
fraudulently obtained data of TRIPS may be implemented. 
3. The office of drug regulator must work for up gradation of physical 
infrastructure and technical skills. 
4. Pharmaceuticals as well as traditional medicines must be provided with 
five years of DE. 
35. Mahanta Leoni; Development of pharmaceutical sectors in the dynamic Indian patent Regime at 
http://www.studentsindlaw.com 
36. Swpro note 27 p. 1. 
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5. Drugs for life threatening diseases like HIV/AIDS may be exempted 
from the provisions of fixed period data protection by the drug regulator 
by placing reliance on the data submitted by the first applicant and grant 
market approval to the subsequent applicants for the same products in 
India. 
6. DE will be protected under the provisions of common law, Law of Torts 
and the Indian Contract Act, 1872. 
7. In order to ensure confidentiality of data, additions must be made to the 
Drugs and Cosmetics Act, 1940 to specify third party liability for 
unauthorized use and make data protection enforceable through courts. 
In world health conference Mrs. Indira Gandhi Said, "'Affluent societies 
are spending vast sums of money understandably on the search for new 
products and processes to alleviate suffering and to prolong life. In the process 
drug manufactures have become a powerful industry. My idea of a better 
ordered world is one in which medical discoveries would be free of patents and 
there would be no profiteering from life or death.'''' 
The Government of India has taken many initiatives for the growth of 
pharmaceutical industry. The union budget of 2007-08 incorporated many 
provisions pharma sector. That is weighted deduction on in house R&D 
expenditure extended for a period five more years until March 31.2012, service 
tax exemption to DCG12 approved CR03s offering trial for technology testing 
and analysis services for testing of new drugs peak customs duty reduced to 
10% etc. 
Before the advent of product patent regime Indian Pharmaceutical 
industry has shown its strongest performance the IPI improved not only in the 
area of production but also has performed as a foreign exchange earner. Total 
production of the industry expanded more than four fold in value terms (in 
domestic currency). The dollar value exports too had a similar increase. The 
first indicator for analyzing the performance of the pharmaceutical industry 
193 
TTC VtuCerWlOTXm ei 9Aedidna[(P(ants 
is the net worth of the firms which is a reflection of their respective market 
values. Here table provides the details^^ 
TABLE NO-8 
NET WORTH OF LEADING INDIAN PHARMACEUTICAL FIRMS 
(US $ MILLION) 
Firm name 
Ranbaxy Lab, Ltd. 
Dr. Reddy's Lab. 
Ltd 
Cipla Ltd. 
Sun Pharmaceutical 
Inds. Ltd. 
Aurobindo Pharm 
Ltd. 
Wockhard Ltd. 
Cadila Healthcare 
Ltd. 
Lupin Ltd. 
Nichola Piramal 
Ind. Ltd 
Orchid Chemicals 
pharm. Ltd. 
Dec 99 
334.8 
81.0 
107.2 
73.5 
29.6 
151.8 
20.2 
15.7 
73.4 
39.4 
Dec 00 
335.9 
88.0 
130.2 
84.2 
50.7 
60.3 
113.7 
15.0 
85.5 
03.5 
Dec 01 
315.6 
100.4 
156.2 
101.9 
60.6 
72.4 
118.9 
79.0 
89.8 
80.8 
Dec 02 
392.08 
303.3 
184.4 
112.3 
75.6 
77.4 
115.6 
71.2 
52.5 
62.8 
Dec 03 
479.3 
373.4 
219.0 
143.9 
110.2 
97.8 
90.7 
79.0 
78.3 
83.1 
Dec 04 
545.5 
445.5 
272.9 
187.1 
164.6 
135.1 
114.2 
97,5 
96.7 
91.1 
Source: CMIE, Prowess Database 
The table mentioned below indicates that most of the top ten firms of the 
industry steep increase in their net worth. Some of the larger firms Dr. Reddy's 
and Cipla, in particular, experienced very high rates of growth of net worth. In 
37 . Dhar Biswajit, "Post 2005 TRIPS Scenario in Patent Protection in the Phamiaceutical Sector. The 
Case of Generic Pharmaceutical Industry in India" available at- http://www.iprpatent.html. 
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the mid 1990 Ranbaxy was the largest Indian pharmaceutical producing firm 
by a considerable distance, but in 2004, while Dr. Reddy's had grown to a 
comparable size firms like Cipla were fast catching pharmaceutical companies 
and their retain market share also shows the growth of IPI. 
TABLE NO-9 
TOP TEN COMPANIES IN THE RETAIL PHARMACEUTICAL 
MARKET IN INDIA 2004 
Rank 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
Company 
Cipla 
Glaxo Smith 
Ranbaxy 
Nicholas Piramal 
Sun pharma 
Dr. Reddy's 
Zydus Cadila 
Aristo pharma 
Alkem Labs 
Alkem LabsAbbort 
India 
Sector 
Indian 
MNC 
Indian 
Indian 
Indian 
Indian 
Indian 
Indian 
MNC 
Indian 
No of 
products 
707 
205 
437 
449 
350 
183 
330 
175 
87 
310 
Annual Sale 
(Rs million 
2004) 
11,285 
11,143 
9,190 
8,720 
6,738 
4,988 
4,959 
4,760 
4,735 
4,477 
Market 
show 
(%) 2004 
5.51 
5.44 
4.48 
9.25 
3.29 
2.43 
2.42 
2.32 
2.31 
2.18 
Source: ORG-MARG 2004 
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The market share of the MNCs has declined consistently over the year to 
about 60 percent by the late 1970s. 50 percent by 1980, 40 percent by the early 
1990s, about one third by the late 1980 and less than a quarter by the early 
2000. 
TABLE NO-10 
TOP IMPORTING COUNTRIES OF DRUGS AND 
PHARMACEUTICAL AND FINE CHEMICALS 2007-2008 
(IN RS. CRORES) 
Year 
1952 
1970 
1978 
1980 
1991 
1998 
2004 
MNCs(%) 
38 
68 
60 
50 
40 
32 
23 
Indian Companies (%) 
62 
32 
40 
50 
60 
68 
77 
Source: Task Force Report 2008, Ministry of Commerce and Industry 
Out of the 298 companies covered by ORG N4ARG (2004) 32 
companies are controlled by MNCs and accounted for only 23 percent of the 
retail pharmaceutical market in India the remaining 226 Indian companies 
contributed to the remaining 77 percent of the market. 
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TABLE NO-11 
TOP IMPORTING COUNTRIES OF DRUGS PHARMACEUTICAL 
AND FINE CHEMICAL 2007-2008 
Rank 
L 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
Country 
USA 
Germany 
Russia 
UK 
China 
Brazil 
Canada 
South Africa 
Nigeria 
Netherlands 
Rs. Crores 
5,534.68 
1,357.72 
1,199.02 
1,077.72 
818.46 
752.62 
738.03 
650.35 
644.08 
504.17 
% Share in India's 
export 
19.1 
4.7 
4.1 
3.7 
2.8 
2.6 
2.5 
2.2 
2.2 
1.7 
Source: Task Force Report 2008, Ministry of Commerce and Industry 
TABLE NO-12 
TOP EXPORTING COUNTRIES OF MEDICINAL & 
PHARMACEUTICAL PRODUCTS TO INDIA (IN CRORE AND %) 
Rank 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
Country 
China 
Switzerland 
USA 
Germany 
Denmark 
Italy 
France 
UK 
Belgium 
Spain 
Rs. Crores 
2,760.90 
912.13 
658.14 
391.66 
287.03 
208.25 
194.82 
160.79 
124.59 
117.44 
% Share in India's 
export 
40.7 
13.4 
9.7 
5.8 
4.2 
3.1 
2.9 
2.4 
1.8 
1.7 
Source: DGCI & S (Directorate General of Commercial Intelligence and 
statistics). 
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It is not that the largest companies are MNCs and all the smaller 
companies are Indian. The largest company in the domestic retail market in 
India is now an Indian company Cipla with a market share of 5.51 percent. It 
has overtaken Glaxo Smith Kline in 2004.^ ^ 
In last ten years there is also an exceptional rise in the export area. This 
rise is due to the initiatives taken for pharmaceutical sector. 
Export Promotion Cell: An export Promotion cell in this sector has 
been incorporated with the objective of 
(a) boosting pharmaceutical exports 
(b) function as a nodal centre 
(c) Promotional activities aiming at accelerating Pharma exports 
(d) Suggestions for modifications in the EXIM policy 
(e) Seminars/ workshops on standard, quality control requirements etc. 
Pharma Export Promotion Council (Pharmexcil): The pharma export 
promotion council (pharmexcil) has been constituted with the objective of 
(a) Facilitation of export of Drugs pharmaceutical. Biotechnology products, 
Herbal Medicines, Diagnostics. 
(b) Export thrust to various products through workshops, conferences and 
seminars and delegate visits. 
38. Sudeep Chaudari, WTO and India's Pharmaceutical Industry p. 18(2005). 
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TABLE: NO. 13 
EXPORT & IMPORT OF DRUGS PHARMACEUTICAL AND FINE 
CHEMICALS, (IN SMILLION). 
Years 
1990-91 
1991-92 
1992-93 
1993-94 
1994-95 
1995-96 
1996-97 
1997-98 
1998-99 
1999-00 
2000-01 
2001-02 
2002-03 
2003-04 
2004-05 
2005-06 
2006-07 
Export 
316.5 
425.6 
411.9 
589.7 
736.1 
911.6 
1055.9 
1207.3 
1333.1 
1343.4 
1614.0 
1733.3 
2226.3 
2324.8 
2,767.5 
3,250.8 
4,076.3 
Import 
641.7 
470.8 
497.3 
682.1 
1,149.4 
1,489.2 
1,493.2 
1500.1 
1166.1 
1398.7 
1338.2 
1544.2 
1,906.3 
2,171.1 
3,034.6 
3,746.5 
4,516.1 
Source: CMIE 
The above table shows the continue growth in import as well as export of 
drugs pharmaceuticals and fine chemicals, especially export has increased 
with a speed in the product patent regime. 
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14. Challenges to IPI in a New Product Patent Regime 
"7/"fl man write a better book, preach a better sermon or make a better 
mouse trap than his neighbour, though he built his house in the woods, the 
world will make a better path to his door.'^ 
(Attributed to Ralph Waldo Emerson 1889). 
The Indian Patent (Amendment) Act, 2005 introduced product patents in 
India and marked the beginning of new patent regime. The concept of product 
patent has developed and is deep rooted in western countries following 
capitalism and open market system thereby encouraging private monopoly 
rights. It prioritizes private property over community property or public 
property. The argument in support of product patents was that since a product 
can be produced through different processes, granting process patent does not 
grant complete monopoly since it keeps open the invention to be exploited 
through any new process. Therefore the first person who invents a product 
cannot get proper reward, as only his invented process is rewarded with patent 
but ultimate result of the process is not patented.^' On the other hand the 
opponents of product patenting advocate that by granting product patent, 
private monopoly keep the invention is few hands where serving of public 
purpose may not be guaranteed. 
The product patent regime has different and several areas for its 
implications on Indian as well as global pharmaceutical industry. Among these 
various areas the most debated one is the prices of drugs or medicine. 
Predications related to the cost of drugs are that it is bound to increase. Because 
most of the MNCs and research based Indian companies have initiated to 
launch their patented molecule. 
39. N.S. Srinivasulu, "Product Patent Regime Patenting Food & Pharmaceutical" M/PR Vol 3 p.A-4 
(2007). 
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The availability of drugs in antibiotic segment and other agents used for 
tropical infection may not be affected but the availability of lifestyle drugs like 
the ones used to grow hairs, relieve impotence, fight cholesterol, ulcers, 
depression, anxiety, allergies, arthritis, diabetes and high blood pressure will be 
affected as in these areas the MNCs investment is high. The drugs used in the 
treatment of diseases like cancer and the AIDS pandemic may become 
40 
expensive. 
(a) Product Patent and Prices of Medicines 
Product patent has direct relation with the prices of medicines. The 
general impression is that drugs which are under patents are expensive 
compared to generic products and once the product patent is place, they will be 
unaffordable to the majority of countries of the developing world. And as a 
consequence their healthcare status will be seriously affected. High prices of 
patented drugs affect not only the patents in developing countries, but also the 
developed world.'*' 
The products patent system which grants monopoly to the patent holder 
for his invention (though for a limited period), deemed to ensure that R & D 
expenses are recouped from product sales over which the patentee has 
exclusive right. The patentee has the right to fix the prices of the patented 
drugs. This can be clear from comparison of India (having process patent 
before 2005) and Pakistan (having product patent) of drugs price. In Pakistan 
prices of medicines are 400 times more expensive than India. Ex-Ranitidine 
(300mg) an antiulcerant; cost Rs. 13.91 in India for a packet of 100 tablets as 
against Rs. 241.44 in Pakistan which is 17.25 times costlier, Rs. 1080.72 in the 
US and Rs. 502.70 in the U.K A packet of 14 tablets of Famotidine (40mg) cost 
40. Sanjeev Chandran, Archana Roy, Lokesh Jain, "Implication of New Patent Regime on India 
Pharmaceutical Industry Challenges and Opportunity" JIPR July p. 269 (2005) 
41. M.D Naif, Impact of New Patent regime on Drugs Prices available at http://www.pharmabiz.com 
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Rs. 6.75 in India Rs. 363-37 in Pakistan, Rs. 1445.67 in the US and Rs. 731.30 
inU.K.'^ 
The product patent of drugs in pharmaceutical sector will drive up the 
prices of vital medicines in poor countries, benefiting narrow corporate 
interests at the expense of public health. To reply the out cry against the 
introduction of product patent honourable minister of Commerce and Industry 
Mr. Kamal Nath stated "The fear that prices of medicines will spiral, is 
unfounded. The fact that 97% of all drugs manufactured in India are off patent, 
and so will remain unaffected, was realized. These covered all the life saving 
drugs as well as medicines of daily use for common ailment. In the patented 
drugs also, in most cases there are always alternatives available. " 
The AIDS epidemic has made evident the fact that the cost of the health 
care and drugs is becoming prohibitive in the entire world is a result of 
implementing the product patent system. The debilitating immune disorder 
currently afflicts some 40 million people worldwide. The more telling fact in 
the data shown is that while most new AIDS drugs are developed in North 
America more than 70 percent of AIDS patients live in Sub-Saharan Africa, 
where few can afford the drugs they desperately need to survive. Effective 
antiretro treatment (ARV) to combat the disease can cost up to US $ 1500 
annually, even the cheapest current cost is US $350 per year which exceeds the 
annual per capita income of many of the most severely affected areas. In poor 
countries, drugs prices are closely connected to exclusive marketing rights 
(EMR) and product patents and patent preventing generic drug production or 
cheap imports put drugs beyond the reach of the common people. For example, 
Flucanazole for ARV was not patented in Thailand. Pfizer was selling the 
drugs for US $6.2 while Thai manufacturer priced the drug for US $ .3,207 
42. Saleem Akhtar, "New Patent Regime and Human Rights; Effect on Health care and Pharmaceutical 
Industry" Indian Journal of Politic July Sept. p. 69 (2005) 
43. Ashish Gupta, " Patent and Politics: The Indian scenario" MIPR Vol. 1, p.A-5 (2007) 
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times cheaper than Pfizer. In South Africa, the same drugs were priced at US 
$21.4 because no generics were available. 
The Director General of WHO Dr. Margtret Chan said, "/ want my 
leadership to be judged by the impact of our work on health of two 
populations' women and people of Africa." 
Irrespective of the competitions, because of the socio welfare 
implication of the pharmaceutical prices all over the world other than in US, 
the prices of medicines are subject to government regulations. In France and 
Italy, the manufacturing price must be approved for a product to be reimbursed 
by the social insurance programme. In the absence of such health security 
schemes and with the very low purchasing power of the people in India, the 
Govt, of India has brought certain essential drugs under the price control. 
Based on India's own experience and on a selective comparison of prices of a 
few drugs in countries where product patent is in force, intellectuals forewom 
that the stronger protection would result in increase in the prices of the drugs 
and thus medicines will be inaccessible to common people.'*^ 
(b) Product Patents and Research & Development 
India is emerging as the favoured destination for collaborative R & D 
bioinformatics, contract research and manufacturing and clinical research as a 
result of growing compliance with internationally harmonized standards such 
as good Laboratory practices (GLP), current good Manufacturing practices and 
Good clinical practices (GCP). With the application of product patent in case of 
pharmaceuticals it is imperative for the Indian industry to acerbate its efforts in 
R & D in this sector. The present level of spend on R & D (about 5% of 
turnover) is much lower as compared to most of the developed countries (15 to 
20%). 
44. Sudipta Sarkar, "Product Patent for the Indian Pharmaceutical Sector under the TRIPS Regime", 
available at http://www.legalservicindia.com. 
45. Ibid., 
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The higher cost of the R & D proves to be an effective entry barrier for 
new firms and hence only firms with large flow of funds become responsible 
for industrial inventive activity. In developing counties, only a few firms have 
sophisticated R & D facilities and others benefit mainly from spillovers of the 
resultant R & D But in order to move on the higher echelon, firms need to 
invest in R & D. More often small firms shy from investing in R & D because 
financial risk is too high as there are more possibilities of failure than success. 
For instance cost of developing one new drug in the US increased from $ 54 
million in 1974 to $ 231 million in 1990. Recent studies indicate that 1 out of 
5000 compounds synthesized during applied research eventually reaches the 
market. Other estimate indicates that of 100 drugs that enter the clinical testing 
about 70 complete phase I, 33 complete phase II and 25-30 clear phase III. 
Only two third of the drugs that enter phase III is ultimately marketed.''^ 
Because of these few reasons India's investment in R & D is very low; it 
was in nineties when the initiatives were seriously taken. Dr. Reddy's 
Laboratories (DRL) was very first one to start a Discovery Research lab in new 
Chemical Entities. 
There had been an apprehension that in the wake of globalization the 
focus of research in the LDCs could change and the major R & D firms may be 
more involved in drug discovery that addresses the global diseases and neglect 
the research that is more relevant for the LDCs. In this context Amit Sen Gupta 
of the National Working Group on Patent laws adds, "/ think for me it's 
frightening that ten or twelve people today are deciding what are the kinds of 
drugs that need to be researched because clearly those drugs are being 
researched not because of the health needs but based on how much profits they 
can bring in. That's why you have research money going into drugs for 
baldness or Viagra but the last drug for tuberculosis was 30 years back. When 
46. Stt/7ra Note 45. 
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you deny people cars or washing machines they don't die, when you deny 
people drugs they die and they die in millions. " 
After years of wavering the union government has now come with a 
scheme involving a Gold Standard Certification (this would entitle them to 
claim a 200 percent Maximum Allowable Post Manufacturing Expense 
(MAPE) component while fixing the product prices in respect of 354 life 
saving drugs proposed to be brought under the control regime. To be eligible 
for the Gold standard the companies are required to meet certain specified 
criteria on R & D activities and they must also have internationally approved 
production facilities and the company will have to spend five percent of its 
turnover, subject to a minimum of Rs. 50 Crore a year on R & D. 
At present Pharmaceutical Research and Development Support Fund is 
also in existence. It is utilized for funding R & D projects of Research 
institutions and industry in the country. Very recently Indian Government has 
announced to invest nearly Rs 2,500 Crore ($ 482m) and a similar amount from 
private players to boost up research and development (R & D) activities and to 
promote innovation in the pharmaceutical sector, as reported by The Hindu. 
According to government officials, the investment will primarily be 
used to do R & D on neglected diseases which have seen low investment from 
developed countries. Moreover the programme aims to make India one of the 
five leading global pharmaceutical innovation hubs by 2020. 
(c) Product Patent and Access to Medicine 
Thirty years ago modem health technology had just awakened and was 
full of promise. Since then its expansion has surpassed all dreams only to 
become a nightmare. For it has become over sophisticated and over costly. It is 
47. Damodaran, "Indian Patent Law in the post TRIPS Decade: S&T Policy Appraisal" JfPR Sept. 
p.419(2008). 
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dictating our health policies unwisely, and what is useful is being applied to too 
few. (Dr. Halfden Mahler, General Director WHO (1973-1988). 
The pharmaceutical industry and many developed countries support 
patent on the ground that R & D is extremity expensive. Industry argues that 
price is only one of the factors determining access to medicines in developing 
countries. This factor is hardly one as there can be no greater factor than price 
in relation to life saving drugs. Lack of access to affordable medicines was a 
reason for the vast majority of deaths that took place due to HIV/AIDS in the 
developing countries. 
It is a known fact that branded or patented products are often priced 
much higher than the price of similar medicines produced by alternative 
methods. Not only are generic drugs cheaper competition from generic 
producers has resulted in prices falling also. Also when a drug company sells a 
product it is forced to price it lower if a generic is available thus making it 
accessible to the poorer sections of the society. The same brand may be sold at 
higher prices in countries where there is no competition from generic 
competition.''^  
On the other hand supporters of product patent say, the introduction of 
product patents will help in development of new and more effective drugs. The 
pharmaceutical industry more than any other sector, thinks patent protection to 
be very important in maintaining their R & D expenditures and technological 
irmovation. They argue that inadequate public health systems rather than cost 
of medicines are the biggest barrier to healthcare for the poor. Other factors 
like infrastructure, development policy, poverty flawed health system cultural 
48. TRIPS, "Drugs and the Poor: How Trade is affecting Access to Medicines" (Notes & Comments) 
CULR p.267 (2005). 
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barriers and lack of political will which affect accessibility of medicine and not 
merely grant of patents and Indian needs to look into those other factors/' 
World Health organization's (WHO) essential drugs policy clearly aims 
at providing a health for all and accessibility of primary healthcare and 
medicine to all the human beings of the world, irrespective of caste, colour 
creed and economic status. Considering the fact that the population of India at 
1.05 billion is second only to China and of that just 35% of the population has 
access to essential drugs. Fifty percent of young children are systematically 
malnourished; India has the highest number of TB patients, HIV positive cases, 
hepatitis B, malaria death & high rate of infant and maternity mortality.^ ° 
(d) Product Patent and Foreign Direct Investment 
FDI flows depend on skills availability, technology status R & D 
capacity, enterprise level competence and institutional and other supporting 
technological infrastructure. There was a sizeable increase in foreign direct 
investment (FDI) inflows during 2004 in India. During January to September 
2004 FDI inflows increased by over 54% to reach US $3042 million ($3 
billion) as against US $1969 million ($1.9 billion) during the corresponding 
year of 2003. As per the revised definition of FDI (inclusive of reinvested 
earnings, other capital etc) as reported by Reserve Bank of India (RBI) FDI 
inflows during 2004 (Jan-Sept) touched a record US $5467 million (5.4 billion) 
as against US $ 4325 million ($4.3 billion) in (Jan-Sept)2003, indicating a rise 
of 26.40% in the 9 month of the calendar year 2004. FDI approvals during the 
same period of 2004 have also gone up by over 95% as compared to previous 
year. 
49. Priyanka Kher, " The Indian Pharmaceutical Industry: Prospects & Development Company Law 
Journal,\o\. 3 p.3 (2005) 
50. Sajeev Chandran, Archana roy, Lokesh Jain," Implications of New Patent Regime on Indian 
Pharmaceutical Industry," JIPR July p.275 (2005) 
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FDI confidence survey, 2004 At KEARNEY has rated India as the 3''' 
most attractive investment destination (behind China and USA) compared with 
is"* position two years ago and 6"' last year. Though, the impact of stronger 
patent on FDI remains inconclusive from the available evidence since IPR is 
only one of the factors in attracting FDI. Correa observes that the perceived in 
adequacies of intellectual property protection did not hinder FDI inflows in 
global terms thus FDI increased substantially in Brazil since 1970 until the debt 
crisis exploded in 1985, while in Thailand FDI boomed during the eighties. In 
contrast developing countries that had adapted stronger protection have not 
received significant FDI inflows. He further observed that FDI in the 
pharmaceutical industry outpaced FDI in most of the other sectors in Brazil 
after patent protection for medicines was abolished in that country. In Italy 
after the introduction of process patent protection in 1978 FDI increased. 
Myriam Orlenna, Executive Director of the Children National Industry 
Association declared, "The trade benefits and investments which were 
promised in exchange for the implementation of a US style patent law have 
never nationalized. Hence it appears that patent production that does not have 
significant impact on FDI."^' 
(e) Pharmaceutical Merger and Acquisition 
Cross-border Merger and Acquisition deals in India's pharmaceutical sector 
have been on the upswing since 2003. European companies have been the most active 
acquirers with 61 percent of all deals, followed by North American firms with 26 
percent. The most significant deal in terms of scale and value has been the January 
2007 acquisition by Mylan, one of the largest generic drug providers in the United 
States, of a majority stake in Indian-based Matrix, the world's second largest API 
manufacturer, in a $548 million deal. According to Mylan, the merger was needed to 
expand its manufacturing platform, obtain a presence in key markets, and tap into 
local technical expertise in the production of generic biologies. Then, in 2006, it 
51. Sudipta Sarkar, "Product for the Indian Pharmaceutical sector under the TRIPS regime", at 
www.legalserviceindia.com 
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acquired Sekhsaria Chemicals, a company focused on process R&D and contract 
manufacturing services. Watson Pharmaceuticals reported that the two acquisitions 
would improve efficiencies and cost management and enhance the company's 
competitive position. 
FIGURE: NO-3 
PHARMACEUTICAL M&A ACTIVITY, 2002-06 
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Source: Bureau van Dijk; Zephyr Mergers and Acquisitions Database. 
Acquisitions by European companies also focused on expanding Indian 
operations including three acquisitions by Iceland-based Actavis during the period 
from 2005-07. In 2005, It acquired Lotus Laboraties, a CRO, in a $27 million 
deal. In 2006, it acquired a manufacturing plant from Grandix Pharmaceuticals 
to obtain "backward integration" with an API and a finished dose development 
and manufacturing unit. Then, in 2007, it acquired Sanmar Specialty Chemicals, a 
developer and manufacturer of API with the goal of continuing its "backward 
integration and reducing costs. In 2006, the French company Merieux 
Alliance, acquired a majority stake in Shantha Biotechnics, an Indian company 
focused on R&D for infectious disease vaccines, to get access to proprietary-
research and a branded product base. M&A activity during this period also 
enabled European firms including AstraZeneca and Solvay to increase their 
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majority stakes in Indian affiliates. The globalization of clinical research and 
manufacturing operations with the goal of reducing costs and accessing Indian 
expertise has resulted in increased M&A activities in India over the last five 
years. Recently India's largest pharmaceutical company Ranbaxy Laboratories, is 
expected, by the end of March 2009 to become a subsidiary of Daiichi 
Sankyo, one of the leading pharmaceutical companies of Japan." 
Thus foreign firms may exercise various options to utilize the potential 
of the Indian market as well as its technically well-equipped pharmaceutical firms 
through outsourcing alliances and competition. Indian firms, for their part, may 
also prefer to follow a combination of the strategy 'Cooperate and Compete' 
precisely to take advantage of increasing attractiveness of the global generic 
market and also to buy time till they become reasonably resource rich to conduct 
expensive R&D. There also appears to be a strong possibility that Indian firms 
may experience a large influx of outsourced jobs such as clinical trials, drug 
discover related R & D and contract manufacturing. India pharmaceutical 
firms appear to be readying themselves for this situation. The discussion above 
shows that the focus of the Indian industrial sector R & D is likely to focus 
more on drug discovery with regards to life-style related diseases than tropical 
diseases. However, there could be significant effects on the accessibility of 
essential medicines mainly to HIV/AIDS afflicted poor African countries that 
at present are getting their supplies of a cheaper copy version of ARVs from 
India. 
Since Ayurvedic and Unani (herbal medicines) do not come under the 
purview of the TRIPS regime and the research in new chemical entities 
involves millions of dollars of investment, the Indian companies should engage 
in R&D in herbal medicine. The companies should try to exploit the Indian 
traditional knowledge in ayurveda and herbal cures and file as many patents for 
herbal medicine as they can. For this the government should set up R&D 
52. Bloodgood Laura; Competitive conditions for foreign Direct Investment in India it 
http://www.google.com. 
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laboratories undertaking research exclusively in the area of herbal medicines 
and support the companies in their research and patent filing. 
Conclusion 
The traditional medicine continues to play an important role in health 
care but the general lack of research on safety and efficacy of traditional 
medicines is of great concern. Fortunately in many developing countries, 
traditional medicine offers a major and accessible source of health care. India 
has also focused on the role of traditional medicine in national health care 
strategies, supporting the development of clinical research into the safety and 
efficacy of traditional medicine, advocating the rational use of traditional 
medicine. Indian System of Traditional Medicine also has a significant 
contribution to the Indian Pharmaceutical Industry. The newly enforced 
product patent regime would be in favour of the traditional medicinal 
knowledge of India. Taking the product patent on traditional herbal drug will 
certainly work to prevent misappropriation of traditional herbal drugs and its 
knowledge by the western countries. On the other hand the newly introduced 
product patent regime directly affects the Indian pharmaceutical industry. The 
leading firms of the industry have been showing considerable dynamism during 
the past decade. The consolidation of the Indian firms, which began in the first 
half of the 1990s, improved considerably since the beginning of the current 
decade. Particularly noteworthy was the increase in the R&D spending of some 
of the leading firms, in particular, Ranbaxy and Dr Reddy's. As a result, R&D 
intensities of the firms have improved significantly. Though country is ready to 
face the challenges in the new regime, even than it is also time to take all the 
areas of pharmaceutical industry such as Indian herbal industry along with it. s 
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TRADITIONAL KNOWLEDGE UNDER PROTECTION OF PLANT 
VARIETIES AND FARMERS RIGHTS ACT 
Historically, systems for the protection of intellectual property were 
applied principally to mechanical inventions of one kind or another or to 
artistic creations. The assignment of Intellectual Property Rights (IPRs) to 
living things is of relatively recent origin in developed countries. Vegetatively 
propagated plants were first made patentable in the US only in 1930. And the 
protection of plant varieties (or plant breeders' rights), a new form of 
intellectual property, only became widespread in the second half of the 20"^  
century. System for the protection of plants derives from the economic 
structure and circumstance of agriculture that prevailed in developed countries 
in this period. That such systems came into being reflected the growing interest 
of private breeders in protecting their intellectual property. Farmers have 
traditionally replanted, exchanged or sold seed from the previous year's crop 
which means that breeders have difficulty in recouping the investments made 
in improved varieties through repeated sales. Patents or Plant Breeders' rights 
(PBRs) normally impose restrictions on farmer ability to sell grown seed and 
this enhances the market for the breeder's seed. Even in the developed 
counties, reuse of seeds remains quite common although for many crops annual 
purchase is now the rule. In developing countries the majority of farmers reuse, 
exchange or sell informally to neighbours and annual purchase of new seed is 
relatively rare in most countries.' 
Structure of plant kingdom is such that it is not capable of being 
protected like other inventions. Plant varieties were originally excluded from 
patentable subject matter because, as "Product of nature" they did not meet the 
requirement of new, non-obvious subject matter and because they could not be 
described with enough specificity to meet the patent statute written description 
requirement. 
I .Ramesh Chandra, Issues of Intellectual Property Rights, p.32 (2004) 
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Most of the courts had in the post taken the view that inventions related 
to plant breeding were not patentable per se but this approach found a radical 
change with the Red Dove decision of the German court and the decision of the 
United States Supreme Court in Sidney A. Diamond v. Ababda M. 
Chakrabarty.^ The court was presented with the novel case of the invention of 
an artificially created life form. It analyzed the case from the point of view of 
the distinction between an invention and a discovery. In the balancing Act the 
court put more weight on the fact that the bacterium was made by human 
beings (manufacture) than on the principle that products of nature did not 
constitute patentable subject matter under United States law. The court found 
support for its position in the existences of Plant Patent Act that makes a clear 
distinction between products of nature and human made inventions rather than 
between living and inanimate things. The Supreme Court observed: 
Thus, a new mineral discovered or a new plant found in the wild is not 
patentable subject matter. Likewise, Einstein could not patent his celebrated 
law and E=MC2, nor could Newton have patented the law of gravity. Such 
discoveries are "manifestation of nature-free to all men and reserved 
exclusively to none. 
The Chakrabarty decision opened the door to the patentability of micro-
organism in the United States.'' 
After this the issue became more specific & turned to the question 
whether only micro organism or plants animals could be protected by patents. 
The first patents for a transgenic animal was granted in 1998 by USPTO.'' 
Patentability of plants animals & micro-organism raised the issues of 
patentability of genes. USPTO guidelines clearly indicate that while the simple 
discovery of a gene would not be patentable if no utility is claimed for the 
2. 447 us 303 (1980) 
3. Phillippe Cullet, Intellectual Property Rights <& Sustainable Development"^. 221 (2005). 
4. United States Patent and Trademark Office. 
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Isolated gene an application for a purified gene isolated from its natural state 
that also indicates the use of the gene is patentable. 
PART- (A) PLANT VARIETY PROTECTION AND FARMERS' 
RIGHTS -NATIONAL PERSPECTIVES: 
After the formation of WTO in mid 1990s all WTO member states are 
committed through TRIPS agreement to promote effective protection of 
Intellectual Property Rights in all the field of technology. Art. 27 (3) (b) of the 
TRIPS Agreement requires that its members shall provide for the Protection of 
Plant Varieties (herein after PVP) either by patenting or by an effective sui-
generis system. The clause in the TRIPS agreement leaves room to the member 
countries. This led to a heated debate as to the system of protection to be 
adopted for plant varieties breeders right provide incentive only to the seed 
industry without taking into consideration the interests of the fanners. The seed 
sector wanted that the plant breeders protection system should be adopted that 
is modeled on the lines of the UPOV Convention without considering the 
farming community but being an agrarian economy it was not considered to be 
in the interest of the country and India opted for the sui-generis system. Hence 
Indian plant variety protection system covers certain issues in protecting plant 
variety rights which International Union for the Protection for New Varieties' 
of Plants (herein after UPOV) model does not cover. Indian government 
acceded to the Convention but included some provisions, which are essential 
for the protection of farmers. 
Sui-Generis System and Plant Variety Protection 
After ratifying the TRIPS agreement India become bound to follow the 
provision of the agreement one hand the agreement exclude plants and animals 
other than micro-organisms and essentially biological processes for the 
214 
t.% ViuferProtection ofcpCant Varieties vSj (Famm ^ RtsAct 
production of plants and animals other than non biological and microbiological 
processes on the other hand the agreement is also concerned for the protection 
of plants and ask to protect the plant varieties either by patent or by an effective 
sui-genesis system/or by combination of both. 
Though the TRIPS agreement neither defines sui-generis nor elaborates 
what makes the sui-generis effective, it does not suggest any existing plant 
variety protection system such as International Union for the Protection of 
Plant Varieties (UPOV) as a model. The Latin word sui-genersis means 
generated by one self and hence also meaning 'of its own kind' or 'unique'!' 
According to the TRIPS agreement member countries can make their own rules 
to protect new plant varieties and that protection must be effective. Member 
country can opt to develop their own sui-generis law or any system or even 
UPOV model. 
This flexibility of the sui-generis system is important for developing 
countries like India for three major reasons. First it will facilitate in striking a 
balance between promotion of private interest in national plant breeding and 
safeguarding the vital public interest good role being served by plant varieties 
in enhancing the livelihood opportunities of farming communities, in poverty 
alleviation, in promoting food security and in conserving the agro biodiversity 
and associated traditional knowledge the second aspect is the conflict between 
TRIPS Agreement and other legally and morally binding international 
declaration, treaties and Conventions concerned with poverty alleviation 
economic development human rights protection and bio-resources 
conservation. The third important aspect is that as an IPR protection device the 
sui-generis system is equivalent to the patent system in the stringency of 
5. Article 27 (3) says: Members may also exclude from patentability (b) plants and animals other than 
microorganism and essentially biological process for the production of plant or animals other than 
non biological and microbiological processes However, Members shall provide for the protection of 
plant varieties either by patents or by an effective sui-genesis system or by any combination there 
of 
6. S. Balaravi, "Effectiveness of Indian Sui genesis Law on PVP and its Potential to Attract Private 
Investment in Crop Improvement" JIPR vol 9 Nov. 2004. 
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offered protection. This is explicit form the TRIPS Agreement Article 27 (3) 
(b) which affirms that plant and animals other than micro-organisms are 
excluded from patentability. Having made such affirmative exclusion, TRIPS 
Agreement avers that protection to plant varieties may be provided by patent or 
by an effective sui-generis system or by any combination there of the option is 
left to the Member states and those states which chose to disallow the 
stringency of patent on plant varieties, shall opt for an effective sui-generis 
system. 
The very first initiative taken to develop Indian legislation on plant 
varieties protection occurred in late 1980s. The first draft of the bill was 
produced in 1993 by the ministry of agriculture, the nodal ministry through the 
bills development. Three drafts have since followed in 1997, 1999 and 2000, 
although only the latter two were introduced in parliament. The last but one 
draft was tabled in the Lok Sabha in December 1999, and referred to a Joint 
Parliamentary Committee (JPC). From January to August 2000 IPC held public 
consultation at various locations through out India and tabled its report along 
with a revised draft in the Lok Sabha on August 25.2000. After almost a decade 
the bill was passed in August 2001 in the form of Protection of Plant Varieties 
and Farmer's Rights Act 2001. 
Rationale Behind Plant Varieties Protection Act 
Act aims to establish an effective system for the protection of plant 
varieties, the rights of the farmers & the breeders and to encourage the 
development of new plant varieties of plants in conformity with the TRIPS 
Agreement. Protection is essential for the research in the area of plant varieties. 
This will facilitate the growth of seed industry in the country and will ensure 
the availability of high quality seeds and planting material to the farmers.^ The 
7. Supra note p. 243 
8. Protection of Plant Varieties and Farmers Rights Act, 2001 
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preamble of the Act states that the protection of plant breeders is essential for 
this agricultural development of the country. The Act primarily extends to 
protect the rights of the farmer while at the same time protecting the rights of 
the plant breeders. The contribution of the farmers in conserving improving and 
making available the plant genetic resource for the development of new plant 
varieties is also protected by the Act.' 
Objectives for Protection of Plant Varieties and Farmers' Rights Act, 2001 
(PPVFR Act) -
1. To protect and benefit the breeders of new plant varieties 
2. To protect and benefit the farmers as cultivators and conservation of 
traditional local plant varieties, which may be used in the development 
of new variety. 
3. To encourage the growth of seed industry through domestic and foreign 
investment so as to encourage high quality seeds and planting material 
to the farmers. 
4. To stimulate investments for research & development both in public & 
private sectors for development of new plant varieties by ensuring appropriate 
returns on such investment. 
Preamble 
An Act to provide for the establishment of an effective system for protection of plant varieties, the 
rights of farmers and plant breeders, to encourage the development of new varieties of plants; 
Whereas it is considered necessary to recognize and protect the rights of the farmers in respect of 
their contribution made at any time in conserving, improving and making available plant genetic 
resources for the development of new plant varieties; 
And whereas for accelerated agricultural development in the country, it is necessary to protect plant 
breeders' rights to stimulate investment for research and development, both in the public and private 
sector, for the development of new plant varieties; 
And whereas, such protection will facilitate the growth of the seed industry in the country which will 
ensure the availability of high quality seeds and plant material to the farmers; 
And whereas to give effect to the aforesaid objectives, it is necessary to undertake measures for the 
protection of the rights of farmers and plant breeders; 
And whereas India, having ratified the Agreement on Trade Related Aspects of Intellectual Property 
Rights should inter alia make provision for giving effect to sub-paragraph (b) of paragraph 3 of 
article 27 in Part II of the said Agreement relating to protection of plant varieties. 
9. Elizabelh Verkey, Law of Plant variety protection, p. 121(2008) 
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India's Protection of Plant Varieties and Farmers' Rights Act, 2001 
"Nothing that congress could do to help farming would be of greater 
value and permanence than to give the plant breeder the same status as the 
mechanical and chemical inventors now have through the law. " 
Thomas Edison 
Knowledge of nature is the raw material for the development of new 
varieties. Diversity is of great importance to plant breeding. Throughout the 
history even the poorest farmer has been a plant breeder, perpetually improving 
seeds, for thousands of years, first by domestication and then simply by 
selecting the best plant in their fields, to provide seed for their next crop. 
Farmers have adopted plants to their needs. They have also progressively 
improved them. Despite the best efforts of the farmers and breeders the 
development of new and more productive varieties with better qualities has 
been achieved only by the development of scientific plant breeding. 
Plant breeders' rights have received recognition at the international level 
in the context of one treaty the International Convention for the Protection of 
New Varieties of Plants (UPOV Convention) 1961. Then it was revised thrice 
i.e. year 1972, 1978, and 1991. The last revision in the year 1991 has 
strengthened the plant breeder rights and conversely restricted the rights of the 
farmers. Generally breeders have exclusive rights to produce or reproduce 
protected varieties to condition them for the purpose of propagation to offer 
sale, to commercialize them including exporting and importing them and to 
stock them in view of production of commercialization.'" There are differences 
between the protection offered to breeders under the 1978 and 1991 Acts of 
UPOV. For instances under the 1991 Act the protection offered to breeders 
extends in some circumstances to the harvested material of the variety." UPOV 
10. UPOV 1991, Article 14. 
11. Phillipe Gullet, Intellectual Property Rights and Sustainable Development, p. 229 (2005). 
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1991 extends the minimum period from 15 to 20 years and for tress and vines 
the minimum is of 25 years.'^ In 1991 Act has included varieties that are 
"essentially derived" from a protected variety. The 1991 Act imposes the 
protection of all plant genera and species within five years for countries which 
were already members of UPOV -1978 and within 10 years for new members.'^  
UPOV has acquired a worldwide importance since 1994 because most 
developing countries do not want to introduce patents for plant varieties and 
seek to adopt on alternative option. 
The plant breeder's rights system in UPOV countries has been used 
mostly for horticultural crops, of which ornamentals alone make up more than 
half of all plant variety protection grants agriculture crops which include 
cereals, fodder, oilseeds, beans and fiber account for only 30 per cent of all 
grants indicating that a number of agricultural crops do not seen to receive any 
stimulus for new variety development from plant variety protection. 
For the time being there is relatively little evidence coming from 
developing countries that have introduced plant breeders' rights following the 
adoption of TRIPS Agreement. This is due to the fact that developing countries 
did not have to introduce plant variety protection before 2000 which plant 
breeders right were formally introduced in the 1970s, it is only in 1994 that 
regulations were adopted which led to the establishment of the plant Breeders 
rights office. Between 1997 and 2003 the office received 578 applications for 
plant breeders of which 46 percent were submitted by local breeders'' primary 
breeders of India are farmers and hence it was necessary to protect the interest 
of farmers. Thus the Indian situation demanded a balancing of the rights of the 
farming community and the breeders. The new Act of protection of plant 
12. UPOV 1991 Article 19. 
13.UPOV 1991 Articles. 
14. C.S. Srinivasan, International Trends in Plant Variety Protection, Available 
at.http://en.scientificcommons.org/c_s_srinivasan 
15. Phillip Cullet, Intellectual Properly Rights and Sustainable Development, p. 235 (2005). 
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varieties and farmer's rights Act is considered as protecting the interests of the 
farmers along side that of the breeders. The national seed corporation was 
established in 1963. The foremost legislation India for the protection of seeds 
was the Seeds Act 1966 which provided for regulating the quality of certain 
seeds for sale.'^ Protection of plant varieties is essential for the research and 
development of research in the area of plant varieties. This will facilitate the 
growth of the seed industry in the country and will ensure the availability of 
high quality seeds and planting material to the farmers.'^  The preamble of the 
Act states that protection of plant breeders is essential for the agricultural 
development of the country. The Act primarily intends to protect the rights of 
the farmers while at the same time protecting the rights of the plant breeders. 
The contribution of the farmers in conserving improving and making available 
the plant genetic resources for the development of new plant varieties is also 
protected by the Act. The Indian law is primarily based on UPOV convocation 
but it includes number of provisions, not present in the UPOV Convention. For 
instance, it recognizes the role of farmers as cultivators and conservers and the 
contribution of traditional rural and tribal communities in the countries agro 
biodiversity by making provision for benefits sharing and compensation and 
also protecting the traditional rights of farmers. This is a sui-generis system to 
16. Seeds Act, 1966 Preamble-
An Act to provide for regulating the quality of certain seeds for sale and for matter connected 
therewith. Seeds Act, 1966 . 
17. PPVFR ACT, 2001 
Preamble-
Ati Act, to provide for the establishment of an effective system for protection of plant varieties, the 
rights of farmers and plant breeders, to encourage the development of new varieties of plants; 
wiiereas it is considered necessary to recognize and protect the rights of the farmers in respect of 
their contribution made at any time in conserving, improving and making available plant genetic 
resources for the development of new plant varieties; 
And whereas for accelerated agricultural development in the country, it is necessary to protect 
plant breeders' rights to stimulate investment for research and development, both in the public and 
private sector, for the development of new plant varieties; 
And whereas, such protection will facilitate the growth of the seed industry in the country which 
will ensure the availability of high quality seeds and plant material to the fanners; 
And whereas to give effect to the aforesaid objectives, it is necessary to undertake measures for the 
protection of the rights of farmers and plant breeders; 
And whereas India, having ratified the Agreement on Trade Related Aspects of Intellectual 
Property Rights should interalia make provision for giving effect to sub-paragraph (b) of 
paragraph 3 of article 27 in Part 11 of the said Agreement relating to protection of plant varieties; 
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provide protection for (a) new varieties (b) essentially derived varieties (c) 
farmers varieties (d) extant varieties. 
Protection of Plant Varieties and Farmers Rights Act, 2001 under 
section 15, talks about the registerable varieties and under section 16 about the 
person who may make an application for registration. 
Varieties Covered by Protection 
The Act makes clear that an application for registration can be made 
only in respect of three kinds of varieties. 
(i) A variety whose genera or species is specified in the official Gazette 
under Sec. 29 (2) 
(ii) An extant variety'* 
(iii) A farmers' variety ' ' 
The term variety has been defined in the Act to include a plant grouping 
other than a microorganism within a single botanical taxon of the lowest known 
rank which can be-
1. Defined by the expression of the characteristics resulting from a given 
genotype of that plant grouping. 
2. Distinguished from another plant grouping by expression of at least one of 
the said characteristics and 
3. Considered as a unit with regard to its suitability for being propagated 
which remains unchanged after such propagation. 
18. PPVFRAct, Sec.2(j) 
"extant variety" means a variety available in India which is— 
(i) notified under section 5 of the Seeds Act, 1966(54 of 1966); or 
(ii) fanners' variety; or 
(iii) a variety about which there is common knowledge; or 
(iv) any other variety which is in public domain. 
19. PPVFR Act, Sec. 2(1) 
"farmers' variety" means a variety which— 
(i) has been traditionally cultivated and evolved by the farmers in their fields; or 
(ii) is a wild relative or land race of a variety about which the farmers possess the common 
knowledge. 
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The inclusion of extant variety and farmer's variety helps to protect 
varieties that do not meet the requirement of novelty. 
The Plant Protection Act of India defined an extant variety as 
(i) a variety which is available in India and includes a variety notified under 
section 5 of the seed Act. 
(ii) A farmer's variety is; 
(iii) A variety about which there is common knowledge or any other variety 
in the pubic domain ^^ 
Farmers' varieties are cultivated & evolved by the farmers using 
traditional methods in their fields, about which they have knowledge. 
Traditionally cultivated and evolved varieties of farmers or the wild relative or 
land race of a variety of which the farmer have common knowledge is 
considered as a farmers' variety. '^ 
Land races are varieties that are developed over many plant generations, 
sometimes encompassing thousands of years by farmers selecting plants with 
desired characteristics. Land races are usually genetically diverse and adapted 
to local environments extant varieties and farmers varieties, though not 
satisfying the requirement of novelty are important to agriculture and hence 
need to be granted protection.^ ^ 
Varieties have be generally considered to be the result of the breeding 
process they are the result of the process of selection and crossing including 
modem techniques such as cell fusion which do not occur under natural 
20. PPVFR Act, Sec. 2 0). 
21.PPVFRAct,2001 Sec. 2(1), 
"fanners' variety" means a variety which— 
(i) has been traditionally cultivated and evolved by the farmers in their fields; or 
(ii) is a wild relative or land race of a variety about which the farmers possess the common 
knowledge. 
22. Elizabeth Verkey, Law of Plant Varieties protection, p. 122 (2008) 
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conditions. This seemed self evident so long breeding was the only way to 
obtain new plants.^^ 
The definition of the term variety can be illustrated by the decision of 
the various Courts verdicts. 
In Yoder Brothers Inc V California Florida Plant Corp,^''Several 
definitions of the term variety were offered. Mr. Duffet Voder's head breeder 
defmed variety as: 
"a group of individual plants which, on the basis of observation by 
skilled floriculturists and according to reasonable commercial tolerances, 
display identical characteristics under similar environments. " 
The definition of the term variety in Pan-American Plant Co. v 
Matsui also throws light on the concept of variety. According to the decision: 
"a variety of chrysanthemum plant is a group of plants which exhibit 
similar essential characteristics which are distinguishable from other group of 
plants by the presence of significant differences with respect to one or more 
characteristic ". 
The Federal Circuit Court in 1995 held that "variety" encompasses a 
single plant the plant shown and described in the specification of the plant 
patent.^ ^ 
Essentially Derived Variety 
The concept of essentially derived varieties emerged with the UPOV 
Convention 1991. Article 14 (5) (c) of the UPOV Convention deals with the 
concept of essentially derived varieties and says. 
23. Ibid, 
24. 537. F. 2d 1347, 193 USPQ 264 (5th Cr. 1976). 
25. 433 F. Supp 693 (N.D Cal 1977). 
26. Imazo Nursery v. Dania Greenhouse 63 F.3d 1560. (Fed Cir 1995). 
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"Essentially derived varieties may be obtained for example by the 
selection of a natural or induced mutant or of a seasonal variant the selection 
of a variant individual from plants of the initial variety back crossing or 
transformation by genetic engineering."" 
The definition of essentially derived variety in the Indian Act is similar 
to that found in the UPOV Convention for a variety to be considered as 
essentially derived it must fulfill three requirements in relation to the initial 
variety while retaining the expression of the essential chrematistics of initial 
variety namely: 
1. Predominant derivation from the initial variety while retaining the 
essential characteristics that result from the genotype or combination of 
genotypes of such initial variety; 
2. Clear distinctiveness from initial variety and 
3. Conformity to the initial variety in the expression of the essential 
characteristics that result from the genotype or combination of 
genotypes of the initial variety. '^' 
Whether a variety is an essentially derived can be decided only by 
scientifically reliable methods. An essentially derived variety should be pre 
dominantly derived from a given variety or a product. Where a plant variety 
has been developed without using that variety there can not be essential 
derivation. 
Persons who may make application- Certain persons have been 
specified by the Act who may make application^^ 
(1) An application for registration under S.14 shall be made by-
(a) Any person claiming to be the breeder of the variety or 
(b) Any successor of the breeder of the variety or 
27.PPVFRAct,2001 Sec. 2 (i). 
li.Id, Sec. 16 
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(c) Any person being the assignee of the breeder of the variety in respect of 
the right to make such application or 
(d) Any farmer or groups farmers or communality of farmers claiming to be 
the breeder of the variety or 
(e) Any person authorized in prescribed manner by a person specified under 
clauses (a) to (d) to make application on his behalf or 
(f) Any university or publicly funded agricultural institution claiming to be 
the breeder of the variety. 
(2) An application under Sub-section (1) may be made by any of the person 
referred to therein individually or jointly with any other person 
Procedure for Registration of New Variety 
The benefits of the Act are extended only to the persons who register the 
variety. A variety protected under the Act only when it is registered. 
Application for registration of varieties can be made by the breeder of the 
variety his successor or assignee any farmer or group of farmers. Every 
application shall be made in writing and signed by the applicant and delivered 
to the Registrar or the Authority at its office. Application and all documents 
have to be filed in triplicate. All affidavits required to be filed under the 
protection of plant varieties and farmers Rights Rules shall be dated and signed 
at the foot and shall contain a statement that the facts and matters stated there 
in are true to the best of the knowledge information and belief of the person 
making the affidavit. Where an application for registration is made by the 
successor or assignee of the breeder he shall furnish proof to that effect at the 
time of application or within six months of making such application. Each 
application should assign single and distinct denomination of the variety to 
which the registration is being sought.^ ' There must also be a statement 
29. Id. Sec. 14 
30.W., Sec. 16.(1 )(d) 
31./^., Sec. 17(1) 
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describing all the details of the variety that brings out its characteristics of 
registering the variety. The applicant shall also make available such quantity of 
seed as is required for testing to evaluate whether it satisfies the standard 
specified. DUS testing is required for all varieties except essentially derived 
verities. The registrar on receipt of the application can either accept it, require it 
to be amended or rejected now the registrar shall advertise such application 
calling for objections from the persons interested in the matter.^ ^ 
Any person can within three months from the date of advertisement, 
give in writing a notice of opposition to the registration. But when, an 
application for registration of a variety other than an essentially derived variety 
has been accepted and either 
(a) The application has not been opposed and the time of notice of opposition 
has expired or 
(b) The application has been opposed and the opposition has been rejected the 
Registrar shall register the variety. On registration of the variet>' the 
Registrar shall issue to the applicant a certificate of registration. '^' 
Where registration of a variety is not completed within 12 months from 
the date of application due to default on the part of the application, the 
application will be considered as abandoned after giving notice to the applicant. 
The certificate of registration issued under this section or sub -section 
(8) of section 23 shall be valid for 9 years in the case of trees and vines and 6 
32. Id, Sec. 19. 
33 Id. Sec. 20. 
34. Id, Sec. 24. (2 ) 
On the registration of the variety (other than an essentially derived variety), The Registrar shall 
issue to the applicant a certificate of registration in the prescribed form and sealed with the seal of 
the Registry and send a copy to the Authority for determination of benefit sharing and to such other 
authority, as may be prescribed, for information. The maximum time required by the Registrar for 
issuing the certificate of registration from the date of filing of the application for registration of a 
variety shall such as may be prescribed. 
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years in the case of other crops and may be reviewed and renewed for the 
remaining period on payment of such fees as may be fixed by the rules made in 
this behalf subject to the condition that the total period of validity shall not 
exceed.''^  
(a) in the case of trees and vines, 18 years from the date of registration of 
the variety 
(b) in the case of extant variety 15 from the date of notification of that 
variety by the central Government under Section 5 of seeds Act, 1966 
and 
(c) in other cases 15 years from the date of registration of the variety 
Essential Requirements for Registration 
A new variety shall be registered under this Act, if it confirms the 
criteria of novelty, distinctiveness, uniformity and stability. The definition of 
the technical criteria of distinctiveness, uniformity & stability (the DUS system 
of the UPOV Convention) are also closely related to the provisions of the 1978 
and 1991 Acts of the UPOV Convention. 
A variety according to the Indian Act is said to be novel if at the date of 
filing of the application for registration for protection, the propagating or 
harvested material of such variety has not been sold or otherwise disposed of 
by or with the consent of its breeders or his successor for purpose of 
exploitation of such variety (a) in India, earlier than one year or (b) outside 
India in case of trees or vines earlier than six years, or in any other case earlier 
than four years before the date of filing of such application. 
It is said to be distinct if it is clearly distinguishable by at least. One 
essential characteristic from any other variety whose existence is a matter of 
common knowledge in any country at the time of filing of the application the 
35. Id, Sec. 24 (6 ) 
36. PPVFRAct,2001 Sec.l5(l). 
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difference between the Indian Act and UK legislation is that the Indian Act 
requires only distinction by at least one essential characteristic, while the UK 
Act requires the distinction by one or more important morphological, 
physiological or other characteristics from any other variety. 
If the particular feature of the propagation of claimed variety is 
sufficiently uniform in its essential characteristics then the variety is said to be 
uniform. 
A variety is said to be stable if its essential characteristics remain 
unchanged after repeated propagation or in the case of a particular cycle of 
propagation at the end of each such cycle. 
Rights Conferred on Registration: 
A certificate of registration confers on the breeder or his assignee an 
exclusive right to produce, sell, market, distribute import or export the variety. 
Provided that in the case of an extant variety, unless a breeder or his successor 
establishes his right the central government and in case where such extant 
variety is notified for a state or for any area there of under section 5 of the 
seeds Act, 1966 the state Government, shall be deemed to be the owner of such 
rights. ^^  
The Act also confers on the breeder to authorize any person to produce, 
sell market distribute or deal with the variety registered under the Act but 
registered agent is not entitled to transfer such right. 
37. W., Sec. 28(1) 
Subject to the other provisions of this Act, a certificate of registration for a variety issued under this 
Act shall confer an exclusive right on the breeder or his successor, his agent or licensee, to produce, 
sell, market, distribute, import or export the variety. Provided that in the case of an extant variety, 
unless a breeder or his successor establishes his right, the Central Government, and in cases where 
such extant variety is notified for a State or for any area thereof under section 5 of the Seeds Act, 
1966 the State Government, shall be deemed to be the owner of such right. 
38. Id.. Sec. 28 (2) 
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Plant Varieties and Farmer's Rights Authority 
The Central Government shall by notification in the Official Gazette 
establish an Authority to be known as The Protection of Plant Variety and 
Farmers' Rights Authority.^' The authority shall function to promote the 
encouragement for the development of new varieties of plants to protect the 
rights of the farmers and breeders/" 
Some other functions would be, the registration of extant varieties, 
developing characterization and documentation of variety registered under this 
Act, documentation, indexing and cataloguing facility of all varieties of plants, 
availability of seeds of the varieties to the farmers and providing compulsory 
licensing, collecting statistics with regard to plant varieties and ensnaring the 
maintenance of Register. This register is called the 'National Register of Plant 
Varieties'. In this register the name of all the registered plant varieties with the 
names and addresses of respective breeders the rights of the breeders in respect 
of the registered varieties. The particulars of the denomination of each 
registered variety its seed or other propagating material along with the 
specification of the salient feature shall be entered in the register. 
Farmers' Rights 
Agriculture plays an important role in Indian economy. On one hand it 
creates employment on the other hand a share in GDP. A study was carried out 
by 'India Today' with the sponsorship of government of India in 2003 for the 
assessment of situation of farmers. The results were come out with alarming 
trends and rising rates of farmers committing suicide different reasons also 
come out as the cause of suicide such as huge debt of farmers, crop failures, 
imbalance of international trade and other social and physiological factors. The 
Protection of Plant Varieties and Farmers Rights Act was the first Act to 
39. W., Sec. 3(1). 
40 .Id. Sec. 3 (2). 
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include a chapter on Farmers' Rights. The PPVFR Act initially emerged as a 
result of the demands of the seed industry for breeders' rights. Chapter on 
farmers' rights was added to the Act due to pressure by NGOs. 
India's PPVFR Act not only upholds, farmers right to save, use and 
exchange seeds and propagating material but also attempts to unable farmers to 
claim special forms of intellectual rights over their varieties. The Act grants 
plant variety protection on new varieties (largely modeled on UPOV), extant 
varieties and essentially derived varieties Extant varieties include farmer's 
varieties, varieties in the public domain & varieties about which there is 
common knowledge. Nine rights can be said to have been given to farmers 
under this Act.'" 
The concept of farmers aright had its origin in the FAO International 
Undertaking on Plant Genetic Resource the resolution defines farmers' rights 
as "rights arising from the past present and ftiture contributions of farmer in 
conserving improving and making available plant genetic resources, 
particularly those in centre of genetic diversity. These rights are vested in 
international community as trustees for present and future generation PPVFR 
Act is a unique Act making India the only country in the world to grant clear 
and explicit rights to farmers." Farmers under PPVFR are those who cultivate 
crops or who conserve and preserve or add value to any wild species or 
traditional variety. 
Under the Act farmers has a right to save, use, sow, resow, exchange, 
share or sell their farm produce including seed of a variety protected under this 
Act provided that that the farmer shall not be entitled top sell branded seed'*^  of 
41. Anitha Ramanna, "State of Farmers Rights in India," The Farmers' Project (2006) 
42. PPVFR Sec. 39 (IV) Explanation: For the purpose of clause (iii) branded seeds means any seed put 
in a package or any other container and labeled in a manner indicating that such seed is of a variety 
protected under this Act. 
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a variety protected under this Act. As a result, farmers are allowed to sell the 
breeders seed under another denomination. 
A farmer means any person who: 
(1) Cultivates crops either by cultivating the land himself or 
(2) Cultivates crops by directly supervising the cultivation of land through 
any other person or 
(3) Conserves and preserves, severally or jointly with any person any wild 
species or traditional varieties through selection and identification of 
their useful properties."*' 
'Farmers variety' A farmers' variety means a variety which: 
(1) has been traditionally cultivated and evolved by the farmers in their 
fields or 
(2) is a wild relative or land race of o variety about which the farmers 
possess the common knowledge.^ '* 
Right against bad seed 
This is a right of a farmer that breeder has to disclose to the farmer the 
expected performance of the variety under given condition and if the variety 
fails to give the expected performance when it was sold to him breeder has to 
give compensation.'* Other kind of protection that has been given to the farmer 
is such as rights of communities. If any person or group of persons or any 
43. Id. Sec. 2 (k). 
44. Id. Sec. 2 (1). 
45. Id. Sec. 39 (2) 
Where any propagating material of a variety registered under this Act has been sold to a farmer or a 
group of farmers or any organisation of farmers, the breeder of such variety shall disclose to the 
farmer or the group of farmers or the organisation of farmers, as the case may be, the expected 
performance under given conditions, and if such propagating material fails to provide such 
performance under such given conditions as the farmer or the group of farmers or the organisation 
of farmers, as the case may be, may claim compensation in the prescribed manner before the 
Authority and the Authority shall after giving notice to the breeder of the variety and after providing 
him an opportunity to file opposition in the prescribed manner and after hearing the parties, it may 
direct the breeder of the variety to pay such compensation as it deems fit, to the farmer or the group 
of farmers or the organisation of farmers, as the case may be. 
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governmental or non governmental organization may on behalf of any village 
or local community in India, file in any centre notified, any claim attributable 
to the contribution of the people of that village or local community, in 
evolution of any variety for the purpose of staking a claim on behalf of such 
village or local community/* The authority after enquiry by the notified centre 
and after giving an opportunity to the breeder to file his objection within a 
period of 3 months and after hearing him if satisfied, grant such compensation 
to be paid to a person or group of persons or governmental or non 
governmental organization which has made the claim/' The compensation is 
to be deposited in the Gene Fund/* 
Disclosure 
Other details supportive of the rights of farmers are the explicit and 
detailed disclosure requirements in the passport data required at the time of 
applying for a breeders certificate. Concealment in the passport date will result 
in the breeders' certificate being cancelled. 
Protection against Innocent Infringement: 
Legislation is also very liberal towards farmers, a farmer who Acts 
without knowledge of the existence of a right established under the protection 
of plant varieties and farmers rights Act 2001 shall not be held liable for 
46. W., Sec. 41 (1). 
47. W., Sec. 41 (3) 
When the Authority, on a report under sub-section (2) is satisfied, after such enquiry as it may 
deem fit, that the variety with which the report is related has been registered under the provision of 
this Act, it may issue notice in the prescribed manner to the breeder of that variety and after 
providing opportunity to such breeder to file objection in the prescribed manner and of being heard, 
it may subject to any limit notified by the Central Government, by order, grant such sum of 
compensation to be paid to a person or group of persons or governmental or non-governmental 
organisation which has made claim under sub-section (I) to the Authority, as it may deem fit.. 
48. M S 41 (4). 
Any compensation granted under sub-section (3) shall be deposited by the breeder of the variety 
in the Gene Fund 
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infringement thereof and hence no court may grant any relief or take 
cognizance of an offence against him for such infringement. 
Exemption from fee: Farmers will be entitled to examine documents 
and papers or receive copies of rules and decision made by the various 
authorities without paying any fees such fess are payable by all other people. 
Farmers are also protected from terminator technology it means breeders are 
forbidden from making a variety that prohibits a plant from germinating second 
time. Breeders will have to submit an affidavit that their variety does not 
contain a 'Gene Use Restricting technology'. 
The concept of benefit sharing gives rights and rewards to farmers for 
contributing to the creation rewards to farmers for contributing to the creation 
of new varieties of agriculture. Farmer will receive all the rights and 
protections of a breeder if the farmer breeds or develop a new variety. 
Breeders' Rights: 
Breeders '^ have a right over the varieties they have developed and have 
been protected by the legislation. On registration the breeder has rights of 
commercialization for the registered variety either in his or her own person or 
through anyone he or she designates these rights include the right to produce, 
sell, market, distribute, import or export a variety. 
Along with the exclusive rights given to breeders their varieties are 
protected through substantial punishment provisions. Penalties are imposed for 
in fringing on the breeders varieties and also on their packaging.^ ^ Falsely 
representing to have registered a variety, is punishable by imprisonment of not 
less than six months nor more than three years or a fine of not less than one 
49. 20 (2) Halsbury's Law of India 2005. 
50. PPVFR Act, 2001 Sec. 44. 
51. Id. Sec. 2 (c) breeder means a person or group of persons or farmer or group of farmers or any 
institution which has bred evolved or developed any variety 
52. Id, Sec. 64. 
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lakh rupees nor more than five lakhs rupees or both.^ ^ The penahy for falsely 
using the breeders "denomination"''' or name is imprisonment of not less than 
three months none more than two years, or a fine not less than 50.000 rupees 
nor more than five lakh rupees or both." To give breeders further strong 
rights, the burden of proof is on the accused to show no false use of the 
breeders' denomination.'^  
Breeders whose rights have been infringed receive injunction and also 
the option of either damages or a share of profits.'' Breeders' rights have been 
strengthened to the extent that if there is mere suspicion of violation or 
infringement the onus of proving innocence is placed on the alleged violator. 
Rights of Researchers 
Article 15(1) of UPOV 1991 is never an infringement of a plant variety 
right to use the variety for further breeding. Sec 30 of Plant Variety Protection 
and Farmers Rights Act 2001 grant rights to the researchers to use any variety 
registered under the Act to any person for the purpose of research '^  as well as, 
an initial source of variety for the purpose of creating other varieties.'^ 
53. Id. Sec. 72. 
54. "denomination", in relation to a variety or its propagating material or essentially derived variety or 
its propagating material, means the denomination of such variety or its propagating material or 
essentially derived variety or its propagating material, as the case may be, expressed by means of 
letters or a combination of letters and figures written in any language; 
55. Id. Sec. 70. 
56. Id. Sec. 69 (3) 
In any prosecution for falsely applying a denomination of a variety registered under this 
Act, the burden of proving the assent of the breeder of such variety shall lie on the accused 
57. W., Sec. 66(1) 
The relief which a court may grant in any suit for infringement referred to in section 65 includes an 
injunction and at the option of the plaintiff, either damages or a share of the profits. 
58. Id., Sec. 30 Nothing contained this Act shall prevent— 
(a) the use of any variety registered under this Act by any person using such variety for conducting 
experiment or research; and 
59. Id. Sec. 30 
(b) the use of a variety by any person as an initial source of variety for the purpose of creating other 
varieties: 
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The provision however, implements a restriction on the use of a 
registered variety "where the repeated use of such variety as a parental line is 
necessary for commercial production of such other newly developed variety".^ " 
In such circumstances, the initial breeders' authorization is needed. Borrowing 
from the United State Constitution the intention of all the legislation is to 
promote the progress of science and other useful and for this reason most 
patent laws have a research exemption to allow further development. '^ 
Protection of Public Interest: 
In the public interest certain varieties may not be registered if it is 
believed that prevention of commercial exploitation of such a variety is 
necessary to protect order or public morality or human animal and plant life 
and health or to avoid serious prejudice to the environment. 
Compulsory Licensing: 
The Act provides for the granting of compulsory license if it is shown 
that the reasonable requirements of the public for seeds have not been satisfied 
or that the seed of the variety is not available to the public at a reasonable price. 
The breeder is entitled to file an opposition the breeder may be ordered by the 
authority to grant a compulsory license under certain term and condition 
including the payment of a reasonable license fee. But a compulsory license 
however will not be awarded if the breeder can demonstrate reasonable ground 
for his or inability to produce the seed.^ ^ 
60. Id. Sec. 30 
Provided that the authorisation of the breeder of a registered variety is required where the repeated 
use of such variety as a parental line is necessary for commercial production of such other newly 
developed variety. 
61. Elizabeth Verkey, Law of Plant Varieties Protectio.' p. 148.(2007) 
62. Sreenivasuiu N.S and MS. Subha Malhai, "Sui Generis System for the Protection of Plant Varieties 
and Farmer's Rights in India" MIPR vol 2 2008. 
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The Seeds Bill 2004 
After the Patent (Amendment) Act 2005 the agriculture area is also 
affected and now the attention needs to be given to the implications of the 
amendments on food security. Parliament considered a proposal for a new 
Seeds Act which has the potential to indirectly bring substantial changes to the 
existing intellectual property regime. The main objectives of this new Seeds 
Bill are. 
• The Seeds Bill, 2004 aims to regulate the quality of seeds sold, and 
replaces the Seeds Act, 1966. 
• All varieties of seeds for sale have to be registered. The seeds are 
required to meet certain prescribed minimum standards. 
• The Bill does not restrict the farmer's right to use or sell his farm seeds 
and planting material, provided he does not sell them under a brand 
name. All seeds and planting material sold by farmers will have to 
conform to the minimum standards applicable to registered seeds. 
• If a registered variety of seed fails to perform to expected standards, the 
farmer can claim compensation from the producer or dealer under the 
consumer protection Act, 1986. 
• The Bill permits self certification of seeds by accredited agencies and 
allows the central government to recognize certification by foreign seed 
certificating agencies. 
• Every seeds producer and dealer, and horticulture nursery has to be 
registered with the sate government. 
Protection of farmer's rights 
• Exemption for farmers: This Bill Exempts a farmer from compulsory 
registration of seed varieties in order to use, exchange, share or sell his 
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farm seeds or planting material. However, it stipulates that he cannot sell 
any seed under a brand name. Also any seed sold by a farmer has to 
conform to the minimum limits of germination, and physical and genetic 
purity as applicable to commercially sold seeds. This last provision 
(minimum standards of germination and purity) could be difficult to 
implement. It is estimated that seeds saved and exchanged by farmers 
constitute above 80% of the seeds planted and there would be a need to 
establish the physical infrastructure required to test these. Such testing 
would also lead to an increase in the cost of seeds.^  
Compensation: The farmer has to approach the Consumer Courts to 
claim compensation if the seeds do not perform to expected levels. 
There is a contradiction between this provision and the PPVFR Act 
which permits farmers to claim compensation through the Authority set 
up under that Act. Given the number of factors (such as climate, 
fertilizer, water) that affect the performance of a crop, it may be difficult 
to prove that underperformance of a crop was on account of poor quality 
of seed. Indeed there have been recent cases where the issue has not 
been fully resolved. Furthermore, it is not clear whether the 
compensation would include the value of the crop or only the cost of the 
seed. 
63. 'Legislative Brief: The Seeds Bill 2004' Available at, http://www.indiatogether.org/2006/jun/law-
sceds.htm 
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Table No. 14: Comparison between Seeds Bill, 2004 & PVFFR Act, 2001 
PPVFR Act, 2001 
Definitions "Farmer" means any person who "Farmer" means any person who 
cultivates crops by cultivating the 
land himself or cuhivates crops by 
directly supervising the cultivation or 
land through any other person; or 
conserves and preserves, severally or 
jointly, with any other person any 
wild species or traditional varieties or 
adds value to such wild species or 
traditional varieties through selection 
and identification of their useful 
properties. 
Registration Establishes a Registration Sub- Establishes a Plant Varieties Registry, 
Committee, which would which would maintain a National 
maintain a National Register of Register of Plant Varieties. 
Seeds. 
Seeds Bill, 2004 
cultivates crops either by 
cultivating the land himself or 
through any other person but 
does not include any individual, 
company, trader or dealer who 
engages in the procurement and 
sale of seeds on a commercial 
basis. 
No specifications 
parentage of variety. 
regarding Specifies details under which a 
variety may be registered such as a 
complete passport data of the parental 
lines from which a variety has been 
derived. 
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Registration is for 15 years for Registration is for 15 years for 
annual/biennial crops and 18 annual/biennial crops and 18 years for 
years for long duration long duration perennials. Registration 
perennials. On expiry, cannot be renewed, 
registration can be renewed for a 
similar period. 
Farmers' A farmer can save, use, A farmer is entitled to save, use, sow. 
Rights exchange, share or sell his farm resow, exchange, share or sell his 
seeds and planting material. He farm produce including seed of a 
cannot sell seeds under a brand variety protected under the Act in the 
name. Seeds sold have to same manner before this Act came 
conform to the minimum limit of into force. He cannot sell branded 
germination, physical purity, seed of a variety protected under the 
genetic purity prescribed by the Act. 
Act. 
Compensation The seed producer, distributor or If a breeder of a propagating material 
vendor will have to disclose the of a variety registered under the Act 
expected performance of a sells his product to a farmer, he has to 
particular variety of seed under disclose the expected performance 
certain given conditions. If the under given conditions. If the 
seed fails to perform to expected propagating material fails to perform, 
standards, the farmer can claim the farmer can claim compensation in 
compensation from the dealer, the prescribed manner before the 
distributor or vendor under the Protection of Plant Varieties and 
ConsumerProtection Act, 1986. Farmers'Rights Authority. 
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enalties Any person who contravenes any Penalty for applying false 
provisions of the Act, prevents a denomination to a variety is 
Seed Inspector from taking imprisonment up to two years and/or 
samples etc. shall be punished for a fine between Rs. 50,000 and Rs. 
the first offence with a fine up to five lakh. Penalty for falsely 
Rs. 500. If the offence is repeated representing a variety as registered is 
he may be imprisoned up to six imprisonment up to three years and/or 
months and/or fined up to Rs. a fine between Rs. one lakh and Rs. 
1,000. five lakh or both. Penalty for 
subsequent offence is imprisonment 
up to three years and/or a fine 
between Rs. two lakh and Rs. 20 
lakh. 
Scheduled Tribes and other Traditional Forest Dwellers (Recognition of 
Forest Rights) Act 2006 
Apart from Plant Variety Protection and Farmers Rights Act 2001 and 
Seeds Bill, 2004 other laws and legislations also protect the rights of the tribal 
community and conserve the biological resources. The present Act recognizes 
and vest forest rights and occupation in forest land in forest dwelling scheduled 
tribes and other traditional forest dwellers who have been residing in such 
forests for generations but whose rights could not be recorded. The Act 
recognizes the right of ownership access to collect use and dispose of minor 
forest produce which has been traditionally collected within or outside village 
boundary. The Act defines the term minor forest produce as all non timber 
forest produced of plant origin including bamboo, brushwood, stumps cane, 
tussar, cocoons, honey wax lac, Tendu leaves, medicinal plants and herbs and 
tubers. The Act also recognizes the rights of rehabilitation of schedule tribes 
and other traditional forest dwellers who have been illegally evicted or 
displaced from forest before 13.12.2005. The rights given under the Act are 
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heritable rights but not transferable. No member of a forest dwelling (either 
scheduled tribe or other traditional forest dweller) shall be evicted or removed 
without recognition and verification procedure is completed the right given 
under the Act can be vested to the individual or family or community who has 
occupied the place when the Act came into force. And that area is also confined 
to 4 hectares per nuclear family. There is an exclusive chapter relating to 
twelve main forest rights. 
The Act grants four types rights-
i. 'Title right' i.e. ownership to land that is being framed by tribal or 
forests dwellers as on December 13, 2005 subject to a maximum of 4 
hectares ownership is only for land that is actually cultivated by the 
concerned family as on the date, meaning no new lands are granted. 
ii. 'User rights' to minor forest produce (also including ownership) to 
grazing areas to pastoralist routes etc. 
iii. 'Relief and development rights' to rehabilitation in case of illegal 
eviction or forced displacement and to basic immunities subject to 
restrictors for protection. 
iv. 'Forest management rights' to protect, forest and wild life. 
India's ability to be one of the first countries in the world to forge a 
national legislation on Farmers' Rights is a significant landmark. India has 
evolved a unique legislation, but still faces the task of implementation. This 
process is likely to be fraught with difficulties not only in balancing 
intellectual property rights with Farmers' Rights, but also in ensuring 
coordination between various legislations such as the PPVFR and the 
National Biodiversity Act and other legislation protecting farmers' rights 
and their traditional knowledge. 
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PART- (B) PLANT VARIETIES PROTECTION AND FARMERS' 
RIGHTS -INTERNATIONAL PERSPECTIVES; 
Natural source material should not be coverable by patents as 
exclusionary rights in any country in the world, because natural source material 
is not novel. In the U.S. and Australia individual plant varieties are patentable. 
In Europe, individual plant varieties per se are not patentable; however, a plant 
which is characterized by a particular gene (as opposed to its whole genome) is 
not included in the definition of a plant variety and is therefore patentable. 
In Europe, transgenic plants are patentable if they are not restricted to a 
specific plant variety, but represent a broader plant grouping. The European 
Directive considers plant cells to be "microbiological products" and as a result 
are patentable. 
The EU Directive 98/44/EC provides a 'farmer's privilege'. Under the 
Directive, farmers are allowed to use patent protected seeds freely for their own 
use and the resulting plant material is free from protection. Farmers are not 
permitted however, to re-sell the patented seed. Member States are able to 
define their own exemptions to patent infringement. 
Plant Variety Protection in United States 
The emergence of the seed industry in the United States gives a pointer 
to the need for protection. The early settlers in United States brought seeds from 
Europe under the mistaken impression that they will sustain them. Since the 
seeds were not suited to the environment, the crops failed. Afterwards, 
production of-seeds were largely in the domain of the wealthy landowners who 
used to import seeds. These seeds were not available to the farmers. It was in 
1819 that seeds became widely available. The Secretary of the Treasury instituted 
a program requesting U.S. ambassadors and military officers stationed around the 
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world to gather seeds from their posts and bring them home for U.S. farmers. In 
1839, the Commissioner of Patents, Henry Ellsworth, secured funding from 
Congress to collect and distribute agricultural seed and statistics. Seeds then 
were distributed through the postal system. The seed program was succeeded 
by the United States Department of Agriculture (USDA) whose primary 
purposes were the procurement, propagation and distribution of new and 
valuable plant varieties. There was not much improvement in the seed industry 
during the period as there was no legal protection. Improvements in the seed 
variety relied on simple selection techniques. The process of improvement 
using (hat method was very slow. Private seed breeding was not rampant for 
lack of necessary incentives. Mendel's work on heredity led to the hybridization 
of seed com. Hybrid varieties had their own built-in protection as their vigour 
and quality wane in course of time. Plant breeders could also control the parent 
line. 
Like almost all the countries in the world, in the beginning, there was 
widespread objection in the United States to the granting of patents to plants. 
Objections against granting patent protection for plants centered around 
various arguments like non-compliance with the requirements of 
patentability, product of nature concept etc. The first objection was that 
breeder's products were not the result of creative process, but only products of 
nature. In 1889 an application which claimed cellular tissues from the rinits 
Australis, separated from other components of the plant to be spun into fibers 
was rejected by the Commissioner. The Commissioner rejected the application 
for patent to cover a fibre identified in the needle of a pine tree on the ground 
that ascertaining the composition of the trees in the forest was "not a patentable 
invention, recognized by statute, any more than to find it new gem or jewel in 
the earth would entitle the discoverer to patent all Items which should be 
subsequently found". The Commissioner added that it would be "unreasonable 
and impossible" to allow patents upon the forest and the plants of the earth. The' 
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Commissioner's ruling formed the basis for the 'product of nature' doctrine, 
that is: 
"While processes devised to extract what is found in nature can be 
patented, objects discovered there cannot be protected. They are not inventions, 
nor can they as a class be made anyone's exclusive property." This doctrine 
was followed by the United States Supreme Court in the American Fruit 
Growers case^'* and the Funk Brothers Seed Co. case.^^ In 1891, in a report to 
the American Association of Nurserymen, the respected plant scientist 
Liberty Hyde Bailey, of Cornell University told the nurserymen that an 
obstacle to any type of intellectual property protection for plants was that new 
types of plants were difficult to define or specify. He pointed out that most 
new varieties were accidents that the nurseryman found rather than the 
product of systematic breeding. It was also added, that "when the time comes 
that men breed plants upon definite laws and produce ' new and valuable 
kinds, then plant patents may possibly become practicable", 
The rediscovery of Mendel's laws made it possible for the breeders to 
ask for intellectual property protection for plants. Hyland C. Kirk, a 
horticultural spokesman, testified before the House Committee on Patents when 
it considered the 1906 bill to establish intellectual property protection for plants. 
Kirk advanced a claim that a person-who discovers a "new variety of plant, tree, 
or vine ... is as truly an inventor and, as such, as justly entitled to protection as 
the originator of a new motor, a new chemical compound, or any other valuable 
combination of materials requiring experiment, deliberation, and design". 
But the Bill did not find a passage before-the Committee. Though a 
failure, the initiative led to the founding of a group led by Paul Starke who had 
obtained the farm of Luther Burbank, a noted plant breeder. Finally the Plant 
64. American Fruit Growers case v. Brogdex Co., 283 US I (1931). 
65. Funk Bros, seed co. v. Kalo Inoculant co., 333 US 127 (1948). 
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Patent Act was passed in 1930. It was introduced in the Senate by John 
G. Townsend, Jr. of Delaware, 
Prior to passage of the Plant Protection Act in 1930, the popular belief 
was that plants, however modified, are products of nature and so not 
patentable. The United States now has three systems under which new varieties 
are protected. 
1. The Plant Patent Act of 1930 (as amended in 1954) protects 
asexually reproduced varieties; 
2. Utility Patents granted under the Patent Statute of 1952; 
3. The Plant Variety Protection ACT of 1970 (as amended) protects 
sexually reproduced varieties. 
1. Plant Patent Act 
"The Plant Patent Act was enacted in 1930 in order to provide 
protection to the breeder of an asexually reproduced plant.'* The Plant Patent Act 
is a sub-chapter of the General Patent Act and the conditions for-obtaining 
protection under the Act is different from that of The Patents Act. Asexual (or 
vegetative) reproduction of plants involves regeneration of vegetative tissues or 
organs into self-supporting plants with properties similar to those of the source 
plant, Asexually reproduced plants are reproduced from a single parent, 
through processes such as grafting, budding, cutting, rooting, and layering. 
Asexual reproduction may occur naturally, or as part of human plant 
breeding. Asexuality reproduced plant is genetically identical to its parent 
plant. 
"Plants resulting from vegetative propagation are essentially extensions 
of the old ones, having a separate physical existence, but identical 
genetically."^ Accordingly, a plant that is reproduced asexually will be 
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capable of reproducing sexually through seed if its parent was capable of such 
reproduction. 
The Court in Chakrabarty case^^ explained the realities of patent law and 
plant breeding at the time the Plant Patent Act was enacted. Prior to 1930, two 
factors were thought to remove plants from patent protection. The first was 
the belief that plants, even those artificially bred, were products of nature for 
purposes of the patent law. ... The second obstacle to patent protection for 
plants was the fact that plants were thought not amenable to the 'written 
description' requirement of the patent law. 
These issues were set at rest by the Congress by enacting the Plant 
Patent Act, which relaxed the stringent requirements of the patent system. The 
1930 Plant Patent Act amended the general utility patent provision to provide: 
"Any person who has invented or discovered any new and useful art, 
machine, manufacture or composition of matter, or any new and useful 
improvements thereof, or who has invented or discovered and asexualiy 
reproduced any distinct and new variety of plant, other than a tuber-propagated 
plant, not known or used by others in this country, before his invention or 
discovery thereof,... may ... obtain a patent therefore." The Plant Patent Act also 
amended Revised Statutes Section 4888 by adding: 
"No plant patent shall be declared invalid on the ground of non-
compliance with this section if the description is made as complete as is 
reasonably possible." 
The 1930 Plant Patent Act conferred patent protection to asexuality 
reproduced plants. Asexual reproduction occurs by grafting, budding, or the 
like, and produces an offspring with a genetic combination identical to that of 
the single parent-essentially a clone. Plants were first explicitly brought 
66. Diamonds. Chakrabarty.447 US 303 (1980). 
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within the scope of patent protection in 1930 when the Plant Patent Act 
included "plants" among the useful things subject to patents. In 1952 plant 
patents were included into a separate Chapter 15 of Title 35 entitled, "Patents 
for plants". Plant patents under the Plant Patent Act have very limited 
coverage and less stringent requirements than Section 101, Utility Patents. 
Although the plant patent provisions were separated from the utility patent 
provisions with the enactment of the 1952 Patent Act, the statute explicitly 
states that "the provisions of this title relating to patents for inventions shall 
apply to patents for plants, except as otherwise provided". Thus, Section 161 
engrafts the Plant Patent Act into the basic patent law and so all the rules, 
regulations, and provisions of the basic patent law has to be applied to plant 
patents. 
The plant patent right provided in 35 USC Section 163 gives the 
exclusive right to propagate the plant by asexual reproduction. Hence asexual 
reproduction is an essential requirement for obtaining plant patent protection. 
Plant Patent Act applies only to asexually reproduced plants and hence ensures 
that the plant breeders reproduce the plants identically in every respect to the 
parent plant. 
Known as the Smiths Plant Patent, the 105th United States Congress 
enrolled as passed by both, the House and the Senate, the Plant Patent 
Amendment Act of 1998 that Protects Agricultural Producers from 
Bootlegged Plant Parts. HR 1197 is a simple technical clarification to a loophole 
in the Plant Patent Act of 1930; When Congress drafted the Plant Patent Act of 
1930, it could not anticipate the technological advances that ' mice, and the 
agricultural industry, would make in the growing of plants breeders and growers 
in the United States are being denied the protection intended by Congress 
when it enacted the Plant Patent Act of 1930 because of an ambiguity in the 
law. 
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The Amendment prevents foreign growers from acquiring a plant in tlie 
11 S. and to grow the plant, and then sell its fruits or flowers in U.S. markets 
without paying any royalty. This practice undercuts U.S. businesses that own (lie 
patents and penalizes growers who honour the U.S. patent. U.S. plant lumbers 
lose a substantial amount of income annually from uncollected royally 
payments due to this practice. HR 1197 clarifies this ambiguity by specifically 
including the coverage of plant parts in the Plant Patent Act of 1930. 
The loss of royalty income affects U.S. domestic research and breeding. 
Tills, in turn, inhibit investment in the plant research and development programs 
which are the foundation of a strong horticultural industry. Those who sell plant 
parts from unauthorized plants, do not pay royalties for varieties illegally 
grown, and enjoy an unfair competitive advantage over both producers who pay 
royalties and the patent holder who also markets the product. 
In order to overcome this, Title 35 Section 163 was amended by the 
Amendment as follows. In the case of a plant patent, the grant shall include the 
right to exclude others from asexually reproducing the plant, and from using, 
offering for sale, or selling the plant so reproduced, or any of its parts, 
Throughout the United States, or from importing the plant so reproduced, nr any 
parts thereof, into the United States. 
The Patent and Trademark Office, while addressing the attempt to obtain 
a plant patent for bacterium normally scientifically classified as a plant, 
Interpreted the term plant in a general sense rather than a strict scientific one." 
The Arzberger decision is known for its ruling that plants do not include 
bacteria. It was held that a bacterium cultivated from soil is not patentable. 
In re Bergy is another historical case in which the Court, while deciding 
the ease, examined the legislative history underlying the plant patent 
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statutes. It found only plants subject to asexual reproduction via budding, 
cutting, or layering to be encompassed by the statute. 
The conditions for obtaining Plant Patent are different from the 
requirements of The Patents Act. Plant Patent Act requires a variety to be 
distinct rather than useful. Distinctness can include habit, colour of flower, 
flavour, productivity etc. It is immaterial whether the characteristics are 
inferior or superior to the existing variety. 
The Imazio Nursery v, Dania Greenhouse,'^^ the Court held that the 
scope of a plant patent is limited to the asexual progeny of a patented plant 
variety. 
There are differences in the requirements for, and coverage of, utility 
'patents and plant variety certificates issued pursuant to the Plant Variety 
Protection Act (PVPA). In order to obtain a utility patent, the plant must be 
new, useful, and non-obvious. In addition, to obtain a utility patent, a 
breeder must describe the plant with sufficient specificity to enable others to 
make and use" the invention after the patent term expires. The description 
requirement for plants includes a deposit of biological material, for example 
seeds, and mandates that such material be accessible to the public. A plant 
variety may receive a Plant Variety Protection (PVP) certificate without a 
showing of usefulness or non-obviousness, but requires that the variety be 
new distinct, uniform, and stable. 
In Pan-America Plant Co. v. Matsuif^ a plant variety was held to be 
substantially different, and hence does not infringe an existing plant patent, 
where the new plant has the ability to asexually reproduce with a far smaller 
percentage of culls than the existing plant. The lack of defectiveness formed a 
67. 63F.3dl560(Fed. Cir. 1995). 
68.433 F. Supp. 693 (N.D. Cal 1977). 
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significantly different characteristic that made it a different variety, despite the 
appearance that the plants seemed to be of the same variety. 
The requirement of novelty and non-obviousness is common in both the Plant 
Patent Act and The Patents Act. In assessing the novelty of a plant variety, 
the contrast between patent law and the Plant Variety Protection Acts is the 
concept of common knowledge. Non-obviousness requires actual inventiveness 
of the invention at the time the invention is made. The Plant variety protection 
Act clarifies that no reasons other than commercialization of the variety as 
provided the section that section shall render the variety a matter of common 
knowledge. 
Infringement of Plant Patent 
The scope of the plant patent is limited to the right to exclude others 
hum asexually reproducing the plant. The sale or purchase of parts of the 
plant may evidence inducement of infringement, but not direct infringement 
of the patent itself The buyer or user of fruit or flowers of a patented plant 
may be liable for inducement of infringement under 35 USC 271(b). In 
Armstrong Nurseries, Inc. The defendant actively induced infringement by 
providing direct infringer with budwood from patented roses. 
In Yoder Brothers, Inc. v California- Florida plant Cor/?. "Voder's 
allegation was that Cal-Florida was infringing its plant patents. Cal-Florida 
responded with the predictable assertions of patent invalidity and non-
infringement. 
Analyzing the legislative history of the plant patent Act the Fifth 
Circuit Court reiterated the Senate Report in defining distinctness which 
stated. 
In order for the new variety to be distinct it must have characteristics 
clearly distinguishable from those of existing varieties and it is immaterial 
whether in the judgment of the Patent Office the new characteristics are inferior 
69. 193 USPQ 264 (5th Cir. 1996). 
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or superior to those of existing varieties. Experience has shown the absurdity of 
many views held as to the value of new varieties at the time of their creation. 
The characteristics that may distinguish a new variety would include, 
among others, those of habit; immunity from disease; or soil conditions; colour 
of flower, leaf, fruit or stems; flavor; productivity, including ever-bearing 
qualities in case of fruits; storage qualities; perfume; form; and ease of asexual 
reproduction. Within any one of the above or other classes of characteristics the 
differences which would suffice to make the variety a distinct variety, will 
necessarily be differences of degree." 
The Court while considering the question of obviousness applied the 
traditional three part test for obviousness, as set out in John Deere case, 
which inquires as to (1) the scope and content of the prior art, (2) the 
differences between the prior art and the cairns at issue, and (3) the level of 
Millinery skill in the prior art to plants and observed: 
"Rephrasing the John Deere tests for the plant world, it might ask about 
(1) the characteristics of prior plants of the same general type, both patented 
and non patented and (2) the differences between the prior plants and the 
claims at issue. We see no meaningful way to apply the third criterion to plants 
i.e. the level of ordinary skill in the prior art. Criteria one and two are 
reminiscent of the distinctness requirement already in the Plant Patent Act. 
Thus, if we are to give obviousness an independent meaning, it must refer to 
something other than observable characteristics". 
Collaborating the invention requirement to the case of plants the 
Yoder Court found that to develop or discover a new variety that retains 
the desirable qualities of the parent stock and adds significant improvements, 
mid to preserve the new specimen by asexually reproducing it constitutes no -
null feat. 
During the trial, Cal-Fiorida had offered as evidence certain documents 
showing that growers had found mutations on the Mandalay variety that were 
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the same as the patented variety Glowing Mandaiay, namely, evidence that the 
sport Glowing Mandaiay had recurred. The testimony at the trial amply 
established that Voder's patented chrysanthemums were distinct to those skilled 
in the field, that is, those in the breeding business. 
The Court found that the only possible probative value of the 
sport recurrence evidence would be to show that a sport of that particular 
size, shape, colour, or other trait is predictable from a given variety of 
parent plant. It was observed by the Court that it must first be determined 
whether Congress intended predictability to negate the possibility of 
invention. 
2. Utility Patents for Plants 
The first patent law was authored by Thomas Jefferson, enacted in 1793, 
and is codified at 35 USC Section 101 as amended, 35 USC Section 101 
provides that: 
"Whoever invents or discovers any new and useful process, machine, 
manufacture, or composition or matter, or any new and useful 
improvements thereof, may obtain a patent therefore, subject to the conditions 
and requirements of Title 35." 
"Patents give the patentee the right to prevent third parties not having his 
consent from making, using or commercializing the invention until the 
expiry of the period of protection. Patents can only include certain 
inventions. Patentable inventions should fulfill certain basic pre-requisites 
with regard to its content. In order to be patentable an invention must be new. 
The invention is considered new if it does not form part of the state of the art 
which means that the invention has not been made public by written or oral 
description, by use, or in any other way before the date of filing of the patent. 
The technical knowledge could have been made public either through a written 
description or in any other way. An oral description of the technical knowledge 
will result in the technical knowledge becoming part of the state of the art. Any 
use or application of the technical knowledge that can make the- substance of 
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the technical knowledge public also leads to the same result. An invention can 
be made public by use. Thus any disclosure that contains sufficient details to 
enable the invention to be utilized can no longer be patented. The invention 
must also represent an inventive step. 
Inventive step embodies the concept that from the point of view of a 
person skilled in the relevant area of technology, the invention does not 
obviously follow from the state of the art. The invention should be other than 
obvious to a skilled man. The condition of inventive step requires that the 
invention must not follow plainly or logically from what is already known. The 
test of obviousness involves a skilled worker's test. If a person skilled in the 
art is able to perform the invention without any further experimentation, 
the invention cannot be considered as fulfilling the test of inventive step. Lord 
Westbury has elaborated the test of inventive step as "the statement must be 
such that a person of ordinary knowledge of the subject would at once 
perceive and understand and be able practically to apply the discovery 
without the necessity of making further experiment. The information given by 
the prior publication must, for the purposes of practical utility be equal to that 
given by the subsequent patent. By this statement is meant that 
experiments with a view to discovering something not disclosed." 
The question of obviousness is answered by hypothesizing what would 
have been obvious at the priority date to a person skilled in the art who had 
access to what was known in the art at that date. The man skilled in the art must 
be sufficiently interested to address his mind to the subject and to consider the 
practical application of the information which he was deemed to have. 
The four tests for obviousness are: 
I. identifying the inventive concept embodied in the patent; 
n. imputing to a normally skilled but unimaginative addressee what 
was common general knowledge in the art at the priority date; 
ni. identifying the differences if any between the matter cited and the 
alleged invention; 
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IV. deciding whether those differences, viewed without any knowledge of the 
alleged invention constituted steps which would have been obvious to the 
skilled man or whether they required any degree of invention. 
Even when the invention satisfies the requirements for obtaining patent 
protection, certain subject matter are excluded from patentability. Laws of nature, 
physical phenomena, and abstract ideas are such excluded category and are not 
patentable. Products of nature that are substantially unaltered are non statutory 
subject-matter. But purified products of nature are entitled to protection. 
Discoveries as such are an excluded category, for to allow a patent to a 
bare discovery would monopolies every application subsequently found for that 
discovery within the duration of the patent. In all the natural sciences there is a 
close relationship between the act of discovery and the act of invention. 
Invention often follows so closely upon the heels of discovery that it can be 
difficult to distinguish between them. The statement of Buckley, J. made nearly a 
century ago by the English judge helps to draw the line: 
"Of course the difference between discovery and invention is very 
familiar. Discovery adds to the amount of human knowledge, but it does so only 
by lifting a veil and disclosing something which before had been unseen or dimly 
seen. Invention also adds to human knowledge, but not merely by disclosing 
something. Invention necessarily involves also the suggestion of an act to be 
done and it must be an act which results in a new product, or a new resuh, or a 
new process, or a new combination for producing an old product or an old result." 
As early as in 1931, the United States Supreme Court distinguished 
between discovery and invention. The claim in American Fruit Growers v. 
Bwgdex Co.^" among others comprised of "Fresh citrus fruit of which the rind 
or skin carries borax in amount that is very small but sufficient to render the fruit 
resistant to blue mold decay." 
70. 283 US 1,12(1931) 
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The Supreme Court held that "addition of borax to the rind of natural 
fruit does not produce from the raw material an article for use which 
possesses a new or distinctive form, quality, or property. The added 
substance only protects the natural article against deterioration by inhibiting 
development of extraneous spores upon the rind. There is no change in the name, 
appearance, or general character of the fruit. It remains a fresh orange, fit only for 
the same beneficial uses as theretofore", v Another landmark decision of the 
Supreme Court in Funk Bros. Seed Co. v. Kalo Inoculant Co., considered the 
concept of product of nature and distinguished between law of nature and the 
handicraft of man. 
The patentee had discovered the existence of certain strains of bacteria 
which, when combined with certain other strains of bacteria, would infect two 
or more leguminous plants without loss of their respective nitrogen-fixing 
efficiencies, and utilized this discovery by segregating some of these mutually 
non-inhibitive strains and combining such strains into composite inoculants. 
Through some mysterious process, leguminous plants are able to take 
nitrogen from the air and fix it in the plant for conversion to organic 
nitrogenous compounds. The ability of these plants to fix nitrogen fi-om the air 
depends on the presence of bacteria of the genus Rhizobium which infect the roots 
of the plant and form nodules on them. Each species of root-nodule bacteria is 
made up of distinct strains which vary in efficiency. Methods of selecting the 
strong strains and of producing a bacterial culture from them have long been 
known. The bacteria produced by the laboratory methods of culture are placed in a 
powder or liquid base and packaged for sale to and use by agriculturists in the 
inoculation of the seeds of leguminous plants. This also has long been well 
known. 
It was the general practice, prior to the Bond patent, to manufacture and 
sell inoculants containing only one species of root-nodule bacteria. The 
inoculants could therefore be used successfully only in plants of the particular 
71. 333 us 127. 
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cross-inoculation group corresponding to this species. There had been a few 
mixed cultures for field legumes. But they had proved generally 
.unsatisfactory because the different species of the Rhizobia bacteria produced 
an inhibitory effect on each other, when mixed in a common base, with the result 
that their efficiency was reduced. Hence it had been assumed that the different 
species were mutually inhibitive. 
"Bond discovered that there are strains of each species of root-nodule 
bacteria which do not exert a mutually inhibitive effect on each other. He also 
ascertained that those mutually non-inhibitive strains can, by certain methods of 
selection and testing, be isolated and used in mixed cultures. Thus he provided 
a mixed culture of Rhizobia capable of inoculating the seeds of plants 
belonging to several cross-inoculation groups. It is the product claims which 
disclose the mixed culture that the Circuit Court of Appeals had held valid. The 
question before the Court was as to the patentability of the product claim. Bond 
does not create stale of inhibition or of non-inhibition in the bacteria. Their 
qualities are the work of nature. Those qualities are of course not patentable. It 
was found that patents cannot issue for the discovery of the phenomena of nature. 
"The qualities of these bacteria, like the heat of the sun, electricity, or the 
qualities of metals, are part of the storehouse of knowledge of ail men. They are 
manifestations "of [laws of nature, free to all men and reserved exclusively to 
none. He who discovers a hitherto unknown phenomenon of nature has no 
claim to a monopoly of it which the law recognizes. If there is to be invention 
from such a discovery, it must come from the application of the law of nature to a 
new and useful end." 
The Circuit Court of Appeals thought that Bond did much more than 
discovers a law of nature, since he made a new and different composition of non-
inhibitive strains which contributed utility and economy to the manufacture 
and distribution of commercial inoculants. But the Supreme Court found that 
the aggregation of species fell short of invention within the meaning of the 
patent statutes. 
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'Discovery of the fact that certain strains of each species of these 
bacteria can be mixed without harmful effect to the properties of either is a 
discovery of their qualities of non-inhibition. It is no more than the 
discovery of some of the handiwork of nature and hence is not patentable. 
The aggregation of select strains of the several species into one product is an 
application of that newly-discovered natural principle. But however 
ingenious the discovery of that natural principle may have been, the 
application of it is hardly more than an advance in the packaging of the 
inoculants. Each of the species of root-nodule bacteria contained in the 
package infects the same group of leguminous plants which it always 
infected. No species acquires a different use. The combination of species 
produces no new bacteria, no change in the six species of bacteria, and no 
enlargement of the range of their utility. Each species has the same effect it 
always had. The bacteria perform in their natural way. Their use in 
combination does not improve in any way their natural functioning. They 
serve the ends nature originally provided and act quite independently of any 
effort of the patentee. 
Once nature's secret of the non-inhibitive quality of certain strains of the 
species of Rhizobium was discovered, the state of the art made the 
production of mixed inoculants a simple step. Even though it may have been 
the product of skill, it certainly was not the product of invention. There is no 
way in which we could call it such unless we borrowed invention from the 
discovery of the natural principle itself. That is to say, there is no invention 
here unless the discovery that certain strains of the several species of these 
bacteria are non-inhibitive and may thus be safely mixed is invention. But 
we cannot so hold without allowing a patent to issue on one of the ancient 
secrets of nature now disclosed. All that remains, therefore, are advantages of 
the mixed inoculants themselves. They are not enough. The Court concluded 
that the product claims did not disclose an invention or discovery within the 
meaning of the patent statutes. 
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The term "invention" includes discovery and the term "process" 
means "process, art or method and includes a new use of a known 
process, machine, manufacture, and composition of matter or material". This 
broad statutory definition of subject-matter has enabled the United States to 
take a lead in widening the scope of subject-matter for which patent protection 
may be obtained. The Supreme Court has noted the breadth of this language in 
Diamond v. Chakrabarty a case relating to bacteria that had been genetically 
modified to enable them to digest oil and so be of use in environmental 
protection against oil spills, in the following words: 
"In choosing such expansive terms as 'manufacture' and 
'composition of matter' modified by the comprehensive 'any', Congress plainly 
contemplated that the patent laws would be given wide scope." 
Congress intended statutory subject-matter to "include anything under 
the sun that is made by man". But Section 101 has its limits and does not 
embrace every discovery. The laws of nature, physical phenomena, and abstract 
ideas have been held not patentable. Thus a new mineral discovered in the earth 
or a new plant found in the wild is not patentable subject-matter. Likewise, 
Einstein could not patent his celebrated law E = mc2; nor could Newton have 
patented the law of gravity. Such discoveries are "manifestations of nature free to 
all men and reserved exclusively to none". Restrictions on patentability are 
limited to abstract ideas, physical phenomena and laws of nature. 
Enabling disclosure 
Utility patent protection balances the interest of the inventor and that of 
the society. Enabling disclosure is the quid pro quo for the grant of the patent 
protection. In addition to the requirements for obtaining patent protection like, 
novelty, non-obviousness and usefulness, a written description is required 
under section 112. 
As a general requirement of patent law, the description given by the 
inventor must enable the skilled person to reproduce the invention. The 
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disclosure must always be sufficient to support the scope of the protection 
claimed. The question whether the specification disclosed the invention clearly 
enough is a question of degree. Since the specification is addressed to the skilled 
man, it is sufficient if the addressee can understand the invention as described 
and can then perform it. It is settled law that to invalidate a patent; the prior 
disclosure had to be an enabling disclosure. The disclosure had to be such as to 
enable the public to make or obtain the invention, This Section requires a patent 
application to describe the invention with sufficient particularity to enable 
someone skilled in the relevant technological field to make and use the 
claimed invention without undue experimentation. Section 112 states as follows: 
"The specification shall contain a written description of the 
invention, and of the manner and process of making and using it, in such full, 
clear, concise, and exact terms as to enable any person skilled in the art to which 
it pertains, or with which it is most nearly connected, to make and use the 
same, and shall set forth the best mode contemplated by the inventor of carrying 
out his invention." 
The specification concludes with one or more claims particularly 
pointing out the subject matter which (he applicant regards as the invention, 
One of the major hurdles encountered in patenting biotechnology inventions is 
the need to comply with the requirements of the first and second paragraphs of 
35 u s e Section 112. 
The first paragraph addresses the requirements of the specification. The 
second that of the claims. 
"The requirement set out in the first paragraph of 35 USC Section 112 is that a 
patent specification contains a written description of— 
1. the invention; 
2. the manner and process of making and using the invention "in such full, 
clear, concise and exact terms as to enable one skilled in the art to 
which it pertains, or with which it is most nearly connected, to make 
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and use" the invention, and that the specification; and 
3. describes the best mode "contemplated" by the inventor for 
carrying out the invention. 
in cases where priority is claimed under 35 USC Section 119 from an 
application filed abroad, that foreign application must comply with the 
requirements of the first paragraph of 35 USC Section 112 for the priority claim 
to be effective. 
The requirement for a written description of the invention and an 
enabling disclosure are separate requirements. 
In Plant Genetic Systems N. V. v DeKalb Genetics Corp,'^ Plant if 
Genetics Systems appealed the decision of the District Court which entered 
judgment for De Kalb. Plant Genetic Systems owned a patent (5,561,236) 
directed to plants, plant cells, and seeds that are genetically engineered to 
resist herbicides. The cell claims of the patent cover all plant, cells, but all of the 
working examples in the patent are "dicots" as opposed to "monocots". '^ Plant 
Genetics Systems filed suit against DeKalb Genetics Corp., alleging that 
its transgenic corn seeds infringes the 236 patent. DeKalb denied 
infringement, arguing that the patent is not enabled for monocots, that the 
scientific community was unable to transform monocots as of the 1987 
priority date, and that the patent includes a limitation that excludes monocots. 
According to Plant Genetics Systems, the patent was a pioneering 
invention and hence was entitled to a lower standard of enablement The Court 
found that under the Act, the scope of the claims must bear a reasonable 
correlation to the scope of enablement by the specification to persons of primary 
skill in the art and that there is no dicta laid down that pioneering inventions are 
entitled to a lower standard of enablement Plant Genetics also challenged the 
district court's construction of the claim limitation "susceptible to infection and 
72. 315 F.3d 1335 (Fed. Cir. 2003). 
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transformation by Agrobacterium and capable of regeneration" to mean that a 
person skilled in the art would understand monocots to be excluded. 
The Federal Circuit found no error in the claim construction and came to 
the conclusion that at the time the patent application was filed the meaning of 
the claims only covered dicots. The Court decided that the specification of the 
patent m that case did not enable the insertion of the bar gene into monocots 
and that the transformation of a monocot was not within the skill of ordinary 
artisans without the need for undue experimentation as of the filing date of that 
patent. The appellate court confirmed that the cell claims of the patent were not 
enabled by the specification and that "practicing stable gene _ transformation for 
monocot cells in 1987 required undue experimentation". 
Deposited of Biological Material 
The quid pro quo of the patent system is that in exchange for the grant of 
a patent the inventor provides the public with full possession of the means or 
carrying out the invention. The enablement requirement ensures that the public 
knowledge is enriched by the patent specification to a degree at least 
commensurate with the scope of the claims. 
When an invention relates to a new biological material, the material may 
not be reproducible even when detailed procedures and a complete 
73 
taxonomic description are included in the specification." In Lundak case , UK 
applicant had deposited the biological material with colleagues at a University 
laboratory prior to the filing and the Patent Office was assured of access to the 
material during the pendency. The description in the Lundak application provided 
a suitable illustration of the specific identification and description which is 
required in an application for patent as filed. In that application an immortal B-
cell line was disclosed and claimed. The cell line was referred to m the 
application as filed as WI-L2-729 HF2. The methods o obtaining and using this 
cell line were also described in the application as tiled. A deposit of the cell line 
was made with the American Type Culture Collection (ATCC) about a week 
73 Lundak, In re,227 USPQ 90(Fed.Cir.I985). 
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after the application was filed in the United States. The United States Court of 
Appeals for the Federal Circuit held that 
the' requirements of access by the Office to a sample of the cell line during 
pendency and public access after grant were met by Lundak's procedures. 
The court further held that the addition of information designating use 
depository accession number and deposit date of the deposited cell Sine on 
ATCC after the filing dale did not violate the prohibition against new mat 
in 55 u s e Section 132. 
"The deposit of biological organisms for public availability satisfies the 
enablement requirement for materials that are not amenable to written 
description or that constitute unique biological materials which cannot be 
duplicated. 
'In the United States there are Rules of practice that lay down how a 
deposit of a biological material has to be made. According to the Rules, 
biological material includes material that is capable of self-replication either 
directly or indirectly. The deposit shall be regarded as acceptable only when 
made according to the provisions of the Rule on Deposit of Biological Materials 
for Patent Purposes. Biological material need be deposited under the Regulations 
only where it is necessary for the satisfaction of the statutory under-quarrymen's 
for patentability. Biological material need not be deposited if it is known and 
readily available to the public or can be made or isolated thought undue 
experimentation. An original deposit of the biological material has to be made 
while the application is pending or before the filing of the application. If the 
deposited material becomes contaminated, k can be replaced. The deposit has to 
be for a term of at least thirty years and at least five years after the last request for 
the sample. A deposit of biological material that is capable of self-replication 
either directly or indirectly must be viable at the time of deposit and during the 
term of deposit. A viability statement for each deposit of a biological material 
not made under the Budapest Treaty must be filed in the application and must 
contain: 
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1. The name and address of the depository; 
2. The name and address of the depositor; 
3. The date of deposit; 
4. The identity of the deposit and the accession number given by the 
depository; 
5. The date of the viability test; 
6. The procedures used to obtain a sample if the test is not done by 
the depository; and 
7. A statement that the deposit is capable of reproduction. 
The depositor may contract with the depository and require that the 
samples of the deposited biological material shall be furnished only if a 
request for a sample is made in writing or other tangible form and contains the 
name and address of the requesting party and the accession number of the 
deposit and is communicated in writing by the depository to the depositor 
along with the date on which the sample was furnished and the name and 
address of the party to whom the sample was fiimished. The applicant must 
make assurances that the deposited material will be irrevocably and without 
restriction released to the public upon the issuance of a patent. For a deposit 
made pursuant to the regulation, the specification should contain: 
1. The accession number for the deposit; 
2. The date of the deposit; 
3. A description of the deposited biological material sufficient to 
specifically identify it and to permit examination; and The name and 
address of depository. 
Plant Variety protection Act 
With the advancements in plant biology and scientific understanding, 
doubts about the ability to distinguish new sexually propagated plant 
varieties from their naturally occurring predecessors abated. Given this new 
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environment, Congress in 1970, extended non-patent protection to seed-
propagated plants by enacting the Plant Variety Protection Act (PVPA). 
Another motivating factor for enacting the PVPA was that the 
governments of several European countries had already "made available in their 
respective countries a form of plant variety protection to developers of sexually 
reproduced plants". The Plant Variety Protection Act, 1970 of United States 
protects sexually reproduced varieties. It creates a statutory scheme that gives 
limited protection to plant varieties that are new, distinct, uniform, and stable.^  
The Congress passed the Plant Variety Protection Act in order to provide 
developers of novel plant varieties with "adequate encouragement for research, 
and for marketing when appropriate, to yield for the public the benefits of new 
varieties". The PVPA extends patent like protection to novel varieties of 
sexually reproduced plants namely, plants grown from seed which parallels 
the protection afforded asexually reproduced plant varieties, that is, varieties 
reproduced by propagation or grafting under Chapter 15 of The Patents Act. 
The PVPA confers patent-like protection for certain sexually reproduced 
plants by providing plant variety protection for "the breeder of any sexually 
reproduced or tuber propagated plant variety (other than fungi or bacteria) that 
has so reproduced the variety. The PVPA is administered by the Plant Variety 
Protection Office of the United States Department of Agriculture. The PVPA 
allows a plant breeder to protect seed crops with a certificate of plant variety 
protection from the Secretary of Agriculture, granting the breeder the right "to 
exclude others from selling the variety, or offering it for sale, or reproducing it" 
for twenty years from the date the certificate is issued. 
The basic requirement for obtaining a certificate of plant variety 
protection is that the new variety must be new, distinct, uniform, and stable. To 
receive protection under the PVPA, therefore, a new plant variety that is 
reproduced from seed must be clearly distinct from other known varieties. The 
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new plant variety must be uniform, such that variations in the sexually 
reproduced plants "are describable, predictable, and commercially 
acceptable". The new plant variety must also be stable so that the essential and 
distinctive characteristics of the variety are present in sexually reproduced 
offspring. 
In Heart Seed Co. Inc. v. Seeds Inc'* differences in morphology as 
compared to seeds of recognized origin, the melanin content of seed 
samples, or the character of seed proteins when resolved by electrophoresis 
were regarded as sufficient bases for protection under the Act. 
The question whether colour can be considered as a distinctive character 
arose in the famous Enola case. ^^  Larry Proctor, the president of Pod-Ners Seed 
Company and the owner of the US patent on a yellow-coloured bean variety. 
filed a lawsuit against 36 small bean seed companies and fanners in Colorado. 
claiming that they are infringing the patent by illegally growing and selling his 
yellow Enola bean. Proctor holds both a US Patent and a US Plant Variet} 
Protection certificate on the Enola yellow bean. 
Enola bean patent was issued in 1999- Proctor had brought the beans to 
the United States and planted the yellow beans in Colorado and allowed them 
to self-pollinate. By selecting yellow beans in several generations, a segregating 
population resulted in which the colour of the beans is uniform, stable and 
changes little by season. It is this distinctive yellow colour that gives the bean 
its novelty. The main question that arose for consideration was the difficulty 
of novelty which was argued to be solely based on its colour and on it's 
previously never having been grown in the United States. 
The Enola bean was invented through asexual reproduction and uas 
considered as distinctive because of its yellow colouring. The bean was also 
74. 7 USPQ 2d 1324 (E.D. Wash. 1987). 
75. See for a detailed discussion, "The Enola Bean Patent Controversy: Biopiracy, Novelty and Fish-and-
Chips, 2002 Duke 2 Tech. Rev. 0008. 
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considered to be distinctive because such colouring exists tiiroughout the seed 
coat and remains uniform and stable from season to season. Such changes 
could make the Enola bean a "new improvement". While assessing novelty 
under 35 USC Section 102, the invention should not be "known or used in this 
country, or patented or described in a printed publication in this or a foreign 
country". According to Proctor the Enola bean is novel because it previously 
had not been grown in the United States; Mere use in Mexico without printed 
publication is insufficient to show a lack of novelty. But Professor James Kelly 
suggested that a document shows use in the United Slates of similar beans of 
Mexican origin dating back the 1930s. This reference could be sufficient to 
show use and knowledge prior to the filing date. Mexico also claims that a 
bean registered in Sinaloa, Mexico in 1978 has the same genetic fingerprint as 
the Enola bean. Such a registration if made in a printed publication would 
invalidate the patent based on Section 102(a). This genetic fingerprint could 
also invalidate the patent under section 101 because the invention would 
neither be new nor a new improvement on the 1978 beans. It is also argued that 
plant varieties, like the original Mexican beans, should qualify as prior art to 
disprove any inventiveness associated with the Enola beam. 
Proctor argued that the Enola bean was patent-able because a new yellow 
shade was obtained, and this shade coupled with the bean being grown in the 
United States for the first time, is sufficient to satisfy the novelty 
requirement. It is this distinctive yellow color that gives the bean its novelty. 
Thus the key question for consideration was whether the supposed difference in 
color between the original Mexican beans and Enola make Proctor's bean new 
variety. 
An application for a certificate of plant variety protection must generally 
provide a description that is "adequate or as complete as is reasonably 
possible". It need not provide the degree and detail of disclosure necessary to 
enable a third party to recreate the new plant variety, as is required of utility 
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patent specifications under 35 USC Section 112. The requirement of enabling 
disclosure can be met by deposit of a sample of the plant in a depository in a 
way that enables a third party to reproduce the invention without undue 
experimentation, thereby satisfying the requirements of 35 USC Section 112. 
The method of deposit was originally developed for microbiological inventions 
but has been adopted for plants. Samples of seeds or plant cell tissue cultures are 
made freely available to the public upon the grant of the patent. The unique 
features of the PVPA are the farmer's and researcher's exception. "Farmer's 
exception allows a farmer who legally purchases and plants a protected variety 
to save the seed from these plants for replanting on his own farm. The 
researcher's exception permits a protected variety to be used for research. 
"The 1970 Plant Variety Protection Act allows a farmer to save seed for 
their own planting needs and also to sell it to a neighbour. This applies to all 
varieties protected prior to 4th April, 1995. The 1970 Act was amended in 
1994. The amended Act prohibits the sale of any farmer saved seed without the 
permission of the variety owner. It also extends protection to tuber reproduced 
plants; varieties essentially derived from the variety, and harvested material 
of the variety. The amendment is applicable to all varieties protected after 4ih 
April, 1995. 
In Asgrow Seed Co. v. Winterboe/'^ the petitioner, Asgrow Seed 
Company, was the holder of PVPA certificates protecting two novel 
varieties of soybean seed, which it calls A1937 and A2234. The respondents, 
Winterboer, are Iowa farmers who in addition to growing crops for sale as food 
and livestock feed, derived a sizeable portion of their income from "brown 
bag" sales of their crops, to other farmers to use as seed. 
During 1990, the Winter Boers planted 265 acres of A1937 and A2234, 
and sold the entire saleable crop, 10,529 bushels, to others for use as seed 
76. 513 us 179(1995). 
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enough to plant 10,000 acres. The average sale price of the respondent's seeds 
was much lower compared to the price for obtaining the seed directly from 
Asgrow. 
Asgrow brought suit against the Winterboers seeking damages and a 
permanent injunction against sale of seed harvested from crops grown from 
A1937 and A2234. the complaint alleged infringement under 7 USC section 
2541(1), for selling or offering to sell Asgrow's protected soybean varieties; 
under Section 2541(3), for sexually multiplying Asgrow's novel varieties as a 
step in marketing those varieties for growing purposes; and under Section 
2541(6), for dispensing the novel varieties to others in a form that could be 
propagated without providing notice that the seeds were of a protected variety. 
Winterboers did not deny that Asgrow held valid certificates of 
protection covering A193 7 and A2243, and that they had sold seed produced 
Horn those varieties for others to use as seed. Their defense rested upon the 
contention that their sales fell within the statutory exemption from 
infringement liability found in 7 USC Section 2543, entitled "Right to save seed 
crop exemption". 
Winterboers argued that this language gave them the right to sell an 
unlimited amount of seed produced from a protected variety, subject only to the 
conditions that both buyer and seller be fanners "whose primary farming 
occupation is the growing of crops for sale for other than reproductive 
purposes," and that ail sales comply with State law. Asgrow maintained that the 
exemption allows a farmer to save and resell to other farmers only the amount 
of seed the seller would need to replant his own fields, a limitation that the 
Winterboers' sales greatly exceeded. It was held by the Supreme Court that a 
farmer who meets the requirements set forth in the proviso to Section 2543 may 
sell for reproductive purposes only such seed as he has saved for the purpose of 
replanting his own acreage. If a farmer saves seeds to replant his acreage, but 
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for some reason changes his plans, he may instead sell those seeds for 
replanting under the terms set forth in the proviso, or of course sell them for 
non-reproductive purposes under the crop exemption. 
The owner of a protected variety may bring civil action against persons 
infringing on his or her rights. The owner may ask a court to issue an injunction 
to prevent others from further violations. It is the owner of the protected variety 
who must bring suit in such cases. Utility patents currently offer protection for 
any plant type or plant parts. A plant variety can also receive double protection 
under a utility patent and plant variety protection. Proof of the distinctiveness, 
uniformity and stability of the new variety lies with the owner. 
Plant Variety Rights in the European Union 
Plant variety rights are not as popular in E.U. as the patents rights 
because of which the same is not in uses as is the issue of patent rights and 
their infringement. Plant variety rights are, indeed, respected and seldom 
litigated within the European plant breeding and seeds industries mainly 
because the rights are granted only when the variety has been listed growing 
traits and ftind to satisfy the agree technical criteria of distinctiveness, 
uniformity and stability, known also as the DUS criteria. 
1. The European Community System 
EC Council Regulation 2100/94 established a system for Community 
plant variety rights (CPVR). The Community system is modeled on the most-
recent UPOV Convention, that is, the International Convention for the 
Protection of New Varieties of Plants, 19 March 1991. National breeders' 
rights systems in the Member States remain in force. Regulation 2100/94 does 
not seek to replace or even harmonize these systems but to offer a 
Community-wide alternative. But it is not possible to hold both a national right 
(whether a patent or a breeder's right) and a Community right for one and the 
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same plant variety; and if a national right has been granted before a 
Community right is granted for the same variety, the national right will be 
suspended for the duration of the Community right. 
2. Primary rights: Article 13(2), Regulation 2100/94 
The holder of CPVR has the exclusive right (Article 13) to do any one 
or more of the following acts (in (a) to (g)) in relation to reproductive material 
(entire plants or plant parts (e.g. seed) capable of producing entire plants) of 
the protected variety -
a) produce or reproduce (multiply) entire plants or plant parts; 
b) condition entire plants or plant parts for the purpose of propagation; 
c) offer entire plants or plant parts for sale; 
d) sell or other market entire plants or plant parts; 
e) export entire plants or plant parts from the Community; 
f) import entire plants or plant parts to the Community; and 
g) stock entire plants or plant parts for any of the purposes mentioned in (a) 
to. 
2 A violation of these exclusive rights can be redressed by compensation or 
injunction, or both: Article 94(1 )(a), Regulation 2100/94. 
3. Secondary rights: Article 13(3), Regulation 2100/94 
If the holder of CPVR did not have a reasonable opportunity to exercise 
his primary rights against the unauthorised use of reproductive material of the 
protected variety, he can enforce secondary against harvested material obtained 
from such unauthorized use. A typical example might be where apples 
harvested from a protected variety of apple tree grown without a licence from 
the owner of the plant variety rights, are stored ready for distribution. The 
apples per se would not be reproductive material, but the apple trees would be. 
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4. Tertiary rights: Article 13(4), Regulation 2100/94 
Again, if the holder of CPVR has not had a reasonable opportunity to 
exercise his primary or his secondary rights, he may have enforcement rights 
against products obtained directly from reproductive or harvested material (e.g. 
apple juice from harvested apples obtained from a protected variety grown 
without a licence). Although provision is made in Regulation 2100/94 for such 
tertiary rights to be granted as part of CPVR, as yet these have not been 
granted. 
5. Rights over other varieties: Article 13(5), Regulation 2100/92 
CPVR extends, beyond the protected variety itself, to (a) varieties which 
are essentially derived from the protected variety; (b) varieties which are not 
distinct from the protected variety but which, having been independently bred 
are not exactly the same as the protected variety); and (c) varieties whose 
production requires the repeated use of the protected variety (such as Fl 
hybrids, where the protected variety is a parental line). (The words "hybrid'" 
and "Fl hybrid" can refer to the first (Fl) generation of a cross between two 
genetically different plants, lines, clones, cultivars, species, or genera; or, 
specifically, an Fl hybrid can denote a variety in which all plants are the Fl 
progeny from the crossing of two uniform inbred lines. Hybrids may occur 
naturally or may be produced by the breeder to give new combinations of genes 
for further selection and breeding.) Prior to the 1991 UPOV Convention, the 
essential characteristics of a protected variety, in other words, the 
characteristics such disease resistance or winter-hardiness which made the 
variety economically valuable, could be "repackaged" as a variety - often 
referred to as a "cosmetic" variety - that was clearly distinguishable from the 
protected variety but which in truth took the worth or substance of the 
protected variety, without violating the plant variety rights. The concept of the 
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'essentially derived' variety introduced by the 1991 UPOV Convention is 
intended to catch, at the very least, the practice of cosmetic breeding, by 
bringing cosmetic varieties within the exclusive rights granted for the variety 
from which they are derived. Enforcement of Plant Variety Rights in the 
European Union International Symposium on the Effective Enforcement of 
Intellectual Property Rights in Turkey. 
6. Farm-saved seed: Article 14, Regulation 2100/94 
Farmers growing certain specified agricultural crops may save seed of a 
protected variety for planting on their own farms: "for the purposes of 
safeguarding agricultural production, farmers are authorized to use for 
propagating purposes in the field, on their own holding the product of the 
harvest which they have obtained by planting, on their own holding, 
propagating material of a variety other than a hybrid or synthetic variety, which 
is covered by a Community plant variety right." Small farmers, that is, farmers 
who do not grow plants on an area bigger than the area which would be needed 
to produce 92 tonnes of cereals, do not have to pay royalties in respect of the 
seed they save; but other farmers must pay royalties which are "sensibly lower 
than the amount charged for the licensed production of propagating material of 
the same variety in the same area". 
7. Exemptions: Article 15, Regulation 2100/94 
Certain acts are outside the scope of CPVR and these include (a) acts 
done privately and for non-commercial purposes; (b) acts done for 
experimental purposes; (c) acts done for the purpose of breeding, or 
discovering and developing other varieties. 
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8. Exhaustion of CPVR: Article 16, Regulation 2100/94 
The grant of CPVR does not extend to acts done in relation to 
reproductive or other varietal material of a protected variety, or a variety 
referred to in article 13(5), or any material derived from such material, which 
has been marketed or disposed of by, or with the consent of, the holder in any 
part of the Community. However, the exclusive rights may be violated if there 
is further propagation of the protected variety which was not intended when the 
material was marketed or disposed of; or if reproductive or other varietal 
material is exported to a third country which does not protect varieties of the 
genus or species to which the protected variety belongs, unless the export is for 
final consumption. 
9. Variety denomination: Article 17, Regulation 2100/94 
Any person who, within the territory of the Community, offers or 
disposes of to others for commercial purposes reproductive or other varietal 
material of a protected variety, or a variety covered by the provisions of Article 
13 (5), must use the designated variety denomination. If a trade mark, trade 
name or similar indication is associated with the designated denomination, this 
denomination must be easily recognizable as such. Failure to use the correct 
denomination is a violation of CPVR: Article 94(1 )(b). Regulation 2100/94. 
10. EC Biotechnological Inventions Directive 98/44 
Article 12(2), Directive 98/44, states that where the holder of a patent 
concerning a biotechnological invention cannot exploit it without infringing a 
prior plant variety right, he may apply for a compulsory licence for non-
exclusive use of the plant Enforcement of Plant Variety Rights in the European 
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Union International Symposium on the Effective Enforcement of Intellectual 
Property Rights in Turkey. 
PROTECTION OF PLANT VARIETIES IN OTHER NEIGHBORING 
COUNTRIES 
(a) Australia 
In Australia, The Patents Act (1990) allows all technologies to be 
patented (except human beings and the biological processes for their 
production) provided that there is an invention, defined as an innovative idea 
which provides a practical solution to a technological problem. In Australia 
individual plant varieties are patentable in Australia, limited exemptions are 
defined within the legislation. The prior use exemption allows someone who 
was utilizing the patented product or process before the priority date of claim to 
continue using the patented product without infringement. The use of a 
patented product on board a foreign vessel that accidentally comes into the 
patent area is also exempted from infringement. While in the U.S plant 
varieties can be protected under the patent system, in the majority of 
jurisdictions including Australia, the protection of plant varieties under the 
patent legislation is not permitted. Having a form of protection in place that is 
available to new plant varieties is thought to be important in order to encourage 
and promote plant breeding, encourage the importation of foreign varieties, 
promote the exportation of plant varieties and generally benefit the market 
place. 
Similarly to the U.S, Australia is both a WTO and UPOV member and 
has implemented the UPOV protection system as a mechanism for complying 
with TRIPS. Australia is signed onto the 1991 convention. As a result, plant 
varieties are protected in Australia by a plant breeder's right (PBR) under the 
plant Breeder's Rights Act (1994). The requirements, term and rights conferred 
by the UPOV convention are implemented under the plant breeder's right act. 
In Australia, a PBR is obtained from and administered by the plant breeder's 
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rights office, in contrast to patents which are granted by IP Australia. Recently 
the plant breeder's rights office was brought within IP Australia. A choice is 
usually made between the two protection systems depending on the level of 
protection sought and the ability to satisfy the necessary requirements. PBRs 
are generally obtained much faster than a patent due to the lack of examination 
and are also much cheaper to obtain. They are therefore desirable where 
protection is required in a short period of time and there is not need to acquire 
rights over the use of the variety for non-commercial purposes. Where 
comprehensive exclusive rights are desired, protection under the patent system 
would be more suitable. 
(b) Malaysia 
Under the Malaysian laws the plant variety rights which are also known 
as plant breeders' right are intellectual property rights granted to the breeders 
of a new plant variety. This plant varieties law protects the interest of the 
breeders' in controlling the propagation material and harvested material of a 
new plant variety which enables the breeders' to receive payment of royalties 
for certain period of time. The introduction of a plant variety law in Malaysia is 
very important as it could play a role in the transformation of Malaysian 
Agriculture. The Minister Agriculture and Agro-Based Industry was of a view 
that: "With the implementation of the Act, plant breeders' in the country would 
be encouraged to produce more superior varieties, while local farming 
communities could have greater access to more superior varieties from abroad" 
Malaysian breeders' have been actively involved in developing plants such as 
palm, rubber, cocoa and rice. The new breeds have played a role in the 
development of agriculture sectors which indirectly contributes to the Malaysia 
economy. This new right basically aims to: 
I. Provide income for the breeder in order to recuperate the investment 
made in the making of such breeds, particularly in the cost of research 
and development. 
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II. Encourage the breeders' to develop new varieties of plants in order to 
provide sustainable progress in agriculture, horticulture and forestry. 
III. Encourage breeders' from other jurisdictions to export their breeds into 
Malaysia. Therefore, Malaysian farmers' are able to use those varieties 
for commercial purposes. In Malaysia, the rights of breeders' of plant 
varieties are provided in the protection of New plant varieties Act 2004 
(PNPVA 2004). The purpose of this article is to give an overview of the 
protection of plant varieties in Malaysia. 
The main provisions of Malaysian PNPVA 2004 were based largely on 
the international Union for the protection of new varieties of plants or UPOV''^  
with reference to the Convention of Biological Diversity^^ By virtue of the 
Article 27 (3) b, Malaysia as the TRIPS signatory country has chosen to enact a 
law of plant varieties based on the sui generic system as provided in the UPOV 
Convention. This law emphasizes on the issues relating to the rights of farmers 
and aborigines particularly on the traditional plant varieties. 
The Malaysian protection of New Plant Varieties Act 2004, The Bill for 
Protection of New plant varieties Act 2004 was initially introduced in the 
Malaysian parliament on September 2003. It was passed on 25"^ . June 2004, but 
was only enforced recently on 1''. January 2007. Prior to PNPVA 2004, there 
was no formal protection on the rights of breeders' however an informal 
registration of new fruits varieties has been available for certification purposes. 
Although patent law is there to protect registered patented intention, 
unfortunately plant varieties have been excluded from this protection. This is 
expressly stated in section 13(2)(b) of The Patents Act 1983. 
"The following shall not be patentable: (b) plant or animal varieties or 
essentially biological processes for the production of plants or animals, other 
than manmade living microorganism, microbiological processes and products 
of such micro-organism processes." 
77. International Union for the protection of New Varieties of plants: What it is, what it Does, UPOV 
publication No. 437(E) January 19,2007 Edition. See also http://www.upov.int. 
78. Reference is also made to existing intellectual property rights in countries like JAPAN, Australia, 
India and Thailand. 
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It is accepted that plant varieties are not patentable but it does not extend 
to the inventions involving plants. The issue of lack of protection seems to be 
remedied by the PNPVA as it allows a breeder of plant variety to apply for 
grant of protection of plant variety. Perhaps, the only uncertain issue relating to 
this is whether or not the genetically modified plant varieties can be both 
registerable under patent and plant variety system. 
(c) China 
China Joined UPOV 1978 system in April 1999. By the year 2004, it has 
notified 5 lists of agricultural and 4 lists of forest plant species, covering 119 
genera and species of 41 agricultural and 78 forest plants. The number of 
application received for protection of plant varieties in agriculture were 2046, 
including 1,875 for field crops, 87 for vegetables, 52 for fruit trees and 32 for 
decorative plants, and in forestry these were 305, including 253 for decorative 
arbors. 
The Chines government permits public research institutes to earn 
income by commercial activities to make up for shortage of their operational 
budgets. Selling plant varieties seems like a natural way for government plant 
breeding institutes to make money. And these sales provide government 
institutes with more incentives to develop and distribute varieties to meet 
farmers' needs. Before the new seed laws was decreed in 2000, state owned 
seed companies (SOSCs) were the sole legal seed marketing unit of major field 
crops seed. Research institutes had to supply new seed varieties to the SOSCs. 
SOSCs conducted seed processing, seed marketing and sold the seeds to 
farmers. These research institutes got very little or no revenue from their new 
variety development except a small amount of revenue from the production and 
supply of breeders' seed to the SOSCs. Monopoly of the SOSCs to seed 
markets was formally eliminated with the adoption of the new seed law in 
2000. For the first time public research institutes and private firms could 
participate in the seed market as stated in the law. China approved its plant 
79. Rufia Hu, Huang j , Pray C and Huang., J, the developments of plant varieties applications in china. 
Journal of intellectual property Rights, 11 (4) (2006) 260-268. 
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variety protection Act (PVPA) in 1997 when the central government decreed 
the plant variety protection regulations. Two years later, the PVPA office was 
set up and started accepting plant variety protection (PVP) applications. PVPA 
was approved in part because of China's plant variety the world trade 
organization (WTO) and in part due to the pressure Chinees' plant breeders' in 
public research institutes who saw it as a way to increase their income and their 
ability to finance plant breeding research. Economists have also argued that 
stronger IPR would strengthen private plant breeding in china. They were 
concerned about the slow growth of government research and development (R 
& D) investment during the 1980s and 1990s and the near absence of private 
sector research, which has been a major source of funding for plant breeding 
research elsewhere in the world. 
(d) Bangladesh 
Bangladesh is predominantly a rural country with agriculture being the 
mainstay of the economy. The majority of the population is either directly or 
indirectly connected with agriculture. In such an agrarian society, farmers have 
relied upon indigenous knowledge for centuries, organizing production on the 
basis of local knowledge transmitted from previous generation where it is built 
upon, modified and refined to suit current circumstances. Farmers grow and 
retain these cultivars mainly due to (i) non-availability of improved varieties 
and/or their seeds, (ii) low input requirements by traditional varieties, (ii) their 
adaptability to specific ecological niches (e.g. deep water rice, salinity tolerant 
varieties of crops, etc.), (iii) their resistance to pests, (iv) their specific qualities 
like finer grain, aroma, specific tastes, etc. It is significant to note that 
traditional varieties suited subsistence farming which is still, the very feature of 
Bangladesh agriculture. 
Today farmers are exposed to modem knowledge of farming but they 
have not abandoned their indigenous knowledge, and this remains true for other 
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traditional occupational groups such as carpenters, potters, weavers, 
blacksmiths, herbal practitioners and fishermen. These groups also continue to 
draw on their local knowledge heritage, intrinsic to daily life, when producing 
their goods and products. 
The Act is known as Plant Varieties Act of Bangladesh 1998*" here some 
provisions of the plant varieties protection in Bangladesh have been mentioned 
Article 4 talks about Definitions: 
"Plant" means any living organism in the Plant Kingdom including 
Fungus Kingdom excluding bacteria and other microorganism. "Plant Variety" 
means a group of plants which has identical or similar genetic and botanical 
characteristics resulting from a given genotype or combination of genotypes 
and having specific, stable properties; it can be distinguished from other plant 
varieties of the same plant specie by the expression of at least one of the said 
characteristics "Farmer" means an individual who practices farming, whether 
subsistence or commercial, excluding a juristic person. 
Article 16 
Period of Plant Protection 
1. The highest period of protection or commercial privileges for the new plant 
variety, shall be-
(a) 7 years for annuals 
(b) 10 years for Bl-annuals 
(c) 15 years for perennials 
(d) 25 years for woody plants, utilizing timber 
80 http://www.grain.org/brl/?clocid=81984&laNvid=l 027 
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The period shall be calculated from the date of receiving the New Plant Variety 
Certificate. 
Article 22 
Farmers' Right and the Plant Protection Fund-
1. The farmers comprising a Community shall be entitled to the following 
Farmers' Right in addition to the rights stipulated in Biodiversity and 
Community Knowledge Protection Act, and over and above benefit 
sharing. For the purpose of this Act any Community engaged in food 
production, whether living in forest, flood plain, or any agro-ecological 
zone, or a member of such Community, women and/or men, will be 
considered as Farmer. 
(a) The Competent Official(s) shall always effectively inform the farmers in 
advance on the access of biological and genetic resources or any part of 
the local indigenous plant variety, common indigenous plant variety and 
wild plant variety. 
(b) The Competent OfFicial(s) shall always provide the name and address of 
the recipients of New Plant Variety Certificate, Commercial Permit or 
Citation of Award mentioning the innovation and/or the name of plant 
variety for which they were issued including a brief description of 
innovation, where applicable. 
(c) Any farmer shall have unhindered access to the governmental information 
concerning the application and application procedures, the findings of the 
examination of the claims and the basis upon which the decision has been 
taken. 
(d) Farmers shall participate in the constitution of National Biodiversity 
Authority by nominating representatives. At least 1/3 (one third) of the 
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people constituting the National Biodiversity Authority must be farmers' 
representatives of whom at least half must be practicing farmers of 
biodiversity based production system. 
Farmers shall have the right to: 
(e) Participate as the plaintiff or file the case as a criminal case or a civil 
case or other cases for the injured Community or the community whose 
right is argued, or of which the farmer is a member. 
(f) receive just compensation for illegal damage caused by the ruling order 
or for any act of a person which causes destruction or reduction of 
biological genetic resources or plant variety or environmental conditions 
in the Community. 
(g) receive the support from the government in conservation, development 
and improvement of local, indigenous or wild plant variety and/or 
reintroduction of traditional varieties. 
(h) receive support from the government for the maintenance of community 
gene banks and research related to conservation in normal household 
conditions. 
(i) submit a petition in court to order the prohibition of monocultures or of 
any act that leads to destruction or reduction of local indigenous plant 
variety or wild plant variety narrowing the genetic base of Bangladesh 
Agriculture. 
(j) appoint an advisor or a representative to exercise the rights pursuant to 
this Act. 
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(k) receive exemption or reduction of import and export tax for equipment 
and raw materials for use in experimenting or implementing non-
commercial plant improvement. 
(1) proceed for Court orders withstanding the banning of any pesticides, 
herbicides or any chemicals, or any genetically modified seed or 
propagation materials detrimental to ecology, environment, health and 
safe food production of the Community. The Court shall accept such 
proceeding as the fundamental right of the Community to protect 
themselves from any harm. 
(m) ask for an equal share of the national budget in science and technology 
to be equally spent for the development and improvement of local and 
indigenous varieties and the development of biodiversity based 
production system. 
(n) participate in research with the National Agricultural Research System 
(o) proceed for a Court order to stop any research or activities that are 
harmful and detrimental to the Community. 
Two more Acts are also enforceable in Bangladesh naming New Plant 
Varieties Protection Act and Biodiversity and Community Knowledge 
Protection Act the aim of these Acts is also to protect the plant varieties 
breeders rights, farmers' rights, to managed, maintained, conserved, reproduced 
and enhanced biodiversity, genetic resources and traditional knowledge, culture 
and various forms of practice related to these resources and to create the legal 
and institutional environment. 
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(e) Argentina*' 
In Argentina no specific law has been framed for the protection of plant 
varieties. The seed law was enacted in 1996 through which regulation of seeds 
as well as the rights of breeders were protected, but thereafter it was felt that 
the rights of farmers have been ignored, so the seed law was modify and it 
includes farmer's privilege. Here farmer's privilege has been discussed as 
under: 
Seeds Law - Farmer's Privilege'^  
Article 1. (The Directorate of the National Seeds Institute decrees that). 
The conditions determining eligibility for the "farmer's privilege" provided for 
in Article 27 of Law 20.247 are the following: 
(a) To be a farmer. 
(b) To have acquired the original seed legally. 
(c) To have obtained the present seed from that legally acquired; 
(d) To set aside from the harvested grain the amount of seed that will be used 
for subsequent sowing, distinguishing it by variety and quantity, prior to 
processing. 
There shall be no farmer's privilege where the farmer has acquired seed 
for sowing otherwise than by setting it aside himself, whether free of charge or 
for consideration (purchase, exchange, donation, etc.). 
(e) The purpose of the seed set aside to be sowing by the farmer on his own 
farm and for his own use. Purposes other than sowing by the farmer shall 
not be covered by Article 27 of Law No. 20.247. The purposes of sale, 
permutation or exchange by the farmer himself or through an intermediary 
8 ]. Modifica: Subject: Measures adopted in connection with the "farmer's privilege " provided 
for in Article 27 of Law No. 20.247. (As published in UPOV Gazette No. 94, December 2002) 
82. http://www.grain.org/brl/?docid=54870&lawid=I014 
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are expressly excluded. The exception shall benefit the farmer alone and 
not third parties. 
(f) The seed set aside for the farmer's own use shall be kept separate from the 
remainder of the grain, its identity and individuality being preserved from 
the time at which it is taken from the land by the farmer, and that identity 
shall be maintained throughout the process of processing, packaging and 
storage up to the time at which it is sown on the farmer's land. A person 
interested in availing himself of the farmer's privilege shall prove 
compliance with the conditions set forth in this Article. 
(f) Portugal 
In Portugal initiatives for the protection of plant varieties have been 
taken. A law for the protection of plant varieties was enacted in 1990 with a 
view to govern the rights of the breeders also.^ '' Certain provision of this 
particular law has been mentioned here: 
Article 2. Plant Varieties Eligible for Protection. 
Breeders' rights may be accorded solely in respect of those plant 
varieties which, 'according to the definition to be laid down by order of the 
Minister of Agriculture, Fisheries and Food, are deemed to be distinct, 
homogeneous, stable and new. 
Article 3. Content of Plant Breeder's Rights. 
(1) The breeders' rights in a plant variety confer on their owner exclusive 
entitlement to produce and market plants of that variety or the 
corresponding reproductive or vegetative propagating material. 
83 http://www.upov.int/export/sites/upov/en/publications/npvlaws/portugal/decree_law_213_90.pdf 
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(2) Plant breeders' rights shall not prevent the use of the protected plant 
variety as initial or basic material for the production of other varieties, 
except where its repeated or systematic use is necessary. 
Article 4. Term of Plant Breeders' Rights. 
(1) Plant breeders' rights shall have a limited term which shall be a 
minimum of 15 or 20 years, depending on whether they relate to 
herbaceous plants or to woody plants. 
(2) Terms may differ according to species or group of species. 
(g) Republic of Korea 
In Republic of Korea for the protection of plant varieties no particular 
law has been framed but there is a law which deals with seed law as well as 
protection of breeders rights known as Seed Industry Law.^ "* Few important 
provisions of this law are as under: 
Article 2. Deflnitions 
For the purposes of this law-
(iii) "seed" means a seed, a mushroom spawn, or vegetative material used 
for the propagation or cultivation of plants; 
(iv) "variety" means a plant grouping within a single botanical taxon of 
the lowest known rank, which grouping, irrespective of whether the 
conditions for the grant of a breeder's right are fully met, can be 
distinguished from any other plant grouping by the expression of at 
least one of the characteristics, and considered as a unit with regard 
to its suitability for being propagated unchanged; 
84 http://www.grain.org/brl/?docid=389&Iawid= 1391 
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(v) "breeder" means the person who has bred, or developed from 
discovery, a variety; 
Article 11. Plants Entitled to Variety Protection 
Species or genus of the plants entitled to variety protection under this 
Law shall be determined in accordance with an Ordinance of the Ministry of 
Agriculture and Forestry. 
Article 12. Conditions of Variety Protection 
Protection shall be granted for a variety, provided such variety is: 
(i) new, 
(ii) distinct, 
(iii) uniform, 
(iv) stable, and 
Article 17. Persons Entitled to Variety Protection 
(1) The entitlement to the breeder's right shall be vested in the breeder or his 
successor in accordance with this law. 
(2) Where two or more persons have bred, or discovered and developed, a 
variety jointly, the entitlement to protection shall be vested in them 
jointly. 
Article 17. Persons Entitled to Variety Protection 
(1) The entitlement to the breeder's right shall be vested in the breeder or his 
successor in accordance with this law. 
(2) Where two or more persons have bred, or discovered and developed, a 
variety jointly, the entitlement to protection shall be vested in them 
jointly. 
286 
7".% VnderProtection qfcpQint 'Varieties ^ Tamers ^ htsAct 
Article 56. Duration of the Variety Protection Right 
The variety protection right shall expire at the end of the twentieth 
(20th) calendar year following the registration of its establishment; for trees 
and fruit trees, it shall expire at the end of the twenty-fifth (25th) year. 
(h) Sri Lanka 
Plant Breeders Rights laws give periodic monopoly rights over new 
varieties of plants. SriLanka does not have such a law and no one could clam 
any rights over a plant variety. However, there was a draft of a PBR, law which 
was presented in July 2001. The enactment of such a law was a requirement 
under the TRIPS agreement [Art 27(3)(b)]. However this provides for a country 
to have a unique (sui-generis) Act to suit their own requirements. Some 
developed countries have PBR laws that make it possible to claim varieties as 
new if they differ in one distinct characteristic. Now the enacted law is known 
as Protection of New Plant Varieties (Breeders' Rights) SriLanka 2001.^ ^ Few 
important provisions of the said Act are here under: 
Definitions: 
1. For the purposes of this Act -
• "breeder" means the person who has bred, or discovered and developed, 
a variety; 
• "holder" means the holder of a breeder's right; 
• "Office" means the National Intellectual Property Office of Sri Lanka 
(NIPOS): 
• "protected variety," means any variety that is the subject of a breeder's 
right, 
85 http://www.grain.org/brl/?docid=908&lawid= 1547 
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• "variety" means a plant grouping within a single botanical taxon of the 
lowest known rank, which grouping, irrespective of whether the 
conditions for the grant of a Breeder's Right are fully met, can be -
(a) defined by the expression of the characteristics resulting from a given 
genotype or combination of genotypes; 
(b) distinguished from any other plant grouping by the expression of at least 
one of the said characteristics; and 
(c) considered as a unit with regard to its suitability for being propagated 
unchanged. 
Plant Breeder's Right 
Criteria for Protection. 
2. Subject to this section and any other formal requirements of this Act, a right 
to be known as a plant breeder's right shall be granted in respect of plant 
varieties of those genera or species specified in the regulations where the 
variety is-
(a) new; 
(b) distinct; 
(c) homogenous/uniform; 
(d) stable; and given a variety denomination, which is acceptable for 
registration in accordance with section 22. 
Exceptions to breeder's right. 
(I) The breeder's right shall not extend to -
(a) acts done privately and for non-commercial purposes; 
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(b) acts done for experimental purposes; and 
(c) acts done for the purpose of breeding other varieties, and, except where the 
provisions of section 14(3) apply, acts referred to in section 14(1) and (2) in 
respect of such other varieties. 
(II) The Minister may by regulations, within reasonable limits and subject to 
the safeguarding of the legitimate interests of the holders of breeder's right, 
restrict the breeder's right in relation to the varieties of any specified plant 
genera or species in order to permit farmers to use for propagating 
purposes, on their own holdings, the product of the harvest which they have 
obtained by planting, on their own holdings, the protected variety or a 
variety covered by section 14(3)(a)(i) or (ii). 
Period of protection 
16. (1) subject to subsection (2), the breeder's right in respect of vines, 
forest trees, fruit trees and ornamental trees including in each case, their 
rootstocks, shall expire twenty five years after the grant thereof 
(2) Protection for all other genera or species shall expire twenty years 
after the grant thereof 7 (3) Where in the cases referred to in section 4(2), a 
variety has already been offered for sale or marketed in Sri Lanka for a period 
of more than one year before the date of the filing of the application, the 
duration of the protection shall be reduced by the number of fiill years minus 
one year that have elapsed since the beginning of the offering for sale or the 
marketing, with the authorization of the breeder or his successor in title, before 
the filing of the application. 
(i) Japan 
The main purpose for plant varieties law is to promote the breeding of 
plant varieties and the rational distribution of propagating material by 
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providing for a system relating to the registration of plant varieties for the 
protection of new plant varieties and regulations relating to the indication of 
designated seeds, so as to contribute to the development of agriculture, forestry 
and fisheries. 
The Act deals with some important provisions such as The term 
"variety" as used in this Act shall mean a plant grouping which can be 
distinguished from any other plant grouping by all or parts of the expressions 
of the important characteristics (hereinafter referred to as "expressions of the 
characteristics") and which can be propagated while maintaining all its 
characteristics without change.**^  
(6) The term "designated seeds" as used in this Act shall mean seed 
(excluding that of trees provided for forestry) which is designated by the 
Minister of Agriculture, Forestry and Fisheries, and appears in the form of 
seeds, spores, stems, roots, seedlings, saplings, scions, rootstocks, spawn or 
other parts of plants specified by the Cabinet Order as requiring certain matters 
to be labeled at the time of sale thereof in order to facilitate identification of its 
quality, and the term "seed dealer" as used in this Act shall mean any person 
engaged in the sale of designated propagating material in the course of 
business. 
(j) Germany 
In Germany, the intellectual property title for plant breeding is called 
"plant variety protection". It protects the unique genetic combination of a new 
variety and the resulting properties of the plant. Germany has enacted its plant 
protection law in 1997. Of which Article 1 of the Act says about. 
86 http://www.upov.int/export/sites/upov/en/publications/npvlaws/japan/japan_act_49_2007.pdf 
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Conditions for Plant Variety Protection 
(1) Protection shall be granted for a plant variety (hereinafter referred to as a 
"variety"), provided such variety is 
1. distinct, 
2. homogeneous, 
3. stable, 
4. new and 
5. designated by means of a registerable variety denomination. 
(2) Protection under this Law shall not be granted for a variety that is the 
subject matter of a Community plant variety right. 
Article 2. Definitions 
For the purposes of this Law: 
la. "Variety" shall mean a grouping of plants or parts of plants, as far as such 
parts are capable of producing entire plants, within a single botanical 
taxon of the lowest known rank, which grouping, irrespective of whether 
the conditions for the grant of a plant variety right are met, can be: 
(a) defined by the expression of the characteristics that results from a 
given genotype or combination of genotypes, 
(b) distinguished from any other plant grouping by the expression of at least 
one of those characteristics and 
(c) considered as a unit with regard to its suitability for being propagated 
unchanged. 
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Article 13. Duration of Variety Protection 
Variety protection shall extend to the end of the twenty-fifth calendar 
year or, in the case of grapevine, hop, potato and tree species, the end of the 
thirtieth calendar year following the year of grant. 
Article 8. Entitlement to Variety Protection 
(1) The original breeder or discoverer of the variety or his successor in title 
shall be entitled to variety protection. If more than one person has bred 
or discovered the variety jointly, the entitlement shall belong to such 
persons jointly. 
(2) The applicant shall be considered the entitled person in proceedings 
before the Federal Office of Plant Varieties unless it comes to the 
knowledge of the Federal Office of Plant Varieties that he is not entitled 
to variety protection. 
Article 10. Effect of Variety Protection 
(1) Subject to Articles 10a and 10b, variety protection shall have the 
effect that the owner of variety protection alone shall be entitled: 
1. (a) to produce, to condition for the purpose of propagation, to 
place on the market, to import or export propagating material of 
the protected variety or (b) to stock such material for any of the 
purposes mentioned in item (a), 
2. To carry out any acts mentioned in item 1 with respect to other plants or 
parts of plants or directly obtained products thereof if propagating 
material was used in their production without the consent of the owner 
of variety protection and the owner of variety protection had had 
no opportunity to exercise his right in relation to such utilization. 
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(3) The effect of variety protection under paragraph (1) shall also extend to: 
1. varieties which are essentially derived from the protected variety 
(initial variety), vk'here this initial variety is not itself an essentially 
derived variety, 
2. varieties which cannot be clearly distinguished from the protected 
variety or 
3. varieties whose production requires the repeated use of the 
protected variety. 
(4) A variety shall be deemed to be an essentially derived variety if: 
1. the initial variety or another variety that is itself derived from the initial 
variety has been predominantly used for its breeding or discovery 
2. it is clearly distinguishable and, 
3. except for the differences that result from the method of derivation 
used, it conforms essentially to the initial variety in the expression of the 
characteristics that result from the genotype or combination of 
genotypes of the initial variety." 
Conventions & Agreements Related to Plant Varieties Protection 
In context of plant varieties protection many international conventions 
and agreements took place. Before the existence of any international 
Convention it was difficult to obtain protection in many countries due to the 
diversity in the domestic laws. Though the legislation for the protection of 
plant varieties is different sin individual country but these conventions and 
agreements are binding to the member countries. Certain Agreements and 
Conventions were held for the protection of Plant varieties has been discussed 
below 
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(a) International Union for the Protection of New Varieties Plant (UPOV) 
Convention 1961 
The importance of UPOV Convention is reflected from its preamble. 
Which states "Convinced of the importance attaching to the protection of new 
varieties of plants not only for the development of agriculture in their territory 
but also for safeguarding the interests of breeders, conscious of the special 
problems arising from the recognition and protection of the right of the creator 
in this field and particularly of the limitations that the requirements of the 
public interest may impose on the free exercise of such a right.. 
"Deeming it highly desirable that these problems to which very many 
states rightly attach importance should be resolved by each of them in 
accordance with uniform and clearly defined principle." UPOV has been 
established by the International Convention for the protection of New Varieties 
of plants (the UPOV Convention) which was signed in Paris in 1961. 
The International Union for the Protection of New Varieties of Plants 
known as UPOV is an intergovernmental organization with headquarters in 
Geneva. The acronym UPOV is derived from the French name of the 
organization Union International Pour La protection Des Obtentions 
Vegetables. The purpose of the UPOV Convention is to ensure that the member 
states of the union acknowledge the achievements of breeders of new plant 
varieties, by making available to them an exclusive property right on the basis 
of a set of uniform and clearly defined principles UPOV Convention 
establishes international rules of the system under which countries grant 
intellectual property rights to individuals or entities that develop new varieties 
of plants. 
The Convention came into force in 1968.Later in order to enable the 
United States of America to join the UPOV Convention, in 1978 when the 
87. UPOV 1961 
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Convention was revised, an exceptional rule allowing protection under two 
forms was introduced in Art.37. It was later revised in Geneva in 1972, 1978 & 
1991. The main Activities of UPOV are concerned with promoting 
international harmonization and cooperation, mainly between its member 
states, and with assisting countries in the introduction of plant variety 
protection legislation. UPOV Convention defines a basic concept of plant 
variety protection that must be included in the domestic laws of the members of 
the union. 
The Salient Features of this Convention-
(i) The UPOV Convention prohibits discrimination against foreign 
nationals 
(ii) It lays down requirements for plants patent system as prevalent in the 
national plan patent laws. Protectable line must be distinguished such 
as new homogenous and stable, 
(iii) Hybrid may be patentable, 
(iv) The protection granted must be for the right to control the protection 
sale and marketing of the reproductive and vegetative propagating 
materials, 
(v) A breeders' right to use another patented material in developing a 
new line should be protected except for direct production of hybrids. 
This material can be imported from another country which is also 
required to be guaranteed under UPOV Convention, 
(vi) The nations should provide the extensive patent protection that is 
required by the Convention, 
(vii) A farmer should be allowed to use a part of his own crop for his own 
seed purposes without infringing the patent, 
(viii) The UPOV Convention should create a international institution to 
work for harmonization of domestic laws. 
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(b) The Trade-Related Aspects of Intellectual Property Rights (TRIPS) 
Although the UPOV Acts have provided IPR protection for plant 
varieties for more than forty years, their significance has recently been 
overshadowed by a different intellectual property Treaty, the Agreement on 
Trade-Related Aspects of Intellectual property Rights ("TRIPS" or the "TRIPS 
Agreement").** Adopted in 1994 as a treaty administered by the WTO, TRIPS 
is the first and only IPR treaty that seeks to establish universal, minimum 
standards of protection across the major fields of intellectual property, 
including patents, Copyrights, Trademarks, Industrial Designs, Integrated 
Circuits and Trade Secrets. Although the TRIPS Agreement devotes only 
minimal attention to plant breeders' rights or plant variety protection ad does 
not even mention the UPOV Acts, its adoption has done more to encourage the 
legal protection of plant varieties than any other international agreement. 
Plant Variety Protection under TRIPS 
Article 27.3(b) contains the only textual provisions of the TRIPS 
Agreement relating to plant variety protection. The Article states in relevant 
part: Members may also exclude from patentability: (b) plants and animals 
other than microorganisms; and essentially biological processes for the 
production of plants or animals other than non-biological and microbiological 
processes. However, Members shall provide for the protection for plant 
varieties either by patents or by an effective Sui-Generis System or by any 
combination thereof 
The meaning of this Article has been the subject of significant debate 
among both WTO Members and nongovernmental organizations (NGOs) with 
differing views over the propriety of IPR protection for plant varieties. A 
88. Vikram Khanna, "Going beyond the Urguary Round Business line" The Hindu. November 8, 1996, 
p. 24. 
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detailed review of that debate and an analysis of Article 27.3(b) are provided 
bellow. For present purposes, two overarching points are worth noting. 
First, TRIP'S provisions on plant varieties do not refer to or incorporate 
any pre-existing intellectual property agreements, including the 1978 and 1991 
UPOV Acts. This omission contrasts sharply with other fields of intellectual 
property, such as patents, copyrights and trademarks, for which TRIPS 
expressly requires WTO Members to comply with the standards of protection 
contained in Preexisting IPR agreements, such as the Berne convention for the 
protection of literary and artistic works ad the Paris Convention for the 
protection of industrial property. As a result of this omission, WTO Members 
are neither required to become members of UPOV nor to enact national laws 
consistent with either UPOV Act in order to comply with their obligations 
under TRIPS. Although the drafting history of TRIPS does not explain this 
markedly different treatment of plant varieties, it seems likely that compliance 
with UPOV was not required because so few WTO Members were party to 
UPOV and those who were could not agree upon which of its two most recent 
Acts should serve as the standard for protection. 
Second, Article 27.3(b) permits WTO Members to protect plant varieties 
using one of three distinct approaches: (1) Patent Law, (2) an effective Sui 
Generis System (3) a combination of elements from both systems. Thus, unlike 
most other areas of intellectual property protected by TRIPS, Article 27.3(b) 
expressly grants Members significant discretion to choose the manner in which 
they will protect plant varieties and it contemplates that discretion may be 
exercised differently by different states.*' This discretion and the opportunity 
for divergent outcomes it engenders have significant consequences. On the one 
hand, TRIPS failure to incorporate and build upon the preexisting UPOV Acts 
may have a disharmonizing effect, with states within the UPOV system 
89. Laurence R .Heifer, Intellectual Property Rights in Plant Varieties: An Overview with Options for 
National Governments, p. 1 Savailable at http://www..fao.org/Legal/Prs-OL/ipo31 .pdf 
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enacting one type of plant variety protection law and states outside of that 
system enacting a different kind of law (which may or may not resemble each 
other). This could create significant jurisdictions. On the other hand, this 
sanctioned diversity of legal approaches allows WTO Members to balance the 
protection of plant breeder's rights against the other important and competing 
societal goals identified in Part I, many of which are found in other 
international Agreements. Seen from this perspective, Article 27.3(b) provides 
a much needed safe space for governments of harmonize conflicting norms and 
policies a space that is lacking in other areas of the TRIPS Agreement. 
The Review of TRIPS Article 27.3(b) 
The last sentence of Article 27.3(b) states that the provisions of this 
subparagraph shall be reviewed four years after the date of entry into force of 
the WTO Agreement. Inasmuch as the WTO Agreement entered into force on 1 
January 1995, the review contemplated by this article should have been 
conducted in 1999. The review was commenced but was not concluded, largely 
as a result of disputes between industrialized and developing nations over the 
scope of the review process. Government submitted additional information and 
proposals to the TRIPS Council in 2000 and 2001, but no formal action was 
taken. With the launching of the Doha Round of trade talks in November 2001, 
however, the review of Article 27.3(b) recommenced in earnest. In June 2002, 
eleven developing states submitted a detailed proposal to amend TRIPS to 
prevent systematic conflicts with the CBD arising from the implementation of 
TRIPS.'" The proposal seeks to compel all WTO Members to require 
applicants for patents relating to biological materials and traditional knowledge 
to disclose certain information as a condition of obtaining legal protection. '^ 
The TRIPS Agreement mandates its signatories to provide patent 
protection for nay inventions in all fields of technology, provided that the 
90. WTO Doc. IP/C/W/356, para. 11 
9\.Id., para. 10 
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inventions are new, involve an inventive step and are capable of industrial 
application.^ ^ However, with regard to plant related inventions, TRIPS permits 
Members to exclude from patentability altogether plants, essentially biological 
processes for the production of plants and plant varieties.^ ^ Thus, as presently 
written, the TRIPS Agreement would permit WTO Members to decline to 
protect plant varieties with a patent. 
(c) The Consultative Group on International Agricultural Research 
(CGIAR) 
Another international network of protecting research needs under the 
auspices of a consortium system has also been set up in the field of agricultural 
research and development system. This is known as 'Consultative Group of 
International Agricultural Research'. CGIAR is an informal association of 
public and private donors founded in 1971 that supports a international network 
of agricultural research centers, each with its own governing body. CGIAR'S 
mission is to engage in research, in partnership with other public and private 
entities, to promote sustainable agriculture in developing nations. With respect 
to plant genetic resource, CGIAR's principle method for achieving this 
objective is ex situ conservation. Networks of gene banks within CGIAR store 
and conserve seeds and propagating materials outside of their natural habitat 
for future use by farmers, researchers and breeders'. The CGIAR network 
holds the world's largest ex situ collection of plant genetic resources for food 
and agriculture. Both developed and developing countries are dependant on this 
group for most of the genetic material. This work is of mutual assistance for all 
countries, including India in so far as exchange availability of research are 
concerned the CGIAR centers provide, in so far as India is concerned some of 
the green revolution varieties that had significant impact on overall food 
production 
92. GRAIN, 2004b; OECD, 2003 pp. 118 and 119. 
93. Article 27(1). 
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(d) Convention on Biological Diversity (CBD) 
With the increasing importance of biological diversity in several areas 
particularly in the areas of agriculture and medicine besides its environmental 
importance its conservation has been urgently required. '^' The Convention on 
Biological Diversity is the first treaty of its kind to address in a comprehensive 
manner the continuous rise in plant and plant extinction world wide. The wide 
ranging implications of its conservation and its economic, scientific, social, 
genetic and ecological values have been recognized. 
The Convention affirms that the states have sovereign rights over their 
own biological resources and are also responsible for conserving their 
biological diversity and for using their biological resource in a sustainable 
manner. Further the Convention desires that the benefits arising out of the use 
of traditional knowledge innovations and practices of indigenous people 
relevant to conservation sustainable use of biodiversity must be shared 
equitably. The need for new and additional financial resources and appropriate 
access to relevant technologies for developing countries was also 
acknowledged. 
The approach of the Convention has been spelt out in clear words in its 
objectives. 
"The conservation of biological diversity the sustainable use of its 
components and the fair and equitable sharing of the benefits arising out of the 
utilization of genetic resources including by appropriate access to genetic 
recourse and by appropriate transfer of relevant technologies taking in to 
account all rights over resource and to technologies and by appropriate 
funding".'' 
94. Sukanta K Nanda .Protection of Plant Varieties in India, (ed) A. K.Kaui, V.K.AIiuja- The Law of 
Intellectual Property Right. In Prospect and Retrospect p-144-150 (2001). 
95. CBD Article I. 
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The Convention states that "each contracting party shall in accordance 
with its particular conditions and capabilities develop national strategies, plans 
or programmes for the conservation and sustainable use of biological diversity 
or adopt for this purpose the existing strategies plans or programmes which 
shall reflect inter-alia the measures set out in this Convention relevant to the 
contracting party concemed."^^ 
Article 15 recognizes sovereign rights of State on its natural resources 
and also recognizes their rights to determine access of other States to them on a 
mutually agreed basis. Hence natural resources, including biological resources 
can not be viewed as a common ownership. 
(e) Agenda 21 
Another international document adopted during the United Nations 
conference on Environment and Development held in the year 1992 obliges 
states "to take appropriate measures for the fair and equitable sharing of 
benefits and result of research and development in plant breeding between the 
sources and users of plant genetic resources." The document further provides 
for appropriate measures for the fair and equitable sharing of the benefits 
derived from research and development and the use of biological and genetic 
resources including biotechnology between the sources of the resources and 
those who use them. 
But the agenda 21 called for the strengthening of the FAO Global 
system on plant genetic resource and its adjustment in accordance with the 
outcome of the negotiations of the Biodiversity Convention. 
96. CBD. Article 6 (a). 
301 
1.% XhdeTProtection qf<PQmt Varieties €i tamers ^ jghtsjict 
(f) International Treaty on Plant Genetic Resources for Food and 
Agriculture (ITPGR) 
This treaty is a landmark international agreement designed to deal with 
til 
the rapid loss of agricultural biodiversity. The treaty came in to force on 29 
June 2004 when the 40"' ratification was deposited at the FAO. India has also 
ratified the international treaty on plant genetic resources for food and 
Agriculture. The treaty reflects the objectives of the biodiversity conversion 
and emphasizes the conservation of biodiversity, their sustainable use and 
benefit sharing. Though the treaty does not directly focus on patents or plant 
breeders' rights it delineates a regime for benefit sharing and access to 
biological diversity which links intellectual property with the treaty. The nation 
of common heritage found in the undertaking was translated to the concept that 
the conservation of biological diversity is a common concern of all countries. 
Other Features of The Treaty 
1. It ensures that sustainable use of plant genetic resources would be to 
promote food and agriculture. '^ 
2. It also acknowledged the role of the farmers in conserving the genetic 
resources. 
3. It recognizes farmer's contribution to conserve and enhance plant 
genetic resources for food and agriculture. 
4. It gives guidelines to the states regarding the protection of traditional 
knowledge. 
5. It considers the genetic resources as raw material for crop genetic 
improvement. 
6. It promotes Farmer's right at national as well as international levels 
realization of farmers' rights is left to the respective national 
government of the contracting states. '* 
97. Article 6.2, ITPGRFA 
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7. It provides different mechanisms of benefit sharing like exchange of 
information, access to and transfer of technology, capacity building and 
the sharing of the benefits arising from commercialization. 
World Intellectual Property Organization (WIPO) 
The world Intellectual Property organization (WIPO) is a specialized 
agency of the United Nations charged with promoting the protection of 
intellectual property throughout the world.'' The WIPO Secretariat undertakes 
wide variety of activities relating to IPRs, including hosting diplomatic 
conferences of government representatives seeking to negotiate new 
international treaties. WIPO's staff also provides technical assistance and 
training to member states and their national intellectual property offices, 
especially in developing countries. More recently, WIPO has created standing, 
expert and intergovernmental committees that conduct studies on particular 
intellectual property topics and intergovernmental committees that conduct 
studies on particular intellectual property topics and generate nonbinding 
guidelines and recommendations for consideration by WIPO members. 
WIPO's recent activities in the area of plant genetic resources have been 
considerable. Issues relating to the intersection of IPRs and PGRs have been 
raised during the negotiation of two multilateral patent agreements (The Patent 
Law Treaty and the Substantive Patent Law Treaty) and have been a principal 
subject of discussion and study in the recently created intergovernmental 
Committee on Intellectual Property and Genetic Resources, Traditional 
Knowledge and Folklore (IGC). 
Developing states first sought to raise issues relating to the intersection 
of IPRs and PGRs during the WIPO sponsored negotiation of the Patent Law 
98. ITPGRFA, Article 9.1, 
99. WIPO Convention, Article 3(i) 
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Treaty in 1999. They proposed the addition of an article in the treaty requiring 
applicants for inventions derived from genetic resources to demonstrate that 
they had received permission to access those resources from the country of 
origin. Industrialized countries opposed the proposal arguing that it addressed 
substantive law issues that were inappropriate for inclusion in a treaty largely 
devoted to procedural issues. As a compromise, the WIPO Secretariat proposed 
the creation of a new intergovernmental committee (the IGC) to study the 
intellectual property aspects of genetic resources and traditional knowledge. 
During the IGC's first five sessions between April 2001 and July 2003, WIPO 
members have supported a wide-ranging work programme for the Committee, 
including: (1) creating a searchable database of clauses in contracts that 
regulate access to genetic resources or require benefit sharing; (2) studying 
technical issues raised by the disclosure of biodiversity related information in 
patent applications; (3) creating databases of traditional knowledge and (4) 
identifying ways to document genetic resources and traditional knowledge in 
the public domain. 
The International Undertaking on Plant Genetic Resources (the 
Undertaking) 
FAO has helped to generate several nonbinding international 
instruments relating to plant genetic resources. The undertaking, the first of 
these instruments, was adopted in 1983. As of 2000, 113 states were signatories 
to the undertaking, thus pledging them to implement the recommendations it 
contains. For many years, the Undertaking served as the central legal 
instrument in FAO's global system for plant genetic resources, a system that 
includes a ftmd for the equitable sharing of benefits and a mechanism to given 
early warning about genetic resources under threat. The Undertaking's 
principal objectives are to ensure that the need for conservation is globally 
recognized and that sufficient funds for this purpose are made available, to 
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assist farmers' and farming communities in the protection and conservation of 
PGRs and of the natural biosphere; and to allow farmers, their communities 
and countries to participate fully in the benefits derived from improved uses of 
PGRs, including through plant breeding. In its initial formulation, the 
Undertaking challenged a private property rights approach to plant genetic 
resources by declaring that all such resources, whether as cultivated by 
farmers' in the field or modified through breeder innovations, were part of the 
common heritage of making and consequently should be available without 
restriction.'°° An interpretation issued adopted by FAO in 1989, however, 
clarified that plant breeders' rights were not incompatible with the 
Undertaking."" It also recognized the interrelationship between the rights of 
traditional farmers' (whose practice of saving seeds provided the raw genetic 
materials for innovation) and the rights of plant breeders' (who use technology 
to achieve that innovation). 
The African Sui-Generis Model legislation: 
The sudden need to implement the TRIPS Agreement has led African 
states to pursue different strategies some states have tried to develop national 
frameworks while other tried to cooperate in the framework of existing 
regional intellectual property rights obligation. Most states realized that the 
difficulties involved in devising a new framework for access and control over 
plant genetic resources and related knowledge necessitated an effort at a 
broader level. As a result the organization of African unity took on the task of 
negotiating among its member states a model law to give member states a 
framework adapted to the needs of the African region that could be relied upon 
100. Article 1 
101. Resolution No. 4/89 adopted by FAO Conference 25tii Session, Rome, 11-20 November 1989. 
102. Phillipe Cullet, Intellectual Property Protection and Sustainable Development, p.264 (2005). 
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when introducing national legal frameworks concerning plant genetic 
resources. 
The African Model legislation for the protection of rights of local 
communities, farmers and breeders and for the regulation of Access to 
Biological Resources (Model Legislation) was adopted in 2000. 
African Model legislation was developed with a view to-
(a) Prevent the disruption of African rural life, health and food production 
which could result from loss of 
(i) Seed and other planting materials which are the foundation of all 
agricultural production; 
(ii) Traditional medicinal plants the basis of health care delivery service for the 
majority of African people, 
(iii) National fiber and dyes the basis of African art and crafts etc. 
(b) Promote and ensure the sharing of benefit that biodiversity traditional 
knowledge, technologies, innovations and practice of African 
communities provide to Multinational Corporation. 
(c) Safeguard to the vital interest of Africa from the consequences of 
Globalization and trade liberating. 
Special Features of African Model Legislation 
1. The main aim of this law is to promote the conservation of local 
biodiversity relate technologies, innovations and practices, food security 
and community rights over their biological resources and knowledge. It 
also recognizes farmers right and their tradition to save and exchange 
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seeds this law recognizes seed security as the bases of food security 
farmers right also include right to use a commercial breeders variety to 
develop other varieties. 
2. The law is based on the principle that the traditional knowledge, 
technologies and biological resources of local communities are as a 
result of the tried and tested practices of several past generations. They 
are held in trust by present generation and no one has the right to create 
exclusive monopoly rights over them. Community rights are inalienable 
the state has a responsibility to protect such rights. 
3. The model laws also give recognition to community rights. These rights 
include the rights of innovation, practice knowledge or technology 
which are governed partially or completely by their own customary 
law."^ ^ 
4. The model law gives exemptions to the rights of breeders it includes the 
right to use a protected variety other than commerce, the right to sell 
plant or propagating material as food, the right to sell within the place 
where the variety is grown and the use of the variety as an initial source 
of variation for developing other verities.'*^ '* 
5. The Model law suggests a system which says access can only be granted 
with the prior consent and informed consent of the state of origin of the 
biological resources as well as with the concerned communities.'°^ It 
specifies provision for consultation with the concerned communities on 
application being made for access. The consultation ensures that 
appropriate responsibility rests with the National Competent 
Authority.'"^ 
103. African Model Legislation for the Protection of Rights of Local Communities, Farmers Breeders 
and for the Regulation of Access to Biological resources. Article 24 
104. W, Article 43 
105. W., Article 3-8 
106. Kolawole O. Adenji, The African Union and the African Model Law available at 
www.eli.org/pdf/Afrcica/adenji.pdf 
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The Model law considers benefit sharing as a right of local communities. It 
says certain amount of benefit must be shared with the retainer of these 
biological resources. Community Gene fund could be a source of benefit 
sharing. The ftind shall be used for financing develop mental projects in the 
local community. Though the model legislation tries to fulfill the requirements 
of Art 27 (3) (b) of TRIPS Agreement and provision of CBD the Model 
legislation constitutes one of the few attempts to integrate plant variety 
protection with other concerns in a single legal instrument. While the Model 
Legislation probably constitutes an appropriate starting point for most African 
countries and is better adopted to local circumstances and needs than a regime 
solely based on the UPOV Convention available evidence seems to indicate 
that African states are under pressure not to follow it. '°^ 
Conclusion 
Basically traditional knowledge relates to the plants and their curative 
medicinal properties. These of plants need protection. The protection of plant 
varieties and associated knowledge derives its life breath from union 
International pour law protection des abstentions vegetables (international 
union for the protection of new varieties of plants. This UPOV convention can 
be consider a grand norm) for the protection of plant varieties. TRIPS 
agreement is one of the most important commercial treaties in modem history. 
TRIPS is an international agreement that requires member countries to provide 
strong intellectual property protection in their domestic law. Article 27(3)(b) of 
the TRIPS agreement provides that member states may exclude essentially 
biological processes for the production of plants or animals other than non-
biological and variety protection, Article 27(3)(b) gives Member countries an 
option to protect plant varieties by patents or an effective sui-generis system or 
both, but TRIPS does not define term sui-generis Article 27(3)(b) expressly 
grants members significant discretion to choose the manner in which they will 
107. Phillip Cullet, Intellectual Property Protection and Sustainable Development, p. 267. (2005). 
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protect plant varieties and it contemplates that this discretion may be exercised 
differently by different states. The TRIPS agreement under Article 27(3)(b) not 
only protect the interest innovations but also rewarding conservation of plant 
varieties. A sui-generis protection system should not stop at protecting the 
interest of innovators but should also seek to provide a framework which 
specifically promotes food security. 
An effective sui-generis system within the meaning of TRIPS Article 27-
3(b) the law most apply to all varieties in all species and balance genera plant 
breeders should be granted an IPR an exclusive rights national treatment. 
National laws governing the protection in the European countries, there 
is a unified approach in Europe towards protecting plant varieties. Majority of 
the European Countries have entered into European patent convention for the 
issues of plant variety rights the objectives of the policy to frame laws was to 
recognize preserve and maintain the knowledge innovations and practices of 
small farmers and local communities embodying traditional lifestyles relevant 
for the conservation and sustainable use of plant agro biodiversity and to 
promote their wider application. 
African Model legislation for the protection of the Rights of local 
communities, farmers and breeder and for the regulation of Access to 
Biological resources (2002) can be consider an example of sui-generis model 
legislation. The model legislation recognizes protect and support the 
inalienable rights of farming communities and local communities over their 
knowledge and technologies. Breeder have also got their rights through for fair 
and equitable sharing of benefits and access to the traditional knowledge of 
communities has been placed in the legislation protection of plant varieties and 
farmer's rights Act, 2001 is the first legislation in the world to grant formal 
rights to the farmers. Indian sui-generis system for the protection of plant 
varieties recognizes the rights of farmers, breeder as well as researchers. 
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Protection of plant breeders' rights will stimulate investment for research and 
development. The grant of such protection will facilitate growth of seed 
industry, which will ensure the availability of high quality seeds and plant 
material to farmers. Also the strong farmers' rights keep the farming 
community alive and Act as an effective deterrent to the take over of the seed 
market by the corporate sector so Indian PPVFR Act, 2001 plays a crucial role 
in protecting the rights of the farmers and plant breeders. 
Newly enacted Forest Rights Act 2006 can also be consider welcoming 
step to protect the right of traditional forest dwellers and their traditional rights 
over the forest produce for their livelihood. 
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T.K. Under CBD and Biopiracy 
TRADITIONAL KNOWLEDGE UNDER CONVENTION ON 
BIOLOGICAL DIVERSITY AND BIOPIRACY 
Each time someone claims a bit of India as tiieir own - and in tiiese 
times of patent wars, we are fighting claims to about 40 products all over the 
world the - country goes into a tailspin. Anger, Confusion, Desperation and 
Determination to fight it out (one more time) do urgent rounds of government 
offices, agricultural bodies and NGO's. Perhaps rightly so, since Basmati, 
Neem and Haldi have never been too for from an Indian's life and the idea that 
someone east may acquire the right to own trade and market it is more than a 
bit jolting.' 
Warning the world against "Scientific and Technological Colonialism" 
India offered to help all developing countries in protecting their wealth of 
traditional knowledge with patents so that it is not exploited by the west for 
making money. 
Part -A. Traditional Knowledge under Convention on Biological Diversity 
To-date one of the most prominent provision on traditional knowledge is 
Article 8 (j) of the CBD which says -"respect, preserve and maintain 
knowledge, innovations and practices of indigenous and local communities 
embodying traditional lifestyles relevant for conservation and sustainable use 
of biological diversity and promote the wider application with the approval 
and involvement of the holders of such knowledge, innovations and practices 
and encourage the equitable sharing of the benefits arising from the utilization 
of such knowledge innovations and practices." 
This Article specifies traditional knowledge which is relevant for the 
preservation or conservation of biological diversity. This term biological 
1. Divya Bhargava, "Patent Act: Biopiracy of Traditional Indian Products: An Overview" available at 
www.countercurrent.org. 
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diversity refers to the variety within the living world. To protect the traditional 
knowledge it is worthwhile to have some quest to know about biological 
diversity. 
1. Meaning of Biodiversity 
The most striking feature of the earth is the existence of life, and the 
most striking feature of life is its diversity. Biodiversity refers to the variability 
amongst the species, population, communities and ecosystems, both wild and 
domestic, that constituent's life of an area or eventually of the entire planet. It 
occurs at three levels viz. (i) species level (ii) genetic level (iii) ecosystem 
level. Biodiversity has long been a source of scientific curiosity but now it is 
increasingly becoming a source of concern. Before the enactment of Biological 
Diversity Act, 2002, India had no specific biodiversity law to safeguard 
biodiversity as national property against unauthorized exploitation. Now the 
enacted law biodiversity says: 
'Biological Diversity' means the variability among living organisms 
from all sources and the ecological complexes of which they are part and 
include diversity with species or between species and of ecosystems. 
'Biological Resources' means plants, animals and micro-organisms or 
part thereof, their genetic material and by products (excluding value added 
products) with actual or potential use or value but does not include human 
genetic material.'' 
Diversity of species in natural habitats is high in warm areas and 
decreases with increasing latitude and altitude. Diversity is usually higher in 
rainfall zones than in drier areas. That is precisely the reason why tropical most 
2. The Biological Diversity Act, 2002 Sec. 2(b). 
3. Id. Sec. 2 (c). 
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forest contains half of the world's species though they occupy only seven 
percent of the land area. 
Biodiversity is not evenly distributed over different parts of the world. 
India ranks sixth among twelve mega biodiversity countries in the world. The 
total number of species in the world is estimated to be around 5 to 30 million 
out of which about 1.4 million species have been described. The total number 
of plant species in India is estimated to be about 45,000. 
Number of Living Species of Alt 
Organisms Currently Known 
Fungi 
69,000 
Algae 
26,900 
Mfrii«ra ~ 
(iMcteria Ir 
otker similar 
fofTn»j 
4,800 
u%i3joom 
Viruses 
1,000 
Protozoa 
30,800 
4.R.L.Java, "Biodiversity Conservation Stratigies For The 21st Century" in P C. Kotwal, Sujoy 
Benerjee; (edj Biodiversity Conservation in Managed and Forests Protected Areas, at p. 16 (2004). 
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Table. No.16: RECORDED No. OF SP.: INDIA AND WORLD 
(ESTIMATED NO. RANGES FROM 2-15 MILLION) 
GROUPS 
Mammals 
Birds 
Reptiles 
Amphibians 
Fishes 
Arthropoda 
Flowering 
Plants 
NO. OF SP. 
(INIDA) 
350 
1224 
408 
197 
2546 
68389 
15000 
NO. OF SP. 
(WORLD) 
4629 
9702 
6550 
4522 
27730 
987949 
250000 
% INDIA 
7.6 
12.6 
6.2 
4.4 
11.7 
6.90 
6.6 
Source: Paper presented at Symposium in Raipur on 8"^  November 2008 
Indian is having two biodiversity hot-spots namely the ' Western Ghats' 
and the 'Eastern Himalayas', which are included amongst the top eight most 
important hot-spots in the world, ten bio-geographic regions, two major realms 
called the Palaeoarctic and the Indo-Malayan; and three biomasses namely the 
tropical humid forests tropical dry/deciduous forests ad the warm deserts and 
semi-deserts. India has 850 species of bacteria, 14500 species of fungi, 6,500 
species of algae, 2000 species of lichens, 2,850 species of bryophytes, 1100 
species of pteridophytes. The endemism (endemic species are confined to a 
particular region or area) of Indian biodiversity is very high. About 33% of the 
country's recorded flora is North-East, Western Ghats, North-West, Himalaya 
and the Andaman - Nicobar Islands. As many as 167 species of crops 320 
species of wild crop relatives and several species of domesticated animals have 
originated here. The genetic diversity within these species is astounding. For 
example, there are 4000 varieties of Rice, hundreds of varieties of Mango, 27 
breeds of cattle and 18 breeds of paltry. The amazing biodiversity is not a freak 
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of nature, but a result of careful selection and even cross breeding over center 
by Indian's farmers and pastoralists.^ 
In crops diversity maintains soil fertility, optimizes soil management in 
rain feed belts acts as insurance against crop failure ensures food security, 
provides a variety of fodder and assures availability of seeds besides acting as a 
treasure chest of potentially valuable but as yet unknown resources. Thus plant 
genetic diversity, both at m^ra-species and /«?er-species levels is a crucially 
important part of farming systems and farming economy. 
NumbiT of Living SfMci«s of Hightr Plants 
Currtntly Known 
Bryopftyttt pcnif 
Wior " ' * " 10,000 
Groups \ 
1,300 ^ ^ I 
Gymnobpenni 
^ 529 
Higher Plants: Total Species, 2 ^ 0 0 0 
5. National Roving Seminar on Traditional Knowledge,13 -14 August 2008 at Dehradun,(Organized by 
Government of India and WIPO) 
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TABLE NO. 17: RECORDED PLANT SP.: INDIA AND WORLD 
TAXA 
Bacteria 
Viruses 
Algae 
Fungi 
Lichens 
Bryophytes 
Pteridophytes 
Gymnosperms 
Angiosperms 
INDIA 
850 
Unknown 
6,500 
14,500 
2,000 
2,850 
1,100 
64 
17,500 
WORLD 
4000 
4000 
40,000 
72,000 
14,000 
16,000 
13,000 
750 
250,000 
% OF INDIA 
21.25 
-
16.25 
20.14 
11.80 
17.80 
8.46 
8.53 
7.00 
Source: Paper presented at Symposium in Raipur on 8'^  November 2008 
(a) Levels of Biodiversity:' Biodiversity can be explored at three levels: 
(i) Genetic (ii) Species and (iii) Ecosystem 
(i) Genetic diversity refers to the diversity (a) between individuals within the 
populations (b) among populations within the species. Species is a 
classification as well as a biological unit with populations interbreeding or 
sharing a common lineage of descent. 
(ii) Species biodiversity is the variability among the different species 
inhabiting a community and it is at the hub of biodiversity. 
(iii) Ecosystem diversity refers to the range of ecosystem occurring in a 
biogeography region. 
The components of diversity can be characterized by distinguishing 
them and quantifying the local distribution of species, similarity among local 
6. R.K. Tondon, Prithipal Singh, Biodiversity, Taxonomy & Ecology, at p. 35 (2003). 
316 
T.K. Under CBD and Biopiracy 
assemblages and the rate of change in species composition with respect to 
ecological conditions. 
(a) Alpha diversity (a): diversity within communities is measured as the 
number of species occurring within an area of a given size and the 
distribution of individuals among the species. 
(b) Beta diversity (P): diversity between communities measures the turnover 
of species between different types of communities or habitats. 
(c) Gamma diversity (y): Total diversity of a region refers to an overall 
diversity within a large area and corresponds to the species richness at 
landscape level. It is the product of the alpha diversity of the communities 
of a landscape and the degree of beta differentiation among them. 
Hot Spots: Hot Spots are biologically rich areas with high diversity and 
a large percentage of endemic species. For example 20% of world plants are 
found on 5% of earth surface a leading environmental conservation 
organization has identified 24 places around the world calls biodiversity hot 
spots. 
Convention on Biological Diversity (CBD)'' defines 'biological 
diversity' as: Biological diversity means the variability among living organisms 
from all sources including inter-alia, terrestrial, marine and other aquatic 
ecosystems and the ecological complexes of which they are part, this include 
diversity within species between species and of ecosystems. 
2. Significance of Biodiversity 
Biodiversity is an extremely important part of life on Earth. It is only the 
variety of living organisms on our planet, but also the interdependence of all 
the living things including humans. It thus creates and maintains ecological 
systems. The most recognizable of which are earth's biomes, which can be 
7. Convention on Biological Diversity at Rio-de Janeiro, 5 June, 1992. 
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divided into the broad categories of forests, tundra, aquaticgrasslands and 
deserts life is infact one of the major features that distinguishes biomes from 
one another. 'Biomes' are defined as the world's major communities classified 
according to the predominant vegetation and characterized by adaptations of 
organisms to that particular environment. Without vegetation or organisms 
these landscapes would be virtually in-distinguishable from one another 
clearly, life plays a major role in the function of ecosystems and the variety or 
diversity, of this life has played a major role in the evolution of the world. ^  
Biodiversity is not only a mutual dependency of plants animals and 
humans but the balance of nature also depends upon it. Value of biodiversity is 
unmeasured but the benefits drawn by human being are-
By Direct use-
• Agriculture- New crops and varieties 
• Pharmaceuticals- About 20,000 plant and animal species are used for 
medicines. 
• Industry- Timber, beverage, spices and fruits etc. 
• Eco-tourism- is affected by the diversity of the species and the range of 
habitats that can be visited e.g. the number of flowering plants, big and 
small games. 
• By Indirect use-
• Ecosystem processes e.g. the loss to rangeland ecosystems in India due 
to removal of cheetah is not known. 
• Option- Willingness of the society to retain un-profitable range of 
habitats/genes/speci es. 
• Non use values:-
8. Trowbridge, Jennifer, "The Significance of Biodiversity: Why Should We Protect The Natural 
Environment" at http://www.semdip.brynmawr.edu/exchange/node/162. 
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• Existence- The value of satisfaction attained by the society by the fact 
that rhino, lion, wild ass, bustard, rauwolfia commifora etc exist. 
• Ethical- Moral and religious values attached to plants and animals. 
At present it is the direct use value of biodiversity which is highly 
valued by local people in developing countries because of the subsistence 
nature of economy. People living in abject poverty, destitution and miseries are 
neither bothered about sustainability nor option, existence or other values of 
biodiversity. International organizational and the developed world on the other 
hand are concerned about the option and existence values of the biological 
resources since their approach has shifted from Quantization Growth to 
Qualitative Development.' 
3. Convention on Biological Diversity 
CBD is the only international treaty that specifically recognizes the role 
of traditional knowledge, innovations & practices in biodiversity conservation 
and sustainable development as well as the need to guarantee their protection 
whether through IPR or other means. 
Convention on Biological Diversity ( hereinafter CBD), concluded on 5 
June 1992, it was the result of discussions at the Rio de Jenerio 1992 United 
Nations Conference on Environment and Development (the Earth Summit) 
towards a strategy for sustainable development following negotiation that had 
commenced in November 1990 under the United Nations Environment 
Programme (UNEP)."' 
The CBD administered by UNEP, establishes principals for the 
protection of the environment while ensuring on going economic development, 
9. P.C Kotwal Sujoy Banerjee, Biodiversity Conservation in Managed Forests and Protected Areas at 
p. 18(2004), 
10. A Brief Introduction to the Convention on Biological Diversity' available at 
www.iisd.ca/biodiv/cbdintro.html. 
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emphasizing conservation of biodiversity, sustainable use and fair and 
equitable benefits sharing of the use of genetic resources. The CBD is a also a 
significant intemafional instrument in the development of rights for indigenous 
and tradifional resources and aims to provide for the equitable sharing of the 
benefits denied from them thereby re-invigorating, national sovereignties with 
respect to biological and intellectual resources. The importance of CBD is that 
of a tool for indigenous and local communities to the conservation of 
biodiversity. 
"CBD discuss the traditional knowledge - "respect, preserve and 
maintain knowledge, innovations and practices of indigenous and local 
communities embodying traditional lifestyles relevant for conservation and 
sustainable use of biological diversity and promote the wider application with 
the approval and involvement of the holders of such knowledge, innovations 
and practices and encourage the equitable sharing of the benefits arising from 
the utilization of such knowledge innovations and practices. " 
CBD is an important re-assertion of the sovereign rights of the states 
over their biological resources. Article 8(j), seems to affirm that the holders 
have rights over their knowledge, innovation and practices whether or not they 
are capable of being protected by IPR. If they are not capable of being 
protected by existing IPR system, still there is an obligation for the government 
to safeguard these entitlements either through a new IPR law or by over legal 
or policy measures. These duties should also extend to use of traditional 
knowledge. 
The CBD also recognizes the importance of traditional use of genetic 
resources in the sustainable preservation of biological diversity. CBD obliges 
each contracting party as per as possible and appropriate to protect and 
encourage customary use of biological resources in accordance with traditional 
11. CBD Article 8(j) 
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cultural practices that are compatible with the conservation or sustainable use 
requirement.'^ 
The CBD established access to the biological resources of developing 
countries on a quid pro quo basis with technology transfer from the 
industrialized countries and asserts that IPRs must not conflict with the 
preservation and sustainable use of biodiversity.'^ Similarly exchange of 
information, Technical and scientific cooperation include the encouragement 
and development of exchange and use of indigenous and traditional knowledge 
and technology is the spirit of CBD.''' 
The CBD was entered into some months before TRIPS and its 
relationship to TRIPS is some what inconsistent. TRIPS recognizes and 
promulgates private monopoly rights particularly with respect to patents 
conversely, the CBD is more concerned with the community control of genetic 
resources. 
The CBD reasserts national sovereignty in contrast to the emphasis on 
international global trade that is encouraged by TRIPS. The economic 
globalization of intellectual property rights advocated in TRIPS is seen as a 
threat to the cultural and social welfare of indigenous and traditional group. 
Numerous critics argue that the spread of western capitalist culture has led to 
the simultaneous erosion of both biological and cultural diversity. The CBD 
has been criticized for its emphasis on state sovereignty an emphasis which 
12. CBD Article 10(c) 
13 .Id.. 16.5 
14. Id, Article 17(2) and Article 18(4) 
Article 17(2) such exchange of information shall include exchange of results of technical, scientific 
and socio-economic research as well as information on training and surveying programmes 
specialized knowledge, indigenous and traditional knowledge as such and in combination with the 
technologies referred to in Article 16 paragraph 1 it shall also where feasible include repatriation of 
information. 
Article 18(4). The contracting parties shall, in accordance with national legislations and policies, 
encourage and develop methods of cooperation for the development and use of technologies, 
including indigenous and traditional technologies, in pursuers of the objections of this convention. 
For this purpose, the contracting parties shall also promote cooperation in the training of personnel 
and exchange of experts. 
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risks generalizing cultural interest «fe ultimately undermining the biodiversity 
that is enriched and protected through the preservation of cultural diversity and 
indigenous and traditional culture. 
By utilizing biological resources and traditional knowledge new 
products can be produced which can claim protection under the TRIPS regime. 
The TRIPS agreement neither directly involves in the protection of traditional 
knowledge nor concerns the protection of biological diversity. The CBD on the 
other hand attempts to protect and preserve biological diversity and traditional 
knowledge. New inventions and products or the usage of traditional knowledge 
and the biological resources can be protected under the TRIPS regime but the 
same shall be beyond the private monopoly and forms common property under 
the CBD regime.'^ TRIPS and the CBD both emphasize on the protection of 
biotechnology industry, this agenda is explicit in the TRIPS agreement through 
an obligation upon assignations to pass intellectual property legislation over 
life forms. The CBD too emphasizes intellectual property laws within which 
protection of traditional knowledge conforms, or at least, remains subject to but 
it does explicitly acknowledge indigenous communities. 
The provisions of the CBD and in particular Article 8(j) have been 
criticized as idealizing traditional lifestyles and romanticizing or essential sing 
indigenous peoples. Article 8(j) has also been subjected to considerable 
criticism by indigenous peoples. It has been noted for example that the phrase 
embodying traditional lifestyles suggest that this provision applies only to 
indigenous people who are isolated fossilized is some cultural time warp living 
in a never changing present and excludes peoples who continuing colonial 
situation in which find. 
Despite its criticism the CBD presents an important resource for 
indigenous rights in traditional knowledge beyond the laws. The CBD 
15. C.B Raju and N.S Sreenivasulu, "Intellectual Property Rights & Traditional knowledge: The Thin 
Line between Bioprospecting and Biopiracy" MIPR Vol-2 p- A-6 2008 
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articulates a system of conservation of Biological diversity as a universal 
cultural heritage through an explicit acknowledgement of customary and 
indigenous knowledge and technologies. 
(a) Salient Features of the Convention on Biological Diversity 
Objectives: 
The conservation of biological diversity, the sustainable use of its 
components and the fair and equitable sharing of benefits arising out of the 
utilization of genetic resources including appropriate access to genetic 
resources, appropriate transfer of relevant technologies taking into account all 
rights over those resources and to technologies and appropriate funding. 
Recognition of the intrinsic value of biological diversity and the need 
for its conservation in natural habitats, that these genetic resources will be 
available through generations, that nations have sovereign rights over their 
genetic resources, that conservation efforts need to be compensated, and 
that communities share the benefits that accrue from the use of these 
resources. 
Countries have the sovereign rights to exploit their own resources while 
pursuing their own environmental policies. They also have the responsibility to 
ensure that the activities within their jurisdiction do not cause damage to the 
environment of other countries or of areas beyond the limits of national 
jurisdiction.'^ 
Conservation and Sustainable use: Countries, in accordance with 
their capabilities, shall develop national programmes for the conservation and 
sustainable use of biological diversity, or adapt existing plans or programmes 
for this purpose, and integrate the conservation and sustainable use of 
16 Convention on Biological Diversity Article 3. 
323 
T.K. Under CBD and Biopiracy 
biodiversity into relevant sectoral or cross sectoral plans, programmes and 
policies 17 
Identification and Monitoring: Countries shall identify important 
components of biodiversity and monitor them through sampling and other 
techniques, with particular attention to those which require urgent 
conservation measures identify activities likely to have significant adverse 
impact on conservation and sustainable use of biological diversity and monitor 
their effects, and maintain and organize data derived from activities 
undertaken following the above. 
In-situ Conservation: Measures to promote the conservation of 
biological diversity outside their natural habitat, require countries to 
establish a system of protected areas, and develop guidelines for their 
management establish means to regulate, manage or control risks associated 
with the use and release of biotechnology which are likely to have adverse 
environmental effects, also taking into account risks to human health subject to 
national legislation, preserve and maintain knowledge and practices of 
indigenous and local communities. The application of such knowledge and 
innovations must also be promoted and the equitable sharing of benefits arising 
from the utilization of such knowledge, innovations of practices must In 
encouraged and cooperate in providing financial and other support, 
particularly to developing countries.'^ 
Ex-situ Conservation: To promote the conservation and maintenance 
of ecosystems and the recovery of viable population of species in their natural 
surroundings, countries shall establish and maintain facilities for ex-situ 
conservation and research, preferably in the country of origin of genetic 
I7,W„ ArticJe6. 
18. M, Article?. 
19. W., Articles. 
324 
T.K. Under CBD and Biopiracy 
resource and cooperate in providing financial and other support for 
• • 20 
maintenance of ex-situ conservation facilities in developing countries. 
Sustainable use: Countries shall integrate conservation and 
sustainable use of biological resource into national decision- making, and 
adopt measures to avoid or minimize adverse impacts on biodiversity 
encourage customary use of bioresearches in accordance with traditional culture 
practices, and encourage cooperation between government authorities and 
private sector in developing methods for sustainable use of resources.^' 
Access to genetic resources: National governments and national 
legislation have the authority to determine access to genetic resources, each 
country must endeavor to create condition facilitate access to genetic resources 
for environmentally sound uses to other countries and not impose restrictions 
that run counter to the objectives of the convention. 
This article recognizes the sovereign rights of countries over the natural 
resources and gives the authority to determine access of genetic resources to 
the respective national government. This access is subject to national 
legislation, prior consent and should be encouraged for environmentally sound 
uses. The scientific research coming out on these genetic resources will be 
with the participation of the nation that has provided these resources. Benefits 
accruing out of these resources are to be shared with the contracting party 
that supplied these resources. 
Access to and transfer of technology: This article recognizes that 
technology includes biotechnology and that achieve the provisions of the 
convention, it is important that technology be transferred on favorable terms 
to the countries that provide the genetic resources. However, the 
Convention states that in areas where the technology pertains to intellectual 
20. Id. Article 9. 
21./c/., Article 10 
22. W., Article 15. 
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property rights and patents, the terms should be in Hne with intellectual 
property rights protection. National laws or policies should be in place so that 
the private sector also facilitates exchange of information and technology. 
Handling of biotechnology and distribution of its benefits: Each 
contracting country has to take measures to ensure that biotechnological 
research based on genetic resources is with the participation of the country 
that has provided the genetic resources and the results and the benefits are 
shared. Countries also have to consider the need for and the modalities of a 
bio-safety protocol which include prior informed agreements relating to safe 
handling and use of genetically modified organisms.^'' 
Financial resources: This article states that based on its capability, 
each country will provide financial support to national activities engaged in 
meeting the objectives of the convention. The developed countries will need 
to pay the incremental costs incurred by developing countries in conserving 
biodiversity and provide financial assistance to developing countries in their 
attempts to meet the convention objectives. 
Financial mechanism: This article states that the mechanism for 
providing financial resources will function under the authority of and be 
accountable to the Conference of Parties (CoP). 
Dispute settlement: In the event of any dispute, the countries 
involved will first attempt to seek solutions through negotiations. Only when 
negotiations fail will they seek the mediation of third party. In the case that both 
the options do not work, it becomes mandatory for the countries to either 
submit the case to the International Court of Justice, or to an arbitration 
23./(/., Article 16. 
24. M, Article 19. 
25. Id., Article 20. 
26. W., Article 21. 
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tribunal. The tribunal will consist of three members, two of which will be 
appointed by the disputing parties.^^ 
Voting rights: While contracting parties are entitled to one vote, 
regional economic organizations can also exercise their right to vote, with the 
number of votes equaling the number of their member countries. 
Relation between CBD and its protocols: A country may become party 
to a CBD protocol only if it is party to the convention. Decisions under any 
protocol shall only be taken by those countries that arc party to the protocol 
concerned.^' 
Financial interim arrangement: The Global Environment Facility 
shall be the institutional structure on an interim basis, for the period between 
the conservations entry into force and the first CoP or until CoP designates 
the institutional structure.^^ 
4. The Biological Diversity Act, 2002 
The CBD states that a member country should be a party on mutually 
agreed terms for the access to genetic resources, but that access requires the 
prior informed consent of the country providing the resource. It also provides 
for an equitable sharing of any benefits arising from the commercial use of 
these resources a traditional knowledge about them. But countries must pass 
domestic legislation to bring these principles into their own laws. India's 
parliament passed the Biodiversity Act in December 2002 to address many of 
India's obligations under CBD. 
The Biodiversity Act 2002 primarily addresses access to genetic 
resources and associated knowledge by foreign individual's institutions or 
27. Id., Article 27. 
28. M, Article 31. 
29. Id, Article 32. 
30. Id, Article 39. 
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compares, to ensure equitable sharing of benefits arising out of the use of these 
resources and Icnowledge to the country and the people. 
The Primary Objectives of the Biological Diversity Act, 2002 are 
• Conservation of Biological Diversity 
• Sustainable use of the components of biodiversity 
• Fair and equitable sharing of benefits arising out of the utilization 
genetic resources and bio-resources. 
The BD Act-2002 covers all biological resources occurring and 
naturalized in India. Besides affirming that biological resources are sovereign 
property of the State, the Act also encompasses all indigenous and traditional 
knowledge associated with the biological resources as these forms are 
intangible component of biological resources, which is the major source of 
piracy by the hio-pirators. Basically the Act promotes conservation and 
National Biodiversity. Authority is empowered to check bio-piracy and to 
regulate transfer the result of any research. The Act provides, "No person shall 
without previous approval of the NBA transfer the results of any research 
relating to any biological resources occurring or obtained from India for 
monetary consideration or otherwise to any person who is not a citizen of India 
or body corporate or organization which is not registered or incorporated in 
India or which has any non Indian participation in its share capital or 
management^'." 
The publication of research paper, research project may involve 
biological resources or information or knowledge publication has not been 
declared transfer under Sec.4. The guidelines framed by the Central 
Government Shield ensure that in guise of publication of research paper, 
traditional knowledge should not go out of country. 
31. The Biological Diversity Act, 2002 Sec. 4 
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Section further of the Act provides, "No person shall apply for any 
intellectual property right by whatever name called in or outside India for any 
invention based on any research or information on biological resources 
obtained from India without previous approval of National Biodiversity 
Authority." While granting approval NBA will impose terms and conditions 
which secure equitable sharing of benefits. The NBA has been given power to 
oppose the grant of intellectual property right in any country outside India on 
any biological resource obtained from India or knowledge associated with such 
biological resources derived from India. 
Along with NBA there is also constitution of State Biodiversity Board 
(SBB) to promote and protect biodiversity. No Indian citizen or person or body 
corporate is allowed to obtain biological resource for commercial utilization 
without obtaining prior approval of SBB. Although it recognizes traditional 
knowledge of the local people and communities including Vaids and Hakims 
but they are kept out of intimation restriction. There is also a provision of post 
intimation strategy. SBB can also restrict and prohibit if it consider any activity 
detrimental or contrary to the objectives of conservation and sustainable use of 
biodiversity and sharing benefits 
Salient Features of the Biological Diversity Act -2002 
• To regulate access to biological resources of the country equitable share in 
benefits arising out of the use of biological resources. 
• To conserve and sustainable use of biological diversity. 
• Setting up of National Biodiversity Authority (NBA), State Biodiversity 
Board (SBB) and Biodiversity Management Committee's (BMCs). 
• NBA and SBB are required to consult BMCs in decisions relating to bio-
resource/related knowledge within their Jurisdiction. 
32 . Id, Sec. 6. 
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• To respect and protect knowledge of local communities traditional 
knowledge related to biodiversity. 
• To secure sharing of benefits with local people as conservers of biological 
resources and holders of knowledge and information relating to the use of 
biological resources. 
• All foreign nationals/organizations require prior approval of NBA for 
obtaining biological resources and/or associated knowledge for use. 
• Indian scientists/individuals require approval of NBA for transferring 
results of research to foreign nationals/organization. 
• Conservation and development of areas of importance from the standpoint 
of biological diversity by declaring them as biological diversity heritage 
sites. 
• Protection and rehabilitation of threatened species. 
• Involvement of institutions of state Government in the broad scheme of the 
implementation of the Biological Diversity Act through constitution of 
committees. 
• Protect India's rich biodiversity and associated knowledge against their use 
by foreign individuals and organizations without sharing benefits arising 
out of such use and check Bio-piracy. 
• Indian Industry needs prior intimation to SBB to obtain bio-resource. SBB 
has right to restrict if found to violate conservation and sustainable use and 
benefit sharing. 
• Provisions for notifying heritage sites by State Government in consultation 
with local body. 
• Creation of National, State and Local Biodiversity fund and its use for 
conservation of biodiversity. Sec. 43. 
• Prior approval is needed from NBA for IPRs in any invention in India or 
outside Indian on Bio-resource. 
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Part -B. Biopiracy 
5. Meaning of Biopiracy 
Bio-piracy is the false claim to invention by corporations & scientists 
and is nothing short of institutionalized theft by the rich. The right of 
indigenous cultures to these resources and knowledge is replaced by monopoly 
of rights in favour of those who have exploited indigenous knowledge and 
biodiversity. 
Bio-piracy is term for the appropriation, generally by means of patents, 
of legal rights over indigenous knowledge particularly indigenous biomedical 
knowledge without compensation to the indigenous groups who originally 
developed such knowledge. A classic case is that of Rosy Periwinkle 
(Madagascar Periwinkle). Research into the plant was prompted by the plants 
traditional medicinal role and resulted in the discovery of a large number of 
biologically active chemicals, including vincrinstine, a lucrative agent useful 
during leukemia chemotherapy. A method for purifying incrusting was initially 
patented and marketed by Eli Lilly. It is widely reported that the country of 
origin did not receive any payment." 
Bio-piracy means "taking biological resource from one country or 
region to another and using it in the latter's industry agriculture and other 
commercial process."''' In the early decades of the present century taking away 
bio-resources from one country to another was not considered illegal and 
therefore the concept of bio-piracy was non existent. With the growth of 
knowledge in the field of biological conservation, especially is terms of in situ 
and ex-situ conservation, bio-piracy received international recognition. 
Countries have now started recognizing their intellectual rights over the 
biological material within their boundaries. 
33. "Meaning of Biopiracy" available at www.wikipedia.org/wiki/biopiracy. 
34. Mohammad Asif, "Intellectual Prophecy Right and Bio-piracy: their Implications for Tribal 
Medicinal Traditions" 48 Social Action 374-391 (1998). 
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Bio-piracy refers to the use of intellectual property system to legitimize 
the exclusive ownership and control over biological resources and biological 
products and processes that have been used over centuries in non industrialized 
culture. When individuals or corporations receive freely traditional knowledge 
from indigenous people and convert it in to private property through 
intellectual property rights, then this exchange of knowledge amounts to 
bio-piracy. 
The word 'Bio-piracy' is a compound word consisting of 'Bio' which is 
short for 'biological' and 'piracy'. According to Concise Oxford Dictionary^^ 
'piracy' means the following: 
1. The practice or an act of robbery of ships at sea. 
2. A similar practice or act in other forms, esp. Hijacking 
3. The infringement of copyright. 
Apart from the use of piracy for rhetorical effect the word does not seem 
to be applicable to the kinds of act referred to as bio-piracy. But on the other 
hand the verb 'to pirate' have two definitions-
1. To appropriate or reproduce (the work or ideas etc of another), without 
permission for one's own benefit. 
2. To plunder 
These definitions seem to be more appropriate since inherent without the 
bio-piracy rhetoric are the notions of unauthorized appropriation and theft. In 
essence, bio-pirates are those individuals and companies accused of one or both 
of the following arts (i) the theft misappropriation of or unfair free riding on 
genetic resources and or traditional knowledge through the patent system, and 
35. Oxford Dictionary on the web. 
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(ii) the unauthorized and uncompensated collection for commercial ends of 
genetic resources or traditional knowledge. 
(a) Bio-piracy and Bio-prospecting 
Bio-piracy or Bio-prospecting refers to unauthorized use of-
(a) Biological resources such as plants, animals and micro organisms 
(b) Traditional communities' knowledge on biological resource. 
Bio-piracy also denotes unequal shares of benefits between a patent 
holder and the indigenous community whose knowledge or resource has been 
used. This clearly shows that the person who commits bio piracy enjoys the 
maximum benefit at the cost of the indigenous people's knowledge, as these 
people are unaware of the importance of their traditional knowledge. It also 
indicates misappropriation and monopolization of traditional population's 
knowledge and biological resources unlawfully.^ ^ 
Meaning thereby bio-piracy can be defined as stealing the knowledge 
from traditional and indigenous communities or individuals. The term can also 
be used to suggest a breach of a contractual agreement on the access and use of 
traditional knowledge to the detriment of the provider and bio-prospecting 
without the consent of the local communities. 
The action group on Erosion Technology and Concentration (ETC) 
Group, Canada (Former RAFI) defines it as the appropriation of the knowledge 
and genetic resources of farming and indigenous communities by individuals 
and institutions seeking exclusive monopoly control (usually patents on plant 
breeder's rights) over these resources and knowledge. 'Bio-prospecting' 
36. An International Export Workshop on Access to Genetic Resources & Benefit Sharing. Available 
at www.google.com 
37. C.B. Raju, N.S, Sreenivasuiu, "IPR & T.K. The Thin Line Between Bio-prospecting and Bio-
piracy" MIPR vol 2 p. A-4 (2008). 
38. National Roving Seminar 0 Traditional Knowledge 13-14 August 2008 Dehradun 
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refers to the use of traditional or indigenous traditional knowledge with the 
prior advanced consent of the community of the people who had preserved it 
and it also concerns sharing the benefits equally with the community.^^ 
Biodiversity prospecting is the exploration extraction and screening of 
biological diversity and indigenous knowledge, for commercially valuable 
genetic and biochemical resources. While it is true that biodiversity prospecting 
does not always involve the use of indigenous knowledge it is clear that 
valuable chemical compounds derived from plants, animals and micro-
organisms are more easily identified and are of greatest commercial value 
when collected with indigenous knowledge and or ground in territories 
traditionally inhabited by indigenous people. 
The newly released discussion document, 'Bio-prospecting: Harnessing 
Benefits for New Zealand' has the following working definition for Bio-
prospecting. 
Bio-prospecting is the collection of biological material and the analysis of 
its material properties, or it molecular biochemical or genetic content for the 
purpose of developing a commercial product. Bio-prospecting policy excludes 
the later steps in the chain of product development.''" 
According to legislative reference Bureau Report Bio-prospecting is the 
removal or use of biological and genetic resources of any organism, mineral or 
other organic substance for scientific research of any organism, mineral or 
other organic substance for scientific research or commercial development. 
When bio-prospecting is pursued without the knowledge and free prior consent 
of the owners of the resources and without benefits shaving it is called bio-
41 
piracy. 
39. Supra Note 37 
40. Sudhir D. Ghatnekar, Bio-prospecting or Bio-piracy, at http://www.expressindia.can/news/fe/daily. 
41. "Bio-prospecting" at http-.//www.oha.org/pdiybio-prospecting/20071130/defmition.doc. 
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According to the Asean Framework agreement on Access to Biological 
and Genetic Resources, 2000 "Bio-prospecting: the search for wild species 
with genes that produce better crops and medicines, or the exploration of 
biodiversity for commercially valuable genetic and biological resources."''^ 
Before 1992 biological resources, were considered common heritage of 
humankind. Scientists could take samples from anywhere in the world without 
any specific permission. The Convention on Biological Diversity (CBD) 
establishes sovereign national rights over biological resources. 
There is a distinct difference between bio-piracy and bio-prospecting. The 
term 'bio-piracy' describes the unauthorized and uncompensated taking and 
use of biological resources. In contrast 'bio-prospecting' refers to the search for 
valuable active chemical compounds in nature, and involves accessing national 
resources through legal means, securing prior informed consent from the 
custodians of the relevant natural resources and promoting equitable benefit 
sharing agreements with appropriate parties. Bio-piracy deprives not only the 
custodians of biological resources but also the country concerned.''^ 
The modus operandi of the MNCs had been to collect the plant varieties 
and their germplasms from poor countries in order to cross breed them with 
other varieties and claim that they had invented something novel, non-obvious 
and of practical use which are the requirements for acquiring patent rights and 
then to patent them in their own country or any other country of their choice. 
Thus even though India is rich in biodiversity and has a rich biodiversity 
related intellectual heritage, bio-piracy directs this wealth away from India and 
drives us our right to use resources and knowledge, for our needs and our 
economic benefits. 
42. Ibid 
43.5MpraNote38 
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6. Bio-piracy of Traditional Medicinal Knowledge 
Nearly all cultures, from ancient times, have used plants as a source of 
medicine. In many developing countries traditional medicine is still the 
mainstay of healthcare and most of the drugs and cures used come from plants. 
In developed countries too people are turning to herbal remedies. Besides, 
modem scientific medicine still depends on plants and the knowledge gained 
from them, for some essential drugs. People in India and China are known to 
have used plants for healthcare for over 5000 years. 
India is one of the world's 12 regions having the largest biodiversity. It 
has 16 agro climatic zones and 45,000 plant species, of which 15,000-20,000 
possess proven medicinal value. According to the World Health organization 
(WHO) more than one billion people rely on herbal medicine to some extent. 
The WHO has listed 21,000 plants worldwide, reported to have medicinal uses. 
It also has a rich medicinal plant flora of some 2,500 species of which at least 
150 are used commercially for pharmaceutical purposes on a fairly large scale. 
There are four well recognized systems of traditional medicine namely. 
Ayurveda, Unani, Siddha, Yoga & Naturopathy and practices based on theories 
beliefs and experiences indigenous to different cultures and used in the 
maintenance of health as well as in the prevention, diagnosis and treatment of 
physical & mental illness. Traditional medicines have a long history and have 
been field tested for centuries by thousands of people, resulting in the 
accumulation of much empirical knowledge in the communities, passed on by 
generations of healers. Traditional medicine is perceived as efficient safe and 
cost effective. Moreover it is accessible to the poor and those living in remote 
44 
areas. 
Indian system of Medicine uses around 25,000 plant species belonging to 
more than 1000 genera. About 800 species are used by industry of which 
44. P.C Trivedi (ed.), Medicinal Plants: Traditional Knowledg, p. 120 (2007). 
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approximately 25% are cultivated. Despite convincing progress in synthetic 
chemistry and biotechnology, plants are the most important sources for 
preventive & creative medical preparations. WHO has estimated that at least 
80% of all the global inhabitants rely on curative medical system of medicine 
for their primary health needs and thus systems are largely plant based. 
Medicinal plant species are still to large extent gathered & collected from 
the wild and relatively few genera are cultivated on commercial scale. Along 
with increasing urbanization, exploitation & bio-piracy led to a steady erosion 
and loss of diversity from the natural habitats of these plants. 
With the advent of Portuguese,, British and French colonists in the Indian 
subcontinent a few hundred years ago, the traditional practices regarded as 
backward practices and created a stigma, which led to the abandoning of these 
ecologically sound practice in favour of modem chemical products imported 
from the west. But now when these developed countries took these natural 
resources in their laboratories & found the medicinal qualities of these 
resources they tried to get patent over these natural products. Being the long 
back practice of these products in India for medicinal and other purposes, India 
has an ultimate right over them. 
When individuals or corporations receive freely traditional knowledge 
from indigenous people and convert this into private property through 
intellectual property right, their exchange of knowledge amounts to bio-piracy. 
Bio-piracy leads to drain of wealth and denies us the right to use our own 
biological resources for our economic benefit. 
Bio-piracy allegedly contributes to inequality between developing 
countries rich in biodiversity, and developed countries served by 
pharmaceutical industry exploiting these resources the manipulation of living 
materials to create new types of medicines and agricultural products is 
45. Ibid, 
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currently worth $ 2 billion a year in the United States. Estimates who that 
biotech profits will soar to $ 50 billion by the year 2000. Most of the raw 
material for this blooming industry comes form the world's dwindling 
rainforests of the southern hemisphere.''^ 
Biotechnology and new patent laws have allowed companies to capitalize 
on even the smallest life forms. The forms the E Merck pharmaceutical 
company has patented microbial samples from nine countries. These include 
soil bacteria from a heather forest on Mt-Kilimanjaro, a Mexican soil fungus 
useful in manufacturing of male hormones, a fungus found in Namibian soil of 
potential use in treating manic depression, soil bacteria in India that serves as 
an antifungal agent and a Venezuelan soil bacteria patented for use in the 
production of antibiotics. The bio-pirates are also on the lookout for profitable, 
patentable plants. In one remarkable example, several North American 
companies including WR Grace have been granted more than 30 US patents on 
the neem tree of India and not only on the tree but also on the indigenous 
knowledge about its many uses."*^  
In another act of bio-piracy, two drugs derived from the say periwinkle-
vincristine and vinblastine earn $100 million annually for pharmaceutical giant 
Elitilly. The plant is indigenous to the rainforest of Madagascar, but the country 
has received nothing in return. 
Intellectual property protection is dividing to tribal communities for their 
medicinal knowledge because the existing intellectual property paradigm 
assumes that such knowledge belongs to an anonymous individual. He or she 
had acquired this knowledge by his own merit or efforts and the community 
has no locus standi in this contexts. As a resuh the paradigm considers such 
knowledge to be located in the public domain. However available data from 
some tribal communities illustrate that this contention is erroneous and 
46. Sudhir D. Ghatnekar "bioprospecting and biopiracy" available at http://www.expressindia.com. 
47. Ibid. 
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simplistic. Tribal medicine is not just an aggregate of the efforts of certain 
individuals like allopathic medicine, homeopathic medicine and other medical 
care models, it is a system too. 
7. Concept of Benefit Sharing and Prior Informed Consents 
(a) Access and Benefit Sharing 
The question of access to genetic resources and to traditional knowledge 
concerns the conditions under which potential user can obtain the resources or 
knowledge they need. Access is linked to benefit sharing insofar as establishing 
the knowledge or resources used in a product or process protected by 
intellectual property rights is a precondition for assessing who are the 
calamities of the benefit sharing. 
Benefit Sharing involves a balance between access to genetic resources 
and fare and equitable sharing of benefits of their use through wide variety of 
monetary and non-monetary mechanisms ranging from profit sharing all 
equitable stakes in the bio-prospecting business and also technology transfer 
and collaborative research. It has been a recurrent theme in international 
debates for the post two decades. In the legal field, benefit sharing is a 
technical tern used in the context of access to and use of human and non human 
genetic resources. Nonhuman genetic resources includes, plants, animals and 
micro organisms the term describes an exchange between those who grant 
access to a particular resource and those who provide compensation or reward 
for its use. 
The justification for benefit sharing in the context of non-human genetic 
resources can be taken straight from the CBD.''^ The CBD identified the 
conservation of biological diversity as a common concern of mankind (Article 
15(1) the CBD indicates that compensation is due for the use of genetic 
48. Convention on Biological Diversity, Rio de Janerio, 5 June, 1992, 
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resources.'*' World leaders meeting at the 2002 World Summit on Sustainable 
Development in Johannesburg^'' South Africa agreed that the distraction of 
biological diversity would continue unabated unless the custodians of this 
natural wealth benefit from this conservation. Compensation is therefore due 
for any use of resources or knowledge whether for research commercial or 
other purposes. 
Context of CBD and PGRFA, Treaty the sharing of benefits, is to be fair 
and equitable. Benefit sharing has after been conceived as a form of financial 
compensation. This monetary benefit can take the form of access fees, royalty 
payment, license fees or contributions to be paid to special financial 
mechanisms setup for this purpose. 
Without fair benefit sharing, the conservation and sustainable use of 
non-human genetic resources will continues to be at risk. Thus it can be said 
that benefit sharing is the action of giving a portion of advantage profit derived 
from its use of non human genetic resources or T.K. to resources provider, in 
order to achieve justice in exchange. Therefore if one uses resources one does 
not own then justice demands some form of compensation in exchange access 
and benefit sharing stake holders. 
Access and Benefit Sharing (ABS) has emerged as the most complex 
issues where the UN-CBD and WTO came on a direct confrontation. Both TRIPS 
Council of WTO and the Conference of Parties (COP) to CBD have been 
considering ironing out these contradictions. CBD began to address the ABS 
issues and their implementafions since the Fourth Meeting of the COP held in 
Brafislva in 1988, which finally led to the development of'Bonn Guidelines'^' 
in October 2001. The Bonn guidelines provide the parties stakeholders with a 
framework to facilitate access to genetic resources and ensure fair and equitable 
49. Id., Article 1 
50. Available at http//www.un.org/events/wsscl/summary/envderjt.html. 
51. See BONN Guidelines, available at http://www.cbd.int/ABS/BONN.SHTML visited on 28.07.2009 
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sharing of benefits through standard practices and procedures of Prior Informed 
Consent (PIC), Mutually Agreed Terms (MAT) and other relevant agreements. 
The Guidelines provide details of an overall strategy and essential steps, elements 
and principles to be adopted in developing ABS regime by parties and 
stakeholders. 
"Benefit-sharing is an important component in any ABS or technology 
transfer contracts involving genetic resources and associated TK. MAT in 
accordance with Article 15.7 of UN-CBD should pay adequate attention to 
reaching an agreement on fair and equitable sharing from the commercial or 
other utilization of the resources ire the TK accessed. The benefit-sharing 
mechanisms and formula may significantly vary depending upon for the purpose 
for which the genetic resources and TK are accessed. The monetary benefits 
(e.g. license fees, royalties) need to be fixed depending upon the actual capital 
inputs including human resources inputs and intellectual inputs provided by the 
participating countries in any joint prospecting bio-partnership programmes. 
Although the Bonn guidelines provide a conceptual as well as practical 
framework for ABS, a coherent framework for benefit arising from sustainable 
use of genetic resources, and traditional knowledge is almost impractical. 
Therefore there is a need for the Like-Minded Megadiverse Countries (LMMC) 
and other regional groups of biodiversity rich countries to strengthen 
collaborative partnership among their members to build up capacity building in 
all relevant areas of biodiversity, biotechnology, intellectual property, 
information management, etc. Such regional cooperation would be helpful to 
develop national legal and policy frameworks on ABS and to harmonize the 
various statutory mechanisms through conscientious discussions, besides 
developing a joint strategic action plan to deal with all ABS and related issues at 
international forums. 
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India has the distinction of being the first in the world in experimenting a 
benefit-sharing model that implemented Article 8 (j) of CBD, in letter and 
spirit. It was the Tropical Botanic Garden and Research Institute (TBGRI), 
Kerala that demonstrated indigenous knowledge system merits support, 
recognition and fair and adequate compensation. 
In this case, the bio-prospectors were a team of biologists farm Tropical 
Botanic Gander and Research Institute (TBGRI) on an Ethrobatanical research 
expedition. They were not looking for Arogyappacha plant directly but were 
intrigued by the fact that the kani guides they had hired were not feeling 
fatigued at all. They eventually persuaded some of the local kani people to 
share their knowledge with them. This was a clear case of transfer of traditional 
knowledge to outsiders who know neither about the plant nor its properties this 
led to the development to drug with ant fatigue properties, called Jcevari. 
TBGRI decided to give 50 percent of the fee and royalty to kani people. 
The TBGRI model got wide acclaim, acceptance and popularity the 
world over, because it was the first of its kind that recognized the resources 
rights and IPR of a traditional community by way of sharing equitably the 
benefits derived out of the use of a knowledge that has been developed, 
preserved and maintained by the community for many generations. 
Such models need to be emulated in similar situation in India and 
elsewhere in the world. 
(b) Prior Informed Consent 
Biological diversity is essential for our planet, human well-being and to 
the livelihood and cultural integrity of people. Its gradual loss, as a result of a 
number of factors, represents a silent emergency that threatens to undermine 
efforts to eradicate poverty and achieve sustainable development throughout the 
world. 
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The 1992 Convention on Biological Diversity provides a 
comprehensive framework for stopping that loss. It is a carefully balanced, 
legally binding international treaty that commits its Parties to the triple 
objective of conserving biological diversity, using natural resources 
sustainable, and fairly and equitably sharing benefits deriving from the use of 
genetic resources. 
The Convention addresses the terms and conditions for access to 
genetic resources and benefit-sharing^^. It recognizes the sovereignty of 
states over their natural resources and provides that access to these resources 
shall be subject to the PIC of the contracting party providing such resources. It 
also provides that access shall be based on MAT in order to ensure the sharing 
of benefits arising from the commercial or other utilization of these genetic 
resources with the contracting party providing such resources. 
Although the Convention of Biological Diversity was adopted in 1992 
and entered into force at the end of 1993, it was not until 1999 that work began 
in earnest to operationalize these provisions. The result is the Bonn Guidelines 
on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits 
arising out of their utilization, so named because of the location of the 
intergovernmental meeting in October 2001, that prepared the first draft, which 
was eventually adopted, with some changes, by the conference of the Parties to 
the convention at its sixth meeting, held in the Hague in April 2002 . 
The guidelines identify the steps in the access and benefit-sharing process, 
with an emphasis on the obligation for users to seek the PIC of providers. 
They also identify the basic requirements for MAT and define the main roles and 
responsibilities of users and providers and stress the importance of the 
involvement of all stakeholders. They also cover other elements such as 
incentives, accountability, means for verification and dispute settlement. 
52. CBD Article 15 
53. Daniel Gervais, the TRIPS Agreement-Drafting History & Analysis, p. 5 (2003). 
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Finally, they enumerate suggested elements for inclusion in material transfer 
agreements and provide an indicative list of both monetary and non-monetary 
benefits. 
Although they are not legally binding, the fact that the Guidelines were 
adopted unanimously by some 180 countries gives them a clear and indisputable 
authority and provides welcome evidence of an international will to tackle 
difficult issues that require a balance and compromise on all sides for the 
common good. 
Basic principles of a PIC system as laid down in Bonn guidelines, includes 
legal certainty and clarity. It laid down that access to genetic resources should be 
facilitated at a minimum cost and the restriction on access to genetic resources 
should be transparent and should be based on legal grounds and should not run 
counter to objectives of CBD. It also laid down elements of a PIC system which 
held that there should be a mechanism for obtaining PIC in consultation with 
relevant stakeholders and there must be a competent authority to grant or 
provide for evidence of PIC. It lays down that PIC must seek adequately advance 
to be meaningful both for those seeking and for those granting access. Decisions 
on application for access to genetic resources should also be taken within a 
reasonable time period. It also pointed to and important fact that prior informed 
consent should be based on the specific uses for which consent has been 
granted. While prior informed consent may be granted initially for specific 
use, any change of use including transfer to third parties may require a new 
application for prior informed consent. Permitted uses should be clearly 
stipulated and further prior informed consent for changes or unforeseen uses 
should be required. 
NIF, an autonomous society established under the Department of Science 
and Technology, Government of India in 2000, works for recognizing, 
respecting and rewarding innovations and outstanding traditional knowledge at 
344 
T.K. Under CBD and Biopiracy 
the grass roots. NIF and the HONEY BEE Network under SRISTI^^ Ahmedabad, 
has been scouting for documenting local innovations and linking their 
innovations for further valorization with Science and Technology experts, 
investors and entrepreneurs. 
NIF has developed a model for facilitating PIC system for local innovators 
and traditional knowledge holders. The PIC models seek the innovators' or 
traditional knowledge holders' consent for partial or full disclosure of their 
innovation and disseminate them through print and web media, and provide NIF 
mediation for value addition, patenting or other kinds of IPR generation based on 
the local innovation or traditional knowledge, and for fixing criteria and the terms 
and conditions for sharing monetary or non-monetary benefits, if any, arising 
from the value addition, micro-venture development, patenting on a local 
innovation or traditional knowledge, and for fixing criteria and the terms and 
conditions for sharing monetary or non-monetary benefits, if any, arising from the 
value addition, micro-venture development, patenting on a local innovation or 
traditional knowledge. The PIC process with regard to traditional knowledge 
holder and other grass root innovations is a quite complex one. This cannot be 
compared with the formal PIC process recommended for other ABS model 
involving Government agencies, R&D institutions and other organizations. The 
awareness, capacities and exposure level of the local innovators to the 
modern regimes of IPR scientific validation, management, trade policies, etc. 
is either minimum or low. Empowering these communities with knowledge and 
awareness on the values and potentials of the rich treasure-trove of knowledge 
they hold is an important exercise, which NIF has been successfully 
accomplishing through their scouting programmes, awareness campaigns, 
competitions and awards distributions conducted for successful innovators. 
However, the whole process of disclosure and dissemination of the local 
innovations, either partially or fully, needs to be examined, whether they affect 
54 Available at www.sristi.org/honeybee.html 
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adversely in eventual exclusion of potential innovations from possible 
valorization and IPR claims and also any possible misappropriation of such 
potentially useful innovations by others, and thereby depriving the local 
innovator of his/her intellectual property and customary rights. 
An important issue regarding PIC is that of whose "consent" is required to 
be obtained when the term PIC is used. The consent of the authority under the 
relevant national law is required in most international debates. This aspect 
would however create problems as the actual custodian of the biological 
resources and associated TK would be the TK holder, and in most cases it is a 
local or indigenous community, or member of such communities. The CBD 
talks of PIC in terms of PIC of the contracting party providing biological and 
genetic resources. This is perhaps an inevitable outcome of an international 
convention aimed at inter se rights and obligations of state parties rather than 
the rights of individuals or communities within their territory. 
There are three variants regarding the involvement of the local and 
indigenous communities in the process of gaining access to biological resources. 
The first forms the basis of guidelines for bio-prospecting adopted by the 
Philippines in its Executive order No. 247^^ it puts the local and indigenous 
communities in the key decision making role as regards access to biological 
resources. The second variant is OAU Model^ ,^ which lay down that the consent 
of local and indigenous communities can be obtained subject to written PIC of 
the concerned traditional communities, as well as, from the national competent 
authority set up to implement the legislation. Third variant is the one that has 
been provided in Decision 391 of the Andean community^^, it lays down that 
55. Krystyna Swiderska, "Developing the Phillipines Executive order No.247 on access to Genetic 
Resources", available at www.cbd.int/doc/casestudies/abs/cs-abs 
56. "Traditional ioiowledge - New Options Offered by African Model Legislation for Protection of 
Rights of Local Communities, Farmers & Breeders", available at www.aripo.org/indexphp 
57. "Decision 391, Common Access to Genetic Resources" available at 
<http//www.sice.oas.org/trade/JLrNAC/decisions?dec391 e.asp> 
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competent national authority should not only determine access but should also 
enter into contractual arrangements within the prospective users of biological 
material, however, the interest of local and indigenous communities should also 
be kept in view. 
The Indian legislation, the Biodiversity Act 2002, does not explicitly 
bring the traditional communities into the decision-making regarding access. 
Access to biological resources can be obtained by referring to be National 
Biodiversity Authority (NBA) the setting up of which has been provided for in 
the legislation. 
In conclusion it can aptly be said that such legislations should be 
implemented that may allow communities themselves to exercise control over 
their knowledge and resources. Principles of equity and justice demand that the 
actual TIC holder's should not be substituted by a government agency as their 
interest may always be the same. However there may b be different problems in 
achieving such an ideal, such as 
(a) Problem may arise as most of the local and indigenous 
communities do not have right and control over the land in which they 
stay. 
(b) There has been disintegration of the bonds within a local 
community owing to sociological and economic forces. Thus, it may 
not be always possible to identify one specific community as the holder 
ofTK. 
(c) The other difficulty is that of conflict in interests between the 
TK holder and the political head of the community due to difference 
in hierarchical equations. This can be seen in the cases where the 
local and indigenous communities may have feudal structures of 
governance which may create a power imbalance and may impede the 
benefits from reaching the actual TK holder. 
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Thus, there is a need to evolve a mechanism for access to biological 
resources that may provide a balance between the two systems that the countries 
have proposed or adopted in their legislation. Therefore, it can be suggested that 
the NBA should include more stakeholders from amongst the traditional 
communities so that its representative character can be improved. 
The Biodiversity convention is the basic treaty concerning the 
regulation of access to biological and genetic resources and benefit sharing 
along with this other guidelines and treaties are there to take about the 
benefit sharing aspect. 
(a) Bonn Guidelines: In 2002, guidelines on access to genetic sources on 
equitable sharing of the benefits were of the Bonn Guidelines is to increase 
transparency and certainty in access procedures so as to foster access by 
users of biological resources and traditional knowledge. On benefit sharing 
aspect Bonn Guidelines includes a number of suggested ways in which 
benefit sharing can be conceived this includes monetary and non monetary 
benefits. Monetary benefits include access fees, the payment of royalties 
research funding and joint ventures. Non monetary benefits include the 
sharing of research and development results, participation in product 
development, training related genetic resources and access to scientific 
information relevant to conservation and sustainable use of biological 
diversity. 
(b) International Treaty on Plant Genetic Resources for Food and 
Agriculture's Regime 
Under the PGRFA treaty, benefit sharing is a direct consequence of 
facilitated access and is meant to provide an incentive for countries to provide 
58. Bonn Guidelines on Access to Genetic Resources and Fair and Equitable Sharing of the Benefit 
Arising out of their Utilization (2002). 
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access to other member states. With regard to monetary benefits, the treaty 
provides that recipients who commercials a product incorporating an accession 
from the muhilateral system must pay an equitable share of the benefits.^ The 
benefits that arise under the benefit sharing arrangement must be primarily 
directed to farmers who conserve and sustainable use plant genetic resources 
for food and agriculture the treaty provides that it is use which triggers the 
benefits arrangement and not only commercial use. Article 13(2) (ii) includes a 
clause which significantly narrows down the scope of provision for the sharing 
of commercial benefits. Under this provision, the obligation to sharing entity 
has a monopoly right such as patent. 
In India benefit sharing schemes have been separate Act and the 
Biodiversity Act. 
(c) Benefit Sharing under the Plant Variety Act, 2001 
Under section 26 which regulates benefit sharing the substantive bases 
for a benefit sharing claim are the extent and nature of the use of genetic 
material of the claimant in the development of a variety and the commercial 
utility and viability as well as demand in the market for the variety.^° Elements 
taken into account include the contribution of the claimant in selecting, 
conserving and providing the genetic material, the contribution of the genetic 
material in providing one or more traits which confer high commercial value to 
the variety, and the contribution of the hybrid variety.^' 
Claims for benefit sharing can be made by a single person, a group of 
persons or even a non-governmental organization." Claim must be brought 
forward within six months from the date of publication of the certificate of 
registration. In case of disagreement, the breeder is entitled to oppose the 
59. PGRFA, Treaty Article 13 (2) d, 
60. Protection of Plant Varieties and Farmers Rights Act, 2001. Sec. 26(5), 
61. Protection of Plant Varieties and Farmers Rights Rules, 2003. Sec. 43, 
62.W. Sec.4I(2)a, 
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claim. The plant variety Authority is left to take a decision on the basis of 
claims and oppositions. 
The Authority plays a central role in the determination of benefit sharing 
because neither the Act nor the Rules specify what percentage of benefits is be 
shared. 
While benefit sharing is only dealt with under section 26,^ ^ the act 
includes another compensation scheme under section. 41. The first distinction 
between section 26 and section 41 is that the former provides a mechanism 
which works well in situations where the certificate of registration specifically 
indicates the geographical origin of a variety while the latter is geared towards 
situations where individuals or communities become aware that they have a 
claim to benefit sharing even though their contribution was not mentioned. 
Section 41 also differs from section 26 insofar as the procedural 
conditions for claims are less stringent and for instance; do not include either a 
time frame for the claim or a requirement to pay a fee. Moreover, the grounds 
for granting compensation are different from section 26. While the latter 
focuses only on the use of the variety compensation is to be awarded where the 
contribution is significant though the threshold for significance is not defended. 
Amounts awarded by the Authority as benefit sharing and compensation 
are to be paid to a National Gene fund The Gene Fund is to be applied to 
generally support and reward farmers for their contribution to conserving and 
improving plants, to initiate capacity building measures on conservation at the 
local level and to pay amounts due as benefit sharing and compensation. The 
Biodiversity act does not refer at all to the concept of prior informed consent. It 
provides for prior approval of the National Biodiversity Authority which can be 
understood as a weak form of the principle of prior informed consent. 
63. The definition of benefits sharing under section 2 specifies that it only applies to section 26. 
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Under the Biodiversity Act, the access and benefit sharing regimes are 
directly linked. In fact, the Authority must ensure while granting access that the 
conditions under which access is provided ensures an equitable sharing of the 
benefits arising out of the use of accessed biological resources and derived 
products.**'' While the Biodiversity Act introduces a number of different types 
of benefits that can be shared, there is still an important emphasis on monetary 
benefits and it cannot be ruled out that most transactions will take the form of 
monetary compensation. Where monetary compensation is chosen, the 
Authority has the discretionary power to have the sum deposited in the 
National Biodiversity Fund set up under the Act or paid to specific individuals 
or groups of individuals in situations where the origin of the biological resource 
can be specifically traced. 
8. Relevant Case Studies 
(a) Indian Cases 
In India, where the awareness of intellectual property law is very low, 
the momentum towards protection of the indigenous properties increased after 
the Basmati turmeric and neem disputes. THE turmeric case, in which India 
succeeded in overturning a patent granted by the United States Patent and 
Trademark Office on turmeric powder, was a land mark in the battle against 
'bio-piracy'. It was the first case in which a Third World country succeeded in 
its objection to a foreign patent on the grounds that it was based on traditional 
knowledge known to the country for generations. By this, the attempt to secure 
a monopoly on turmeric powder for use in wound healing was defeated. This 
case threw into prominence some of the main issues concerning the position of 
traditional knowledge of scientific importance under the patents regime, and 
also highlighted the difficulty in protecting knowledge that was known for 
centuries, but which was not articulated in a form found within Western 
64. Biological Diversity Act, 2002. Sec. 21(1). 
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cultural paradigms. A number of consequences have followed from this case, 
one of which has been the effort to record the traditional knowledge of India, 
in an attempt to ensure that similar patents are not granted again anywhere in 
the world. Few cases of biopiracy in India are as under: 
(i) THE TURMERIC PATENT CASE 
Two U.S. based Indian nationals Suman K. Das and Hari Har P. Cohy 
were granted U.S. Patent No. 5,401,504 on 28 March 1995 on the "Use of 
Turmeric in Wound Healing", which was assigned to the University of 
Mississippi Medical Centre, U.S.A.^ ^ 
The media coverage of the patent generated debate and discussion on the 
issue, and the Council of Scientific and Industrial Research (CSIR), an 
autonomous institution under the Department of Science and Technology, 
Government of India, decided to file for re-examination of the patent. There 
were many challenges before them. The claimed subject matter was the use of 
"turmeric powder and its administration", both oral as well as locally applied, for 
wound healing. It was therefore necessary to find adequate evidence in the form 
of printed and published information that would constitute prior traditional use 
of the claimed invention. The biggest challenge before CSIR was, that despite 
the fact that the use of turmeric was known to every Indian household for ages, 
finding documented information on the use of turmeric powder per se through 
oral as well as topical route for wound healing was a tough task. 
After an extensive search, thirty-two references were located, some of 
which were more than one hundred years old, and in the languages of Sanskrit, 
Urdu and Hindi. These were then translated, and authenticated as being true 
translations.^^ They were then field as part of the re-examination request, which 
was admitted by the USPTO as raising substantially new questions of 
65. TED Case Study Turmeric available at http://www.American.edu/ted/turmeric/htm. 
66. "IPR Issues Relating to Agricultural Sector -turmeric case", available at 
http://www.vuatkerela/org/static/eng/wta/ipr_issues/tuniieric.htm. 
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patentability. The turmeric case failed to meet the novelty criteria the USPTO 
upheld the objections raised and cancelled the patent. 
Though, the Turmeric case was a success story, it also revealed a variety 
of problem areas in challenging what was obvious to people in India, based on 
the laws of a foreign jurisdiction. The lessons leamt and problem areas as 
identified by the CSIR after the Turmeric experience can be summarized thus: 
a) There is a wide gap in the availability of information for patent 
examination purposes relating to TK bases from third-world countries. 
This needs to be documented and put into the public domain to discourage 
the grant of patents based on the centuries-old use of natural product 
from biodiversity-rich regions of the world; 
b) It may not be feasible to make such an investment (of filing for re-
examination) each time where an "invention" is claimed on a 
biological resource and its traditional use, challenging a large number 
of patents would mean wasting money and time. The commercial impetus 
to take up such cases is a grey area. Whether it should be the 
responsibility of the State to take up such cases in the future whenever 
there are no private entities willing to initiate action is a question to 
which there are no clear answers. The "affected interest' may not be 
easily tracked unless there is a substantial market potential for the 
patented product; 
c) The ex parte nature of the proceedings throws up further challenges in that 
the re-examination field for should be self-explanatory and clear. There 
is no scope for an oral hearing or classifications when the process of 
re-examination is ongoing. 
(ii) Neem Patent Case 
The patent No. 0436257 Bl was granted to the United States 
Department of Agriculture and the multinational corporation W.R. Grace for the 
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fungicide derived from seeds of Neem Tree.^ ^ The main claim of the patent was: 
"A method for controlUng fiingi on plants comprising contacting the fungi with 
a neem oil formulation containing OA to J0% of hydrophobic extracted neem 
oil which is substantially free of azadirachtin, 0-005 to 5.0% of emulsifying 
surfactant, and 0 to 99% water . 
In June 1995, a legal opposition against the grant of this patent was filed 
in the European Patent Office (EPO) by the three groups i.e., the Delhi-based 
Research Foundation for Science, Technology and Ecology, the Green Party in 
the European Parliament, Brussels, and the International Federation of Organic 
Agriculture Movements (IFOAM), based in Germany in solidarity with the 
Neem Campaign.^ ^ 
The main grounds of opposition to the present patent was that the claimed 
fungicidal effect of hydrophofaic extracts of neem seeds was known and used 
for centuries on a broad scale in India, as a pesticide, medicine as well as 
fertilizer. In Ayurvedic medicine, to cure dermatological diseases and in 
traditional Indian agricultural practice, to protect crops from flingal infections. 
This traditional Indian knowledge was in fact known to Indians since ancient 
times, after testimony from an Indian business that had been using neem for 
the same purpose years before they asserted that the patent in question lacked 
two basic statutory requirements for the grant of a European patent namely 
"Novelty" & "Morality". (Article 54 of the European Patent Convention (EPC)^° 
lays down requirements of novelty. 
(1) An invention shall be considered to be new if it does not form part of the 
state of the art. 
67. "EPO Evokes Neem Patent Rights" available at http://www.financialexpress.com/news/EPO-
revokes-neem-patent-rights/127729/ 
68. Ibid. 
69. "EPO upholds decision to revoke Neem Patent" available at 
http://www.ifom.org/press/neem_patent-victory_html. 
70. "European Patent Convention" available at 
http://www.epo.Org/patents/law/legal-texts/html/epc/1973/e/ar54.html 
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(2) The state of the art shall be held to comprise everything made available to 
the public by means of a written or oral description, by use, or in any 
other way, before the date of filing of the European patent application. 
The opposition division of the EPO revoked the patent in 2000 after 
opponents successfully argued that there was prior public use and that 
claims therefore not novel The second ground that was raised was that 
that the patent was contrary to "morality" Article 53(a) of the EPC,'" 
because the so-called inventors claimed monopoly property rights on a 
method which forms part of the TK base of India-in essence stealing it, and 
theft is regarded as immoral in European culture. 
The Neem Campaign mobilized worldwide support to protect indigenous 
knowledge systems and resources of the Third World from piracy by the West, 
particularly in light of emerging threats from intellectual property rights regimes 
under WTO and TRIPS. 
The Neem patent was the first case to challenge European and US 
patents on grounds of bio-piracy. This patent was revoked on the 8^"^  of May, 
2005 by the EPO^l 
(iii) Basmati Rice Patent Case 
Rice Tec Inc, was issued the Patent number 5663484 on Basmati rice on 
September 2, 1997, This caused grave repercussions for India and Pakistan 
because not only India lost out on the 45,000 tons US import market, which 
formed 10 percent of the total basmati exports, but also its position in crucial 
71. "European Patent Convention" available at 
http://www.epo.Org/patents/law/legal-texts/html/epc/1973/e/ar53.html. 
72 Mr.Afsar Jafri, "Landmark Victory in World's First case against Bio-Piracy - European Patent 
Office upholds decision to revoke neem patent", available at 
http://www.navdanya.org/news/05MARCH08.htm 
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markets like the European Union, the United Kingdom, Middle East and West 
Asia7^ 
Basmati is a long aromatic kind of Indian rice, the name basmati has 
been derived from Hindi word for fragrance which seems to be an appropriate 
connection with the aromatic scent of the basmati rice. It has a particular class 
and it has at least 400 varieties available in India & Pakistan.^ "* Rice is an 
important aspect of life in the Southeast and other parts of Asia. For centuries, 
it has been the cornerstone of their food and culture. The farming communities 
throughout the region developed, nurtured, and conserved over a hundred 
thousand distinct varieties of rice to suit different tastes and needs. It was for 
this reason that patenting of Basmati by Rice Tec Inc. was perceived as not 
only intellectual property and cultural theft, but it was also directly threatened 
the farming communities in Southeast Asia. The Government of India reacted 
immediately after learning of the Basmati patent issued to Rice Tec Inc. and 
stated that it would approach the US patent office and urge them to re-examine 
the patent to a United States firm to grow and sell rice under the Basmati brand 
name in order to protect India's interests, particularly those of growers and 
exporters. Furthermore, a high inter-ministerial group comprising of 
representatives of the ministries and departments of commerce, industry, 
external affairs. Council for Scientific and Industrial Research (CSIR), 
Agriculture, Bio-technology, All India Rice Exporters Association (AIREA), 
APEDA and Indian Council of Agricultural Research (ICAR) were mobilized 
to begin an in-depth examination of the case.'^ The contents and implications of 
the patent are currently being analyzed in consultation with patent attorneys and 
agricultural scientists. In the presence of widespread uprising among farmers 
and exporters, the nation of India as a whole has felt confident of being able to 
73. P.Ramchandran, "Challenging the Basmati Patent" available at 
http://www.thehindu.eom/fline/f] 1710/17100790.htm 
74. K.P.S. Mahawalkar & Vishal Mahawalkar, "Protection of TK and IPR: Indian and International 
Perspectives" Volxl MDU Law Journal 2006. 
75. Ranjit Devraj, "Basmati patent win Not Final, Say food security expert" available at 
http://www.twnside.org.sg/title/basmati.htm 
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successfully challenge the Basmati patent by Rice Tec Inc. However, 
judgment on these issues is awaited with interest. 
Sagar and Suri from a law firm representing India in the dispute, 
criticized the procedures for granting patents in the US claimed it diametrically 
"J ft 
opposite to the one followed in India and Europe . According to them, India first 
examines a patent application, then widely publishes it for third parties to 
challenge, and only then grants the patent. On the other hand the US keeps the 
patent application a closely guarded secret and grants it without allowing other 
parties to challenge it. After grant of patent third parties are allowed to petition 
against the patent as India is currently doing in the Basmati case. This criticism 
clearly illustrates the shortfalls in the patent process in the US that ultimately 
needs to be revised to prevent future cases like this from occurring. 
(iv) Wheat Patent Case 
Wheat the Golden grain is called "Kanak" in North Western India. It is the 
staple of a large majority. Wheat diversity has been evolved by Indian farmers 
over millennia for taste, for nutrition, for ecological adaptation to cold climates 
and hot climates, dry regions and wet regions. 
On 21^' May 2003, the European Patent Office in Munich granted a 
patent to Monsanto better known as the world's largest trader in genetically 
engineered plants, with the number EP 445929, with the simple title "plants", 
even though plants are not patentable in European Law. The patent covers 
wheat exhibiting a special baking quality, derived from native Indian wheat 
with the patent, Monsanto holds a monopoly on the farming, breeding, and 
processing of a range of wheat varieties with low elasticity.^^ 
76. Francois Meinbert, "Basmati rice update" available at 
http://www.biotech_info.net/basmati_rice.htm 
77. Vandana Shiva "Wheat Biopiracy" available at 
http://www.zmag.Org/zspace/veiwcommentaryprint/l 921. 
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. The wheat variety which has been pirated from India has been recorded as 
NapHal in the gene banks from which Monsanto got the wheat and in 
Monsanto's patent claims. The name NapHal is not the name of an Indian 
variety. Indian varieties were fiilly documented by Howard in "Wheats of 
India". NapHal means "no seeds", and is not, and cannot be an indigenous 
seed variety because farmers bred seed to produce seed.''^  
NapHal is the name given by W.Koelz, USDA. However, Koelz clearly 
did not make the collections himself, but was handed over the varieties, since the 
locations are inaccurate. Thus, the discrepancy in the location and in the name 
indicates that the variety referred to as "NapHal", was pirated, not collected. 
Vandana Shiva, Director of Research Foundation for Science, 
Technology and Ecology (RFSTE) has challenged Monsanto wheat bio-piracy 
both in the Indian Supreme Court and In the European Patent Office in Munich 
with Greenpeace. She submitted to the EOF on 17^ '' February 2004 that "The 
patent is a blatant example of bio-piracy as it is tantamount to the theft of the 
results of endeavors in cultivation made by Indian farmers. In the countries of 
the southern hemisphere, it is frequently the small farmers who make a 
decisive contribution to agricultural diversity and secure sufficient food supplies 
by freely swapping seeds and breeding regionally modified forms of crops.. ."^ ^ 
Monsanto thus has unscrupulously exploited the fruits of the farmers. The 
company is able to restrict not only the farmers and processing of crops, but also 
trade in crops, in the countries for which the patent has been granted. At: the 
same time it can block the free exchange of the seed, thus preventing other 
growers and farmers from working with the patented seeds. 
Thus, this case highlights the fact that if such bio-piracy based patents 
are not challenged and crop lines and products based on unique properties 
78. Ibid., 
79. Ibid.. 
358 
T.K. Under CBD and Biopiracy 
evolved through indigenous breeding became the monopoly of MNC's, in 
future we will have to pay royalties for our innovations especially in light of 
the Patent Cooperation Treat and upward harmonization of patent law. 
Monsanto's wheat bio-piracy patent should be a wake up call to 
citizens and governments of the world. It is yet another example of why the 
TRIPS of WTO need to be changed, and why traditional knowledge and 
o n 
community rights need to be legally recognized and protected. 
(v) Benefit-Sharing Arrangements with the Kani Tribes of Kerala 
Below mentioned case study is related to the benefit sharing 
arrangement that has been made between the Tropical Botanical Garden and 
Research Institute (TBGRI) a publicly funded research institute based in 
Trivandrum and the Kani tribes of Kerala, involving the medicinal plant called 
arogyapaacha (Trichopus zeylantcits). The Kani tribes were using the fruit of 
this plant as an instant source of energy and vitality. The know-how about the 
plant was provided by three Kani tribal members to the team of TBGRI 
scientists during a research operation in the forest areas inhabited by the Kanis. 
Detailed scientific investigation of the plant was subsequently carried 
out by the TBGRI, including chemical screening to isolate the active 
principles, and pharmacological screening. The TBGRI scientists 
developed a drug, "Jeevani", by adding three other medicinal plants as 
ingredients. 
In a separate resolution approved both by the Governing Body and the 
Executive Committee of the TBGRI, it was decided that the Kani tribes would 
receive 50 percent of the license fee, as well as 50 percent of the royalties 
obtained by the TBGRI on sales of the drug, as part of the benefit-sharing 
arrangement for divulging the information. In November 1997, with the 
80. Ibid. 
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assistance of the TBGRI, a trust was registered, under the name of Kerala 
o I 
Kani Samudaya Kshema Trust comprising of nine members. All the nme 
registered members of the Trust were Kani tribesmen. The president and 
vice-president of the Trust were the two Kanis who imparted the traditional 
knowledge to the TBGRI regarding arogyapaacha. The objectives of the 
Trust are: 
a) welfare and development activities for Kanis in Kerala; 
b) preparation of a biodiversity Register to document the knowledge-
base of the Kanis; and 
c) evolving and supporting methods to promote sustainable use and 
conservation of biological resources. 
A first payment of US$ 13,000, and royalties of US$ 500 for the 
benefit-sharing formula, was deposited in the account of the Kani Samudaya 
Kshema Trust at Kuttichal Union Bank^^ . 
The case involving the Kanis appeared to be a solution towards the 
evolution of a framework for benefit-sharing with traditional communities at 
the first instance. However, this case also threw up its usual share of 
problems. Kanis from other areas expressed their misgivings about the 
arrangements, especially in relation to the fact that the TBGRI had not 
consulted them. From the TBGRI's point of view, there was no legal 
requirement, and they were not told of any customary requirements for 
seeking the permission of the medicinal practitioners among the Kanis before 
using the plant. Further, the Kanis according to them were not an organized 
81. "The equator Initiative the innovative partnership awards for sustainable development in tropical 
ecosystems" available at http://www.equatorinitiative.net.files/2002-0184/nom. 
82 " The Equator Initiative - The innovative partnership awards for sustainable development in tropical 
ecosystems, available at 
<http.7/www.equatorinitiative.org/images/stories/nominations/Nom2002/2002-
0184_nom_keralakanitrust_india.pdf> 
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community with an identifiable governance structure, which could have been 
approached for permission. 
B. International Cases 
(i) The Hoodia Case 
The San tribes of the Kalahari are among the oldest communities in 
Southern Africa. They are holders of traditional knowledge on the use of Hoodia 
gordonii, a succulent plant found in the Kalahari dessert, which they have 
historically consumed to stave off hunger on their long journeys . The San 
peoples were initially unaware that the South African Council for Scientific and 
Industrial Research (CSIR), an arm of the South African government, had been 
granted a patent on P57, an appetite suppressant derived of an extract of the 
Hoodia succulent through research carried out by the CSIR, and had plans to 
commercialize a Hoodia pharmaceutical product without their consent or their 
sharing of the benefits derived from the patent and commercialization . 
With the involvement of NGOs, the San people and the CSIR negotiated 
one of the first benefit sharing agreements that gives the San people a share of 
royalties derived from the sale of products containing the patented P57. 
Although the agreement has received criticism, it serves as an example for 
potential future benefit sharing agreements and other mechanisms to ensure that 
traditional communities receive recognition for their knowledge and gain a fair 
share of the commercialization of the products based on such knowledge. 
The case serves as an example of the necessity of ensuring PIC of 
traditional knowledge holders and, in cases where such prior informed consent 
has been achieved and a patent or other form of intellectual property is 
granted over elements derived from biodiversity of which traditional 
83. Viviana Munoz Tellez, "Recognising the traditiona icnowiedge of the San people : Hoodia case of 
benefit sharing", available at 
<http://www.ipngos.org/NGO%20Briefings/Hoodia%20case%20of%20benefit%20sharinepdl> 
84. Ibid.. 
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communities are knowledge holders, ensuring that the benefits of their 
commercial exploitation are equitably shared. 
The Hoodia case also highlights the need to ensure that the national 
legislation with respect to the biodiversity provides adequate recognition to 
the rights of traditional communities, in accordance with the principles and 
objectives set out in the CBD and the Bonn Guidelines. The Hoodia case 
highlighted the fact that South Africa currently lacks a regulatory framework that 
can properly ensure the legal protection of the rights of the rural communities 
over biodiversity, including recognition of PIC and protection of traditional 
knowledge. In this regard, it is important to ensure that adequate legislation is 
developed, whether based on the intellectual properly system or a sui generis 
model 
(ii) Shaman Pharmaceuticals Case 
Shaman Pharmaceuticals, a company located in San Francisco (USA), is 
integrating indigenous knowledge, modem science and reciprocity into Novel 
Drug Discovery Approach and focusing on isolating bio-active compounds 
from tropical plants, particularly those which have history of medicinal use^^ 
Its field research teams consist of ethno-botanists, western trained 
medical doctors, local botanical collaborators, indigenous healers and herbalists. 
These teams assist in focused selection and collection of plant candidates for 
screening and development from various locations for further work in Sharman. 
Their community reciprocity strategy for sharing of benefits is driven by the 
expressed needs of the people from the communities they derive their 
collaborators. This includes short, medium and long-term reciprocity 
arrangements. 
(a) Short-term compensation included building an airstrip extension in 
85. Prabuddha Ganguli, Intellectual Property Rights - Unleashing the Kknowledge Economy p 154 
(2001). 
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the Ecuadorian Amazon, organizing public health workshops and 
forest conservation workshops, offering direct medical care to their 
partner communities and providing clean drinking water systems to 
communities in Ecuador and Indonesia, 
(b) Medium term approaches have been to provide scholarships and 
fellowships to scientists working in the field of traditional medicine and 
also to enhance infrastructural features for research in science and 
technology for the community. 
As art of their long-term strategy, the company has formed a Healing 
Forest Conservancy as a nonprofit organization dedicated to conserve cultural 
and diversity, and sustain the development and management of natural and bio-
cultural resources that are part of the heritage of native populations. 
(iii) Collecting Traditional Medicines In Nigeria 
In 1992, three U.S. agencies undertook a programme to collect and 
experiment on plants and traditional medicines throughout the world. The 
agencies, the National Cancer Institute, the National Science Foundation and 
the U.S. Agency for International Development, joined together to form an 
International Co-operative Biodiversity Group (ICBG) programme. 
One of the project teams under the ICBG programme working in Nigeria 
devised an interesting arrangement for sharing the benefits arising out of the bio-
prospective that the programme had undertaken. The team members agreed to a 
three-part arrangement for compensating the local people for the traditional 
knowledge. 
I. The team was to ensure that specific monetary benefits went to the 
communities at each stage of its research; 
86. Lisa Onaga, "Cashing in on Nature's Pharmacy," available at 
<http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid= 11306540>. 
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II. Representatives from these communities were to decide how this 
money would be spent; and 
in. A legal trust was to be created to ensure that the decisions taken by 
the representatives were actually implemented. 
The monetary benefits to the local communities were to be provided 
initially from the project funds. After that the royalties earned by the project by 
making the technologies available to commercial enterprises were to be shared 
with the communities, with the latter getting at 25 percent share. Fifty percent 
of this share was to be provided to the local government in whose jurisdiction 
the project lay, with the other half going to the town or village where the 
project was located. Besides these arrangements, the team was to also provide 
5 percent of all commercial drug profits to all projects in the particular region 
of Nigeria where the project was based in order to promote rural health, 
traditional medicines and biodiversity conservation. The drug company had also 
to agree to provide the drug at an affordable cost to all Nigerians afflicted with 
the disease for which the drug was the cure. 
In this case it appears that ICBG tern had provide a structure for realization 
of the objective of benefit-sharing, even though questions may be asked about 
the magnitude of payments and the likely beneficiaries of this arrangement. The 
issue seems to be the most relevant, since given the structure of benefit-sharing 
that was proposed but it does seem that the communities themselves would not 
have got any substantial monetary benefits. 
(iv) The In Bio-Merck Agreement 
In this case the two organizations the National Institute of Biodiversity 
of Costa Rica (INBIO) and the pharmaceutical manufacturer Merck Sharp and 
87. Morrice M. Jwu and Sarah A. Laird, "The International Cooperative Biodiversity Group; Drug 
Development and Biodiversity Conservation in Africa," Available at <http://www.cbd.int/doc/case-
studies/abs/cs-abs-icbg-africa.pdf> 
88. Ibid.. 
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Dohme, head quartered in the United States, were involved.^ ^ The Agreement 
entered into by the two organizations in 1991 was the first formal attempt to 
include benefit-sharing arrangements.'^ The parties to the contract agreed to 
collaborate in the investigation of the existent biodiversity in Costa Rica's 
tropical forests in order to establish its potential applications to human and 
animal health. 
Under the terms of the Agreement, FKBIO had the following obligations: 
(a) to establish the necessary facilities in Costa Rica for the collection 
and processing of plants, insects and environmental samples; 
(b) to provide Merck Sharp and Dohme with a specific number of plants, 
insects and environmental samples for a period of two years; and 
(c) to provide for processing of the samples of plants and insects in a 
laboratory established by INBIO at the University of Costa Rica. 
The corresponding obligations of Merck Sharp and Dohme were the following:-
(a) Merck was to provide INBIO with a research fund of USS 1 million 
during the first two years of the Agreement and was to contribute 
to the establishment of laboratories needed for processing of the samples 
at INBIO and at the University of Costa Rica; 
(b) Merck was to make an assessment of the samples provided by FNBIO 
through biological experiments owned by Merck to detect potential 
activity of compounds for use on human and animal health and 
agriculture; and Merck was to give unique numeric identification to 
all samples sent by INBIO and was to keep an identification system 
which would allow the parties to the contract to identify all products 
from which there was a possibility of obtaining royalties. 
89. John Ebarlee, "Assessing the benefits of bio-prospecting in Latin America," available at 
<http://www.idrc.ca/en/ev-5571 -201 -1 -DO_TOPIC.html> 
90. Ibid.. 
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The NBIO-Merck Agreement provided that all inventions arising from 
the samples supplied by INBIO would belong to Merck. Consequently, the 
patents on these inventions were also to be taken out by Merck. 
Although the INBIO-Merck case was the first significant case of 
benefit-sharing involving the supplies of genetic resources and the commercial 
interests, the single most noticeable lacuna was the absence of any involvement 
of local communities. Not only were the local communities not involved in the 
process of formalization of the Agreement, there was no explicit arrangement to 
share the benefits according to INBIO with the communities, 
(v) Brazzein Berries Case 
Brazzein is a sweet-tasting protein extracted from the West African 
fruit of the climbing plant Oubli. The plant grows in Gabon and Cameroon, 
where the fruit has been consumed by the apes and the natives for a long time. 
The Texas companies Prodigene and Nectar Worldwide were among the 
licensees to use Wisconsin Alumni Research Foundation patents on brazzein, and 
genetically engineer the enzyme into maize. '^ 
Despite the fact that the sweet taste of the berries was well known in West 
Africa, the university claims that their production of the sweet compound 
(brazzein) is its own invention and they don't owe anything to the people of 
West Africa as they are not legally required to do so. This fact, which involved 
appropriation of legal rights by means of patents over indigenous biomedical 
knowledge without compensation to the indigenous groups, is considered by 
Genetic Resources Action International (GRAIN), Geneva and Green Peace of 
an act of Bio-piracy^^. 
91. Someshwar Singh, "Rampant biopiracy of south's biodiversity," Available at 
<http://en.wikipedia.org/wiki/Brazzein> 
92. Ibid 
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(vi) The Enola. Bean Patent 
U.S. Patent No. 5,894,079, the Enola bean, or yellow bean, patent was 
granted to John Proctor, the President of seed company POD-NERS, LLC, 
after he brought the bean seeds back from Mexico^ .^ With the patent granted, 
Proctor has an exclusive monopoly on yellow beans and can exclude the 
importation or sale of any yellow bean exhibiting the yellow shade of the 
Enola beans. The International Center for Tropical Agriculture CIAT is legally 
challenging the patent, arguing that the patent claims are invalid, failing to 
meet novelty and non-obviousness requirements and disregarding available 
prior art. The USPTO has yet to rule on the re-examination '^'. 
Proctor planted the yellow beans in Colorado and allowed them to self-
pollinate. By selecting yellow beans in several generations, a segregating 
population resulted in which the color of the beans is uniform, stable and 
changes little by season. Proctor openly admits the Mexican origin of the beans. 
However, he believes that his seeds are patentable because a new yellow shade 
was obtained and this shade, coupled with the bean being grown in the United 
States for the first time, is sufficient to satisfy the novelty requirement. It is 
difficult for many to understand how this patent could have been granted when 
its novelty appears to be based solely on its color and that it was previously 
never grown in the United States. It raises serious issues such as whether a color 
can be patented and how the novelty requirement can be satisfied when these 
beans, that Proctor bought while vacationing in Mexico, have been grown for 
centuries. 
93. "US-Mexico ;egal battle erupts over patented Enola Bean", available at <http://www.greens.org/s-
r/22/22-21.htnil> 
94. Silvia Reibein & Hope Shand, "Enola Bean Challenge", available at 
<http://www.biotechinfo.net/enola_bean.html> 
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Customs officials at the U.S.-Mexico border are reportedly inspecting 
beans, searching for any patent-infringing beans being imported into the United 
States. Because of this bean alone and the threat of infringement, some export 
sales have dropped over 90 percent also affecting the market for other non-
yellow beans.^ ^ 
Conclusion 
Convention on Biological diversity can be considered as framework of an instrument 
to protect traditional knowledge at international and national level. CBD has focused 
on traditional knowledge and it different aspects of conservation and sustainable use 
of biodiversity and access to and benefit sharing from use of genetic resources. The 
Biodiversity Act 2002 in India has also taken guidelines from CBD. It is an 
innovative legislation with adequate measures to safeguard biodiversity and economic 
interests of local communities. Section 4 and Section 6 of the BD Act 2002 at some 
extent protect the traditional knowledge from false claims of IPR. 
Cases of biopiracy in India present the clear picture how the industrialized 
countries misappropriated the traditional knowledge of our country to convent it into 
wealth. These cases demonstrate that the persons or companies who commit biopiracy 
unless they are caught, enjoys the maximum benefit at the cost of indigenous peoples 
knowledge. At international level also the cases of biopiracy indicates 
misappropriation and monopolization of traditional population's knowledge and 
biological resources unlawfully. Government and the international community must 
take bold steps to protect all types of traditional knowledge possessed by the tribal 
people. Traditional knowledge is not valuable only for those who depend on it but 
95.DanielleB.Goldberg,"TEDCaseStudy-EnolaBean",availableat http://www.america.edu/TED/enola-
bean/htm> 
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also equally important for the growth of modem industries of the country. Especially 
our's traditional medicinal knowledge needs special attention, otherwise captions 
containing 'dadi maa ke nuskhe' in the daily magazines will no more be available for 
us to read 
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CONCLUSION 
Intellectual property is a world wide accepted phenomenon which 
requires fierce study and research. Traditional and indigenous life and its 
properties are annihilating to tremendously changing world of today. 
Historically the concept of patents is based on legal and social justification. 
The legal justification is that inventor should have exclusive rights over his 
invention as a reward and the social justification is that not to grant monopoly 
right, because they are privileges granted by the government to encourage 
research and inventions thereby providing new avenues for the economic 
growth and development. 
The primary object of the intellectual property laws is to safeguard 
intellectual creations which are either in written form or expressed in some 
form or other and to define their boundary areas in the interest of society. It is 
an established fact that every law has some public oriented goals and 
intellectual property law is no exception to this established rule. It has some 
objectives to achieve for the promotion of intellectual, cultural, political and 
economic expectations. 
The WTO is a potentially and very useful trade regulating body. Unlike 
other many international organizations, it allocates one vote for each country 
with no discrimination based on wealth or population. This could be very 
beneficial for developing countries, but unfortunately the developed countries 
are in much bath bargaining position. TRIPS treaty was created by WTO in 
1995. Most of the members of the WTO had preciously banned patents of 
biological resources, but TRIPS makes it mandatory to allow some of these 
patents. Although biopiracy has been an old issue. TRIPS has drastically in 
creased its prevalence and the patentability of life forms and genetic material. 
There are number of economic concerns associated with biopiracy and TRIPS 
in developing countries. 
The debate over whether TRIPS will boost or blight is a complex one. 
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Advocates of TRIPS assert that agreement could provide benefits of GMO'S 
and other fruits of Hfe patents that could drastically in prove living standards in 
the poor countries of the world through increased agriculture productivity. 
Opponents of TRIPS argue that stealing T.K, patenting it, and selling it back to 
its creators will do nothing to improve the lives of the world's poor. No doubt 
T.K is effectively stolen and used to benefit corporation rather then locals. 
Martin Khor of the Third world network calls this, reverse transfer of 
technology, where the poor developing countries are transferring knowledge 
and thus technology to the rich developed countries. 
There are number of international conventions and treaties towards the 
protection of originality and novelty. For instance WTO regime, Agreement on 
Trade Related Aspect of Intellectual Property Rights, Berne Convention, Doha 
convention and guidelines issued by united nations have had great impact on 
development and protection of intellectual property worldwide. 
Ideas and knowledge are ever increasingly becoming important in this 
fast changing techno-advance world whereby knowledge and creativity have 
become a part and parcel of trade. Intellectual property has not left any field 
untouched like medicine, films, books, computer software and music 
recordings. The best known and arguably economically, the most valuable 
form of protections of rights by the law of intellectual property come in the 
form of the patent. A.patent is in essence, the grant of a monopoly is not 
absolute; patents are only granted for a limited period and are accompanied by 
public discloses enabling others in the field to consider and perhaps 
subsequently improve on it. 
Traditional knowledge is a valuable heritage of the communities and 
culture that develop and maintain it and are also important for other societies 
and the world as a whole. Infact the importance of traditional knowledge has 
only been recently acknowledged by other disciplines and sectors of society 
and is now considered as a subject of protection under intellectual property law 
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regime. It is essential to preserve the benefits of icnowledge for the mankind. 
Because it culturally, socially and economically valuable. 
Traditional knowledge plays an important lead role towards the new 
developments and manufacturing sector and the products launched in the 
developed countries. Since the complexities associated with traditional 
knowledge require that steps be taken for the protection of this valuable asset 
both at the national and international level. As a result of this a number of 
countries are taken required steps for the protection of traditional knowledge 
from theft and consequent misuse. 
Patents in India have their origin by the 1856 Act. After independence, 
relative inaccessibility and affordability, or even non availability of essential 
life saving medicines led to the government to appoint two committees: the 
Tek Chand Patents Enquiry committee (1948-50) and the Ayyangar Committee 
(1959). Consequent to the recommendations of these committees the Indian 
Patents law was enacted in 1970. The Indian Patent Act, 1970 was also enacted 
with a view to make patents serve the needs of economy as well as to make 
them a vehicle of rapid growth. 
Traditional knowledge is a valuable heritage of the communities and 
cultures that develop and maintain it, as well as for other societies and the 
world as a whole. Traditional knowledge importance recently has been 
acknowledged by other disciplines and sectors of society and it is now 
considered a subject of protection under intellectual property law. It is essential 
to preserve the benefits of traditional knowledge for the marjcind because it is 
culturally, socially and economically valuable. Traditional knowledge is an 
important lead to the developed countries for their new developments and 
manufacture of new products. There is a need for steps to be taken and worked 
for its protection at national and international levels. All member countries of 
WTO are trying to fiilfiU the minimum requirements of TRIPS and also trying 
to cover the traditional knowledge within the ambit of intellectual property law. 
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Defensive as well as positive protections have been taken by the countries. 
Though efforts have been done to protect traditional knowledge through 
various aspects of intellectual property laws, but still there is requirement to 
enact the stringent law for the protection of traditional knowledge. The sui-
generis system is considered to be the only course left after the experience of 
sui-generis PVPFR Act, 2001. It has to be concerned both at the national and 
international level. In India profit of Traditional knowledge Digital library has 
been accomplished and has been made available to EPO for consultation from 
2009. At international level different organization like WIPO, WHO, WTO, 
UNESCO, UNCTADE are also at work for the protection of traditional 
knowledge within the ambit of their international from work. WIPO has 
received legislations as to traditional knowledge from many countries. These 
legislations are useful for us in formulating legislative and administrative 
strategy for protected traditional knowledge. 
The enactment of the Patents Act, 1970 has proven a boon for Indian 
pharmaceutical industry (especially the generic pharma segment). The 
traditional medicine continues to play an important role in health care but the 
general lack of research on safety and efficacy of traditional medicines is of 
great concern. Fortunately in many developing countries, traditional medicine 
offers a major and accessible source of health care. India has also focused on 
the role of traditional medicine in national health care strategies, supporting the 
development of clinical research into the safety and efficacy of traditional 
medicine, advocating the rational use of traditional medicine. Indian 
Pharmaceutical Industry also has a significant contribution of Indian System of 
Traditional Medicine. The newly enforced product patent regime would be in 
favour of the traditional medicinal knowledge of India. Taking the product 
patent on traditional herbal drug will certainly work to prevent 
misappropriation of traditional herbal drugs and its knowledge by the western 
countries. 
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The Patents Act, 1970 abolished product patents for food, 
pharmaceuticals and chemicals and restricted the grant of patents in these fields 
only to process patents. The term of patent was restricted to 7 years in these 
process patents against 14 years for others, in general fields. The compulsory 
licence exemptions were reinforced by the introduction of the licence of right 
provision. This Patents Act, 1970 provided an impetus for the growth of the 
generic pharmaceutical industry in India. During 25 years, from 1970-1995, the 
share of the national sector of the pharmaceutical industry recorded a growth 
from 15% to nearly 18% or near about. During this period, India became net 
exporter of pharmaceuticals occupying the y^ largest in terms of values. 
Through the three amendments to the Patents Act, 1970 India has made 
the patent laws, TRIPS compliant with the third patent amendment the was 
introduced, with the omission of section 5 of the Patent Act dealing with 
compulsory licensing of pharmaceuticals for export purpose. It is considered as 
response to a response to India's international commitments. Many lacunas 
have been pointed out in the provisions of compulsory licence such as the three 
years period after the grant of patent. This period might create havoc where 
deceases spread in epidemic proportions, the grant of patent would be a 
monopoly, the other point to be considered is that if the emergency situation 
arises within a period of 3 years, companies may take advantage and may 
challenge any application for the grant of compulsory licence. The drugs 
present in the provisions of the Act. These companies export their drugs into 
India rather than applying for patents for those drugs in India. 
The Indian pharmaceutical industry which had commerce export of bulk 
drugs and formulations to least developed countries in late 70s and 80s has now 
emerged as a major global player. Fulfilling its commitment to be TRIPS 
compliant adoption of non-infringing processes for filing DMF (Drug Master 
File and ANDAs Abbreviated Drug Applications) have greatly helped the 
Indian pharmaceutical industry to achieve greater height of market penetration 
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and technological progress. 
In the new product patent regime it was assumed that the availability of 
drugs will be affected, but Doha Declaration is one of the significant 
achievements of the efforts of the developing and the least developed countries 
to gain access to the patented medicines. Particularly it facilitates use of the 
patent right of the innovation without authorization of the patent holders for 
public uses. Paragraph 6 of the declaration and the waiver introduced enable 
now the countries to utilize the compulsory licence not only for the domestic 
purposes but also for export purposes which would help those countries 
without pharmaceutical production capacities. This provision nullifies the 
concern among the least developed countries and health activists, created by 
major generic producers such as India Adhering to the TRIPS Agreement. The 
domestic patent amendment Act in India also facilitates production of patented 
drugs and thereby access to medicines to a large extent both within and outside 
the country. It seems the movement utilizing the CL as facilitated by the Doha 
Declaration gains more momentum and the role of drug cartels could be 
reduced with more contribution by generic producers such as in our country. 
In the new product regime challenges before Indian Pharmaceutical 
Industry is to start spending and investing in research & development (R&D). 
During the process patent regime research & development investment was 
almost nil, though industry was in its bloom through the process of reverse 
engineering, but now the capacity of Indian pharmaceutical manufacturers has 
been on rise. The detailed study in the chapter indicate that the larger 
companies have initiated activities to increase investment in research and 
development (R & D) applications for process and product patents. On the 
other hand, efforts in small or medium scale units have been directed at 
improving the quality of production to meet the international standards and 
competition in the generic sector as well as to improve the export prospects. 
Indian companies can also exploit the lower costs of drug discovery R & D in 
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India to their advantage and invite foreign companies for collaborative 
research, the incentive India offers to MNC'S in terms of cost effective, skilled 
R & D manpower and facilities for clinical research might lead to several 
global companies shifting their R & D activities to India or manufacturing and 
research activities to India. In post TRIPS scenario the pharmaceutical MNC'S 
are geared for mergers and acquisitions to create large corporate structures to 
tackle skill requirements and to use already existing market network and 
established brand equity. This will lead to economic development and rapid 
increase in the technological capabilities of Indian firms. 
It is inevitable that the industry now has to face challenges and the 
opportunities that have been placed by the product patent regime. The main 
point of concern was to the affordability and availability of drugs for India drug 
is not a matter of trade but concern with life and death of the people attracted 
by severe disease like HIV-AIDS, cancer, epilepsy, and tuberculosis. It was 
doubted that price of life saving drugs would shoot-up and would become out 
of the reach of millions of people in developing counties. According to official 
estimates, nearly one fourth of the people are living below poverty line. The 
reasons given for the inaccessibility and unaffordability is that the flood of 
patent applications would result in high cost economy and sufferings for the 
ailing people by the poor quality of patent. But this reason does not seem to be 
a solid reason. Going thru a detailed in depth study reaches to the conclusion 
that at least for few years, cost of majority of the drugs for common, almost are 
not expected to rise. Of course some drug makers have to pay royalty to the 
MNCs but these payments are negotiable. The central Government has power 
to scrap patents or at least ask multinational pharma companies to sell their 
products at reasonable prices. Because of the rise of R & D investment in the 
product regime results in the production of quality drugs which would be easily 
available to the public. India's main advantage of low cost production of 
generic drugs will certainly help in the accessibility of all drugs to the reach of 
a common man. 
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It is also expected that the patient shall soon assume the role of a 
consumer in the pharmaceutical market and price of medicine is expected to be 
lower due to development and expanding of alternative system of medicine in 
the traditional knowledge, regime which is going to be emerged as an 
important competitor to the existing pharmaceutical market. This chapter 
mentions the contribution of Indian traditional system of medicine and also 
analyzed the overall performance of Indian pharmaceutical industry. 
United States in early 1930's has opted the Patent Act for the protection 
of plants, and now it has three acts for the protection of plants but India being a 
member of WTO also realized the need to protect the interests of plant 
breeders, farmers and promote conservation of genetic resources and seed 
industry. Though the enacted law is primarily based on UPOV Convention 
1961 and which can be consider a grundnorm for the protection of plant 
varieties but the Indian law also includes a number of provisions which were 
not present in UPOV Convention. The Protection of Plant Varieties and 
Farmers' Rights Act, 2001 not only protects the breeder's right but also 
recognizes the farmers' rights. TRIPS is an international agreement that 
requires member countries to provide strong intellectual property protection in 
their domestic law. Article 27.3(b) of the TRIPS agreement provides that 
member states may exclude essentially biological processes for the protection 
of plants or animals other than non-biological and variety protection, Article 
27.3(b) gives Member countries an option to protect plant varieties by patents 
or an effective sui-generis system or both. Though the TRIPS agreement 
mandates the member states to give effective protection to plant breeder's right, 
even then Indian law gives recognition to the farmers' right. Indian legislation 
is the first in the world, which grants formal rights to farmers. The Indian 
plants varieties law recognizes the role of farmers as cultivators and conservers 
and the contribution of traditional rural and tribal communities in the country's 
agro biodiversity by making provision for benefit sharing and compensation 
and also protecting the traditional rights of farmers. The traditional rights 
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include rights to use, save, share or sell his form produce of variety under this 
Act but the condition attached to it, that the sale is not for the purpose of 
reproduction under a commercial marketing arrangement. Even then by giving 
the farmers their traditional rights is equal to the recognition of their role in the 
grov/th of agriculture as well as in the economy of the country. Indian breeders, 
mainly working in the public research system have deluded a large number of 
new varieties. In the absence of plant breeder's rights these varieties would be 
freely available to others for exploitation. So by putting a system of plant 
breeder's rights in action through law in India would provide protection to the 
public research system and varieties developed by them. In future researcher's 
access to foreign germplasm may get linked to the provisions of the plant 
breeder's right. This is also a fact that in the absence of plant breeder's rights 
foreign companies would be hesitant to organize buy back production of seeds 
in India for export to their countries for fear of unauthorized use of their 
genetic material. 
The Protection of Plant Varieties Farmers'Rights Act, 2001 tries to 
strike a balance between the monopoly rights granted to the intellectual 
property rights holders and the benefits of society through the provisions of 
compulsory licensing, researcher's rights, exclusion of certain varieties from 
registration etc. Though certain loopholes are also present in the Act such as to 
avail the monopoly right registration of the variety is necessary and for 
retaining registration they have to pay royalty to the Government on the other 
hand it can also be consider as a check on the breeder's monopoly right. In the 
absence of this provision, obligation relating to benefit sharing and payment of 
compensation will not be workable by amending the provisions of the Act these 
loopholes can be closed. By enactment of PPVFR Act,2001 legislators tried to 
maintain the equilibrium between the Indian dual goals of protection of 
agrarian economy and protection of private investment in the development of 
new plant varieties and also recognizing the protecting the rights of plant 
breeders and farmers. 
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CBD affirms the sovereign rights of the states over their biological 
resources and India being a member of CBD decided to bring a piece of 
legislation in the form of Biological Diversity Act, 2002. The Biodiversity Act 
also plays an important role in the conservation of biodiversity protection of 
traditional knowledge, equitable sharing of benefits and to regulate access to 
biological resources. Section 3,4 6 and 7 the key provisions relating to regulate 
access to biological resources and traditional knowledge and exemption to 
certain persons such growers and cultivator. Voids & Hakims make a good 
combination of access and denial at some extent it is being able to present 
biopiracy. Since it is an innovative legislation with adequate measures to 
safeguard biodiversity and protection of economic interest of local and 
traditional comminutes, it will work as a tool for protection of traditional 
knowledge after the averseness of different state holders and its effective 
implementation. 
It is now an established fact that TK plays an important role in the 
global economy and is valuable not only to those who depend on it in their 
daily lives but also to modern industry and agriculture. Most of the traditional 
societies depend on this knowledge for their food and healthcare needs. 
Consequently, bio-prospecting has become a mega billion dollar global 
industry and biotech firms are engaged in building cross-border value chains 
on an unprecedented scale in a bid to discover and develop new active 
ingredients from traditional medicine. This has not only created strong incentives 
for bio-informatics and bio-prospecting, but also for bio-piracy. 
Rampant bio-piracy deprives the holders of TK of any benefits. Loss of 
biodiversity and associated TK will not only deprive the world of a unique 
knowledge-base but also threaten the very survival of local communities. IPR 
laws must, therefore, benefit all holders of such IPRs equally whether they are 
huge multinationals, spending billions of dollars on research or traditional 
local communities where knowledge has simply been passed on to one 
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generation to other. Communities and countries that are rich in bio-diversity and 
knowledge of traditional medicine may gain if they are able to share in trade and 
investment benefits provided their knowledge is used with 'prior informed 
consent' and they participate in the design of benefit streams from trade and 
investment that arise from the global development of the healthcare industry. 
However, the traditional knowledge does not lend itself easily to 
concepts of property in any form of known Intellectual Property Rights. To hail 
it as a sui-generis is inadequate without a system of use rights and obligations 
that can be created and operated at least at a national level. It is doubtfiil that an 
international sui-generis system can be instituted without first constructing 
national sui-generis systems although it would be useful that international 
guidelines be agreed upon so that at some stage the national systems created 
maybe harmonized. 
India and many other countries have introduced sui-generis system to 
protect their plant varsities. There is a need to include other issues in these sui-
generis system that go beyond the framework of the TRIPS agreement. For 
instance, the concept of Farmer's Rights emphasizes the need to maintain 
genetic diversity in the farmer's fields. 
The other pertinent question would be as to who are entitled to seek 
protection of which forms of traditional knowledge and who may confer 
recognition and status on the holders of traditional knowledge in a sui-generis 
modality raises a number of questions about the role of communities and 
functions of communally held knowledge in traditions that are part of heritage 
and culture as well as living traditions of habitat presentation and human 
interactions. At last to conclude it can be said that for the protection if traditional 
Indian knowledge, a separate sui generis system is required. Traditional 
knowledge is not an area of patent. Patent requires novelty essential elements of 
patentability which cannot be fulfill by traditional knowledge. The new patent 
regime does not directly affect the traditional knowledge. If the patent regime 
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affect it would be at the extent of the aspect of traditional medicines. On one 
hand where for the protection of plant varieties a separate sui-generis law has 
been framed which was also not an area of patent on other hand the need of an 
hour is to frame a sui-generis law for the protection of traditional Indian 
knowledge. 
On the basis of above study it can be said that what has been hypothesized 
by the researcher has been proved correct. India being a signatory of WTO 
TRIPS agreement has make its provisions in compliance to the agreement. In case 
of traditional knowledge TRIPS agreement does not specifically talks about its 
protection though other legislations have tried to protect the country's rich 
heritage at some extent even then there is an urgent need of a sui-generis 
legislation which can protect our long back cultural heritage. 
The discussion carried out in five chapters of this research work has made 
it crystal clear that a lot of steps have been taken by the international communit>' 
for the protection of valuable asset in the form of traditional knowledge yet there 
are certain gaps which need to be filled so as to make protection of traditional 
knowledge regime effective. It is necessary for the effective and integrated 
implementation of the three Acts, Protection of Plant Varieties and Fanners' 
Rights Act, 2001, Biodiversity Act, 2002 and Seeds Bill 2004, to protect the T.K. 
In India a National patent programme should be started to make masses aware of 
its benefits challenges and be ready to face global new patent regime. Patent 
literacy is a must for India. The following important suggestion may be advanced 
for taking certain initiatives for the protection traditional knowledge. 
SUGGESTIONS 
No doubt, protection of T.K is a global problem demand globalss 
solution. This T.K should be respected in all patent laws. Since T.K is oflen 
owned by an entire community, the entire community should have some share 
in the patent rights. This is one of the surest ways to fight biopiracy. This is 
also proposed that traditional communities should be integrated mainstream of 
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the country origin. It is submitted tiiat the TRIPS trade treaty needs to be 
revised to protect traditional knowledge and prevent bio-piracy. Further the 
TRIPS and CBD treaties should made workable to altercate contradictions and 
inconsistencies in the two agreements. 
Public awareness campaign should be lunched by the government as 
there is an urgent need to educate the T.K holders, and communities. The effect 
of product patent would be more profound on pharmaceuticals but India should 
set up a new agenda as new challenges are a head. It is well recognized fact that 
there exist basic human rights to a clean and safe natural environment. The 
effects of Bio-piracy and industrial agriculture also clearly threaten. These 
human rights surveying the existing material on protection of T.K researcher 
reached on the conclusion that the jobs, livelihood, employment, food security 
and safety, equity, the precautionary principle should not be ignored for IP 
regime in biodiversity. 
1. In India, in order to check bio-piracy an exercise has been initiated to 
prepare easily navigable computerized database of documented TK 
relating to use of medicinal and other plants, known as Traditional 
Knowledge Digital Library (TKDL). However, documentation of TK is 
only one of the means of giving recognition to knowledge holders. Mere 
documentation may not enable sharing of benefits out of the use of such 
knowledge unless it is backed by some kind of mechanism for protecting 
knowledge. Documentation of TK may only serve a defensive purpose, 
namely that of preventing the patenting of this knowledge in the form 
of which it exists. 
2. The Bio-Diversity Act, 2002, which regulates access to genetic 
resources and associated knowledge, contains no provision for the 
involvement of communities in decision-making. The Act is very much 
influenced by Bonn Guidelines. The National Bio-Diversity Authority 
(NBA) is the principal body for granting access to genetic resources. 
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Thus, there is a need to include more staiceholders from amongst the 
tradhional communities so that its representative nature may be 
improved. 
3. National level mechanisms and legal provisions to prevent bio-piracy as 
well as to install informed consent mechanisms to ensure reward to TK 
holders should also be given international recognition for their effective 
implementation and for their enforcement in other countries. Thus, there is 
a need for development of an international mechanism for protecting TK. 
4. Considering the fact that TK also needs international protection, it is 
imperative to define the characteristics of the international mechanism, 
which must include the foUowing:-
(a) Local protection of the rights of the TK holders through national sui 
generis regimes including customary laws. 
(b) There is an urgent need for the effective enforcement of municipal 
level sui generis regimes through positive comity of protection of TK 
which include co-ordination and co-operation amongst national 
authorities of various countries in undertaking measures for protection of 
TK. 
(c) A procedure whereby the use of TK from one country is allowed 
particularly for seeking IPR protection, or commercialization, 
only after such use is disclosed and PIC is obtained from the competent 
national authority of the country of origin. 
5. That patent must not be granted with out prior consent of the country, 
origin should be incorporated. No patenting plants should be carried out 
with out prior informed consent of government and communities holders in 
country origin. 
6. Prior informed consent for the use of TK is necessary whether the use of 
383 
Concbision 
TK is commercial or non-commercial. The right to TK should be treated as 
basic Human Rights. 
7. Since development of an appropriate form of protection for the 
knowledge of local communities is of great importance, therefore, 
there is a need for various bio-diversity rich developing countries to 
work together inter-governmental expedition towards developing 
an international instrument for the recognition of diverse national 
sui generis system. Thus, various bio-diversity rich countries should take 
steps for the preservation and protection of TK, and should come 
together for making concerted efforts in order to obtain international 
recognition of their national level systems of protection of TK. 
8. There is a long felt need to harmonize the provision of TRIPS and 
CBD. The CBD while reaffirming the sovereign rights of nations over 
their biological resources, calls for equitable sharing of benefits arising out 
of the utilization of these resources and associated TK TRIPS 
agreement, on the other hand, recognizes IPR to be private rights and 
provides for rewarding inventions without referring to the source of 
biological material and associated TK and without commitment for fair 
and equitable sharing of benefits with the country of origin of such 
knowledge. The adverse implications of the TRIPS Agreement on 
protection and sustainable use of TK needs to be rectified. The TRIPS 
Agreement should be used not only to reward the inventors but also th^ -^  
local people and community who have conserved and developed the 
TK, which provide valuable base for such inventions. Therefore, the 
developing countries must utilize the mandate given by Doha 
Ministerial Declaration on the relationship between CBD and TRIPS, 
which needs to be harmonized, 
9. An action may be taken on the following three broad fronts: -
(a) To put into place well considered legislations and 
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complimentary arrangements which would help address the 
needs of the holder of TK. 
(b) To establish the institutional structure needed for effective 
implementation of the legislations; and 
(c) To review various legislations enacted both by the Central 
Government and different State Governments, with a view to 
amend those that may undermine the rights of the traditional 
communities over the resources they have been using. 
10. Institutional structures should be established to provide the traditional 
communities with an opportunity to partake of the benefits arising out of 
the biological diversity and/or associated knowledge. The need for an 
institutional structure arises from the fact that the use of contracts for the 
sharing of benefits suffers at least two limitations which need to be taken 
into consideration. In the first place, they are voluntary agreements 
between the parties concerned. Given their nature, contracts cannot 
be relied upon as a way of realizing the objectives of the CBD. The second 
and the more important limitation of contracts is that it would prevent fair 
and equitable sharing of benefits which may arise when the parties 
involved are of vastly unequal bargaining strengths, as usually large 
companies having significant market power and the traditional 
communities, are at the fringe of the market system. 
11. If bio-piracy has to stop, then the U.S. patent laws must change, and 
Article 102 must be redrafted to recognise prior art of other countries. 
This is especially important given that the U.S. patent laws have been 
globalizing through the TRIPS agreement of the WTO. Article 102 lays 
down that "A person shall be entitled to a patent unless: 
A. The invention was known or used by others in this country or patented 
or described in a publication in this or a foreign country before the 
385 
ConcCusion 
invention thereof by the applicant for patent: OR 
B. The invention was patented or described in a trade publication in this 
or a foreign country or in public use or on sale in this country more 
than one year prior to the date of the application for patent in the 
United States. " 
Thus, use in a foreign country does not constitute 'prior art' in U.S. patent 
law. This is the basis of bio-piracy of traditional Indian knowledge systems, 
and indigenous uses of biological resources being patented. The U.S. style patent 
laws can only pirate indigenous knowledge. They cannot recognize or protect it. 
The issue of providing legal protection on TK in line with the existing 
IPR regime is a complex one because of the very nature and clustered 
pattern of distribution of TK held within and between various communities 
across the world. Positive and defensive protection measures along with 
development ofsui- generis laws may perhaps be the best and immediate options 
for countries like India to provide intellectual property rights to TK holders. 
Thus, it can aptly be said that unless India, acquires the R&D along with 
industrial capabilities in order to use its knowledge base after giving due share to 
the custodians of these knowledge, the nation will not be in a position to take 
the advantage of the new patent system. This makes a strong case for a sui 
generis law in India to recognize and protect the interest of the custodians of 
TK. If the TRIPS Agreement is designed to promote industrial growth 
based on the western technological development, the sui-generis legislation 
must be one to protect and promote traditional knowledge for the revival and 
growth of the village industries in India for the economic prosperity of the down 
trodden lots of these villages. It is this legislative vacuum and the technological 
and industrial backwardness in India that are responsible for the transfer of the 
traditional knowledge to scientific community in the developed nations to reap 
the new fortunes without any obligations to the custodians of TK. This is in 
clear violation of the basic human rights-cultural, social and economic -of these 
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people. As India leapfrogs into this new century of knowledge based industry 
and growth, its growth and development may not be determined only by its 
strategies of generation of new knowledge and innovation but also by the 
protection and exploitation of existing traditional knowledge and intellectual 
property. Thus, in India there exists an urgent need to both protect and utilize the 
existing traditional knowledge. 
To mitigate the problem of protecting traditional knowledge, the 
Government of India has taken steps to create a Traditional Knowledge Digital 
Library (TKDL) on traditional medicinal plants and systems, which will also 
lead to a Traditional Knowledge Resources Classification (TKRC).Though 
linking this to an internationally accepted International Patent Classification 
(IPC) System will mean building a bridge between the knowledge contained in 
an old Sanskrit Shloka and the computer screen of a patent examiner in 
Washington. Even then the traditional knowledge existing in this vast population 
of India needs more attention to protect not only the medicinal knowledge but 
every aspect of the traditional knowledge. Hopefully this will eliminate the 
problem of the grant of wrong patents since the examiner, all over the world 
wilt be aware of the Indian rights to that knowledge. 
There is an urgent need for a timely legislation so that Traditional 
Knowledge in India may be protected without wasting any more time because 
delay can cause big national loss. The researcher therefore proposes the following 
model law to be adopted in our country. 
1. The objectives of the model law should -
(a) Must be to promote respect for the protection preservation wider 
application and development of the traditional knowledge of the tribal, 
indigenous and local communities to promote the fair equitable 
distribution of the benefits derived from the use of that Traditional 
Knowledge. 
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(b) To promote the use of the knowledge for the benefit of the traditional 
knowledge holders. 
(c) To ensure that the use of knowledge takes place with the prior informed 
consent of traditional knowledge holders 
(d)To protect and support the inalienable rights of local communities 
including farmers and breeders over their knowledge and technologies 
(e) To recognize and provide compensation for the knowledge practices and 
innovations of indigenous people and local communities in the 
conservation and sustainable use of ecological of the components of 
biodiversity. 
(0 To ensure the effective participation of concerned communities in 
deciding on the distribution of benefits deriving from knowledge and 
technologies. 
(g)To encourage national and grassroots scientific and technological 
capacity. 
(h)To avoid situations where patents are granted for invention made or 
developed on the basis of Traditional Knowledge of the holders. 
2. The model law must include sciences, technologies and cultural 
manifestations. Genetic resources, seeds, traditional medicinal 
knowledge systems and practices, knowledge of the properties of fauna 
and flora, oral traditional visual and performing art such as yoga and 
skills and overall "Community Knowledge", which can be considered as 
knowledge relating to conservation and sustainable use of biological 
resources and which is of socio-economic value, and which has been 
developed over the year in traditional on local communities. 
3. Certain Conditions must be laid down for the Access to TK which are as 
under-
(a) The applicant shall provide a description of the innovation, practices, 
388 
Concbision 
knowledge or technology related to biological resource and proposes 
mechanism of benefit sharing. 
(b) Local communities must have a right to refuse access to their TK where 
such access will be detrimental to the integrity of their national or 
cultural heritage. 
(c) Authorization of access to associated TK must be subject to the prior 
consent and prior agreement of the owner 
(d) A time period for the access to associated traditional knowledge must 
be framed along with a condition of renewable accusation period should 
be framed. 
4. There should be certain conditions laid down for the protection of 
traditional knowledge which are as follows: 
(a) Indigenous or local communities should be granted the rights on the 
condition that they created developed, held preserved or are in use of 
that knowledge 
(b) The TK require that protection should not be publicly known outside the 
population or local community in which it has originated. 
5. The scope of the model legislation should relate to the fact that the 
Owner of TK shall have the right to-
(a) Object to its direct or indirect reproduction imitation and /or use by 
unauthorized third parties for commercial purposes. 
(b) Assign, transfer or license the rights in the traditional knowledge 
including transfer by succession. 
(c) Refuse access to their TK where such access will be detrimental to the 
integrity of their natural or cultural heritage 
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(d) Farmers' Rights include the right to the protection of farmer's traditional 
knowledge relevant plant ad animal genetic resources Exceptions to 
such right. 
(i) No Legal barriers shall be placed on the traditional knowledge exchange 
system of the local communities in the exercise of their rights 
(ii) Legislation should not affect access, use and exchange of knowledge 
and technologies by and between local communities. 
6. A holder of traditional rights must be local and indigenous communities 
including traditional practitioners and traditional professional groups 
and as well as Farming community. It may be an artisan or craftsman. 
7. The Rights may be acquired in the following manner: 
a. There must be a system of registration of the knowledge (TK) which can 
protect the TK at district, state and national level. 
b. Being India a vast countries comprising many tribal communities, 
registration can be done on the area wise tribal communities' knowledge 
c. This step can be taken at village level -
(a) Misappropriation, unauthorized use of TK and economic exploitation 
products or processes developed from TK without confirming the 
provisions of lawftil access should be liable to be fined 
(b) Negligence in such cases need to be punishable. 
(c) The civil remedies that are provided to include injunctions damages and 
accounts of profits. The model law must also provides for a maximum 
imprisonment of 3 years and a maximum fine of rupees two lakhs 
(8) Access and Benefit sharing and Prior Informed Consent 
a) Access to traditional knowledge for the purpose of research scientific 
study, commercial use, biotechnological and industrial application shall 
apply for prior informed consent of the TK holders. 
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b) Fair allocation of the benefits resulting from such use by prior 
agreement with owner of TK. 
c) Access permit should also be subject to payment and the state and the 
community shall be entitled to have a share in the earnings derived from 
any knowledge. 
d) The State shall ensure that at least fifty percent of benefits derived shall 
be channeled to the concerned local community. 
Violation of the proposed provisions should be penalized. It may be 
imposed in terms of fine or through penal sanctions against the violators. 
For the suggestions to be meaningful it has to be implemented to serve the 
interests of different groups. The government should do a great service by 
amending or enacting a new and appropriate legislation on the lines suggested by 
the researcher. It is submitted that the universities, Bio-technological institutions 
lawyers, and academicians can debate over the suggested action plan and 
remedies and help in benefiting the community and T.K. holders. 
Lastly our submission is that India needs to protect the Traditional 
Knowledge by enacting suitable legislation on the line of African Model or it 
must be sui-generic in character as Traditional Knowledge has different 
characters 
391 
^i66qgmpfry 
(BiSGograpfiy 
BIBLIOGRAPHY 
Books & Articles: 
1. Ahmed Rais, WTO and Indian Agriculture (Mittal Publications, 
New Delhi, 2009). 
2. Chandra Ramesh, Issue of Intellectual Property Rights (Isha 
Book Publication. Delhi 2004). 
3. Cornish W.R, Intellectual Property, Copy Right And Allied 
Rights (Universal Law Publishing House, New Delhi 1999). 
4. CuUet Phillipe, Intellectual Property Rights and Sustainable 
Development (Lexis Nexis Butterworths, New Delhi, 2005). 
5. Daniel Gervais, Intellectual Property Trade And Development 
Strategies To Optimise 'Economic Development In Trips-Plus 
Era (Oxford University Press, New York, 2004). 
6. Daniel Gervais, The TRIPS Agreement-Drafting History And 
Analysis (Sweet and Maxwell, London, 2003); 
7. David Bainbridge, Intellectual Property (Pearson Education, 
Delhi, 2002). 
8. Ganguli Prabuddha, Intellectual Property Rights-Unleashing 
The Knowledge Economy (Tata Me Graw-Hill Publishing 
Company, New Delhi, 2001). 
9. Malbon Justin and Lawson Charles, Interpreting and 
Implementing the TRIPs Agreement Is it Fair? Edward Elgar 
Cheltenham, (UK. Northampton, MA, USA, 2008). 
10. Nair R. Latha and Kumar Rajendra, Geographical Indications-
A Search for Identity, (Lexis Nexis Butterworths, New Delhi, 
2004,). 
11. Narayanan P., Copy Right and Industrial Design (Eastern 
Law House, New Delhi, 2002). 
12. Narayanan P., Intellectual Property Law (Eastern Law House, 
New Delhi, 2001). 
392 
(BiSGograpfiy 
13. Pillai Manoj, Kochupillai Mrinalini, Abraham Vineet, Pandey 
Abhai, and others, Patent Procurement in India. Available at 
www.patentsoffice.nic.in 
14. Raju C.B., Intellectual Property Rights (Serial Publications, 
Delhi, 2007). 
15. Singh Shiv Sahai, The law of Intellectual Property Rights (Deep 
& Deep Publications, New Delhi, 2004). 
16. Trivedi P.C, Medicinal Plants Traditional knowledge, (l.K 
International, New Delhi, 2006). 
17. Vashishth Vikas, Law and Practice oflPR (Bharat Law House, 
New Delhi, 2002). 
18. Verkey Elizabeth, Laws of Plant Varieties Protection (Eastern 
Book Company, Lucknow, 2007) 
19. Verma S.K., Intellectual Property Rights, Global Vision 
(Indian Law Institute, New Delhi, 2004). 
20. Wadehra B.L., Law Relating To Intellectual Property. (Universal 
Law Publishing House, New Delhi, 2007). 
21. Sudeep Chaudari, WTO and India's Pharmaceutical Industry (Oxford 
Publication New Delhi, 2005). 
22. "African Model Legislation for the protection of the rights of 
local communities, farmers' breeders' and for the regulation of 
access of biological resources," available at 
<http://www.grain.org/brl_files/oau-model-law-en.pdf> visited 
on 13.05.2008. 
23. "Benefit Sharing Model Experiment by Tropican Botanic Garden 
and Research Institute (TGBRI) - a National Centre of 
Excellence on Tropical Plant Diversity, Ministry of Environment, 
Govt. of India", available at 
<http//www. cbd. int/doc/cas=studies/abs/cs_absjbgri_in_en_pdf> 
visited on 18.04.2008. 
393 
(BiBSograpfiy 
24. "Competitiveness of the Indian Pharmaceutical Industry in the 
New Product Patent Regime." March 2005 FICCI report for 
National Manufacturing Competitiveness council (NMCC), 
available at www.scribd.com 16405502/Pharma /doc/ 
25. "Impact of Product Patent on FDI in Indian Pharmaceutical 
Industry" <http://ezinearticles.com/7Impact-of-Product-Patent-
on-FDI-in-Indian-Pharmaceutical-Industry&id=89594, 
26. "India to Prevent Traditional Medicinal Knowledge from 
Biopiracy," available at www. healthnews track.com. 
27. "Intellectual Property Rights" Current Science, vol, 78, No 11, 10 
June 2000. 
28. "Intergovernmental Committee on Intellectual Properties & 
Genetic Resources, Traditional Knowledge, Folklore" available at 
<http://www.wipo.int/edocs/mdocs/tk/en/wipo_ 
rtkf_JO/wipo_grtkJc _ 37.pdf> visited on 10.04.2008. 
29. "Joanna Van Gruisen, "Medicinal Plant Trade in India", CBI 
Bulletin, 21-22, 1996 (Feb). 
30. "Legislative Brief: The Seeds Bill 2004" available at 
www. indiatogether. org. 
31. "Overview of Pharmaceutical Sector" available at 
http://www.naukrihub.com. 
32. "Patent Rights, Patent Abuse", editorial Economic and Political 
Weekly 20 Jan 2007. 
33. "The Asean framework Agreement on Access to Biological and 
Genetic resources" available at 
<http://www.grain.org/bl_files/asean-access-2000-en.pf> visited 
on 18.05.2008. 
34. "The Equator Initiative-the innovative partnership awards for 
sustainable development in tropical ecosystems," available at 
<http://www.equatorinitiative.net-files/2002-0184/nom-
394 
(BiBGography 
_keralakanitrust_India.pdf> visited on 20.05.2008. 
35. "The Indian Patent Law of 1970 and the Amendment of 2005" 
available at http://patentoffice.nic.in/ipr/patent/patents.htm. 
36. "TRIPS Agreement and its Impact on Health" Report on a 
National Workshop Yangon, Myanmar, 13-15 October 2003. 
http://www.searo. who. int/LinkFiles/Reports _HSD-277-MMR.pdf 
37. "TRIPs Drugs and the Poor; How trade is effecting Access to 
Medicines," Notes and Comments CULR,2005. 
38. Akhtar Saleem, "New Patent Regime and Human Rights: Effect on 
Health care and Phamiaceutical Industry" Indian Journal of 
Politic July Sept. 2005. 
39. Akhtar Saleem, "New Patent Regimes Protection of Indian's 
Heritage" In A.K. Koul V.K. Ahuja (ed.) The Law of Intellectual 
Property Rights: In Prospect & Retrospect Faculty of Law, 
University of Delhi 2001. 
40. Akhtar Saleem, "The Protection of Traditional Knowledge 
under Intellectual Property Rights Regime" In Rais Ahmed (ed.) 
WTO and Indian Agriculture, (Mittal Publications, New Delhi 
2009). 
41. Amit Sen Gupta "A Long Road to Travel: Declaration on TRIPs 
at Doha" People Democracy, Vol- XXV, No 48, Dec. 2001. 
42. Anuradha, R.V, "Biopiracy and Traditional Knowledge" at 
vmw.hinduonnet.com./folio/foO 105/010503 80.htm 
43. Artha Maria, "Benefit Sharing", available at <www. 
sciencemag.org/cgi/content/summary/219/5489/49> visited on 
10.04.2008. 
44. Basant Rakesh., "IPR Regime Compression of Pharma Prices In 
India and Pakistan," EPW 29 Sep 2007. 
45. Bhatnagar M.P. Country Report: "TRIPs Implementation in 
India" available at www.atrip.org/12.htm 
395 
(BiBGograpfiy 
46. Bhatnagar, Jaya Garg Vidisha., "India: Patent Law in India" 
www.mondaq.com/ads/adredirf.asp. 
47. Biswal Meeta and Biswal Debudutta., "Issues Relating to 
Traditional Knowledge System and Intellectual Property 
Rights."available at-
www.fao.org/DOCREP/ARTICLE/WFC/XII/0911-A3.HTM 
48. Bruce Abramson, "India Journey Towards an Effective Patent 
System" Policy Research Working, papers Aug 2002 available at-
www.theinformationist.com/.../The%20Not-Quite-
Yet%20lnformation%20Economy/ 
49. Cecilia Oh, "Intellectual Property Rights and Biological 
Resources" Journal of Intellectual Property Rights p. 400-
413(2003). 
50. Chawla Gitanjali. "India's New TRIPs Compliant Patent Law" 
Intellectual Property Review Oct.2007 available at 
www.Asialaw.htm 
51. Damodaran, A.D., "Indian Patent law in the Post TRIPs decade: 
SST Policy Appraisal" J/P/? Vol, 13, Sep 2008. 
52. Damodaran, A.D., "Traditional Knowledge, Intellectual Property 
Rights and Biodiversity Conservation: Critical Issues and Key 
Challenges," J/Pi?, Vol 13, Sep. 2008, pp 509-513. 
53. Danielle B.Goldberg, "TED case study -Enola Bean", 
available at <http://www.america. edu/TED/enola-bean.htm> 
visited on 21.04.2008. 
54. Das, Kasturi, "India Combating Biopiracy-The Legal Way", 
available athttp://www.indiatogether.net/2005/may/env-
biopiracy.htm > 
55. Dhar Biswajit, "Post 2005 TRIPs Scenario in Patent Protection in 
the Pharmaceutical Sector: The Case of the Generic 
Pharmaceutical Industry" (2006) available at-
396 
(BiBHograpliy 
www.iprsonline.org/unctadictsd/discription.htm. 
56. Dhawan Rajeev, "Power without Responsibility on Aspect of the 
Indian Patent Legislation" J7L/, vol,33 Jan- March 1993. 
57. Douglas Sandes, "Indigenous People on International Stage", 43 
Social Action 1-7(1993). 
58. Dutt Bharvi, "Tamarind-based innovations: Analysis of Patents'" 
JIPR, Vol 6, May 2001, p-215-226 
59. Erfani Mohamud, Enforcement and Non-enforcement of TRJPs 
Agreement available at <http://www.google .co.in 
60. Francois Meienbert, "Basmati Rice Update", available at 
<http://www. biotechjnfo. net/basmatij-ice, /z/m > visited on 
22.03.2008. 
61. G.Chin Khan Muan, "Traditional knowledge and convention of 
biological diversity", available at 
< http//www. aippfoundation. org/Ri-ID/TK%20and%20cbd.pdf. > 
visited on 16.04.2008. 
62. Gopakumar K.M., Saxena Sanjeev "Seed Bill 2004: For Whom"? 
J/L/2004. 
63. Gopalakrishnan N.S., "Patents Amendement Bill, 1995-A 
Critique" (1996) 3 SCC (Jour), 1 
64. Gopalakrishnan N.S., "The Patents (second Amendment) Bill 
1999, An Analysis," Practical Lawyer, 1999. 
65. Gupta Ashish, "Patent and Politics: The Indian scenario" MIPR 
vol 1 2007 p A-5. 
66. Hemanth Kumar H.S., "Geographical Indications regime in India 
a Tool for protecting traditional knowledge"? MIPR vol 1, 2008. 
67. Indian Regime on Protection of Pharmaceutical Industry 
Innovations, available at.www.mondaq.com/article.asp?article 
68. International Conference on Access and Benefit Sharing for 
Genetic Resources March 6-7, 2008, New Delhi, India.avalable 
397 
at-.www.ris.org.in/K.%20VENKATARAMAN.pdf 
69. Jafri Afsar, "Landmark victory in world's first case against 
biopiracy- European Patent Office Upholds decision to revoke 
Neem Patent", available at 
<http://www.navdanaya.org/news/05march8.htm> visited on 
20.03.2008. 
70. Jatkar Archana A., "The Indian Patent (Amendment^ Act 2005 
and the Novartis Case" available at.wwwcuts-intemational.rog, 
71. Jean. O. Lanjouw & Margaret Macleod., "Pharmaceutical 
Research and Development for Low Income Countries Global 
Trends and Participation by Indian Firms," Economic and 
Political Weekly, 24 Sep 2005. 
72. Jena, K.C., "Remedies for infringement of Intellectual Property 
Rights," Apex Court Expression (2003) 4 ACE (J). 
73. John Ebarlee, "Assessing the Benefits of Bioprospecting in Latin 
America", available at <http;//www.idrc.ca/en/ev-557/201-l-Do 
TOPIC.htm>vwM£/on23.04.2008. 
74. Justice Katju Markandey., "Intellectual Property Rights and the 
Challenges faced by the Pharmaceutical Industry" (2004) 4 SCC 
(Jour) 46. 
75. Kantroo A.K., "Intellectual Property Debates: Protection of 
Biodiversity Genetic Resources and Ecosystems" p.9 GLR 2005-
2006. 
76. Keayla B.K., "Patent System: Implication for Health care and 
Pharma Industry, JIPR, vol-6 May 2001. 
77. Khader Feroz AH, "Transcending Differences: The challenge for 
Pharmaceuticals in the Post TRIPs Indian Patent Regime." JIPR 
vol 13 Sept. 2008. 
78. Kiichiru Hayashu, "The International Environment for Access 
to Genetic Resources", available at 
398 
<http//www. mri. co.jp/E/PAPER/PP01022300.pdf>v\s'itQd on 
6.04.2008 
79. Kochhar Sudhir, "Institution and Capacity Building for the 
Evolution of Intellectual Property Rights Regime in India: V-
Analysis of Review of TRIPs Agreement and R & D Prospects in 
India Agriculture under IPR Regime", ICAR, July 11,2008. 
80. Krishna Sunil B., "Enforcement of Intellectual Property Rights in 
India" MIPR Vol 3, 2007. 
81. Krishnakumar R., b "Concern of Intellectual Property Rights," 
Frontline 1, 1999. 
82. Kumar Ashok Ram, "Impact of TRIPs on Indian Pharma" 
Cronicle Special. Dec. 2, 2004. 
83. Kumar Mayank, "Parallel Imports in the Pharmaceutical Sector: 
Benefits for Development and Least Developed Countries" MIPR 
Vol 1,2009. 
84. Lalitha N., "Intellectual Property Protection for Plant Varieties, 
Issues in Focus" Economic and Political Weekly. 8 May 2004. 
85. Lisa Onaga, "Cashing in on Nature's Pharmacy," available at 
http"//pubmedicintra/nih.gov/articlerender.fgci?artid=1083874> 
visited on 24.04.2008. 
86. M. D. Janodia, S. Pandey, J. Venkara Rao, D. Sreedhar, V. S. 
Ligade & N. Udupa "Patents Regime in India: Issues, Challenges 
and Opportunities in Pharmaceutical Sector." The Internet 
Journal of Third World Medicine. 2008 Volume 7 Number 1. 
87. Madgulkar Ashwini R., "TRIPS: India Patent Protection for 
Pharmaceuticals"available at- www.pharmainfo.net. 
88. Mahalwar K.P.S., Mahalwar Vishal., "Protection of Traditional 
Knowledge and Intellectual Property Rights: Indian and 
International Perspectives" MDU Law Journal vol XI Part-I 
2006. 
399 
(BiBGograpliy 
89. Meera Bisal "Issues Relating to Traditional Knowledge," 
available at 
<http://www.fao.org/DOCREP/ARTICLE/WEC/XII/0911 -
A3.HTM> visited on 13.04.2008. 
90. Mishra Veena, "TRIPs, Product Patents and Pharmaceuticals" 
Economic and Political Weekly Dec. 1, 2001. 
91. N.S. Srinivasulu Mathai Subha., "Sui-Generis system for the 
Protection of Plant Varieties and Farmer's Rights in India" MIPR 
Vol 2, 2008. 
92. Nadagoudar Kiran M, "International Legal Regime Relating to 
Protection of Traditional Knowledge: An Analysis" 19 
Karnataka Law Journal 33-44 (2005). 
93. Nair Gopakumar G., "Indian Patent Law and Pharma Industry." 
http://www.gnaipr.com/Articles/Indian%20Patent%20Law%20and%2 
0Pharma%20Industry.pdf 
94. Nair M.D., "Impact of New Patent Regime on Drug Prices" 
www.pharmabiz.com. 
95. Nair M.D., "TRIPs and Public Health: The Doha Declaration" 
JIPR vol 7 May 2002. 
96. Neem Based Natural Product Innovations: Analysis of Patents, 
MMS Karki, JIPR Vol 6, Jan 2001, p-27-37. 
97. Okan Arihan A. Mine gen9ler Ozkan, "Traditional Medicine and 
Intellectual Property Rights." J. Fac. Pharm, Ankara 36(2) 135-
151,2007 
98. PAI, Yogesh A., "WTO Negotiations and the Way Forward" 5 
December 2008, Bhopal, India Centre for Trade and 
Development (Centad) New Delhi, India. 
99. Parvez Imran, Sharma Anand., Khan, Mohd Arif Bansal 
Pariskhit., "TRIPs impact R & D : Fact and Implication for Indian 
Pharma Industry,"http://www.expresspharmaonline.com/cgi-bin/ 
400 
(BiSGograpfiy 
eceprint/masterPFP.cgi?doc-
100. Peter Drahos and Ruth Mayne Palgrave Macmillan., "Global 
Intellectual Right, Knowledge Access and Development", 
available at-
nebridgebooks.com/Global_Intellectual_Property_Rights_ 
101. Pillai Manoj., "The Patents (Amendment) Act, 2005 and TRIPs 
compliance A Critique" JIPR May 2005. 
102. Prajneshu Meenakshi., "Patenting on Clove" & JIPR vol 7 Jan 
2002. 
103. Prof. Akhtar Saleem; New Patent Regime and Human Rights: 
Effect on Health care and Pharmaceutical Industry; Indian 
Journal of Politics; July September, 2005 p. 69. 
104. Professor Michael Blakeney, "Biprospecting and Biopiracy " EC-
ASEAN Intellectual Property Rights Co-operation Programme 
(ECAP IIII). http://www.ecap-
project.org/fileadmin/ecapII/pdf/en/activities/regional/aun_sept_0 
7/biopiracy.pdf 
105. Pushpangadan P., Narayanan K. Nair., "Value Addition and 
Commercialization of Biodiversity and Associated Traditional 
Knowledge. In the Context of the Intellectual Property regime," 
JIPR, vol 10, Sep. 2005 P-441-453. 
106. Raghavan Srividhya., "New Paradigms for Protection of 
Biodiversity" J/?/? vol 13, Sept. 2008. 
107. Ram Prabhu, "India's New "TRIPs Compliant" Patent Regime 
Between Drugs Patent and Right to Health Problem" Chicago-
Kent-Journal of Intellectual Property, 2006. 
108. Rangnekar Dawijen., "No Pills for Poor People? Understanding 
the Disembowelment of India's Patent Regime" EPW A Feb 
2006. 
109. Rao, C. Niranjan., "Para 6 of WTO Doha Declaration Non 
401 
(BiBGograpfiy 
Solution of the TRIPs Problem" Economic and Political Weekly, 
Jan 28, 2006. 
110. Ravi, S. Bala, "Effectiveness of Indian Sui-Generis law on Plant 
Variety Protection and its Potential to Attract Private Investment 
in Crop Improvement. JIPR Vol 9 Nov.2004. 
111. Reddy G.B., "Access to the Health are in Third world countries 
impact of TRIPs Agreement on product patenting of Drugs with 
special reference to India," Journal of Indian Legal Thought 
2003. 
112. Regi. K.Josph, "Estimating India's Trade in Drugs and 
Pharmaceuticals," Economic and Political Weekly 10 Jan 2009, 
113. RFSTE, Greenpeace & Bread for the world launch campaign 
against Monsonto's biopiracy of Indian wheat, available at 
<http://www.navdanya.org/news/03august5.htm> visited on 
25.04.2008. 
114. Sahai Suman, How Do We Protect Our Genetic Resources, 
Economic And Political Weekly, vol xxxi, no27, July 6, 1996. 
115. Sampath Padamshree Gehl., "India's Product Patent Protection 
Regime: Less or More of Pills for the Poor"? available at 
http://www.merit.unu.edu/publications/wppdf/2006/wp2006-019.pdf 
116. Sarkar, Sudipta., "Product patent for the Indian Pharmaceutical 
Sector under the TRIPS regime." www.legialserviceindia.com 
117. Sengupta Arghya., "Pareller Imports in Pharmaceutical sector: 
Must India be More liberal"? JIPR Vol 12 July 2007. 
118. Seshia Shaila., "Plant Variety Protection and Farmer's Rights 
Law Making and Cultivation of Varietals Control" Economic and 
Political Weekly 6 July 2002. 
119. Shiva Vandana., "Wheat Biopiracy" 
http://www.zmag.org/zspace/ veiwcommuntaryprint/1921. 
120. Singhatiya Arvind., "Impact of Product Patent on FDI in Indian 
402 
(BiBGograpfiy 
Pharmaceutical Industry." http://ezinearticles.com/7Impact-of-
Product-Patent-on~FDI-in~Indian-Pharmaceutical-
Industry&id=89594 
121. Sudhir D. Ghatnekar "Bioprospecting and Biopiracy at 
www.expressindia.com 
122. Sundaram, Karthik., "The Neem Patent case and Traditional 
knowledge," J5CL 2005. 
123. Thapliyal, Arvind., "Challenges to India's Patent Regime Pharma 
Industry", available at www.Legalserviceindia.com 
124. Udgoonkar Sangeeta., "The Recording of Traditional 
Knowledge: Will it Prevent 'Bio-Piracy"? Current Science, vol 
82, No 4, 25 reb 2002. 
125. Valson M.C., "Biodiversity Conservation: Challenges and Legal 
Solutions" C(/L^ 1999. 
126. Venkataraman K., "India's Biodiversity Act 2002 and its Role in 
Conservation" Tropical Ecology 50(1) 2009. 
127. Venkataraman K., "Intellectual Property Rights, Traditional 
Knowledge and Biodiversity of India" JIPR vol 13, July 2008. 
128. Venkataraman K., "Implementation of Biological Diversity Act & 
ABS through National biodiversity authority." Available at 
http://veensnott.blogspot. com/2009/05/traditional-indian-
medicine-take-look.html. 
129. Vepachedu Sreenivasarao, "Changes in Patent Law, Obviousness 
Test/ Inventive Step" Manupatra Intellectual Property Report 
Vol, 2, 2007. 
130. Verma R.P., Bhandari, Arvind., "Swot Analysis of Indian 
Pharmaceutical Industry,"available at www.pharma.tech.com. 
131. Verma S.K., "Biodiversity and Intellectual Property Rights" JILI 
vol 39 1997. 
403 
(BiSSograpAy 
(C) JOURNALS:-
1. Company Law Journal 
2. Indian Journal of Medical Ethics 
3. Journal of Intellectual Property Rights 
4. Manupatra Intellectual Property Reports 
5. Patent and Trade Mark Cases 
6. Cochin University Law Review 
7. Kamataka Law Journal 
8. Journal Law of Indian Law Institute 
9. Journal of Indian Legal Thought 
10. Harward Law Review 
11. Kashmir Law Journal 
12. The Internet Journal of Third World Medicine 
13. Apex Court Expression 
14. Report on Patent Cases 
(D) NEWSPAPERS & MAGAZINES:-
1. The Economic & Political Weekly 
2. The Economic Times 
3. The Frontline 
4. The Hindu 
5. The Times of India 
(E) WEB SOURCES:-
L www.google.com. 
2. www.asiatimes.com 
3. www.expresspharmaonline.com 
4. www.fmdarticles.com 
5. www.icommons.org 
6. www.indiainbusiness.com 
7. www.mondaq.com 
8. www.legalserviceindia.com 
9. www.lessig.org 
10. www.manupatra.com 
404 
(BiSGograpfiy 
11. www.mirandah.com 
12.www.naukrihub.com 
13. www.panosaids.org 
14. www.patentoffice.nic.in 
15. www.pharmabiz.com 
16. www.pharmaceutical-drug-manufacturers.com 
17.www.pharmainfo.net 
18. www.rediff.com 
19. www.researchandmarkets.com 
20. www.studentindlaw.com 
21. www.wikipedia.org 
22. www.youandaids.com 
Legislations: 
1. Agreement on Trade Related Aspects of Intellectual Property Rights 
(TRIPS) 
2. Convention on Biological Diversity. 
3. International Convention for the Protection of New Varieties of Plants, 
1991. 
4. The Patents Act, 1970 
5. ThePatents(Amendment) Act, 1999 
6. The Patents (Amendment) Act, 2005 
7. The Designs Act, 1911 
8. The Designs Act, 2000 
9. Drugs and Cosmetics Act, 1940 
10. The Indian Forest Act, 1921 
ll.The Pharmacy Act, 1948 
12. The Trade Marks Act, 1999 
13.The Wildlife (Protection) Act, 1972 
14. The Biodiversity Act, 2002 
15. The Geographical Indication 
405 
(BiBGograpfiy 
16, Plant Varieties Protection & Farmers' Rights Act, 2001 
17.The Seeds, Act, 1966 
18. The Copyrights Act 
19. Scheduled Tribes and other Traditional Forest Dwellers (Recognition of 
Forest Rights) Act, 2006. 
20. The Plant Patent Act 1930 (U.S.) 
21. Utility Patents granted under the Statute of 1952. (U.S.) 
22. The Plant Variety Protection Act 1970. (U.S.) 
406 
JLvpewl^ 
PROTECTION OF PLANT VARIETIES AND FARMERS' RIGHTS 
ACT, 2001 (53 OF 2001) 
CHAPTER I 
PRELIMINARY 
Short title and commencement -
(1) These rules may be called the Protection of Plant Varieties and Farmers' Rights 
Rules, 2003. 
(2) They shall come into force on the date on which the Act shall come into force. 
Definitions - In these rules, unless the context otherwise requires, -
a. "Act" means the Protection of Plant Varieties and Farmers' Rights Act, 2001(53 of 
2001); 
b. "Authority" means the Protection of Plant Varieties and Farmers' Rights Authority 
established under sub-section (1) of section 3; 
c. "Chairperson" means the chairperson of the Authority appointed under clause (a) of 
sub-section (5) of section 3; 
d. "fee' means the fee specified in the Second Schedule; 
e. "Form" means a Form specified in the First Schedule; 
f "Gazette" means the Official Gazette of the Government of India; 
g. "journal" means the monthly Journal of the Authority; 
h. "non-official member" means a member of the Authority other than a member, ex-
officio; 
i. "notice" means a notice issued by the Tribunal or the Registrar or the Authority under 
the Act; 
j . "Registrar" means a Registrar of Plant Varieties appointed under sub-section (4) of 
section 12 and includes the Registrar General of Plant Varieties appointed under sub-
section (3) of that section; 
k. "Schedule" means a Schedule annexed to these rules; 
1. "section" means a section of the Act; 
m. "representation" means any written communication addressed to the Authority or the 
Registrar in any proceeding under the Act; 
n. all other words and expressions used, but not defined in these rules, but defined in the 
Act, shall have the meanings respectively assigned to them in the Act. 
Details of particulars to be furnished while making an application or representation ~ 
(1) Save in case of forms specified by the Authority under the Act, every person making 
an application or representation under the Act or these rules, shall furnish the 
particulars in the Forms specified in the First Schedule; 
(2) If any application or representation has been filed without furnishing all the 
particulars as specified in the relevant Forms specified in the First Schedule, the 
Authority or the Registrar, as the case may be, shall give one month's notice to the 
applicant or the person, who has filed the application or the representation to file such 
particulars. 
(3) In the event the applicant or the person, who has filed the application or the 
representation, defaults or fails to rectify the application or the representation, as the 
case may be, in terms of the notice under sub rule (2) within one month as allowed, 
the said application or the representation shall be liable to be rejected without any 
further notice. 
(4) Where no Form is specified for any purpose, the applicant may adopt as nearly as 
may be a Form specified in the First Schedule with such modifications and variations 
as may be considered necessary. 
4. Office of the Authority -
(1) The office of the Authority shall, for all proceedings under the Act, be the head office of 
the Authority at New Delhi or the branch office, as the case may be, within whose 
territorial limits -
a. the applicant for registration of the plant variety or the fanners' right has his principal 
place of business or domicile; or 
b. the applicant for registration of the plant variety or the fanners' right, whose name is first 
mentioned in the application, resides or has his principal place of business or domicile, if 
the application is made jointly in the names of two or more persons; or 
c. the agent or licensee of the registered breeder has his principal place of business or 
domicile. 
(2) Notwithstanding anything contained in sub-rule (1), until the branch offices are 
established, the appropriate office for all proceedings under the Act shall be the head 
office of the Authority at New Delhi. 
5. Address for service of notices, etc. 
(1) Every person including the applicant, concerned in any proceeding to which the Act or 
these rules apply, shall furnish to the Authority or the Registrar the complete address for 
service in India and that address shall be treated for all purposes connected with such 
proceedings or the rights granted, as the address of the person or persons in the 
proceedings. 
(2) Unless such an address is given, the Authority or the Registrar shall be under no 
obligation either to proceed or deal with any proceeding or to send any notice that may be 
required to be given under the Act or these rules. 
6. Procedure regarding application, representation and issue of notices -
(1) Every application or representation shall be made in writing, signed by the applicant or the 
person who has made the representation, and delivered to the Registrar or the Authority at 
its office. 
(2) The names and addresses of the applicants and other persons shall be given in full, 
together with their nationality and such other particulars, as are necessary for their 
identification and for sending communications to them. 
(3) (a) All applications, representations and documents filed or required to be 
filed under the Act or the rules shall be filed in triplicate; 
Provided that in cases where the Registrar or the Authority requires more than 
three copies of such applications, representations, or documents, the applicant or 
the person, who has filed the application or the representation, shall be required to 
supply as many copies as is specified by the Authority or the Registrar, 
(b) In case of failure to furnish the required number of copies within a period of three 
months, the Registrar or the Authority may reject the application or the 
representation or may treat the application or representation as withdrawn. 
(4) Any application, representation or document required to be sent to or filed with the office 
of the Authority or the Registrar may be delivered either by hand or by registered letter 
with acknowledgement due or electronic mail, addressed to the Authority or to the 
Registrar at their office. 
(5) If any application or a representation or document is delivered to the Authority or the 
Registrar by hand, an acknowledgement receipt shall be issued by the Authority or the 
Registrar's office with its seal. 
(6) In case of delivery by registered post with acknowledgement due or by electronic mail, it 
shall be presumed to have been filed, or given at the time when the same has been 
received by the office concerned. 
(7) Any written communication addressed to an applicant or the holder of any right under the 
Act, at his address in the Register of Plant Varieties maintained under the Act or at the 
address for service fun}ished under rule 5 in any proceedings under the Act or these 
rules, at the address appearing on the application or notice of opposition or reply or 
counter reply or any such representation, shall be presumed to be properly addressed : 
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(8) Provided that in cases where the receipt of such a representation or application has been 
delayed beyond the normal period of delivery or transmission, such a delay may be 
condoned. 
(9) All notices and written communications addressed to an applicant or to any holder of 
right, in any proceeding under the Act or these rules, and all documents forwarded to the 
applicant or the holder of any right or an opponent shall, except when they are sent by 
special messenger, be sent by registered post acknowledgement due or by electronic 
mail. 
(10) (a) The acknowledgement receipt issued by the office concerned or the postal certificate 
receipt shall be the sufficient proof as to the delivery or sending of any document 
under the Act or these rules, 
(b) In case of transmission by electronic mail, the electronic receipt withjhe recognised 
digital signature, by the applicant or the person, who has made the representation, 
shall be the proof of the receipt. 
7. Application not to be admitted in certain cases -
No application or representation shall be made to the authority or registrar covering the 
subject-matter already included in an earlier application made by the same person, and 
such subsequent application shall not be admitted by the registrar or the authority, as the 
case may be. 
8. Fees-
(1) The amount of fees payable in respect of the registration of plant varieties and grant of any 
right under the Act or any application or notice of opposition or reply or counter reply 
required to be filed under the Act and other matters shall be as per the rates specified in 
the Second Schedule. 
(2) (a) The fees payable may either be paid in cash or may be sent by money order or postal 
order or bank draft or cheque payable to the Authority or the Registrar, as the case may 
be, at their respective offices, drawn on a scheduled bank at the place where the office is 
situated. 
Explanation: For the purposes of these rules, "scheduled bank" means a bank included in the 
Second Schedule to the Reserve Bank of India Act, 1934 (2 of 1934). 
(b) Any cheque or draft (not including the fees in cash) on which the value specified 
therein cannot be collected in cash within the time allowed for the payment of the 
fees, shall be accepted at the discretion of the Registrar. 
(c) The stamps shall not be received in the payment of any fees payable under these rules. 
(d) Where a fee is payable in respect of the filing of a document or application or 
representation, the date on which the entire fee is paid shall be the date of filing of the 
document or the representation. 
(3) Where any test is required to be conducted under any of these rules, the applicant or the 
concerned person shall be required to pay the requisite fee specified in the Second 
Schedule. 
(4) Any application or representation or document shall be liable to be rejected on account 
of non-payment of fees and no test shall be conducted unless and until the parties 
interested deposit the required amount of fees as specified in the Second Schedule. 
9. Size, etc., of documents -
All documents and copies of documents, except affidavits and drawings, sent to or left 
at the office of the Authority or otherwise furnished to the Registrar shall be written, 
typewritten, lithographed, or printed (either in the Hindi or in the English language 
unless otherwise directed or allowed by the Authority or the Registrar-General) in large 
and legible characters with deep indelible ink with lines widely spaced upon one side 
only of strong white paper of a size of approximately 33.00 centimetres by 20.50 
centimetres (13 inches by 8 inches) or 29.7 centimetres by 21 centimetres (11 3/4 inches 
by 8 1/4 inches) with a margin of at least four centimetres (one and a half inches) on the 
left-hand part thereof 
10. Affidavits -
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The affidavits required to be filed under these rules shall be dated and signed at the foot 
and shall contain a statement that the facts and matters stated therein are true to the best 
of the knowledge, information and belief of the person making the affidavit. 
CHAPTER n 
PLANT VARIETIES AND FARMERS' RIGHTS PROTECTION AUTHORITY 
11. Manner of Selection and Appointment of the Chairperson -
(1) The Chairperson shall be appointed by the Central Government on the basis of a panel of 
names recommended by a Selection Committee comprising of the following, namely:-
a. Secretary, Department of Agriculture and Co-operation, Government of India -
Chairman. 
b. Secretary, Department of Agriculture Research and Education, Government of India -
Member. 
c. One Expert nominated by Ministry of Agriculture, Government of India - Member. 
(2) The Department of Agriculture and Cooperation of the Central Government shall act as 
the nodal department for the selection and appointment of the Chairperson. 
(3) The Chairperson shall be of the rank of the Secretary to the Government of India and the 
appointment as chairperson shall either be on deputation or on contract basis. 
(4) If the Selection Committee constituted under sub rule (1), recommends any person who 
is not a government servant but fulfills qualifications given in clause (a) of sub-section (5) 
of section 3, such appointment may be made on contract basis. 
12. Term of Office of the Chairperson -
The Chairperson shall hold office for a term of five years or up to the age of sixty-five 
years, whichever is earlier, and shall be eligible for re-appointment: Provided that no 
Chairperson shall hold office for a total period exceeding ten years, or after he has 
attained the age of sixty-five years, whichever is earlier.. 
13. Salary, allowances, conditions of service, leave, pension, provident fund etc. of the 
Chairperson -
The Chairperson shall be entitled to such salary, allowances, leave, pension, provident 
fund and other perquisites as are admissible to a Secretary to the Government of India. 
14. Resignation or removal of the Chairperson from office in certain cases -
(1) The Chairperson may resign from his office by giving notice in writing to the Central 
Government. 
(2) The Central Government shall remove the Chairperson from office if he, -
a. is or at any time has been, adjudicated as an insolvent; 
b. has been convicted of an offence which, in the opinion of the Central Government, 
involves moral turpitude; 
c. has become physically or mentally incapable of acting as the Chairperson; 
d. has failed in discharging the duties and responsibilities under the Act and the rules 
made hereunder. 
e. has acquired such financial or other interest as is likely to affect prejudicially his 
function as the Chairperson; 
f. has, in the opinion of the Central Government, so abused his position as to render his 
continuation in office detrimental to the public interest; 
g. any other substantiated ground which is unbecoming of a public servant under the 
Government of India: Provided that the chairperson shall not be removed under this 
sub-rule unless he has been given a reasonable opportunity of being heard in the 
matter. 
15. Term and allowances of non-official members -
(1) Every non-official member of the Authority shall hold office for a period of three 
years from the date of his appointment. 
(2) The Central Government shall appoint new non-official member of the Authority 
within six months of the expiration of the term of the non-official member. 
(3) A non-official member shall be entitled to sitting allowance and travelling expenses, 
at such rate as may be fixed by the Central Government from time to time in this 
regard. 
16. Proceedings of the Authority -
(1) The Authority shall meet atleast twice in a year at the head quarters of the Authority 
or at such place as may be decided by the Chairperson. 
(2) The Chairperson shall, upon a written request of not less than five members of the 
Authority or upon a direction of the Central Government, call a special meeting of the 
Authority. 
(3) At least fifteen days' notice of an ordinary meeting and three days' notice of a special 
meeting specifying the purpose, the time and the place at which such meeting is to be 
held, shall be given to the members. 
(4) Every meeting shall be presided over by the Chairperson and in his absence, by a 
Presiding Officer to be chosen by the members present from amongst themselves. 
(5) The decision of the Authority shall be taken by a majority of the votes of the members 
present and voting and in the event of equality of votes, the Chairperson or in his 
absence, the member presiding over the meeting shall have a second or casting vote. 
(6) Every member shall have one vote. 
(7) The quorum for the meeting of the Authority shall be five. 
(8) No member shall be entitled to bring forward for the consideration of a meeting any 
matter of which he has not given ten days' notice to the Member-Secretary unless the 
Chairperson, in his discretion, permits him to do so. 
(9) The notice of the meeting may be given to the members by delivering the same by 
messenger or sending it by registered post to his last known place of residence or 
business or in such other manner as the Chairperson or the Member-Secretary may, in 
the circumstances of the case, think fit. 
17. Chairman and proceedings of the Standing Committee -
(1) The Chairperson shall select a member of the Standing Committee appointed by him 
under sub-section (7) of section 3 from amongst the members of that Committee to 
preside over its meeting. 
(2) In the absence of the member selected under sub-rule (1), the meeting of the Standing 
Committee shall be presided over by the member who shall be elected by the 
members present at meeting from amongst themselves. 
(3) The decision in the meeting of the Standing Committee shall be taken by a majority 
of the members present and voting and in the event of equality of votes, the member 
selected under sub-rule (1) or in his absence, the member presiding over the meeting 
shall have a second or casting vote. 
(4) Every member shall have one vote. 
(5) The quorum for the meeting of the Standing Committee shall be three. 
(6) The convener of the Standing Committee may, in consultation with the Authority, 
determine the venue of its meetings any where in India ; and serve notice of such 
meeting to all members at least fifteen days in advance. 
18. Appointment of Expert Committee by the Authority -
(1) The Authority may appoint such experts or consultants as it considers necessary to 
seek guidance and assistance in technical areas demanding specialized advisory 
inputs, to enable the Authority for efficient discharge of its duties and functions. 
(2) The Authority may appoint such other committees as may be necessary for the 
efficient discharge of its duties and functions. 
(3) The Authority may, in consultation with the Central Government, fix the quantum of 
remuneration, payable to the experts and consultants. 
19. Salary, Allowances and Conditions of service of the Registrar-Genera! -
(1) The Registrar-General shall be an official equivalent to the rank of the 
Additional/Joint Secretary to the Government of India and he shall be appointed by 
the Authority on deputation or transfer or on contract basis. 
(2) The Registrar-General shall be governed by the Central Government rules in respect 
of his salary and other allowances including pension, leave, travelling and daily 
allowances as are admissible to an Additional Secretary to the Government of India. 
(3) The Registrar-General shall be a person having proven managerial, or legal or 
Intellectual Property Rights or agricultural development experience. 
(4) The term of office of the Registrar-General shall be a period of five years or until he 
attains the age of sixty years, whichever is earlier : Provided that no candidate who 
may not have at least two years tenure in the office shall be appointed as Registrar-
General. 
(5) A person on completion of one term as Registrar-General shall be eligible for a 
second term of three years or until he attains the age of sixty years, whichever is 
earlier. 
20. The method of appointment of officers and other employees of the Authority -
(1) The Authority may make recruitment and appointment to the posts of officers 
specified in the Fourth Schedule. 
(2) The Authority shall after advertising the posts in the Employment News and atleast 
one national daily recruit officers and other employees of the Authority by the 
method of direct recruitment or contract basis by selection after conducting 
interview. 
(3) Notwithstanding anything contained in sub-rule (1) and subject to the approval of the 
Central Government the Authority may also appoint such other officers and 
employees as may be required by it on transfer or deputation basis or on contract 
basis. 
(4) The salary, allowances and other conditions of service of the officers and employees 
of the Authority shall be the same as applicable to Central Government servants of 
equivalent rank. 
(5) If any question on the service conditions of any officer or employee of the Authorit>' 
arises, it shall be decided by the Central Government. 
21. Powers and Duties of the Chairperson -
(1) In addition to the duties specified in the Act, the Chairperson shall have powers of 
general superintendence and directions in the conduct and management of the affairs 
of the Authority, to enable the Authority in effectively discharging its duties and 
overseeing the compliance of the provisions of the Act, and the rules and regulations 
made thereunder. 
(2) The Chairperson shall also discharge such other duties and functions as the Authority 
may by general or special order in writing delegate to him or the Central Government 
may authorise him to discharge from time to time. 
(3) The Chairperson shall convene, preside over and conduct the meetings of the 
Authority and be responsible for carrying out all decisions taken by the Authority. 
(5) The Chairperson shall guide and facilitate the development of new plant varieties by 
protecting the rights of the breeders, researchers, farmers, and community of farmers 
as provided under the Act. 
(6) The Chairperson shall facilitate and act on his satisfaction for compulsory licensing 
of registered plant varieties and advise the Central and the State Governments on the 
restriction of public use of any such registered plant varieties which may invite action 
under sub-rule (4). 
22. General functions of the Authority -
(1) The Authority shall advice the Central Government in relation to the provisions 
contained in the sub-section (2) of section 29 for specifying and notifying the genera 
and species for the purposes of registration of new plant varieties other than extant 
varieties and fanners' varieties. 
(2) The Authority shall register extant varieties under clause (a) of sub-section (2) of 
section 8 within such period as may be determined by it with suitable test criteria to 
conform distinctiveness, uniformity and stability (hereinafter referred to as PUS) of 
such varieties. 
(3) The Authority shall develop DUS test and other test criteria and conduct such tests for 
characterization of each variety of crop species notified by the Central Government. 
(4) The Authority shall compile and maintain a database on all varieties of common 
knowledge including all registered extant and farmers' varieties and such varieties 
being cultivated outside India for each crop species prior to grant for registration for 
new varieties belonging to such species. 
(5) The Authority shall be entitled to call for and procure the details of any crop variety 
under use in the country for the purpose of bringing the same into its database. 
(6) Any public or private institution, community or individual involved in the 
production and use of seed of such varieties shall be required to provide full 
information on its characteristics or and a true sample of seed of such variety. 
(7) The Authority shall keep a record of the production and sale of seed of all registered 
varieties. 
(8) It shall be necessary for all breeders of registered varieties to supply certified figures 
on annual seed production and sales to the Authority within a period not exceeding 
three months from the completion of such reporting period. 
(9) The Authority, if required shall also be entitled to call for such figures specifically 
relating to any region of the country. 
23. Matters to be included in the National Register of Plant Varieties -
The National Register of Plant Varieties shall contain the following particulars of 
each registered variety, namely: -
(1) Registration Number; 
(2) Nationality of Breeder(s); 
(3) Denomination as granted; 
(4) Date of Grant of Registration; 
(5) Date on which application was received; 
(6) Provisional number given to the application; 
(7) Date of Gazette notification; 
(8) Grouping of the plant variety (new, extant or farmers); 
(9) Classification of the variety (typical variety, hybrid variety or essentially derived 
variety); 
(10) Denomination of variety. Common Crop name to which the variety belongs, 
Taxonomical Lineage of the Crop in Botanical names; 
(11) Key Passport data of the variety; 
(12) Essential characters making the variety distinct; 
(13) Starting date of protection; 
(14) Expiry date of protection; 
(15) Date of revocation with other details (grounds etc.); 
(16) Name and address of the applicant(s); 
(17) Address for service of document(s); 
(18) Name and address of the breeder(s) (in case breeder is not the applicant); 
(19) Name and address of the legal representative (if applicable); 
(20) Name, address and other details of the licensee and terms of license (if applicable); 
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(21) Name, address and other details of the agent with jurisdictional rights, if any (if 
appointed); 
(22) Type of crop; 
(23) Name of the family, genus, species, variety and common name; 
(24) Name and address of the breeder of initial variety (in case of essentially derived 
variety); 
(25) Details of the acquisition of propagating material/ seeds (if applicable); 
(26) Details of parental material used in the development (if applicable); 
(27) Name and address of the contributor(s) of genetic material (if applicable); 
(28) Any other feature specified by the Authority or Registrar-General; 
(29) Country of origin of the plant variety; 
(30) Brief description of the variety along with characteristic details of the nearest variety 
including results of DUS testing, supplemented with the drawings or photographs or 
both; 
(31) In case of compulsory licensing, name and address of licensee with other details 
(terms and conditions, revocation, etc), if applicable; 
(32) Declaration and details of the renunciation to the variety (if applicable); 
(33) Details of benefit sharing; 
(34) Details of opposition, revocation, restoration, maintenance (whatever applicable); 
(35) In the case of varieties protected outside India prior to registration in the country, 
following additional information shall be entered in the National Register of plant 
varieties namely: -
a. Name of the country (Les) where protection is made along with the denomination of 
the variety in each of them, 
b. Date of first protection with country, 
c. Variation in important trait with respect to first filing, 
d. Country wherein the Variety was first commercialized with date, 
e. Any other feature specified by the Authority or Registrar-General; 
(36) In case of a convention application, the following information shall also be furnished, 
namely :-
a. Name of the convention country 
b. Passport data of the convention application 
c. Date of application 
d. (d)Date of grant of registration 
e. Registration number 
f. Denomination as accepted 
g. Dateof Gazette notification 
h. Starting date of protection 
i. Expiry date of protection 
j . Whether the variety has been sold or otherwise disposed of within and outside the 
country, if so, details thereof 
(37) Any changes made in any entry. 
CHAPTER III 
REGISTRATION OF PLANT VARIETY 
24. Registration of Extant Plant Varieties under sub-section (2) of section 15 -
(1) The Registrar shall register every extant variety within three years from 
the date of its notification under the Act, with respect to the genera 
and species eligible for registration subject to conformity to the criteria 
of distinctiveness, uniformity, and stability as laid down under the 
regulations: 
(2) Provided that the Registrar may, for reasons to be recorded in writing, 
register an extant variety after the expiry of the said period of three 
years. 
25. Application to authorize a person to register a variety under clause (e) of sub-section 
(1) of section 16 
An application to authorize a person to register a variety under clause (e) of sub-
section (I) of section 16 shall be made in Form PV-1, given in the First Schedule, 
by a person specified in sub-section (1) of that section. 
26. The fee payable under clause (g) of sub-section (1) of section 18 for making 
application for registration of plant variety -
The fee for making application for registration of a plant variety under section 14 
shall be such as specified in column (3) of the Second Schedule for the purpose. 
27. Proofof the right of making application under sub-section (3) of section 18 -
(1) Where an application for registration is made by the successor or assignee of the 
breeder under sub-section (3) of section 18, he shall furnish documentary proof, at the 
time of making such application or within six months of making such an application, 
as to the right to make such an application for registration. 
(2) The documentary proof, in case of an assignment, shall be furnished in the manner 
specified in Form PV - 2, given in the First Schedule and in case of succession, or a 
succession certificate or any other document in support of succession proving the 
applicant to be the successor shall be furnished. 
28. Fee for conducting tests under section 19 -
The applicant shall deposit the requisite fee for the purpose as 
specified in column (3) of the Second Schedule, with the Registrar for 
conducting the required tests under section 19. 
29. Manner and method for conducting tests under section 19 -
(1) (a) The Authority shall charge separate fees for conducting DUS test and special test on 
each variety. 
(b)The special tests shall be conducted only when DUS testing fails to establish the 
requirement of distinctiveness. 
(c)The DUS testing shall be field and multi-location based for at least two crop seasons 
and special tests be laboratory based. 
(d)The fee for DUS and special tests shall be such as provided in column (3) of the 
Second Schedule for the purpose. 
(2) If the Registrar, afiter initial scrutiny of the application for registration, is satisfied that the 
application is in order, he shall notify the applicant to deposit the requisite fee, as 
specified in column (3) of the Second Schedule, within a period of two months for 
conducting the DUS test. 
(3) On receipt of the fee, demanded under sub-rule (1), the Registrar shall consider the 
application for further processing. 
(4) The DUS test shall be necessary for all new varieties except essentially derived variety. 
(5) The manner of testing essentially derived varieties shall be decided by the Authority on a 
case-to-case basis. 
(6) The DUS test shall be conducted on a minimum of two locations. 
(7) The Authority may recognize and empanel institutions having adequate facilities for 
conducting DUS or special tests in the country for conducting such tests. 
(8) The Authority shall notify the adopted methods of conducting the DUS and special tests. 
(9) The Authority shall develop and publish in its journal guidelines for the DUS test for 
each crop. 
(10) The samples of seeds or propagules in respect of which an application for registration has 
been made and parental lines under registration submitted for the DUS and special tests 
and deposited at the National Gene Bank shall present the maintainable standards of 
genetic purity, and uniformity and germination, sanitary and phytosanitary standards. 
30. Advertising of application for registration under section 21 -
(1) Every application for registration of a variety which has been accepted and the details 
thereof including specifications shall, upon such acceptance under sub-section (1) of 
section 20, be advertised by the Registrar in the manner specified in Form - 0-1 of the 
Third Schedule. 
(2) In every such advertisement under sub-rule (I), the Registrar shall mention the place or 
places where a specimen of the variety may be inspected. 
(3) The contents of such advertisement shall include -
(a), name, passport data and source of parental line or initial variety used to develop the 
variety in respect of which an application for registration has been made ; 
(b). description of the variety bringing out its character profile as specified under the DUS 
test Schedule; 
(c). essential characteristics conferring distinctiveness to the variety ; 
(d). important agronomic and commercial attributes of the variety ; 
(e). photographs or drawings, if any, of the variety submitted by the applicant; and 
(f). claim, if any, on the variety. 
31. Notice of opposition under sub-section (2) of section 21 -
(1) Any interested person, may within three months from the date of advertisement of an 
application for registration, may give a notice of opposition to the registration of a plant 
variety in Form PV-3 of the First Schedule. 
(2) The fee payable for filing an opposition referred to in sub-rule (1) shall be as specified in 
column (3) of the Second Schedule : 
Provided that no such fee shall be payable in respect of an opposition made by a farmer 
or group of farmers, or village community. 
(3) A copy each of the notice of opposition received against a specific application shall be 
referred to the applicant by the Registrar within three months from the last date of filing 
of opposition. 
(4) An applicant shall be entitled to submit point-wise counter statement to the opposition not 
later than two months from the date of service of the copy of the notice of opposition, 
failing which the Registrar shall decide the merits of the opposition and notify his 
decision by giving reasons therefor. 
(5) Every counter-statement under sub-rule (4) shall be in Form PV-4 of the First Schedule. 
(6) The copies of counter to opposition submitted by the applicant within the time specified 
in sub-rule(4), shall be conveyed to the person opposing the application, within a period 
of thirty days of its receipt, requiring the opposing person to submit the final opposition 
within a period of thirty days from the date of service of the counter from the applicant. 
(7) The Registrar, may at his discretion, allow any correction of error or amendments in the 
notice of opposition or counter statement if such alteration is requested by the persons 
concerned in writing. 
(8) (a) The security referred to in sub-section (8) of section 21 shall be payable as an amount 
decided by the Authority. 
(b) In case the opposition is found to be frivolous, the Registrar may direct payment of cost 
as determined by him to the applicant from out of the security amount received and the 
balance of the security amount shall be deposited in the Authority. 
(c) In case the opposition succeeds, the security amount shall be refunded to the opposition 
party. 
32. Compliance with Time Schedule -
(1) The time schedule provided for advertisement, opposition, defence, hearing and 
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amendment of specification under these rules shall not be extended and failure in 
compliance with these time schedules shall forfeit the opportunity granted. 
33. Manner of submitting evidence and time limit for filing notice of opposition, 
counter-statement or producing evidences under section 21 -
(1) Any evidence, upon which the opponent may rely, shall be submitted in duplicate to the 
Registrar with a copy to the applicant within one month from the receipt of counter-
statement of the applicant. 
(2) Any evidence upon which the applicant may rely shall be submitted in duplicate to the 
Registrar with a copy to the opponent within thirty days from the date of receipt of 
opponent's evidence. 
(3) No further evidence shall be submitted by either party except by leave or directions of the 
Registrar. 
(4) The copies of all the documents, except plant variety application, referred to in the notice 
of opposition or in any counter-statement filed in connection with the opposition shall be 
in triplicate unless the Registrar directs otherwise. 
(5) Where a document, is in a language other than English, and is referred to or relied upon 
in the notice, statement or evidence, an attested translation in English thereof shall be 
furnished in triplicate. 
(6) The time-limit for filing the evidence shall not ordinarily be extended except by a special 
order of the Registrar given on an application filed by the person seeking extension of 
time and on payment of the fee specified in the Second Schedule and such an application 
for extension shall be in Form- PV 5 of the First Schedule. 
34. Application for the registration of essentially derived variety under section 23 -
(1) The application for registration of an essentially derived variety shall be 
accompanied by the following documents, namely: 
(a) an affidavit sworn by the applicant stating that such a variety does not contain any gene 
or gene sequence involving terminator technology ; 
(b) a statement giving details of the brief description of the characteristics of the variet> to 
substantiate novelty, distinctiveness, uniformity and stability; and 
(c) the details of parental material used. 
(2) The application under sub-rule (1) shall be accompanied by the fee as specified for the 
purpose in column (3) of the Second Schedule. 
35. Manner and method for conducting test under section 23 -
The tests referred to in sub-section (3) of section 23 shall be conducted by the Authority 
in consultation with the Central Government. 
36. Certificate of registration under section 23 -
The Registrar shall issue to the applicant a certificate of registration of an essentially 
derived variety in the manner specified in Form 0-2 of the Third Schedule and send a 
copy of the registration to the Authority and to such other body (les) as may be notified 
by the Central Government for information. 
CHAPTER IV 
REGISTRATION AND BENEFIT SHARING 
37. Certificate of registration under section 24 -
(1) The certificate of registration of a plant variety, other than an essentially derived variety, 
under sub-section (2) of section 24 shall be in Form 0-2 of the Third Schedule. 
(2) The Registrar shall issue the certificate of registration under sub-section (2) of section 24 
within three years of the date of filing of application subject to the fulfillment of all other 
requirements. 
(3) A copy of the certificate of registration issued under sub-section (2) of section 24 shall be 
sent to the Authority; and to such other body or agency, which the Central Government 
may, by notification in the official gazette specify. 
38. Notice to the applicant under section 24 -
(1) If, within a period of twelve months, the application for registration of a plant variety 
other than an essentially derived variety is not completed in the circumstances given in 
sub-section (3) of section 24, the Registrar shall issue thirty days notice to the applicant at 
the address of his principal place of business in India, or if, he has no principal place of 
business in India, at the address for service in India stated in the application, but if the 
applicant has authorized an agent for the purpose of the application, the notice shall be 
sent to the agent and a duplicate thereof to the applicant for filing of the application or 
such further time as the Registrar may allow for completion of registration. 
(2) The notice under sub-rule (1) shall be in Form 0-3 of the Third Schedule. 
39. Renewal and revision of registration under section 24 -
(1) (a) On receipt of an application from the applicant, the Authority may review and renew 
the initial duration of registration as mentioned in sub-section (6) of section 24. 
(b) Every application for review and renewal under sub-rule (1) shall be made in Form 
PV-6 of the First Schedule and filed during twelve to eighteen months prior to the expiry 
of the initial period of registration. 
(c) Every application under sub-rule (I) shall be accompanied with the fee payable for the 
remaining years under the initial period of registration, at the rate fixed for the year 
preceding the year of application, along with arrears, if any. 
(2) (a) The renewal of registration may be applied for either for the remaining period of total 
aggregate duration of validity of the registration or for any period within such remaining 
period. 
(b) In case, the applicant prefers for a period less than the total aggregate duration, no 
application shall be entertained for the further renewal of registration. 
(3) (a) The fee payable for such extended period of registration beyond nine years in the case 
of trees and vines and six years in the case of other crop varieties, as the case may be, 
shall be based on average annual fee levied during the last two years of the said initial 
period of registration. 
(b) The annual fee shall be uniform for the extended period of the registration and be payable 
in advance in single instalment. 
(4) The Authority shall within such intervals as it thinks appropriate publish a list of varieties 
registered as well as renewed under the Act with the particulars of the period of 
registration, name and address of right holders periodically in its journal and in the 
Official Gazette. 
40. Publication of contents of the certificate inviting claims for beneflt sharing under 
section 26 -
Upon the issuance of the registration certificate under sub-section (8) of section 23, or 
sub-section (2) of section 24, the Authority shall, for the purpose of inviting claims for 
benefit sharing under the Act, shall advertise the following details of the registration 
certificate, namely -
(a) the registration number along with the date of grant, 
(b) the name and address of the applicant or breeder in whose name the certificate has been 
issued or registered, 
(c) denominationof the variety, 
(d) name of the family, genus, species, variety and common name, 
(e) parentage and geographical location of the variety, 
(f) the details of the distinguishing features or the characteristics, 
(g) in case of'essentially derived variety', the details of the 'initial variety' from which the 
'essentially derived variety' is claimed to have been derived. 
(h) the name and address of the contributor, nature and amount of the contribution or the 
community knowledge used in the development of the plant variety. 
(i) the terms and conditions of the agreement, if any, entered into between the breeder and 
the contributor. 
(j) if the variety is sold or otherwise disposed of, details thereof. 
41. Benefit sharing claim under section 26 -
12 
(1) Upon the publication of the particulars of a certificate under sub-section (1) of section 26, 
a person or group of persons or firm or a non-governmental organization can make a 
claim under sub-section (2) of that section for benefit sharing in Form PV-7 of the First 
Schedule within a period of six months from the date of such publication. Provided that 
in special circumstances, the Authority may extend the time limit beyond the period of six 
months. 
(2) The person or persons or firm or the non-governmental organization, who has made an 
application for benefit sharing, shall provide the following information, namely : 
(a) the contribution made by the person or the group of persons or firm or community or the 
non-governmental organisations to the genetic development of the plant variety ; 
(b) the capacity in which the person or the group of persons or the non-governmental 
organisation is making the claim for benefit sharing ; 
(c) in case of "essentially derived varieties", the terms and conditions in which authorisation 
has been given; 
(d) the commercial viability or the actual market performance of the variety so registered. 
(3) An applicant for benefit sharing shall pay the fee as specified for the purpose, in column 
(3) of the Second Schedule. 
42. Opposition to a claim for benefit sharing under section 26 -
(1) On receipt of a copy of the claim for benefit sharing, the registered breeder of the plant 
variety may accept the claim and accordingly intimate the same to the Authority within a 
period of three months from the date of such receipt.. 
(2) In the eventuality of the plant breeder failing or defaulting to tender the intimation under 
sub-rule(l) within the period of three months, referred to in sub-rule(l) it shall be 
presumed that he has no opposition to such claim and the claim shall be decided 
accordingly. 
(3) If, within a period of three months of receipt of notice of claim, the breeder of the plant 
variety files his opposition to the claim for benefit sharing, such an opposition shall be 
taken into consideration while disposing or deciding the claim for benefit sharing. 
(4) Every notice of opposition, under sub-rule(3) shall be in Form PV-8 of the First 
Schedule. 
(5) The Authority, upon receiving the reply from the registered breeder, shall furnish a copy 
of such reply to the claimant for benefit sharing. 
(6) The registered breeder or the claimant to benefit sharing shall furnish supporting 
document and other evidence, which shall be duly considered by the Authority while 
disposing of any claim for benefit sharing. 
43. Determination of benefit sharing under section 26 -
The Authority shall, by order, determine the amount of benefit sharing to a variety 
according to clauses (a) and (b) of sub-section (5) of section 26 and taking into account 
the following criteria, namely -
(a) the contribution of the claimant in selecting, conserving and providing the genetic 
material, 
(b) the contribution of such genetic material in providing one or more traits which conferred 
high commercial value to the variety, and 
(c) the contribution of such genetic material to impajt high combining ability to the parents 
of the hybrid variety relating to benefit sharing. 
44. Reference for recovering benefit sharing under section 26 -
In case of default or failure on the part of the breeder of the variety to deposit the amount 
of benefit sharing in the Gene Fund, as per the order of the Authority of section 26, 
required under sub-section(6) within a period of three months from the date of such 
order, the Registrar shall make a reference to the District Magistrate under sub-section 
(7) of that section 26 in Form 0-4 of the Third Schedule. 
45. Application for registration of title of agent or licensee under section 28 -
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(1) An application under sub-section (4) of section 28 for registration as an agent or 
licensee, as the case may be, shall be made in Form PV-9 of the First Schedule. 
(2) The application for title by a licensee or an agent shall be accompanied by three attested 
copies of the agreement or instrument of entitlement or any other documentary 
evidence. 
(3) The proposed agent or licensee may also be required to produce such other documents 
and information as may be required by the Registrar in support of the proof of title. 
(4) The applicant under sub-section (4) of section 28 shall pay the fee as specified for the 
purpose in column (3) of the Second Schedule. 
46. Referenceof disputes of entitlement under section 28 -
(1) While referring a dispute under sub-section (4) of section 28 to the Authority for 
determination the Registrar shall furnish all the relevant information related to dispute 
with three copies of all the documents and evidence available with his office. 
(2) On receipt of an order of the Authority in respect of the dispute, the Registrar shall 
furnish copies of the order to the persons involved for necessary compliance. 
47. Certificate of registration of entitlement under section 28 -
The certificate of registration to be issued to a registered licensee or an agent by the 
Registrar under sub-section (4) of section 28 shall be in Form 0-5 of the Third 
Schedule. 
48. Application and procedure for varying or cancelling terms of registration under 
section 28 -
(1) An application under clauses (a), (b), (c), (d), or (e) of sub-section (9) of section 28 for 
variation or cancellation of the terms of registration of a registered breeder or his 
successor or any other person shall be in Form PV-10 of the First Schedule. 
(2) Every applications under sub-rule (1) shall be accompanied by a fee as specified for the 
purpose in column (3) of the Second Schedule. 
49. Notice and proceedings under section 28 -
(I) The Registrar shall issue notice of every application under sub-section (10) of section 28 
in Form O- 6 of the Third Schedule to the registered breeder or the agent or the licensee. 
(2) Any person to whom a notice has been issued under sub-rule (!) and who intends to 
oppose or intervene in any proceedings under section 28, shall, within three months of 
the receipt of such notice, give notice of opposition or intervention to the Registrar in 
Form PV-11 of the First Schedule. 
(3) On receipt of a notice of opposition or intervention the Registrar shall furnish a copy of it 
to the applicant. 
(4) The Registrar may accept or refuse the application or accept it subject to any condition, 
modification or limitation as directed by the Authority and shall inform the parties in 
writing accordingly. 
CHAPTER V 
SURRENDER AND REVOCATION OF CERTIFICATE OF REGISTRATION AND 
RECTIFICATION AND CORRECTION OF REGISTER 
50. Surrender of certificate of registration under section 33 -
The registered breeder may at any time, by giving notice to the Registrar offer to 
surrender his certificate of registration of plant variety in Form PV-12 of the First 
Schedule, under sub-section (1) of section 33. 
51. Procedure on application for surrender of certificate of registration under section 33 
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(1) The Registrar shall give notice in Form 0-7 of the Third Schedule, every notice of 
offer made under rule 50 to the registered agent or the licensee relating to such 
certificate. 
(2) (a) Any person who has been given a notice of surrender of certificate of registration 
under sub-rule (1), who intends to oppose the surrender, shall within three month of 
the receipt of such notice, give notice of opposition to the Registrar in Form PV-13 of 
the First Schedule, and shall send therewith a written statement setting out the nature 
of the opponents' interest, the facts relied upon along with the notice of opposition. 
(b) The Registrar shall thereupon serve the notice of opposition along with the written 
statement received by him to the applicant. 
(3) If the applicant desires to contest the opposition, he shall file or leave at the 
appropriate office a reply statement setting out fully the grounds upon which 
the opposition is contested, within a period of three month from the date of receipt of 
the copy of the written statement by him under sub-rule (2) and deliver to the opponent 
a copy thereof 
(4) The applicant or any person to whom a notice under sub-rule (1) has been issued may, 
make an application to the Registrar in Form FV-14 of the First Schedule, for seeking 
an opportunity of being heard. 
(5) On receipt of an application, under sub-rule(4), the Registrar may fix the time and 
place of hearing and issue notice to the parties accordingly and the interested parties 
may appear and give or file evidence in support of their case. 
(6) The Registrar may accept or refuse the application or accept it subject to any condition, 
amendments, modifications or limitations and shall, accordingly, inform the parties in 
writing. 
(7) If the Registrar accepts the registered breeder's offer of surrender of the plant variety, 
he shall by order direct the registered breeder to return the certificate of registration and 
on receipt of such certificate, the Registrar shall, by order, notify the surrender in the 
Official Gazette. 
52, Application for revocation of protection granted to a breeder under section 34 -
Any person may make an application to the Authority in Form PV-15 of the First 
Schedule, for revocation of protection granted to a breeder in respect of a variety on 
any of the grounds laid down under clauses (a) to (h) of section 34. 
53. Procedure on application for revocation under rule 52 -
(1) The Authority shall issue notice in Form 0-8 of the Third Schedule, to the registered 
breeder of any application received by it under rule 52. 
(2) (a) In case the registered breeder intends to oppose the application for revocation of 
protection, he shall, within three months from the date of receipt of such notice, give 
notice of opposition to the Authority in Form PV-16 of the First Schedule, and shall 
send therewith a written statement, setting out the facts upon which he bases his case 
and the relief sought. 
(b) The Registrar shall serve the notice of opposition along with the written statement 
received by him to the applicant. 
(3) If the applicant desires to contest the opposition, he shall file or leave at the 
appropriate office, a reply setting out the grounds upon which the opposition is 
contested, within a period of three months from the date of receipt of the copy of 
the written statement by him under sub-rule (2) and deliver to the opponent a copy 
thereof 
(4) (a) The applicant and the registered breeder may make an application to the Registrar in 
Form PV-17 of the First Schedule, seeking an opportunity of being heard. 
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(b) The Registrar may, on receipt of such appUcation, fix such time and place for hearing 
and issue notice to the parties accordingly and the interested parties may appear and give 
or file evidence in support of his case. 
(c) The Registrar may, accept or refuse the application or accept it subject to any 
condition, amendments, modifications or limitations and shall, accordingly inform the 
parties in writing. 
(5) If the Authority accepts the application for revocation of the plant variety, it may direct, 
by order, the registered breeder to return the certificate of registration and on receipt of 
such a certificate, the Registrar shall by order notify the revocation of the plant variety in 
the Official Gazette. 
54. Payment of annual fee for retention of registration under section 35 -
The registered breeder, agent and licensee shall pay an annual fee for retention of 
registration at such rate as specified for the purpose in column (3) of the Second 
Schedule. 
55. Application for cancellation or change of certificate of registration under section 
36-
(1) Any person may make an application for changing the certificate of registration on the 
grounds laid down under sub-section (I) of section 36 to the Registrar. 
(2) Every application under sub-rule (1) shall be made in Form PV-18 of the First 
Schedule and shall be accompanied by a statement of the grounds on which it is made. 
56. Procedure on application for cancellation or change of certificate of registration 
under section 36 -
The Registrar may accept or refuse the application or accept it subject to any condition, 
amendment, modification or limitation as he may think fit to impose and shall inform 
the concerned parties in writing accordingly : 
Provided that no application shall be rejected unless the applicant has been given a 
reasonable opportunity to make a representation against such rejection. 
57. Application to rectify the register under section 36 -
Any person may make an application to the Registrar, in Form PV-19 of the First 
Schedule, stating the grounds on which it is made, for making, expunging or varying 
the entry on the grounds laid down under sub -section (2) of section 36. 
58. Procedure on application to rectify the Register under rule 57 -
The Registrar may accept or refuse the application for making, expunging or varying 
the entry or accept it subject to any condition, amendment, modification or limitation 
as he may think fit to impose and shall inform the concerned parties in writing 
accordingly; 
Provided that no application shall be rejected unless the applicant has been given a 
reasonable opportunity to make a representation against such rejection. 
59. Cancellation or change of registration or rectification of the Register by the 
Registrar under section 36 -
(1) The Registrar while exercising the powers under sub-section (4) of section 36 to cancel 
the registration, may make changes to the registration, or in case of rectification of the 
register, shall give notice in Form 0-9 of the Third Schedule to the registered 
breeder, agent or licensee, if any, and to any other person who appears to the Registrar to 
have any interest in the plant variety, and shall state the grounds on which the Registrar 
intends to take any action. 
(2) If any person who has been given a notice under sub-rule (1) intends to oppose the action 
of the Registrar, he shall within three month from the date of the receipt of such notice, 
give the notice of opposition to the Registrar in Form PV-20 of the First Schedule, 
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and shall send therewith a written statement setting out the facts upon which he bases his 
case and the relief sought for. 
(3) The Registrar after hearing the person to whom a notice under sub-rule (1) has been 
given may pass such order as he may think fit and shall, accordingly, inform the parties 
in writing. 
60. Application for correction of Register by the registered breeder under section 37 -
An application for correction of the Register may be made by the registered breeder of 
the plant variety to the Registrar under sub-section (1) of section 37 in Form PV-21 of 
the First Schedule, for making any change as laid down in clauses (a) to (c) of sub-
section (1) of that section. 
61. Procedure on application for correction of the Register under rule 60 -
The Registrar may accept or refuse the application made under rule 60 for correction of 
register or accept it subject to any condition, amendments, modifications or limitations 
as he may think fit and shall, accordingly, inform the parties in writing. 
62. Application for correction of the Register by the registered agent or licensee under 
section 37 -
An application for correction of the Register may also be made by the registered agent 
or the licensee to the Registrar under sub-section (2) of section 37 in Form PV-22 of the 
First Schedule on the grounds laid down in sub-section (2) of that section. 
63. Provided that no application shall be rejected unless the applicant has been given a 
reasonable opportunity to make a representation against such rejection. 
64. Alteration of denomination of a registered variety under section 38 -
(1) An application, to delete any part or to add or to alter the denomination of a registered 
variety, under sub-section (I) of section 38, shall be made by the breeder to the Registrar 
in Form PV-23 of the First Schedule. 
(2) The Registrar may determine whether and subject to what conditions, if any, the 
amendments shall be allowed. 
(3) (a) The Registrar shall advertise the application for alteration in denomination in the 
Gazette or a journal or a daily newspaper and shall also advertise the nature of the 
proposed alteration in the denomination therein. 
(b) The Registrar shall issue notice to all the persons, who, in his opinion, may have an 
interest in the matter. 
65. Procedure on application for alteration of denomination under rule 64 -
(1) Any interested person may, within three months from the date of advertisement of an 
application for alteration in denomination of a registered variety, under sub-section (2) of 
section 38, give a notice of opposition to the proposed change in denomination of a 
registered variety in Form PV -24 of the First Schedule. 
(2) The Registrar shall serve a notice to the breeder about the opposition received for the 
proposed change in denomination and shall give an opportunity to both the parties of 
being heard, if so desired, before deciding the matter. 
(3) In the event of leave being granted for alteration of denomination, the denomination as 
so altered shall be advertised in Gazette or a journal or a daily newspaper in Form O-ll 
of the Third Schedule. 
CHAPTER VI 
FARMERS' RIGHTS 
66. Claim for compensation under section 39 -
(1) Any farmer, group of farmers or the organisation of the farmers may make an 
application, under sub-section (2) of section 39, to the Authority to claim 
compensation. 
(2) Every application under sub-rule (I) shall be in Form PV-25 of the First Schedule. 
67. Procedure on application for claim for compensation under rule 66 -
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(1) The Authority shall give notice to the registered breeder about the compensation 
claim received in respect of the registered variety. 
(2) After receiving a notice from the Authority under sub-rule (1), the registered breeder 
may, within three months from the date of receipt of such notice, file notice of 
opposition in Form PV-26 of the First Schedule. 
(3) In the eventuality of the breeder failing or defaulting to tender his opposition, within a 
period of three months, from the date of receipt of the notice for compensation, it 
shall be presumed that he has no opposition to such claim and accordingly such claim 
shall be decided. 
(4) The Authority shall, upon receiving opposition from the breeder give opportunity to 
both the parties of being heard and may direct the breeder to pay such compensation 
to the farmer, the group of farmers or the organisation of the fanners, as the case may 
be as it deems fit. 
68. Issue of notice under section 41 -
(1) On receiving the report from the centre notified under sub-section (1) of section 41, 
in respect of claims filed by a person or group of persons or governmental or non-
governmental organisation, for compensation to the people of any village or local 
community for their contribution in the development of new variety, and if satisfied, 
the Authority may issue notice to the registered breeder or his assignee or registered 
agent in Form 0-12 of the Third Schedule. 
(2) Upon receiving the notice from the Authority, the registered breeder or his assignee 
or registered agent may file objection to the claim for compensation within three 
months in Form PV-27 of the First Schedule. 
(3) The Authority, upon receiving objection from the registered breeder or his assignee 
or registered agent, shall give opportunity of being heard to both the parties and after 
deciding on the eligibility for and quantum of compensation shall, direct, the breeder 
to pay compensation to the person, the group of persons or governmental or non-
governmental organisation which has made the claim under sub-section (1) of section 
41 and deposit the requisite funds within a period of two months with the Gene Fund 
69. Manner of receiving benefit sharing under section 45 -
The breeder of a variety or essentially derived variety shall deposit the amount of 
benefit sharing, as required under sub-section (6) of section 26, with the Gene Fund. 
70. Manner of applying the Gene Fund under section 45: -
(1) The Authority shall pay the amount of benefit sharing, compensation required for use 
of genetic material towards evolution of new and essentially derived variety, to meet 
expenditure incurred for conservation and sustainable use of genetic resources and 
for the framing of schemes related to benefit sharing. 
(2) The Gene Fund shall be applied for meeting the following purposes in accordance 
with the priority made hereunder :-
(a) to support and reward farmers, community of farmers, particularly the tribal and rural 
communities engaged in conservation, improvement and preservation of genetic 
resources of economic plants and their wild relatives, particularly in areas identified 
as agro-biodiversity hot spots; 
(b) for capacity building on ex situ conservation at the level of the local body, 
particularly in regions identified as agro-biodiversity hot spots and for supporting in-
situ conservation; 
(c) on benefit sharing and compensation in accordance with sub-section (5) of section 26 
and sub-section (3) of section 41; and 
(d) on transaction cost of administering the Gene Fund. 
CHAPTER VII 
COMPULSORY LICENSE 
71. Compulsory licensing under section 47 -
(1) Any interested person may, after the expiry of three years from the date of issuance of 
a certificate of registration of a variety make an application to the Authority, in the 
Form PV-28 of the First Schedule along with the fee specified under the Second 
Schedule under sub-section (1) of section 47 for grant of compulsory license. 
(2) The application for compulsory license under sub-section (1) shall -
(a) specifies particulars of variety denomination, generic and specific name of the variety 
or varieties concerned, 
(b) contain the grounds for issue of compulsory license with supporting documents, and 
(c) be supported by -
i) qualification, technical and financial capabilities of the person making such request 
with evidence, 
ii) particulars of the holder of the right to the variety, 
iii) written evidence that the person, making such request, has exhausted all measures for 
voluntary license. 
(3) If after considering the application under sub-rule (1), the Authority is satisfied that 
a prima facie case has not been made for grant of compulsory license, it shall notify 
the applicant accordingly. 
(4) On receipt of an application for grant of compulsory license under sub- rule( 1), the 
Authority shall serve notice to the breeder of such variety or his assignee or 
registered agent inviting his opposition within one month from the receipt of such 
notice. 
(5) On receiving a notice under sub-rule(4), the registered breeder or his assignee or 
registered agent may give notice of opposition in Form PV-29 of the First Schedule, 
which shall be supported by documentary proof to substantiate the ground or grounds 
of opposition. 
(6) If after giving an opportunity to both the parties of being heard, the Authority is 
satisfied that there is a need for the grant of compulsory license, he may order the 
breeder or his assignee or registered agent to license the variety on such terms of 
royalties and other remuneration as it may deem fit. 
72. Manner of making material available under section 50 -
The Authority shall make available to the licensee of such compulsory license, the 
reproductive material of the licensed variety from the Gene Bank or any other centre, 
including the initial breeder of such variety. 
73. Revocation of compulsory license under section 52 -
1 (a) Any person in respect of compulsory license aggrieved may, under sub-section (1) 
of secfion 52, make an application in Form PV-30 of the First Schedule to the 
Authority, for revocation of compulsory license on any of the grounds specified in 
sub-section (1) of section 47 or section 52. 
(b) The application under sub-rule(l), shall be supported by evidence. 
2. The Authority on its own motion or on receipt of the application from the aggrieved 
person under sub-rule(l), may give notice to the licensee. 
3. The licensee may file an opposition to an application under sub-rules (1) or a 
proceeding under sub-rule(2), in Form PV-31 of First Schedule with the Authority, 
4. The Authority shall after considering the opposition filed under sub-rule (3) and after 
giving an opportunity to the licensee of being heard passing an order of revocation or 
refiise to grant such order, 
CHAPTER VIII 
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74. 
(0 
(2) 
FINANCE, ACCOUNTS AND AUDIT 
Financial and administrative powers of the Chairperson under section 63 -
The Chairperson shall exercise such financial and administrative powers over the 
functions of the Authority as are exercisable by a Head of Department under the 
General Financial Rules in accordance with the accounts and financial rules of the 
Government of India. 
The Chairperson may, delegate such financial and administrative powers in writing 
as he may deem fit, to a member or any subordinate officer of the Authority not 
below the rank of a Registrar or equivalent subject to the condition that the member 
or officer so authorised shall, write exercise such delegated powers continue to be 
under the direction, control and supervision of the Chairperson. 
CHAPTER IX 
MISCELLANEOUS 
75. Manner of authorising registered agent or registered licensee under 
section 81 -
(1) A breeder of a variety or it's propagating material or essentially derived variety or it's 
propagating material registered under the Act, may make an application under section 
81, in Form PV-32 of the First Schedule, for authorising the registered agent or 
registered licensee or his assignee to institute appropriate proceedings in any court of 
law on his behalf 
(2) Where any authorization has been made under sub-rule (1), the service upon the 
agent of any document relating to any proceeding or matter under the Act or these 
rules shall be presumed to be a service upon the person so authorizing him; and all 
communications directed to be made to a person in respect of any proceeding or 
matter may be addressed to such agent, and all appearances before the Authority 
relating thereto may be made by or through such agent. 
(3) Notwithstanding any thing contained in sub-rules (1) and (2), the Authority may, if it 
considers necessary, require the signature or presence of an applicant, opponent or 
party to such proceeding or matter. 
76. Manner of issuing certified copy under section 84 -
Any interested person may, under section 84, make an application in Form PV-33 of 
the First Schedule, along with fee specified in the Second Schedule, to the Authority 
or Registrar for obtaining certified copies of any entry in the Register, certificates or 
extracts of plant variety application or other records maintained by the Authority and 
any document required in any proceedings under this Act and pending before such 
Authority or Registrar; and he may make a request in similar manner and for similar 
purpose to inspect such entry or document. 
Forms 
First Schedule 
{See rule 3(1)} 
Form 
number 
0) 
PVl 
PV2 
PV3 
PV4 
PV5 
Sections And Rules 
(2) 
Section 16(1) (e) and Rule25 
Section I8(3)and Rule27 (2) 
Section 21(2) and Rule 31 
Section 21(4) and Rule 31(5) 
Section 21 and Rule 33(6) 
Title 
(3) 
Application for authorization 
Proof of Right to file Application 
Notice of Opposition 
Counter-Statement 
Request for Extension of Time 
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PV6 
PV7 
PV8 
PV9 
PVIO 
P V l l 
PV12 
PV13 
PV14 
PV15 
PV16 
PV17 
PV18 
PV19 
PV20 
PV21 
PV22 
PV23 
PV24 
PV25 
PV26 
FV27 
PV28 
PV29 
PV30 
Section 24(6) and Rule 39 
Section 26(2) and Rule 41 
Section 26(3) and Rule 42 
Section 28(4) and Rule 45 
Section 28(9) and Rule 48 
Section 28 (10) and Rule 49 
Section 33(1) and Rule 50 
Section 33(3) and RuleSl (2) 
Section 33(4) and Rule 51(4) 
Section 34 and Rule 52 
Section 34 and Rule 53 
Section 34 and Rule 53(4) 
Section 36(1) and Rule 55 
Section 36(2) and Rule 57 
Section 36(4) and Rule 59 
Section 37(1) and Rule 60 
Section 37 (2) and Rule 62 
Section 38(1) and Rule 64 
Section 38(2) and Rule 65 
Section 39(2) and Rule 66 
Section 39(2) and Rule 67(2) 
Section 41(3) and Rule 68 
Section 47(1) and Rule 71(1) 
Section 47(3) and Rule 71(5) 
Section 52(1) and Rule 73(1) 
Renewal of Registration 
Benefit Sharing Application 
Notice of Opposition 
Registration as an Agent or Licensee 
Application for Variation/Cancellation 
of the term of Registration 
Notice of Opposition against variation/ 
cancellation of the term of Registration 
Application to Surrender the Certificate of 
Registration of a Plant Variety 
Notice of Opposition for offer to surrender 
the Certificate 
Notice of Intention to attend Hearing 
Application to Revoke Certificate of 
Registration 
Notice of Opposition to application to 
Revoke Certificate of Registration 
Application for an opportunity of being 
heard 
Application for Cancellation or Change of 
the Certificate of Registration of a Plant 
Variety 
Application for correction in National 
Plant Variety Register 
Notice of Opposition for Application for 
correction in National Plant Variety 
Register 
Application for correction in National 
Plant Variety Register by Owner/ Breeder 
Application for correction in National 
Plant Variety Register by Registered 
Agent or Licensee 
Application to alter Denomination of a 
Registered Plant Variety 
Notice of Opposition to Application to 
Alter Denomination of a Registered Plant 
Variety 
Application for Claiming Compensation 
Notice of Opposition to Application for 
Claiming Compensation 
Notice of opposition to application for 
claiming compensation 
Application for grant of compulsory 
license 
Notice of Opposition to an Application for 
Grant of Compulsory License 
Application for Revocation of Compulsory 
License 
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PV31 
PV32 
PV33 
Section 53 and Rule 73(3) 
Section 81 and Rule 75(1) 
Section 84 & Rule 76 
Notice of Opposition for Application for 
Revocation of Compulsory License 
Form of Authorization to Institute Suit. 
Request for Certified Copy 
Second Schedule 
(see rule 8) 
FEE 
Serial 
number 
(1) 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
Fees payable on matters 
(2) 
Conducting Tests 
Notice of Opposition 
Extension of Time 
Fees for Registration of Essentially 
Derived Varieties 
Renewal Fee 
Application for Benefit Sharing 
Application for Registering as Agent 
/Licensee 
Application for variation/ 
cancellation of the terms of 
Registration 
Notice of Opposition to Application 
for variation/cancellation of terms of 
Registration 
Amount of fee 
(3) 
Dependent on the 
nature and type of 
test subject to a 
maximum of Rs. 
50,000/- per entry 
Rsl500/-
Rs. 1500 per month 
Individual-5000 
Educational-7000 
Commercial-10000 
lndividuai-5000 
Educational-7000 
Commercial-10000 
Per year 
Rs 5000 
Rs 10000 
Individual-3000 
Educational-5000 
Commercial-7000 
Rs.1500/-
Form 
number 
(4) 
PV3 
PV5 
PV6 
PV7 
PV9 
PVIO 
PV II 
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Third Schedule 
{See rule 2(c)} 
Forms To Be Used By Registrar And The Central Government 
Form 
Number 
0-1 
0-2 
0-3 
0 -4 
0-5 
0-6 
0-7 
0-8 
0-9 
O-IO 
0-11 
0-12 
Sections and Rules 
Section 21(1) and Rule 30 
Section 23 (8) and 24(2) and 
Rule 36, 37 
Section 24(3) and Rule 38 
Section 26(7) and Rule 44 
Section 28 (4) and Rule 47 
Section 28(10) and Rule 49 
Section 33(2) and Rule 51 
Section 34 and Rule 53 
Section 36(4) and Rule 59 
Section 37(2) and Rule 63 
Section 38(2) and Rule 65(3) 
Section 41(1) and Rule 68 
Title 
Form of advertisement 
Certificate of registration 
Notice for non completion of registration 
Reference to District Magistrate for 
collection of benefit sharing amount 
Certificate of registration as agent/ 
licensee 
Notice to breeder/agent/ licensee 
To notify offer made for surrender of 
registered variety. 
Notice of application for revocation of 
registered variety 
Change in National Register 
Correction in National register 
Advertisement of Alteration in 
Denomination 
Notice for change in Denomination 
Fourth Schedule 
{See rule 20(1)} 
SI. 
No(l) 
1 
2 
3 
Name of 
post (2) 
Financial 
Advisor 
Legal 
Advisor 
Senior 
Accounts 
Officer 
Number 
of posts 
(3) 
1 
2 
1 
Equivalent Post 
under the Central 
Government (4) 
Director 
Deputy Secretary 
Under Secretary 
Scale of 
pay (5) 
14,300-
18,300 
10,000-
15,200 
10,000-
15,200 
Qualifications and 
experience 
(6) 
A Degree from a 
recognized University or 
equivalent at least eight 
years experience in 
financial/Accounts 
management. 
An Advocate at least eight 
years practice as such and 
having special knowledge 
in Intellectual Properties, 
Management and 
Transactions. 
A Degree in Commerce 
from a recognized 
University or equivalent 
with at least eight years 
experience as an Accounts 
Officer. 
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4 
5 
6 
Accounts 
Officer 
Technical 
Assistant 
Computer 
Assistant 
1 
6 
5 
Assistant Director 
Technical 
Assistant 
8000-
13,500 
5,500-
9,000 
5,500-
9,000 
A Degree in Commerce or 
Economics as one of the 
subject at Degree level 
from a recognized 
University with at least six 
years experience on 
accounts related matters. 
A Degree in Agricultural 
Science or allied field like 
botany or biotechnology 
with at least 4 year 
experience in plant varietal 
improvements and seed 
development activities. 
A Degree from a 
recognized University in 
Computer Applications and 
at least one year experience 
in Data Base Management. 
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THE BIOLOGICAL DIVERSITY ACT, 2002 
No. 18 OF 2003 
(s" February, 2003) 
An Act to provide for conservation of biological diversity, sustainable use of its components 
and fair and equitable sharing of the benefits arising out of the use of biological resources, 
knowledge and for matters connected therewith or incidental thereto. 
Whereas India is rich in biological diversity and associated traditional and contemporary 
knowledge system relating thereto; 
And whereas India is a party to the United Nations Convention on Biological Diversity signed 
th 
at Rio Janerio on the 5 day of June, 1992; 
III 
And whereas the said Convention came into force on the 29 December, 1993; 
And whereas the said Convention reaffirms the sovereign rights of the States over their 
biological resources; 
And whereas the said Convention has the main objective of conservation of biological 
diversity, sustainable use of its components and fair and equitable sharing of the benefits 
arising out of utilization of genetic resources; 
And whereas it is considered necessary to provide for conservation, sustainable utilization and 
equitable sharing of the benefits arising out of utilization of genetic resources and also to give 
effect to the said Convention. 
Be it enacted by Parliament in the Fifty-third Year of the Republic of India as follows:-
CHAPTERI 
PRELIMINARY 
1. (I) This Act may be called the Biological Diversity Act, 2002. 
(2) It extends to the whole of India. 
(3) It shall come into force on such date as the Central Government may, by notification 
in the Official Gazette, appoint: 
Provided that different dates may be appointed for different provisions of this Act and 
any reference in any such provision to the commencement of this Act shall be construed 
as a reference to the coming into force of that provision. 
2. In this Act, unless the context otherwise requires:-
(a) "benefit claimers" means the conservers of biological resources, their by products, 
creators and holders of knowledge and information relating to the use of such 
biological resources, innovations and practices associated with such use and 
application; 
(b) "biological diversity" means the variability among living organisms from all sources 
and the ecological complexes of which they are part and includes diversity within 
species or between species and of eco-systems; 
(c) "biological resources" means plants, animals and micro-organisms or parts thereof, 
their genetic material and by-products (excluding value added products) with actual 
or potential use or value, but does not include human genetic material; 
(d) "bio-survey and bio-utilisation" means survey or collection of species, sub-species, 
genes, components and extracts of biological resource for any purpose and includes 
characterization, inventorisation and bioassay; 
(e) "Chairperson" means the Chairperson of the national Biodiversity Authority or, as the 
case may be, of the State Biodiversity Board; 
(f) "commercial utilization" means end uses of biological resources for commercial 
utilization such as drugs, industrial enzymes, food flavours, fragrance, cosmetics, 
emulsifiers, oleoresins, colours, extracts and genes used for improving crops and 
livestock through genetic intervention, but does not include conventional breeding or 
traditional practices in use in any agriculture, horticulture, poultry, dairy fanning, 
animal husbandry or bee keeping; 
(g) "fair and equitable sharing" means sharing of benefits as determined by the National 
Biodiversity Authority under section 21; 
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(h) "local bodies" means Panchayats and Municipalities, by whatever name called, within 
the meaning of clause (1) article 243B and clause (1) of article 243Q of the 
Constitution and in the absence of any Panchayats or Municipalities, institutions of 
self-government constituted under any other provision of the Constitution or any 
Central Act or State Act; 
(i) "member" means a member of the National Biodiversity Authority or a State 
Biodiversity Board and includes the Chairperson; 
(j) "National Biodiversity Authority" means the National Biodiversity Authority 
established under section 8; 
(k) "prescribed" means prescribed by rules made under this Act; 
(1) "regulations" means regulations made under this Act; 
(m) "research" means study or systematic investigation of any biological resource or 
technological application, that uses biological systems, living organisms or 
derivatives thereof to make or modify products or processes for any use; 
(n) "State Biodiversity Board" means the State Biodiversity Board established under 
section 22; 
(o) "sustainable use" means the use of components of biological diversity in such 
manner and at such rate that does not lead to the decline of the biological diversity 
thereby maintaining its potential to meet the needs and aspirations pf present and 
future generations; 
(p) "value added products" means products which may contain portions or extracts of 
plants and animals in unrecognizable and physical inseparable form. 
CHAPTER II 
Regulation of Access to Biological Diversity 
(1) No person referred to in sub-section (2) shall, without previous approval of the 
National Biodiversity Authority, obtain any biological resource occurring in India or 
knowledge associated thereto for research or for commercial utilization or for bio-
survey and bio-utilisation. 
of India, and such institutions in other countries, if such collaborative research 
projects satisfy the conditions specified in sub-section (3). 
(2) All collaborative research projects, other than those referred to in sub-section (!) 
which are based on agreements concluded before the commencement of this Act and 
in force shall, to the extent the provisions of agreement are inconsistent with the 
provisions of this Act or any guidelines issued under clause (a) of sub- section (3), be 
void: 
(3) For he purposes of sub-section (1), collaborative research projects shall -
(a) conform to the policy guidelines issued by the Central Government in this behalf; 
(b) be approved by the Central Government 
6. (1) No person shall apply for any intellectual property right, by whatever name 
called, in or outside India for any invention based on any research or information on a 
biological resource obtained from India without obtaining the previous approval of 
the National Biodiversity Authority before making such application: 
(2) The persons who shall be required to take the approval of the National Biodiversity 
Authority under sub-section (1) are the following, namely :-
(a) a person who is not a citizen of India; 
(b) a citizen of India; who is a non-resident as defined in clause (30) of section 243 of 
1961 of the Income-tax Act, 1961; 
(c) a body corporate, association or organization -
(i) not incorporated or registered in India; or 
(ii) incorporated or registered in India under any law for the time being in force which 
has any non-Indian participation in its share capital or management. 
4. No person shall, without the previous approval of the National Biodiversit)' 
Authority, transfer the results of any research relating to any biological resources 
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occurring in, or obtained from, India for monetary consideration or otherwise to any 
person who is not a citizen of India who is non-resident as defined in clause (30) of 
the Income-tax Act, 1961 or a body corporate or organization which is not registered 
or incorporated in India or which has any non-Indian participation in its share capital 
or management. 
Explanation - For the purposes of this section, "transfer" does not include publication of 
research papers or dissemination of knowledge in any seminar or workshop, if such 
publication is as per the guidelines issued by the Central Government. 
5. (1) The provisions of sections 3 and 4 shall not apply to collaborative research projects 
involving transfer or exchange of biological resources or information relating thereto 
between institutions, including Government sponsored institutions 
Provided that if a person applies for a patent, permission of the National 
Biodiversity Authority may be obtained after the acceptance of the patent but 
before the sealing of the patent by the patent authority concerned: 
Provided further that the National Biodiversity shall dispose of the application for 
permission made to it within a period of ninety days from the date of receipt thereof 
6. (2) The National Biodiversity Authority may, while granting the approval under this 
section, impose benefit sharing fee or royalty or both or impose conditions including 
the sharing of financial benefits arising out of the commercial utilization of such 
rights. 
(3) The provisions of this section shall not apply to any person making an application for 
any right under any law relating to protection of plant varieties enacted by Parliament. 
(4) Where any right is granted under law referred to in sub-section (3), the concerned 
authority granting such right shall endorse a copy of such document granting the right to 
the National Biodiversity Authority. 
7. No person, who is a citizen of India or a body corporate, association or organization 
which is registered in India, shall obtain any biological resource for commercial 
utilization, or bio-survey and bio-utilisation for commercial utilization except after giving 
prior intimation to the State Biodiversity Board concerned: 
Provided that the provisions of this section shall not apply to the local people and 
communities of the area, including growers and cultivators of biodiversity, and voids and 
hakims, who have been practising indigenous medicine. 
CHATER III 
NATIONAL BIODIVERSITY AUTHORITY 
8. (1) With effect from such date as the Central Govemment may, by notification in the 
Official Gazette, appoint, there shall be established by the Central Govemment for the 
purposes of this Act, a body to be called the National Biodiversity Authority. 
(2) The National Biodiversity Authority shall be a body corporate by the name aforesaid, 
having perpetual succession and a common seal, with power to acquire, hold and dispose 
of property, both movable and immovable, and to contract, and shall by the said name sue 
and be sued. 
(3) The head office of the National Biodiversity Authority shall be at Chennai and the 
National Biodiversity Authority may, with the previous approval of the Central 
Govemment, establish offices at other places in India. 
(4) The National Biodiversity Authority shall consist of the following members, namely:-
(a) a Chairperson, who shall be an eminent person having adequate knowledge and 
experience in the conservation and sustainable use of biological diversity and in 
matters relating to equitable sharing of benefits, to be appointed by the Central 
Govemment; 
(b) there ex officio members to be appointed by the Central Government, one 
representing the Ministry dealing with Tribal Affairs and two representing the 
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Ministry dealing with Environment and Forests of whom one shall be the Additional 
Director General of Forests or the Director General of Forests; 
(c) seven ex officio members to be appointed by the Central Government to represent 
respectively the Ministries of the Central Government dealing with -
(i) Agriculture Research and Education; 
(ii) Biotechnology; 
(iii) Ocean Development; 
(iv) Agriculture and Cooperation; 
(v) Indian Systems of Medicine and Homeopathy; 
(vi) Science and Technology; 
(vii) Scientific and Industrial Research; 
(d) five non-official members to be appointed from amongst specialists and scientists 
having special knowledge of, or experience in, matters relating to conservation of 
biological diversity, sustainable use of biological resources and equitable sharing of 
benefits arising out of the use of biological resources, representatives of industry, 
conservers, creators and knowledge-holders of biological resources. 
9. The term of office and conditions of service of the Chairperson and the other 
members other than ex officio members of the National Biodiversity Authority shall 
be such as may be prescribed by the Central Government. 
10. The Chairperson shall be the Chief Executive of the National Biodiversity Authority 
and shall exercise such powers and perform such duties, as may be prescribed. 
11. The Central Government may remove from the National Biodiversity Authority any 
member who, in its opinion, has -
(a) been adjudged as an insolvent; or 
(b) been convicted of an offence which involves moral turpitude; or 
(c) become physically or mentally incapable of acting as a member; or 
(d) so abused his position as to render his continuance in office detrimental to the 
public interest; or 
(e) acquired such financial or other interest as is likely to affect prejudicially his 
functions as a member. 
12. (1) The National Biodiversity Authority shall meet at such time and place and 
shall observe such rules of procedure in regard to the transaction of business 
at its meetings (including the quorum at its meetings) as may be prescribed. 
(2) The Chairperson of the National Biodiversity Authority shall preside at the meetings 
of the National Biodiversity Authority. 
(3) If for any reason the Chairperson is unable to attend any meeting of the National 
Biodiversity Authority, any member of the National Biodiversity Authority chosen by 
the members present at the meeting shall preside at the meeting. 
(4) All questions which come before any meeting of the National Biodiversity Authority 
shall be decided by a majority of votes of the members present and voting and in the 
event of equality of votes, the Chairperson or, in his absence, the person presiding, 
shall have and exercise a second or casting vote. 
(5) Every member who is in any way, whether directly, indirectly or personally, 
concerned or interested in a matter to be decided at the meeting shall disclose the 
nature of his concern or interest and after such disclosure, the member concerned or 
interested shall not attend that meeting. 
(6) No act or proceeding of the National Biodiversity Authority shall be invalidated 
merely by reason of-
(a) any vacancy in, or any defect in the constitution of, the National Biodiversity 
Authority; or 
(b) any vacancy in, or any defect in the constitution of, any defect in the 
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appointment of a person acting as a member; or 
(c) any irregularity in the procedure of the National Biodiversity Authority not 
affecting the merits of the case. 
13. (I) The National Biodiversity Authority may constitute a committee to deal with 
agro-biodiversity. 
Explanation - For the purposes of this sub-section, "agro-biodiversity" means biological 
diversity of agriculture related species and their wild relatives. 
(2) Without prejudice to the provisions of sub-section (1), the National Biodiversity 
Authority may constitute such number of committees as it deems fit for the efficient 
discharge of its duties and performance of its function under this Act. 
(3) A committee constituted under this section shall-co-opt such number of persons, who 
are not the members of the National Biodiversity Authority, as it may think fit and the 
persons so co-opted shall have the right to attend the meetings of the committee and 
take part in its proceedings but shall not have the right to vote. 
(4) The persons appointed as members of the committee under sub-section (2) shall be 
entitled to receive such allowances or fees for attending the meetings of the committee 
as may be fixed by the Central Government. 
14. (1) The National Biodiversity Authority may appoint such officers and other 
employees as it considers necessary for the efficient discharge of its functions under 
this Act. 
(2) The terms and conditions of service of such officers and other employees of the 
National Biodiversity Authority shall be such as may be specified by regulations. 
15. All orders and decisions of the National Biodiversity Authority shall be authenticated 
by the signature of the Chairperson or any other member authorized by the National 
Biodiversity Authority in this behalf and all other instruments executed by the 
National Biodiversity Authority shall be authenticated by the signature of an officer of 
the National Biodiversity Authority authorized by it in this behalf 
16. The National Biodiversity Authority may, be general or special order in writing, 
delegate to any member, officer of the National Biodiversity Authority or any other 
person subject to such conditions, if any, as may be specified in the order, such of the 
powers and functions under this Act (except the power to prefer an appeal under 
section 50 and the power to make regulations under section 64 as it may deem 
necessary. 
17. The salaries and allowances payable to the members and the administrative expenses 
of the National Biodiversity Authority including salaries, allowances and pension 
payable to, or in respect of, the officers and other employees of the National 
Biodiversity Authority shall be defrayed out of the Consolidated Fund of India. 
CHAPTER IV 
FUNCTIONS AND POWERS OF THE NATIONAL BIODIVERSITY AUTHORITY 
18. (1) It shall be the duty of the National Biodiversity Authority to regulate activities 
referred to in section 3, 4 and 6 and by regulations issue guidelines for access to 
biological resources and for fair and equitable benefit sharing. 
(2) The National Biodiversity Authority may grant approval for undertaking any activity 
referred to in section 3, 4 and 6. 
(3) The National Biodiversity Authority may -
(a) advise the Central Government on matters relating to the conservation of 
biodiversity, sustainable use of its components and equitable sharing of benefits 
arising out of the utilization of biological resources; 
(b) advise the State Governments in the selection of areas of biodiversity importance 
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to be notified under sub-section (1) of section 37 as heritage sites and measures 
for the management of such heritage sites; 
(c) perform such other functions as may be necessary to carry out the provisions of 
this Act. 
(4) The National Biodiversity Authority may, on behalf of the Central Government, take 
any measures necessary to oppose the grant of intellectual property rights in any 
country outside India on any biological resource obtained from India or knowledge 
associated with such biological resource which is derived from India. 
CHATER V 
APPROVAL BY THE NATIONAL BIODIVERSITY AUTHORITY 
19. (1) Any person referred to in sub-section (2) of section 3 who intends to obtain any 
biological resource occurring in India or knowledge associated thereto for research or 
for commercial utilization or for bio-survey and bio-utilisation or transfer the results 
of any research relating to biological resources occurring in, or obtained from, India, 
shall make application in such form and payment of such fees as may be prescribed, 
to the National Biodiversity Authority. 
(2) Any person who intends to apply for a patent or any other form of intellectual 
property protection whether in India or outside India referred to in sub-section (1) of 
section 6, may make an application in such form and in such manner as may be 
prescribed to the National Biodiversity Authority. 
(3) On receipt of an application under sub-section (1) or sub-section (2), the National 
Biodiversity Authority may, after making such enquiries as it may deem fit and if 
necessary after consulting an expert committee constituted for this purpose, by order, 
grant approval subject to any regulations made in this behalf and subject to such 
terms and conditions as it may deem fit, including the imposition of charges by way 
of royalty or for reasons to be recorded in writing, reject the application. 
Provided that no such order for rejection shall be made without giving an opportunity 
of being heard to the person affected. 
(4) The National Biodiversity Authority shall give public notice of every approval granted 
by it under this section. 
20. (1) No person who has been granted approval under section 19 shall transfer any 
biological resource or knowledge associated thereto which is the subject matter of the 
said approval except with the permission of the National Biodiversity Authority. 
(2) Any person who intends to transfer any biological resource or knowledge 
associated thereto referred to in sub-section (1) shall make an application in such 
manner as may be prescribed to the National Biodiversity Authority. 
(3) On receipt of an application under sub-section (2), the National Biodiversity 
Authority may, after making such enquiries as it may deem fit and if necessary after 
consulting an expert committee for this purpose, by order, grant approval subject to 
such terms and conditions as it may deem fit, including the imposition of charges by 
way of royalty or for reasons to be recorded in writing, reject the application: 
Provided that no such order for rejection shall be made without giving an opportunity 
of being heard to the person affected. 
(4) The National Biodiversity Authority shall give public notice of every approval 
granted by it under this section. 
21. (1) The National Biodiversity Authority shall while granting approvals under section 
19 or section 20 ensure that the terms and conditions subject to which approval is 
granted secures equitable sharing of benefits arising out of the use of accessed 
biological resources, their by-products, innovations and practices associated with 
their use and applications and knowledge relating thereto in accordance with mutually 
agreed terms and conditions between the person applying for such approval, local 
bodies concerned and the benefits claimers. 
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(2) The National Biodiversity Authority shall, subject to any regulations made in this 
behalf, determine the benefit sharing which shall be given effect in all or any of the 
following manner, namely:-
(a) grant of joint ownership of intellectual property rights to the National 
Biodiversity Authority, or where benefit claimers are identified, to such benefit 
claimers; 
(b) transfer of technology; 
(c) location of production, research and development units in such areas which will 
facilitate better living standards to the benefit claimers; 
(d) association of Indian scientists, benefit claimers and the local people with 
research and development in biological resources and bio-survey and bio-
utilisation; 
(e) setting up of venture capital fund for aiding the cause of benefit claimers; 
(f) payment of monetary compensation and other non-monetary benefits to the 
benefit claimers as the National Biodiversity Authority may deem fit. 
(3) Where any amount of money is ordered by way of benefit sharing, the National 
Biodiversity Authority may direct the amount to be deposited in the National 
Biodiversity Fund: 
Provided that where biological resource or knowledge was a result of access from 
specific individual or group of individuals or organizations, the National Biodiversit>' 
Authority may direct the amount to be paid directly to such individual or group of 
individuals or organizations in accordance with the terms of any agreement and in 
such manner as it deems fit. 
(4) For the purposes of this section, the National Biodiversity Authority shall, in 
consultation with the Central Government, bi regulations, frame guidelines. 
CHAPTER VI 
STATE BIODIVERSITY BOARD 
22. (I) With effect from such dates as the State Government may, by notification in the 
Official Gazette, appoint in this behalf, there shall be established by that Government 
for the purposes of this Act, a Board for the State to be known as the 
(name of the State) Biodiversity Board. 
(2) Notwithstanding anything contained in this section, no State Biodiversity Board 
shall be constituted for a Union territory and in relation to a Union territory, the 
National Biodiversity Authority shall exercise the powers and perform the functions 
of a State Biodiversity Board for that Union territory: 
Provided that in relation to any Union territory, the National Biodiversity Authority 
may delegate all or any of its powers or functions under this sub-section to such 
person or group of persons as the Central Government may specify. 
(3) The Board shall be a body corporate by the name aforesaid, having perpetual 
succession and a common seal, with power to acquire, hold and dispose of property, 
both movable and immovable, and to contract, and shall by the said name sue and be 
sued. 
(4) The Board shall consist of the following members, namely:-
(a) a Chairperson who shall be an eminent person having adequate knowledge and 
experience in the conservation and sustainable use of biological diversity and in 
matters relating to equitable sharing of benefits, to be appointed by the State 
Government; 
(b) not more than five ex officio members to be appointed by the State Government to 
represent the concerned Departments of the State Government; 
(c) not more than five members to be appointed from among the experts in matters 
relating to conservation of biological diversity, sustainable use of biological 
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resources and equitable sharing of benefits arising out of the use of biological 
resources. 
(5) The head office of the State Biodiversity Board shall be at such place as the State 
Government may, by notification in the Oificiai Gazette, specify. 
23. The functions of the State Biodiversity Board shall be to -
(a) advise the State Government, subject to any guidelines issued by the Central 
Government, on matters relating to the conservation of biodiversity, sustainable 
use of its components and equitable sharing of the benefits arising out of the 
utilization of biological resources; 
(b) regulate by granting of approvals or otherwise requests for commercial utilization 
or bio-survey and bio-utilisation of any biological resource by Indians; 
(c) perform such other functions as may be necessary to carry out the provisions of 
this Act or as may be prescribed by the State Government. 
24. (1) Any citizen of India or a body corporate, organization or association registered in 
India intending to undertake any activity referred to in section 7 shall give prior 
intimation is such form as may be prescribed by the State Government to the State 
Biodiversity Board. 
(2) On receipt of an intimation under sub-section (1), the State Biodiversity Board 
may, in consultation with the local bodies concerned and after making such enquiries 
as it may deem fit, by order, prohibit or restrict any such activity if it is of opinion 
that such activity is detrimental or contrary to the objectives of conservation and 
sustainable use of biodiversity or equitable sharing of benefits arising out of such 
activity: 
Provided that no such order shall be made without giving an opportunity of being 
heard to the person affected. 
(3) Any information given in the form referred to in sub-section (1) for prior 
intimation shall be kept confidential and shall be disclosed, either intentionally or 
unintentionally, to any person not concerned thereto. 
25. The provisions of sections 9 to 17 shall apply to a State Biodiversity Board and shall 
have effect subject to the following modifications, namely:-
(a) references to the Central Government shall be construed as references to 
the State Government: 
(b) references to the National Biodiversity Authority shall be construed as 
references to the State Biodiversity Board: 
(c) reference to the Consolidated Fund of India shall be construed as 
reference to the Consolidated Fund of the State. 
CHAPTER VII 
FINANCE, ACCOUNTS AND AUDIT OF NATIONAL BIODIVERSITY 
AUTHORITY 
26. The Central Government may, after due appropriation made by Parliament by law in 
this behalf, pay to the National Biodiversity Authority by way of grants or loans such 
sums of money as the Central Government may think fit for being utilized for the 
purposes of this Act. 
27. (1) There shall be constituted a Fund to be called the National Biodiversity Fund and 
there shall be credited thereto -
(a) any grants and loans made to the National Biodiversity Authority under section 26; 
(b) all charges and royalties received by the National Biodiversity Authority under this 
Act; and 
(c) all sums received by the National Biodiversity Authority from such other sources as 
may be decided upon by the Central Government. 
(2) The Fund shall be applied for -
(a) channeling benefits to the benefit claimers; 
32 
(b) conservation and promotion of biological resources and development of areas from 
where sucii biological resources or knowledge associated thereto has been accessed; 
(c) socio-economic development of areas referred to in clause (b) in consultation with the 
local bodies concerned. 
28. The National Biodiversity Authority shall prepare, in such form and at such time each 
fmancial year as may be prescribed, its annual report, giving a full account of its 
activities during the previous financial year and furnish, to the Central Government, 
before such date as may be prescribed, its audited copy of accounts together with 
auditors' report thereon. 
29. (1) The National Biodiversity Authority shall prepare a budget, maintain proper 
accounts and other relevant records (including the accounts and other relevant records 
of the National Biodiversity Fund) and prepare an annual statement of account in 
such form as may be prescribed by the Central Government in consultation with the 
Comptroller and Auditor-General of India. 
(2) The accounts of the National Biodiversity Authority shall be audited by the 
Comptroller and Auditor-General of India at such intervals as may be specified by 
him and any expenditure incurred in connection with such audit shall be payable by 
the National Biodiversity Authority to the Comptroller and Auditor-General of India. 
(3) The Comptroller and Auditor-General of India and any other person appointed by 
him in connection with the audit of the accounts of the National Biodiversity 
Authority shall have the same rights and privileges and authority in connection with 
such audit as the Comptroller and Auditor-General generally has in connection with 
the audit of the Government accounts and, in particular, shall have the right to 
demand the production of books, accounts, connected vouchers and other documents 
and papers and to inspect any of the offices of the National Biodiversity Authority. 
(4) The accounts of the National Biodiversity Authority as certified by the 
Comptroller and Auditor-General of India or any other person appointed by him in 
this behalf together with the audit report thereon shall be forwarded annually to the 
Central Government. 
30. The Central Government shall cause the annual report and auditor's report to be laid, 
as soon as may be after they are received, before each House of Parliament. 
CHAPTER VIII 
FINANCE, ACCOUNTS AND AUDIT OF STATE BIODIVERSITY BOARD 
31. The State Government may, after due appropriation made by the State Legislature by 
law in this behalf, as the State Government may think to fit for being utilized for the 
purposes of this Act. 
32. (1) There shall be constituted a Fund to be called the State Biodiversity Fund and 
there shall be credited thereto; 
a. any grants and loans made to the State Biodiversity Board under section 31; 
b. any grants or loans made by the National Biodiversity Authority; 
c. all sums received by the State Biodiversity Board from such other sources as 
may be decided upon by the State Government 
(2) The State Biodiversity Fund shall be applied for -
a. the management and conservation of heritage sites; 
b. compensating or rehabilitating any section of the people economically affected 
by notification under sub-section (1) of section 37; 
c. conservation and promotion of biological resources; 
d. socio-economic development of areas from where such biological resources or 
knowledge associated thereto has been accessed subject to any order made 
under section 24, in consultation with the local bodies concerned; 
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e. meeting the expenses incurred for the purposes authorized by this Act 
33. The State Biodiversity Board shall prepare, in such form and at such time in each 
financial year as may be prescribed, its annual report, giving a full account of its 
activities during the previous financial year, and submit a copy thereof to the State 
Government. 
34. The accounts of the State Biodiversity Board shall be maintained and audited in such 
manner as may, in consultation with the Accountant-General of the State, be 
prescribed and the State Biodiversity Board shall furnish, to the State Government, 
before such date as may be prescribed, its audited copy of accounts together with 
auditor's report thereon. 
35. The State Government shall cause the annual report and auditor's report to be laid, as 
soon as may be after they are received, before the House of State Legislature. 
CHAPTER IX 
DUTIES OF THE CENTRAL AND THE STATE GOVERNMENTS 
36. (1) The Central Government shall develop national strategies, plans, programmes for 
the conservation and promotion and sustainable use of biological diversity including 
measures for identification and monitoring of areas rich in biological resources, 
promotion of in situ, and ex situ, conservation of biological resources, incentives for 
research, training and public education to increase awareness with respect to 
biodiversity. 
(2) Where the Central Government has reason to believe that any rich in biological 
diversity, biological resources and their habitats is being threatened by overuse, abuse 
or neglect, it shall issue directives to the concerned State Government to take 
immediate ameliorative measures; offering such State Government any technical and 
other assistance that is possible to be provided or needed. 
(3) The Central Government shall, as far as practicable wherever it deems 
appropriate, integrate the conservation, promotion and sustainable use of biological 
diversity into relevant sectoral or cross-sectoral plans, programmes and policies. 
(4) The Central Government shall undertake measures, -
(i) wherever necessary, for assessment of environmental impact of that project which is 
likely to have adverse effect on biological diversity, with a view to avoid or minimize 
such effects and where appropriate provide for public participation in such 
assessment; 
(ii) to regulate, manage or control the risks associated with the use and release of living 
modified organisms resulting from biotechnology likely to have adverse impact on 
the conservation and sustainable use of biological diversity and human health. 
(5) The Central Government shall endeavour to respect and protect the knowledge of 
local people relating to biological diversity, as recommended by the National 
Biodiversity Authority through such measures, which may include registration of 
such knowledge at the local, State or national levels, and other measures for 
protection, including sui generic system. 
Explanation - For the purposes of this section,-
(a) "ex situ conservation" means the conservation of biological diversity outside their 
natural habitats; 
(b) "in situ conservation" means the conservation of ecosystems and natural habitat 
and the maintenance and recovery of viable populations of species in their natural 
surroundings and, in the case of domesticated or cultivated species, in the 
surroundings where they have developed their distinctive properties. 
37. (1) Without prejudice to any other law for the time being in force, the State 
Government may, from time to time in consultation with the local bodies, notify in 
the Official Gazette, areas of biodiversity importance as biodiversity heritage sites 
under this Act. 
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(2) The State Government, in consultation with the Central Government, may frame 
rules for the management and conservation of all the heritage sites. 
(3) The State Government shall frame schemes for compensating or rehabilitating any 
person or section of people economically affected by such notification. 
38. Without prejudice to the provisions of any other law for the time being in force, the 
Central Government, in consultation with the concerned State Government, may from 
time to time notify any species which is on the verge of extinction or likely to become 
extinct in the near future as a threatened species and prohibit or regulate collection 
thereof for any purpose and take appropriate steps to rehabilitate and preserve those 
species. 
39. (1) The Central Government may, in consultation with the National Biodiversity 
Authority, designate institutions as repositories under this Act for different categories 
of biological resources. 
(2) The repositories shall keep in safe custody the biological material including 
voucher specimens deposited with them. 
(3) Any new taxon discovered by any person shall be notified to the repositories or 
any institution designated for this purpose and he shall deposit the voucher specimens 
with such repository or institution. 
40. Notwithstanding anything contained in this Act, the Central Government may, in 
consultation with the National Biodiversity Authority, by notification in the Official 
Gazette, declare that the provisions of this Act shall not apply to any items, including 
biological resources normally traded as commodities. 
CHAPTER X 
BIODIVERSITY MANAGEMENT COMMITTEES 
41. (1) Every local body shall constitute a Biodiversity Management Committee within its 
area for the purpose of promoting conservation, sustainable use and documentation of 
biological diversity including preservation of habitats, conservation of land races, folk 
varieties and cultivars, domesticated stocks and breeds of animals and micro 
organisms and chronicling of knowledge relating to biological diversity. 
Explanation - For the purposes of this sub-section, 
(a) "cultivar" means a varietj' of plant that has originated and persisted under 
cultivation or was specifically bred for the purpose of cultivation; 
(b) "folk variety" means a cultivated variety of plant that was developed, grown and 
exchanged informally among farmers; 
(c) "landrace" means primitive cultivar that was grown by ancient farmers and their 
successors. 
(2) The National Biodiversity Authority and the State Biodiversity Boards shall consult 
the Biodiversity Management Committees while taking any decision relating to the 
use of biological resources and knowledge associated with such resources occurring 
within the territorial jurisdiction of the Biodiversity Management Committee. 
(3) The Biodiversity Management Committees may levy charges by way of collection 
fees from any person for accessing or collecting any biological resources for 
commercial purposes from areas falling within its territorial jurisdiction. 
CHAPTER XI 
LOCAL BIODIVERSITY FUND 
42. The State Government may, after due appropriation made by State Legislature by law 
in this behalf, pay to the Local Biodiversity Funds by way of grants or loans such 
sums of money as the State Government may think fit for being utilized for the 
purposes of this Act. 
43. (1) There shall be constituted a Fund to be called the Local Biodiversity Fund at 
every area notified by the State Government where any institution of self-government 
is functioning and there shall be credited thereto -
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(a) any grants and loans made under section 42; 
(b) any grants or loans made by the National Biodiversity Authority; 
(c) any grants or loans made by the State Biodiversity Boards; 
(d) fees referred to in sub-section (3) of section 41 received by the Biodiversity 
Management Committees; 
(e) all sums received by the Local Biodiversity Fund from such other sources as may be 
decided upon by the State Government 
44. (1) Subject to the provisions of sub-section (2), the management and the custody of 
the Local Biodiversity Fund and the purposes for which such Fund shall be applied, 
be in the manner as may be prescribed by the State Government. 
(2) The Fund shall be used for conservation and promotion of biodiversity in the areas 
falling within the jurisdiction of the concerned local body and for the benefit of the 
community in so far such use is consistent with conservation of biodiversity. 
45. The person holding the custody of the Local Biodiversity Fund shall prepare, in such 
form and during each financial year at such time as may be prescribed, its annual 
report, giving a full account of its activities during the previous financial year, and 
submit a copy thereof to the concerned local body. 
46. The accounts of the Local Biodiversity Fund shall be maintained and audited in such 
manner as may, in consultation with the Accountant-General of the State, be 
prescribed and the person holding the custody of the Local Biodiversity Fund shall 
furnish, to the concerned local body, before such date as may be prescribed, its 
audited copy of accounts together with auditor's report thereon. 
47. Every local body constitution a Biodiversity Management Committee under sub-
section (1) of section 41, shall cause, the annual report and audited copy of accounts 
relating to such Committee to be submitted to the District Magistrate having 
jurisdiction over the area of the local body. 
CHAPTER XII 
MISCELANEOUS 
48. (1) Without prejudice to the foregoing provisions of this Act, the National 
Biodiversity Authority shall, in the discharge of its functions and duties under this 
Act, be writing to it from rime to time: 
Provided that the National Biodiversity Authority shall, as far as practicable, be given 
opportunity to express its views before any direction is given under this sub-section. 
(2) The decision of the Central Government whether a question is one of policy or not 
shall be final. 
49. (1) Without prejudice to the foregoing provisions of this Act, the State Biodiversity 
Board shall, in the discharge of its functions and duties under this Act, be bound by 
such directions on questions of policy as the State Government may give in writing to 
it from time to time: 
Provided that the State Biodiversity Board shall, as far as practicable, be given an 
opportunity to express its views before any direction is given under this sub-section. 
(2) The decision of the State Government whether a question is one of policy or not 
shall be final. 
50. (1) If a dispute arises between the National Biodiversity Authority and a State 
Biodiversity Board, the said Authority or the Board, as the case may be, may prefer 
an appeal to the Central Government within such time as may be prescribed. 
(2) Every appeal made under sub-section (1) shall be in such form as may be prescribed 
by the Central Government. 
(3) The procedure for disposing of an appeal shall be such as may be prescribed by the 
Central Government; 
Provided that before disposing of an appeal, the parties shall be given a reasonable 
opportunity of being heard. 
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(4) If a dispute arises between the State Biodiversity Boards, the Central Government 
shall refer the same to the National Biodiversity Authority. 
(5) While adjudicating any dispute sub-section (4), the National Biodiversity Authority 
shall be guided by the principles of natural justice and shall follow such procedure as 
may be prescribed by the Central Government. 
(6) The National Biodiversity Authority shall have, for the purpose of discharging its 
functions under this section, the same powers as are vested in a civil court under the 
Code of Civil Procedure, 1908 in respect of the following matters, namely:-
a. summoning and enforcing the attendance of any person and examining him on 
oath; 
b. requiring the discovery and production of documents; 
c. receiving evidence on affidavits; 
d. issuing commissions for the examination of witness or documents; 
e. reviewing its decisions; 
f. dismissing an application for default or deciding it ex parte: 
g. setting aside any order of dismissal of any application or any order passed by it ex 
parte; 
h. any other matter which may be prescribed. 
(7) Every proceeding before the National Biodiversity Authority shall be deemed to be a 
judicial proceeding within the meaning of sections 193 and 228, and for the purpose 
of section 196, of the Indian Penal Code and the National Biodiversity Authority shall 
be deemed to be a civil court for all the purposes of section 195 and Chapter XXVI of 
the Code of Criminal Procedure, 1973. 
51. All members, officers and other employees of the National Biodiversity Authority or 
the State Biodiversity Board shall be deemed, when acting or purporting to act in 
pursuance of any of the provisions of this Act, to be public servants within the 
meaning of section 21 of the Indian Penal Code.. 
52. Any person, aggrieved by any determination of benefit sharing or order of the 
National Biodiversity Authority or a State Biodiversity Board under this Act, may file 
am appeal to the High Court within thirty days from the date of communication to 
him, of the determination or order of the National Biodiversity Authority or the State 
Biodiversity Board, as the case may be: 
Provided that the High Court may, if it is satisfied that the appellant was prevented by 
sufficient cause from filing the appeal within the said period, allow it to be filed 
within a further period not exceeding sixty days. 
53. Every determination of benefit sharing or order made by the National Biodiversity 
Authority or a State Biodiversity Board under this Act or the order made by the High 
Court in any appeal against any determination or order of the National Biodiversity 
Authority or a State Biodiversity Board shall, on a certificate issued by any officer of 
the National Biodiversity Authority or a State Biodiversity Board or the Registrar of 
the High Court, in the same manner as a decree of that court. 
Explanation - For the purposes of this section and section 52, the expression "State 
Biodiversity Board" includes the person or group of persons to whom the powers or 
functions under sub-section (2) of section 22 have been delegated under the proviso to 
that sub-section and the certificate relating to such person or group of persons under this 
section shall be issued by such person or group of persons, as the case may be. 
54. No suit, prosecution or other legal proceedings shall lie against the Central 
Government or the State Government or any officer of the Central Government or the 
State Government or any member, officer or employee of the National Biodiversity 
Authority or the State Biodiversity Board for anything which is in good faith done or 
intended to be done under this Act or the rules or regulations made there under: 
55. (1) Whoever contravenes or attempts to contravene or abets the contravention of the 
provisions of section 3 or section 4 or section 6 shall be punishable with 
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imprisonment for a term which may extend to five years, or with fine which may 
extend to ten lakh rupees and where the damage caused exceeds ten lai<h rupees such 
fine may commensurate with the damage caused, or with both. 
(2) Whoever contravenes or attempts to contravene or abets the contravention of the 
provisions of section 7 or any order made under sub-section (2) of section 24 shall be 
punishable with imprisonment for a term which may extend to three years, or with 
fine which may extend to five lakh rupees, or with both. 
56. If any person contravenes any direction given or order made by the Central 
Government, the State Government, the National Biodiversity Authority or the State 
Biodiversity Board for which no punishment has been separately provided under this 
Act, he shall be punished with a fine which may extend to one lakh rupees and in case 
of a second subsequent offence, with fine which may extend to two lakh rupees and in 
the case of continuous contravention with additional fine may extend to two lakh 
rupees everyday during which the default continues. 
57. (1) Where an offence or contravention under this Act has been committed by a 
company, every person who at the time the offence or contravention was committed 
was in charge of, and was responsible to, the company for the conduct of the business 
of the company, as well as the company, shall be deemed to be guilt>' of the offence 
or contravention was committed without the knowledge or that he had exercised all 
due diligence to prevent the commission of such offence or contravention. 
(2) Notwithstanding anything contained in this sub-section (1), where an offence or 
contravention under this Act has been committed by a company and it is proved that 
the offence or contravention has been committed with the consent or connivance of, 
or is attributable to, any neglect on the part of any director, manager, secretary or 
other officer of the company, such director, manager, secretary or other officer shall 
also be deemed to be guilty of the offence or contravention and shall be liable to be 
proceeded against and punished accordingly. 
Explanation - For the purposes of this section, -
(a) "company" means any body corporate and includes a firm or other association of 
individuals: and 
(b) "director" in relation to a firm, means a partner in the firm 
58. The offences under this Act shall be cognizable and non-bailable. 
59. The provisions of this Act shall be in addition to, and not in derogation of, the 
provisions in any other law, for the time being in force, relating to forests or wildlife. 
60. The Central Government may give directions to any State Government as to the 
carrying into execution in the State of any of the provisions of this Act or any rule or 
regulation or order made thereunder. 
61. No Court shall take cognizance of any offence under this Act except on a complaint 
made by -
(a) the Central Government or any authority or officer authorized in this behalf by 
that Government; or 
(b) any benefit claimer who has given notice of not less than thirty days in the 
prescribed manner, of such offence and of his intention to make a complaint, to 
the Central Government or the authority or officer authorized as aforesaid. 
62. (1) The Central Government may, by notification in the Official Gazette, make rules 
for carrying out the purposes of this Act. 
(2) In particular, and without prejudice to the generality of the foregoing power, such 
rules may provide for all or any of the following matters, namely:-
a. terms and conditions of service of the Chairperson and members under section 9; 
b. powers and duties of the Chairperson under section 10; 
c. procedure under sub-section (1) of section 12 in regard to transaction of business 
at meetings; 
d. form of application and payment of fees for undertaking certain activities under 
sub-section (1) of section 19; 
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e. the form and manner of making an application under sub-section (2) of section 
19; 
f form of application and the manner for transfer of biological resource or 
knowledge under sub-section (2) of section 20; 
g. form in which, and the time of each financial year at which, the annual report of 
the National Biodiversity Authority shall be prepared and the date before which 
its audited copy of accounts together with auditor's report thereon shall be 
furnished under section 28; 
h. form in which the annual statement of account shall be prepared under sub-
section (1) of section 29; 
i. the time within which and the form in which, an appeal may be preferred, the 
procedure for disposing of an appeal and the procedure for adjudication, under 
section 50; 
j . the additional matter in which the National Biodiversity Authority may exercise 
powers of the civil court under clause (h) of sub-section (6) of section 50; 
k. the manner of giving notice under clause (b) of section 61; 
I. any other matter which is to be, or may be, prescribed, or in respect of which 
provision is to be made, by rules. 
(3) Every rule made under this section and every regulation made under this Act shall 
be laid, as soon as may be after it is made, before each House of Parliament, while it 
is in session, for a total period of thirty days which may be comprised in one session 
or in two or more successive sessions, and if, before the expiry of the session 
immediately following the session or the successive sessions aforesaid, both Houses 
agree in making any modification in the rule or regulation or both Houses agree that 
the rule or regulation should not be made, the rule or regulation shall thereafter have 
effect only in such modified form or be of no effect, as the case may be; so, however, 
that any such modification or annulment shall be without prejudice to the validity of 
anything previously done under that rule or regulation. 
63. (1) The State Government may, by notification in the Official Gazette, make rules for 
carrying out the purposes of this Act. 
(2) In particular, and without prejudice to the generality of the foregoing power, such 
rules may provide for all or any of the following matters, namely:-
a. the other functions to be performed by the State Biodiversity Board under clause 
(c) of section 23; 
b. the form in which the prior intimation shall be given under sub-section {1) of 
section 24; 
c. the form in which, and the time of each financial year at which, the annual report 
shall be prepared under section 33; 
d. the manner of maintaining and auditing the accounts of the State Biodiversity 
Board and the data before which its audited copy of the accounts together with 
auditor's report thereon shall be furnished under section 34; 
e. management and conservation of national heritage sites under section 37; 
f. the manner of management and custody of the Local Biodiversity Fund and the 
purposes for which such Fund shall be applied under sub-section (I) of section 
44; 
g. the form of annual report and the time at which such report shall be prepared 
during each financial year under section 45; 
h. the manner of maintaining and auditing the accounts of the Local Biodiversity-
Fund and the date before which its audited copy of the accounts together with 
auditor's report thereon shall be furnished under section 46; 
i. any other matter which is to be, or may be, specified. 
(3) Every rule made by the State Government under this section shall be laid, as soon 
as may be after it is made, before each House of the State Legislature where it 
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consists of two Houses, or where such Legislature consists of one House, before that 
House. 
64. The National Biodiversity Authority shall, with the previous approval of the Central 
Government, by notification in the Official Gazette, make regulations for carrying out 
the purposes of this Act. 
65. (1) If any difficulty arises in giving effect to the provisions of this Act, the Central 
Government may, by order, not inconsistent with the provisions of this Act, remove 
the difficulty; 
Provided that no such order shall be made after the expiry of a period of two years 
from the commencement of this Act. 
(2) Every order made under this section shall be laid, as soon as may be after it is 
made, before each House of Parliament. 
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CONVENTION ON BIOLOGICAL DIVERSITY 
5 JUNE 1992 
Preamble 
The Contracting Parties, 
Conscious of the intrinsic value of biological diversity and of 
the ecological, genetic, social, economic, scientific, educational, 
cultural, recreational and aesthetic values of biological diversity and 
its components. 
Conscious also of the importance of biological diversity for 
evolution and for maintaining life sustaining systems of the biosphere, 
Affirming that the conservation of biological diversity is a 
common concern of humankind. 
Reaffirming that States have sovereign rights over their own 
biological resources, 
i?eaffirming also that States are responsible for conserving their 
biological diversity and for using their biological resources in a 
sustainable manner, 
Concerned that biological diversity is being significantly 
reduced by certain human activities. 
Aware of the general lack of information and knowledge regarding 
biological diversity and of the urgent need to develop scientific, 
technical and institutional capacities to provide the basic 
understanding upon which to plan and implement appropriate measures, 
Noting that it is vital to anticipate, prevent and attack the 
causes of significant reduction or loss of biological diversity at 
source, 
Noting also that where there is a threat of significant reduction 
or loss of biological diversity, lack of full scientific certainty 
should not be used as a reason for postponing measures to avoid or 
minimize such a threat, 
Noting further that the fundamental requirement for the 
conservation of biological diversity is the in-situ conservation of 
ecosystems and natural habitats and the maintenance and recovery of 
viable populations of species in their natural surroundings. 
Noting further that ex-situ measures, preferably in the country 
of origin, also have an important role to play. 
Recognizing the close and traditional dependence of many 
indigenous and local communities embodying traditional lifestyles on 
biological resources, and the desirability of sharing equitably 
benefits arising from the use of traditional knowledge, innovations and 
practices relevant to the conservation of biological diversity and the 
sustainable use of its components. 
Recognizing also the vital role that women play in the 
conservation and sustainable use of biological diversity and affirming 
the need for the full participation of women at all levels of policy-
making and implementation for biological diversity conservation, 
Stressing the importance of, and the need to promote, 
international, regional and global cooperation among States and 
intergovernmental organizations and the non-governmental sector for the 
conservation of biological diversity and the sustainable use of its 
components. 
Acknowledging that the provision of new and additional financial 
resources and appropriate access to relevant technologies can be 
expected to make a substantial difference in the world's ability to 
address the loss of biological diversity. 
Acknowledging further that special provision is required to meet 
the needs of developing countries, including the provision of new and 
additional financial resources and appropriate access to relevant 
technologies. 
Noting in this regard the special conditions of the least 
developed countries and small island States, 
Acknowledging that substantial investments are required to 
conserve biological diversity and that there is the expectation of a 
broad range of environmental, economic and social benefits from those 
investments. 
Recognizing that economic and social development and poverty 
eradication are the first and overriding priorities of developing 
countries. 
Aware that conservation and sustainable use of biological 
diversity is of critical importance for meeting the food, health and 
other needs of the growing world population, for which purpose access 
to and sharing of both genetic resources and technologies are 
essential. 
Noting that, ultimately, the conservation and sustainable use of 
biological diversity will strengthen friendly relations among States 
and contribute to peace for humankind, 
Desiring to enhance and complement existing international 
arrangements for the conservation of biological diversity and 
sustainable use of its components, and 
determined to conserve and sustainably use biological diversity 
for the benefit of present and future generations. 
Have agreed as follows: 
Article 1. Objectives 
The objectives of this Convention, to be pursued in accordance 
with its relevant provisions, are the conservation of biological 
diversity, the sustainable use of its components and the fair and 
equitable sharing of the benefits arising out of the utilization of 
genetic resources, including by appropriate access to genetic resources 
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and by appropriate transfer of relevant technologies, taking into 
account all rights over those resources and to technologies, and by 
appropriate funding. 
Article 2. Use of Terms 
For the purposes of this Convention: 
"Biological diversity" means the variability among living organisms 
from all sources including, inter alia, terrestrial, marine and other 
aquatic ecosystems and the ecological complexes of which they are part; 
this includes diversity within species, between species and of 
ecosystems. 
"Biological resources" includes genetic resources, organisms or parts 
thereof, populations, or any other biotic component of ecosystems with 
actual or potential use or value for humanity. 
"Biotechnology" means any technological application that uses 
biological systems, living organisms, or derivatives thereof, to make 
or modify products or processes for specific use. 
"Country of origin of genetic resources" means the country which 
possesses those genetic resources in in-situ conditions. 
"Country providing genetic resources" means the country supplying 
genetic resources collected from in-situ sources, including populations 
of both wild and domesticated species, or taken from ex-sicu sources, 
which may or may not have originated in that country. 
"Domesticated or cultivated species" means species in which the 
evolutionary process has been influenced by humans to meet their needs. 
"Ecosystem" means a dynamic complex of plant, animal and micro-organism 
communities and their non-living environment interacting as a 
functional unit. 
"Ex-situ conservation" means the conservation of components of 
biological diversity outside their natural habitats. 
"Genetic material" means any material of plant, animal, microbial or 
other origin containing functional units of heredity. 
"Genetic resources" means genetic material of actual or potential 
value. 
"Habitat" means the place or type of site where an organism or 
population naturally occurs. 
"Jn-situ conditions" means conditions where genetic resources exist 
within ecosystems and natural habitats, and, in the case of 
domesticated or cultivated species, in the surroundings where they have 
developed their distinctive properties. 
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"In-situ conservation" means the conservation of ecosystems and natural 
habitats and the maintenance and recovery of viable populations of 
species in their natural surroundings and, in the case of domesticated 
or cultivated species, in the surroundings where they have developed 
their distinctive properties. 
"Protected area" means a geographically defined area which is 
designated or regulated and managed to achieve specific conservation 
objectives. 
"Regional economic integration organization" means an organization 
constituted by sovereign States of a given region, to which its member 
States have transferred competence in respect of matters governed by 
this Convention and which has been duly authorized, in accordance with 
its internal procedures, to sign, ratify, accept, approve or accede to 
it. 
"Sustainable use" means the use of components of biological diversity 
in a way and at a rate that does not lead to the long-term decline of 
biological diversity, thereby maintaining its potential to meet the 
needs and aspirations of present and future generations. 
"Technology" includes biotechnology. 
Articie 3. Principle 
States have, in accordance with the Charter of the United Nations 
and the principles of international law, the sovereign right to exploit 
their own resources pursuant to their own environmental policies, and 
the responsibility to ensure that activities within their jurisdiction 
or control do not cause damage to the environment of other States or of 
areas beyond the limits of national jurisdiction. 
i4rticle 4. Jurisdictional Scope 
Subject to the rights of other States, and except as otherwise 
expressly provided in this Convention, the provisions of this 
Convention apply, in relation to each Contracting Party: 
(a) In the case of components of biological diversity, in areas 
within the limits of its national jurisdiction; and 
(b) In the case of processes and activities, regardless of 
where their effects occur, carried out under its jurisdiction or 
control, within the area of its national jurisdiction or beyond the 
limits of national jurisdiction. 
Article 5. Cooperation 
Each Contracting Party shall, as far as possible and as 
appropriate, cooperate with other Contracting Parties, directly or, 
where appropriate, through competent international organizations, in 
respect of areas beyond national jurisdiction and on other matters of 
mutual interest, for the conservation and sustainable use of biological 
diversity. 
Article 6. General Measures for Conservation and Sustainable Use 
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Each Contracting Party shall, in accordance with its particular 
conditions and capabilities: 
(a) Develop national strategies, plans or programmes for the 
conservation and sustainable use of biological diversity or adapt for 
this purpose existing strategies, plans or programmes which shall 
reflect, inter alia, the measures set out in this Convention relevant 
to the Contracting Party concerned; and 
(b) Integrate, as far as possible and as appropriate, the 
conservation and sustainable use of biological diversity into relevant 
sectoral or cross-sectoral plans, programmes and policies. 
Article 7. Identification and Monitoring 
Each Contracting Party shall, as far as possible and as 
appropriate, in particular for the purposes of Articles 8 to 10: 
(a) Identify components of biological diversity important for 
its conservation and sustainable use having regard to the indicative 
list of categories set down in Annex I; 
(b) Monitor, through sampling and other techniques, the 
components of biological diversity identified pursuant to subparagraph 
(a) above, paying particular attention to those requiring urgent 
conservation measures and those which offer the greatest potential for 
sustainable use; 
(c) Identify processes and categories of activities which have 
or are likely to have significant adverse impacts on the conservation 
and sustainable use of biological diversity, and monitor their effects 
through sampling and other techniques; and 
(d) Maintain and organize, by any mechanism data, derived from 
identification and monitoring activities pursuant to subparagraphs (a), 
(b) and (c) above. 
Article 8. In-situ Conservation 
Each Contracting Party shall, as far as possible and as 
appropriate: 
(a) Establish a system of protected areas or areas where special 
measures need to be taken to conserve biological diversity; 
(b) Develop, where necessary, guidelines for the selection, 
establishment and management of protected areas or areas where special 
measures need to be taken to conserve biological diversity; 
(c) Regulate or manage biological resources important for the 
conservation of biological diversity whether within or outside 
protected areas, with a view to ensuring their conservation and 
sustainable use; 
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(d) Promote the protection of ecosystems, natural habitats and 
the maintenance of viable populations of species in natural 
surroundings; 
(e) Promote environmentally sound and sustainable development 
in areas adjacent to protected areas with a view to furthering 
protection of these areas; 
(f) Rehabilitate and restore degraded ecosystems and promote 
the recovery of threatened species, inter aiia, through the development 
and implementation of plans or other management strategies; 
(g) Establish or maintain means to regulate, manage or control 
the risks associated with the use and release of living modified 
organisms resulting from biotechnology which are likely to have adverse 
environmental impacts that could affect the conservation and 
sustainable use of biological diversity, taking also into account the 
risks to human health; 
(h) Prevent the introduction of, control or eradicate those 
alien species which threaten ecosystems, habitats or species; 
(i) Endeavour to provide the conditions needed for 
compatibility between present uses and the conservation of biological 
diversity and the sustainable use of its components; 
(j) Subject to its national legislation, respect, preserve and 
maintain knowledge, innovations and practices of indigenous and local 
communities embodying traditional lifestyles relevant for the 
conservation and sustainable use of biological diversity and promote 
their wider application with the approval and involvement of the 
holders of such knowledge, innovations and practices and encourage the 
equitable sharing of the benefits arising from the utilization of such 
knowledge, innovations and practices; 
(k) Develop or maintain necessary legislation and/or other 
regulatory provisions for the protection of threatened species and 
populations; 
(1) Where a significant adverse effect on biological diversity 
has been determined pursuant to Article 7, regulate or manage the 
relevant processes and categories of activities; and 
(m) Cooperate in providing financial and other support for in-
situ conservation outlined in subparagraphs (a) to (1) above, 
particularly to developing countries. 
Article 9. Ex-situ Conservation 
Each Contracting Party shall, as far as possible and as 
appropriate, and predominantly for the purpose of complementing in-situ 
measures: 
(a) Adopt measures for the ex-situ conservation of components 
of biological diversity, preferably in the country of origin of such 
components; 
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(b) Establish and maintain facilities for ex-situ conservation 
of and research on plants, animals and micro-organisms, preferably in 
the country of origin of genetic resources; 
(c) Adopt measures for the recovery and rehabilitation of 
threatened species and for their reintroduction into their natural 
habitats under appropriate conditions; 
(d) Regulate and manage collection of biological resources from 
natural habitats for ex-situ conservation purposes so as not to 
threaten ecosystems and in-situ populations of species, except where 
special temporary ex-situ measures are required under subparagraph (c) 
above; and 
(e) Cooperate in providing financial and other support for ex-
situ conservation outlined in subparagraphs (a) to (d) above and in the 
establishment and maintenance of ex-situ conservation facilities in 
developing countries. 
Article 10. Sustainable Use of Components of Biological Diversity 
Each Contracting Party shall, as far as possible and as 
appropriate: 
(a) Integrate consideration of the conservation and sustainable 
use of biological resources into national decision-making; 
(b) Adopt measures relating to the use of biological resources 
to avoid or minimize adverse impacts on biological diversity; 
(c) Protect and encourage customary use of biological resources 
in accordance with traditional cultural practices that are compatible 
with conservation or sustainable use requirements; 
(d) Support local populations to develop and implement remedial 
action in degraded areas where biological diversity has been reduced; 
and 
(e) Encourage cooperation between its governmental authorities 
and its private sector in developing methods for sustainable use of 
biological resources. 
Article 11. Incentive Measures 
Each Contracting Party shall, as far as possible and as 
appropriate, adopt economically and socially sound measures that act as 
incentives for the conservation and sustainable use of components of 
biological diversity. 
Article 12. Research and Training 
The Contracting Parties, taking into account the special needs of 
developing countries, shall: 
(a) Establish and maintain programmes for scientific and 
technical education and training in measures for the identification, 
conservation and sustainable use of biological diversity and its 
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components and provide support for such education and training for the 
specific needs of developing countries; 
(b) Promote and encourage research which contributes to the 
conservation and sustainable use of biological diversity, particularly 
in developing countries, inter alia, in accordance with decisions of 
the Conference of the Parties taken in consequence of recommendations 
of the Subsidiary Body on Scientific, Technical and Technological 
Advice; and 
(c) In keeping with the provisions of Articles 16, 18 and 20, 
promote and cooperate in the use of scientific advances in biological 
diversity research in developing methods for conservation and 
sustainable use of biological resources. 
Article 13. Public Education and Awareness 
The Contracting Parties shall: 
(a) Promote and encourage understanding of the importance of, 
and the measures recjuired for, the conservation of biological 
diversity, as well as its propagation through media, and the inclusion 
of these topics in educational programmes; and 
(b) Cooperate, as appropriate, with other States and 
international organizations in developing educational and public 
awareness programmes, with respect to conservation and sustainable use 
of biological diversity. 
Article 14. Impact Assessment and Minimizing Adverse Impacts 
1. Each Contracting Party, as far as possible and as appropriate, 
shall: 
(a) Introduce appropriate procedures requiring environmental 
impact assessment of its proposed projects that are likely to have 
significant adverse effects on biological diversity with a view to 
avoiding or minimizing such effects and, where appropriate, allow for 
public participation in such procedures; 
(b) Introduce appropriate arrangements to ensure that the 
environmental consequences of its programmes and policies that are 
likely to have significant adverse impacts on biological diversity are 
duly taken into account; 
(c) Promote, on the basis of reciprocity, notification, exchange 
of information and consultation on activities under their jurisdiction 
or control which are likely to significantly affect adversely the 
biological diversity of other States or areas beyond the limits of 
national jurisdiction, by encouraging the conclusion of bilateral, 
regional or multilateral arrangements, as appropriate; 
(d) In the case of imminent or grave danger or damage, 
originating under its jurisdiction or control, to biological diversity 
within the area under jurisdiction of other States or in areas beyond 
the limits of national jurisdiction, notify immediately the potentially 
affected States of such danger or damage, as well as initiate action to 
prevent or minimize such danger or damage; and 
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(e) Promote national arrangements for emergency responses to 
activities or events, whether caused naturally or otherwise, which 
present a grave and imminent danger to biological diversity and 
encourage international cooperation to supplement such national efforts 
and, where appropriate and agreed by the States or regional economic 
integration organizations concerned, to establish joint contingency 
plans. 
2. The Conference of the Parties shall examine, on the basis of 
studies to be carried out, the issue of liability and redress, 
including restoration and compensation, for damage to biological 
diversity, except where such liability is a purely internal matter. 
Article 15. Access to Genetic Resources 
1. Recognizing the sovereign rights of States over their natural 
resources, the authority to determine access to genetic resources rests 
with the national governments and is subject to national legislation. 
2. Each Contracting Party shall endeavour to create conditions to 
facilitate access to genetic resources for environmentally sound uses 
by other Contracting Parties and not to impose restrictions that run 
counter to the objectives of this Convention. 
3. For the purpose of this Convention, the genetic resources being 
provided by a Contracting Party, as referred to in this Article and 
Articles 16 and 19, are only those that are provided by Contracting 
Parties that are countries of origin of such resources or by the 
Parties that have acquired the genetic resources in accordance with 
this Convention. 
4. Access, where granted, shall be on mutually agreed terms and 
subject to the provisions of this Article. 
5. Access to genetic resources shall be subject to prior informed 
consent of the Contracting Party providing such resources, unless 
otherwise determined by that Party. 
6. Each Contracting Party shall endeavour to develop and carry out 
scientific research based on genetic resources provided by other 
Contracting Parties with the full participation of, and where possible 
in, such Contracting Parties. 
7. Each Contracting Party shall take legislative, administrative or 
policy measures, as appropriate, and in accordance with Articles 16 and 
19 and, where necessary, through the financial mechanism established by 
Articles 20 and 21 with the aim of sharing in a fair and equitable way 
the results of research and development and the benefits arising from 
the commercial and other utilization of genetic resources with the 
Contracting Party providing such resources. Such sharing shall be upon 
mutually agreed terms. 
Article 16. Access to and Transfer of Technology 
1. Each Contracting Party, recognizing that technology includes 
biotechnology, and that both access to and transfer of technology among 
Contracting Parties are essential elements for the attainment of the 
objectives of this Convention, undertakes subject to the provisions of 
this Article to provide and/or facilitate access for and transfer to 
other Contracting Parties of technologies that are relevant to the 
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conservation and sustainable use of biological diversity or make use of 
genetic resources and do not cause significant damage to the 
environment. 
2. Access to and transfer of technology referred to in paragraph 1 
above to developing countries shall be provided and/or facilitated 
under fair and most favourable terms, including on concessional and 
preferential terms where mutually agreed, and, where necessary, in 
accordance with the financial mechanism established by Articles 20 and 
21. In the case of technology subject to patents and other intellectual 
property rights, such access and transfer shall be provided on terms 
which recognize and are consistent with the adecfuate and effective 
protection of intellectual property rights. The application of this 
paragraph shall be consistent with paragraphs 3, 4 and 5 below. 
3. Each Contracting Party shall take legislative, administrative or 
policy measures, as appropriate, with the aim that Contracting Parties, 
in particular those that are developing countries, which provide 
genetic resources are provided access to and transfer of technology 
which makes use of those resources, on mutually agreed terms, including 
technology protected by patents and other intellectual property rights, 
where necessary, through the provisions of Articles 20 and 21 and in 
accordance with international law and consistent with paragraphs 4 and 
5 below. 
4. Each Contracting Party shall take legislative, administrative or 
policy measures, as appropriate, with the aim that the private sector 
facilitates access to, joint development and transfer of technology 
referred to in paragraph 1 above for the benefit of both governmental 
institutions and the private sector of developing countries and in this 
regard shall abide by the obligations included in paragraphs 1, 2 and 3 
above. 
5. The Contracting Parties, recognizing that patents and other 
intellectual property rights may have an influence on the 
implementation of this Convention, shall cooperate in this regard 
subject to national legislation and international law in order to 
ensure that such rights are supportive of and do not run counter to its 
objectives. 
Article 17. Exchange of Information 
1. The Contracting Parties shall facilitate the exchange of 
information, from all publicly available sources, relevant to the 
conservation and sustainable use of biological diversity, taking into 
account the special needs of developing countries. 
2. Such exchange of information shall include exchange of results of 
technical, scientific and socio-economic research, as well as 
information on training and surveying programmes, specialized 
knowledge, indigenous and traditional knowledge as such and in 
combination with the technologies referred to in Article 16, paragraph 
1. It shall also, where feasible, include repatriation of information. 
Article 18. Technical and Scientific Cooperation 
1. The Contracting Parties shall promote international technical and 
scientific cooperation in the field of conservation and sustainable use 
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of biological diversity, where necessary, through the appropriate 
international and national institutions. 
2. Each Contracting Party shall promote technical and scientific 
cooperation with other Contracting Parties, in particular developing 
countries, in implementing this Convention, inter alia, through the 
development and implementation of national policies. In promoting such 
cooperation, special attention should be given to the development and 
strengthening of national capabilities, by means of human resources 
development and institution building. 
3. The Conference of the Parties, at its first meeting, shall 
determine how to establish a clearing-house mechanism to promote and 
facilitate technical and scientific cooperation. 
4. The Contracting Parties shall, in accordance with national 
legislation and policies, encourage and develop methods of cooperation 
for the development and use of technologies, including indigenous and 
traditional technologies, in pursuance of the objectives of this 
Convention. For this purpose, the Contracting Parties shall also 
promote cooperation in the training of personnel and exchange of 
experts. 
5. The Contracting Parties shall, subject to mutual agreement, 
promote the establishment of joint research programmes and joint 
ventures for the development of technologies relevant to the objectives 
of this Convention. 
Article 19. Handling of Biotechnology and Distribution of its 
Benefits 
1. Each Contracting Party shall take legislative, administrative or 
policy measures, as appropriate, to provide for the effective 
participation in biotechnological research activities by those 
Contracting Parties, especially developing countries, which provide the 
genetic resources for such research, and where feasible in such 
Contracting Parties. 
2. Each Contracting Party shall take all practicable measures to 
promote and advance priority access on a fair and equitable basis by 
Contracting Parties, especially developing countries, to the results 
and benefits arising from biotechnologies based upon genetic resources 
provided by those Contracting Parties. Such access shall be on mutually 
agreed terms. 
3. The Parties shall consider the need for and modalities of a 
protocol setting out appropriate procedures, including, in particular, 
advance informed agreement, in the field of the safe transfer, handling 
and use of any living modified organism resulting from biotechnology 
that may have adverse effect on the conservation and sustainable use of 
biological diversity. 
4. Each Contracting Party shall, directly or by requiring any 
natural or legal person under its jurisdiction providing the organisms 
referred to in paragraph 3 above, provide any available information 
about the use and safety regulations required by that Contracting Party 
in handling such organisms, as well as any available information on the 
potential adverse impact of the specific organisms concerned to the 
Contracting Party into which those organisms are to be introduced. 
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Article 20. Financial Resources 
1. Each Contracting Party undertakes to provide, in accordance with 
its capabilities, financial support and incentives in respect of those 
national activities which are intended to achieve the objectives of 
this Convention, in accordance with its national plans, priorities and 
programmes. 
2. The developed country Parties shall provide new and additional 
financial resources to enable developing country Parties to meet the 
agreed full incremental costs to them of implementing measures which 
fulfil the obligations of this Convention and to benefit from its 
provisions and which costs are agreed between a developing country 
Party and the institutional structure referred to in Article 21, in 
accordance with policy, strategy, programme priorities and eligibility 
criteria and an indicative list of incremental costs established by the 
Conference of the Parties. Other Parties, including countries 
undergoing the process of transition to a market economy, may 
voluntarily assume the obligations of the developed country Parties. 
For the purpose of this Article, the Conference of the Parties, shall 
at its first meeting establish a list of developed country Parties and 
other Parties which voluntarily assume the obligations of the developed 
country Parties. The Conference of the Parties shall periodically 
review and if necessary amend the list. Contributions from other 
countries and sources on a voluntary basis would also be encouraged. 
The implementation of these commitments shall take into account the 
need for adequacy, predictability and timely flow of funds and the 
importance of burden-sharing among the contributing Parties included in 
the list. 
3. The developed country Parties may also provide, and developing 
country Parties avail themselves of, financial resources related to the 
implementation of this Convention through bilateral, regional and other 
multilateral channels. 
4. The extent to which developing country Parties will effectively 
implement their commitments under this Convention will depend on the 
effective implementation by developed country Parties of their 
commitments under this Convention related to financial resources and 
transfer of technology and will take fully into account the fact that 
economic and social development and eradication of poverty are the 
first and overriding priorities of the developing country Parties. 
5. The Parties shall take full account of the specific needs and 
special situation of least developed countries in their actions with 
regard to funding and transfer of technology. 
6. The Contracting Parties shall also take into consideration the 
special conditions resulting from the dependence on, distribution and 
location of, biological diversity within developing country Parties, in 
particular small island States. 
7. Consideration shall also be given to the special situation of 
developing countries, including those that are most environmentally 
vulnerable, such as those with arid and semi-arid zones, coastal and 
mountainous areas. 
Article 21. Financial Mechanism 
1. There shall be a mechanism for the provision of financial 
resources to developing country Parties for purposes of this Convention 
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on a grant or concessional basis the essential elements of which are 
described in this Article. The mechanism shall function under the 
authority and guidance of, and be accountable to, the Conference of the 
Parties for purposes of this Convention. The operations of the 
mechanism shall be carried out by such institutional structure as may 
be decided upon by the Conference of the Parties at its first meeting. 
For purposes of this Convention, the Conference of the Parties shall 
determine the policy, strategy, programme priorities and eligibility 
criteria relating to the access to and utilization of such resources. 
The contributions shall be such as to take into account the need for 
predictability, adequacy and timely flow of funds referred to in 
Article 20 in accordance with the amount of resources needed to be 
decided periodically by the Conference of the Parties and the 
importance of burden-sharing among the contributing Parties included in 
the list referred to in Article 20, paragraph 2. Voluntary 
contributions may also be made by the developed country Parties and by 
other countries and sources. The mechanism shall operate within a 
democratic and transparent system of governance. 
2. Pursuant to the objectives of this Convention, the Conference of 
the Parties shall at its first meeting determine the policy, strategy 
and programme priorities, as well as detailed criteria and guidelines 
for eligibility for access to and utilization of the financial 
resources including monitoring and evaluation on a regular basis of 
such utilization. The Conference of the Parties shall decide on the 
arrangements to give effect to paragraph 1 above after consultation 
with the institutional structure entrusted with the operation of the 
financial mechanism. 
3. The Conference of the Parties shall review the effectiveness of 
the mechanism established under this Article, including the criteria 
and guidelines referred to in paragraph 2 above, not less than two 
years after the entry into force of this Convention and thereafter on a 
regular basis. Based on such review, it shall take appropriate action 
to improve the effectiveness of the mechanism if necessary. 
4. The Contracting Parties shall consider strengthening existing 
financial institutions to provide financial resources for the 
conservation and sustainable use of biological diversity. 
Article 22. Relationship with Other International Conventions 
1. The provisions of this Convention shall not affect the rights and 
obligations of any Contracting Party deriving from any existing 
international agreement, except where the exercise of those rights and 
obligations would cause a serious damage or threat to biological 
diversity. 
2. Contracting Parties shall implement this Convention with respect 
to the marine environment consistently with the rights and obligations 
of States under the law of the sea. 
Article 23. Conference of the Parties 
1. A Conference of the Parties is hereby established. The first 
meeting of the Conference of the Parties shall be convened by the 
Executive Director of the United Nations Environment Programme not 
later than one year after the entry into force of this Convention. 
Thereafter, ordinary meetings of the Conference of the Parties shall be 
held at regular intervals to be determined by the Conference at its 
first meeting. 
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2. Extraordinary meetings of the Conference of the Parties shall be 
held at such other times as may be deemed necessary by the Conference, 
or at the written request of any Party, provided that, within six 
months of the request being communicated to them by the Secretariat, it 
is supported by at least one third of the Parties. 
3. The Conference of the Parties shall by consensus agree upon and 
adopt rules of procedure for itself and for any subsidiary body it may 
establish, as well as financial rules governing the funding of the 
Secretariat. At each ordinary meeting, it shall adopt a budget for the 
financial period until the next ordinary meeting. 
4. The Conference of the Parties shall keep under review the 
implementation of this Convention, and, for this purpose, shall: 
(a) Establish the form and the intervals for transmitting the 
information to be submitted in accordance with Article 26 and consider 
such information as well as reports submitted by any subsidiary body; 
(b) Review scientific, technical and technological advice on 
biological diversity provided in accordance with Article 25; 
(c) Consider and adopt, as required, protocols in accordance 
with Article 28; 
(d) Consider and adopt, as required, in accordance with 
Articles 29 and 30, amendments to this Convention and its annexes; 
(e) Consider amendments to any protocol, as well as to any 
annexes thereto, and, if so decided, recommend their adoption to the 
parties to the protocol concerned; 
(f) Consider and adopt, as required, in accordance with Article 
30, additional annexes to this Convention; 
(g) Establish such subsidiary bodies, particularly to provide 
scientific and technical advice, as are deemed necessary for the 
implementation of this Convention; 
(h) Contact, through the Secretariat, the executive bodies of 
conventions dealing with matters covered by this Convention with a view 
to establishing appropriate forms of cooperation with thera; and 
(i) Consider and undertake any additional action that may be 
required for the achievement of the purposes of this Convention in the 
light of experience gained in its operation. 
5. The United Nations, its specialized agencies and the 
International Atomic Energy Agency, as well as any State not Party to 
this Convention, may be represented as observers at meetings of the 
Conference of the Parties. Any other body or agency, whether 
governmental or non-governmental, qualified in fields relating to 
conservation and sustainable use of biological diversity, which has 
informed the Secretariat of its wish to be represented as an observer 
at a meeting of the Conference of the Parties, may be admitted unless 
at least one third of the Parties present object. The admission and 
participation of observers shall be subject to the rules of procedure 
adopted by the Conference of the Parties. 
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Article 24. Secretariat 
1. A secretariat is hereby established. Its functions shall be: 
(a) To arrange for and service meetings of the Conference of the 
Parties provided for in Article 23; 
(b) To perform the functions assigned to it by any protocol; 
(c) To prepare reports on the execution of its functions under 
this Convention and present them to the Conference of the Parties; 
(d) To coordinate with other relevant international bodies and, 
in particular to enter into such administrative and contractual 
arrangements as may be required for the effective discharge of its 
functions; and 
(e) To perform such other functions as may be determined by the 
Conference of the Parties. 
2. At its first ordinary meeting, the Conference of the Parties 
shall designate the secretariat from amongst those existing competent 
international organizations which have signified their willingness to 
carry out the secretariat functions under this Convention. 
Article 25. Subsidiary Body on Scientific, Technical 
and Technological Advice 
1. A subsidiary body for the provision of scientific, technical and 
technological advice is hereby established to provide the Conference of 
the Parties and, as appropriate, its other subsidiary bodies with 
timely advice relating to the implementation of this Convention. This 
body shall be open to participation by all Parties and shall be 
multidisciplinary. It shall comprise government representatives 
competent in the relevant field of expertise. It shall report regularly 
to the Conference of the Parties on all aspects of its work. 
2. Under the authority of and in accordance with guidelines laid 
down by the Conference of the Parties, and upon its request, this body 
shall: 
(a) Provide scientific and technical assessments of the status 
of biological diversity; 
(b) Prepare scientific and technical assessments of the effects 
of types of measures taken in accordance with the provisions of this 
Convention; 
(c) Identify innovative, efficient and state-of-the-art 
technologies and know-how relating to the conservation and sustainable 
use of biological diversity and advise on the ways and means of 
promoting development and/or transferring such technologies; 
(d) Provide advice on scientific programmes and international 
cooperation in research and development related to conservation and 
sustainable use of biological diversity; and 
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(e) Respond to scientific, technical, technological and 
methodological questions that the Conference of the Parties and its 
subsidiary bodies may put to the body. 
3. The functions, terms of reference, organization and operation of 
this body may be further elaborated by the Conference of the Parties. 
Article 26. Reports 
Each Contracting Party shall, at intervals to be determined by 
the Conference of the Parties, present to the Conference of the 
Parties, reports on measures which it has taken for the implementation 
of the provisions of this Convention and their effectiveness in meeting 
the objectives of this Convention. 
Article 27. Settlement of Disputes 
1. In the event of a dispute between Contracting Parties concerning 
the interpretation or application of this Convention, the parties 
concerned shall seek solution by negotiation. 
2. If the parties concerned cannot reach agreement by negotiation, 
they may jointly seek the good offices of, or request mediation by, a 
third party. 
3. When ratifying, accepting, approving or acceding to this 
Convention, or at any time thereafter, a State or regional economic 
integration organization may declare in writing to the Depositary that 
for a dispute not resolved in accordance with paragraph 1 or paragraph 
2 above, it accepts one or both of the following means of dispute 
settlement as compulsory: 
(a) Arbitration in accordance with the procedure laid down in 
Part 1 of Annex II,-
(b) Submission of the dispute to the International Court of 
Justice. 
4. If the parties to the dispute have not, in accordance with 
paragraph 3 above, accepted the same or any procedure, the dispute 
shall be submitted to conciliation in accordance with Part 2 of Annex 
II unless the parties otherwise agree. 
5. The provisions of this Article shall apply with respect to any 
protocol except as otherwise provided in the protocol concerned. 
Article 28. Adoption of Protocols 
1. The Contracting Parties shall cooperate in the formulation and 
adoption of protocols to this Convention. 
2. Protocols shall be adopted at a meeting of the Conference of the 
Parties. 
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3. The text of any proposed protocol shall be communicated to the 
Contracting Parties by the Secretariat at least six months before such 
a meeting. 
Article 29. Amendment of the Convention or Protocols 
1. Amendments to this Convention may be proposed by any Contracting 
Party. Amendments to any protocol may be proposed by any Party to that 
protocol. 
2. Amendments to this Convention shall be adopted at a meeting of 
the Conference of the Parties. Amendments to any protocol shall be 
adopted at a meeting of the Parties to the Protocol in question. The 
text of any proposed amendment to this Convention or to any protocol, 
except as may otherwise be provided in such protocol, shall be 
communicated to the Parties to the instrument in question by the 
secretariat at least six months before the meeting at which it is 
proposed for adoption. The secretariat shall also communicate proposed 
amendments to the signatories to this Convention for information. 
3. The Parties shall make every effort to reach agreement on any 
proposed amendment to this Convention or to any protocol by consensus. 
If all efforts at consensus have been exhausted, and no agreement 
reached, the amendment shall as a last resort be adopted by a two-third 
majority vote of the Parties to the instrument in question present and 
voting at the meeting, and shall be submitted by the Depositary to all 
Parties for ratification, acceptance or approval. 
4. Ratification, acceptance or approval of amendments shall be 
notified to the Depositary in writing. Amendments adopted in accordance 
with paragraph 3 above shall enter into force among Parties having 
accepted them on the ninetieth day after the deposit of instruments of 
ratification, acceptance or approval by at least two thirds of the 
Contracting Parties to this Convention or of the Parties to the 
protocol concerned, except as may otherwise be provided in such 
protocol. Thereafter the amendments shall enter into force for any 
other Party on the ninetieth day after that Party deposits its 
instrument of ratification, acceptance or approval of the amendments. 
5. For the purposes of this Article, "Parties present and voting" 
means Parties present and casting an affirmative or negative vote. 
Article 30. Adoption and Amendment of Annexes 
1. The annexes to this Convention or to any protocol shall form an 
integral part of the Convention or of such protocol, as the case may 
be, and, unless expressly provided otherwise, a reference to this 
Convention or its protocols constitutes at the same time a reference to 
any annexes thereto. Such annexes shall be restricted to procedural, 
scientific, technical and administrative matters. 
2. Except as may be otherwise provided in any protocol with respect 
to its annexes, the following procedure shall apply to the proposal, 
adoption and entry into force of additional annexes to this Convention 
or of annexes to any protocol: 
(a) Annexes to this Convention or to any protocol shall be 
proposed and adopted according to the procedure laid down in Article 
29; 
(b) Any Party that is unable to approve an additional annex to 
this Convention or an annex to any protocol to which it is Party shall 
so notify the Depositary, in writing, within one year from the date of 
the communication of the adoption by the Depositary. The Depositary 
shall without delay notify all Parties of any such notification 
received. A Party may at any time withdraw a previous declaration of 
objection and the annexes shall thereupon enter into force for that 
Party subject to subparagraph (c) below; 
(c) On the expiry of one year from the date of the 
communication of the adoption by the Depositary, the annex shall enter 
into force for all Parties to this Convention or to any protocol 
concerned which have not submitted a notification in accordance with 
the provisions of subparagraph (b) above. 
3. The proposal, adoption and entry into force of amendments to 
annexes to this Convention or to any protocol shall be subject to the 
same procedure as for the proposal, adoption and entry into force of 
annexes to the Convention or annexes to any protocol. 
4. If an additional annex or an amendment to an annex is related to 
an amendment to this Convention or to any protocol, the additional 
annex or amendment shall not enter into force until such time as the 
amendment to the Convention or to the protocol concerned enters into 
force. 
Article 31. Right to Vote 
1. Except as provided for in paragraph 2 below, each Contracting 
Party to this Convention or to any protocol shall have one vote. 
2. Regional economic integration organizations, in matters within 
their competence, shall exercise their right to vote with a number of 
votes equal to the number of their member States which are Contracting 
Parties to this Convention or the relevant protocol. Such organizations 
shall not exercise their right to vote if their member States exercise 
theirs, and vice versa. 
Article 32. Relationship between this Convention and Its 
Protocols 
1. A State or a regional economic integration organization may not 
become a Party to a protocol unless it is, or becomes at the same time, 
a Contracting Party to this Convention. 
2. Decisions under any protocol shall be taken only by the Parties 
to the protocol concerned. Any Contracting Party that has not ratified, 
accepted or approved a protocol may participate as an observer in any 
meeting of the parties to that protocol. 
Article 33. Signature 
This Convention shall be open for signature at Rio de Janeiro by 
all States and any regional economic integration organization from 5 
June 1992 until 14 June 1992, and at the United Nations Headquarters in 
New York from 
15 June 1992 to 4 June 1993. 
Article 34. Ratification, Acceptance or Approval 
1. This Convention and any protocol shall be subject to 
ratification, acceptance or approval by States and by regional economic 
integration organizations. Instruments of ratification, acceptance or 
approval shall be deposited with the Depositary. 
2. Any organization referred to in paragraph 1 above which becomes a 
Contracting Party to this Convention or any protocol without any of its 
member States being a Contracting Party shall be bound by all the 
obligations under the Convention or the protocol, as the case may be. 
In the case of such organizations, one or more of whose member States 
is a Contracting Party to this Convention or relevant protocol, the 
organization and its member States shall decide on their respective 
responsibilities for the performance of their obligations under the 
Convention or protocol, as the case may be. In such cases, the 
organization and the member States shall not be entitled to exercise 
rights under the Convention or relevant protocol concurrently. 
3. In their instruments of ratification, acceptance or approval, the 
organizations referred to in paragraph 1 above shall declare the extent 
of their competence with respect to the matters governed by the 
Convention or the relevant protocol. These organizations shall also 
inform the Depositary of any relevant modification in the extent of 
their competence. 
Article 35. Accession 
1. This Convention and any protocol shall be open for accession by 
States and by regional economic integration organizations from the date 
on which the Convention or the protocol concerned is closed for 
signature. The instruments of accession shall be deposited with the 
Depositary. 
2. In their instruments of accession, the organizations referred to 
in paragraph 1 above shall declare the extent of their competence with 
respect to the matters governed by the Convention or the relevant 
protocol. These organizations shall also inform the Depositary of any 
relevant modification in the extent of their competence. 
3. The provisions of Article 34, paragraph 2, shall apply to 
regional economic integration organizations which accede to this 
Convention or any protocol. 
Article 36. Entry Into Force 
1. This Convention shall enter into force on the ninetieth day after 
the date of deposit of the thirtieth instrument of ratification, 
acceptance, approval or accession. 
2. Any protocol shall enter into force on the ninetieth day after 
the date of deposit of the number of instruments of ratification, 
acceptance, approval or accession, specified in that protocol, has been 
deposited. 
3. For each Contracting Party which ratifies, accepts or approves 
this Convention or accedes thereto after the deposit of the thirtieth 
instrument of ratification, acceptance, approval or accession, it shall 
59 
enter into force on the ninetieth day after the date of deposit by such 
Contracting Party of its instrument of ratification, acceptance, 
approval or accession. 
4. Any protocol, except as otherwise provided in such protocol, 
shall enter into force for a Contracting Party that ratifies, accepts 
or approves that protocol or accedes thereto after its entry into force 
pursuant to paragraph 2 above, on the ninetieth day after the date on 
which that Contracting Party deposits its instrument of ratification, 
acceptance, approval or accession, or on the date on which this 
Convention enters into force for that Contracting Party, whichever 
shall be the later. 
5. For the purposes of paragraphs 1 and 2 above, any instrument 
deposited by a regional economic integration organization shall not be 
counted as additional to those deposited by member States of such 
organization. 
Article 37. Reservations 
No reservations may be made to this Convention. 
Article 38. Withdrawals 
1. At any time after two years from the date on which this 
Convention has entered into force for a Contracting Party, that 
Contracting Party may withdraw from the Convention by giving written 
notification to the Depositary. 
2. Any such withdrawal shall take place upon expiry of one year 
after the date of its receipt by the Depositary, or on such later date 
as may be specified in the notification of the withdrawal. 
3. Any Contracting Party which withdraws from this Convention shall 
be considered as also having withdrawn from any protocol to which it is 
party. 
Article 39. Financial Interim Arrangements 
Provided that it has been fully restructured in accordance with 
the requirements of Article 21, the Global Environment Facility of the 
United Nations Development Programme, the United Nations Environment 
Programme and the International Bank for Reconstruction and Development 
shall be the institutional structure referred to in Article 21 on an 
interim basis, for the period between the entry into force of this 
Convention and the first meeting of the Conference of the Parties or 
until the Conference of the Parties decides which institutional 
structure will be designated in accordance with Article 21. 
Article 40. Secretariat Interim Arrangements 
The secretariat to be provided by the Executive Director of the 
United Nations Environment Programme shall be the secretariat referred 
to in Article 24, paragraph 2, on an interim basis for the period 
between the entry into force of this Convention and the first meeting 
of the Conference of the Parties. 
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Article 41. Depositary 
The Secretary-General of the United Nations shall assume the 
functions of Depositary of this Convention and any protocols. 
Article 42. Authentic Texts 
The original of this Convention, of which the Arabic, Chinese, 
English, French, Russian and Spanish texts are equally authentic, shall 
be deposited with the Secretary-General of the United Nations. 
IN WITNESS WHEREOF the undersigned, being duly authorized to that 
effect, have signed this Convention. 
Done at Rio de Janeiro on this fifth day of June, one thousand nine 
hundred and ninety-two. 
Annex I 
IDENTIFICATION AND MONITORING 
1. Ecosystems and habitats: containing high diversity, large numbers 
of endemic or threatened species, or wilderness; required by migratory 
species; of social, economic, cultural or scientific importance; or, 
which are representative, unique or associated with key evolutionary or 
other biological processes; 
2. Species and communities which are: threatened; wild relatives of 
domesticated or cultivated species; of medicinal, agricultural or other 
economic value; or social, scientific or cultural importance; or 
importance for research into the conservation and sustainable use of 
biological diversity, such as indicator species; and 
3. Described genomes and genes of social, scientific or economic 
importance. 
Annex II 
Part 1 
ARBITRATION 
Article 1 
The claimant party shall notify the secretariat that the parties 
are referring a dispute to arbitration pursuant to Article 27. The 
notification shall state the subject-matter of arbitration and include, 
in particular, the articles of the Convention or the protocol, the 
interpretation or application of which are at issue. If the parties do 
61 
not agree on the subject matter of the dispute before the President of 
the tribunal is designated, the arbitral tribunal shall determine the 
subject matter. The secretariat shall forward the information thus 
received to all Contracting Parties to this Convention or to the 
protocol concerned. 
Article 2 
1. In disputes between two parties, the arbitral tribunal shall 
consist of three members. Each of the parties to the dispute shall 
appoint an arbitrator and the two arbitrators so appointed shall 
designate by common agreement the third arbitrator who shall be the 
President of the tribunal. The latter shall not be a national of one of 
the parties to the dispute, nor have his or her usual place of 
residence in the territory of one of these parties, nor be employed by 
any of them, nor have dealt with the case in any other capacity. 
2. In disputes between more than two parties, parties in the same 
interest shall appoint one arbitrator jointly by agreement. 
3. Any vacancy shall be filled in the manner prescribed for the 
initial appointment. 
Article 3 
1. If the President of the arbitral tribunal has not been designated 
within two months of the appointment of the second arbitrator, the 
Secretary-General of the United Nations shall, at the request of a 
party, designate the President within a further two-month period. 
2. If one of the parties to the dispute does not appoint an 
arbitrator within two months of receipt of the request, the other party 
may inform the Secretary-General who shall make the designation within 
a further two-month period. 
Article 4 
The arbitral tribunal shall render its decisions in accordance 
with the provisions of this Convention, any protocols concerned, and 
international law. 
Article 5 
Unless the parties to the dispute otherwise agree, the arbitral 
tribunal shall determine its own rules of procedure. 
Article 6 
The arbitral tribunal may, at the request of one of the parties, 
recommend essential interim measures of protection. 
Article 7 
The parties to the dispute shall facilitate the work of the 
arbitral tribunal and, in particular, using all means at their 
disposal, shall: 
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(a) Provide it with all relevant documents, information and 
facilities; and 
(b) Enable it, when necessary, to call witnesses or experts and 
receive their evidence. 
Article 8 
The parties and the arbitrators are under an obligation to 
protect the confidentiality of any information they receive in 
confidence during the proceedings of the arbitral tribunal. 
Article 9 
Unless the arbitral tribunal determines otherwise because of the 
particular circumstances of the case, the costs of the tribunal shall 
be borne by the parties to the dispute in equal shares. The tribunal 
shall keep a record of all its costs, and shall furnish a final 
statement thereof to the parties. 
Article 10 
Any Contracting Party that has an interest of a legal nature in 
the subject-matter of the dispute which may be affected by the decision 
in the case, may intervene in the proceedings with the consent of the 
tribunal. 
Article 11 
The tribunal may hear and determine counterclaims arising 
directly out of the subject-matter of the dispute. 
Article 12 
Decisions both on procedure and substance of the arbitral 
tribunal shall be taken by a majority vote of its members. 
Article 13 
If one of the parties to the dispute does not appear before the 
arbitral tribunal or fails to defend its case, the other party may 
request the tribunal to continue the proceedings and to make its award. 
Absence of a party or a failure of a party to defend its case shall not 
constitute a bar to the proceedings. Before rendering its final 
decision, the arbitral tribunal must satisfy itself that the claim is 
well founded in fact and law. 
Article 14 
The tribunal shall render its final decision within five months 
of the date on which it is fully constituted unless it finds it 
necessary to extend the time-limit for a period which should not exceed 
five more months. 
Article 15 
The final decision of the arbitral tribunal shall be confined to 
the subject-matter of the dispute and shall state the reasons on which 
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it is based. It shall contain the names of the members who have 
participated and the date of the final decision. Any member of the 
tribunal may attach a separate or dissenting opinion to the final 
decision. 
Article 16 
The award shall be binding on the parties to the dispute. It 
shall be without appeal unless the parties to the dispute have agreed 
in advance to an appellate procedure. 
Article 17 
Any controversy which may arise between the parties to the 
dispute as regards the interpretation or manner of implementation of 
the final decision may be submitted by either party for decision to the 
arbitral tribunal which rendered it. 
Part 2 
CONCILIATION 
Article 1 
A conciliation commission shall be created upon the request of 
one of the parties to the dispute. The commission shall, unless the 
parties otherwise agree, be composed of five members, two appointed by 
each Party concerned and a President chosen jointly by those members. 
Article 2 
In disputes between more than two parties, parties in the same 
interest shall appoint their members of the commission jointly by 
agreement. Where two or more parties have separate interests or there 
is a disagreement as to whether they are of the same interest, they 
shall appoint their members separately. 
Article 3 
If any appointments by the parties are not made within two months 
of the date of the request to create a conciliation commission, the 
Secretary-General of the United Nations shall, if asked to do so by the 
party that made the request, make those appointments within a further 
two-month period. 
Article 4 
If a President of the conciliation commission has not been chosen 
within two months of the last of the members of the commission being 
appointed, the Secretary-General of the United Nations shall, if asked 
to do so by a party, designate a President within a further two-month 
period. 
Article 5 
The conciliation commission shall take its decisions by majority 
vote of its members. It shall, unless the parties to the dispute 
otherwise agree, determine its own procedure. It shall render a 
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proposal for resolution of the dispute, which the parties shall 
consider in good faith. 
Article 6 
A disagreement as to whether the conciliation commission has 
competence shall be decided by the commission. 
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144. 
145. 
146. 
147. 
148. 
149. 
150. 
151. 
152. 
Central African Republic 
Chile 
Costa Rica 
Djibouti 
Dominican Republic 
El Salvador 
European Economic Community 
France 
Guatemala 
Guyana 
Haiti 
Hungary 
Honduras 
Ireland 
Japan 
Mexico 
Morocco 
Nicaragua 
Nigeria 
Panama 
Papua New Guinea 
Portugal 
Republic of Korea 
Russian Federation 
Senegal 
Slovenia 
Solomon Islands 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June ,1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
13 June 1992 
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153. Spain 13 June 1992 
154. Suriname 13 June 1992 
155. Tunisia 13 June 1992 
156. Cameroon 14 June 1992 
157. Iran 14 June 1992 
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THE SCHEDULE 
THE SEEDS BILL, 2004 
A 
BILL 
to provide for regulating the quality of seeds for sale, import and export and to facilitate 
production and supply of seeds of quality and for matters connected therewith or 
incidental thereto. 
BE it enacted by Parliament in the Fifty-Fifth Year of the Republic of India as 
follows :-
CHAPTER I 
PRELIMINARY 
Short title, 1.(1) This Act may be called the Seeds Act, 2004. 
extent, (2) It extends to the whole of India . 
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application and (3) 
commencement. 
(4) 
Save as otherwise provided in this Act, it shall apply to-
(a) every dealer; and 
(b) every producer of seed except when the seed is 
produced by him for his own use and not for sale. 
It shall come into force on such date as the Central 
Government may, by notification, appoint. 
Definitions. 2. In this Act, unless the context otherwise requires, -
(1) "agriculture" includes horticulture, forestry and cultivation of 
plantation, medicinal and aromatic plants; 
(2) "Central Seed Testing Laboratory" means the Central Seed 
Testing Laboratory established or declared as such under sub-section 
(1) of section 32; 
(3) "Certification Agency" means an agency established under 
section 26 or accredited under section 27 or recognised under section 
30; 
(4) "Chairperson" means the Chairperson of the Committee; 
(5) "Committee" means the Central Seed Committee constituted 
under sub-section (1) of section 3; 
(6) "container" means a box, bottle, casket, tin, barrel, case, 
receptacle, sack, bag, wrapper or other thing in which any article or 
thing is placed or packed; 
(7) "dealer" means a person who carries on the business of buying 
and selling, exporting, or importing seed, and includes an agent of a 
dealer; 
(8) "export" means taking out of India by land, sea or air; 
(9) "farmer" means any person who cultivates crops either by 
cultivating the land himself or through any other person but does not 
include any individual, company, trader or dealer who engages in the 
procurement and sale of seeds on a commercial basis; 
(10) "horticulture nursery" means any place where horticulture 
plants are, in the regular course of business, produced or propagated 
and sold for transplantation; 
(11) "import" means bringing into India by land, sea or air; 
(12) "kind" means one or more related species or sub-species of 
crop plants each individually or collectively known by one common 
name such as cabbage, maize, paddy and wheat; 
(13) "member" means a member of the Committee; 
(14) "misbranded" - A seed shall be deemed to be misbranded if-
(i) it is a substitute for, or resembles in a manner likely to deceive, 
another variety of seed under the name of which it is sold, and is not 
plainly and conspicuously labelled so as to indicate its true nature; 
(ii) it is falsely stated to be the product of any place or country; 
(iii) it is sold by a name which belongs to another kind or variety of 
seed; 
(iv) false claims are made for it upon the label or otherwise; 
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(v) when sold in a package which has been sealed or prepared by, or 
at the instance, of the dealer and which bears his name and address, 
the contents of each package are not conspicuously and correctly 
stated on the outside thereof within the limits of variability prescribed 
under this Act; 
(vi) the package containing it, or the label on the package bears any 
statement, design or device regarding the quality or the kind or variety 
of seed contained therein, which is false or misleading in any material 
particular or if the package is otherwise deceptive with respect to its 
contents; 
(vii) it is not registered in the manner required by or under this Act; 
(viii) its label contains any reference to registration other than the 
registration number; 
(ix) its label does not contain a warning or caution which may be 
necessary, and sufficient, if complied with, to protect human, animal 
and plant life and health or to avoid serious prejudice to the 
environment; 
(x) the package containing it or the label on the package bears the 
name of a fictitious individual or company as the dealer of the kind or 
variety; or 
(xi) it is not labelled in accordance with the requirements of this Act 
or the rules made thereunder; 
(15) "notification" means a notification published in the Official 
Gazette; 
(16) "prescribed" means prescribed by rules made under this Act; 
(17) "producer" means a person, group of persons, firm or 
organisation who grows or organizes the production of seeds; 
(18) "registered kind or variety", in relation to any seed, means any 
kind, or variety thereof, registered under section 13; 
(19) "Registration Sub-Committee" means the Registration Sub-
Committee constituted under sub-section (1) of section 7; 
(20) "regulation" means a regulation made by the Committee under 
this Act; 
(21) "seed" means any type of living embryo or propagule capable 
of regeneration and giving rise to a plant of agriculture which is true 
to such type; 
(22) "Seed Analyst" means a Seed Analyst appointed under section 
33; 
(23) "Seed Inspector" means a Seed Inspector appointed under 
section 34; 
(24) "seed processing" means the process by which seeds and 
planting materials are dried, threshed, shelled, ginned or delinted (in 
cotton), cleaned, graded or treated; 
(25) "spurious seed" means any seed which is not genuine or true to 
type; 
(26) "State Government" ,in relation to a Union territory, means the 
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administrator thereof; 
(27) "State Seed Testing Laboratory", in relation to any State, 
means the State Seed Laboratory estabhshed or declared as such under 
sub-section (2) of section 32 for that State; 
(28) "transgenic variety" means seed or planting material 
synthesized or developed by modifying or altering the genetic 
composition by means of genetic engineering; 
(29) "variety" means a plant grouping except micro-organism within 
a single botanical taxon of the lowest known rank, which can be 
(i) defined by the expression of the characteristics resulting from a 
given genotype of that plant grouping; 
(ii) distinguished from any other plant grouping by expression of at 
least one of the said characteristics; and 
(iii) considered as a unit with regard to its suitability for being 
propagated, which remains unchanged after such propagation, 
and includes propagating material of such variety, extant variety, 
transgenic variety, fanners' variety and essentially derived variety. 
Footnote: "essentially derived variety", in respect of a variety (the 
initial variety) shall be said to be essentially derived from such initial 
variety when it-
(a) is predominantly derived from such initial variety, or from a 
variety that itself is predominantly derived from such initial variety, 
while retaining the expression of the essential characteristics that 
result from the genotype or combination of genotypes of such initial 
variety; 
(b) is clearly distinguishable from such initial variety; and 
(c) conforms (except for the differences which result from the act 
of derivation) to such initial variety in the expression of the essential 
characteristics that result from the genotype or combination of 
genotypes of such initial variety; 
Extant variety - "extant variety" means a variety available in India 
which is-
(a) notified under section 5 of the Seeds Act, 1966; or 
(b) farmers' variety as defined in PVP Act; or 
(c) a variety about which there is common knowledge; or 
(d) any other variety which is in public domain. 
Constitution of 
Central Seed 
Committee. 
Composition of 
the Committee. 
CHAPTER II 
THE CENTRAL SEED COMMITTEE, REGISTRATION AND 
OTHER SUB-COMMITTEES 
3. (1) The Central Govemment shall, by notification, constitute, for 
the purpose of this Act, a Committee to be called the Central Seed 
Committee. 
4.(1) The Committee shall consist of a Chairperson, members, ex-
officio and other members, to be nominated by the Central 
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Government. 
(2) The Secretary to the Government of India in the Department 
of Agriculture and Co-operation, Ministry of Agriculture, shall be 
Chairperson, ex officio. 
(3) The Committee shall consist of the following members, ex 
officio namely :-
(i) the Agriculture Commissioner, Department of Agriculture 
and Co-operation, Government of India; 
(ii) the Deputy Director General (Crop Sciences), Indian Council 
of Agricultural Research; 
(iii) the Deputy Director General (Horticulture), Indian Council of 
Agricultural Research; 
(iv) the Joint Secretary in charge of seeds in the Department of 
Agriculture and Co-operation, Government of India 
(v) the Horticulture Commissioner, Department of Agriculture 
and Co-operation, Government of India; 
(vi) a representative of the Department of Bio-technology, 
Government of India, not below the rank of Joint Secretary to the 
Government of India; 
(vii) a representative of the Ministry of Environment and Forests, 
Government of India, not below the rank of Joint Secretary to the 
Government of India. 
(4) The Committee shall consist of the following other members 
to be nominated by the Central Government, namely:-
(i) the Secretary (Agriculture) from five States, one each from 
three out of the five geographical zones of the country as mentioned 
in the Schedule on rotation basis; 
(ii) Director, State Seed Certification Agency from one State 
which is not represented under clause (i); 
(iii) Managing Director, State Seeds Corporation, from one State 
which is not represented under clause (i) or clause (ii); 
(iv) two representatives of farmers; 
(v) two representatives of seed industry; 
(vi) two specialists or experts in the field of seed development. 
(5) The Committee may associate with it, in such manner, on such 
terms and for such purposes as it may deem fit, any person whose 
assistance or advice it may desire in complying with any of the 
provisions of this Act, and a person so associated shall have the right 
to take part in the discussion of the Committee relevant to the 
purposes for which he has been associated, but shall not have the 
right to vote and shall be entitled to receive such allowances or fees 
as may be fixed by the Central Government. 
(6) A Member nominated under sub-section (5) shall, unless his 
seat becomes vacant earlier by resignation, death or otherwise, be 
entitled to hold office for two years fi-om the date of his nomination 
but shall be eligible for re-nomination provided that the said member 
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shall hold office only for so long as he holds the appointment by 
virtue of which his nomination was made. 
(7) Save as otherwise provided, the terms and conditions of 
service of the members shall be such as may be prescribed. 
(8) A member other than an ex officio member may resign his 
office by giving notice in writing to the Central Government and on 
such resignation being accepted, he shall be deemed to have vacated 
his office. 
(9) A person shall be disqualified for being nominated or 
appointed as a member if he-
(i) has been convicted and sentenced to imprisonment for an 
offence which, in the opinion of the Central Government, involves 
moral turpitude; or 
(ii) is an undischarged insolvent; or 
(iii) is of unsound mind and stands so declared by a competent 
court. 
(10) No act or proceeding of the Committee shall become invalid 
merely by reason of-
(i) any vacancy therein, or any defect in the constitution thereof; 
or 
(ii) any defect in the appointment of a person acting as the 
Chairperson or a member of the Committee; or 
(iii) any irregularity in the procedure of the Committee not 
affecting the merits of the case. 
(11) The Central Government may, at any time, remove from 
office any member other than member, ex-officio after giving him a 
reasonable opportunity of showing cause against the proposed 
removal. 
5. The Committee shall be responsible for and shall have all the 
powers for the effective implementation of this Act and shall advise 
the Central Government and the State Governments on matters 
relating to-
(a) seed programming and planning; 
(b) seed development and production; 
(c) export and import of seeds; 
(d) standards for registration, certification and seed testing; 
(e) seed registration and its enforcement; 
(f) such other matters as may be specified by the Central 
Government. 
6. The Committee may, by notification, specify-
(a) the minimum limits of germination, genetic and physical 
purity, and seed health, with respect to any seed of any kind of 
variety; 
(b) the mark or label to indicate that such seed conforms to the 
minimum limits of germination, genetic and physical purity, and 
seed health specified under clause (a), and other particulars, such 
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as expected performance of the seed in accordance with the 
information provided by the producer under section 14 which 
such mark or label may contain. 
7.(1) The Committee shall constitute a Sub-Committee to be called 
the Registration Sub-Committee consisting of a Chairman and such 
nimiber of other members, to assist him in the discharge of the 
functions of the Committee, as may be prescribed. 
(2) It shall be the duty of the Registration Sub-Committee-
(a) to register seeds of varieties after scrutinizing their claims as 
made in the application in such manner as may be prescribed; 
(b) to perform such other functions as are assigned to it by the 
Committee. 
(3) The Committee may appoint as many other Sub-Committees 
including a Sub-Committee on Seed Certification as it deems fit 
consisting wholly of the members of the Committee or wholly of 
other persons or partly of members of the Committee and partly of 
other persons as it thinks fit to exercise such powers and perform such 
duties as may be delegated to them. 
8. The Committee may, subject to the previous approval of the 
Central Government, make regulations for the purpose of regulating 
its own procedure and the procedure of any Sub-Committee thereof 
9. The Central Government shall -
(a) appoint a person to be the Secretary of the Committee; and 
(b) provide the Committee with such technical and other officers and 
employees as may be necessary for the efficient performance of the 
functions of the Committee under this Act. 
10. (1) The Committee shall meet as and when necessary at such time 
and place and shall observe such procedure in regard to transaction of 
business at its meetings (including the quorum at meetings) as may be 
provided by regulations. 
(2) The Chairperson or, in his absence, the Agricultural 
Commissioner or, in the absence of both the Chairperson and the 
Agriculture Commissioner, any member chosen by the members 
present from amongst themselves, shall preside at a meeting of the 
Committee. 
(3) All questions at a meeting of the Committee shall be decided 
by a majority of votes of the members present and voting and in the 
case of an equality of votes, the Chairperson or, in his absence, the 
Agriculture Conmiissioner or, in the absence of both the Chairperson 
and the Agriculture Commissioner the person presiding shall have 
and exercise a second or casting vote 
11. Every State Government shall establish a State Seed Committee 
t o -
(a) advise the Committee on registration of regional or local seeds of 
any kind or variety; 
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(b) advise the State Government on registration of seed producing 
units, seed processing units, seed dealers and horticulture nurseries; 
(c) maintain, in each district, a list of seed dealers, seed producers, 
seed processing units and horticulture nurseries; 
(d) seek information from persons engaged in the production, 
supply, distribution, trade or commerce in seeds of any kind or 
variety regarding stocks, prices, sales and other information in the 
manner as may be prescribed; 
(e) advise the State Government and the Committee on all matters 
arising out of the administration and implementation of this Act; and 
(f) carry out other functions assigned to, by, or under this Act. 
CHAPTER III 
REGISTRATION OF KINDS AND VARIETIES OF SEEDS, 
ETC. 
12.(1) For the purposes of this Act, a register of all kinds and 
varieties of seed to be called the National Register of Seeds shall be 
kept by the Registration Sub-Committee wherein all specifications, as 
may be prescribed, shall be maintained. 
(2) Subject to the directions of the Committee, the Register shall 
be kept under the control and management of the Registration Sub-
Committee. 
(3) The Registration Sub-Committee shall, within such intervals and 
in such manner as it thinks appropriate, publish the list of kinds and 
varieties of seed which have been registered during that interval. 
13.(1) No seed of any kind or variety shall, for the purpose of sowing 
or planting by any person, be sold unless such seed is registered under 
sub-section (2) by the Registration Sub-Committee in such manner as 
may be prescribed. 
(2) Subject to the provisions of sections 14 and 15, the 
Registration Sub-Committee may register, or refuse any kind or 
variety of seed on the basis of information furnished by the producer 
on the results of multi-locational trials for such period as may be 
prescribed to establish the performance of that seed. 
(3) The Registration Sub-Committee may grant provisional 
registration as prescribed to the varieties of seeds which are available 
in the market on the date of commencement of this Act. 
(4) Registration made under this Act shall be valid for a period of 
fifteen years in the case of annual and biennial crops, and eighteen 
years for long duration perennials. 
(5) At the expiry of the period granted under sub-section (4), the 
kind or variety of seed may be re-registered for a like period by the 
Registration Sub-Conmiittee on the basis of information fiimished by 
the producer on the results of such trials as may be prescribed under 
sub-section (2) to re-establish performance of the kind or variety of 
seed. 
(6) The Registration Sub-Committee shall have the power to issue 
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such directions to protect the interests of a producer against any 
abusive act committed by any third party during the period between 
the date of filing of application for registration and the date of 
decision by the Committee on such application. 
14.(1) Every application for registration under sub-section (1) 
section 13 shall be made in such form and contain such particulars 
and be accompanied by such fees as may be prescribed. 
(2) On receipt of any such application for the registration of a kind 
or variety of seed, the Registration Sub-Committee may, after such 
enquiry as it deems fit and after satisfying itself that the kind or 
variety of seed to which the application relates conforms to the claims 
made by the importer or by the seller, as the case may be, as regards 
the efficacy of the kind or variety of seed and its safety to human 
beings and animals, register the kind or variety, as the case may, of 
the seed on such conditions as may be specified by it and allot a 
registration number thereto and issue a certificate of registration. 
(3) The Registration Sub-Committee may, having regard to the 
efficacy of the seeds and its safety to human beings and animals, vary 
the conditions subject to which a certificate of registration has been 
granted and may, for that purpose, require the certificate holder by 
notice in writing to deliver the certificate to it within such time as 
may be specified in the notice. 
15. (1) Notwithstanding anything contained in section 14, no seed of 
any transgenic variety shall be registered unless the applicant has 
obtained clearance in respect of the same as required by or under the 
provisions of the Environment (Protection) Act, 1986: 
Provided that the Registration Sub-Committee may, subject to 
clearance under the said Act, grant provisional registration, for a 
period not exceeding two years on the basis of information furnished 
by the producer on the results of multi-locational trials in the 
prescribed manner. 
(2) Save as otherwise provided in sub-section (1), the form and 
marmer in which and procedure for registration of transgenic variety 
of seed and the fee payable thereto shall be the same as applicable in 
case of registration under section 14. 
Cancellation of 
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16.(1) The Registration Sub-Committee may cancel any registration 
granted under section 13 or section 15 or any one or more of the 
following grounds, namely:-
(a) that the holder of the certificate has violated any of the terms and 
conditions of the registration; or 
(b) that the registration has been obtained by misrepresentation or 
concealment of essential data; or 
(c) that the variety is not performing in accordance with the 
information provided by the producer under sub-section (3) of section 
14 or has become obsolete or has outlived its utility; or 
(d) that prevention of commercial exploitation of such variety of 
seeds is necessary. 
(i) in the public interest; 
(ii) to protect public order or public morality; or 
(iii) to protect human beings, animal and plant life and health to 
avoid serious prejudice to the environment. 
(2) No order of cancellation of registration under this section shall 
be made unless the holder thereof or the affected person concerned 
has been given a reasonable opportunity of showing cause in respect 
of the grounds for such cancellation. 
Notification of 17. The Registration Sub-Committee shall notify the cancellation of 
cancellation of registration of a seed of any kind or variety made under section 13 
registration of or any registration made under section 15 in the Official Gazette 
seeds of kinds 
and varieties. 
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18. Notwithstanding anything contained in this Act, no registration 
of any kind or variety of seed shall be made under this Act, if 
prevention of commercial exploitation of such kind or variety is 
necessary to protect public order or public morality or human, animal 
or plant life and health, or to avoid serious prejudice to the 
environment. 
(2) A kind or variety of seed containing any technology, which is 
harmful, or potentially harmful, shall not be registered. 
Explanation.- For the purposes of this sub-section, the expression 
"technology" includes genetic use restriction technology and 
terminator technology. 
19. The Committee may, for conducting trials to assess performance, 
accredit centers of the Indian Council of Agricultural Research, State 
Agricultural Universities and such other organizations fulfilling the 
eligibility requirements as may be prescribed, to conduct trials to 
evaluate the performance of any kind or variety of seed. 
Compensation 20. Where the seed of any registered kind or variety is sold to a 
to farmer. farmer, the producer, distributor or vendor, as the case may be, shall 
disclose the expected performance of such kind or variety to the 
farmer under given conditions, and if, such registered seed fails to 
provide the expected performance under such given conditions, the 
farmer may claim compensation from the producer, distributor or 
vendor under the Consumer Protection Act, 1986. 
Seed 21.(1) No producer shall grow or organize the production of 
producers seed unless he is registered as such by the State Government 
and seed under this Act. 
processmg 
units to be 
registered. 
(2) No person shall maintain a seed processing unit 
unless such unit is registered by the State Government 
under this Act. 
(3) The State Government shall register a producer or 
seed processing unit if he or it meets the specifications 
prescribed by the Central Government in terms of 
infrastructure, equipment and qualified manpower. 
(4) Every application for registration under sub-section 
(3) shall be made in such form and manner and shall be 
accompanied by such fee as may be prescribed. 
(5) The State Government may, after making such 
enquiry and subject to such conditions as it thinks fit, grant a 
certificate for maintaining a seed producing or a seed 
processing unit in such form as may be prescribed. 
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(6) Every seed producing and processing units shall 
furnish periodic returns to the Seed Certification Agency in 
such form and at such time as may be prescribed on the 
quantity of seeds of different kinds or varieties processed by 
them. 
(7) The State Government may, after giving the holder 
of certificate of registration under sub-section (1), or sub-
section (2), as the case may be, suspend or cancel the 
registration if— 
(a) such registration has been obtained by 
misrepresentation as to a material particular relating 
to the specification in terms of infrastructure, 
equipment or availability of qualified manpower; or 
(b) any of the provisions of this Act or the rules made 
thereunder has been contravened. 
22.(1) Every person who desires to carry on the business of 
selling, keeping for sale, offering to sell, bartering, import or 
export or otherwise supply any seed by himself, or by any 
other person on his behalf shall obtain a registration 
certificate as a dealer in seeds from the State Government. 
(2) Every applicant for dealership under sub-section (1) 
shall be required to ftimish information about seed stocks, 
sales and other related information as may be prescribed. 
(3) Even application for registration under sub-section( 1) 
shall be made in such form and manner and shall be 
accompanied by such fee as may be prescribed. 
(4) The State Government may, after making such 
enquiry and subject to such conditions as it thinks fit, grant a 
certificate of registration as a dealer in seeds in such form as 
may be prescribed. 
(5) Every dealer registered under this section shall 
furnish such information and returns regarding seed stocks, 
seed lots, expiry date of seed lots and other related 
information as may be prescribed to the State Govemment. 
(6) The State Govemment may, after giving the dealer 
an opportunity of being heard, suspend or cancel a certificate 
granted under this Act if-
(a) such registration had been obtained by 
misrepresentation of any material fact; 
(b) contravenes any of the provisions of this Act or the 
rules made thereunder. 
23.(1) No person shall conduct or carry on the business 
of horticulture nursery unless such nursery is registered 
with the State Govemment. 
(2) Every application for registration under sub-section 
(I) shall be made in such form and contain such 
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particulars and shall be accompanied by such fee as may 
be prescribed. 
24. Every person who is a holder of a registration of a 
horticulture nursery under section 23 shall-
(a) keep a complete record of the origin or source 
of every planting material and performance 
record of mother trees in the nursery; 
(b) keep a layout plan showing the position of the 
root-stocks and scions used in raising the horticulture 
plants; 
(c) keep a performance record of the mother trees 
in the nursery; 
(d) keep the nursery plants as well as the parent 
trees used for the production or propagation of 
horticulture plants free from infectious or 
contagious insects, pests or diseases affecting 
plants. 
(e) furnish such information to the State 
Government on the production, stocks, sales and 
prices of planting material in the nursery as may 
be prescribed. 
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CHAPTER IV 
REGULATION OF SALE OF SEED AND 
SEED CERTIFICATION AGENCIES 
25. No person shall himself, or by any other person on his 
behalf, carry on the business of selling, keeping for sale, 
offering to sell, bartering, import or export or otherwise 
supply any kind of seed of any registered kind or variety 
unless-
(a) 
(b) 
(c) 
(d) 
(e) 
26 
such seed is identifiable as to its kind or variety; 
such seed conforms to the minimum limit of 
germination and genetic, physical purity, seed health 
specified under clause (a) of section 6; 
the container of such seed bears in the 
prescribed manner, the mark or label bearing the 
correct particulars thereof, specified under clause (b) 
of section 6; 
the container of such seed, in the case of 
transgenic varieties, bears a declaration to this effect 
as specified in sub-clause (2) of section 15; 
he complies with such other requirements as 
may be prescribed. 
The Committee may, in consuUation with the State 
Government, by notification, establish a State Seed 
Certification Agency for the State to carry out the functions 
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entrusted to the State Seed Certification Agency by or under 
this Act: 
27.(1) The Committee may in consultation with the State 
Government and the State Seed Committee, accredit -
(a) organizations to carry out certification, on the 
fulfillment of such criteria, as may be prescribed, or 
(b) individuals or seed producing organisations to carry 
out self- certification, in such manner as may be 
prescribed. 
(2) The accredited individuals and seed producing 
organisations shall be subject to such inspection and control 
of the Committee, the concemed State Government and State 
Seed Certification Agency, as may be prescribed. 
(3) The accreditation may be withdrawn by the 
Committee, for reasons to be recorded in writing and after 
giving to the concemed organization or individual, as the 
case may be, a reasonable opportunity of being heard. 
28.(1) Any person selling, keeping for sale, offering to sell, 
bartering or otherwise supplying any seed of any registered 
kind or variety may, if he desires to have such seed certified 
by the State Seed Certification Agency, apply to that Agency 
for the grant of a certificate for the purpose. 
(2) Every application under sub-section (1) shall be made 
in such form, shall contain such particulars and shall be 
accompanied by such fee as may be prescribed. 
(3) On receipt of an application under sub-section (1), the 
State Seed Certification Agency may, after such enquiry as it 
thinks fit and after satisfying itself that the seed to which the 
application relates conforms to the prescribed standards, 
grant a certificate in such form and on such conditions as 
may be prescribed: 
Provided that such standards shall not be lower than 
the minimum limit of germination, genetic and physical 
purity specified for that seed under clause (a) of section 6. 
29. If the State Seed Certification Agency is satisfied, 
either on a reference made to it in this behalf or otherwise, 
that-
(a) the certificate granted by it under section 28 has been 
obtained by misrepresentation as to an essential fact; or 
(b) the holder of the certificate has, without reasonable 
cause, failed to comply with the conditions subject to which 
the certificate has been granted or has contravened any of the 
provisions of this Act or the rules made thereunder, 
then, without prejudice to any other penalty to which the 
holder of the certificate may be liable under this Act, the 
State Seed Certification Agency may, after giving the holder 
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of the certificate an opportunity of showing cause, revoke the 
certificate. 
30. The Central Government may, on the 
recommendation of the Committee and by notification, 
recognise any seed certification agency estabHshed in any 
foreign country, for the purposes of this Act. 
CHAPTER V 
APPEALS 
31.(1) Any person aggrieved by a decision of the 
Registration Sub-Committee under section 14, section 16 or 
section 27 or of the State Seed Certification Agency under 
section 28 or section 29 may, within thirty days from the date 
on which the decision is communicated to him prefer an 
appeal to such authority (hereinafter referred to as the 
appellate authority) as the Central Government may think fit 
to constitute: 
Provided that the appellate authority may entertain an 
appeal after the expiry of the said period of thirty days if it is 
satisfied that the appellant was prevented by sufficient cause 
from filing the appeal in time. 
(2) An appellate authority shall consist of a single person 
or three persons as the Central Government may think fit, to 
be appointed by that Government. 
(3) The form and manner in which an appeal may be 
preferred under sub-section (1), the fee payable for such 
appeal and the procedure to be followed by the appellate 
authority shall be such as may be prescribed. 
(4) On receipt of an appeal preferred under sub-section 
(1), the appellate authority shall, after giving the appellant 
and the other party an opportunity of being heard, dispose of 
the appeal as expeditiously as possible. 
CHAPTER VI 
SEED ANALYSIS AND SEED TESTING 
32.(1) The Central Government may, by notification, 
establish a Central Seed Testing Laboratory or declare any 
seed-testing laboratory as the Central Seed Testing 
Laboratory to carry out the fiinctions entrusted to the Central 
Seed Testing Laboratory by or under this Act in the 
prescribed manner 
(2) The State Government may, in consultation with the 
Committee, and by notification, establish one or more State 
Seed Testing Laboratories or declare any seed testing 
laboratory in the Government or non-Government sector as a 
State Seed Testing Laboratory where analysis of seed of any 
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kind or variety shall be carried out under this Act in the 
prescribed manner. 
(3) Every Seed Testing Laboratory referred to in sub-
section (1) shall have as many Seed Analysts as the Central 
Government may consider necessary. 
(4) Every Seed Testing Laboratory referred to in sub-
section (2) shall have as many Seed Analysts as the State 
Government may consider necessary. 
Seed 33.(1) In case of the Central Seed Laboratory, the Central 
Analysts. Government and in other cases the State Government may, 
by notification, appoint such persons as the Government 
thinks fit and having the prescribed qualifications to be Seed 
Analysts and define the local limits of their jurisdiction. 
(2) Every Central Seed Testing Laboratory established or 
declared under sub-section (1) of section 32 and every State 
Seed Testing Laboratory established or declared under sub-
section (2) of that section shall have as many Seed Analysts 
as the Central Government or the State Government, as the 
case may be, specify. 
Seed 34.(1) The State Government may, by notification, appoint 
Inspectors. such persons as it thinks fit, having the prescribed 
qualifications, to be Seed Inspectors and define the areas 
within which they shall exercise jurisdiction. 
(2) Every Seed Inspector shall be subordinate to such 
authority as the State Government may specify in this behalf 
of 35.(1) The Seed Inspector may-
(a) take samples of any seed of any kind or variety from-
Powers 
Seed 
Inspectors. (i) 
(ii) 
(lii) 
any person selling such seed; or 
any person who is in the course of 
conveying, delivering or preparing to deliver 
such seed to a purchaser or a consignee; or 
a purchaser or a consignee after delivery 
ofsuchseed tohim; 
(b) send such sample for analysis to the Seed Analyst of 
the area within which such sample has been taken; 
(c) enter and search, at all reasonable times, with such 
assistance, if any, as he considers necessary, any place in 
which he has reason to believe that an offence under this Act 
has been or is being committed and order in writing the 
person in possession of any seed in respect of which the 
offence has been or is being committed, not to dispose of any 
stock of such seed for a specific period not exceeding thirty 
days or, unless the alleged offence is such that the defect may 
be removed by the possessor of the seed, seize the stock of 
such seed; 
(d) examine any record, register, document or any other 
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material object found in any place mentioned in clause (c) 
and seize the same if he has reason to believe that it may 
furnish evidence of the commission of an offence punishable 
under this Act; and 
(e) exercise such other powers as may be necessary for 
carrying out the purposes of this Act or any rule or regulation 
made thereunder. 
(2) The power conferred by this section includes the 
power to break-open any container in which any seed of any 
kind or variety may be contained or to break-open the door 
of any premises where any such seed may be kept for sale: 
Provided that the power to break-open the door shall 
be exercised only after the owner or any other person in 
occupation of the premises, if he is present therein, refiises to 
open the door on being called upon to do so. 
(3) Where the Seed Inspector takes any action under 
clause (a) of sub-section (1), he shall, as far as possible, call 
not less than two persons to be present at the time when such 
action is taken and take their signatures on a memorandum to 
be prepared in such form and manner as may be prescribed. 
(4) The provisions of the Code of Criminal Procedure, 1973, 
or in relation to the State of Jammu and Kashmir, the 
provisions of any corresponding law in force in that State, 
shall, so far as may be, apply to any search or seizure under 
this section as they apply to any search or seizure made 
under the authority of a warrant issued under section 94 of 
the said Code, or, as the case may be, under the 
corresponding provisions of the said law. 
CHAPTER VII 
EXPORT AND IMPORT OF SEEDS 
Import of 36.(1) All import of seeds-
seeds. (a) shall be subject to the provisions of the Plants, Fruits 
and Seeds (Regulation of Import into India) Order, 1989, 
or any corresponding order made under section 3 of the 
Destructive Insects and Pests Act, 1914; 
(b) shall conform to minimum limits of germination, genetic 
and physical purity, and seed health as prescribed under 2 of 
section 6; and 1914. 
(c) shall be subject to registration as may be granted on the 
basis of information ftimished by the importer on the 
results of multi-locational trials for such period as may 
be prescribed to establish performance. 
(2) The Central Government may, by notification, permit 
to import an uru^egistered variety in such quantity and subject 
to fulfilling such conditions as may be specified in that 
notification for research purposes. 
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Export of 37. The Central Government may, on the advice of the 
seeds. Committee, restrict, by notification, the export of seeds of 
any kind or variety if it is deemed that such export may 
adversely affect the food security of the country, or if it is 
felt that the reasonable requirements of the public will not be 
met, or on such other grounds as may be prescribed. 
CHAPTER VIII 
OFFENCES AND PUNISHMENT 
38. If any person-
(a) contravenes any provision of this Act or any rule 
made thereunder; or 
(b) imports, sells, stocks or exhibits for sale or barter; 
and or otherwise supplies any seed of any kind or variety 
deemed to be misbranded ; or 
(c) imports, sells, stocks or exhibits for sale or barter, or 
otherwise supplies any seed of any kind or variety without a 
certificate of registration; or 
(d) obstructs the Committee, Registration Sub-
Committee or Seed Certification Agency or Seed Inspector 
or Seed Analyst or any other authority appointed or duly 
empowered under this Act in the exercise of its powers or 
discharge of their duties under this Act or the rules made 
thereunder, 
he shall, on conviction, be punishable - with fine which shall 
not be less than five thousand rupees but which may extend 
to twenty five thousand rupees. 
(2) If any person sells any seed which does not conform 
to the standards of physical purity, germination or health or 
does not maintain any records required to be maintained 
under this Act or the rules made thereunder he shall, on 
conviction, be punishable with fine which shall not be less 
than five thousand rupees but which may extend to twenty-
five thousand rupees. 
(3) If any person furnishes any false information relating 
to the standards of genetic purity, misbrands any seed or 
supplies any spurious seed or spurious transgenic variety, 
sells any non-registered seeds he shall, on conviction be 
punishable with imprisonment for a term which may extend 
to six months or with fine which may extend to fifty 
thousand rupees or with both. 
39. When any person has been convicted under this Act 
for the contravention of any of the provisions of this Act or 
the rules made thereunder, the seed in respect of which the 
contravention has been committed shall be forfeited to the 
Central Government. 
Offences by 40.(1) Where an offence under this Act has been committed 
Forfeiture of 
property. 
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by a company, every person who at the time the ofFence was 
committed was in charge of, and was responsible to the 
company for the conduct of the business of the company, as 
well as the company, shall be deemed to be guilty of the 
offence and shall be liable to be proceeded against and 
punished accordingly: 
Provided that nothing contained in this sub-section 
shall render any such person liable to any punishment under 
this Act if he proves that the offence was committed without 
his knowledge and that he exercised all due diligence to 
prevent the commission of such offence. 
(2) Notwithstanding anything contained in sub-section (1), 
where an offence under this Act has been committed by a 
company and it is proved that the offence has been 
committed with the consent or connivance of, or is 
attributable to any neglect on the part of, any director, 
manager, secretary or other officer of the company, such 
director, manager, secretary or other officer shall also be 
deemed to be guilty of that offence and shall be liable to be 
proceeded against and punished accordingly. 
Explanation. - For the purpose of this section,-
(a) "company" means any body corporate and includes a 
firm or other association of individuals; and 
(b) "director", in relation to a firm, means a partner in the 
firm. 
CHAPTER IX 
POWER OF CENTRAL GOVERNMENT 
41. The Central Government may give such directions to 
any State Governments as may appear to the Central 
Government to be necessary for carrying into execution in 
the State any of the provisions of this Act or of any rule 
made there under. 
42.(1) Without prejudice to the foregoing provisions of this 
Act, the Committee shall, in the discharge of its functions 
and duties under this Act, be bound by such directions on 
questions of policy as the Central Government may give in 
writing to it fi-om time to time. 
(2) The decision of the Central Government whether a 
question is one of policy or not shall be final. 
43. (1) Nothing in this Act shall restrict the right of the 
farmer to save, use, exchange, share or sell his farm seeds 
and planting material, except that he shall not sell such seed 
or planting material under a brand name or which does not 
conform to the minimum limit of germination, physical 
91 
Protection of 
action taken 
in good faitli. 
Power to 
remove 
difliculties. 
Power of 
Central 
Government 
to make rules. 
purity, genetic purity prescribed under clause (a) or clause 
(b) of section 6. 
(2) The Central Government may, by notification, and 
subject to conditions, if any, as it may specify therein, 
exempt from all or any of the provisions of this Act or the 
rules made thereunder, any educational, scientific or research 
or extension organization. 
CHAPTER X 
MISCELLANEOUS 
44. No suit, prosecution or other legal proceeding shall 
lie against the Government or any person for anything which 
is in good faith done or intended to be done under this Act. 
45. (1) If any difficulty arises in giving effect to the 
provisions of this Act, the Central Government may, by order 
published in the Official Gazette, make such provisions not 
inconsistent with the provisions of this Act as may appear to 
be necessary for removing the difficulty: 
Provided that no order shall be made under this section 
after the expiry of two years from the date of commencement 
of this Act. 
(2) Every order made under sub-section (1) shall be laid 
before each House of Parliament. 
46.(1) The Central Government may by notification, make 
rules to carry out the provisions of this Act. 
(2) In particular and without prejudice to the generality 
of the foregoing power, such rules may provide for all or any 
of the following matters, namely:-
(a) the terms and conditions of service of members of 
the Committee under sub-section (7) of section 4; 
(b) the matters to be specified under clause (f) of 
section 5; 
(c) the fiinctions of the registration sub-committee 
under sub-section (1) of section 7; 
(d) the manner of scrutinizing applications under clause 
(a) of sub-section (2) of section 7; 
(e) the specifications which shall be maintained in the 
National Register of Seeds of kinds or varieties under 
sub-section (1) of section 12; 
(f) the manner of registration of seed of any kind or 
variety under sub-section (1) and (3) of section 13; 
(g) the period for which multi-locational trials shall be 
conducted under sub-section (2) of section 13; 
(h) the form of application and the particulars which 
should be furnished in such application under sub-
section (1) of section 14; 
(i) the eligibility requirement which an organization 
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shall fulfil for accreditation under section 19; 
(j) the specification required to be fulfilled for 
registration as a producer or seed producing unit under 
sub-section (3) of section 21; 
(k) the form and manner in which an application for 
registration under sub-section (3) of section 21 shall be 
made and the fee with which such application shall be 
accompanied under sub-section (5) of said section 21; 
(1) the form in which a certificate for maintaining a 
seed producing or seed processing unit may be granted 
under sub-section (5) of section 21; 
(m) the form in which and time within which periodic 
returns shall be filled under sub-section (6) of section 
21; 
(n) the information which an application for dealership 
in seeds shall be furnished under sub-section (2) of 
section 22; 
(o) the form and manner in which an application for 
registration as seed dealer under sub-section (1) of 
section 22 shall be made and the fee which shall 
accompany such application under sub-section (3) of 
that section; 
(p) the form in which a certificate of registration as a 
dealer in seeds shall be granted under sub-section (4) 
of section 22; 
(q) the information and return which a registered dealer 
shall furnish to the State Government under sub-
section (5) of section 22; 
(r) the form in which an application for registration of 
a horticulture nursery shall be made, the particulars 
which such application shall contain and fee which 
shall accompany such application under sub-section 
(2) of section 23; 
(s) the information on production, stocks, sales and 
prices of planting material in a nursery shall be 
furnished to the State Government under section 24; 
(t) the requirement which a person carrying on 
business of selling, etc. of any registered kind or 
variety of seeds shall comply with under clause (e) of 
section 25; 
(u) the criteria to be fulfilled under clause (a) and the 
manner of carrying out self-certification under clause 
(b) of sub-section (1) of section 27; 
(v) the inspection and control of the Committee, the 
concerned State Government and the State Seeds 
Certification Agency for accrediting individuals and 
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seed producing organizations under sub-section (2) of 
section 27; 
(w) the form of application and the particulars to be 
furnished in such application and the fee which shall 
accompany such application under sub-section (2) of 
section 28; 
(x) the form in which and the conditions subject to 
which a certificate shall be granted under sub-section 
(3) of section 28; 
(y) the form and manner in which an appeal shall be 
preferred and the fee which such appeal shall 
accompany under sub-section (3) of section 31; 
(z) the manner in which a Central Seed Testing 
Laboratory established or declared under sub-section 
(1) of section 32 shall carry out its functions; 
(za) the manner of carrying out analysis of seeds shall be 
made under sub-section (2) of section 32; 
(zb) the qualifications which a person to be appointed as 
Seed Analysts shall possess under sub-section (1) of 
section 33; 
(zc) the qualifications which a person to be appointed as 
Seed Inspector shall possess under sub-section (1) of 
section 34; 
(zc) the form and manner in which the memorandum shall 
be prepared under sub-section (3) of section 35; 
(zd) the grounds on which the Central Government may 
restrict export of seeds under section 37; 
(ze) any other matter which is to be or may be prescribed. 
47. (1) The Committee may, with the previous approval of 
the Central Government, by notification, make regulations 
not inconsistent with the provisions of this Act and the rules 
made thereunder, to provide for all matters for which 
provision is necessary or expedient for the purpose of giving 
effect to the provisions of this Act. 
(2) In particular and without prejudice to the generality of 
the foregoing power, such regulations may provide for all or 
any of the following matters, namely:-
(a) the procedure for conduct of business to be transacted by 
the Committee or any Sub-Committee thereof under section 
8; 
(b) the procedure in regard to transaction of business at 
meetings of the Committee (including the quorum at 
meetings)under sub-section (1) of section 10. 
48, Every rule and every regulation made under this Act 
shall be laid as soon as may be after it is made, before each 
House of Parliament, while it is in session, for a total period 
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before of thirty days which may be comprised in one session or in 
Parliament. two or more successive sessions, and if, before the expiry of 
the session immediately following the session or the 
successive sessions aforesaid, both Houses agree in making 
any modification in the rule or regulation or both Houses 
agree that the rule or regulation should not be made, the rule 
or regulation shall, thereafter, have effect only in such 
modified form or be of no effect, as the case may be; so, 
however, that any such modification or annulment shall be 
without prejudice to the validity of anything previously done 
under that rule or regulation. 
Repeal and 49. On the commencement of this Act, the Seeds Act, 
savings. 1966 shall stand repealed; 
Provided that such repeal shall not affect,-
(a) the previous operation of the law so repealed or 
anything duly done or suffered thereunder; or 
(b) any right, privilege, obligation or liability acquired, 
accrued or incurred under the law so repealed; or 
(c) any penalty, forfeiture or punishment incurred in respect 
of any offence committed against the Act so repealed; or 
(d) any investigation, proceeding, legal proceeding or 
remedy in respect of any such right, privilege, obligation, 
liability, penalty, forfeiture or punishment as aforesaid; and 
any such investigation, proceedings, legal proceeding or 
remedy may be instituted, continued or enforced; any such 
penalty forfeiture or punishment may be imposed as if this 
Act had not been passed: 
Provided further that, subject to the first proviso and 
any saving provisions made elsewhere in this Act anything 
done, any action taken, any rule made, any notifications or 
orders issued under the provisions of the Act so repealed 
shall, in so far as they are not inconsistent with the 
provisions of this Act, be deemed to have been done, taken, 
made or issued under the corresponding provisions of this 
Act, and shall continue to be in force accordingly, unless and 
until expressly or implied repealed by any thing done, action 
taken, rules made or, notification or orders issued under this 
Act. 
(2) Notwithstanding such repeals any kind or variety of 
seeds that has been notified under the law as so repealed 
shall be deemed to have been registered under this Act, and 
any seed certification agency established under section 18 of 
the Seeds Act, 1966 shall be deemed to have been 
established or recognized, as the case may be, under this 
Act. 
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THE SCHEDULE 
[See section 4(4)(i),(ii) and (iii) ] 
GEOGRAPHICAL ZONES 
ZONE-I ANDHRA PRADESH, KARNAKATA, KERALA, LAKSHADWEEP , 
PONDICHERRY AND TAMIL NADU. 
ZONE-II ANDAMAN AND NICOBAR ISLANDS , BIHAR , CHHATISGARH, 
JHARKHAND, MADHYA PRADESH, ORISSA AND WEST BENGAL . 
ZONE-III ARUNACHAL PRADESH , ASSAM , MANIPUR, MEGHALAYA, 
MIZORAM, NAGALAND , SIKKIM AND TRIPURA. 
ZONE-IV DADRA AND NAGAR HAVELI, DAMAN AND DIU , GOA , 
GUJARAT , RAJASTHAN AND MAHARASHTRA . 
ZONE-V CHANDIGARH, HARYANA, HIMACHAL PRADESH, JAMMU AND 
KASHMIR, NATIONAL CAPITAL TERRITORY OF DELHI, PUNJAB, 
UTTRANCHAL AND UTTAR PRADESH. 
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